<SEC-DOCUMENT>0000875045-17-000007.txt : 20170202
<SEC-HEADER>0000875045-17-000007.hdr.sgml : 20170202
<ACCEPTANCE-DATETIME>20170202074612
ACCESSION NUMBER:		0000875045-17-000007
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170202
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170202
DATE AS OF CHANGE:		20170202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		17566733

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8-kbioverativspinxoff.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sC5B672D8BE993E8B900BFA9C7DD1010F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Date of Report (Date of earliest event reported):  January 31</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">&#32;2017</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="biogenlogostandarda09.jpg" alt="biogenlogostandarda09.jpg" style="height:45px;width:138px;"></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:24pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">Biogen Inc. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Exact name of registrant as specified in its charter) </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.703125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:42%;"></td><td style="width:28%;"></td><td style="width:30%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">0-19311</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">33-0112644</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(State or other jurisdiction of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Commission File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(IRS Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">225 Binney Street, Cambridge, Massachusetts 02142</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Address of principal executive offices; Zip Code)</font></div><div style="line-height:120%;text-indent:348px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Registrant&#8217;s telephone number, including area code:  </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(617) 679-2000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Not Applicable</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Former name or former address, if changed since last report.)</font></div><div style="line-height:120%;text-indent:348px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1.01 &#160;&#160;&#160;&#160;Entry into a Material Definitive Agreement</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Separation Agreement with Bioverativ Inc.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">On February&#160;1, 2017, Biogen Inc. (&#8220;Biogen&#8221;) completed the previously announced separation of its hemophilia business, and certain other assets and liabilities, into a separate, independent publicly traded company by way of a distribution of all of the then outstanding shares of common stock of Bioverativ Inc. (&#8220;Bioverativ&#8221;) through a dividend in-kind of Bioverativ&#8217;s common stock, par value $0.001 per share, to Biogen&#8217;s stockholders of record as of the close of business on January 17, 2017 (the entire transaction being the &#8220;Separation&#8221;).  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In connection with the Separation, Biogen entered into a separation agreement with Bioverativ, dated as of January 31, 2017, that, among other things, sets forth our agreements with Bioverativ regarding the principal actions to be taken in connection with the Separation, including the distribution. The separation agreement identifies assets to be transferred, liabilities to be assumed and contracts to be assigned to each of Bioverativ and Biogen as part of the Separation, and it provides for when and how these transfers, assumptions and assignments will occur.  Biogen and Bioverativ are also each subject to nine-month non-solicit and two-year non-compete restrictions.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The foregoing description of the separation agreement is only a summary and is qualified in its entirety by reference to the complete terms and conditions of the separation agreement, which is attached as Exhibit 2.1 to this Current Report on Form 8-K and incorporated herein by reference.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.01 &#160;&#160;&#160;&#160;Completion of the Acquisition or Disposition of Assets</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">As described above, on February 1, 2017, Biogen completed the Separation. In the Separation, Biogen stockholders received one share of Bioverativ common stock for every two shares of Biogen common stock held at the close of business on January 17, 2017. Biogen did not issue fractional shares of Bioverativ&#8217;s common stock in the distribution. Eligible stockholders are entitled to receive cash in lieu of fractional shares.  </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;8.01 &#160;&#160;&#160;&#160;Other Events</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">On February 1, 2017, Biogen issued a press release announcing the completion of the Separation. A copy of the press release is attached hereto as Exhibit&#160;99.1 and is incorporated herein by reference.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9.01 &#160;&#160;&#160;&#160;Financial Statements and Exhibits  </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:14%;"></td><td style="width:86%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Separation Agreement, dated as of January 31, 2017, by and between Biogen Inc. and Bioverativ Inc.*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Press Release of Biogen Inc. dated February 1, 2017 </font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">*  Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K.  Biogen hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Signatures</font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:264px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Biogen Inc.</font></div><div style="line-height:120%;text-align:left;padding-left:264px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">By:</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;__/s/ Steven N. Avruch_________</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Steven N. Avruch</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Chief Corporation Counsel and Assistant Secretary</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Date: February 2, 2017</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT INDEX  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:14%;"></td><td style="width:86%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Separation Agreement, dated as of January 31, 2017, by and between Biogen Inc. and Bioverativ Inc.*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Press Release of Biogen Inc. dated February 1, 2017</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">*  Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K.  Biogen hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ex21_separationxagreement.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3408EDC39CFB928AA3FBFB4F416514B2"></a></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SEPARATION AGREEMENT</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">by and between</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BIOGEN INC.</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">and</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BIOVERATIV INC.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;<br>Dated as of January 31, 2017</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s877591A6D38A16218893FB4F41987088"></a></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Page</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s16D7BFB001F4573B7A28FB4F41E18067"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Article I</font></a><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;"><br>DEFINITIONS AND INTERPRETATION</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sB813D551DEA0F1BA5FB8FB4F42036DA7"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 1.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;2</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s3E11FF3C319DCA81657BFB4F4236E9C2"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 1.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">References; Interpretation</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;15</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s2F1190215CCC3F53AD29FB4F425FD32D"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Article II</font></a><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;"><br>THE SEPARATION</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s869C00B5F7FEC76D5AD3FB4F4291C610"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 2.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;16</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sA440AE8220B738B58171FB4F42A9510C"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 2.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Restructuring: Transfer of Assets; Assumption of Liabilities</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;16</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s37AAE7E950FE3361BD94FB4F42DC03EC"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 2.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Treatment of Shared Contracts</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;18</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sF776F193D6F9C8BB44BAFB4F42FDBE6B"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 2.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Intercompany Accounts</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;19</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s04D823D504131BA6B39EFB4F432F88FF"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 2.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Limitation of Liability</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;19</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sD333B6B4433D63BCCDF4FB4F4359AE79"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 2.6</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Transfers Not Effected at or Prior to the Distribution Effective Time; Transfers Deemed Effective as of the Distribution Effective Time</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;20</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sCDE9D872E28F817E240CFB4F438B93E6"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 2.7</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Further Assurances</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;22</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s491ADA38B9B6C8DDBC27FB4F43A46392"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 2.8</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Novation of Biogen Retained Liabilities; Indemnification</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;23</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">i</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s82EAC423AE3B9A7299BCFB4F43D66BAB"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 2.9</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Novation of Bioverativ Liabilities; Indemnification</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;24</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s189197A41E5875E74873FB4F43F72689"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 2.10</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Disclaimer of Representations and Warranties</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;25</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s72517E23587402304B99FB4F442970A9"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 2.11</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Cash Management</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;26</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s9C45FB271B3F822C2F5AFB4F445317F2"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Article III</font></a><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;"><br>CERTAIN ACTIONS AT OR PRIOR TO THE DISTRIBUTION</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s401405E1AD4E554CE6FCFB4F4485EDA3"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 3.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Transaction Agreements</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;26</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s5C75F58315EA6C45B81DFB4F449D56EF"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Article IV</font></a><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;"><br>THE DISTRIBUTION</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s1AD0C1038B76ED04D971FB4F44D0FAAA"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 4.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Stock Dividend; Distribution</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;26</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sCBE12DFF001F817E7A25FB4F44F12E3E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 4.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Fractional Shares</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;27</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sC619F2EAE7594E5935CEFB4F4523FE19"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 4.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Actions in Connection with the Distribution</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;27</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s155EEAD1FD384D6A261CFB4F454DFB87"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 4.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Sole Discretion of Biogen</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;28</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sA48FCE9F51DB5F2B32A8FB4F457FE95E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 4.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Conditions to Distribution</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;28</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s68B1F07AC51E20899A77FB4F459892D9"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Article V</font></a><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;"><br>CERTAIN COVENANTS</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sF3DA6477A7306AB62D55FB4F45CA0E3E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 5.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Non-Solicit; Non-Hire</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;29</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ii</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sC5A4DD972E0CDADF9E3BFB4F45EA4B5E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 5.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Certain Restrictions</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;30</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s7EE9BCE9266336CE1472FB4F461DCD42"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 5.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">No Right to Use Regulatory Information</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;31</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sD5A660CF3FEBD88F0B3AFB4F4647CD5F"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 5.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Use of Retained Names and Marks</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;32</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s7529497EB1B89D337D16FB4F46797E89"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Article VI</font></a><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;"><br>INDEMNIFICATION</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sC9CB8D24CED40D466FBDFB4F46928399"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 6.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Release of Pre-Distribution Claims</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;34</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s259712C776BE38BD519DFB4F46C408F1"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 6.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Indemnification by Biogen</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;37</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sDBF50AE8D58E7C6E5A3BFB4F46E513E4"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 6.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Indemnification by Bioverativ</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;37</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sA269EFE702DCDA6C1344FB4F4717724A"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 6.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Procedures for Indemnification</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;37</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s36E7EAF5F0DC85A7F8A5FB4F47388338"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 6.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Indemnification Obligations Net of Insurance Proceeds and Other Amounts</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;40</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s6E1BB24E8A6C6B6A1804FB4F4775EC7D"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 6.6</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Contribution</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;41</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sB32DBCB966FE5AE64F38FB4F478E95B1"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 6.7</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Additional Matters; Survival of Indemnities</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;41</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s992F57F622489DFBC309FB4F47BD8CB4"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Article VII</font></a><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;"><br>PRESERVATION OF RECORDS; ACCESS TO INFORMATION; CONFIDENTIALITY; PRIVILEGE</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s5D9D2643CC58737CE2F3FB4F47DEC968"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 7.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Preservation of Information</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;42</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">iii</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s6004DEDB667B2CCE4CB4FB4F4811F4C3"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 7.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Financial Statements and Accounting</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;43</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s95E722E7EBB0FE863E0AFB4F483C8FA9"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 7.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Provision of Information</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;43</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s3012CAA63DDDC8FE9202FB4F486ED7DA"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 7.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Witness Services; Cooperation</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;45</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sF34B73FD4282C0196700FB4F4887FAB6"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 7.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Reimbursement; Other Matters</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;45</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sFCDA82E5F5FBCE78DE21FB4F48B9088A"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 7.6</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Confidentiality</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;45</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sD170909BFBF1D53A66B1FB4F48DA465F"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 7.7</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Privilege Matters</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;47</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s6C16E7665CB9BB2A52F3FB4F490B6BB9"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 7.8</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Ownership of Information</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;50</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sC86D7C52F316247B7708FB4F4935A485"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 7.9</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Other Agreements</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;50</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s21403D3FEDB9641C0647FB4F496900FB"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Article VIII</font></a><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;"><br>DISPUTE RESOLUTION</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s916B631389B085B105EAFB4F4981D57E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 8.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Negotiation.</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;50</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sDAF044E9036327187415FB4F49B2EA63"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 8.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Continuity of Service and Performance</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;51</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sBF5E10B47C312688C637FB4F49D4F2E7"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Article IX</font></a><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;"><br>INSURANCE MATTERS</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sD6E5DA506247FC11028BFB4F4A05F688"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 9.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Rights to Biogen Policies</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;51</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sF3DAFB5BEABB30BB0F4FFB4F4A2FE671"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 9.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Claims</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;52</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">iv</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sC44DD52FB126BFA454C7FB4F4A61F489"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Article X</font></a><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;"><br>MISCELLANEOUS</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s099D105FFD980A34AEADFB4F4A7A5CD0"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Complete Agreement; Construction</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;52</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s985DD00D63638DB1089BFB4F4AAE9EAA"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Transaction Agreements</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;53</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s93C8E52192C691778D1CFB4F4ACDED23"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;53</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sFEF990CC9845DCE3D35BFB4F4AFF27EF"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Survival of Agreements</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;53</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sE72803DDF82617CBA201FB4F4B29BB50"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Fees, Costs and Expenses</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;53</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sCCB143C70FE1C0E1499FFB4F4B5D4769"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.6</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;54</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s89D263F00AAD24A593BCFB4F4B7657E9"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.7</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Waivers</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;54</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sDAB4910E30185EBB5E63FB4F4BA73732"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.8</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Assignment</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;54</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s1904166F48E659863B53FB4F4BC8CC9E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.9</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Successors and Assigns</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;54</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s1C7E4C29FE6AA2EFA550FB4F4BF9FECA"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.10</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Termination and Amendment</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;55</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s457334C7D6DF86AEB752FB4F4C23DB84"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.11</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Payment Terms</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;55</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sE49935B6A5024FB12361FB4F4C57A478"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.12</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Specific Performance</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;55</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s7F4477445664020F0390FB4F4C6DF3D7"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.13</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Subsidiaries</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;56</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">v</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sAC13915EA9A8F187B252FB4F4CA086CA"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.14</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Third Party Beneficiaries</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;56</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sF93FC4679ED47154543FFB4F4CC12A85"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.15</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Titles and Headings</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;56</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sF3CFB2F6E64DE15EE52CFB4F4CF35A0E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.16</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Exhibits and Schedules</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;56</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sE9ED9292F01601C2CE6FFB4F4D1D1541"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.17</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;56</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s654C734C26DD8D2A5367FB4F4D4FD5C0"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.18</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Consent to Jurisdiction.</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;56</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s87D50A3BCA4F81C67A1AFB4F4D6837E4"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.19</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Waiver of Jury Trial</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;57</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s63D5830F37404CEB4A04FB4F4D9C837C"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.20</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;57</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sD85066B48DD247085A41FB4F4DBBEA36"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.21</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Public Announcements</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;57</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sA406A453DEE60B13595DFB4F4DED1D53"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.22</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Interpretation</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;58</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s6250CA36A487200873F5FB4F4E176606"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.23</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">No Duplication; No Double Recovery</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;58</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sE70517B955CEF3E7C37BFB4F4E49D45F"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.24</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">No Waiver</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;58</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sA2DF31FBC3CEE8AF28F4FB4F4E621E24"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Section 10.25</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">No Admission of Liability</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;58</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">List of Exhibits</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit A&#160;&#160;&#160;&#160;Employee Matters Agreement</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B&#160;&#160;&#160;&#160;IP License Agreement</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit C&#160;&#160;&#160;&#160;Manufacturing and Supply Agreement</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit D&#160;&#160;&#160;&#160;Tax Matters Agreement</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit E&#160;&#160;&#160;&#160;Transition Services Agreement</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">vi</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">List of Schedules</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.75213675213675%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:41%;"></td><td style="width:59%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(12)(ii)(1)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Registered Bioverativ Intellectual Property</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(12)(ii)(2)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Other Bioverativ Intellectual Property</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(12)(vii)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Contracts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(12)(xiii)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Other Bioverativ Assets</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(12)(xiv)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Real Property</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(12)(xv)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Tangible/Fixed Assets</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(14)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Description of Bioverativ Discovery and Research and Development Projects</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(19)(vii)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Other Bioverativ Liabilities</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(19)(ix)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Actions</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(20)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Products</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(35)(i)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Excluded Manufacturing Related Assets</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(35)(ii)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Excluded Intellectual Property</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(35)(iii)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Excluded Contracts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(36)(i)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Excluded Liabilities</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(36)(ii)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Biogen Distribution Disclosure Document Liabilities</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 2.3(a)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Shared Contracts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 2.4</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Settlement of Intercompany Accounts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 2.5</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Contracts Surviving Separation</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">vii</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Index of Defined Terms</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Defined Term</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:16px;text-indent:622px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Action&#160;&#160;&#160;&#160;1.1(1)</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Affiliate</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(2)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Agreement</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Preamble</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Ancillary Agreements</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(3)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Assets</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(4)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Assume</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.2(b)(iii)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Biogen</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Preamble</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Biogen Claim</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.3</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Biogen Common Stock</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(5)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Biogen Designees</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(6)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Biogen Group</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(7)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Biogen Indemnitees</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(8)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Biogen Released Liabilities</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1(a)(i)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Biogen Retained Assets</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(9)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Biogen Retained Business</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(10)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Biogen Retained Liabilities</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(11)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Bioverativ</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Preamble</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Assets</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(12)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Balance Sheet</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(13)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Business</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(14)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Claim</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Common Stock</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(15)</font></div></td></tr></table><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">viii</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Designees</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(16)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Group</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(17)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Indemnitees</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(18)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Liabilities</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(19)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Records</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(12)(xii)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Released Liabilities</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1(a)(ii)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Board</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Recitals</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Business Day</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(21)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Claiming Party</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.4(b)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Commission</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(22)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Confidential Information</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(23)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Consents</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(24)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Contract</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(25)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Conveyancing and Assumption Instruments</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(26)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Copyrights</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(48)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Delaware Courts</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.18</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Direct Claim</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.4(b)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Dispute Notice</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.1</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Disputes</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.1</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Distribution</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Recitals</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Distribution Agent</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(27)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Distribution Date</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(28)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Distribution Disclosure Documents</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(29)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Distribution Effective Time</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(30)</font></div></td></tr></table><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ix</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Distribution Ratio</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(30)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">DMF Business</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(10)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Employee Matters Agreement</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(33)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Exchange Act</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(34)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Excluded Assets</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(34)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Excluded Liabilities</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(36)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Field of MS</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(10)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Field of Non-Malignant Hematology</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(10)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Final Determination</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(39)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Form 10</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(40)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Governmental Entity</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(41)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Group</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(42)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Indemnifiable Losses</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(43)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Indemnifying Party</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(44)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Indemnitee</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(45)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Indemnity Payment</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.5(a)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Information Statement</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(46)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Insurance Proceeds</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(47)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Intellectual Property</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(48)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Intercompany Account</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(49)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Internal Reorganization</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(50)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">IP License Agreement</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(51)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Know-How</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(48)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Law</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(52)</font></div></td></tr></table><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">x</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Liabilities</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(53)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Manufacturing and Supply Agreement</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(76)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">NASDAQ</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(55)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Negotiation Period</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.1</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Parties</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Preamble</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Party</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Preamble</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Patents</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(48)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Person</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(56)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Policies</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(57)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Prime Rate</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(58)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Privilege</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(58)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Privileged Information</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.17(b)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Products</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(20)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Record Date</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(60)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Registered</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(61)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Regulatory Authorization Date</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(61)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Representatives</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(61)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Securities Act</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(64)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Security Interest</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(65)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Separation</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Recitals</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Shared Contract</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(64)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Shared Privileged Information</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.17(b)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Subsidiary</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(67)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Tax</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(68)</font></div></td></tr></table><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">xi</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Tax Contest</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(69)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Tax Matters Agreement</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(70)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Tax Opinion</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.5(c)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Tax Returns</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(71)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Taxing Authority</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(72)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Third Party</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(73)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Third Party Agreements</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(74)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Third Party Claim</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.4(b)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Third Party Proceeds</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.5(a)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Trademarks</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(48)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Transaction Agreement</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(76)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Transfer</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.2(b)(i)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:16px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">Transition Services Agreement</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1(76)</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">xii</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sA2D685E83B9F6F74D072FB4F41D45057"></a></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SEPARATION AGREEMENT</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This SEPARATION AGREEMENT (this &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), dated as of January 31, 2017, is entered into by and between Biogen Inc. (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Biogen</font><font style="font-family:inherit;font-size:12pt;">&#8221;), a Delaware corporation, and Bioverativ Inc. (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bioverativ</font><font style="font-family:inherit;font-size:12pt;">&#8221;), a Delaware corporation and a wholly owned subsidiary of Biogen. &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Parties</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Biogen or Bioverativ, individually or collectively, as the case may be.  Each capitalized term used and not elsewhere defined herein has the meaning set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 1.1</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">W I T N E S S E T H:</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Biogen, acting together with its Subsidiaries, currently conducts the Biogen Retained Business and the Bioverativ Business;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, the Board of Directors of Biogen (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Board</font><font style="font-family:inherit;font-size:12pt;">&#8221;) has determined that it is appropriate, desirable and in the best interests of Biogen and its stockholders to separate Biogen into two separate, publicly traded companies, one for each of (i) the Biogen Retained Business, which shall be owned and conducted, directly or indirectly, by Biogen and its Subsidiaries and (ii) the Bioverativ Business, which shall be owned and conducted, directly or indirectly, by Bioverativ and its Subsidiaries (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Separation</font><font style="font-family:inherit;font-size:12pt;">&#8221;);</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, as part of and to implement the Separation, Biogen shall cause the Distribution Agent to issue pro rata to the Record Holders pursuant to the Distribution Ratio, all of the issued and outstanding shares of Bioverativ Common Stock (such issuance, the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Distribution</font><font style="font-family:inherit;font-size:12pt;">&#8221;) on the terms and conditions set forth in this Agreement;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, it is appropriate and desirable to set forth the principal corporate transactions required to effect the Separation and certain other agreements relating to the relationship of Biogen and Bioverativ and their respective Subsidiaries following the Distribution;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, (i) the Board has (x) determined that the Separation and the other transactions contemplated by this Agreement and the Ancillary Agreements (as defined below) have a valid business purpose, are in furtherance of and consistent with its business strategy and are in the best interests of Biogen and its stockholders and (y) approved this Agreement and each of the Ancillary Agreements and (ii) the board of directors of Bioverativ has approved this Agreement and each of the Ancillary Agreements to which Bioverativ is a party; </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, it is the intention of the Parties that the Separation will qualify as a transaction that is tax-free for U.S. federal income tax purposes under Section 355 and Section 368(a)(1)(D) of the Internal Revenue Code of 1986; and </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, this Agreement is intended to be a &#8220;plan of reorganization&#8221; within the meaning of Treas. Reg. Section 1.368-2(g);</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW, THEREFORE, in consideration of the foregoing and the mutual agreements, provisions and covenants contained in this Agreement, the Parties hereby agree as follows:</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s16D7BFB001F4573B7A28FB4F41E18067"></a></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-left:0px;padding-bottom:16px;padding-top:16px;text-align:center;text-indent:0px;"><font style="padding-bottom:16px;padding-top:16px;text-align:center;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:0px;">Article I</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;"><br>DEFINITIONS AND INTERPRETATION</font></div><div><a name="sB813D551DEA0F1BA5FB8FB4F42036DA7"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 1.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:12pt;">. As used in this Agreement, the following terms shall have the following meanings:</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Action</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any demand, action, claim, suit, countersuit, arbitration, inquiry, subpoena, case, litigation, proceeding or investigation (whether civil, criminal, administrative or investigative) by or before any court or grand jury, any Governmental Entity or any arbitration or mediation tribunal.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Affiliate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, when used with respect to a specified Person and at a point in, or with respect to a period of, time, a Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such specified Person at such point in or during such period of time.  For the purposes of this definition, &#8220;control&#8221;, when used with respect to any specified Person means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities or other interests, by Contract or otherwise.  It is expressly agreed that no Party or member of its Group shall be deemed to be an Affiliate of the other Party or a member of such other Party&#8217;s Group solely by reason of having common stockholders or one or more directors in common or by reason of having been under common control of Biogen prior to the Distribution Effective Time.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Ancillary Agreements</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Transaction Agreements other than this Agreement, all Conveyancing and Assumption Instruments and any and all other agreements entered into by the Parties or members of their respective Groups (but as to which no Third Party is a party) in connection with the Separation or the other transactions contemplated by the Transaction Agreements.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assets</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all rights, title and ownership interests in and to all rights, properties, claims, Contracts, businesses, or assets (including goodwill), wherever located (including in the possession of vendors or other third parties or elsewhere), of every kind, character and description, whether real, personal or mixed, tangible or intangible, whether accrued, contingent or otherwise, in each case, whether or not recorded or reflected on the books and records or financial statements of any Person.  Except as otherwise specifically set forth herein or in the Tax Matters Agreement, the rights and obligations of the Parties with respect to Taxes shall be governed by the Tax Matters Agreement and, therefore, Taxes (including any Tax items, attributes or rights to </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">receive any Tax Refunds (as defined in the Tax Matters Agreement)) shall not be treated as Assets governed by this Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(5)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Biogen Common Stock</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the common stock of Biogen, par value $0.0005 per share.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(6)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Biogen Designees</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean any and all entities (including corporations, general or limited partnerships, trusts, joint ventures, unincorporated organizations, limited liability entities or other entities) designated by Biogen and that will be members of the Biogen Group as of immediately prior to the Distribution Effective Time.  For clarity, members of the Biogen Group party to any Conveyancing and Assumption Instrument shall be a Biogen Designee for purposes of this Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(7)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Biogen Group</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) prior to the Distribution Effective Time, Biogen and each entity that will be a Subsidiary of Biogen immediately following the Distribution Effective Time and (b) from and after the Distribution Effective Time, Biogen and each entity that is a Subsidiary of Biogen.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(8)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Biogen Indemnitees</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the members of the Biogen Group and their respective past, present and future directors, officers, employees and agents, in each case in their respective capacities as such, and each of the heirs, executors, administrators, successors and assigns of any of the foregoing.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(9)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Biogen Retained Assets</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (i) any and all Assets of Biogen or any of its Subsidiaries that are not Bioverativ Assets and, after the Distribution Effective Time, any and all Assets that are acquired or otherwise become Assets of any member of the Biogen Group and (ii) any Assets that are held by the Bioverativ Group or the Biogen Group immediately prior to the Distribution Effective Time not exclusively related to the Bioverativ Business that were inadvertently omitted or assigned that, had the Parties given specific consideration to such Assets as of the date of this Agreement, would have otherwise been classified as a Biogen Retained Asset based on the principles set forth in this Section 1.1(9); </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, that no Asset shall be a Biogen Retained Asset solely as a result of this clause (ii) unless a claim with respect thereto is made by Biogen on or prior to the date that is fifteen (15) months after the Distribution Date.  For clarity, Biogen Retained Assets shall include all Excluded Assets.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(10)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Biogen Retained Business</font><font style="font-family:inherit;font-size:12pt;">&#8221; means those businesses, operations and activities of Biogen or any of its Subsidiaries (whether or not such businesses, operations or activities are or have been terminated, divested or discontinued) other than the Bioverativ Business and, after the Distribution Effective Time, those entities or businesses acquired or established by or for any member of the Biogen Group.</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(11)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Biogen Retained Liabilities</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (i) all Liabilities of Biogen or any of its Subsidiaries that are not Bioverativ Liabilities, and, after the Distribution Effective Time, all Liabilities of each member of the Biogen Group and (ii) any and all other Liabilities of Biogen or any of its Subsidiaries immediately prior to the Distribution Effective Time that were inadvertently omitted or assigned that, had the Parties given specific consideration to such Liabilities as of the date of this Agreement, would have otherwise been classified as a Biogen Retained Liability based on the principles set forth in this Section 1.1(11); </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, that no Liability shall be a Biogen Retained Liability solely as a result of this clause (ii) unless a claim with respect thereto is made by Biogen or Bioverativ on or prior to the date that is fifteen (15) months after the Distribution Date.  For clarity, Biogen Retained Liabilities shall include all Excluded Liabilities.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(12)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bioverativ Assets</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the following, but in each case excluding the Excluded Assets:</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">all interests in the capital stock of, or any other equity interests in, the members of the Bioverativ Group held, directly or indirectly, by Biogen immediately prior to the Distribution Effective Time (other than the capital stock of Bioverativ);</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">all Intellectual Property that is exclusively related to the Bioverativ Business, including the Registered Intellectual Property identified on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(12)(ii)(1)</font><font style="font-family:inherit;font-size:12pt;">&#32;and all Intellectual Property identified on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(12)(ii)(2)</font><font style="font-family:inherit;font-size:12pt;">;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">any and all Assets that are expressly allocated by this Agreement or any Ancillary Agreement (or the Schedules hereto or thereto) as Assets which have been or are to be retained by, or Transferred to, any member of the Bioverativ Group, including any and all cash and cash equivalents expressly allocated to Bioverativ pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.11</font><font style="font-family:inherit;font-size:12pt;">;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">any and all Assets reflected on the Bioverativ Balance Sheet (including accounts receivable outstanding as of the Distribution Date but excluding cash and cash equivalents, the allocation of which shall be governed by </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.11</font><font style="font-family:inherit;font-size:12pt;">) or the accounting records supporting such balance sheet, subject to any dispositions of any of such Assets subsequent to the date of the Bioverativ Balance Sheet;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">any and all Assets acquired by or for any member of the Bioverativ Group subsequent to the date of the Bioverativ Balance Sheet which, had they been so acquired on or before such date and owned as of such date, would have been reflected on the Bioverativ Balance Sheet if prepared on a consistent basis, </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">subject to any dispositions of any of such Assets subsequent to the date of the Bioverativ Balance Sheet;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">all rights and claims of either Party or any of its Subsidiaries as of the Distribution Effective Time to the Bioverativ Products, including all rights and claims of either Party or any of its Subsidiaries as of the Distribution Effective Time to all clinical study data, reports and analyses, product registrations and applications and marketing registrations and applications (which shall include all United States Food and Drug Administration and other similar regulatory approvals and licenses related to, and all related applications and other information submitted for the purposes of or prepared in connection with obtaining the approval for, a Bioverativ Product) to the extent related to the Bioverativ Products;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">all Contracts to which either Party or any member of its Group is a party or by which it or any member of its Group or any of their respective Assets is bound, in each case, as of immediately prior to the Distribution Effective Time exclusively related to the Bioverativ Business and any rights or claims arising thereunder, including the Contracts listed on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(12)(vii)</font><font style="font-family:inherit;font-size:12pt;">;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(viii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the portion of any Shared Contract that relates to the Bioverativ Business;  </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ix)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">all transferable licenses, permits, registrations, approvals and authorizations of either Party or any of the members of its Group as of immediately prior to the Distribution Effective Time which have been issued by any Governmental Entity and which relate exclusively to, or are used exclusively in, the Bioverativ Business or the Bioverativ Assets, and any rights or claims arising thereunder; </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(x)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">any and all Bioverativ Product Drug Product (as defined in the Manufacturing and Supply Agreement) and Finished Goods (as defined in the Manufacturing and Supply Agreement) inventory held by or for the account of Biogen or any of its Subsidiaries immediately prior to the Distribution Effective Time;</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt"> </sup>&#160;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">all rights, claims, credits, causes of action or rights of set-off against Persons other than members of the Biogen Group relating exclusively to the Bioverativ Business or the Bioverativ Assets, including unliquidated rights under Third Party manufacturers&#8217; and vendors&#8217; warranties;</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">to the extent in the possession of any member of the Biogen Group or the Bioverativ Group immediately prior to the Distribution Effective Time (and other than Intellectual Property) (A) all business records to the extent exclusively related to the Bioverativ Assets or Bioverativ Liabilities, including the company minute books and related equity or membership records of the members of the Bioverativ Group, information and records used to demonstrate compliance with applicable Law and any other compliance records related to the Bioverativ Business; (B) all of the separate financial and property Tax records of the members of the Bioverativ Group that do not form part of the general ledger of any member of the Biogen Group; and (C) all other books, records, ledgers, files, documents, correspondence, lists, plats, drawings, photographs, product literature, equipment test records, advertising and promotional materials, distribution lists, customer lists, supplier lists, studies, reports, operating, production and other manuals, manufacturing and quality control records and procedures, research and development files, accounting and business books, records, files, documentation and materials, in all cases whether in paper, microfilm, microfiche, computer tape or disc, magnetic tape or any other form, to the extent exclusively related to the Bioverativ Business (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bioverativ Records</font><font style="font-family:inherit;font-size:12pt;">&#8221;); </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that: (x) Biogen shall be entitled to retain a copy of any and all Bioverativ Records; (y) Biogen shall be entitled to retain any materials in clauses (A) and (C) that are not reasonably practicable to identify and extract subject to the right of access pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.3</font><font style="font-family:inherit;font-size:12pt;">; and (z) Biogen shall be entitled to redact any portion of the Bioverativ Records to the extent related to any matter other than the Bioverativ Business; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that such retained materials shall be deemed Confidential Information of Bioverativ and subject to the provisions of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.6</font><font style="font-family:inherit;font-size:12pt;">;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xiii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Assets listed or described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(12)(xiii)</font><font style="font-family:inherit;font-size:12pt;">&#32;(which for the avoidance of doubt is not a comprehensive listing of all Bioverativ Assets and is not intended to limit other clauses of this definition of &#8220;Bioverativ Assets&#8221;); </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xiv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the facilities and other real property listed or described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(12)(xiv)</font><font style="font-family:inherit;font-size:12pt;">;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">all tangible equipment (including information technology, equipment and machinery), infrastructure, wires, supplies and other tangible property that is owned by, leased to or licensed to Biogen or any of its Subsidiaries immediately prior to the Distribution Effective Time and exclusively related to the Bioverativ Business, including the information technology Assets listed or described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(12)(xv)</font><font style="font-family:inherit;font-size:12pt;">; </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xvi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">any and all other Assets that relate exclusively to or are used exclusively in the Bioverativ Business or exclusively related to a Bioverativ Asset that are held by the Bioverativ Group or the Biogen Group immediately prior to the Distribution Effective Time; and </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xvii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">any and all other Assets that were inadvertently omitted or assigned that, had the Parties given specific consideration to such Assets as of the date of this Agreement, would have otherwise been classified as Bioverativ Assets based on the principles set forth in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 1.1(12)</font><font style="font-family:inherit;font-size:12pt;">; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, that no Asset shall be a Bioverativ Asset solely as a result of this clause (xvii) unless a claim with respect thereto is made by Bioverativ on or prior to the date that is fifteen (15) months after the Distribution Date.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding the foregoing or anything to the contrary herein, &#8220;Bioverativ Asset&#8221; shall not include any rights or interests in or to any Intellectual Property except to the extent set forth in clause </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">(ii)</font><font style="font-family:inherit;font-size:12pt;">&#32;of this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 1.1(12)</font><font style="font-family:inherit;font-size:12pt;">&#32;(including the Schedules referred to in Section 1.1(12)(ii)).</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(13)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bioverativ Balance Sheet</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the pro forma balance sheet of the Bioverativ Group, including the notes thereto, as of September 30, 2016, as included in the Information Statement.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(14)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bioverativ Business</font><font style="font-family:inherit;font-size:12pt;">&#8221; means: (i) the business, operations and activities conducted at any time prior to the Distribution Effective Time by either Party or any of its Subsidiaries to the extent relating to, arising out of or resulting from the Bioverativ Products (including the discovery, research, development, importation, exportation, marketing, distribution, promotion and sale of such Bioverativ Products worldwide); and (ii) the business, operations and activities conducted at any time prior to the Distribution Effective Time by or on behalf of either Party or any of its Subsidiaries to the extent related to the discovery, research and development projects listed and described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(14)</font><font style="font-family:inherit;font-size:12pt;">, including the operations and activities of any member of the Bioverativ Group conducted prior to the Distribution Effective Time relating to the foregoing.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(15)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bioverativ Common Stock</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the common stock of Bioverativ, par value $0.001 per share.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(16)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bioverativ Designees</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all entities (including corporations, general or limited partnerships, trusts, joint ventures, unincorporated organizations, limited liability entities or other entities) designated by Bioverativ and that </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">will be members of the Bioverativ Group as of immediately prior to the Distribution Effective Time.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(17)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bioverativ Group</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) Bioverativ and each entity that is a Subsidiary of Bioverativ or will be a Subsidiary of Bioverativ immediately following the Distribution Effective Time and (b) on and after the Distribution Effective Time, Bioverativ and each entity that is a Subsidiary of Bioverativ.  For clarity, members of the Bioverativ Group party to any Conveyancing and Assumption Instrument shall be a Bioverativ Designee for purposes of this Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(18)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bioverativ Indemnitees</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the members of the Bioverativ Group and their respective past, present and future directors, officers, employees and agents, in each case in their respective capacities as such, each of the heirs, executors, administrators, successors and assigns of any of the foregoing.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(19)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bioverativ Liabilities</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, without duplication, but in each case excluding the Excluded Liabilities:</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">any and all Liabilities to the extent relating to, arising out of or resulting from the conduct of the Bioverativ Business, as conducted at any time, including prior to, at or after the Distribution Effective Time (including any Liability to the extent relating to, arising out of or resulting from any act or failure to act by any director, officer, employee, agent or representative (whether or not such act or failure to act is or was within such Person&#8217;s authority) of the Bioverativ Group or the Biogen Group);</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">any and all Liabilities to the extent relating to, arising out of or resulting from the conduct of any business by any member of the Bioverativ Group at any time after the Distribution Effective Time (including any Liability to the extent relating to, arising out of or resulting from any act or failure to act by any director, officer, employee, agent or representative (whether or not such act or failure to act is or was within such Person&#8217;s authority) of the Bioverativ Group);</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">any and all Liabilities to the extent relating to, arising out of or resulting from any Bioverativ Asset, whether arising before, on or after the Distribution Effective Time;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">any and all Liabilities that are expressly contemplated by this Agreement or any Ancillary Agreement (or the Schedules hereto or thereto) as Liabilities to be Assumed or retired or satisfied by any member of the Bioverativ Group; </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">any and all Liabilities reflected on the Bioverativ Balance Sheet or the accounting records supporting such balance sheet (including all outstanding accounts payable as of the Distribution Date) and any and all Liabilities incurred by or for Bioverativ or any member of the Bioverativ Group or Biogen Group subsequent to the date of the Bioverativ Balance Sheet which, had they been so incurred on or before such date, would have been reflected on the Bioverativ Balance Sheet if prepared on a consistent basis, subject to any discharge of any of such Liabilities subsequent to the date of the Bioverativ Balance Sheet; it being understood that (A) the Bioverativ Balance Sheet shall be used to determine the types of, and methodologies used to determine, those Liabilities that are included in the definition of Bioverativ Liabilities pursuant to this clause </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">(v)</font><font style="font-family:inherit;font-size:12pt;">; and (B) the amounts set forth on the Bioverativ Balance Sheet with respect to any Liabilities shall not be treated as minimum amounts or limitations on the amount of such Liabilities that are included in the definition of Bioverativ Liabilities pursuant to this clause </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">(v)</font><font style="font-family:inherit;font-size:12pt;">;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">any and all Liabilities to the extent relating to, arising out of or resulting from the manufacture of Bioverativ Products prior to the Distribution Effective Time by any member of the Bioverativ Group or the Biogen Group;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Liabilities listed or described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(19)(vii)</font><font style="font-family:inherit;font-size:12pt;">;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(viii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">any and all Liabilities relating to, arising out of or resulting from any untrue statement or alleged untrue statement of a material fact or omission or alleged omission to state a material fact required to be stated therein or necessary to make the statement therein not misleading, with respect to all information contained in the Distribution Disclosure Documents, except to the extent specifically enumerated in clause (ii) of the definition of &#8220;Excluded Liabilities&#8221;; </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ix)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">any and all Liabilities arising directly or indirectly from Actions to the extent relating to the Bioverativ Assets, the Bioverativ Business or any Bioverativ Liability, including in respect of any alleged tort, breach of Contract, violation or noncompliance with Law or any licenses, permits, registrations, approvals and authorizations, whether arising prior to, on or after the Distribution Date, including the Actions listed on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(19)(ix)</font><font style="font-family:inherit;font-size:12pt;">; </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(x)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">any and all other Liabilities that are held by the Bioverativ Group or the Biogen Group immediately prior to the Distribution Effective Time that were inadvertently omitted or assigned that, had the Parties given specific consideration to such Liabilities as of the date of this Agreement, would have </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">otherwise been classified as a Bioverativ Liability based on the principles set forth in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 1.1(19)</font><font style="font-family:inherit;font-size:12pt;">; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, that no Liability shall be a Bioverativ Liability solely as a result of this clause </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">(x)</font><font style="font-family:inherit;font-size:12pt;">&#32;unless a claim with respect thereto is made by Biogen or Bioverativ on or prior to the date that is fifteen (15) months after the Distribution Date.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(20)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bioverativ Products</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the products described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(20)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(21)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Business Day</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any day other than Saturday or Sunday and any other day on which commercial banking institutions located in New York, New York are required, or authorized by Law, to remain closed.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(22)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Commission</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(23)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Confidential Information</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Party, all confidential or proprietary information to the extent concerning: (i) such Party or any of its Subsidiaries, (ii) with respect to Bioverativ, the Bioverativ Business, any Bioverativ Assets or any Bioverativ Liabilities and (iii) with respect to Biogen, the Biogen Retained Business, any Biogen Retained Assets or any Biogen Retained Liabilities, in each case including any such information furnished pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VII</font><font style="font-family:inherit;font-size:12pt;">&#32;or otherwise pursuant to this Agreement or any Ancillary Agreement; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that &#8220;Confidential Information&#8221; shall not include any Information that is (i) in the public domain or known to the public through no fault of the receiving Party or any of its Subsidiaries, (ii) lawfully acquired after the Distribution Effective Time by the receiving Party or any of its Subsidiaries from Third Parties not known to be subject to confidentiality obligations with respect to such information or (iii) independently developed by the receiving Party or any of its Subsidiaries after the Distribution Effective Time without reference to any Confidential Information of the disclosing Party or any of its Subsidiaries.  For the avoidance of doubt, subject to the foregoing proviso, any information that Bioverativ receives from any Third Party Manufacturer (as defined in the Manufacturing and Supply Agreement) or other third party contractor retained by any member of the Biogen Group regarding its technology, products, business or objectives shall be deemed to be Confidential Information of Biogen, and any pricing or other information relating to the Drug Product  (as defined in the Manufacturing and Supply Agreement) or Finished Goods  (as defined in the Manufacturing and Supply Agreement) shall be deemed to be the Confidential Information of both Parties.</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(24)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Consents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any consents, waivers, notices, reports or other filings to be obtained from or made, including with respect to any Contract, or any registrations, licenses, permits, authorizations to be obtained from, or approvals from, or notification requirements to, any Third Parties, including any Governmental Entity.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(25)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Contract</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any agreement, contract, subcontract, obligation, binding understanding, note, indenture, instrument, option, lease, promise, arrangement, release, warranty, license, sublicense, insurance policy, benefit plan, purchase order or legally binding commitment or undertaking of any nature (whether written or oral and whether express or implied).</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(26)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Conveyancing and Assumption Instruments</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, collectively, the various Contracts (other than any Transaction Agreement) by and between or among any member(s) of the Biogen Group, on one hand, and any member(s) of the Bioverativ Group, on the other hand, including related local asset transfer agreements or intellectual property assignment agreements and other documents entered into prior to the Distribution Effective Time and to be entered into, in each case to effect the Transfer of Assets and the Assumption of Liabilities in the manner contemplated by the Transaction Agreements, in such form or forms as the applicable parties thereto agree.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(27)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Distribution Agent</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Computershare Trust Company, N.A.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(28)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Distribution Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the date, as shall be determined by the Board, on which the Distribution occurs.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(29)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Distribution Disclosure Documents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Form 10 and all exhibits thereto (including the Information Statement), any current reports on Form 8-K and the registration statement on Form S-8 related to securities to be offered under Bioverativ&#8217;s employee benefit plans, in each case as filed or furnished by Bioverativ with or to the Commission in connection with the Distribution and including any amendments or supplements thereto.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(30)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Distribution Effective Time</font><font style="font-family:inherit;font-size:12pt;">&#8221; means 12:01 a.m. on February 1, 2017, Eastern time, on the Distribution Date.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(31)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Distribution Ratio</font><font style="font-family:inherit;font-size:12pt;">&#8221; means one share of Bioverativ Common Stock for every two shares of Biogen Common Stock.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(32)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">DMF Business</font><font style="font-family:inherit;font-size:12pt;">&#8221; means discovering, researching, developing, importing, exporting, manufacturing, marketing, distributing, promoting or selling anywhere in the world any pharmaceutical product that contains dimethyl fumarate.</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(33)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employee Matters Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Employee Matters Agreement by and between Biogen and Bioverativ, in the form attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;A</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(34)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exchange Act</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Securities Exchange Act of 1934.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(35)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Excluded Assets</font><font style="font-family:inherit;font-size:12pt;">&#8221; means: (i) the manufacturing related Assets listed or described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(35)(i)</font><font style="font-family:inherit;font-size:12pt;">; (ii) the Intellectual Property listed or described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(35)(ii)</font><font style="font-family:inherit;font-size:12pt;">; (iii) the Contracts listed or described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(35)(iii)</font><font style="font-family:inherit;font-size:12pt;">; (iv) all cash and cash equivalents, except to the extent expressly allocated to the Bioverativ Group pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.11</font><font style="font-family:inherit;font-size:12pt;">; (v) any and all Bioverativ Product Drug Substance (as defined in the Manufacturing and Supply Agreement) inventory and other raw materials used in the manufacture of Bioverativ Product Drug Product (as defined in the Manufacturing and Supply Agreement) held by or for the account of Biogen or any of its Subsidiaries immediately prior to the Distribution Effective Time; (vi) subject to the rights of the Bioverativ Group pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article IX</font><font style="font-family:inherit;font-size:12pt;">, all Policies binders and claims and rights thereunder and all prepaid insurance premiums (other than any insurance policies acquired prior to the Distribution Effective Time directly by and in the name of Bioverativ or a member of the Bioverativ Group); (vii) any and all work papers of Biogen&#8217;s auditors and any other Tax records (including accounting records) of any Biogen Group member (which will be addressed in the Tax Matters Agreement); and (viii) any and all Assets that are expressly contemplated by this Agreement or any Ancillary Agreement (or the Schedules hereto or thereto) as Assets which have been or are to be retained by, or Transferred to, any member of the Biogen Group.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(36)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Excluded Liabilities</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (i) the Liabilities listed or described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(36)(i)</font><font style="font-family:inherit;font-size:12pt;">, (ii) with respect to all information contained in the Distribution Disclosure Documents, any and all Liabilities relating to, arising out of or resulting from any untrue statement or alleged untrue statement of a material fact or omission or alleged omission to state a material fact required to be stated therein or necessary to make the statement therein not misleading described in the sections of the Distribution Disclosure Documents referenced in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(36)(ii)</font><font style="font-family:inherit;font-size:12pt;">&#32;that is expressly related to the Biogen Group and not related to the Bioverativ Group or the Bioverativ Business and (iii) any and all Liabilities to the extent expressly contemplated by this Agreement or by any Ancillary Agreement (or the Schedules hereto or thereto) as Liabilities to be Assumed or discharged by any member of the Biogen Group.</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt"> </sup>&#160;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(37)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Field of Hemoglobinopathies</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the diagnosis, prevention, or treatment of any of the following indications: hemoglobinopathies, hemophilia, sickle </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">cell, thalassemia, anemias, myelodysplastic syndrome, myelofibrosis, agranulocytosis, Von Willebrand disease and Wiskott-Aldrich syndrome.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(38)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Field of MS</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the diagnosis, prevention, or treatment of multiple sclerosis.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(39)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Final Determination</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Tax Matters Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(40)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Form 10</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the registration statement on Form 10 (Registration No. 001-37859) filed by Bioverativ with the Commission under the Exchange Act in connection with the Distribution, including any amendment or supplement thereto.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(41)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governmental Entity</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any nation or government, any state, municipality or other political subdivision thereof and any entity, body, agency, commission, department, board, bureau or court, whether domestic, foreign, multinational, or supranational exercising executive, legislative, judicial, regulatory, self-regulatory or administrative functions of or pertaining to government and any executive official thereof.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(42)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Group</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) with respect to Biogen, the Biogen Group and (b) with respect to Bioverativ, the Bioverativ Group, as the context requires.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(43)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnifiable Losses</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all Liabilities, including damages, losses, deficiencies, obligations, penalties, judgments, settlements, claims, payments, fines and other costs and expenses of any and all Actions and demands, assessments, judgments, settlements and compromises relating thereto and the reasonable fees and expenses of attorneys&#8217;, accountants&#8217;, consultants&#8217; and other professionals&#8217; incurred in the investigation or defense thereof or the enforcement of rights hereunder.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(44)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnifying Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to any Direct Claim or Third Party Claim, the Party which is or may be required pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;to provide indemnification pursuant to such claim.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(45)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnitee</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to any Direct Claim or Third Party Claim, the Biogen Indemnitee or Bioverativ Indemnitee, as the case may be, that may be entitled to indemnification hereunder with respect to such claim.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(46)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Information Statement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Information Statement attached as Exhibit 99.1 to the Form 10, to be distributed or made available to the holders </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">of shares of Biogen Common Stock in connection with the Distribution, including any amendment or supplement thereto.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(47)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Insurance Proceeds</font><font style="font-family:inherit;font-size:12pt;">&#8221; means those monies (a) received by an insured from a Third Party insurance carrier or (b) paid by a Third Party insurance carrier on behalf of an insured, in either case net of any applicable deductible or retention.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(48)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Intellectual Property</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all intellectual property, whether registered or unregistered, of every kind and description throughout the world, including all U.S. and non-U.S.: (i) trademarks, trade dress, service marks, certification marks, logos, slogans, design rights, names, corporate names, trade names, Internet domain names, social media accounts and addresses and other similar designations of source or origin, together with the goodwill symbolized by any of the foregoing (collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Trademarks</font><font style="font-family:inherit;font-size:12pt;">&#8221;); (ii) patents and patent applications, and any and all related national or international counterparts thereto and utility models, including any divisionals, continuations, continuations-in-part, reissues, reexaminations, substitutions and extensions thereof (including supplementary protection certificates) (collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221;); (iii) copyrights and copyrightable subject matter, excluding Know-How</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">(collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Copyrights</font><font style="font-family:inherit;font-size:12pt;">&#8221;); (iv) rights in Software; (v) trade secrets, and all other confidential or proprietary information, know-how, clinical data, non-clinical data, pre-clinical data, in-vitro data, inventions, processes, formulae and methodologies, excluding Patents (collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Know-How</font><font style="font-family:inherit;font-size:12pt;">&#8221;); (vi) all applications and registrations for the foregoing; and (vii) all rights and remedies against past, present, and future infringement, misappropriation, or other violation thereof.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(49)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Intercompany Account</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any receivable, payable or loan between any member of the Biogen Group, on the one hand, and any member of the Bioverativ Group, on the other hand, except for any such receivable, payable or loan that arises pursuant to this Agreement or any Ancillary Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(50)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Internal Reorganization</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the allocation and transfer or assignment of Assets and Liabilities, including by means of the Conveyance and Assumption Instruments, resulting in (a) the Bioverativ Group owning and operating the Bioverativ Business, and (b) the Biogen Group continuing to own and operate the Biogen Retained Business, as described in the steps plan provided to Bioverativ by Biogen prior to the date hereof, as updated from time to time by Biogen at its sole discretion prior to the Distribution.</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(51)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">IP License Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Intellectual Property License Agreement by and between Biogen and Bioverativ, in the form attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(52)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Law</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any applicable U.S. or non-U.S. federal, national, supranational, state, provincial, local or similar statute, law, ordinance, regulation, rule, code, income tax treaty, order, requirement or rule of law (including common law) or other binding directives promulgated, issued, entered into or taken by any Governmental Entity.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(53)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Liabilities</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all indebtedness, liabilities, costs, expenses, interest and obligations, whether accrued or fixed, absolute or contingent, matured or unmatured, known or unknown, reserved or unreserved, or determined or determinable, including those arising under any Law, Action, or in connection with any dispute, whether asserted or unasserted, or order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Entity and those arising under any Contract or any fines, damages or equitable relief which may be imposed and including all costs and expenses related thereto.  Except as otherwise specifically set forth herein or in the Tax Matters Agreement, the rights and obligations of the Parties with respect to Taxes shall be governed by the Tax Matters Agreement and, therefore, Taxes shall not be treated as Liabilities governed by this Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(54)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Manufacturing and Supply Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Manufacturing and Supply Agreement by and between Biogen and Bioverativ, in the form attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit C</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(55)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">NASDAQ</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Nasdaq Stock Market LLC.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(56)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Person</font><font style="font-family:inherit;font-size:12pt;">&#8221; mean an individual, a general or limited partnership, a corporation, a trust, a joint venture, an unincorporated organization, a limited liability entity, any other entity and any Governmental Entity.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(57)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Policies</font><font style="font-family:inherit;font-size:12pt;">&#8221; means insurance policies and insurance contracts of any kind (other than life and benefits policies or contracts), including primary, excess and umbrella policies, commercial general liability policies, fiduciary liability, directors and officers liability, product liability, automobile, property and casualty, workers&#8217; compensation and employee dishonesty insurance policies and bonds, together with the rights, benefits and privileges thereunder.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(58)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Prime Rate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the &#8220;prime rate&#8221; as published in </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">The Wall Street Journal</font><font style="font-family:inherit;font-size:12pt;">, Eastern Edition.</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(59)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Privilege</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all privileges, immunities or other protections from disclosure which may be asserted under applicable Law, including attorney-client privilege, business strategy privilege, joint defense privilege, common interest privilege and protection under the work-product doctrine.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(60)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Record Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means January 17, 2017, as determined by the Board as the record date for determining the holders of record of Biogen Common Stock entitled to receive Bioverativ Common Stock in the Distribution.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(61)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Registered</font><font style="font-family:inherit;font-size:12pt;">&#8221; means issued by, registered or filed with, renewed by or the subject of a pending application before any Governmental Authority or Internet domain name registrar.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(62)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Regulatory Authorization Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the date of receipt by the Bioverativ Group of all of the US Required Regulatory Authorizations and the Canadian Required Regulatory Authorization, each as defined in the Transition Services Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(63)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Representatives</font><font style="font-family:inherit;font-size:12pt;">&#8221; means with respect to any Person, any of such Person&#8217;s directors, officers, employees, agents, consultants, advisors, accountants, attorneys or other representatives.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(64)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Securities Act</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Securities Act of 1933. </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(65)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Security Interest</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any mortgage, security interest, pledge, lien, charge, claim, option, right to acquire, voting or other restriction, right-of-entry, covenant, condition, easement, encroachment, restriction on transfer, or other encumbrance of any nature whatsoever, excluding restrictions on transfer under securities Laws.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(66)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Shared Contract</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Contracts listed or described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 2.3(a)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(67)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Subsidiary</font><font style="font-family:inherit;font-size:12pt;">&#8221; means with respect to any Person (i) a corporation, fifty percent (50%) or more of the voting or capital stock of which is, as of the time in question, directly or indirectly owned by such Person and (ii) any other Person in which such Person, directly or indirectly, owns fifty percent (50%) or more of the equity or economic interest thereof or has the power to elect or direct the election of fifty percent (50%) or more of the members of the governing body of such Person.</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">17</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(68)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tax</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Taxes</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Tax Matters Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(69)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tax Contest</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning as set forth in the Tax Matters Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(70)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tax Matters Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Tax Matters Agreement by and between Biogen and Bioverativ, in the form attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit D</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(71)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tax Returns</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Tax Matters Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(72)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Taxing Authority</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Tax Matters Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(73)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Person other than the Parties or any of their respective Subsidiaries.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(74)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third Party Agreements</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Contract between or among a Party (or any member of its Group) and any Third Party (it being understood that to the extent that the rights and obligations of the Parties and the members of their respective Groups under any such Contracts constitute Bioverativ Assets or Bioverativ Liabilities, or Biogen Retained Assets or Biogen Retained Liabilities, such Contracts shall be assigned or retained pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article II</font><font style="font-family:inherit;font-size:12pt;">).</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(75)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Transaction Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any of this Agreement, the Employee Matters Agreement, the IP License Agreement, the Manufacturing and Supply Agreement, the Tax Matters Agreement and the Transition Services Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(76)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Transition Services Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Transition Services Agreement by and between Biogen and Bioverativ, in the form attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit E</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div><a name="s3E11FF3C319DCA81657BFB4F4236E9C2"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 1.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">References; Interpretation</font><font style="font-family:inherit;font-size:12pt;">. References in this Agreement to any gender include references to all genders, and references to the singular include references to the plural and vice versa.  Unless the context otherwise requires, the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; when used in this Agreement shall be deemed to be followed by the phrase &#8220;without limitation&#8221;.  Unless the context otherwise requires, references in this Agreement to Articles, Sections, Exhibits and Schedules shall be deemed references to Articles and Sections of, and Exhibits and Schedules to, this Agreement.  Unless the context otherwise requires, the words &#8220;hereof&#8221;, &#8220;hereby&#8221; and &#8220;herein&#8221; and words of similar meaning when used in this Agreement </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">18</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">refer to this Agreement in its entirety and not to any particular Article, Section or provision of this Agreement.  The words &#8220;written request&#8221; when used in this Agreement shall include email.  Reference in this Agreement to any time shall be to Eastern time unless otherwise expressly provided herein.  Unless the context requires otherwise, references in this Agreement to &#8220;Biogen&#8221; shall also be deemed to refer to the applicable member of the Biogen Group, references to &#8220;Bioverativ&#8221; shall also be deemed to refer to the applicable member of the Bioverativ Group and, in connection therewith, any references to actions or omissions to be taken, or refrained from being taken, as the case may be, by Biogen or Bioverativ shall be deemed to require Biogen or Bioverativ, as the case may be, to cause the applicable members of the Biogen Group or the Bioverativ Group, respectively, to take, or refrain from taking, any such action.  The word &#8220;or&#8221; shall not be exclusive.  References to any &#8220;statute&#8221; or &#8220;regulation&#8221; are to such statute or regulation as amended, modified, supplemented or replaced from time to time (and, in the case of any statute, include any rules and regulations promulgated under such statute) and to any &#8220;section of any statute or regulation&#8221; include any successor to such section.  References to any Governmental Entity include any successor to such Governmental Entity, and references to any Affiliate include any successor to such Affiliate.  Whenever the last day for the exercise of any right or the discharge of any duty under this Agreement falls on other than a Business Day, the Party having such right or duty shall have until the next Business Day to exercise such right or discharge such duty.  Unless otherwise indicated, the word &#8220;day&#8221; shall be interpreted as a calendar day.</font></div><div><a name="s2F1190215CCC3F53AD29FB4F425FD32D"></a></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE II</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">THE SEPARATION</font></div><div><a name="s869C00B5F7FEC76D5AD3FB4F4291C610"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:12pt;">. Subject to the terms and conditions of this Agreement, the Parties shall use, and shall cause their respective Subsidiaries to use, commercially reasonable efforts to consummate the transactions contemplated hereby, a portion of which may have already been implemented prior to the date hereof, including the completion of the Internal Reorganization.</font></div><div><a name="sA440AE8220B738B58171FB4F42A9510C"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Restructuring: Transfer of Assets; Assumption of Liabilities</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Internal Reorganization</font><font style="font-family:inherit;font-size:12pt;">. Prior to the Distribution Effective Time, the Parties shall complete the Internal Reorganization, except for such steps (if any) as Biogen in its sole discretion shall have determined need not be completed or may be completed after the Distribution Effective Time; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that any such determination shall not limit the Parties' respective obligations under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.2(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">19</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Transfer of Assets and Assumption of Liabilities</font><font style="font-family:inherit;font-size:12pt;">.  Unless otherwise provided in this Agreement or in any Ancillary Agreement, on or prior to the Distribution Effective Time and to the extent not previously effected pursuant to the Internal Reorganization: </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Biogen shall, and shall cause the applicable members of the Biogen Group to, contribute, assign, transfer, convey and deliver (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Transfer</font><font style="font-family:inherit;font-size:12pt;">&#8221;) to Bioverativ, or the applicable Bioverativ Designees, and Bioverativ or such Bioverativ Designees shall accept from Biogen and the applicable members of the Biogen Group, all of Biogen&#8217;s and such Biogen Group member&#8217;s respective direct or indirect right, title and interest in and to all Bioverativ Assets held by Biogen or a member of the Biogen Group (it being understood that if any Bioverativ Asset shall be held by a Person all of the outstanding equity of which is included in the Bioverativ Assets to be Transferred pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.2(b)(i)</font><font style="font-family:inherit;font-size:12pt;">, such Bioverativ Asset may be considered to be so Transferred to Bioverativ or the applicable Bioverativ Designee as a result of the Transfer of all of the equity interests in such Person from Biogen or the applicable member(s) of the Biogen Group to Bioverativ or the applicable Bioverativ Designee); and</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Bioverativ shall, and shall cause the applicable members of the Bioverativ Group to, Transfer to Biogen or the applicable Biogen Designees, and Biogen or such Biogen Designees shall accept from Bioverativ and the applicable members of the Bioverativ Group, all of Bioverativ&#8217;s and such Bioverativ Group member&#8217;s respective direct or indirect right, title and interest in and to all Biogen Retained Assets held by Bioverativ or a member of the Bioverativ Group (it being understood that if any Biogen Retained Asset shall be held by a Person all of the outstanding equity of which is included in the Biogen Retained Assets to be Transferred pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.2(b)(ii)</font><font style="font-family:inherit;font-size:12pt;">, such Biogen Retained Asset may be considered to be so Transferred to Biogen or the applicable Biogen Designee as a result of the Transfer of all of the equity interests in such Person from Bioverativ or the applicable member(s) of the Bioverativ Group to Biogen or the applicable Biogen Designee). </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assumption of Liabilities</font><font style="font-family:inherit;font-size:12pt;">. (i) Biogen shall, or shall cause another member of the Biogen Group to, accept, assume (or, as applicable, retain) and perform, discharge and fulfill, in accordance with their respective terms (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assume</font><font style="font-family:inherit;font-size:12pt;">&#8221;; and  &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assumption</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall have the correlative meaning), all of the Biogen Retained Liabilities and (ii) Bioverativ shall, or shall cause another member of the Bioverativ Group to Assume all the Bioverativ Liabilities, in each case regardless of (A) when or where such Liabilities arose or arise, (B) where or against whom such Liabilities are asserted or determined, (C) whether such </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">20</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Liabilities arise from or are alleged to arise from negligence, gross negligence, recklessness, violation of law, willful misconduct, bad faith, fraud or misrepresentation by any member of the Biogen Group or the Bioverativ Group, as the case may be, or any of their past or present respective directors, officers, employees, or agents, (D) which entity is named in any action associated with any Liability and (E) whether the facts on which such Liabilities are based occurred prior to, on or after the date hereof.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Parties shall use their respective commercially reasonable efforts to obtain the Consents required to Transfer any Contracts, licenses, permits, authorizations and other Assets as contemplated by this Agreement.  Notwithstanding anything herein to the contrary, no Contract or other Asset shall be Transferred if it would violate applicable Law or, in the case of a Contract, the rights of any Third Party to such Contract; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, that </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.6</font><font style="font-family:inherit;font-size:12pt;">, to the extent provided therein, shall apply to such Asset or Contract.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">It is understood and agreed by the Parties that certain of the Transfers or Assumptions referenced in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.2(b)</font><font style="font-family:inherit;font-size:12pt;">&#32;have heretofore occurred and, as a result, no additional Transfers or Assumptions by any member of the Biogen Group or Bioverativ Group, as applicable, shall be deemed to occur upon the execution of this Agreement with respect thereto.  Moreover, to the extent that any member of the Biogen Group or Bioverativ Group, as applicable, is liable for any Biogen Retained Liability or Bioverativ Liability, respectively, by operation of Law immediately following any Transfer in accordance with this Agreement or any Conveyancing and Assumption Instruments, there shall be no need for any other member of the Biogen Group or Bioverativ Group, as applicable, to Assume such Liability in connection with the operation of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.2(b)</font><font style="font-family:inherit;font-size:12pt;">&#32;and, accordingly, no other member of such Group shall Assume such Liability in connection with </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.2(b)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In connection with, and in furtherance of, the Transfers of Assets and the Assumptions of Liabilities contemplated by this Agreement, the Parties shall execute or cause to be executed, on or after the date hereof by the appropriate entities to the extent not executed prior to the date hereof, any Conveyancing and Assumption Instruments necessary to evidence the valid Transfer to the applicable Party or member of such Party&#8217;s Group of all right, title and interest in and to its accepted Assets and the valid and effective Assumption by the applicable Party or member of such Party&#8217;s Group of its respective Liabilities for Transfers and Assumptions to be effected pursuant to Delaware Law or the Laws of one of the other states of the United States or, if not appropriate for a given Transfer or Assumption, and for Transfers or Assumptions to be effected pursuant to non-U.S. Laws, in such form as the Parties shall reasonably agree.</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">21</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Biogen hereby waives compliance by itself and each and every member of the Biogen Group with the requirements and provisions of any &#8220;bulk-sale&#8221; or &#8220;bulk transfer&#8221; Laws of any jurisdiction that may otherwise be applicable with respect to the transfer or sale of any or all of the Biogen Retained Assets to Biogen or any member of the Biogen Group. </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Bioverativ hereby waives compliance by itself and each and every member of the Bioverativ Group with the requirements and provisions of any &#8220;bulk-sale&#8221; or &#8220;bulk transfer&#8221; Laws of any jurisdiction that may otherwise be applicable with respect to the transfer or sale of any or all of the Bioverativ Assets to Bioverativ or any member of the Bioverativ Group.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding anything in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.2</font><font style="font-family:inherit;font-size:12pt;">&#32;to the contrary, no Biogen Group member shall be required to undertake any action or arrangement contemplated by this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.2</font><font style="font-family:inherit;font-size:12pt;">&#32;that would result in, or could reasonably be expected to result in, Tax treatment that is inconsistent with the conclusions set forth in the Tax Opinion.</font></div><div><a name="s37AAE7E950FE3361BD94FB4F42DC03EC"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Treatment of Shared Contracts</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Unless the Parties otherwise agree or the benefits of any Contract described in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.3</font><font style="font-family:inherit;font-size:12pt;">&#32;are expressly conveyed to the applicable Party pursuant to an Ancillary Agreement, in the case of a Shared Contract, the Parties shall use commercially reasonable efforts to cause such Shared Contract to be: (i) assigned in relevant part to a member of the Bioverativ Group (or to a member of the Biogen Group if the contracting party is a member of the Bioverativ Group) if so assignable; (ii) appropriately amended, prior to, on or after the Distribution Effective Time; or (iii) replaced or otherwise addressed with suitable arrangements, in each case so that each Party or their respective Subsidiaries shall be entitled to the rights and benefits and shall assume the related portion of any obligations and Liabilities inuring to their respective businesses; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that in no event shall either Party or its respective Subsidiaries be required to assign or amend any Shared Contract in its entirety or to assign a portion of any Shared Contract that is not assignable or cannot be amended by its terms (including any terms imposing Consents or conditions on an assignment where such Consents or conditions have not been obtained or fulfilled). If any Shared Contract cannot be so partially assigned, or cannot be amended, or if such assignment or amendment would impair the benefit the parties thereto derive from such Shared Contract and such Shared Contract is not replaced or otherwise addressed with suitable arrangements, Biogen and Bioverativ shall, and shall cause each member of their respective Groups to, take such other reasonable and permissible actions to cause (with the costs and expenses of any such actions following the Distribution to be shared equally between the Parties): (A) the Assets associated with that portion of each Shared Contract that relates to the Bioverativ Business to be enjoyed by a member of the Bioverativ Group; (B) the Liabilities associated with that portion of each Shared Contract that relates to the Bioverativ </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">22</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Business to be borne by a member of the Bioverativ Group; (C) the Assets associated with that portion of each Shared Contract that relates to the Biogen Retained Business to be enjoyed by a member of the Biogen Group; and (D) the Liabilities associated with that portion of each Shared Contract that relates to the Biogen Retained Business to be borne by a member of the Biogen Group.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except for payments required in accordance with the performance of the applicable Shared Contract, nothing in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.3</font><font style="font-family:inherit;font-size:12pt;">&#32;shall obligate either Party or any of member of its Group to make any payment, incur any Liability or offer or grant any accommodation for the benefit of the other Party or any member of the other Party&#8217;s Group, in each case, in order to effect any transaction (other than the pass-through of rewards and burdens of the applicable portions of the Shared Contracts in accordance with this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.3</font><font style="font-family:inherit;font-size:12pt;">) (except to the extent advanced, assumed or agreed in advance to be reimbursed by the other Party or any member of the other Party&#8217;s Group).  </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each of Biogen and Bioverativ shall, and shall cause the members of its Group to, (A) treat for all Tax purposes the portion of each Shared Contract inuring to its respective Businesses as Assets owned by, and/or Liabilities of, as applicable, such Party as of the Distribution Effective Time and (B) neither report nor take any Tax position (on a Tax Return or otherwise) inconsistent with such treatment (unless required by applicable Tax Law or good faith resolution of a Tax Contest).</font></div><div><a name="sF776F193D6F9C8BB44BAFB4F42FDBE6B"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Intercompany Accounts</font><font style="font-family:inherit;font-size:12pt;">.  Each Intercompany Account which exists and is reflected immediately prior to the Distribution Effective Time in any general ledger account or other records of Biogen, Bioverativ or any of their respective Affiliates, shall be: (a) closed as of the Distribution Effective Time and satisfied or settled within thirty (30) days following the Distribution Date by the relevant members of the Biogen Group and the Bioverativ Group by (i) one or a related series of distributions of or contributions to capital, (ii) payment by the relevant obligor to the relevant obligee or (iii) dividends or a combination of the foregoing, in each case as determined by Biogen or (b) otherwise terminated effective as of the Distribution Effective Time.  The parties hereby agree that the Intercompany Accounts shall be settled, as applicable, as described on Schedule 2.4.  For the avoidance of doubt, the obligation to satisfy, settle or terminate Intercompany Accounts shall survive the Distribution Effective Time.</font></div><div><a name="s04D823D504131BA6B39EFB4F432F88FF"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Limitation of Liability</font><font style="font-family:inherit;font-size:12pt;">.  Except as provided in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.5</font><font style="font-family:inherit;font-size:12pt;">&#32;and in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">, neither Biogen nor Bioverativ nor any member of their respective Groups shall have any Liability to the other or any member of the other Party&#8217;s Group based upon, arising out of or resulting from any agreement, arrangement, course of dealing or understanding existing on or prior to the Distribution Effective Time other than pursuant to (i) this Agreement or any Ancillary Agreement, (ii) any Contract listed or described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 2.5</font><font style="font-family:inherit;font-size:12pt;">; (iii) any Third Party </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">23</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Agreement or (iv) any other Contract or agreement entered into in connection with the consummation of the transactions contemplated by the Transaction Agreements, and any such Liability, whether or not in writing, that is not reflected in any of the foregoing, is hereby irrevocably cancelled, released and waived effective as of the Distribution Effective Time.  No such terminated agreement, arrangement, course of dealing or understanding (including any provision thereof that purports to survive termination) shall be of any further force or effect after the Distribution Effective Time. </font></div><div><a name="sD333B6B4433D63BCCDF4FB4F4359AE79"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Transfers Not Effected at or Prior to the Distribution Effective Time; Transfers Deemed Effective as of the Distribution Effective Time</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If and to the extent that the valid, complete and perfected Transfer to the Bioverativ Group of any Bioverativ Asset or Assumption by the Bioverativ Group of any Bioverativ Liability, in each case contemplated hereby, would be a violation of applicable Law or require any Consent in connection with the Separation that has not been obtained or made by the Distribution Effective Time then, unless the Parties mutually shall otherwise agree, the Transfer to the Bioverativ Group of such Bioverativ Assets or the Assumption by the Bioverativ Group of such Bioverativ Liabilities, as the case may be, shall be automatically deemed deferred and any such purported Transfer or Assumption shall be null and void until such time as all legal impediments are removed or such Consent has been obtained or made.  Notwithstanding the foregoing, any such Bioverativ Asset or Bioverativ Liability shall continue to constitute a Bioverativ Asset or Bioverativ Liability, as applicable, for all other purposes of this Agreement. </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If and to the extent that the valid, complete and perfected Transfer to the Biogen Group of any Biogen Retained Asset or Assumption by the Biogen Group of any Biogen Retained Liability, in each case contemplated hereby, would be a violation of applicable Law or require any Consent in connection with the Separation that has not been obtained or made by the Distribution Effective Time then, unless the Parties mutually shall otherwise agree, the Transfer to the Biogen Group of such Biogen Retained Assets or the Assumption by the Biogen Group of such Biogen Retained Liabilities, as the case may be, shall be automatically deemed deferred and any such purported Transfer or Assumption shall be null and void until such time as all legal impediments are removed or such Consent has been obtained or made.  Notwithstanding the foregoing, any such Biogen Retained Assets or Biogen Retained Liabilities shall continue to constitute Biogen Retained Assets and Biogen Retained Liabilities for all other purposes of this Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">With respect to Assets and Liabilities described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.6(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.6(b)</font><font style="font-family:inherit;font-size:12pt;">, taking into account any applicable restrictions or considerations relating to the contemplated Tax treatment of the transactions contemplated hereby, each of Biogen and Bioverativ shall, and shall cause the members of its respective Group to, (i) treat for all Tax </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">24</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">purposes (A) the deferred Assets as assets having been Transferred to and owned by the Person entitled to such Assets not later than the Distribution Effective Time and (B) the deferred Liabilities as having been Assumed by the Person intended to be subject to such Liabilities not later than the Distribution Effective Time and (ii) neither report nor take any Tax position (on a Tax Return or otherwise) inconsistent with such treatment (unless required by a change in applicable Tax Law or good faith resolution of a Tax Contest).</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In the event that any Transfer of Assets or Assumption of Liabilities intended to be effected hereunder has not been consummated at or prior to the Distribution Effective Time, whether as a result of the provisions of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.6(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.6(b)</font><font style="font-family:inherit;font-size:12pt;">&#32;or for any other reason (other than with respect to Shared Contracts, which shall be governed solely by </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.3</font><font style="font-family:inherit;font-size:12pt;">): </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">unless the Parties shall otherwise agree, the Parties and their respective Group members shall cooperate and use commercially reasonable efforts to seek to obtain, in accordance with applicable Law, any necessary Consents for the Transfer of all Assets and the Assumption of all Liabilities contemplated to be Transferred or Assumed, as applicable, pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article II</font><font style="font-family:inherit;font-size:12pt;">&#32;to the fullest extent permitted by applicable Law; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that, except to the extent expressly provided in this Agreement or any of the Ancillary Agreements or as otherwise agreed between Biogen and Bioverativ, neither Biogen nor Bioverativ shall be obligated to make any payment, incur any Liability or offer or grant any accommodation (financial or otherwise, regardless of any provision to the contrary in any underlying Contract, including any requirements for the securing or posting of any bonds, letters of credit or similar instruments, or the furnishing of any guarantees) to any Third Party to obtain or make such Consent; and</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">(A) the Party (or the applicable member of its Group) retaining such Asset shall thereafter hold (or shall cause such member in its Group to hold) such Asset in trust for the use and benefit of the Party entitled thereto (at the expense of the Party entitled thereto) and (B) the Party intended to Assume such Liability shall, or shall cause the applicable member of its Group to, pay or reimburse the Party retaining such Liability for all amounts paid or incurred in connection with the retention of such Liability.  To the extent the foregoing applies to any Contracts to be assigned for which any necessary Consents are not received prior to the Distribution Effective Time, the treatment of such Contracts shall, for the avoidance of doubt, be subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.8</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.9</font><font style="font-family:inherit;font-size:12pt;">, to the extent applicable.  In addition, the Party (or the applicable member of its Group) retaining such Asset or Liability shall (or shall cause such member in its Group to) </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">25</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">treat, insofar as reasonably possible and to the extent permitted by applicable Law, such Asset or Liability in the ordinary course of business in accordance with past practice and take such other actions as may be reasonably requested by the Party to which such Asset is to be Transferred or by the Party Assuming such Liability in order to place such Party, insofar as reasonably possible and to the extent permitted by applicable Law, in the same position as if such Asset or Liability had been Transferred or Assumed as contemplated hereby, and so that all the benefits and burdens relating to such Asset or Liability, including possession, use, risk of loss, potential for income and gain, and dominion, control and command over such Asset or Liability, are to inure from and after the Distribution Effective Time to the applicable member or members of the Biogen Group or the Bioverativ Group entitled to the receipt of such Asset or required to Assume such Liability.  In furtherance of the foregoing, the Parties agree that, as of the Distribution Effective Time, each Party shall be deemed to have acquired complete and sole beneficial ownership over all such Assets, together with all rights, powers and privileges incident thereto, and shall be deemed to have Assumed in accordance with the terms of this Agreement all such Liabilities, and all duties, obligations and responsibilities incident thereto, which such Party is entitled to acquire or required to Assume pursuant to the terms of the Transaction Agreements.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If and when the Consents or conditions, the absence or non-satisfaction of which caused the deferral of Transfer of any Asset or deferral of the Assumption of any Liability pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.6(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.6(b)</font><font style="font-family:inherit;font-size:12pt;">, are obtained or satisfied, the Transfer or Assumption of the applicable Asset or Liability shall be effected without further consideration in accordance with and subject to the terms of this Agreement (including </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.2</font><font style="font-family:inherit;font-size:12pt;">) or the applicable Ancillary Agreement, and shall, to the extent possible without the imposition of any undue cost on any Party, be deemed to have become effective as of the Distribution Effective Time.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Party (or the applicable member of its Group) retaining any Asset or Liability due to the deferral of the Transfer of such Asset or the deferral of the Assumption of such Liability pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.6(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.6(b)</font><font style="font-family:inherit;font-size:12pt;">&#32;or otherwise shall (i) not be obligated, in connection with the foregoing, to expend any money unless the necessary funds are advanced, assumed, or agreed in advance to be reimbursed by the Party (or the applicable member of its Group) entitled to such Asset or the Person intended to be subject to such Liability, other than reasonable attorneys&#8217; fees and recording or similar or other incidental fees, all of which shall be promptly reimbursed by the Party (or the applicable member of its Group) entitled to such Asset or the Person intended to be subject to such Liability and (ii) be indemnified for all Indemnifiable Losses or other Liabilities arising out of any actions (or </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">26</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">omissions to act) of such retaining Party taken (or not taken) at the written direction of the other Party (or the applicable member of its Group) in connection with and relating to such retained Asset or Liability, as the case may be.</font></div><div><a name="sCDE9D872E28F817E240CFB4F438B93E6"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Further Assurances</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In addition to and without limiting the actions specifically provided for elsewhere in this Agreement and subject to the limitations expressly set forth in this Agreement, including </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.6</font><font style="font-family:inherit;font-size:12pt;">, each of the Parties shall cooperate with each other and shall use (and shall cause its respective Subsidiaries to use) commercially reasonable efforts, from and after the Distribution Effective Time, to take, or to cause to be taken, all actions, and to do, or to cause to be done, all things reasonably necessary on its part under applicable Law or contractual obligations to consummate and make effective the transactions contemplated by this Agreement and the Ancillary Agreements as promptly as reasonably practicable.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Without limiting the foregoing, from and after the Distribution Effective Time:</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">each Party shall cooperate with the other Party to execute and deliver, and use commercially reasonable efforts to cause to be executed and delivered, all instruments, including instruments of Transfer or title, and to make all filings with, and to obtain all Consents, and to take or cause to be taken all such other actions as such Party may reasonably be requested to take by any other Party from time to time, as promptly as reasonably practicable, consistent with the terms of this Agreement and the Ancillary Agreements, in order to effectuate the provisions and purposes of this Agreement and the Ancillary Agreements and the Transfers of the applicable Assets and the assignment and Assumption of the applicable Liabilities and the other transactions contemplated hereby and thereby; and</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">in the event that any Party (or member of such Party&#8217;s Group) receives any Assets (including the receipt of payments made pursuant to Contracts and proceeds from accounts receivable with respect to such Asset) or is liable for any Liability that is otherwise allocated to any Person that is a member of the other Group pursuant to this Agreement or the Ancillary Agreements, such Party agrees to promptly Transfer, or cause to be Transferred, without further consideration such Asset or Liability to the other Party so entitled thereto (or to a member of such other Party&#8217;s Group as designated by such other Party) and, prior to any such Transfer, such Asset or Liability, as the case may be, shall be held in accordance with the provisions of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.6</font><font style="font-family:inherit;font-size:12pt;">; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, that the </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">27</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">provisions of this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.7(b)(ii)</font><font style="font-family:inherit;font-size:12pt;">&#32;are not intended to, and shall not, be deemed to constitute an authorization by any Party to permit the other to accept service of process on its behalf and no Party is or shall be deemed to be the agent of any other Party for service of process purposes.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">From and after the Distribution Effective Time, with respect to any Action where any Party hereto is a defendant, when and if requested by such Party, the other Party shall use commercially reasonable efforts to petition the applicable court to remove the requesting Party as a defendant to the extent that such Action relates solely to Assets or Liabilities that the other Party (or any member of such other Party&#8217;s Group) has been allocated pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article II</font><font style="font-family:inherit;font-size:12pt;">, and the other Party shall cooperate and assist in any required communication with any plaintiff or other related Third Party.</font></div><div><a name="s491ADA38B9B6C8DDBC27FB4F43A46392"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Novation of Biogen Retained Liabilities; Indemnification</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Other than with respect to Shared Contracts, which shall be governed solely by </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.3</font><font style="font-family:inherit;font-size:12pt;">, each of Biogen and Bioverativ, at the request of the other Party, shall use its commercially reasonable efforts to obtain, or to cause to be obtained, as soon as reasonably practicable, any Consent, substitution or amendment required to novate or assign all obligations and other Liabilities for which a member of the Biogen Group and a member of the Bioverativ Group are jointly or severally liable and that constitute Biogen Retained Liabilities, or to obtain in writing the unconditional release of all members of the Bioverativ Group to such arrangements, so that, in any such case, the members of the Biogen Group will be solely responsible for such Liabilities; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that except as expressly provided in any of the Ancillary Agreements, any Third Party Agreement, or as otherwise agreed between Biogen and Bioverativ, neither Biogen nor Bioverativ shall be obligated to make any payment, incur any Liability or offer or grant any accommodation (financial or otherwise, regardless of any provision to the contrary in any underlying Contract, including any requirements for the securing or posting of any bonds, letters of credit or similar instruments, or the furnishing of any guarantees) to any Third Party from whom any such Consent, substitution, amendment or release is requested.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If Biogen or Bioverativ, as applicable, is unable to obtain, or to cause to be obtained, any such required Consent, substitution, amendment or release with respect to any such Liability, the applicable member of the Bioverativ Group shall from and after the Distribution Effective Time continue to be bound by such obligation or other Liability and, unless not permitted by the terms thereof or by Law, from and after the Distribution Effective Time, Biogen shall or shall cause a member of the Biogen Group to, as agent or subcontractor for such member of the Bioverativ Group pay, perform and discharge fully such Liability to the extent that it does not constitute a Bioverativ Liability.  Bioverativ shall cause each member of </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">28</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Bioverativ Group without further consideration to promptly pay and remit, or cause to be paid or remitted, to Biogen or to another member of the Biogen Group specified by Biogen, all money, rights and other consideration received by Bioverativ or any member of the Bioverativ Group in respect of such performance (unless any such consideration is a Bioverativ Asset).  If and when any such Consent, substitution, amendment or release shall be obtained or the Liability shall otherwise become assignable or able to be novated, without payment of further consideration, Bioverativ shall promptly assign, or cause to be assigned, such Liability to Biogen or to another member of the Biogen Group specified by Biogen, and Biogen shall, or shall cause such other member of the Biogen Group to, Assume such Liability.</font></div><div><a name="s82EAC423AE3B9A7299BCFB4F43D66BAB"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Novation of Bioverativ Liabilities; Indemnification</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Other than with respect to Shared Contracts, which shall be governed solely by </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.3</font><font style="font-family:inherit;font-size:12pt;">, each of Biogen and Bioverativ, at the request of the other party, shall use its commercially reasonable efforts to obtain, or to cause to be obtained, as soon as reasonably practicable, any Consent, substitution or amendment required to novate or assign all obligations or other Liabilities for which a member of the Biogen Group and a member of the Bioverativ Group are jointly or severally liable and that constitute Bioverativ Liabilities, or to obtain in writing the unconditional release of all parties to such arrangements other than any member of the Bioverativ Group, so that, in any such case, the members of the Bioverativ Group will be solely responsible for such Liabilities; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that except as expressly provided in any of the Ancillary Agreements, any Third Party Agreement, or as otherwise agreed between Biogen and Bioverativ, neither Biogen nor Bioverativ shall be obligated to make any payment, incur any Liability or offer or grant any accommodation (financial or otherwise, regardless of any provision to the contrary in any underlying Contract, including any requirements for the securing or posting of any bonds, letters of credit or similar instruments, or the furnishing of any guarantees) to any Third Party from whom any such Consent, substitution, amendment or release is requested.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If Biogen or Bioverativ, as applicable, is unable to obtain, or to cause to be obtained, any such required Consent, substitution, amendment or release with respect to any such Liability, the applicable member of the Biogen Group shall from and after the Distribution Effective Time continue to be bound by such obligation or other Liability and, unless not permitted by the terms thereof or by Law, from and after the Distribution Effective Time, Bioverativ shall or shall cause a member of the Bioverativ Group to, as agent or subcontractor for such member of the Biogen Group pay, perform and discharge fully such Liability to the extent that it does not constitute a Biogen Retained Liability.  Biogen shall cause each member of the Biogen Group without further consideration to promptly pay and remit, or cause to be paid or remitted, to Bioverativ or to another member of the Bioverativ Group specified by Bioverativ, all money, rights and other consideration received by Biogen or any </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">29</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">member of the Biogen Group in respect of such performance (unless any such consideration is a Biogen Retained Asset).  If and when any such Consent, substitution, amendment or release shall be obtained or the Liability shall otherwise become assignable or able to be novated, without payment of further consideration, Biogen shall promptly assign, or cause to be assigned, such Liability to Bioverativ or to another member of the Bioverativ Group specified by Bioverativ, and Bioverativ shall, or shall cause such other member of the Bioverativ Group to, Assume such Liability.</font></div><div><a name="s189197A41E5875E74873FB4F43F72689"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Disclaimer of Representations and Warranties</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">EACH OF BIOGEN (ON BEHALF OF ITSELF AND EACH MEMBER OF THE BIOGEN GROUP) AND BIOVERATIV (ON BEHALF OF ITSELF AND EACH MEMBER OF THE BIOVERATIV GROUP) UNDERSTANDS AND AGREES THAT, EXCEPT AS EXPRESSLY SET FORTH HEREIN, IN ANY ANCILLARY AGREEMENT, NO PARTY TO THIS AGREEMENT, ANY ANCILLARY AGREEMENT OR ANY OTHER AGREEMENT OR DOCUMENT CONTEMPLATED BY THIS AGREEMENT, ANY ANCILLARY AGREEMENTS OR OTHERWISE, IS REPRESENTING OR WARRANTING IN ANY WAY, AND HEREBY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, AS TO THE ASSETS, BUSINESSES OR LIABILITIES CONTRIBUTED, TRANSFERRED OR ASSUMED AS CONTEMPLATED HEREBY OR THEREBY, AS TO ANY CONSENTS REQUIRED IN CONNECTION HEREWITH OR THEREWITH, AS TO THE VALUE OR FREEDOM FROM ANY SECURITY INTERESTS OF, AS TO NONINFRINGEMENT, VALIDITY OR ENFORCEABILITY OR ANY OTHER MATTER CONCERNING, ANY ASSETS OR BUSINESS OF SUCH PARTY, OR AS TO THE ABSENCE OF ANY DEFENSES OR RIGHT OF SETOFF OR FREEDOM FROM COUNTERCLAIM WITH RESPECT TO ANY ACTION OR OTHER ASSET, INCLUDING ACCOUNTS RECEIVABLE, OF ANY PARTY, OR AS TO THE LEGAL SUFFICIENCY OF ANY CONTRIBUTION, ASSIGNMENT, DOCUMENT, CERTIFICATE OR INSTRUMENT DELIVERED HEREUNDER TO CONVEY TITLE TO ANY ASSET OR THING OF VALUE UPON THE EXECUTION, DELIVERY AND FILING HEREOF OR THEREOF.  EXCEPT AS MAY EXPRESSLY BE SET FORTH HEREIN OR IN ANY ANCILLARY AGREEMENT, ALL SUCH ASSETS ARE BEING TRANSFERRED ON AN &#8220;AS IS, WHERE IS&#8221; BASIS (AND, IN THE CASE OF ANY REAL PROPERTY, BY MEANS OF A QUITCLAIM OR SIMILAR FORM DEED OR CONVEYANCE) AND THE RESPECTIVE TRANSFEREES SHALL BEAR THE ECONOMIC AND LEGAL RISKS THAT (I) ANY CONVEYANCE SHALL PROVE TO BE INSUFFICIENT TO VEST IN THE TRANSFEREE GOOD TITLE, FREE AND CLEAR OF ANY SECURITY INTEREST AND (II) ANY NECESSARY CONSENTS OR GOVERNMENTAL APPROVALS ARE NOT OBTAINED OR THAT ANY REQUIREMENTS OF LAWS OR JUDGMENTS ARE NOT COMPLIED WITH.</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">30</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each of Biogen (on behalf of itself and each member of the Biogen Group) and Bioverativ (on behalf of itself and each member of the Bioverativ Group) further understands and agrees that if the disclaimer of express or implied representations and warranties contained in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.10(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;is held unenforceable or is unavailable for any reason under the Laws of any jurisdiction outside the United States or if, under the Laws of a jurisdiction outside the United States, both Biogen or any member of the Biogen Group, on the one hand, and Bioverativ or any member of the Bioverativ Group, on the other hand, are jointly or severally liable for any Biogen Retained Liability or any Bioverativ Liability, then the Parties intend that, notwithstanding any provision to the contrary under the Laws of such non-U.S. jurisdictions, the provisions of this Agreement and the Ancillary Agreements (including the disclaimer of all representations and warranties, allocation of Liabilities among the Parties and their respective Subsidiaries, releases, indemnification and contribution of Liabilities) shall prevail for any and all purposes among the Parties and their respective Subsidiaries. </font></div><div><a name="s72517E23587402304B99FB4F442970A9"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 2.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Cash Management</font><font style="font-family:inherit;font-size:12pt;">.  From the date of this Agreement until the Distribution, Biogen and its Subsidiaries shall be entitled to use, retain or otherwise dispose of all cash generated by the Bioverativ Business and the Bioverativ Assets in accordance with the ordinary course operation of Biogen&#8217;s cash management systems.  Prior to the Distribution Date, in connection with the intended capitalization of the Bioverativ Group, Biogen shall cause to be contributed to Bioverativ an amount in cash and cash equivalents, as Biogen may determine in its sole discretion.  All cash and cash equivalents held by any member of the Bioverativ Group as of the Distribution shall be a Bioverativ Asset and all cash and cash equivalents held by any member of the Biogen Group as of the Distribution shall be a Biogen Retained Asset.</font></div><div><a name="s9C45FB271B3F822C2F5AFB4F445317F2"></a></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE III</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CERTAIN ACTIONS AT OR PRIOR TO THE DISTRIBUTION</font></div><div><a name="s401405E1AD4E554CE6FCFB4F4485EDA3"></a></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 3.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Transaction Agreements</font><font style="font-family:inherit;font-size:12pt;">. At or prior to the Distribution Effective Time, Biogen and Bioverativ shall enter into, or (where applicable) shall cause a member or members of their respective Groups to enter into each Transaction Agreement (other than this Agreement). </font></div><div><a name="s5C75F58315EA6C45B81DFB4F449D56EF"></a></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE IV</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">THE DISTRIBUTION</font></div><div><a name="s1AD0C1038B76ED04D971FB4F44D0FAAA"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 4.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Stock Dividend; Distribution</font><font style="font-family:inherit;font-size:12pt;">. On or prior to the Distribution Effective Time, in furtherance of the Separation, Bioverativ shall issue to Biogen as a stock dividend such number of shares of Bioverativ Common Stock as may be requested by Biogen after consultation with Bioverativ in order to effect the Distribution (or Biogen and Bioverativ </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">31</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">shall take or cause to be taken such other appropriate actions to ensure that Biogen has the requisite number of shares of Bioverativ Common Stock), which shares as of the date of issuance shall represent (together with such shares previously held by Biogen) all of the issued and outstanding shares of Bioverativ Common Stock.  Subject to the conditions and other terms set forth in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article IV</font><font style="font-family:inherit;font-size:12pt;">, Biogen shall cause the Distribution Agent on the Distribution Date to make the Distribution, including by crediting the appropriate number of shares of Bioverativ Common Stock to book entry accounts for each Record Holder or designated transferee or transferees of such Record Holder.  For stockholders who own Biogen Common Stock through a broker or other nominee, their shares of Bioverativ Common Stock will be credited to their respective accounts by such broker or nominee.  No action by any stockholder (or such stockholder&#8217;s designated transferee or transferees) shall be necessary to receive the applicable number of shares of Bioverativ Common Stock (and, if applicable, cash in lieu of any fractional shares) to which such stockholder is entitled in the Distribution.</font></div><div><a name="sCBE12DFF001F817E7A25FB4F44F12E3E"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 4.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Fractional Shares</font><font style="font-family:inherit;font-size:12pt;">.  Biogen registered stockholders who, after aggregating the number of shares of Bioverativ Common Stock (or fractions thereof) to which such stockholder would be entitled on the Record Date, would be entitled to receive a fraction of a share of Bioverativ Common Stock in the Distribution, will be entitled to receive cash in lieu of fractional shares.  Fractional shares of Bioverativ Common Stock will not be distributed by Biogen in the Distribution.  The Distribution Agent shall, as soon as practicable after the Distribution Date, (a)&#160;determine the number of whole shares and fractional shares of Bioverativ Common Stock allocable to each such Biogen stockholder, (b)&#160;aggregate all such fractional shares into whole shares and sell the whole shares obtained thereby in open market transactions at then prevailing trading prices on behalf of holders who would otherwise be entitled to fractional share interests, and (c)&#160;distribute to each such holder, or for the benefit of each such beneficial owner, such holder&#8217;s or owner&#8217;s pro rata share of the aggregate net cash proceeds of these sales, after making appropriate deductions for any amount required to be withheld for U.S. federal income tax purposes.  Biogen shall bear the cost of brokerage fees and transfer Taxes incurred in connection with these sales of fractional shares, which such sales shall occur as soon after the Distribution Date as practicable and as determined by the Distribution Agent.  None of Biogen, Bioverativ</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">or the Distribution Agent will guarantee any minimum sale price for the fractional shares of Bioverativ Common Stock.  Neither Biogen nor Bioverativ will pay any interest on the proceeds from the sale of fractional shares.  The Distribution Agent will have the sole discretion to select the broker-dealers through which to sell the aggregated fractional shares and to determine when, how and at what price to sell such shares.  Neither the Distribution Agent nor the selected broker-dealers will be Affiliates of Biogen or Bioverativ. </font></div><div><a name="sC619F2EAE7594E5935CEFB4F4523FE19"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 4.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Actions in Connection with the Distribution</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Prior to the Distribution Date, Bioverativ shall file such amendments and supplements to its Form 10 as Biogen may reasonably request, and such amendments as may be necessary in order to cause the same to become and remain effective as required by Law, including filing such amendments and supplements to its Form 10 as may be required by the Commission or federal, state or non-U.S. securities Laws. Biogen shall, or at Biogen&#8217;s election, Bioverativ shall, mail (or deliver by electronic means where not prohibited by Law) to the holders of Biogen Common Stock, at such time on or prior to the Distribution Date as Biogen shall determine, the Information Statement included in its Form 10 (or a Notice of Internet Availability of the Information Statement), as well as any other information concerning Bioverativ, its business, operations and management, the transaction contemplated herein and such other matters as Biogen shall reasonably determine are necessary and as may be required by Law.  Promptly after receiving a request from Biogen, Bioverativ shall prepare and, in accordance with applicable Law, file with the Commission any such documentation that Biogen reasonably determines is necessary or desirable to effectuate the Distribution, and Biogen and Bioverativ shall each use commercially reasonable efforts to obtain all necessary approvals from the Commission with respect thereto as soon as practicable.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Bioverativ shall use commercially reasonable efforts in preparing, filing with the Commission and causing to become effective, as soon as reasonably practicable (but in any case prior to the Distribution Effective Time), an effective registration statement or amendments thereof which are required in connection with the establishment of, or amendments to, any employee benefit plans of Bioverativ.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">To the extent not already approved and effective, Bioverativ shall use commercially reasonable efforts to have approved and made effective, the application for the original listing on NASDAQ of the Bioverativ Common Stock to be distributed in the Distribution, subject to official notice of distribution.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Nothing in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 4.3</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be deemed to shift or otherwise impose Liability for any portion of the Form 10 or Information Statement to Biogen.</font></div><div><a name="s155EEAD1FD384D6A261CFB4F454DFB87"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 4.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Sole Discretion of Biogen</font><font style="font-family:inherit;font-size:12pt;">. Biogen, in its sole discretion, shall determine the Distribution Date, the Distribution Effective Time and all other terms of the Distribution, including the form, structure and terms of any transactions or offerings to effect the Distribution and the timing of and conditions to the consummation thereof.  In addition, Biogen may, in accordance with </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 10.10</font><font style="font-family:inherit;font-size:12pt;">, at any time and from time to time until the completion of the Distribution decide to abandon the Distribution or modify or change the terms of the Distribution, including by accelerating or delaying the timing of the consummation of all or part of the Distribution.  Without limiting the foregoing, Biogen shall have the right not to complete the Distribution if, at any time prior to the Distribution Effective Time, the Board shall have </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">33</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">determined, in its sole discretion, that the Distribution is not in the best interests of Biogen or its stockholders, that a sale or other alternative is in the best interests of Biogen or its stockholders or that it is not advisable at that time for the Bioverativ Business to separate from Biogen.</font></div><div><a name="sA48FCE9F51DB5F2B32A8FB4F457FE95E"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 4.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Conditions to Distribution</font><font style="font-family:inherit;font-size:12pt;">. Subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 4.4</font><font style="font-family:inherit;font-size:12pt;">, the obligation of Biogen to consummate the Distribution is subject to the prior or simultaneous satisfaction, or, to the extent permitted by applicable Law, waiver by Biogen, in its sole discretion, of the following conditions.  None of Bioverativ, any other member of the Bioverativ Group, or any Third Party shall have any right or claim to require the consummation of the Distribution, which shall be effected at the sole discretion of the Board.  Any determination by Biogen, and any subsequent amendment, revision, withdrawal or change thereto made by Biogen prior to the Distribution and concerning the satisfaction or waiver of any or all of the conditions set forth in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 4.5</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be conclusive and binding on the Parties.  The conditions are for the sole benefit of Biogen and shall not give rise to or create any duty on the part of Biogen or the Board to waive or not waive any such condition.  Each Party will use its commercially reasonable efforts to keep the other Party apprised of its efforts with respect to, and the status of, each of the following conditions:</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Commission shall have declared effective the Form 10, no stop order relating thereto will be in effect, no proceedings seeking any such stop order shall be pending before or threatened by the Commission, and the Information Statement (or the Notice of Internet Availability of the Information Statement) shall have been distributed to holders of Biogen Common Stock;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the shares of Bioverativ Common Stock to be distributed shall have been approved and accepted for listing by NASDAQ, subject to official notice of distribution;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the receipt and continuing validity of an opinion (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tax Opinion</font><font style="font-family:inherit;font-size:12pt;">&#8221;) from tax counsel or other Third Party advisor, that is in form and substance acceptable to Biogen, substantially to the effect that, among other things, the Separation will, based upon and subject to the assumptions, representations and qualifications set forth therein, qualify as a transaction that is tax-free for U.S. federal income tax purposes under Section 355 and Section 368(a)(1)(D) of the Internal Revenue Code of 1986;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the receipt and continuing validity of an opinion from an independent appraisal firm to the Board, that is in form and substance acceptable to Biogen in its sole discretion, confirming the solvency of Bioverativ after the Distribution and, as to the compliance by Biogen in declaring to pay the Distribution, with surplus requirements under Delaware corporate law;</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">34</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">all permits, registrations and Consents required under the securities or blue sky laws of states or other political subdivisions of the United States or of other foreign jurisdictions in connection with the Distribution shall have been received;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">no order, injunction, or decree issued by any Governmental Entity of competent jurisdiction,  or other legal restraint or prohibition preventing the consummation of the Distribution or any of the related transactions shall be pending, threatened, issued or in effect, and no other event outside the control of Biogen shall have occurred or failed to occur that prevents the consummation of all or any portion of the Distribution;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Internal Reorganization shall have been effectuated prior to the Distribution, except for such steps (if any) as Biogen in its sole discretion shall have determined need not be completed or may be completed after the Distribution Effective Time;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Board shall have declared the Distribution and approved all related transactions (and such declaration or approval shall not have been withdrawn);</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Bioverativ shall have executed and delivered each of the other Transaction Agreements; and</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(j)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">no events or developments shall have occurred or shall exist that, in the sole and absolute judgment of the Board, make it inadvisable to effect the Distribution or would result in the Distribution and related transactions not being in the best interest of Biogen or its stockholders.</font></div><div><a name="s68B1F07AC51E20899A77FB4F459892D9"></a></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE V</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CERTAIN COVENANTS</font></div><div><a name="sF3DA6477A7306AB62D55FB4F45CA0E3E"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 5.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Non-Solicit; Non-Hire</font><font style="font-family:inherit;font-size:12pt;">.  Commencing on and for a period of nine (9) months following the Distribution Date, neither Party nor any of its Subsidiaries will: (a) without the prior written consent of the other Party, directly or indirectly, on their own behalf or in the service or on behalf of others, solicit, aid, induce or encourage any employee of the other Party to terminate or breach an employment, contractual or other relationship with the other Party (or any of its Subsidiaries), or (b) hire or otherwise employ any employee of the other Party (or any of its Subsidiaries); </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that nothing in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.1</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be deemed to prohibit (i) any general solicitation for employment through advertisements and search firms not specifically directed at employees of such other Party (or any of its Subsidiaries), provided that the soliciting Person has not encouraged or advised such firm to approach any such employee, (ii) the solicitation or hiring of an individual whose employment was terminated by such other Party (or any of its Subsidiaries), (iii) the solicitation or hiring of </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">35</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">an individual formerly employed by a Party (or any of its Subsidiaries) at any time after six (6) months following such individual&#8217;s termination of his or her employment with such other Party or (iv) the hiring by any Party of any individual (y) not solicited by such Party in breach of this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.1</font><font style="font-family:inherit;font-size:12pt;">&#32;and (x) with the prior written consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed), it being understood that the Party whose consent is requested may take into account, among other things, its own hiring needs and competitive considerations.</font></div><div><a name="sC5A4DD972E0CDADF9E3BFB4F45EA4B5E"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 5.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Certain Restrictions</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Biogen Restricted Business</font><font style="font-family:inherit;font-size:12pt;">. From the Distribution Effective Time through the second (2nd) anniversary of the Distribution Date (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Restricted Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;), Biogen shall not, and shall cause the other members of its Group not to, engage in the Biogen Restricted Business or own, operate, control, share any revenues of or have any profit or other equity interest in any business engaged in the Biogen Restricted Business. &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Biogen Restricted Business</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean discovering, researching, developing, importing, exporting, manufacturing, marketing, distributing, promoting or selling anywhere in the world any product in the Field of Hemoglobinopathies.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bioverativ Restricted Business</font><font style="font-family:inherit;font-size:12pt;">. During the Restricted Period, Bioverativ shall not, and shall the other members of its Group not to, engage in the Bioverativ Restricted Business or own, operate, control, share any revenues of or have any profit or other equity interest in any business engaged in the Bioverativ Restricted Business. &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bioverativ Restricted Business</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean, collectively, (x) discovering, researching, developing, importing, exporting, manufacturing, marketing, distributing, promoting or selling anywhere in the world any product in the Field of MS and (y) the DMF Business.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exceptions</font><font style="font-family:inherit;font-size:12pt;">. Notwithstanding anything to the contrary set forth in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.2</font><font style="font-family:inherit;font-size:12pt;">, nothing in this Agreement shall prohibit, preclude or in any way restrict either of the Biogen Group or the Bioverativ Group from:</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">undertaking any activity expressly contemplated by this Agreement, the Transition Services Agreement or any other Ancillary Agreement;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">purchasing or acquiring, or being the holder or beneficial owner for passive investment purposes of, equity securities of a Person that, directly or indirectly, engages in (x) with respect to the Biogen Group, the Biogen Restricted Business and (y) with respect to the Bioverativ Group, the Bioverativ Restricted Business; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;that, in the case of this clause (ii), the aggregate holdings of such Group of such equity securities in such Person during </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">36</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Restricted Period shall not exceed five percent (5%) of the outstanding equity securities of such Person;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">purchasing or acquiring or forming a joint venture (whether by merger, an asset, stock or equity acquisition, contribution or otherwise), and thereafter being the holder or beneficial owner of, at least fifty percent (50%) or more of the equity securities or consolidated assets of a Person that, directly or indirectly, engages in (x) with respect to the Biogen Group, the Biogen Restricted Business and (y) with respect to the Bioverativ Group, the Bioverativ Restricted Business; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;that, in the case of this clause (iii), (x) with respect to the Biogen Group, Biogen and (y) with respect to the Bioverativ Group, Bioverativ, shall cause such Person, as promptly as practicable following such purchase or acquisition (and in no event later than twelve (12) months after such purchase or acquisition), to cease engaging in (x) with respect to the Biogen Group, the Biogen Restricted Business and (y) with respect to the Bioverativ Group, the Bioverativ Restricted Business, during the Restricted Period, whether by divestiture or otherwise, for as long as such Person shall remain a member of the Biogen Group or the Bioverativ Group, as the case may be.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Dispositions</font><font style="font-family:inherit;font-size:12pt;">.  If Biogen or Bioverativ undergoes a Change of Control after the Distribution Effective Time and prior to the end of the Restricted Period, then the restrictions in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.2</font><font style="font-family:inherit;font-size:12pt;">&#32;shall terminate.  &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change of Control</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean, with respect to Biogen or Bioverativ, as applicable, the occurrence after the Distribution Effective Time of any of the following: (A) the sale, conveyance, transfer or other disposition (however accomplished), in one or a series of related transactions, of all or substantially all of the assets of such Party&#8217;s Group to a Third Party that is not an Affiliate of such Party; (B) the consolidation, merger or other business combination of such Party with or into any other to a Third Party that is not an Affiliate of such Party, immediately following which the stockholders of such Party immediately prior to such transaction fail to own in the aggregate at least a majority of the voting power in the election of directors of all the outstanding voting securities of the surviving Person in such consolidation, merger or business combination or of its ultimate publicly traded parent entity; (C) a transaction or series of transactions in which any Person or &#8220;group&#8221; (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) acquires at least thirty-five (35%) of the outstanding voting securities of such Party and effective control of such Party (other than a reincorporation, holding company merger or similar corporate transaction in which each of such Party&#8217;s stockholders owns, immediately thereafter, interests in the new parent company in substantially the same percentage as such stockholder owned in such party immediately prior to such transaction); or (D) a majority of the board of directors of such Party ceasing to consist of Continuing Directors.  &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Continuing Directors</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean, with respect to a Party, any member of the Board of Directors of the Party who (a) was a member of such Board of Directors on the </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">37</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Distribution Date or (b) was nominated for election or elected to such Board of Directors with the approval of a majority of the Continuing Directors who were members of such Board of Directors at the time of such nomination or election.</font></div><div><a name="s7EE9BCE9266336CE1472FB4F461DCD42"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 5.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Right to Use Regulatory Information</font><font style="font-family:inherit;font-size:12pt;">. Except as the Parties may otherwise agree in writing or as would otherwise be permitted by Law: (a) no member of the Biogen Group shall have a right of reference to or otherwise be entitled to use any regulatory filings or other regulatory information owned or controlled by any member of the Bioverativ Group for any products or product candidates in the Bioverativ Business; and (b) no member of the Bioverativ Group shall have a right of reference to or otherwise be entitled to use any regulatory filings or other regulatory information owned or controlled by any member of the Biogen Group for any products or product candidates in the Biogen Retained Business.</font></div><div><a name="sD5A660CF3FEBD88F0B3AFB4F4647CD5F"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 5.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Use of Retained Names and Marks</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Bioverativ hereby acknowledges that Biogen or its Affiliates or its or their licensors own all right, title and interest in and to the company names (including &#8220;Biogen&#8221; and &#8220;Biogen Hemophilia&#8221;), trade names, logos, trade dress and other Trademarks, together with all variations, translations, transliterations and acronyms thereof and all company names, Trademarks, Internet domain names, social media accounts, addresses and all other identifiers and other identifiers of source or goodwill containing, incorporating or associated with any of the foregoing, excluding, on and after the Distribution Date, Intellectual Property included in the Bioverativ Assets (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Retained Names and Marks</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and that, except as expressly provided below, any and all right of Bioverativ to use the Retained Names and Marks shall terminate as of the Distribution Date and shall immediately revert to Biogen or its Affiliates, along with any and all goodwill associated therewith.&#160; Bioverativ further acknowledges that it has no rights in any of the Retained Names and Marks, and that it is not acquiring any rights, directly or indirectly, to use the Retained Names and Marks, except as expressly provided herein.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Bioverativ shall, during the six (6) months following the Regulatory Authorization Date (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Applicable Transition Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;), be entitled to use (and shall have a limited non-exclusive, non-transferable license to use, without the right to sublicense, the Retained Names and Marks used therein or thereon), solely in connection with the operation of the Bioverativ Business as operated immediately prior to the Distribution Date, all of the Bioverativ Business&#8217;s existing stocks of signs, letterheads, invoices, advertisements and promotional materials and all website content and other documents and materials in existence and used by Biogen or its Affiliates in the Bioverativ Business as of the Distribution Effective Time, and contained in the Bioverativ Assets (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Existing Stock</font><font style="font-family:inherit;font-size:12pt;">&#8221;), in each case, containing the Retained Names and Marks, after which Applicable Transition Period Bioverativ shall cause the removal or obliteration of all Retained Names and Marks from such Existing </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">38</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Stock or cease using such Existing Stock; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that the Applicable Transition Period shall be twelve (12) months following the Regulatory Authorization Date for (A) all Existing Stock to the extent related to Bioverativ Products and (B) Bioverativ's use of &#8220;formerly Biogen Hemophilia&#8221; as a tag line or in any Bioverativ logo.  Notwithstanding the foregoing, with respect to any and all Existing Stock related to Bioverativ Products, Bioverativ shall be permitted to use Retained Names and Marks in or on such Existing Stock following the Applicable Transition Period to the extent required or permitted by any applicable Governmental Entity; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, that Bioverativ shall use commmercially reasonable efforts to cease using Retained Names and Marks as soon as practicable following the expiration of the Applicable Transition Period.  Upon Biogen&#8217;s request, Bioverativ shall promptly execute all assignment, transfer and other documents, and, at Biogen&#8217;s sole cost and expense, take all steps, in each case, that are necessary to confirm, effectuate or otherwise evidence Biogen&#8217;s and its Affiliates&#8217; or any of its or their licensors&#8217; rights, title and interests in and to, and control over, the Retained Names and Marks, including any registration or application thereof.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except as expressly provided in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.3</font><font style="font-family:inherit;font-size:12pt;">&#32;or to the extent contemplated in the IP License Agreement, no other right to use the Retained Names and Marks,  any other rights in the Trademarks of Biogen or its Affiliates (or any of its or their licensors) is granted by Biogen or its Affiliates to Bioverativ, its Affiliates or, after the Distribution Date, the Bioverativ Business, whether by implication or otherwise, and nothing hereunder permits Bioverativ, its Affiliates or, after the Distribution Date, the Bioverativ Business to use the Retained Names and Marks in any manner, other than in connection with the Existing Stock as set forth in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4</font><font style="font-family:inherit;font-size:12pt;">, or to register or seek to register, or to permit any Third Party to register or to seek to register, any of the Retained Names and Marks or any other rights in Trademarks of Biogen or its Affiliates not transferred to Bioverativ or Bioverativ&#8217;s Affiliates pursuant to this Agreement in any jurisdiction.&#160; Bioverativ shall ensure that all use of the Retained Names and Marks in connection with the Bioverativ Business, after the Distribution Date, as provided in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4</font><font style="font-family:inherit;font-size:12pt;">, shall (i) be only with respect to goods and services of a level of quality equal to or greater than the quality of goods and services with respect to which Biogen and its Affiliates used the Retained Names and Marks immediately prior to the Distribution Date, (ii) comply with all reasonable trademark usage restrictions or other guidelines furnished by Biogen or its Affiliates, as applicable, to Bioverativ with respect to the use of such Retained Names and Marks and (iii) comply with all applicable Laws.  Any and all goodwill generated by the use of the Retained Names and Marks as permitted under this</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4</font><font style="font-family:inherit;font-size:12pt;">&#32;shall inure solely to the benefit of Biogen and its Affiliates (or its or their licensors), and if Bioverativ obtains any goodwill, right, title or interest in or to any of the Retained Names and Marks, Bioverativ shall assign and hereby irrevocably assigns to Biogen or its Affiliates all such goodwill, rights, title and interests.&#160; In any event, Bioverativ shall not, and shall cause its Affiliates not to, and, after the Distribution Date, the Bioverativ Business not to, use the Retained </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">39</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Names and Marks in any manner that would damage or tarnish the reputation of Biogen or its Affiliates or the goodwill associated with the Retained Names and Marks, or take any action that would adversely affect Biogen&#8217;s or its Affiliates&#8217; (or its or their licensor(s)&#8217;) rights in any of the Retained Names and Marks or the validity, enforceability or distinctiveness of any of the Retained Names and Marks or any registrations or applications therefor.&#160; Following the Applicable Transition Period, Bioverativ shall cease all use of any of the Retained Names and Marks and it shall not, and shall cause its Affiliates not to, adopt, use, register or seek to register any rights in Trademarks that are substantially similar to, confusingly similar to or dilutive of any of the Retained Names and Marks (including the trade dress used with the Bioverativ Products prior to the Distribution Date).</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Bioverativ agrees that none of Biogen or its Affiliates (or any of its or their licensors) shall have any responsibility for claims by Third Parties arising out of, or relating to, the use by Bioverativ or any of its Affiliates of any Retained Names and Marks after the Distribution Date, other than such claims that the use of the Retained Names and Marks in connection with the Bioverativ Business in accordance with the terms and conditions of this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4</font><font style="font-family:inherit;font-size:12pt;">&#32;or the IP License Agreement infringes the Intellectual Property rights of any Third Party.&#160; Bioverativ hereby acknowledges and agrees that in the event of any breach or threatened breach of this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.4</font><font style="font-family:inherit;font-size:12pt;">, Biogen shall have the right to specific performance and injunctive or other equitable relief in accordance with </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 10.12</font><font style="font-family:inherit;font-size:12pt;">, in addition to any and all other rights and remedies at law or in equity, and all such rights and remedies shall be cumulative.</font></div><div><a name="s7529497EB1B89D337D16FB4F46797E89"></a></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE VI</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">INDEMNIFICATION</font></div><div><a name="sC9CB8D24CED40D466FBDFB4F46928399"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 6.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Release of Pre-Distribution Claims</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except (x) as provided in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1(b)</font><font style="font-family:inherit;font-size:12pt;">, (y) as may be otherwise expressly provided in this Agreement or in any Ancillary Agreement and (z) for any matter for which either Party is entitled to indemnification pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">: </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Biogen, for itself and each member of the Biogen Group and, to the extent permitted by Law, all Persons who at any time prior to the Distribution Effective Time were directors, officers, agents or employees of any member of the Biogen Group (in their respective capacities as such), in each case, together with their respective heirs, executors, administrators, successors and assigns, does hereby remise, release and forever discharge Bioverativ and the other members of the Bioverativ Group and all Persons who at any time prior to the Distribution Effective Time were stockholders, directors, officers, agents or employees of any member of the Bioverativ Group (in their respective capacities </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">40</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">as such), in each case, together with their respective heirs, executors, administrators, successors and assigns, from any and all (A) Biogen Retained Liabilities and (B) Liabilities existing or arising: (1) in connection with the implementation of the Separation (including the Distribution); or (2) from actions, inactions, events, omissions, conditions, facts or circumstances occurring or existing prior to the Distribution Effective Time (whether or not such Liabilities cease being contingent, mature, become known, are asserted or foreseen, or accrue, in each case before, at or after the Distribution Effective Time), in each case to the extent relating to, arising out of or resulting from the Biogen Retained Business, the Biogen Retained Assets or the Biogen Retained Liabilities, whether at Law or in equity (including any right of contribution), whether arising under any Contract, by operation of Law or otherwise, in each case, existing or arising from any acts or events occurring or failing to occur or alleged to have occurred or to have failed to occur or any conditions existing or alleged to have existed on or before the Distribution Effective Time, including in connection with the Separation and any of the other transactions contemplated hereunder and under the Ancillary Agreements (such liabilities, the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Biogen Released Liabilities</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and in any event shall not, and shall cause its respective Subsidiaries not to, bring any Action against any member of the Bioverativ Group in respect of any Biogen Released Liabilities; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that nothing in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1(a)(i)</font><font style="font-family:inherit;font-size:12pt;">&#32;shall relieve any Person released in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1(a)(i)</font><font style="font-family:inherit;font-size:12pt;">&#32;who, after the Distribution Effective Time, is a director, officer or employee of any member of the Bioverativ Group and is no longer a director, officer or employee of any member of the Biogen Group from Liabilities arising out of, relating to or resulting from his or her service as a director, officer or employee of any member of the Bioverativ Group after the Distribution Effective Time.  Notwithstanding the foregoing, nothing in this Agreement shall be deemed to limit Biogen, any member of the Biogen Group, or their respective Affiliates from commencing any Actions against any Bioverativ officer, director, agent or employee, or their respective heirs, executors, administrators, successors and assigns with regard to matters arising from, or relating to criminal acts by any such officers, directors, agents or employees.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Bioverativ, for itself and each member of the Bioverativ Group and, to the extent permitted by Law, all Persons who at any time prior to the Distribution Effective Time were directors, officers, agents or employees of any member of the Bioverativ Group (in their respective capacities as such), in each case, together with their respective heirs, executors, administrators, successors and assigns, does hereby remise, release and forever </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">41</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">discharge Biogen and the other members of the Biogen Group and all Persons who at any time prior to the Distribution Effective Time were stockholders, directors, officers, agents or employees of any member of the Biogen Group (in their respective capacities as such), in each case, together with their respective heirs, executors, administrators, successors and assigns, from any and all (A) Bioverativ Liabilities and (B) Liabilities existing or arising: (1) in connection with the implementation of the Separation (including the Distribution); or (2) from actions, inactions, events, omissions, conditions, facts or circumstances occurring or existing prior to the Distribution Effective Time (whether or not such Liabilities cease being contingent, mature, become known, are asserted or foreseen, or accrue, in each case before, at or after the Distribution Effective Time), in each case to the extent relating to, arising out of or resulting from the Bioverativ Business, the Bioverativ Assets or the Bioverativ Liabilities, whether at Law or in equity (including any right of contribution), whether arising under any Contract, by operation of Law or otherwise, in each case, existing or arising from any acts or events occurring or failing to occur or alleged to have occurred or to have failed to occur or any conditions existing or alleged to have existed on or before the Distribution Effective Time, including in connection with the Separation and any of the other transactions contemplated hereunder and under the Ancillary Agreements (such liabilities, the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bioverativ Released Liabilities</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and in any event shall not, and shall cause its respective Subsidiaries not to, bring any Action against any member of the Biogen Group in respect of any Bioverativ Released Liabilities; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that for purposes of this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1(a)(ii)</font><font style="font-family:inherit;font-size:12pt;">, the members of the Bioverativ Group shall also release and discharge any officers or other employees of any member of the Biogen Group, to the extent any such officers or employees served as directors or officers of any member of the Bioverativ Group prior to the Distribution, from any and all Liabilities or responsibilities for any and all past actions or failures to take action, in each case in their respective capacities as directors or officers, as the case may be, of any such member of the Bioverativ Group, prior to the date of the Distribution.  Notwithstanding the foregoing, nothing in this Agreement shall be deemed to limit Bioverativ, any member of the Bioverativ Group, or their respective Affiliates from commencing any Actions against any Biogen officer, director, agent or employee, or their respective heirs, executors, administrators, successors and assigns with regard to matters arising from, or relating to criminal acts by any such officers, directors, agents or employees.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Nothing contained in this Agreement, including </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.5</font><font style="font-family:inherit;font-size:12pt;">, shall impair or otherwise affect any right of any Party and, as applicable, a member </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">42</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">of such Party&#8217;s Group, as well as their respective heirs, executors,  administrators, successors and assigns, to enforce this Agreement, any Ancillary Agreement or any agreements, arrangements, commitments or understandings contemplated in this Agreement or in any Ancillary Agreement to continue in effect after the Distribution Effective Time.  In addition, nothing contained in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;shall:</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">release any Person from any Liability Assumed, Transferred or expressly allocated to a Party or a member of such Party&#8217;s Group pursuant to or as contemplated by, or any other Liability of any member of such Group under, this Agreement or any Ancillary Agreement including (A) with respect to Biogen, any Biogen Retained Liability, (B) with respect to Bioverativ, any Bioverativ Liability, (C) any Liability expressly preserved pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.5</font><font style="font-family:inherit;font-size:12pt;">&#32;and (D) any Liability that the Parties may have with respect to indemnification or contribution pursuant to this Agreement or otherwise for Actions brought against the Parties by Third Parties, which Liability shall be governed by the provisions of this Agreement and, in particular, this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;and, if applicable, the appropriate provisions of the Ancillary Agreements;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">release any Person from any Liability provided for in or resulting from any other Contract or understanding that is entered into after the Distribution Effective Time between any Party (and/or a member of such Party&#8217;s Group), on the one hand, and the other Party (and/or a member of such Party&#8217;s Group), on the other hand; </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">release any Person other than the Persons released in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1(a)</font><font style="font-family:inherit;font-size:12pt;">; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, that the Parties agree not to bring any Action or permit any other member of their respective Group to bring any Action against a Person released in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;with respect to such Liability; and</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">release any Bioverativ Employee from any Contract with any member of the Biogen Group to the extent related to the Biogen Retained Assets, Biogen Retained Liabilities or Biogen Retained Business.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In addition, nothing contained in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;shall release Biogen from indemnifying any director, officer or employee of Bioverativ who was a director, officer or employee of Biogen or any of its Affiliates prior to the Distribution Effective Time, as the case may be, with respect to which he or she was entitled to such indemnification pursuant to an obligation existing immediately prior to the Distribution Effective Time; it being understood that if the underlying obligation giving rise to such Action is established by a court of competent jurisdiction to be a Bioverativ Liability, Bioverativ shall indemnify Biogen for such Liability (including Biogen&#8217;s </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">43</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">costs to indemnify the director, officer or employee) in accordance with the provisions set forth in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each Party shall not, and shall not permit any member of its Group to, make any claim for offset, or commence any Action, including any claim of contribution or any indemnification, against any other Party or any member of any other Party&#8217;s Group, or any other Person released pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1(a)</font><font style="font-family:inherit;font-size:12pt;">, with respect to any Liabilities released pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1(a)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If any Person associated with a Party (including any director, officer or employee of a Party) initiates any Action with respect to claims released by this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1</font><font style="font-family:inherit;font-size:12pt;">, the Party with which such Person is associated shall be responsible for the reasonable fees and expenses of counsel of the other Party and/or the members of such Party&#8217;s Group, as applicable, and such other Party shall be indemnified for all Liabilities incurred in connection with such Action in accordance with the provisions set forth in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div><a name="s259712C776BE38BD519DFB4F46C408F1"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 6.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnification by Biogen</font><font style="font-family:inherit;font-size:12pt;">. In addition to any other provisions of this Agreement requiring indemnification and except as otherwise specifically set forth in any provision of this Agreement or of any Ancillary Agreement, following the Distribution Effective Time, Biogen shall and shall cause the other members of the Biogen Group to indemnify, hold harmless and defend the Bioverativ Indemnitees from and against any and all Indemnifiable Losses of the Bioverativ Indemnitees to the extent relating to, arising out of, by reason of or otherwise in connection with (a) the Biogen Retained Liabilities, including the failure of any member of the Biogen Group or any other Person to pay, perform or otherwise discharge any Biogen Retained Liability in accordance with its respective terms, whether arising prior to, on or after the Distribution Effective Time, or (b) any breach by Biogen of any provision of this Agreement or any Ancillary Agreement unless such Ancillary Agreement expressly provides for separate indemnification therein, in which case any such indemnification claims shall be made thereunder (each, a &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bioverativ Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221;). </font></div><div><a name="sDBF50AE8D58E7C6E5A3BFB4F46E513E4"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 6.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnification by Bioverativ</font><font style="font-family:inherit;font-size:12pt;">. In addition to any other provisions of this Agreement requiring indemnification and except as otherwise specifically set forth in any provision of this Agreement or of any Ancillary Agreement, following the Distribution Effective Time, Bioverativ shall and shall cause the other members of the Bioverativ Group to indemnify, hold harmless and defend the Biogen Indemnitees from and against any and all Indemnifiable Losses of the Biogen Indemnitees to the extent relating to, arising out of, by reason of or otherwise in connection with (a) the Bioverativ Liabilities, including the failure of any member of the Bioverativ Group or any other Person to pay, perform or otherwise discharge any Bioverativ Liability in accordance with its respective terms, whether prior to, on or after the Distribution Effective Time, or (b) any breach by Bioverativ of any provision of this Agreement </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">44</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">or any Ancillary Agreement unless such Ancillary Agreement expressly provides for separate indemnification therein, in which case any such indemnification claims shall be made thereunder (each, a &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Biogen Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div><a name="sA269EFE702DCDA6C1344FB4F4717724A"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 6.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Procedures for Indemnification</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Direct Claims</font><font style="font-family:inherit;font-size:12pt;">. Other than with respect to Third Party Claims, which shall be governed by </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4(b)</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">if a Bioverativ Indemnitee has made a determination that it is or may be entitled to indemnification in respect of any Bioverativ Claim, the Bioverativ Indemnitee shall so notify Biogen as promptly as reasonably possible after becoming aware of the existence of such Bioverativ Claim; and</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">if a Biogen Indemnitee has made a determination that it is or may be entitled to indemnification in respect of any Biogen Claim, the Biogen Indemnitee shall so notify Bioverativ as promptly as reasonably possible after becoming aware of the existence of such Biogen Claim</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(any such claim made pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4(a)(i)</font><font style="font-family:inherit;font-size:12pt;">&#32;or this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4(a)(ii)</font><font style="font-family:inherit;font-size:12pt;">, a &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Direct Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each such notice shall be in writing and shall describe in reasonable detail the basis for the claim for indemnification hereunder and set forth, to the extent known, the estimated amount of Indemnifiable Losses for which indemnification may be sought hereunder relating to such claim (including, to the extent practicable, the method of computation thereof); </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that the failure to provide such written notice shall not release the Indemnifying Party from any of its obligations except and solely to the extent the Indemnifying Party shall have been actually materially prejudiced as a result of such failure.  The Indemnifying Party will have a period of forty-five (45) days after receipt of any such notice under this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;to respond to the claimant thereto.  If the Indemnifying Party fails to respond within such period, the claim specified in such notice from the Indemnitee shall be conclusively determined to be a indemnifiable claim for which the Indemnifying Party shall be liable to the applicable Indemnitee(s) hereunder.  </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third Party Claims</font><font style="font-family:inherit;font-size:12pt;">. If a claim or demand is made against an Indemnitee by any Third Party (a &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third Party Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221;) as to which such Indemnitee is or may be entitled to indemnification pursuant to this Agreement, Biogen (on behalf of the Biogen Indemnitees) or Bioverativ (on behalf of the Bioverativ Indemnitees), as applicable (such claimant, the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Claiming Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;), shall notify the Indemnifying Party of the Third Party Claim in </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">45</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">writing and in reasonable detail describing the basis for any claim for indemnification hereunder, referring to the provisions of this Agreement or any Ancillary Agreement in respect of which such right of indemnification is claimed by such Indemnitee or arises and including copies of all Third Party written notices and documents received by the Claiming Party (and any or all of its Indemnitees) relating to the Third Party Claim promptly (and in any event within twenty (20) days) after receipt by such Indemnitee of written notice of the Third Party Claim; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that the failure to provide notice of any such Third Party Claim pursuant to this sentence shall not release the Indemnifying Party from any of its obligations except and solely to the extent the Indemnifying Party shall have been actually materially prejudiced as a result of such failure.  Thereafter, the Claiming Party shall deliver to the Indemnifying Party, promptly (and in any event within five (5) Business Days) after the receipt thereof by the Claiming Party (or any of its Indemnitees), copies of any and all additional Third Party written notices and documents (including court papers) received by the Claiming Party (or any of its Indemnitees) relating to the Third Party Claim.  For all purposes of this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4(b)</font><font style="font-family:inherit;font-size:12pt;">, each Party shall be deemed to have notice of the matters listed or described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1.1(19)(ix)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Subject to the provisions of this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4(c)</font><font style="font-family:inherit;font-size:12pt;">, the Indemnifying Party has the right, exercisable by written notice to the Claiming Party within thirty (30) days after receipt of notice from the Claiming Party pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4(b)</font><font style="font-family:inherit;font-size:12pt;">, to assume and conduct the defense (including, subject to the conditions of this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4(c)</font><font style="font-family:inherit;font-size:12pt;">, settlement) of such Third Party Claim in accordance with the limits set forth in this Agreement with counsel selected by the Indemnifying Party and reasonably acceptable to the applicable Indemnitees.  If the Indemnifying Party does not assume the defense of a Third Party Claim in accordance with this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4(c)</font><font style="font-family:inherit;font-size:12pt;">, the Indemnitee may defend the Third Party Claim.  If the Indemnifying Party has assumed the defense of a Third Party Claim as provided in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4(c)</font><font style="font-family:inherit;font-size:12pt;">, the Indemnifying Party shall not be liable for any legal expenses subsequently incurred by the Indemnitee in connection with the defense of the Third Party Claim; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that if (w) in the reasonable judgment of the Indemnitee, after consultation with outside counsel, there exists a conflict of interest between the Indemnifying Party and the applicable Indemnitee(s) in the defense of such Third Party Claim by the Indemnifying Party, (x) the party making such Third Party Claim is a Governmental Authority with regulatory or other authority over the Indemnitee or any of its material assets, (y) the Third Party Claim seeks injunctive or other nonmonetary relief that, if granted, would reasonably be expected to have a material and adverse effect on the Indemnitee&#8217;s business or (z) the Indemnifying Party fails to take reasonable steps necessary to defend diligently such Third Party Claim, the Indemnitee may assume its own defense, and the Indemnifying Party shall be liable for all reasonable costs or expenses paid or incurred in connection with such defense.  The Indemnifying Party or the Indemnitee, as the case may be, has the right to participate in (but, subject to the prior sentence, not control), at its own expense, the defense of any Third Party Claim that the other Person is defending as provided in this </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">46</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Agreement.  The Indemnifying Party, if it has assumed the defense of any Third Party Claim as provided in this Agreement, may not, without the prior written consent of the Indemnitee (not to be unreasonably withheld, conditioned or delayed), consent to a settlement or compromise of, or the entry of any judgment arising from, any such Third Party Claim.  The Indemnitee may consent to a settlement or compromise of, or the entry of any judgment arising from, any Third Party Claim, the defense of which has not been assumed by the Indemnifying Party, only with the prior written consent of the Indemnifying Party, not to be unreasonably withheld, conditioned or delayed.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Claiming Party and the Indemnifying Party shall (and the Claiming Party shall cause the applicable Indemnitee(s) to) make reasonably available to each other and their respective agents and representatives all relevant records available to them that are necessary or appropriate for the defense of any Third Party Claim, subject to any </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">bona fide</font><font style="font-family:inherit;font-size:12pt;">&#32;claims of attorney-client privilege, and each of the Indemnifying Party and the Claiming Party shall use its reasonable efforts to assist, and to cause the employees and counsel of such party to assist, in the defense of such Third Party Claim.  If a Party asserts its right to participate in the defense and investigation of any Third Party Claim, the Party controlling the defense and investigation of such Third Party Claim shall act in good faith and reasonably consult and cooperate with the Indemnified Party or the Indemnifying Party, as the case may be, in connection with any appearances, briefs, arguments and proposals made or submitted by or on behalf of any party in connection with the Third Party Claim (including considering in good faith all reasonable additions, deletions or changes suggested by the Indemnified Party or the Indemnifying Party, as the case may be, in connection any filings made with any Governmental Entity or proposals to the Third Party claimant in connection therewith).  With respect to any Third Party Claim that implicates both Parties in any material respect due to the allocation of Liabilities, responsibilities for management of defense and related indemnities pursuant to this Agreement or any of the Ancillary Agreements, the Parties agree to use commercially reasonable efforts to cooperate fully and maintain a joint defense (in a manner that, to the extent reasonably practicable, will preserve for all Parties any Privilege with respect thereto). The Party that is not responsible for managing the defense of any such Third Party Claim shall, upon reasonable request, be consulted with respect to significant matters relating thereto and may, if necessary or helpful, retain counsel to assist in the defense of such claims. Notwithstanding the foregoing, nothing in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4(d)</font><font style="font-family:inherit;font-size:12pt;">&#32;shall derogate from a Party&#8217;s right to control the defense of any Action in accordance with </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each of the Parties agrees that at all times from and after the Distribution Effective Time, if an Action is commenced by a Third Party naming two (2) or more Parties (or any member of such Parties&#8217; respective Groups) as defendants and with respect to which one or more named Parties (or any member of such Party&#8217;s Group) is a nominal defendant and/or such Action is related solely to an Asset or Liability that the other Party has been allocated </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">47</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">under this Agreement, any Ancillary Agreement or any Third Party Agreement, then the other Party or Parties shall use commercially reasonable efforts to cause such nominal defendant to be removed from such Action, as soon as reasonably practicable.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The provisions of this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4</font><font style="font-family:inherit;font-size:12pt;">&#32;(other than this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4(f)</font><font style="font-family:inherit;font-size:12pt;">) and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.7</font><font style="font-family:inherit;font-size:12pt;">&#32;(other than </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.7(g)</font><font style="font-family:inherit;font-size:12pt;">) shall not apply to Taxes (Taxes being governed by the Tax Matters Agreement).</font></div><div><a name="s36E7EAF5F0DC85A7F8A5FB4F47388338"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 6.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnification Obligations Net of Insurance Proceeds and Other Amounts</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Any recovery by any Party (including any of its Indemnitees) for any Indemnifiable Loss subject to indemnification pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be calculated (i) net of Insurance Proceeds actually received by such Party (or any of its Indemnitees) with respect to any Indemnifiable Loss and (ii) net of any proceeds actually received by such Party (or any of its Indemnitees) from any Third Party with respect to any such Liability corresponding to the Indemnifiable Loss (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third Party Proceeds</font><font style="font-family:inherit;font-size:12pt;">&#8221;), in the case of (i) and (ii) net of the costs of collection thereof and any increase in premium attributable thereto under applicable Third Party Policies.  Accordingly, the amount which any Indemnifying Party is required to pay pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;to any Indemnitee pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be reduced by any Insurance Proceeds or Third Party Proceeds theretofore actually recovered by or on behalf of the Indemnitee corresponding to the related Indemnifiable Loss.  If an Indemnitee receives a payment required by this Agreement from an Indemnifying Party corresponding to any Indemnifiable Loss (an &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnity Payment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and subsequently receives Insurance Proceeds or Third Party Proceeds, then the Indemnitee shall pay to the Indemnifying Party an amount equal to the excess of the Indemnity Payment received over the amount of the Indemnity Payment that would have been due if the Insurance Proceeds or Third Party Proceeds had been received, realized or recovered before the Indemnity Payment was made.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Insurers and Other Third Parties Not Relieved</font><font style="font-family:inherit;font-size:12pt;">. The Parties hereby agree that an insurer or other Third Party that would otherwise be obligated to pay any amount shall not be relieved of the responsibility with respect thereto or have any subrogation rights with respect thereto by virtue of any provision contained in this Agreement or any Ancillary Agreement, and that no insurer or any other Third Party shall be entitled to a &#8220;windfall&#8221; (e.g., a benefit they would not otherwise be entitled to receive, or the reduction or elimination of an insurance coverage obligation that they would otherwise have, in the absence of the indemnification or release provisions) by virtue of any provision contained in this Agreement or any Ancillary Agreement.  Each Party shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to collect or recover, or allow the Indemnifying Party to collect or recover, or cooperate with each other in collecting or recovering, any Insurance Proceeds that may be </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">48</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">collectible or recoverable respecting the Liabilities for which indemnification may be available under this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">.  Notwithstanding the foregoing, an Indemnifying Party may not delay making any indemnification payment required under the terms of this Agreement, or otherwise satisfying any indemnification obligation, pending the outcome of any Actions to collect or recover Insurance Proceeds, and an Indemnitee need not attempt to collect any Insurance Proceeds prior to making a claim for indemnification or receiving any Indemnity Payment otherwise owed to it under this Agreement or any Ancillary Agreement. </font></div><div><a name="s6E1BB24E8A6C6B6A1804FB4F4775EC7D"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 6.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Contribution</font><font style="font-family:inherit;font-size:12pt;">. If the indemnification provided for in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;is unavailable for any reason to an Indemnitee (other than failure to provide notice with respect to any Third Party Claims in accordance with </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4(b)</font><font style="font-family:inherit;font-size:12pt;">) in respect of any Indemnifiable Loss, then the Indemnifying Party shall, in accordance with this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.6</font><font style="font-family:inherit;font-size:12pt;">, contribute to the Indemnifiable Losses incurred, paid or payable by such Indemnitee as a result of such Indemnifiable Loss in such proportion as is appropriate to reflect the relative fault of Bioverativ and each other member of the Bioverativ Group, on the one hand, and Biogen and each other member of the Biogen Group, on the other hand, in connection with the circumstances which resulted in such Indemnifiable Loss.  Solely for purposes of determining relative fault pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.6</font><font style="font-family:inherit;font-size:12pt;">: (i) any fault associated with information contained in the Distribution Disclosure Documents shall be deemed to be allocated to Bioverativ and the other members of the Bioverativ Group; (ii) any fault associated with the conduct of the Biogen Retained Business prior to the Distribution Effective Time shall be deemed to be allocated to Biogen and the other members of the Biogen Group, and no such fault shall be deemed to be the fault of Bioverativ or any other member of the Bioverativ Group; and (iii) any fault associated with the conduct of the Bioverativ Business prior to the Distribution Effective Time shall be deemed to be the fault of Bioverativ and the other members of the Bioverativ Group, and no such fault shall be deemed to be the fault of Biogen or any other member of the Biogen Group.</font></div><div><a name="sB32DBCB966FE5AE64F38FB4F478E95B1"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 6.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Additional Matters; Survival of Indemnities</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The agreements contained in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;shall remain operative and in full force and effect, regardless of (i) any investigation made by or on behalf of any Indemnitee; and (ii) the knowledge by the Indemnitee of Indemnifiable Losses for which it might be entitled hereunder.  The agreements contained in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;shall survive the Distribution.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The rights and obligations of each Party and their respective Indemnitees under this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;shall survive (i) the sale or other Transfer by any Party or its respective Subsidiaries of any Assets or businesses or the assignment by it of any Liabilities and (ii) any merger, consolidation, business combination, sale of all or substantially all of the Assets, restructuring, recapitalization, reorganization or similar transaction involving either Party or any of its Subsidiaries.</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">49</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except to the extent set forth in any Ancillary Agreement, absent fraud or willful misconduct by an Indemnifying Party, the provisions of this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be the sole and exclusive remedy of an Indemnitee for any monetary or compensatory damages or losses resulting from any breach of this Agreement or any Ancillary Agreement and each Indemnitee expressly waives and relinquishes any and all rights, claims or remedies such Person may have with respect to the foregoing other than under this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;against any Indemnifying Party. </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding the foregoing, to the extent any Ancillary Agreement provides procedures for indemnification or contribution that differ from the provisions set forth in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">, the terms of the Ancillary Agreement will govern.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Any amounts payable pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be paid without duplication, and in no event shall any Party receive any payment in respect of an Indemnifiable Loss or receive contribution under different provisions of any Ancillary Agreement in respect of the same Liabilities.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Any amount to be paid or reimbursed by an Indemnifying Party (or a member of such Party&#8217;s Group) to an Indemnitee pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be paid in accordance with the procedures set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 10.11</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Parties shall report for all Tax purposes any amounts payable pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;in accordance with Section 13.01 of the Tax Matters Agreement.</font></div><div><a name="s992F57F622489DFBC309FB4F47BD8CB4"></a></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE VII</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">PRESERVATION OF RECORDS; ACCESS TO INFORMATION; CONFIDENTIALITY; PRIVILEGE</font></div><div><a name="s5D9D2643CC58737CE2F3FB4F47DEC968"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 7.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Preservation of Information</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except as otherwise required or agreed in writing, or as otherwise provided in any Ancillary Agreement, with regard to any information referenced in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.3</font><font style="font-family:inherit;font-size:12pt;">, each Party shall use its commercially reasonable efforts, at its sole cost and expense, to retain, until the latest of, as applicable, (i) the date on which such Information is no longer required to be retained pursuant to Biogen&#8217;s applicable record retention policy as in effect immediately prior to the Distribution, including, without limitation, pursuant to any &#8220;Litigation Hold&#8221; issued by Biogen or any of its Subsidiaries prior to the Distribution, (ii) the concluding date of any period as may be required by any applicable Law, (iii) the concluding date of any period during which such Information relates to a pending or threatened Action which is known to the members of the Biogen Group or Bioverativ Group, as applicable, in possession of such Information at the time </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">50</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any retention obligation with regard to such Information would otherwise expire, and (iv) the concluding date of any period during which the destruction of such Information could interfere with a pending or threatened investigation by a Governmental Entity which is known to the members of the Biogen Group or Bioverativ Group, as applicable, in possession of such Information at the time any retention obligation with regard to such Information would otherwise expire; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, that with respect to any pending or threatened Action arising after the Distribution, clause (iii) of this sentence applies only to the extent that whichever member of the Biogen Group or Bioverativ Group, as applicable, is in possession of such Information has been notified in writing pursuant to a &#8220;Litigation Hold&#8221; by the other Party of the relevant pending or threatened Action.  The Parties agree that upon written request from either Party that certain Information relating to the Bioverativ Business, the Biogen Retained Business or the transactions contemplated hereby be retained in connection with an Action, the other Party shall use reasonable efforts to preserve and not to destroy or dispose of such Information without the consent of the requesting Party.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Biogen and Bioverativ intend that any transfer of information that would otherwise be within the attorney-client or attorney work product privileges not operate as a waiver of any potentially applicable privilege.</font></div><div><a name="s6004DEDB667B2CCE4CB4FB4F4811F4C3"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 7.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Financial Statements and Accounting</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">From the Distribution Effective Time until the completion of each Party&#8217;s audit for the fiscal year ending December 31, 2017, each Party agrees to provide reasonable assistance and, subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.6</font><font style="font-family:inherit;font-size:12pt;">, reasonable access to its properties, books and records, other information in its possession and control and personnel, and to use its commercially reasonable efforts to cooperate with the other Party&#8217;s requests, in each case to enable (i) such other Party to meet its timetable for dissemination of its earnings releases, financial statements and management&#8217;s assessment of the effectiveness of its disclosure controls and procedures and its internal control over financial reporting in accordance with Items 307 and 308, respectively, of Regulation S-K, (ii) such other Party&#8217;s accountants to timely complete their review of the quarterly financial statements and audit of the annual financial statements of such other Party, including, to the extent applicable to such Party, its auditor&#8217;s audit of its internal control over financial reporting and management&#8217;s assessment thereof in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 and the Commission&#8217;s and Public Company Accounting Oversight Board&#8217;s rules and auditing standards thereunder and (iii) such other Party to respond to any written request or official comment from a Governmental Entity, including in connection with responding to a comment letter from the Commission; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, that in connection with this clause (iii), each Party shall provide reasonable access on the terms set forth in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.2</font><font style="font-family:inherit;font-size:12pt;">&#32;for a period of three (3) years following the Distribution Date.</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">51</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Nothing in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VII</font><font style="font-family:inherit;font-size:12pt;">&#32;shall require any Party to violate any agreement with any Third Party regarding the confidentiality of Information relating to that Third Party or its business; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that in the event that a Party is required under this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.2</font><font style="font-family:inherit;font-size:12pt;">&#32;to disclose any such Information, such Party shall use commercially reasonable efforts to seek to obtain such Third Party&#8217;s written consent to the disclosure of such Information.</font></div><div><a name="s95E722E7EBB0FE863E0AFB4F483C8FA9"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 7.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Provision of Information</font><font style="font-family:inherit;font-size:12pt;">. Other than in circumstances in which indemnification is sought pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;(in which event the provisions of such </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;shall govern) or for matters related to provision of Tax records (in which event the provisions of the Tax Matters Agreement shall govern), and subject to appropriate restrictions for Privileged Information or Confidential Information:</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">From and after the Distribution Effective Time, and subject to compliance with the terms of the Ancillary Agreements, upon the prior written reasonable request by, and at the expense of, Bioverativ for specific and identified information that: (i) primarily relates to Bioverativ or the Bioverativ Business, as the case may be, prior to the Distribution Effective Time; (ii) is necessary for Bioverativ to comply with the terms of, or otherwise perform under, any Shared Contract or Ancillary Agreement to which Biogen and/or Bioverativ are parties; (iii) is otherwise required by Bioverativ with regard to reasonable compliance with reporting, disclosure, filing or other requirements imposed on Bioverativ (including under applicable securities laws) by a Governmental Entity having jurisdiction over Bioverativ; or (iv) is otherwise for use in any other judicial, regulatory, administrative or other proceeding or in order to satisfy audit, accounting, claims, regulatory, Action or other similar requirements, as applicable, Biogen shall provide, as soon as reasonably practicable following the receipt of such request, appropriate access or, to the extent such information is reasonably practicable to identify and extract, copies of such information (or the originals thereof if Bioverativ has a reasonable need for such originals) in the possession or control of Biogen or any of its Subsidiaries, but only to the extent such items so relate and are not already in the possession or control of Bioverativ or any of its Subsidiaries; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, that, to the extent any originals are delivered to Bioverativ pursuant to this Agreement, a Shared Contract or the Ancillary Agreements, Bioverativ shall, at its own expense, return them to Biogen within a reasonable time after the need to retain such originals has ceased; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">further</font><font style="font-family:inherit;font-size:12pt;">, that, in the event that Biogen, in its sole discretion, determines that any such access or the provision of any such information (including information requested under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.2</font><font style="font-family:inherit;font-size:12pt;">) would violate any Law or Contract with a Third Party or waive any attorney-client privilege, rights under the work product doctrine or other applicable privilege, Biogen shall not be obligated to provide such information requested by Bioverativ.  Notwithstanding the foregoing, Biogen shall not be obligated to provide any requested information pursuant to clause (iii) or (iv) above following the date that is eighteen (18) months from the date of this Agreement (or such later time or times as the Parties may agree).</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">52</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">From and after the Distribution Effective Time, and subject to compliance with the terms of the Ancillary Agreements, upon the prior written reasonable request by, and at the expense of, Biogen for specific and identified information that: (i) primarily relates to Biogen or the Biogen Retained Business, as the case may be, prior to the Distribution Effective Time; (ii) is necessary for Biogen to comply with the terms of, or otherwise perform under, any Shared Contract or Ancillary Agreement to which Biogen and/or Bioverativ are parties; (iii) is otherwise required by Biogen with regard to reasonable compliance with reporting, disclosure, filing or other requirements imposed on Biogen (including under applicable securities laws) by a Governmental Entity having jurisdiction over Biogen; or (iv) is otherwise for use in any other judicial, regulatory, administrative or other proceeding or in order to satisfy audit, accounting, claims, regulatory, Action or other similar requirements, as applicable, Bioverativ shall provide, as soon as reasonably practicable following the receipt of such request, appropriate access or, to the extent such information is reasonably practicable to identify and extract, copies of such information (or the originals thereof if Biogen has a reasonable need for such originals) in the possession or control of Bioverativ or any of its Subsidiaries, but only to the extent such items so relate and are not already in the possession or control of Biogen or any of its Subsidiaries; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;that, to the extent any originals are delivered to Biogen pursuant to this Agreement, a Shared Contract or the Ancillary Agreements, Biogen shall, at its own expense, return them to Bioverativ within a reasonable time after the need to retain such originals has ceased; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">further</font><font style="font-family:inherit;font-size:12pt;">, that, in the event that Bioverativ, in its sole discretion, determines that any such access or the provision of any such information (including information requested under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.2</font><font style="font-family:inherit;font-size:12pt;">) would violate any Law or Contract with a Third Party or waive any attorney-client privilege, the work product doctrine or other applicable privilege, Bioverativ shall not be obligated to provide such information requested by Biogen.  Notwithstanding the foregoing, Bioverativ shall not be obligated to provide any requested information pursuant to clause (iii) or (iv) above following the date that is eighteen (18) months from the date of this Agreement (or such later time or times as the Parties may agree).</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In connection with the provision of information under this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.3</font><font style="font-family:inherit;font-size:12pt;">, the providing Party shall be entitled to redact any portion of the information to the extent related to any matter other than the receiving Party's business.  Each of Biogen and Bioverativ agree to make their respective personnel available during regular business hours to discuss the information exchanged pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.3</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div><a name="s3012CAA63DDDC8FE9202FB4F486ED7DA"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 7.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Witness Services; Cooperation</font><font style="font-family:inherit;font-size:12pt;">. At all times from and after the Distribution Effective Time, each of Biogen and Bioverativ shall use its commercially reasonable efforts to make available to the other Party, upon reasonable written request, its and its Subsidiaries&#8217; officers, directors, employees and agents (taking into account the business demands of such individuals) as witnesses to the extent that (i)&#160;such Persons may reasonably be required to testify in connection with the prosecution or defense of any Action in which the requesting </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">53</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Party may from time to time be involved (except for claims, demands or Actions in which one or more members of one Group is adverse to one or more members of the other Group) and (ii)&#160;there is no conflict in the Action between the requesting Party and the other Party.  Notwithstanding any provisions of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VII</font><font style="font-family:inherit;font-size:12pt;">&#32;to the contrary, after the Distribution Effective Time, each Party shall use commercially reasonable efforts to assist (or cause the other members of its Group to assist) the other with respect to any Action or potential Action upon the request of such other Party, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;that any such expenses incurred in connection therewith shall be at such other Party&#8217;s sole expense.</font></div><div><a name="sF34B73FD4282C0196700FB4F4887FAB6"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 7.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Reimbursement; Other Matters</font><font style="font-family:inherit;font-size:12pt;">. Except to the extent otherwise contemplated by this Agreement or any Ancillary Agreement, a Party providing information, access to information or services to the other Party pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VII</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be entitled to receive from the recipient, upon the presentation of invoices therefor, payments for such amounts, relating to supplies, disbursements and other out-of-pocket expenses (which shall not include the costs of salaries and benefits of employees of such Party or any pro rata portion of overhead or other costs of employing such employees which would have been incurred by such employees&#8217; employer regardless of the employees&#8217; service with respect to the foregoing), as may be reasonably incurred and properly paid under applicable Law in providing such information, access to such information or services.</font></div><div><a name="sFCDA82E5F5FBCE78DE21FB4F48B9088A"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 7.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Confidentiality</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except as otherwise provided herein, in any Ancillary Agreement, or in any Contract between a Party or its Subsidiaries, on the one hand, and their respective employees, on the other hand, each of Biogen and Bioverativ shall hold, and shall cause the other members of their respective Groups and their respective Representatives to hold, in strict confidence, with at least the same degree of care that applies to Biogen&#8217;s Confidential Information pursuant to policies and procedures in effect as of the Distribution Effective Time, and not disclose or release, or permit to be disclosed or released, all Confidential Information of the other Party that is either in the first Party's  possession (including Confidential Information in its possession prior to the Distribution Effective Time) or furnished by the other Party or any member of its Group or their respective Representatives at any time pursuant to this Agreement or any Ancillary Agreement, and shall not use any such Confidential Information other than for such purposes as may be expressly permitted hereunder or under any Ancillary Agreement.  If any Confidential Information is disclosed to any member of the other Party&#8217;s Group in connection with providing services to any member of such first Party&#8217;s Group under this Agreement or any Ancillary Agreement, then such disclosed Confidential Information shall be used by the applicable member of such other Party&#8217;s Group only as required to provide such services.  </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">54</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding anything the contrary in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.6</font><font style="font-family:inherit;font-size:12pt;">, each Party may disclose, or may permit disclosure of, the other Party's Confidential Information: (i) to its Representatives who have a need to know such information for non-commercial purposes and are informed of the obligation to hold such information confidential and in respect of whose failure to comply with such obligations, the first Party will be responsible or (ii) if any Party or any other member of its Group is required or requested to disclose any such Confidential Information by judicial or administrative process or by other requirements of Law or stock exchange rule or is advised by outside counsel in connection with an Action brought by a Governmental Entity that it is advisable to do so.  Notwithstanding the foregoing, in the event that any demand or request for disclosure of Confidential Information is made by a Third Party pursuant to clause (ii) above, each Party, as applicable, shall promptly notify (to the extent permissible by Law) the Party to whom the Confidential Information relates of the existence of such requirement or request and shall provide such affected Party a reasonable opportunity to seek an appropriate protective order or other remedy, which such Party will cooperate in obtaining to the extent reasonably practicable.  In the event that such appropriate protective order or other remedy is not obtained, the Party which faces the disclosure requirement shall furnish only that portion of the Confidential Information that is required to be disclosed and shall take commercially reasonable steps to ensure that confidential treatment is accorded such Confidential Information. </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each of Biogen and Bioverativ shall inform their respective Representatives who have or have access to the other Party&#8217;s Confidential Information of their obligation to hold such information confidential in accordance with the provisions of this Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Without limiting the foregoing, when any Confidential Information is no longer needed for the purposes contemplated by this Agreement or any Ancillary Agreement, each Party shall, at its option and as promptly as practicable after receiving a written request from the other Party, either (i) return to such other Party all such information in a tangible form (including all copies thereof and all notes, extracts or summaries based thereon) or (ii) certify to such other Party that the first Party has destroyed such information (and such copies thereof and such notes, extracts or summaries based thereon); </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, that such first Party&#8217;s Representatives may retain one (1) copy of such information to the extent required by applicable Law or professional standards, and shall not be required to destroy any such information located in back-up, archival electronic storage.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each Party acknowledges that it and its respective Subsidiaries may presently have and, following the Distribution Effective Time, may gain access to or possession of confidential or proprietary information of, or personal information relating to, Third Parties (i) that was received under confidentiality or non-disclosure agreements entered into between such </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">55</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Third Parties, on the one hand, and the other Party (or another member of its Group), on the other hand, prior to the Distribution Effective Time; or (ii) that, as between the two Parties, was originally collected by the other Party (or another member of its Group) and that may be subject to and protected by privacy, data protection or other applicable Laws. As may be provided in more detail in an applicable Ancillary Agreement, each Party agrees that it shall hold, protect and use, and shall cause the other members of its Group and its and their respective Representatives to hold, protect and use, in strict confidence the confidential and proprietary information of, or personal information relating to, Third Parties in accordance with privacy, data protection or other applicable Laws and the terms of any agreements that were either entered into before the Distribution Effective Time or affirmative commitments or representations that were made before the Distribution Effective Time by, between or among the other Party (or other member(s) of its Group), on the one hand, and such Third Parties, on the other hand.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Parties agree that irreparable damage may occur in the event that the provisions of this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.6</font><font style="font-family:inherit;font-size:12pt;">&#32;were not performed in accordance with their specific terms.  Accordingly, it is hereby agreed that the Parties shall have the right to seek specific performance and injunctive or other equitable relief in accordance with </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 10.12</font><font style="font-family:inherit;font-size:12pt;">, in addition to any and all other rights and remedies at law or in equity, and all such rights and remedies shall be cumulative.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">For the avoidance of doubt and notwithstanding any other provision of this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.6</font><font style="font-family:inherit;font-size:12pt;">, (i) the sharing of Privileged Information shall be governed solely by </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.7</font><font style="font-family:inherit;font-size:12pt;">, and (ii) information that is subject to any confidentiality provision or other disclosure restriction in any Ancillary Agreement shall be governed by the terms of such Ancillary Agreement.</font></div><div><a name="sD170909BFBF1D53A66B1FB4F48DA465F"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 7.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Privilege Matters</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Pre-Distribution Services</font><font style="font-family:inherit;font-size:12pt;">. The Parties recognize that legal and other professional services that have been and will be provided prior to the Distribution Effective Time have been and will be rendered for benefit of Biogen and its Subsidiaries, including the members of the Bioverativ Group.  Accordingly, with respect to such pre-Distribution services, the Parties agree as follows:</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">(A) Biogen shall be entitled, in perpetuity, to control the assertion or waiver of all privileges and immunities in connection with any Privileged Information that relates solely to the Biogen Retained Business, whether or not the Privileged Information is in the possession or under the control of a member of the Biogen Group or the Bioverativ Group and (B) Biogen shall also be entitled, in perpetuity, to control the assertion or waiver of all privileges </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">56</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">and immunities in connection with any Privileged Information that relates solely to any Biogen Retained Liabilities resulting from any Actions that are now pending or may be asserted in the future, whether or not the Privileged Information is in the possession or under the control of a member of the Biogen Group or the Bioverativ Group;  </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">(A) Bioverativ shall be entitled, in perpetuity, to control the assertion or waiver of all privileges and immunities in connection with any Privileged Information that relates solely to the Bioverativ Business, whether or not the Privileged Information is in the possession or under the control of a member of the Bioverativ Group or the Biogen Group and (B) Bioverativ shall also be entitled, in perpetuity, to control the assertion or waiver of all privileges and immunities in connection with any Privileged Information that relates solely to any Bioverativ Liabilities resulting from any Actions that are now pending or may be asserted in the future, whether or not the Privileged Information is in the possession or under the control of a member of the Bioverativ Group or the Biogen Group;   </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If Biogen and Bioverativ do not agree as to whether certain information is Privileged Information, then the information shall be treated as Privileged Information, and the Party who believes such information is Privileged Information shall be entitled to control the assertion or waiver of all privileges and immunities in connection with any such information unless the Parties otherwise agree;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Bioverativ agrees that it shall not (and shall cause the members of its Group not to) waive, or allege or purport to waive, any Privilege which could be asserted under any applicable Law, and in which Biogen (or any member of its Group) has a Privilege, without the written consent of Biogen; and</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Biogen agrees that it shall not (and shall cause the members of its Group not to) waive, or allege or purport to waive, any Privilege which could be asserted under any applicable Law, and in which Bioverativ (or any member of its Group) has a Privilege, without the written consent of Bioverativ.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Post-Distribution Services</font><font style="font-family:inherit;font-size:12pt;">. The Parties recognize that legal and other professional services will be provided following the Distribution Effective Time to each of Biogen (or any member of its Group) and Bioverativ (or any member of its Group).  The Parties </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">57</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">further recognize that certain of such post-Distribution services will be rendered solely for the benefit of Biogen (or any member of its Group) or Bioverativ (or any member of its Group), as the case may be, while other such post-Distribution services may be rendered jointly to both Biogen (or any member of its Group) and Bioverativ (or any member of its Group) with respect to claims, proceedings, litigation, disputes, or other matters which involve one or more members of both the Biogen Group and the Bioverativ Group.  With respect to such post- Distribution services and related information subject to Privilege (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Privileged Information</font><font style="font-family:inherit;font-size:12pt;">&#8221;), the Parties agree as follows:</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">All Privileged Information based on post-Distribution services rendered jointly to both one or more members of the Biogen Group and Bioverativ Group relating to any claims, proceedings, litigation, disputes or other matters which involve both the Biogen Group and the Bioverativ Group (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Shared Privileged Information</font><font style="font-family:inherit;font-size:12pt;">&#8221;) shall be subject to a shared Privilege among such parties involved in the claims, proceedings, litigation, disputes or other matters at issue; and</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Privileged Information relating to post-Distribution services provided solely to one of Biogen (or any member of its Group) or Bioverativ (or any member of its Group) shall not be deemed shared between the Parties (or among the members of their respective Groups).</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">No Party may (or cause or permit any member of its Group to) waive, or allege or purport to waive, any Privilege which could be asserted under any applicable Law with respect to Shared Privileged Information, without the written consent of the other Party, which shall not be unreasonably withheld or delayed;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If a dispute arises between or among the Parties or their respective Group members regarding whether a Privilege should be waived to protect or advance the interest of any Party (or members of its Group) with respect to Shared Privileged Information, each Party agrees that it shall negotiate in good faith, shall endeavor to minimize any prejudice to the rights of the other Party's Group, and shall not unreasonably withhold consent to any request for waiver by the other Party, and each Party specifically agrees that it shall not withhold consent to waive for any purpose except to protect the legitimate interests of its Group; and</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;text-indent:168px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If, within fifteen (15) days of receipt by the requesting Party of written objection, the Parties have not succeeded in </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">58</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">negotiating a resolution to any dispute regarding whether a Privilege should be waived with respect to Shared Privileged Information, and the requesting Party determines that a Privilege should nonetheless be waived to protect or advance the legitimate interests of its Group, the requesting Party shall provide the objecting Party fifteen (15) days&#8217; written notice prior to effecting such waiver.  Each Party specifically agrees that failure within fifteen (15) days of receipt of such notice to commence proceedings to enjoin such waiver under applicable Law shall be deemed full and effective consent to such waiver.  In the event proceedings are commenced as described above, the Parties agree that any such Privilege shall not be waived by either Party until the final determination of such dispute.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Parties agree that Shared Privileged Information shall continue to be held subject to Privilege even if adversity of interest may subsequently be discerned or arise between Parties or their respective Group members.  Further, in the event a Party or any member of its Group becomes adverse to the other Party or any member of its Group, each Party agrees that it shall not (and shall not cause or permit any member of its Group to) seek to disqualify any law firms who have or have had access to Shared Privileged Information from continuing to represent members of the other Party's Group, as applicable, solely by having, or having had access to such Shared Privileged Information.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Nothing in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.7</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be construed or interpreted to restrict the right or authority of the Parties to enter into any further agreement, not otherwise inconsistent with the terms of this Agreement, concerning the sharing of Privileged Information.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The transfer of all information pursuant to this Agreement is made in reliance on the agreement of Biogen or Bioverativ as set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.6</font><font style="font-family:inherit;font-size:12pt;">&#32;and this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.7</font><font style="font-family:inherit;font-size:12pt;">, to maintain the confidentiality of Privileged Information, and to assert and maintain any applicable Privilege.  The access to information being granted pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.2</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.3</font><font style="font-family:inherit;font-size:12pt;">, the agreement to provide witnesses and individuals pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.4</font><font style="font-family:inherit;font-size:12pt;">, the furnishing of notices and documents and other cooperative efforts contemplated by </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4</font><font style="font-family:inherit;font-size:12pt;">&#32;and the transfer of Privileged Information between the Parties and the members of their respective Groups pursuant to this Agreement shall not be deemed a waiver of any Privilege that has been or may be asserted under this Agreement or otherwise.</font></div><div><a name="s6C16E7665CB9BB2A52F3FB4F490B6BB9"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 7.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Ownership of Information</font><font style="font-family:inherit;font-size:12pt;">. Any information owned by one Party or any of its Subsidiaries that is provided to a requesting Party pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VII</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be deemed to remain the property of the providing Party.  Unless expressly set forth herein, nothing contained in this Agreement shall be construed as granting a license or other rights to any Party with respect to any such information, whether by implication, estoppel or otherwise.</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">59</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sC86D7C52F316247B7708FB4F4935A485"></a></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 7.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Other Agreements</font><font style="font-family:inherit;font-size:12pt;">. The rights and obligations granted under this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VII</font><font style="font-family:inherit;font-size:12pt;">&#32;are subject to any specific limitations, qualifications or additional provisions on the sharing, exchange or confidential treatment of information set forth in any Ancillary Agreement.</font></div><div><a name="s21403D3FEDB9641C0647FB4F496900FB"></a></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE VIII</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">DISPUTE RESOLUTION</font></div><div><a name="s916B631389B085B105EAFB4F4981D57E"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 8.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Negotiation</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;In the event of (i) a controversy, dispute or Action arising out of, in connection with, or in relation to the interpretation, performance, nonperformance, validity or breach of this Agreement or the Ancillary Agreements or otherwise arising out of, or in any way related to, this Agreement or the Ancillary Agreements or the transactions contemplated hereby or thereby, including any Action based on contract, tort, statute or constitution, or (ii) a claim with respect to the inadvertent transfer or omission of an Asset or Liability as contemplated by the definition of &#8220;Biogen Retained Asset&#8221;, &#8220;Biogen Retained Liability&#8221;, &#8220;Bioverativ Asset&#8221; or &#8220;Bioverativ Liability&#8221;, respectively (collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Disputes</font><font style="font-family:inherit;font-size:12pt;">&#8221;), the appropriate executives of the Parties who have authority to settle the Dispute (or such other individuals designated by the respective executives) shall negotiate for a reasonable period of time to settle such Dispute; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, that such reasonable period shall not, unless otherwise agreed by the Parties in writing, exceed fifteen (15) Business Days from the time of receipt by a Party of written notice of such Dispute (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Dispute Notice</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  If the Dispute has not been resolved within fifteen (15) Business Days after receipt of the Dispute Notice, the respective Chief Executive Officers or their respective designees (with full settlement authority) of Biogen and Bioverativ shall meet in person (or where necessary, by phone) at a mutually acceptable time and, if applicable, place, and thereafter as often as they reasonably deem necessary, to attempt in good faith to resolve the Dispute.  If the Dispute has not been resolved within forty-five (45) days after receipt of the Dispute Notice (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Negotiation Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;), the Parties shall be permitted to seek any and all remedies pursuant to this Agreement or the Ancillary Agreements in addition to any and all other rights and remedies at law or in equity.  The Parties shall not assert the defenses of statute of limitations and laches arising during the period beginning after the date of receipt of the Dispute Notice, and, other than with respect to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VIII</font><font style="font-family:inherit;font-size:12pt;">, any contractual time period or deadline under this Agreement or any Ancillary Agreement to which such Dispute relates occurring after the Dispute Notice is received shall not be deemed to have passed until such Dispute has been resolved.  Notwithstanding anything in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 8.1</font><font style="font-family:inherit;font-size:12pt;">&#32;to the contrary, nothing in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 8.1</font><font style="font-family:inherit;font-size:12pt;">&#32;shall preclude either Party from seeking interim or provisional relief, including a temporary restraining order, preliminary injunction or other interim equitable relief concerning a Dispute, prior to the expiration of the Negotiation Period, if necessary to protect the interests of such Party.</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">60</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sDAF044E9036327187415FB4F49B2EA63"></a></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 8.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Continuity of Service and Performance</font><font style="font-family:inherit;font-size:12pt;">. Unless otherwise agreed in writing, the Parties shall continue to provide service and honor all other commitments under this Agreement, any Shared Contract and each Ancillary Agreement during the course of a Dispute with respect to all matters not subject to such Dispute.</font></div><div><a name="sBF5E10B47C312688C637FB4F49D4F2E7"></a></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE IX</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">INSURANCE MATTERS</font></div><div><a name="sD6E5DA506247FC11028BFB4F4A05F688"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 9.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Rights to Biogen Policies</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Bioverativ acknowledges and agrees that, from and after the Distribution Effective Time, except as expressly provided in this Agreement or any Ancillary Agreement, neither Bioverativ nor any member of the Bioverativ Group shall have any rights to or under any Policies of Biogen, other than any insurance Policies acquired prior to the Distribution Effective Time, including any renewal thereof, directly by and in the name of Bioverativ or a member of the Bioverativ Group or as expressly provided in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.5</font><font style="font-family:inherit;font-size:12pt;">&#32;or this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article IX</font><font style="font-family:inherit;font-size:12pt;">.  For the avoidance of doubt, Bioverativ acknowledges and agrees that the Bioverativ Group and not any member of the Biogen Group shall be responsible for establishing any and all insurance programs required to comply with the Bioverativ Group&#8217;s contractual obligations and such other insurance Policies required by Law or as necessary or appropriate to operate the Bioverativ Business, including with respect to general liability, product liability, workers&#8217; compensation, directors&#8217; and officers&#8217; liability and fiduciary liability.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Parties acknowledge that, as of the Distribution Date, Biogen&#8217;s director and officer liability insurance policies will provide insurance coverage for directors and officers of Bioverativ who served as directors, officers or employees of Biogen or any of its Subsidiaries prior to the Distribution Effective Time, for (i) wrongful acts occurring prior to the Distribution Effective Time related to the Biogen Retained Business and (ii) certain non-indemnifiable wrongful acts occurring prior to the Distribution Effective Time related to the Bioverativ Business.  Biogen agrees not to terminate or amend this coverage in a manner materially adverse to these individuals.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement shall not be considered as an attempted assignment of any insurance Policy or as a contract of insurance and shall not be construed to waive any right or remedy of any member of the Biogen Group in respect of any of the Biogen insurance Policies and programs or any other contract or policy of insurance.  The Biogen Group may, at any time, without liability or obligation to any member of the Bioverativ Group, amend, commute, terminate, buy-out, extinguish liability under or otherwise modify any insurance Policies (and claims of the Bioverativ Group pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article IX</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be subject to any such amendments, commutations, terminations, buy-outs, extinguishments and modifications).</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">61</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">No member of the Biogen Group shall have any obligation to secure extended reporting for any claims under any member of the Biogen Group&#8217;s claims-made or occurrence-reported liability policies for any acts or omissions by any member of the Bioverativ Group incurred prior to the Distribution Effective Time.  </font></div><div><a name="sF3DAFB5BEABB30BB0F4FFB4F4A2FE671"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 9.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Claims</font><font style="font-family:inherit;font-size:12pt;">.  Nothing in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article IX</font><font style="font-family:inherit;font-size:12pt;">&#32;will be construed to limit or otherwise alter in any way the indemnity obligations of the Parties, including (i) with respect to the Bioverativ Group, Bioverativ Liabilities, (ii) with respect to the Biogen Group, Biogen Retained Liabilities and (iii) those created by this Agreement, by operation of law or otherwise.  The Parties acknowledge that Biogen has used its commercially reasonable efforts to structure its director and officer insurance Policies consistent with such indemnity obligations.</font></div><div><a name="sC44DD52FB126BFA454C7FB4F4A61F489"></a></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE X</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;"><br>MISCELLANEOUS</font></div><div><a name="s099D105FFD980A34AEADFB4F4A7A5CD0"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Complete Agreement; Construction</font><font style="font-family:inherit;font-size:12pt;">. This Agreement, including the Exhibits and Schedules, and the Ancillary Agreements shall constitute the entire agreement between the Parties with respect to the subject matter hereof and shall supersede all previous negotiations, commitments, course of dealings and writings with respect to such subject matter.  In the event of any inconsistency between this Agreement and any Schedule hereto, the Schedule shall prevail.  In the event and to the extent that there shall be a conflict between the provisions of this Agreement and the provisions of any Ancillary Agreement, this Agreement shall control (except with respect to the Tax Matters Agreement, the IP License Agreement and the Employee Matters Agreement, in which case such Ancillary Agreement shall control).  Except as expressly set forth in this Agreement or any Ancillary Agreement: (i) all matters to the extent relating to Taxes and Tax Returns of the Parties and their respective Subsidiaries shall be governed exclusively by the Tax Matters Agreement and (ii) for the avoidance of doubt, in the event of any conflict between this Agreement or any Ancillary Agreement, on the one hand, and the Tax Matters Agreement, on the other hand, with respect to such matters, the terms and conditions of the Tax Matters Agreement shall govern, except to the extent expressly provided herein or therein.</font></div><div><a name="s985DD00D63638DB1089BFB4F4AAE9EAA"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Transaction Agreements</font><font style="font-family:inherit;font-size:12pt;">. Except as expressly set forth herein, this Agreement is not intended to address, and should not be interpreted to address, the matters specifically and expressly covered by the other Transaction Agreements.</font></div><div><a name="s93C8E52192C691778D1CFB4F4ACDED23"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:12pt;">. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">62</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">effective when one or more such counterparts have been signed by each of the Parties and delivered to each of the Parties.</font></div><div><a name="sFEF990CC9845DCE3D35BFB4F4AFF27EF"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Survival of Agreements</font><font style="font-family:inherit;font-size:12pt;">. Except as otherwise contemplated by this Agreement or any Ancillary Agreement, all covenants and agreements of the Parties contained in this Agreement and each Ancillary Agreement shall survive the Distribution Effective Time and remain in full force and effect in accordance with their applicable terms.</font></div><div><a name="sE72803DDF82617CBA201FB4F4B29BB50"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Fees, Costs and Expenses</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except as otherwise agreed to in writing by the Parties, all out-of-pocket fees, costs and expenses incurred at or prior to the Distribution Effective Time in connection with, and as required by, the preparation, execution, delivery and implementation of this Agreement and any Ancillary Agreement, the Distribution Disclosure Documents and the consummation of the transactions contemplated hereby and thereby, including the Separation, shall be borne and paid by Biogen; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that Biogen shall bear the expense of all recordation of Intellectual Property Transferred at or prior to the Distribution Effective Time pursuant to this Agreement, whether such recordation occurs prior to or after the Distribution Effective Time.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except as otherwise expressly provided in this Agreement (including this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 10.5</font><font style="font-family:inherit;font-size:12pt;">) or any Ancillary Agreement, or as otherwise agreed to in writing by the Parties, each Party shall bear its own out-of-pocket fees, costs and expenses incurred or accrued after the Distribution Effective Time; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that, except as otherwise expressly provided in this Agreement, any fees, costs and expenses incurred in obtaining any Consents or novation from a Third Party in connection with the Transfer to or Assumption by a Party or its Subsidiary of any Assets or Liabilities in connection with the Separation shall be borne by the Party or its Subsidiary to which such Assets are being Transferred or which is Assuming such Liabilities.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">With respect to any post-Distribution expenses incurred pursuant to a request for further assurances granted under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.7</font><font style="font-family:inherit;font-size:12pt;">, the Parties agree that any and all fees, costs and expenses incurred by either Party shall be borne and paid by the requesting Party; it being understood that no Party shall be obliged to incur any Third Party accounting, consulting, advisor, banking or legal fees, costs or expenses, and the requesting Party shall not be obligated to pay such fees, costs or expenses, unless such fee, cost or expense shall have had the prior written approval of the requesting Party.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding the foregoing, each Party shall be responsible for paying its own internal fees, costs and expenses (e.g., salaries of personnel). </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">63</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sCCB143C70FE1C0E1499FFB4F4B5D4769"></a></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;">. All notices, requests, claims, demands and other communications under this Agreement and, to the extent applicable and unless otherwise provided therein, under each of the Ancillary Agreements shall be in English, shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in person, by overnight courier service, by facsimile with receipt confirmed (followed by delivery of an original via overnight courier service) or by registered or certified mail (postage prepaid, return receipt requested) to the respective Parties at the following addresses (or at such other address for a Party as shall be specified in a notice given in accordance with this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 10.6</font><font style="font-family:inherit;font-size:12pt;">):</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">To Biogen:</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Biogen Inc.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">225 Binney Street</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cambridge, MA 02142</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: Chief Legal Officer</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">To Bioverativ:</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bioverativ Inc.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">225 Second Avenue</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Waltham, MA 02451</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: Chief Legal Officer</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s89D263F00AAD24A593BCFB4F4B7657E9"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waivers</font><font style="font-family:inherit;font-size:12pt;">. Any consent required or permitted to be given by any Party to the other Party under this Agreement shall be in writing and signed by the Party giving such consent and shall be effective only against such Party (and its Group).</font></div><div><a name="sDAB4910E30185EBB5E63FB4F4BA73732"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assignment</font><font style="font-family:inherit;font-size:12pt;">. No party may assign any rights or delegate any obligations arising under Agreement, in whole or in part, directly or indirectly, without the prior written consent of the other Party, and any attempt to so assign any rights or delegate any obligations arising under this Agreement without such consent shall be void.  Notwithstanding the foregoing, no such consent shall be required for any such assignment or delegation (i) with respect to Biogen, to a Subsidiary of Biogen (so long as such Subsidiary remains a Subsidiary of Biogen), (ii) with respect to Bioverativ, to a Subsidiary of Bioverativ (so long as such Subsidiary </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">64</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">remains a Subsidiary of Bioverativ) or (iii) to a </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">bona fide</font><font style="font-family:inherit;font-size:12pt;">&#32;Third Party in connection with a merger, reorganization, consolidation or the sale of all or substantially all the assets of a Party so long as the resulting, surviving or transferee entity assumes all the obligations of the assigning Party by operation of Law or pursuant to an agreement in form and substance reasonably satisfactory to the non-assigning Party; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that in the case of each of the preceding clauses (i) and (ii), no assignment permitted by this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 10.8</font><font style="font-family:inherit;font-size:12pt;">&#32;shall release the assigning Party from liability for the full performance of its obligations under this Agreement.</font></div><div><a name="s1904166F48E659863B53FB4F4BC8CC9E"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Successors and Assigns</font><font style="font-family:inherit;font-size:12pt;">. The provisions of this Agreement and the obligations and rights hereunder shall be binding upon, inure to the benefit of and be enforceable by (and against) the Parties and their respective successors and permitted assigns.</font></div><div><a name="s1C7E4C29FE6AA2EFA550FB4F4BF9FECA"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination and Amendment</font><font style="font-family:inherit;font-size:12pt;">. This Agreement (including </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;hereof) may be terminated, modified or amended, and the Distribution may be amended, modified or abandoned, at any time prior to the Distribution Effective Time by and in the sole discretion of Biogen without the approval of Bioverativ or the stockholders of Biogen.  In the event of such termination, no Party shall have any liability of any kind to the other Party or any other Person by reason of such termination.  After the Distribution Effective Time, this Agreement may not be terminated, modified or amended except by an agreement in writing signed by Biogen and Bioverativ.</font></div><div><a name="s457334C7D6DF86AEB752FB4F4C23DB84"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Payment Terms</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except as set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;or as otherwise expressly provided to the contrary in this Agreement or in any Ancillary Agreement, any amount to be paid or reimbursed by a Party (and/or a member of such Party&#8217;s Group) to the other Party (and/or a member of such other Party&#8217;s Group) under this Agreement shall be paid or reimbursed hereunder within sixty (60) days after presentation of an invoice or a written demand therefor, in either case setting forth, or accompanied by, reasonable documentation or other reasonable explanation supporting such amount.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except as set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;or as expressly provided to the contrary in this Agreement or in any Ancillary Agreement, any amount not paid when due pursuant to this Agreement (and any amount billed or otherwise invoiced or demanded and properly payable that is not paid within sixty (60) days of such bill, invoice or other demand) shall bear interest at a rate per annum equal to the Prime Rate, from time to time in effect, plus two percent (2%), calculated for the actual number of days elapsed, accrued from the date on which such payment was due up to the date of the actual receipt of payment.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Without the consent of the party receiving any payment under this Agreement specifying otherwise, all payments to be made by either Biogen or Bioverativ under </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">65</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">this Agreement shall be made in U.S. dollars.  Except as expressly provided herein, any amount which is not expressed in U.S. dollars shall be converted into U.S. dollars by using the exchange rate published on Bloomberg at 5:00 p.m., Eastern time, on the day before the relevant date, or in </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">The Wall Street Journal</font><font style="font-family:inherit;font-size:12pt;">, Eastern Edition, on such date if not so published on Bloomberg.  Except as expressly provided herein, in the event that any indemnification payment required to be made hereunder or under any Ancillary Agreement may be denominated in a currency other than U.S. dollars, the amount of such payment shall be converted into U.S. dollars on the date notice of the claim is given to the Indemnifying Party.</font></div><div><a name="sE49935B6A5024FB12361FB4F4C57A478"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Specific Performance</font><font style="font-family:inherit;font-size:12pt;">. From and after the Distribution, in the event of any actual or threatened default in, or breach of, any of the terms, conditions and provisions of this Agreement or any Ancillary Agreement, the Parties agree that the Party or Parties to this Agreement or such Ancillary Agreement who are or are to be thereby aggrieved shall, subject to the terms of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VIII</font><font style="font-family:inherit;font-size:12pt;">, have the right to seek specific performance and injunctive or other equitable relief of its or their rights under this Agreement or such Ancillary Agreement, in addition to any and all other rights and remedies at law or in equity, and all such rights and remedies shall be cumulative.  The Parties agree that, from and after the Distribution, the remedies at law for any breach or threatened breach of this Agreement or any Ancillary Agreement, including monetary damages, are inadequate compensation for any Indemnifiable Loss, that any defense in any Action for specific performance that a remedy at law would be adequate is hereby waived, and that any requirements for the securing or posting of any bond with such remedy are hereby waived.</font></div><div><a name="s7F4477445664020F0390FB4F4C6DF3D7"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Subsidiaries</font><font style="font-family:inherit;font-size:12pt;">. Each of the Parties shall cause to be performed, and hereby guarantees the performance of, all actions, agreements and obligations set forth herein to be performed by any Subsidiary of such Party or by any entity that becomes a Subsidiary of such Party at or after the Distribution Effective Time, in each case to the extent such Subsidiary remains a Subsidiary of the applicable Party.</font></div><div><a name="sAC13915EA9A8F187B252FB4F4CA086CA"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third Party Beneficiaries</font><font style="font-family:inherit;font-size:12pt;">. Except (i) as provided in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article VI</font><font style="font-family:inherit;font-size:12pt;">&#32;relating to Indemnitees and for the releases under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.1</font><font style="font-family:inherit;font-size:12pt;">&#32;of any Person as provided therein and (ii) as specifically provided in any Ancillary Agreement, this Agreement is solely for the benefit of the Parties and shall not be deemed to confer upon Person other than the Parties any remedy, claim, liability, reimbursement, cause of Action or other right beyond any that exist without reference to this Agreement.</font></div><div><a name="sF93FC4679ED47154543FFB4F4CC12A85"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Titles and Headings</font><font style="font-family:inherit;font-size:12pt;">. Titles and headings to sections herein are inserted for the convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">66</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sF3CFB2F6E64DE15EE52CFB4F4CF35A0E"></a></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibits and Schedules</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Exhibits and Schedules shall be construed with and as an integral part of this Agreement to the same extent as if the same had been set forth verbatim herein.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Subject to the prior written consent of the other Party (not to be unreasonably withheld or delayed), each Party shall be entitled to update the Schedules from and after the date hereof until the Distribution Effective Time.</font></div><div><a name="sE9ED9292F01601C2CE6FFB4F4D1D1541"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.17</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:12pt;">. This Agreement and any Dispute shall be governed by and construed in accordance with the Laws of the State of Delaware, without giving effect to the conflicts of laws principles thereof that might lead to the application of laws other than the Laws of the State of Delaware.</font></div><div><a name="s654C734C26DD8D2A5367FB4F4D4FD5C0"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.18</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Consent to Jurisdiction</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;All Actions that, directly or indirectly, arise out of or relate to this Agreement shall be heard and determined exclusively in the Court of Chancery of the State of Delaware; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that if such court does not have jurisdiction over such Action, such Action shall be heard and determined exclusively in any Delaware state court or United States federal court sitting in the State of Delaware (such courts, &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Delaware Courts</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  Each of the Parties further agrees that service of any process, summons, notice or document by U.S. registered mail to such Party&#8217;s respective address set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 10.6</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be effective service of process for any Action in the Delaware Courts with respect to any matters to which it has submitted to jurisdiction in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 10.18</font><font style="font-family:inherit;font-size:12pt;">.  Consistent with the foregoing in this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 10.18</font><font style="font-family:inherit;font-size:12pt;">, each of the Parties hereby (a) submits to the exclusive jurisdiction of any federal or state court sitting in the State of Delaware for the purpose of any Action brought by any party hereto that, directly or indirectly, arises out of or relates to this Agreement; (b) irrevocably waives and releases, and agrees not to assert by way of motion, defense, or otherwise, in or with respect to any such Action, any claim that (i) such Action is not subject to the subject matter jurisdiction of at least one of the above-named courts; (ii) its property is exempt or immune from attachment or execution in the State of Delaware; (iii) such Action is brought in an inconvenient forum; (iv) that the venue of such Action is improper; or (v) this Agreement or the transactions contemplated by this Agreement may not be enforced in or by any of the above-named courts; and (d) agrees not to move to transfer any such Action to a court other than any of the above-named courts.</font></div><div><a name="s87D50A3BCA4F81C67A1AFB4F4D6837E4"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.19</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waiver of Jury Trial</font><font style="font-family:inherit;font-size:12pt;">. EACH OF THE PARTIES HEREBY IRREVOCABLY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY ACTION OR LIABILITY, DIRECTLY OR INDIRECTLY, ARISING OUT OF, RELATING TO, </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">67</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT.  EACH OF THE PARTIES HEREBY (A) CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY SUCH ACTION OR LIABILITY, SEEK TO ENFORCE THE FOREGOING WAIVER; AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">SECTION 10.19</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div><a name="s63D5830F37404CEB4A04FB4F4D9C837C"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.20</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">. In the event any one or more of the provisions contained in this Agreement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and therein shall not in any way be affected or impaired thereby.  The Parties shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions, the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.</font></div><div><a name="sD85066B48DD247085A41FB4F4DBBEA36"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.21</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Public Announcements</font><font style="font-family:inherit;font-size:12pt;">. From and after the Distribution Effective Time, Biogen and Bioverativ shall consult with each other before issuing, and each shall give the other the opportunity to review and comment upon, that portion of any press release or other public statement, including a statement made to its investors, that relates to the transactions contemplated by this Agreement or the Ancillary Agreements, and shall not issue any such press release or make any such public statement prior to such consultation, except (a)&#160;as may be required by applicable Law, court process or obligations pursuant to any listing agreement with any national securities exchange or national securities quotation system; (b) for disclosures made that are substantially identical to disclosure contained in any Distribution Disclosure Document or any prior written public statement not made in violation of this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 10.21</font><font style="font-family:inherit;font-size:12pt;">; or (c)&#160;with respect to a Party, for disclosure concerning the ordinary course operation of such Party's business (other than any Dispute), notwithstanding that the disclosure may relate to arrangements under the Manufacturing and Supply Agreement or Transition Services Agreement (including the exhibits and schedules thereto). </font></div><div><a name="sA406A453DEE60B13595DFB4F4DED1D53"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.22</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Interpretation</font><font style="font-family:inherit;font-size:12pt;">. The Parties have participated jointly in the negotiation and drafting of this Agreement.  This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the Party drafting or causing any instrument to be drafted.</font></div><div><a name="s6250CA36A487200873F5FB4F4E176606"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.23</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Duplication; No Double Recovery</font><font style="font-family:inherit;font-size:12pt;">. Nothing in this Agreement or any Ancillary Agreement is intended to confer to or impose upon any Party a duplicative right, </font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">68</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">entitlement, obligation or recovery with respect to any matter arising out of the same facts and circumstances (including with respect to the rights, entitlements, obligations and recoveries that may arise out of one or more of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.2</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.3</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.4</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.5</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.6</font><font style="font-family:inherit;font-size:12pt;">).</font></div><div><a name="sE70517B955CEF3E7C37BFB4F4E49D45F"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.24</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Waiver</font><font style="font-family:inherit;font-size:12pt;">. No failure to exercise and no delay in exercising, on the part of any Party, any right, remedy, power or privilege hereunder or under the other Ancillary Agreements shall operate as a waiver hereof or thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder or thereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.</font></div><div><a name="sA2DF31FBC3CEE8AF28F4FB4F4E621E24"></a></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 10.25</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Admission of Liability</font><font style="font-family:inherit;font-size:12pt;">. The allocation of Assets and Liabilities herein (including on the Schedules hereto) is solely for the purpose of allocating such Assets and Liabilities between Biogen and Bioverativ and is not intended as an admission of liability or responsibility for any alleged Liabilities vis-&#224;-vis any Third Party, including with respect to the Liabilities of any non-wholly owned subsidiary of Biogen or Bioverativ.</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Signature Page Follows</font><font style="font-family:inherit;font-size:12pt;">]</font></div><div><a name="sF4F4031E6B0CA921CEEBFB4F4E953048"></a></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the day and year first above written.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:32px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:32px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;padding-top:32px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Paul Clancy &#160;&#160;&#160;&#160;</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:318px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:&#160;&#160;&#160;&#160;Paul Clancy <br>Title:&#160;&#160;&#160;&#160;Executive Vice President, Chief Financial Officer</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:32px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;padding-top:32px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BIOVERATIV INC.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:32px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">69</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;padding-top:32px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ John G. Cox&#160;&#160;&#160;&#160;</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:318px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:&#160;&#160;&#160;&#160;John G. Cox <br>Title:&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:32px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;padding-top:32px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Signature Page to Separation Agreement</font><font style="font-family:inherit;font-size:12pt;">]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex991pressrelease2-1x17.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s29FA6CF26389FF27CE11FB804678B150"></a></div><div><div style="line-height:120%;text-align:left;"><img src="biogenlogostandarda09.jpg" alt="biogenlogostandarda09.jpg" style="height:53px;width:162px;"></div></div><div><br></div><div style="line-height:120%;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:13px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.2991452991453%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;color:#4bacc6;font-weight:bold;">MEDIA CONTACT:</font></div><div style="font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;font-weight:bold;">Biogen </font></div><div style="font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;">Matt Fearer</font></div><div style="font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;">Ph: +1 781 464 3260</font></div><div style="font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;color:#0000ff;text-decoration:underline;">public.affairs@biogen.com</font></div><div style="font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;color:#4bacc6;font-weight:bold;">INVESTOR CONTACT:</font></div><div style="font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;font-weight:bold;">Biogen</font></div><div style="font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;">Ben Strain</font></div><div style="font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;">Ph: +1 781 464 2442</font></div><div style="font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;color:#0000ff;text-decoration:underline;">IR@biogen.com</font></div><div style="font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;background-color:#ffffff;color:#4f81bd;font-weight:bold;">Biogen Completes Separation of Global Hemophilia Business, Bioverativ  </font></div><div style="line-height:138%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10.5pt;background-color:#ffffff;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:center;font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;background-color:#ffffff;font-style:italic;">Bioverativ Common Stock to Be Traded on The NASDAQ Global Select Market   &#8211;</font></div></td></tr></table><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;background-color:#ffffff;color:#4bacc6;font-weight:bold;">Cambridge, Mass., February 1, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;">&#32;&#8211; </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Biogen Inc. (NASDAQ: BIIB) today announced the completion on February 1, 2017 of the separation of its global hemophilia business. The new company, known as Bioverativ, is an independent, publicly traded global biotechnology company focused on hemophilia and other rare blood disorders. Bioverativ common stock will begin &#8220;regular way&#8221; trading on Thursday, February 2, 2017, under the symbol &#8220;BIVV&#8221; on the NASDAQ Global Select Market.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">On December 20, 2016, Biogen announced that its board of directors approved the separation of Biogen and Bioverativ, and declared a special dividend distribution of one share of Bioverativ common stock for every two shares of Biogen common stock held as of the close of business on January 17, 2017, the record date for the distribution.  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;background-color:#ffffff;">As previously announced, Biogen&#8217;s common stock trades on the NASDAQ Global Select Market in the &#8220;regular way&#8221; under the symbol "BIIB" and in the "ex-distribution" market under the symbol "BIIBV.&#8221; Biogen stockholders who have sold their shares of Biogen common stock in the regular way market after January 17, 2017, the record date for the distribution, and on or prior to February 1, 2017, will have sold their right to receive shares of Bioverativ common stock in the distribution.  Shares of Biogen common stock in the "ex-distribution" market trade without the right to receive shares of Bioverativ common stock in the distribution.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Biogen was advised by Goldman, Sachs &amp; Co. and Guggenheim Securities, LLC</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-style:italic;">.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">About Biogen </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;background-color:#ffffff;">Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer&#8217;s disease, Parkinson&#8217;s disease and amyotrophic lateral sclerosis. Building on its heritage in biologics, Biogen also manufactures and commercializes high-quality biosimilars. For </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;background-color:#ffffff;">more information, please visit www.biogen.com. Follow us on social media &#8211; Twitter, LinkedIn, Facebook, YouTube.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Safe Harbor </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">This press release contains forward-looking statements, including, without limitation, statements relating to the completion of the spin-off of Biogen&#8217;s hemophilia business, the implementation of the special dividend distribution of Bioverativ shares to Biogen stockholders, the anticipated trading on the NASDAQ Global Select Market of securities in Biogen and Bioverativ, the expected business operations for Biogen and Bioverativ following completion of the spin-off, and the potential of Biogen&#8217;s commercial business and pipeline programs. These forward-looking statements may be accompanied by such words as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;will&#8221; and other words and terms of similar meaning. You should not place undue reliance on these statements.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, uncertainty of whether the anticipated benefits of the spin-off can be achieved; and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen&#8217;s most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;">###</font></div><div style="line-height:120%;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>biogenlogostandarda09.jpg
<TEXT>
begin 644 biogenlogostandarda09.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      ! !+     $  0$L
M 0 !_^%%'VAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T
M(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*
M/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB
M061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R+S V
M+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT
M=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B
M/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+VIP96<\+V1C.F9O<FUA=#X*
M(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY":6]G
M96Y?3&]G;U\Q,C S,30\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT
M/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C Q-2TP-"TP,E0Q,SHS,3HP-BTP-#HP,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,34M,#0M,#)4,3<Z,S$Z
M,#E:/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E
M/C(P,34M,#0M,#)4,3,Z,S$Z,#8M,#0Z,# \+WAM<#I#<F5A=&5$871E/@H@
M(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-3
M-B H36%C:6YT;W-H*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP
M.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V/"]X;7!'26UG.G=I9'1H
M/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH96EG:'0^.#@\+WAM<$=)
M;6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^
M2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @(#QX;7!'
M26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5"3$%%<T%!1"\W44%S54=H
M=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%"3$%!04%!14$F(WA!
M.T%117-!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%
M0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-
M1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"
M=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X
M04%%46=!5T%%04%W15(F(WA!.T%!25)!44U2068O14%A24%!04%(05%%0D%1
M14%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!04%!
M04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)
M1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!
M.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$
M,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&
M;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA
M2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I
M<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU5
M14954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H
M85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/
M>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A
M5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!
M.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$
M05%!0T5135)!1#A!.5$V:'%&<EE7<C-.>3-'3E!$8VLF(WA!.VYO04\U>55)
M1U)O35I3049L-6QR+VY(6&)Q-5=7,VQA>F=I64Y&1$=E<$)Q3UHO82M85$YP
M:3 P04XY,T)Y6G!%-V)-4S@P969V3D8F(WA!.R]C=$9C6&)15S4S4S-T-GAX
M;&9E:#5.+W-I8VM.3&I!<7)A-35P4S9P1DA-2E)Z<E4O=%8V,7IL3F9O>FAN
M6#A*-4YA9#9,-7 X=S8F(WA!.UA+<E=6-TEQ1')!-4QX2#5O,5(Y,EDP33AO
M.&DR47E32$EV6'9*+VY7,C$V4#!::T9V<4M#<E)!+T,T2%9O-C<O35IS=%!Q
M:&LR-5,F(WA!.V,O2&LT=F5Y8DUP=&1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<D(F(WA!
M.TYD=3,Q8E=8=#!.8F$Q67AO=EEU3FYB-SES,D=+4$)'*W!C5$I,:6PW:V<Q
M=7E%24LP,T=:1TM6=$UW=TQZ1&)E<&)/-D0Y-496;#DF(WA!.W=/;WI*27-/
M3T1U>#-4-S=J24-4.$HR664R64]R,#1Z67I%."MN=EIK37)T64]60TYW96UC
M5$]W85!.;D=,271'9VYH=4EP-%=+4W@F(WA!.W-'5G@R27EN>$-$635U4D-,
M,E14<G-8;&Q&8T19=79X061M1WI$-S@V5$)L-#1#6&4U65)'5W$W1EA9<3=&
M6%EQ-T9867$W1EA9<3<F(WA!.T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3AU,$<Y16(K<7AQ>%!);C-/*V)B3$8Q.$-O95EB,5I7
M6G9(2EDF(WA!.V\P:DE71S-*<35Z36DT<%E$0T%*-4%H<6=:9W Y<3=::DYZ
M,&9Y:&)#-C Q6DAB*S9C># W-T%%9F<R8V0R-4%1>C=F>$,O,&9O8C@F(WA!
M.TUB1$QR5T96;T9&0FUM1S=K9TTV.'%K+V\Y,%!26D14-E%-,R]:>#E"2&TR
M0D]C,D-867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%DF(WA!.W$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EAJ1C9(,#-5<G%Z8EEW4TUG.3%"
M*T4O4TTS8V96148Q:W934T5T=C<T1E,F(WA!.WI-06\V:VUG>7E-86$U4UEH
M<2MR=$MR43)T44<R85@R+W=!;BMU1U4K9UEI2T4P5%%B+U5B=$Q7>&=A85IU
M>6I91'A9.49(=6-O>5HF(WA!.TDT-#A5:E%B0D5Y3D(V9G!':FY38DYB2G@K
M*U5L<&HP<34V-7=F84]Q3V9+6E91-40S3V)J:'=I:S9T639K6FEX1&%'8S9"
M05ET4%4F(WA!.VMB>4U7*VIP+T1/:#!-2W@K.6TX1B].;EA.871F>D$Q5T,R
M,4,U9VA4-G9W:6IM:U)25S)J2F]Q:T1Q8S=N<WI$0U=N:51%13<Y4$TF(WA!
M.W9$.7-A;DI(57E%6E-!,C9N*V%'2TIR,VUP,35*<4XX>2M);6U)+UAM8V-'
M3"MB2#5",7<Q3V,X<%0K6F,K=F5A:TA*.5)V;$A3<E0F(WA!.U1!9FDR15E-
M4B]H:CAG<#%/8V,U5"M:5&)29GI3.#AA5D]S:39N3&529S%E0SA9>G%W.$-8
M2F-F-T9H;5!M-TYW5$@P,3=T;DEW9'(F(WA!.S9J1V9Q36@U-R]T9E%V:S=Z
M6%DK84Y$:3%3,$)J2DIJ=4E'3E=I;%=N2D-E+U5%2'=/8W!Q.4Y,1$UX3#(R
M:3%C9%)J130O161X94@F(WA!.R]M>G)M=%=V-6=A<D)B86AC=U%P.5@T4E)Z
M4TEO<F)2:S!64T(Q3V1*,EIH:$Q4>$II0V0K;FU8:W4R3E1K:G%:0TUP06)D
M5"].1#$F(WA!.V(X;F)U-G5V26QP3F144%!-6EIW6DI73'-12D-"=7A*>E(Y
M<7A%8S5!1F-N;RMX<'EL<&]M4G,W+V5Z6$YC-U8R2W5X5C)+=7A6,DLF(WA!
M.W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W-C,79Y3G!M<C9Q="]0
M2DI(5D%S,&-D0GI+.4-73F4R,EI/3%93:$=G,%1W0U(F(WA!.W-V4&9/+S5A
M87-M<7$R:G=T8S9F3TMO<&-F=5=!,U9I>$=X-F<O4FU41%=X16)M86-F3'!I
M1#9E4WI34'EG,T5U<C-15F5V,64S,THF(WA!.RMB<TYV;T@P-6<U*S%W3F]$
M-7-O85@K8U=D861P5VUA5&)F5G10=#!T-'4O2'%X.%=9+T5X*V5A5%!Q2C5$
M8VIB;'AI23="6F0R,$8F(WA!.W@O94Q6:#!98D5::'I!4$Y*0S=43D5A86-!
M36936#=B539$=RME5# K;$TU95,P>35&5D9#<4M+;V]"-T1.*T%!2T-8>E X
M06Y&+S4F(WA!.TUF5B\K:F8O04MH67,W4'-R+T8T+T@W>3A$,C,O:E4O:"]U
M43EF.$%Y52\X;#E:+SA:6B\K5'):;T\Q+SA94'<K-39F<U X07A74'@F(WA!
M.RLY;DQO:VE-:G%(4FA2;%E60D(W14A.8414='E(>G8K9&9L=E,Y1SAY=U-A
M9$5T=D9F465T2D%G;VEY0GER1E%.;$1#;7<W-3%N6D<F(WA!.V]L:WAN:4XX
M2F5)-V4P<TU754=);U-(3'I:1"]!330W,T4S<6$S8C%R1'AT-4MB,$16:T<S
M>D@V<WA/,V]I;TAR=CA!;V,S,F%K9E<F(WA!.T]M,S95-C@U96%V>7-S9DUL
M-6$V-6]X=3E5:CE0-GAC0S-J:S5C;VM:4&E:,4IO:$$V6FHV5%1A<5=-1T5Q
M:C<O3GDY8G).2$1+634F(WA!.TE84&%Z=V<Y1UEE4TY1.'8V:#5E:'5D071V
M<65M33AG:F=+3$A29S5$2&EP66)N,WI8-GE'4T]1:DEB:S=4435-8SA13TU6
M1#5*:G$F(WA!.RMT859O.6DY.7%D>6QR87 Q:V,Y5#1+0E9M4'-"6$MC5T=7
M4UA$15=7-TYN:&EJ>%1.0C4S9F8X-4%E5V]P:6QN65A6,&<V>71W:4(F(WA!
M.R]W0E5%<V9V<&TS:#)(:TDS241P36YT1FA";T-24E=J9FYR-5)V<&QH=EDU
M.4Y:>E%3>6=015!#<DE3=R]W0T)P;&58<UA,15A'<$XF(WA!.VU$="]"33%+
M-"LO:SE&:&UH;6E3848Q;&EK54Y(26A$2WEK5D)"1WA">E5K14=I-W-%15=/
M4VYE6'1P6E=S=#-E5$I"8E%R>6QM:TDF(WA!.U962'54:&A!>4Y!5U54;4EG
M;5)O0C5Z<78U*V568F%5>#).=&,S-%5K97%!26]Z+T%+=DTX+W956G0X9EEM
M56HQ15(K,3!E6#)H=U(F(WA!.TY217!F6CDO-FM"8B]W1$]1,FQ-=T9Z;S@X
M83$S36-Q4T=N>4EJ+UAL<W5W<&1*0G!J-U-9*W-$.6XW14)R=B]!1&M(3S-+
M4%%T3D4F(WA!.UDS0S-&-&549CAI;WE!1"]!3$TU8F@W1$@X8W9L*W8Y:E)Q
M4&%1.'-C9FI,.5$O5WIB.'!V3D]P95I03$UT-7%5;VUV67)Q4T8R0W$F(WA!
M.VYW.%9D9FA5055!96UA,W105%)W-4MJ>7 R,UDK<FQN=SA5+W%%:45F-7$O
M351Y=#5:8C!T475#.3111T9L05!5;6]E-491<2]W0WDF(WA!.UE:5G!T0FQZ
M8GA',V5E5&1Q*S!S3VXR;696,T1N*U!E=W1V*V-H9$<U,%A38FMP6%EM4TU'
M;GDS+UAM>"]K2V8X-$]R+W="16U,*V(F(WA!.TPW1U=E5F9Z4CAQ95I*;'1B
M5UHW82MB-TYP8V=)-V8V:$):1RM13F9B34A5.6Y:8TES:30Y-&1J;RLQ8T]C
M,44Q3'5,3&-W2%I04$PF(WA!.VHX."]*;'9C4W=01F4X-&Y:1W!%;$MQ84=N
M-WI.=$AS8DU29G K9C=(4WHW93 X4U%E3&)Y+V%Y4'ID-34X=BM6<F1:3E-L
M2FYL1EDF(WA!.TQ324)P;D$W:%-1079U5%1-5%,V4$IN4' U9"]2>G1:<CA7
M;D9Z3R]D,5E68B\X04]196=.3T9N,'DV:6A*;UI&84YY4&9J5F8Q-7,F(WA!
M.UID:#5+,FM(57@Y;SA23SA:5CA(;S)H-CEP3W5A96PO<&1W='IB4'-76%EQ
M,4ML6%4W<7=R,$]A:DYG;FIL=WE&1C-M1%51>7@T;T<F(WA!.W=J.'%B;EEQ
M-&=%54\T4%59:TMG<FI4165P:F)G9D$W:DU42G!!95=Y;TXY1W5Z,&10=E Y
M37AJ;W Y-%9F0F]39S%N:S5F-4LW9FDF(WA!.V-N1%%F>FEQ85)24GA)16I5
M2V\V05IN>&=):6=Q-TI+*UIV>FDO.$%*:C9V+W="1R]W1#%#>%HR6%I8*TQX
M*U S;#1(='8X07AQ9G<F(WA!.R]W0GE'4BM14'IE,&)Y,35:9S!M-G-R;6%A
M2C5'85-,:'A03GEW*S!W4&9-5%AD;'IZ6D1-14)Z*WIU,G-E1$-)4T5I4F9D
M,RLY:T4F(WA!.VXO3U%M9T-.:D9P9# P;%!H5FUJ544K-4)A;C-::41S3$HQ
M:TA.4'1*:7)A379S95<V+W)(;4AZ,35K8353,65E-F122&)79'5R4#8F(WA!
M.V-3;EIF2'%X3$UE-3=$3C-G>%DY3FIQ-DAE93DU,U5:<W5S>E="6C9!9$(K
M3W(S6#AR9DDX;FQ846Y7-V]D579M170U>$E)44M#16HF(WA!.T)(6&I5,5!I
M5&Y-.7!A>G@U-V933U@V,W-/>61"*UAX,&9R;'HO53A:+T],+W=!;5!Q+R]!
M16(O05!53$9N43EL9C1V2#0O95AL93(F(WA!.R]W1$=P+T0O04A)974O:W4V
M4B]L,V%/-T)54U,T6FU/=T%%:D5K-6]E,6AE;U!W96XW1% K0W@K4#-L-'0K
M65!N3S<X,#8Y3&-L,D<F(WA!.VYW33!E;G=B9TQ'1#ES:BM:-E9B-W4R9$9O
M9$E-34LO:5!.-5!T3%A(55I#9C12.5 T.#)9*U10>4]B5F1*:#%,5V)Y4S!&
M,&]K9W0F(WA!.UE62$U2<TMQ>G,Q44-W,S0P+W!M=C%F8E!"37AG3')Q-U11
M.6=E2D%4>45I*U%(-E5K+TUB.'),;GEP1$AF,C%W8C-42E@Y3FY:94TF(WA!
M.VM4:U954%-O26%N,G1V1$UN461P1$]E16EP3THR;C)19$]/2THT;V9C;E U
M2"MD<#=457@U879*0S%L96-M<W52<C9C=TA)<5!"6D$F(WA!.T1T+TXX>FU0
M,GAO>$M0:41M3V9U+UDU6%E'=4U:*T1,-EIC=DDO="LO=T(V2B\U>4(Q,C@O
M4T=N-D5J1F)146DX;%5D2&0S94YA+S8F(WA!.V=J3E!N:T]W.$DT6E0V,U1:
M-U(V:5A&2$=/5E@K4&MK;C529FPY<#-M939U-WI6950V9EEL1BMR27A8,5I(
M<6%->2]%1E5$=%-T974F(WA!.UI(86UU;&A!169Q3&ED:F1M>#%"37 O5$AP
M,VPV5G(S-4PK5&(S5%I9=$]T4#!F9D)38F4T4U-2:'IP.$ED6%IW5G(Q-S5P
M.%!A*V$F(WA!.TUG6DAI:3<W561H-F5C4TEJ:&PP3#4S=#57=&)U3U9O,&MA
M1G=X:&Q536IC5#EL,3=G.41N5WE(14LW,V@T;FAL9&-U.3E'95DO35<F(WA!
M.VHK569)9S%84F)',W-P9%)33#9L1$9':4M:6FLU0C-#9V-U0T%N9G)3;F9/
M4C K0V5F4'=42E!$9"]"-W)686Y(<&10>#0T9V-65C<F(WA!.WHK>#1D-5@X
M=F%T-7HX>6DP17A-,#5A93EV2DMS55%%8S5$-&UP04$X4TTV6%4U-&%F2&1B
M1%E"-4A386%E<7IC3C=N8VXY3#)C9FLF(WA!.U8U2"MP*V=F<E)N<%0V,S9V
M>#%P,30P-&8X3&Y/+WEZ;G4Y<3=Q97$O:T148TYB,S,S*T(Y:GAN>FXU5#%$
M>6HU9TYJ2DM804%N<W(F(WA!.W1+<5=3<#1T=#EL;$LP4'9N4F%457AZ-"M,
M-$502S8W4GDP=5AH=GI"92LO;&8U=&9Z3#57:'5,;'57;U=R9E9R,#E/5'%!
M5FMP+VPF(WA!.W%15#<Q>FQU,&1,-$]59V939'<Y;C)6<E!(=V=N-FAS9G@U
M=FUZ5U K3W1E+W=$35),+WA--3)'3#9"-V<X2G%F-WE8.5DO93E",&HF(WA!
M.WE:-6<O37I6-S-Z1F4S2#%$5'!*4VM-:DM:1S1R.6U+2DMQ3TM$6718<C1M
M=6%R3'$X96IG36-2>%,O1S5D,6@P3UA8>FQL:V5'1C<F(WA!.V9Q2#8K+S1P
M6BM96#576'9L2T-'*VIU:&9A9$LT:6%8:#9B>'E%16=-=%=&1%$P3F8W8G1$
M,FQ(3U1%:7!/4#)L,E),5$%30C1O+V,F(WA!.VIV>4LQ<64P.#1(5&52*W)A
M;$,V=$A88C%)5DUI=CA!34MR1#9C<3=:=VE72&DV>% S-TYV<R]N36,O0C!K
M4'1'+S8S,$IN2U!B3W@F(WA!.U8R2W5X5C)+=7A6,DMU>%8X>F9N1B\U3696
M+RMJ9CA!-FA9<S=,<W(O1C0O2#=Y.$0R,R]!23%0-&8W:THQ-4@O2C9$>DXU
M9&@Q9#DF(WA!.U5A,6%:-44Y15%H=U!467(Y<FUV5VYH;5!R3S%4:'E'2$1F
M>&-V461I1%!I1U%Y<3<V2C8O=T1Z:G1">%!$6%=$9&EB645F:$M->%(F(WA!
M.S(X9C5N,B]S8W,K>E$V5"MZ.7)Z=GI:-5$X=V53=%9H5V58:5I+=EI8.7-Z
M2T<T;F5H*T9L6F%I;WIB85A663E213$X45A387I26F0F(WA!.TI-5V9C43E:
M+THS.'A,>E@T-71',6%4,613=%4Y5T,U26]:65%1<$0P+V)5:V(Y=V99:S9,
M=%A11$95-&939G9E:S=&-U1L;4)H4&4F(WA!.UDS=G9$>E X-'8X07E9*W(O
M=T12=B\Q0WA:=65Y=CA!1C0O2#=Y-D1T=CA!>'%F=R]W0GE'92M6-W%3,2])
M92MM:C)F,')T05)S4C8F(WA!.VMH46XO:',Q97!J>&$T03DX6&0V3U)J,F-3
M3S98,VPT,V\Y<DAD-G99,FMN.3-C6$555"]!0V1W<"]8;E$U6F--0V4T1C54
M5'=%.&LF(WA!.UEN:U-".7(W04%#9TMO;T)S04]G1V-!*VY-6B]-=3)I=5!)
M971*2TMQ=',P;R\Q;VE(52\X175:;EHX:4TX83<S03=49TIA95E0.$$F(WA!
M.TXK-V0X,6583&U3,3AW85IC>$=K:TXQ038O3EI!8S=(55(T<V-G931V0C93
M4FIM9U(O3T@S=EI0>GDX;%AU;W=1*UER1F9597=H358F(WA!.S=&*S$V25EU
M<G(T.%-Z8W,U+W-B5FE"3T]8.%(R.3<Q2&(K9VQK07EX+VA'+W4O63@Y+TQB
M.'A*9DM&,V-,3$%B<E1R>FHV.%-M:G$F(WA!.WE6;S96,C9':$AF>'IA.6]A
M05IW2TY31'!/>2LP>G!P14580U103F4O4#A!,'1T3VQJ,%-X=5)F4TMY<$YD
M0TY%:DI&031#4$QY23@F(WA!.TYS,6U$<T]81C9Y3TAY+T%D>'%084](0V9$
M:DQI.#8O5UAL,VLW>6AQ9FUJ5C1R2S!J65%"9V)Y-G X155D9'E4,')4-TDW
M;DXQ<3DF(WA!.U9(1$1I4%!O3SDU-U$V2V5O;4EX-614,T0X8VYO6"]/441E
M9VYL+U0T=FAT;UDU:7$O-G9P;W8S05IQ97=X9DA).#EV,'4X.7!$47@F(WA!
M.WA(3&8Y1'HW>6PU,#%F>71C6$9X<&EW;5<U45)U,'E&-DM$5V=O5C9N3G1Q
M=$I$3T%*6',V5%)A*V5M2DU+,S<R5&8X<C,X.&9Y,F8F(WA!.R]);'8K83AW
M=C5&=V8P=FTW1"]21'%/-E!Y+V%X<GID-3(Q;GI63F)Z86]S264Q5FMJ34M&
M3FU)2G)5=%AP;5IP9$A$04-),W4V+U<F(WA!.S8O2G%31$]T=34V0B]W030X
M6%1#.#%Q,'(X3'AW4V=D9U5:,2]W0TXX,5AB<V1O;C-U-SEM<&)Z2'4O4SAR
M,6HO:G)8=B]-4DPO>$TF(WA!.S5V35@P1#-"-3-5+S-K=C9X*SDY4V528DM+
M>CAM-DQ"14%Q:7IH9'%D0SAI0U)Z.4Q-5&Y%-C):;&UK5"]/3#9&;TE#1T-!
M2#@P2D(F(WA!.RMD64(O3"LX<4]K<T90.$%K84UY=7E0.%E(=5 S3T@R-2]I
M<W9H.3=Y2#AN9B]*:C92+S!C9CA!54Q,;2]W0S%F.%AL.%!V1'I(66XF(WA!
M.RM.42M0*S5,-EIZ:EAV;EEQ-T9867$W1EA9<3=&6%EQ*UIV>FDO.$%*:C9V
M+W="1R]W1#%#>%HR6%I8*TQX*U S;#1(='8X07AQ9G<F(WA!.R]W0GE(<B\U
M2V8X06MV<E O:DQ0+W=!;E=Z461R+S1W9F@Y>C O668K2W@K4#-S-GI73S-E
M4&8X-4(V<EE.86%:<%-Y2SDX<W)816DF(WA!.T%G<VMF1&E/6&AY2C(K5V1"
M,DAI;&-P9G<X;FUF851.2&AJ1"M+-RM$1"]Y55=5+VU"6FQ!94MX5&U3;E1J
M-E)'+SA!<VE->BLQ>5 F(WA!.WDU.30K.3%F64E0-6M6,T9$+VY&+W=#5$@Q
M9B]!2TXO*V]73$HY;&8T=D@T+V57=G1V.$%X<69W+W=">4AP2&M,4S,Q6#AL
M-VI4-'@F(WA!.WEL=5DW>$E2-'EC,DMF.$%$05IP.6)K-$Y92F0S0S<O04Q/
M>$A*;T]%8WE*9F58:&QJ9%!:,S%V9&]+=F)3<$MO.3!935 Q6C P-#@F(WA!
M.U533SDT-T9K-$I#439',S$W65AT=&8R548W875*3&4U:E=72G@S5GA56G=-
M-$=-:D4X=RMM=VU*>$5H>4Q&9GIB,6%$5'9);6]H,D$F(WA!.VQV1D9R06@V
M<S!P;S%0:VY)-6YD;#1J4%!(>3-D9C)X;4=05%-V.$%I,BMB-2\X04I/;5-A
M<#5U,&EY4F58<5A58E-$+VEU3G95:U F(WA!.S!)<$]D5G)-;D)I;$QY94PW
M4'A(2FYH169Z:#EM-2MX;3,U-F5:.5-N.'=N449K85!4<DY),V5*5%%34WE+
M2#5.5')X0D%!4%1.8C(F(WA!.TYP;VI(-&XX4F1T-U%A=5IY948O0U!T3$EF
M>34X<69L<G)(:S(Q93=T-%HW-G)I*V%757!-<W9):6YW=7!694E(1VYB,W)M
M3'(Y5'$F(WA!.V-E63!323E/-7IU>DY(<&-U;D9G1UA7*V0O:FPK=&M56#59
M+VQ81S1D8D-!:V1!,3%--"ML5VQ)3UE:-U(Q4C9N-40Y5&UX-THP9TXF(WA!
M.SA)*UHO5WDO5&)$5&)',%-$5&])<F$P1S92=TMQ2G8S05AB9GAZ07E4;$DS
M26MN>F1L:GAX:$=O9T%E5'EF.$$U>4@P*U)R9E)T4E4F(WA!.T@P-#-M=#5$
M,D1/1F10.$%I1%IV97=S;3AO*S1V3V4P=4TX34ID0EDK9CA!66LO+T%$:B]!
M2VYB=V59<BMW:UE,2F4R-&%'=C=4470F(WA!.U5Q4&9I>% P6FMD=5EY8UEK
M3V@K.7AF6GI+0FML13@U1#=N=D]C=3EI>')Z6"M96&QZ>79C,C%T<6IY971C
M<7IQ<TMH>7%+86-N1E$F(WA!.U%'3W<K4GI-,#)H>5IG5$AO-$]R-U)X86-G
M5$\U4G9L<GID;U!M4T-79E-*,FY306A:=55C:V9&;7%14&I6461H,GEV56%8
M2FA.5$8F(WA!.U<R85A763@T2GAM-CAI*U8Y62\T-C$W+T%->$5V+T5Z;F(T
M=F](=40U-7%F-WE8.5DO92MR4$MV+TM,-E O>D$R,R]*;&,T9E4O,W,F(WA!
M.W8V>"LY.4<P=CDQ1"MQ4'59>BMD9B]K=G)Z+VI,0B]Y9%A->G-J+T=".&9U
M9&8R-2]I<W9H.3=Y1#AN9B]*:C92+S!C9CE1<W5B+W0F(WA!.U@O1C5F1#=W
M.'@R2B]J55!J+W53*VUC-#$W-3)+=7A6,DMU>%8R2W5X5C)+=FUB.#1V.$%Y
M62MR+W=$4G8O,4-X6C)86E@K3'@K4#,F(WA!.VPT2'1V+T=P+T0O8VA)=% X
M,F5:.4]T5G1B1%9,<3%T;$I+=WA3=6E!<V%M9T(W;DUN2G!C8WIC;V=N,T](
M:3%U8DA(:&I+44AV4D(F(WA!.S@K*V1I0T1R=#E1-V)816<O56-J*U-W+WI)
M+TIS4&%/;R]N>2MA5E)X-FAQ5C5X:E=7.'9:,G)243!S<G0Y1E=*>3AM34(P
M041J050F(WA!.WE3-GEK9FE8=G8U4F9L,V,K6$Q76%4Y555*<3$T=G!R1%5(
M,%EA:'5*23(U35%#9D-G.3@U8G146&I-4D=0,&HW4SEN,DXR66-%5$\F(WA!
M.V8Q>2MW4$Q0>FDO.&U0<2\O4G8O04Y1<U=B=G-R+T8T+T@W>3@W,C,O:E4O
M:"]U43EF.$%Y52\X;#E:+SA:6B\K5'):;T\Q+SA94'<F(WA!.RLU-F9S4#A!
M>%=0>"LY-3,K8FXU8EAM;39L4')U;'='6%-R<&I,8W!'0U1B>4YU-4E(4TYJ
M=40P2%1B8DYT,E@R9TIX14I(,41L-2\F(WA!.W1D2#)Z,EA+17IL9TQG9'HU
M2'(X1TPK5R]W07AF3G9L,C).<'!T-5,P2DQ#,VQ26D55;F-L95%Q=C!';5IU
M;S!'3$MB:TXS6#94=% F(WA!.TYG2$1%*VYU2T8Q>GI,-6XX,3,X4#$K85,Y
M=4LX3&$R:E191G4P8V%$<6%E1E1L;4A4-'-%5'=I:#%A=%)Q<S)P:T]).%(V
M069O1#(F(WA!.V(X<%!Y,6PX=GA.<D=R24)Q.7=N0TM$<C9%4C-.86)C,C<K
M03(X8S4S=%1T05I4=U$K9V9A.5@R4#)78T$T-2]79G-(-C)'+VYV4#4F(WA!
M.V)N,2M(-FY+>C8Q0V=I,4)504U156)P>6%V.$%E0W1.<3=D855Z661I>'E$
M1V(K:G K3S4Q6'1$3$5C9S14*SA(4'4O=&5E6$=I-G@F(WA!.V)+<EA.:&-1
M<31$25I);E%-1T914E5#;TEZ8E)Z45!)9R]&,&MT4&MJ>FI)9D%O9C9P9&8W
M-68O04E%+S!Y9D5/.6@T8W4T<3)N-G F(WA!.W%M;#-);G-,;5=Z=450,C1M
M6D<R-T=N6#5(27IX>&U+:T%1>7A:<#1Z8U-9;#=T-58Q84@X>F9).3=P5W(P
M5%5,8W)(4$]G02M0-U4F(WA!.TTT561#4W U065"-D$U>D=P>$A2-7A+2#!N
M.$5066%034YF<'I#9C%$;BMG=D<Y8CAV95I02T]S2VPP:VQR8W=V>71B>4EK
M22]%-U F(WA!.T9)2V8Q2&9/:'<U.&5E1S(T4$UF<F57>C9B3G!P-S=%8VHK
M;W-K:"]03'HS2&%#0FYT<%I!05!R3'<O=DYV.$%66E4O-%A-33EJ64,F(WA!
M.V(S.3%U9D@R9S%!1F5K*V1F9TUC=&),>E8U,3$U:6=K,4158F=G>E1T<VE,
M-'5W2$9%2&(W:&U:2V5,5'<O;7A$9W=H;3%E5')+4C8F(WA!.SDS-F<K:V9*
M6&Q3,3AR-D)$<&-,97!)0UI,<65L4%5M86Y*=FQS05!96GE'<S%*>EI$22]$
M,U!D84A2># K25%(>%!E6'DU<D@O2%<F(WA!.W9F.$%M26PO-&UC-UA&.4$Y
M=V90=%0O95,O<D@W,S%:-58O-5)F4B\K64<R+W=#5$LU=RMP+W9:9C%J.3<V
M3G!F-W%(.55F8WAN.#8F(WA!.R]W1'E8,34O>&QG+S5/<FU:,E(O:D$K4#-/
M=C=C+WA76'<K.35"*U1V+VMX.4DO-D]0.$%Q1FQZ9CEQ+S1V3#1F94AM3WA0
M.&%H.&8F(WA!.SEY6&\O;6)Z>C5P<W9-,3%$87EI3S!S;D-F5E1':%%K>'4X
M87EK;S!X86-X9THV9$(X86IR,3%';C!72U=-13AZ,2]6,#(V,S-046$F(WA!
M.W)86EE:4T%D;SE09V%V66XQ5G1895!J,4Q.23<U,DMU>%8R2W5X5C)+=7A6
M05A8;"]18G5D<FDV,#(Q=4HS<'IM;&=J9'I154976E,F(WA!.U110VU7>'HU
M26EH26=E.7!L<#AC:EIJ16XS0E,O=T%+*U8O*W)062\Y23!0+TY/4R]--68U
M,'9M569L8U@X>5!Y1'8X2RM6+RMR4%DF(WA!.R]W1%-.1"]Z5&HK6GDO>G!F
M37(K5GAF>DDO24DR,7-,1WI5<F%7.%9U<#9R16EO3G9:44UQ;$]5=5IT=&I#
M3651<%AY3$I!6%AL+U$F(WA!.V)U9')I-C R,75*,W!Z;6QG:F1Z455&5UI3
M5%%#;5=X>C5):6A)9V4Y<&QP.&-J6FI%;C-"1E=L;F%78TEG=$E)-V5"86Q9
M;VQ614(F(WA!.TIQ84MO07E%<&U2<VUY,E%G26EG2T-R:U=34E@S:U1Y8F93
M1U,U,&$P95)J5FY72E59;C-+8U-C>6]A,TY(65-,:5I.0F=M8DU),S<F(WA!
M.VMB<&9L-U%D2W%D3C K,W,R8EIN:&E21TDY,D%Q9G!Y<DIN;E V<$5T=4Q4
M-#AF,%)%9F-%=WEP=69);7)095%E66)Y4S=54&526&,F(WA!.VI80WE#;TUI
M>45S1T(X5WIV8U%">&EU5F9O9DY--6Q(3DEN-FA)+T\S,&@U82]->GEL<FQP
M2$ET.49:,V)!97):,TQR139V,T,X<4(F(WA!.W@W<FY)86IS-TQJ4$EK9#1E
M-C!V86U$34)59TID>#)0-U=1=G$R;$I(-FHS<T-X.65B4V]&*SAN35%9<$AO
M6$]/4TDS<U!$4'IV,3<F(WA!.WER<6PY67)P1'<S5CE#2"MU6&M&0W!5.&5#
M8S$R96TU-C=F5&Y49&HT8W-);FIS4C9!=DED=F%J1&ML2&=Q56AZ22LW>B]1
M>4PO;D@F(WA!.W93-W%(5&17,4M24W1V95-24E<U3E)Y.4%/6$DX4E=10W9J
M6$U4=#-)1$M-4GI&+V(O635V<S-H26A/6C5324$K1B]R97$S9&Q:,VLF(WA!
M.T17.35"2&-W3CEQ2UI&:U$O3E="1V%/37I%,D1296IN0TUH56A94TTO;#$U
M1TUV<2]O4S U94AP:FHO=U R9G=Z2B]0-39R:DQI9GDF(WA!.V1P-W9G:CAK
M-W,W0WAS64)"6E<X5G)!3VM52TQ'9R\R2V=$36%C-5-.>4YL>6]9-'A&4D%!
M.&QF27,P<V)Y=C5:9&DW-E):37I%;&TF(WA!.TYV15-397!*-#5C3E1K+VY3
M*UIA1'!C4B]H:CAG;4UC8V-587AX<45J44)54E%!;U5#9T%!-D%:551B8T)3
M>3=S-U,X:$U&,T)(8U$F(WA!.TY1=$9+<75H24Y25E="1T=->D4R1%)23T%K
M2TES25<Q.'8V1&%4<F-7=6TR='9/;&5%,%5%84]+:6AO>7%#2V<P>6-S*U-1
M;WE*2'8F(WA!.V$T-F9(13))>$(Y=U)%=&A9>3--9#%,8GA36$U)<$9/>4M:
M14AG<D562#!:051K0E%/>EE94DIS:F18>4Q*,DMU>%8R2W5X5C)+=7@F(WA!
M.U8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMS1#@Y9FQ(;S-M835B54E*
M:G R<4U+4U-Q;V5/5VY1>4I69FDW8V=F;EA.<&]U,4HF(WA!.S12=VMC55A4
M.6]D:EDY465)2&AN.2]V96,S9C5#96-O;5!O5#)D>6TO16E2,%DO34UG2#0U
M=&\Y=#14>D5G-D]F<S=N0C)-5#@O,4LF(WA!.T50-48K97!';S1T65)51&LX
M,5)V,RM"6$\R5%!B3T%D+W=!;4$Y;G119C5V>B]9>6IY-R]!330O=WA3<$YR
M.2M*,5AC,FQO0W%K*T(F(WA!.VQA:E4K4V<K*UE79G1W:U9J1F5:+U4W1%1E
M>F="=DQ++TEF<B]S970R9&YA,E9R1F%7:U-W5S!#:$EO:T9&5E(P04=A1V-Z
M23)D>5@F(WA!.W!9445104)10W1K5U1S5F1I<G-69&ER<U9D:7)S5F1I<B\O
M6CPO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL
M<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X
M;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^
M"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,#<X,#$Q-S0P
M-S(P-C@Q,3@R,D%!-#$R-#%"-3@Y-S<\+WAM<$U-.DEN<W1A;F-E240^"B @
M(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z,#<X,#$Q-S0P-S(P
M-C@Q,3@R,D%!-#$R-#%"-3@Y-S<\+WAM<$U-.D1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS
M0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^<')O;V8Z<&1F
M/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV
M961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M/'-T4F5F.FEN<W1A;F-E240^=75I9#HY,C<V8S!E8RUD.61A+3(X-#DM.3DQ
M-BTQ.6%E,38V,S%E,C,\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @
M(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,#,X,#$Q-S0P-S(P-C@Q,3@P
M.#-%144Q040S0T1$034\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @
M(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$
M0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^<')O;V8Z<&1F
M/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I
M=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D9%-T8Q,3<T,#<R,#8X,3$X,C)!1C$S
M0D4T0T(X.38U/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#$T+3$R+3 R5#$T.C,P.C$Q+3 U.C P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*$UA8VEN=&]S:"D\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C W.# Q,3<T,#<R,#8X,3$X,C)!030Q,C0Q0C4X.3<W/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#$U+3 T+3 R5#$S.C,Q.C V+3 T.C P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU
M<W1R871O<B!#4S8@*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H
M86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O
M;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@(" @(" @(" \:6QL
M=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R.E-T
M87)T=7!0<F]F:6QE/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @
M(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F
M.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z
M4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP
M86-K970@96YD/2)W(C\^_^)]$$E#0U]04D]&24Q%  $2  B <$%$0D4"$
M<')T<D--64M,86(@!]  !P :  4 *0 U86-S<$%04$P     041"10
M                 /;6  $     TRU!1$)%
M                                       *9&5S8P   /P   !T8W!R
M=    7     K=W1P=    9P    403)",    ;   *(&03)",@   ;   *(&
M03)",0  H[@  *(&0C)!,  !1<   CBT0C)!,0 #?G0  CBT0C)!,@ %MR@
M CBT9V%M=  '[]P  )"19&5S8P         :52Y3+B!796(@0V]A=&5D("A3
M5T]0*2!V,@
M                                                      !T97AT
M     $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,L($EN8RX  %A96B
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MW%_,8+UAK&*;8XED>&5F9E1G0F@P:1YJ"VKX:^5LTFV^;JIOEG""<6QR5G-
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M_P"  (  Y;1_S7]4S#]_I7[#LHQ_E'YIF']_GGY,?>-_P7YC8D%__GZ21&&
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MY"^#B\#:S:R"G+J"MI*!SK1ZGO2!-J[?ANB TZFP;C& DZ3M5%R 9:#8-]V
M=)Y8$52! XNWXRF#),R5S*^"-L4[M9B!9;Y#G@. RK?+A@F :;'=;7> ,ZR-
M4\: "*A6-TV "J-<$*Z ;(M'XDZ"T-B[R]J!YM!.M,2!$\AAG36 =,$4A4Z
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MJWDZ?=&P_'DR;&2LBWEG6CBH9'G41N^DKGIJ,>NAYGL'%_"B<GN^  "1*(
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MT9^2>OJM#YR/:8NHCYGX5WFD6I?61'V@DI9P+_B=GI:D%R>=9X^H  ".7H
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M\W_X<<*YD']*84JT;7[B4 VOGG[$/:VK7W[E*5VH9G\R#X6IPX!$  ",_H
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M*J30<!:UJJ&'7Z*P;Y[?3HFKDYT'/'VG.IRL*+BCX)IN$$ZD!HL&  ",&8
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M?(9!9D/"A83Z5IF\O80A1C^W2X.>-+ZRD8.!(0NOE8/X".:O*(/^  "*+X
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M5*EV9DJ^**8!5L*X/:..1H2RPJ*A-3VM^*#I(@JJ@I<$"N>I3X=?  "*@(
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M0Z@L<+-X%J-.5I%XV)[K.=9Y9IPJ$W)XIHTFYU=T3,L+T'ETRL/JN09U4KT
MH1EU^;9VB,QVQ+!H;^AWGJKA5>=X9*8<.3-XXZ'1$KEX"(RHYI%T ]<IS[AT
M><\,N#IT]L<QH$5UE+_(A_]V7+CW;R]W.++H549X *XM.*9X=Z9-$B5WBXQ$
MX>.$+G?ES#.#HW@[M?*#+GB8GOZ"T7D,AUJ"BWF=;O""77I+56""3WL".2:"
MF7O3$]^$G7R.X!^"H(*]RO>"*8'WM-V!Q8%-G=^!>8#,AB.!0X!T;;.!*8!
M5!Z!,( >-^Z!@X L$GB#(("FWH2!2HVKR4Z X8O>LU& AXHOG&> 48C#A-2
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M#;'CB4B54:UU=H62SJE68R"0DZ7+3N:.IZ-*.5F- *%;( R,D)6K +V)&X"
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M]HR#@'V@@(K^;MN=1(FR7%6:68BK2,N7Q8?A,Z&5T8=X&A.6&H@X  "*=X
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M5+<A?82=T+*+:]>:@ZYZ69"7AJN#1FR4[ZE",<Z2V*&L&/>2M9#A  "'L(
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M!))P=%FHW)"(8[*DZ8[?4DJA0(V$/\B>'XRA*X&;VXRH$AN<[HKB  "'&8
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M]7.M:MFV0W0K6R>QRG3,2HJMGG6'.).J%'9&)%*H*W:W"EBJ!W<7  "&#(
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M9Y?6:36QB)6<676LWY.]2/FHC))5-UVDTY'&(\.B:Y'H"W2BE(>_  "$PH
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MPGH17UZ_:WG94'"Z27G:0)FUAWH-+U*QJ'I6&T>P,7I?! NN+WQ&  "#(H
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MZIRS7O>Z8)I'4 JU#)AF0%NP)9==+WFL )=Y'$NIHY,A!CNFSH0W  "#'8
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MGJ,9@DJ0>I_Z<&B.@9S\7<F,PYI32C:+1I@_-26*%I>4&]&*+)+/  "#E8
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M?7]>>@J<EG\-:1^9[7[@5T:7>G[01#N59G[9+V*4!W[H%525>'\(  "$!(
MF$JA98A*B0V>8X=$>1B;AH93:$Z8V86$5H"6<X3C0Y.49(1J+MZ2_X0K%0>4
M/H2   "#*(  EWZ@?)#=B$.=?(]">$>:H8V]9W27]XQ85=&5@8L:0OR3>XHU
M+FR2#(G1%,J3&XE   "";(  EM>?L)FKAY><N9=Z=Y>9WY579LF7+Y-352^4
MMY&-0GN2FY! +@R1)Y .%)*2%(U&  "!SH  ED:?'**/AQB<*)_/=Q691)T-
M9CF6BIIT5)V4%9A!0?^1_);)+;20;9:%%&&1.(W(  "!2X  E<Z>L:N7AIV;
MO:A.=I*8TJ3Y9;:6#J'75!Z3E9]108>1@IX0+5B/Z9O@%#F0A(VL  " X(
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M.H5W;<.DJX2B7>NA38/Y31&>0X.!.P";M(,V)N":-8,M#3^;M8,1  " DX
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M,ZTJ:Y6A@JG 6Z.=]J:]2O^:Q:3Z.4Z8'Z+$)<B649F,#4.6H(CW  "  (
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M<HKA8ENM/HFP4U6I-XBM0W2EAH?P,C&BDX>>'I"A-(@K!O&?^H2Q  "  (
M??"T_I0&<$^PK9) 8@BL<9"74P*H8H\F0R6DJHX2,?ZAG8VU'H&@(XW@!R&>
MHX32  "  (  ?9^T:9OF< NP$IFV8<:KR9>94KZGKY7$0N*C]I2",=*@WI1Z
M'GZ?+I*G!TZ=>(3Q  "  (  ?6JSZ:/E;]BOCJ%089"K/9[-4H:G&YRI0JRC
M7)MP,9R@2IKB'F:>?)2-!WF<=H4.  "  (  ?3:SFZQ';]"O*ZE6882JP:9=
M4F2F@J/K0I"BK:+#,92?CY_S'G:=R929!Z";Q84H  "  (  <J_%2&S>9:7
MK&VT6!V\.6Z?2=.W[&^5.G6T 7"!*5.Q-'$M%):QZ7"X  "K*71[  "  (
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M'X_+5[*V3HY426>QJ(TB.D&M;(Q>*:BJ(8R%%B>I6(N# ?&BZH%0  "  (
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M0X"!W71'*02"@753!3R#NW:-NDR O72SJ1" C76-EK. 9796@T^ 2W<7;N6
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M-'U&4"F$N'UU.E&$<GV9(%6$]'V0  "#YGZ*J=&&]H9:F:2&#X6WB)"%/H4
M=HN$AH138WF#[8/#3UR#>8-).::#.(+C'\:#F(*X  "";X  J*6%PX_;F)B$
MX(Z*AX.$%XTB=6*#9XNV8F^"UHID3FN"=8E*..&",HAN'S*"9HA[  "!+H
MIZN$UYE^EY:#^I=^AH&#,)5<=&^"@),S88R!\9$P3:J!AH]X.$6!18Y2'K6!
M6(W=  " ((  IN*$'*,RELB#1:"(A:V"=IVL<YF!PIK*8,2!-Y@F30" S97R
M-\> =I2Z'E& ;))7  "  (  IDJ#CZT(EB."OJFZA/B!YZ8F<N&!)J*,8!*
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M!I28>S>+?I+$:C6*%)#P6%Z(U8]&16V'U(WQ,,N'*8U-%TF'K(P%  "  (
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M$')1<SR8PW,Z8R:6HW0B4?"4MG4,/V63*G7I*M.2=79Z$#B4]77R  "  (
MCYB<(7G9@769NGH2<GV7;7I-8F"54WJ543V3:GKI/LN1X7M *EF1''MQ$ :3
M+WLE  "  (  CL^:S((]@)*8;H';<826+8%Y89"4$X$F4'N2-X#J/BJ0LX#"
M*=Z/XH"I#]*1DH"J  "  (  C@"9M(JH?\:768FY<+25'8C'8+23!X?>3]:1
M'(<,/9N/H(9Z*7>.P88^#ZV0%H5[  "  (  C568QI-'?Q>6>)'+< &4/)!
M8 J2'XZZ3S.0,XU@/26.GXQJ*2*-MHQ=#XN.P(F1  "  (  C,:8&)OW?IJ5
MSYGX;X*3B9?47WJ18)6Y3IZ/=9/Q/*6-XI+-*,^,V)+%#VF-G8IK  "  (
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MB'BB9R*@DWCE5^^=TGD]1[";5'F@-@"99WG^(>N8S'H5")V99WJG  "  (
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M&YZY9'Z<%YQM55&9+)HX15"6E9BF-!>4CIAA(,:3;Y5_".B2 (8&  "  (
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M?7X66W>H\WW=332EE'W#/<>BF7W&+-"@:GW1&.>@6GV\ JR;^GZO  "  (
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MOJ,96BZD_*#02[BA79[)/'N>*9WS*^N;OIN3&-&:\I#( ZR5C()\  "  (
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M(X+:4%:R%8)+0K2N*X'7-!2JMX&:(Y2HA8&>#ZFI,(&N  ":;(    "  (
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MW8 B@!=_IX #;Q-_>7_>7-M_9'_"28!_9G^M-'A_?G^4&LI_X7]7  "  (
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M8JQN>_Q[(:C9:MYZY*4\6/YZTJ(=1AEZX* :,:]ZQIV?&+AY\I"W  "  (
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M4X97<_R&:X7#8_6%DH4=4O6$V82!0)R$7(0,+%N$((._$G>$Z(.&  "  (
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MJ(OO:#^.#XKT61B,B8GK20:++HC]-YR*)8A;(^N)P(AK"MF)9X84  "  (
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MS&OB8#2<?VU!4;F:76Z50@&8@&_2,*.72G#4'&:7SW$'!""6$''2  "  (
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MGI#$71666(^&3KJ4*XY(/VV20(U.+L20RHST&X:098RD!,>-*8,[  "  (
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MDW%S5)BDM'(W1MZB W,!-^V?N7.Z)QN><G0N$I*@$W.8  "5H'@P  "  (
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M)I3U4IR?,Y.?1/.<7Y)9-D"9])&S)>F889&\$H*8K8R#  "0)X    "  (
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M&G892/VMT'9A/ 2JJW:Z+:JH('<+'1>G,G<&":BG>G<X  "/OW\6  "  (
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M+)B]2*.HD9>!.X>E-):$+5*B;98M'3.A 9-."I*@(H<F  ", (    "  (
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M?HFQ!\%RY84^MUQ:>:!CI<Q=5IV>DVI?]9JZ@#%B<)?>;#UDWI4Q5VIG&I+
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MR)='?Q1M[I4_;?!O"Y,G6^YP+I$T2-QQ-X^(-%EQQ8YQ&Y!P78U8  "  (
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M,)S*= MTGIIX8^=U")@34M=UAI7S0*%V )1F+-IV!Y/^$_5U=XU^  "  (
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MQ7B7;+B!>'DJ782!,GFH30"!#7H>.R.!!WJ!)RR!,GJK#6:!T7I=  "  (
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M8*&L:2]\$Y\X6?9[O)RQ2=9[AYJL.'9[:YG@)29[#)<C#(I[7XAZ  "  (
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M6'Y$81F(:WYD4K"'CGYJ0U&&RWYM,C:&9WYW'IV&C'YC!HR%QGZO  "  (
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MUH,^5=R02(+[2#N.RH*A.82-AH)6*3",OH(W%7:-9()H ."))X"7  "  (
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MCF3Q39.@;6:P0&R>>VA6,=*<_VF_(/.<U6J*#$^>^FG]  "+^W+,  "  (
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M&(=Y2R28\(;X/BB6W(9F+_J5,H8.'^:4;89$#*R4=(4-  "%SH    "  (
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M"VF00="IB6JT-3BG.&O.)QBEK&R:%@JF<VQ\!#FC\VUX  "&9WK=  "  (
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M,HK]0*JB@XIG-#*?_HG/)EV>(8G*%?^>$8DV!4V9JX.6  ""%H    "  (
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MWX@*=R9GIH=69O=I4X:,5=9J[87,0W]L3H4K+XALYX2_%NEL<H3   "  (
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M>8W>;$%MG(S#70)NJXN13,9OL(I[.TAP?HFF)_IP<(EI#RYR68=P  "  (
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M5FLI9<U\EVS85QE\W&YF1S)]+6_8-;Y]EG$3(>9^&'&V",5_AG&;  "  (
M?IAYIG'*<@YZ#7+W9)9Z:'0%5BYZNW3W1EM[('73-1=[AW:((71[U';0"+)]
M<'<+  "  (  ?8!WB7I+</EX"WK<8XQX>7M)52QXVGN91;1Y/WOA-(MYJ7P;
M(1EYP'P@"*I[H7R6  "  (  ?(]UUX+><"QV:X+?8LUVX8*M5%]W1H)<1.5W
MK((0,_)X H'?()]WXX'5"(-Z'X%<  "  (  >\MT<8MJ;V9U$(K>8@QUB8H0
M4Z5U\8DH1#1V6(A=,UQVH(?9($IV.X@/"')XV(55  "  (  >S%S4I/P;LYS
M^Y+@87-T<Y%_4Q-TU9 $0Z-U.8[,,LMU>HXK']QTX(X-"&-WSH6K  "  (
M>KYR>)Q\;E=S)YK]8/-SFYD04I-S\I<.0S5T296!,G1T>I42'X%SMI+6""QW
M"H6&  "  (  =4Z*MU?::8")^UKP7+*)?%W>3J2))V";/S2(_F,;+?.)2F4I
M&7^*^67S ?6*%&<8  "  'Q?=%B(&U_G:+.'F6)36^B'+F2>3?B&V6;%/JF&
MJVBY+8Z&XFI+&4^(,&J[ BR';&OZ  "  '^#<VJ%D6?G9ZR%/FFS6PN$Z6MF
M32.$H6SY/?B$>&YD+0>$H6]]&0"%F6^@ DZ%$W$V  "  (  <G"#/V_?9J&#
M"'$96?:"QW(X3$J"C',^/32"<'0C+&V"CG3*&)R#-G2R EV#"G;-  "  (
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M8)="5M-\+)6_23M[UI0B.I=[C9,2*EM[29+_%U%Z=8^/ I!\H(&\  "  (
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MO'853IN)\7;"09Z)+G=0,V:(GW?((P.(HG?]#PR)4W>4  "!3GSE  "  (
M9/>)XGSP6>Z),'U+3@"(9WU[00F'GWV-,MZ'!'V9(MF&S'VC#PO_XGT024-#
M7U!23T9)3$4  A*'$GVU  " &X    "  (  9%J(B(2+65*'YH1W36B'((0O
M0':&5(/0,EJ%L(.*(H"%6(.)#S.%(8-'  "  (    "  (  8]Z'@(Q%60V&
M[XOE32^&'XLD0#^%+(H[,B^$9XFP(C:$!HH!#N6#H(?R  "  (    "  (
M8WR&L9096*V&(9-\3,N%39)3/^&$3Y$&,>.#<Y!N(@*"[9 J#MN"78H+  "
M (    "  (  7.">\57?4D*=65B?1L"<"%M%.?F:^UVX*XF:?5^^&DF;S6"X
M!H2<2F$$  "#HVU)  "  (  7 :<W5T=4:R;65]51C>9]&%Y.968P&-R*U&8
M%&4,&E"9$66T!M^8W67C  ""$'(Q  "  (  6U^:A61#4/69&V7\19^7O6>B
M.066A&DF*NJ5Q6I6&B:6AVJU!Q>5G&KD  " EW<4  "  (  6K:80&M:4#B6
MYVR>1-&5EVW..&J486[C*FJ3GV^Q&=V4,V_.!RZ2L7 C  "  'ME  "  (
M6@R63'*!3Y*5!'-;1#"3MW0<-\:2?'2W*@*1JW4M&922''4A!S&0*G7>  "
M '\N  "  (  67.4MWG(3P:3?7I#0[&2+GJ5-U&0Z7K#*9B0!'K?&7&0+7K,
M!SN-^'O1  "  (    "  (  6/"3:X$33I:2/H$[0TR0ZH$C-NV/EX#L*2Z.
MI8#.&2".J8#K!U",'(#@  "  (    "  (  6(B27(A@3B^1.H@[0N>/YH?$
M-I".AH<V*-R-?H<&&+>-<X='!RN*HX39  "  (    "  (  6#>1CH_E3@F0
M<H^C0L./%8[.-F^-D(W;*.*,5XW"&/F,"(RA!W*)5(4)  "  (    "  (
M4*:J851-1F*HF%;2.TVG#5D]+NREY%MI((:EV5SW#I>HHUT(  "@"&!\  "
M '$N  "  (  3\:HE%LJ1<2FS%TW.K^E'E\R+H6CP6#W(%NC;6(K#L>ELF('
M  "=;&45  "  '7X  "  (  3SVF4V'O12VDEF...D&BZV48+A&A?F9Y(!.A
M!V=6#M&BX6<*  ":WFGN  "  'H\  "  (  3L>D"VBG1*.B66G>.:2@MFL!
M+:&?26P '\">OVR1#L:@/VPH  "8=V\K  "  'W_  "  (  3DNB"V]Q1"N@
M:W!..3.>Q7$1+2N=3'&D'XR<I7'V#L"=V7&. #66 '4)  "  (    "  (
M3=>@:G9@0\J>TW;P..2=*'=5+.N;GG>1'UB:UW><#MB;J7=> '&3VGI4  "
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M!HU?=T-63XPK9S]96HKR5D)<*XG41"M>;HCF,*E?%(A2&/Q@38A)  "  (
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M[9,G;1%;E9&.7>Q> H_J3;]@-HY[/%MASHUQ*6]A;HU)$8)FJHIB  "  (
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M#&\W9P!JMG"A6)5L0''R2+UMKG,B-WUNS'0K)!=NX73+"TYS7G2S  "  (
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MJ)@@8MMAI99*5(1C9)1A12EDY9+6-'AEOI(;(<ED8I%1"FMN9(<+  "  (
M>/UY[E+^;01Z8E:/8 U[ %GV4==[L%TI0D=\:& ?,/]]06*N'.)^;&0C!(2
MZ63M  "  'D@=[-V8%M(:_5W*%XO7PYW\F#O4/]XN&.%091Y?67F,'1Z1V?J
M'(A[!6CQ!)M^*6FR  "  'S =GUS#6.7:K!T%V747?QU"6?S3_QUZFGK0+EV
MOVNX+\5W?6TU'!!WRVW6!)Q[Q6ZY  "  '_O=41P!6O?:7-Q.FU]7+IR3V[^
M3Q!S17!@/^)T+G&:+R%TWW*6&Z9TNG+B!)]YL70H  "  (  =!-M5W0W:$MN
ML'4Z6Z)OWG8=3@5PYW;>/SQQUG>,+IER>W@2&UAQ[G@B!*UX&7FS  "  (
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M>'IB4(AV'GK50YIVG7LE-7]V_WMD)7UW'WN2$==WN7M@  "  'X)  "  (
M9JYRR(&S6\MSO8';3_9T:X'%0PMTXX&,-.EU.8%C)/=U+X%D$:EUVH&)  "
M (    "  (  9A)Q28F:6S1R38E53V)S 8B]0H)S=(@%-&=SNX>+)')SB8>;
M$4MT:H;!  "  (    "  (  99AP%I&&6KYQ*)#J3NMQX(_;0A-R2XZS- MR
M?HX")"]R(8XV$1%S/XKP  "  (    "  (  8*:,;U&85@>+[53<2G>+J5?]
M/9R+E5KD+QJ+UUUE'@B-*5[Z"8".:E\I  "  &EI  "  'YP7X^)4EC^52N)
M$5N[2:J(WEY5//6(Q&"\+J&([F+&'<F)^6/X":2*J&/]  "  &XI  "  (
M7I^&06!C5"V&,6*82->&%V2O/"^&!&:6+@6&)&@I'6*&]6C]":.'46CK  "
M '-D  "  (  7;"#:&?)4S*#=VEZ1]6#<6L-.V>#:FQZ+56#B6V<'..$)&X8
M"8:$9VX,  "  'A;  "  (  7,: Z&\]4DZ!$G!Q1O2!''&%.HN!%7)O+,"!
M)W,M'&>!CG-C"6&!XW.*  "  'RL  "  (  6_1^QW;$48A_"G>%1CU_'W@<
M.=U_%WB.+"-_%'CB'"5_*'CQ"5I_M'F9  "  (    "  (  6SQ\\'X]4-=]
M3WZ219E];WZT.4=]9'ZW*YM]3WZZ&]%])'[$"8U]TG\S  "  (    "  (
M6JQ[>87+4'1[^87.149\&X5X.09[\83]*V][MH3#&XU[6H4;"5)\7(/?  "
M (    "  (  6CMZ2HUL4 5ZUXTK1-EZ_XQM.*=ZS8N2*R=Z=8M(&V)YV8LR
M"4Q[*H9)  "  (    "  (  5*66W% ]2HR5\5-5/XF53U9*,R:5 ECZ),^5
M=UL6$N^84ENH 8*4I5V-  "  &T4  "  (  4YZ3_5<_2;R31%G@/L62IUQ=
M,HB21%Z;)&>2B&!/$MB4YV"9 =21"F)I  "  ''X  "  (  4LN1#%X_2-R0
M>6!G/@J/[&)M,=B/AV0Y(^2/KV6'$IN1I&6. @:-RV=G  "  ';D  "  (
M4@".0F5 2 :-R&;Q/2B-2VB!,2^,Z6GA(U2- 6K0$DJ.DVJ= A^*\&RD  "
M 'L\  "  (  43F+R&Q51T2+:6V6/&N*]VZU,'2*CV^>(N.*BG ]$?Z+OF_F
M BV(>'):  "  '\&  "  (  4(*)JW. 1IF)9W1<.]*(_74-+^J(C'6/(FF(
M:'77$>*)'W6( D6&57A*  "  (    "  (  3^*'XGJI1@R'N'LM.UB'5'MU
M+X"&U7N7(@2&DWNF$:B&Y7N+ G"$@GU7  "  (    "  (  3V"&8X'$18B&
M4H'P.MB%]H'7+PR%<(&G(9N%$8&F$2^%&('# F&#$8%U  "  (    "  (
M3OB%-(DS15J%1HE .KF$\XB]+Q"$.(@4(>V#@X@:$>2#'8<D M>!M('L  "
M (    "  (  2%BB<4Y?/M^A/%%"-&F@9U/V*%F@*%9.&<.A<U>_"*.C&UAE
M  "1E%_D  "  '!Z  "  (  1T>?YE3^/?B>[%=W,WB>&EG%)X^=KUN\&46>
MH5S8"*>?<UU9  ".W&1^  "  '51  "  (  1IN=#5N=/32<+5VL,L*;;U^.
M)MN:^6$D&,.;O6'J")>;SF)0  ",0VE1  "  'FI  "  (  1@>:/&(Z/(29
M;V/<,?:8O&56)D"81V:+&$>8[6<&"("83&=?  ")WFY\  "  'V   "  (
M1627N&CH.]V7#&HI,5Z66&M ):B5TFP*%_N63&Q+"'65#VRO  "'QG0O  "
M (    "  (  1,65DV^^.TJ5"G"G,.246W%?)4R3OG'3%[B4 ''0")*2*7)D
M  "&$'EG  "  (    "  (  1#N3PG:<.L^36G<Y,(*2KG>6)/B2 7>\%VB2
M'G>9"(*/TGB;  "$LGW*  "  (    "  (  0\F207V0.FV1]GWM,#*13WWX
M),.0B'W:%T*0<WW("%*-\'YX  "#18    "  (    "  (  0X"1!(3&.B60
MSH3T+_&0,H2S))F/681E%TJ/!82'"(6,68-8  ""<8    "  (    "  (
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MN'Y-;WI-Q'YR8&91=GZ,4$Y4OWZI/O17'7[4*_56P'\)%(=>9']8  "  (
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M/(1X95M1RH095QA4^(.P1\!7I8-9-QE9)H,I)*98D8-$#3QIH8,3  "  (
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MHXFY6S96GHCX3;-9*H@G/P=;%H>&+MY;?(=!')U<Y(?%!M-T>(2=  "  (
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MQ&@25.)HG&GW1]YJ-FN].49KA&U-*/!L$6Z"%5UM;FZI /-^97&6  "  (
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M (XS4/=<7HTV1")>,HPB-B!?/XMJ)F=>88N)$[!D.(GS 0]^-8"X  "  (
M9.-Z#$U:6=QZN%#X3@=[B%2"00-\9%?=,G1]3%K;(91^@%T-#,R H%UX  "
M &6=  "  'NT8T5UPE3?6*AVP5@"3/UWNEL%0"IXI%W8,<AY@F!3(1QZ9V(1
M#+1\K&(]  "  &I(  "  '[T8?%QIUR#5UUR[E\72^YT$F&0/R]U#V/7,/IU
MYF70((%V>&<>#'QY06<:  "  &]6  "  (  8+!MU60R5AMO468T2K!PEV@=
M/C=QK&G?,!YR?FM9']5RLVP_##!V6&P@  "  '31  "  (  7X1J7&OH50-L
M!&U?2:1M:6Z\/2QNBV_S+WAO3W#Y'TMO'7&("_YST'%N  "  'FR  "  (
M7G9G1G.R5 9I&72D2+YJG'5T/&IKQW8B+L]L=':P'P-KVW;]"_1QF7<?  "
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M5WA_3E-\381_U5:*0GF 8%EQ-BR \5P;*!.!L5Y)%O&#,U]#!(V$"&!N  "
M &WQ  "  (  5DA[6EJS3%1\'UU 07M\R5^J-3Y]7V'7)U-^ F.1%FM^^V0O
M!(J MF56  "  ',D  "  (  52MWHF'U2S%XDF/]0%9Y567D-%AY]V>:)HAZ
M?VCF%=-Z^&DO!'-]W&IO  "  '@@  "  (  5!IT.6E'2BEU4FK./U5V+VPV
M,V)VT&UL)>)W-VY8%4=WA&Y>!%I[:6_C  "  'QR  "  (  4R9Q+'"K24-R
M;W&[/H1S9'*F,J%T!G-G)3=T/7/K%05TAW/3!&)Y0W7?  "  (    "  (
M4E%N=W@*2'-OYWBI/<1P]GD:,?5QEGEK)*%QFWF?%*)R)GF !)!X2GMS  "
M (    "  (  4:9L)W]T1^]MS'^X/5AN]W^Q,:AOB7^-)&5O4G^)%$)P.G^P
M!%QXHH G  "  (    "  (  425J/X;R1V]L 8;I/-QM089X,3EMSH7S)!%M
M9(7;%!!NI(6X!%%XM8+K  "  (    "  (  3.^-H$K70V"-:DXV.-6-@U%I
M++V-_U1$'E6/7U97#("1W5;V  ")BEPT  "  &RM  "  (  2Y.)RU&40CB)
MYE2+-[6*%U=0*\6*?UF^'9F+F%ML##F-%5O6  "&3F#?  "  '&.  "  (
M2H6%^EAG01R&2UKI-KR&E%T\*M>&\U\['-R'U&"$"^2(GF"_  "#5&6Z  "
M ':(  "  (  28V"5%]'0!>"R&%/-:N#(V,K*@&#@62_'""$,66K"XB$MV7"
M  " JFK>  "  'KK  "  (  2)M^\68\/R=_CV?.-,)__FDW*1Z 3VI7&Y6
MP6KX"SN!8&K]  "  '!Y  "  'Z^  "  (  1[I[XFU,/DU\L&YP,_Y]-F]H
M*'%]?7 B&OM]IG!L"Q-^AG"'  "  '95  "  (    "  (  1OAY,71=/95Z
M+74=,UQZRW6G)^9[!78#&G)ZYW83"M1\-G9L  "  'M'  "  (    "  (
M1D]VT'ML/.MX WO0,KUXO'OX)UUX[7P &?IXA'O["FUZ;WRM  "  ']X  "
M (    "  (  1=-TVX*\/(=V1(+@,F]W((*?)SIW.8)+&B1V<H);"LYXM8(&
M  "  (    "  (    "  (  0)F914BK-[*8K4OE+:.8E$[4(:J945$[$GF<
M,E)3 U*9OE1@  "$LE^*  "  ' -  "  (  /S>5O$\$-E25CE'9+"R5F51B
M($N60%9F$6Z8H5<O PF5%5D_  "!KF1   "  '4!  "  (  /D&2%E5X-3J2
M&5?A*QZ2/EH"'SJ2UUN@$*"4PUP? M*0SUXN  "  &DC  "  'ET  "  (
M/6^.?5O]-%".GUWV*AB.U5^I'F>/9&#H#_^0UV$J JJ-!F,Z  "  &Y6  "
M 'U8  "  (  /)J+%&*:,W2+:60F*42+K65T'9F,(F9+#Z>-$&9G IF)Q6B'
M  "  '0$  "  (    "  (  .\N'\FE=,J:(AVJ!*)"(Y6MK'0:)0FOQ#S^)
MI&O6 J:' VXP  "  'D[  "  (    "  (  .Q6%*7 I,?2%_G#O)_B&=W%Y
M'(V&OW&T#N>&KG&& I:$Q713  "  'V8  "  (    "  (  .GR"NW<*,5V#
MSW=\)W:$97>N'"Z$EW>H#J.$27>2 FZ# GHK  "  (    "  (    "  (
M.@V JGXG,.>!]GY/)PN"K'XQ&^."S'X!#I&"7'XN HF!B'[_  "  (    "
M (    "  (    #__P  __\  /__  !M9G0R      0#"0   0
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MC,HHO(8?AMF9K+)L=&F+/*W'=/I\G:DZ=:UMOJ2S=HQ>L* :=YU/HIM@>.)
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MDGYGJK4$D E;#:Z!C<).H*?6BYA"E*#\B8,W2IGFAW4M!Y*,A7LD:(L6@ZJ
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MCGDTH91_)WG+G*9JP7J$EZ56F'M6DFU"JWQ7C-DO5WV!AI_..7>\NFBZ[W@
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M!'64E;9YIW:GDGYF.G?=CT-3&'DUB_! .GJZB%4N(7QUA$;#W7(:J3*QUW,
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M=*CYGR9O3:3)G#ECCZ!LF,=7CIORE1=+PY>"D8) 5I,?C@ ULXZHBI$KZ8I
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M@9,F;H&F@,B4:X;)CH^'8X71C5IYH(3>B^QK28/VBE9<SX,IB+Q.6H)\ARE
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M'VKYDO!L+&UAD!9;-V_^C31*K'+*BCHZAG7CAQ,K>WD[@ZBLT&-XI$"=3V7
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M?JDQ0HOZ?OLJ7(CX?V D(H8^?\(?)H/9@!98M9DO@WI0YY;G@UM(WI0X@NY
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M)E,!C7"+ E</C#Q]/UK[BN)NY5[WB71@/F,PB A1E6>NAIU#;FQLA3 UQW&
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M>#PG$WN8>U.1!V%T<&&$GV1 <>-WE&;T<U=I^6FT=,);W&RH=C5-MV_3=[]
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M#U"KC0-@HE;ZBRM2'UV9B4Q$+&1]AV(VV&NMA5XJ[W+>@TN6*#QUFR&)GD,
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M?[<HGG8A@!F.#T@4APN"!DUCAFAU;5*0A;)H.U?-A/5:L5U'A#U-)F,*@XU
M)&D,@N,SKF]9@C4HJW6=@82-.48,CXN!2TN3CA!TRU#VC'EGLU9GBMA:.UP6
MB4!,O&(4AZL_WVA*AA8SG&[#A&XHM74P@KN,HD1ZEY: P4HKE4AT3D^TDL]G
M255+D$Y9ZULAC=M,AF%'BV8_KV>JB.DS?&Y.AE$HOG39@[R,OF1=4&. <&;)
M5+=SNFE460YF?FP!76A8WF[88=5+)7'H9FT]X'4Q:S\Q)7C7<( EP'R]=EB*
M[%_X63)_%V+E7,ARD67;8%IEAVCH8^Y8$&PD9Y%*AF^>:UL]=G-2;U@Q 7=?
M<[8E\7N;>(N)5%OQ8@U]IU]39-AQ?6*I9Z!DD681:FA73VFH;3])^FV$<#8]
M)'&=<U<PZW8+=LHF''J<>IF'PEA1:LY\+UP4;,]P$U_ ;L]C>F-]<,U68&=W
M<M5)2&NR=/H\LW H=S\PPG3K><$F07F\?'Z&6%4:<W1ZY%DM=+!NYUTK=>-B
M:F$Z=Q%5JF6#>$I(N&H7>9@\76[@>OPPJ'/M?(DF87C\?C:%*E)3>_QYUU:M
M?'1M_%KR?-AAFE]*?3)4^&/:?9)(2FBQ?@4\&VW#?H@PDW,4?QTF>WA9?[V$
M-D_WA$UX_52,A )M/%D-@Y-@\EVD@Q149&)T@IU'W6>(@C([[6S0@=(PB7);
M@7(FD7?1@1"#>4X&C%1X5%+-BT9LH%=_B@)@:UQ%B*=3ZV%)AU='=&:6AA [
MK6P0A- P?W'$@X,FHW=B@C""]$R"D_1WUU%RDC!L)U9&D!9?_%LOC=U3E6!7
MB[)'.F7+B9 [>FMRAW P7W%1A4(FL7<*@Q^"&VN.4,-VMFUM5/YJ[F]P64->
MJW&/7912#G/.8?Y%978^9I<Y/'C?:VHMK7O2<*\C>W[X=GN 8F=A60!U<6FX
M7))IWVP;8"5=SFZ38[]177$O9VY$Y'0":T<X[W<';U,MHWI9<\ CP'W,>)9^
M[V.+84AT%69.9"-HSVD*9OY<WFO7:=Q0HV[,;,Y$8''];^,XIG5@<R,MFGD)
M=K$C_'S#>HM]B& -:8ERPF,M:ZAGFF8[;<=<#FE6;^I/^VRD<A9#\G K=& X
M<W/D=LPMFW??>78D,7O=?%9\.ES\<;%QJ6!G<QEFE6/ ='I;#&<F==9/26K
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
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M@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM.
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M_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2SQ).+ML*/C[K
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MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
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M;W^LHG6*I)Q\DYR8@YJ5E(J@CY&2I8J.FZB&C:2K@XROK(&-O:R"C+^K@XK
MJ8.*P:F#BL&I@XK!J8.*P:F#BL&I@XK!J8.*P:F#BL&I@XK!J?^+)PG_CC<7
M_YP\'_^C.R;_JCTM_[% ,_2X13CJOTP\XL=50-/"6E+'NF%CN[-G<K"M;7ZG
MIW.)GJ%ZDI:=@)F/FHB?B9>0I(24F*A_DZ*J?)*MJWJ2NJQ[D<"K?8_!J7Z.
MP:A^CL&H?H[!J'Z.P:A^CL&H?H[!J'Z.P:A^CL&H?H[!J/^,)PG_CS86_YTZ
M'O^E.B7_K3LK_+0^,/&\0S3GQ4PVWLM2/\[&65'"OF!BMKAF<*NQ;'VAK'*(
MF*=XD9"C?IB)H(6>@IV-HWV;EJ=XF9^I=9BJJG.9MZMTF,"J=Y3!J7B3PJAX
MD\*H>)/"J'B3PJAXD\*H>)/"J'B3PJAXD\*H>)/"J/^,)PG_D346_Y\X'?^G
M."/_KSDH^;@\+.["0B[ES4PMV-!//<G)5U"\PUY@L+QD;Z6W:GR;LG"&DJUV
MCXJI?):"IH.<?*2+H7:BDZ5RH9VG;Z"HJ6V@M:EMH,&H<)O"IW*9PJ=RF<*G
M<IG"IW*9PJ=RF<*G<IG"IW*9PJ=RF<*G<IG"I_^-)@G_E#05_Z$V&_^J-B'_
MLS8E];XY)^K)0";@UDDHT=5./,/.5DZVR%Q?JL)C;9^]:'J4N&Z$B[1TC8.Q
M>I1\KH&:=:R(GG"KD:)KJ9ND:*FFIF:ILZ9FJL.E::3$I6NAQ*5KH<2E:Z'$
MI6NAQ*5KH<2E:Z'$I6NAQ*5KH<2E:Z'$I?^.)@G_ES,4_Z,T&O^M,Q[^N#(@
M\,4U(./3/QS8WD4FRMM-.KW35$RPSEM=H\EA:YC$9W>-P&R!A+URB7RZ>)!U
MN'^6;[:'FFJUD)UEM)J@8K.EH6&TL:)@M<*A8J_&HF2KQJ)DJ\:B9*O&HF2K
MQJ)DJ\:B9*O&HF2KQJ)DJ\:B9*O&HO^0)@G_FS$2_Z8Q%_^Q+AKWOBT:Y\XQ
M%]G>.1G-XT0HPN!-.+7;4TJHU5E:G-!?:)#,97.&R6M]?<9QA77$=XMNPWZ0
M:<&&E&3 CY=@P)J:7<"EFUO L9M:P<&;6[S*G%VWRIU=M\J=7;?*G5VWRIU=
MM\J=7;?*G5VWRIU=M\J=7;?*G?^1)@G_GR\1_ZHM%/^W*!7MR"82VMPI#LSD
M-AW!YD NMN-(/JK@3DR>W599DMI=98C68V]^U&IX=M)P?V[0=X5HSW^)8\Z'
MC5_.D)!;S9J26<VEDU?.LI-6S\*35LO0E%?%SY57Q<^55\7/E5?%SY57Q<^5
M5\7/E5?%SY57Q<^55\7/E?^3)@G_HRP._[ F#_7 'PW?U1L'S>0G$\'K-".U
MZCTSJ>=%0IWE2U"1XU)<AN)89GS@7VYTWV9U;-YM>F;>=7]AW7V"7=R&A5K;
MCXA8V9B*5MBABU38K(M4V+>,4]C)BU/6UHM3UM:+4];6BU/6UHM3UM:+4];6
MBU/6UHM3UM:+4];6B_^7) G_J28*_K@<">;.$07.XQ<(P.XF%[3P,BBH[CLX
MG.U#1I'L2U*&[%)<?.M99'/K7FMJZF1P9>AL=6'F='A>Y'Q[6^*#?5G@BW]6
MWY*!5=Z:@U/>HH-2W:J$4=VVA%'=OX11W;^$4=V_A%'=OX11W;^$4=V_A%'=
MOX11W;^$4=V_A/^?(0;_L!L%Z<4- ]#9"P+ [A@,L_8F'*?U,2R;]3LZD/5$
M1X7U3%%\]5-:<_598&OS7V9E\&9J8>UM;5WK='!:ZGIS6.B!=%;GAW94YHUX
M4^64>5'DFWI0Y*%[3^.J?$[CL'Q.X[!\3N.P?$[CL'Q.X[!\3N.P?$[CL'Q.
MX[!\3N.P?/^H' +KO P!S<P) ,'@# 2R^AD0I?PG()K],BZ/_3T[A?Y%17O_
M34YR_U15:_M:6F3X8%]@]F=B7/1M95GR<F=7\7AI5?!^:E/O@VQ1[HEM4.V/
M;D[LE&]-ZYIP3.NA<4OJIG)+ZJ9R2^JF<DOJIG)+ZJ9R2^JF<DOJIG)+ZJ9R
M2^JF<O>S#0#,PP@ O]$( +'O#@:D_QL3F?\I(8[_-"Z$_S\Y>_]'07'_3DAJ
M_U1.8_]:4E[^8%9:_&985_ML6E7Z<5Q3^79>4?AZ7T_W?V!.]H1A3/6)8DOU
MCF-*])1D2?.:94CSGF9(\YYF2/.>9DCSGF9(\YYF2/.>9DCSGF9(\YYF2/.>
M9LV[!0"]QP8 L=@' :/_$ B8_Q\4C?\L((/_-RMZ_T$T</]'.VC_34%A_U1%
M7/]:25C_7TM5_V5-4O]J3U#_;E%._W)23/]W4TO_>U1)_W]52/Z$5D?^B%=&
M_8U71/V36$3\EEE$_)991/R6643\EEE$_)991/R6643\EEE$_)991/R66;V_
M! "PS@0 HN & I?_$PB,_R(3@_\N'7G_."5N_SXM9O]%,E__3#=9_U([5?]8
M/E'_74!/_V)"3/]F0TK_:D1)_VY%1_]R1D;_=D=%_WI(0_]^2$+_@DE!_X9*
M0/^+2S__CTL__X]+/_^/2S__CTL__X]+/_^/2S__CTL__X]+/_^/2Z_& @"B
MU@( EO<* HO_%@>"_R0/=_\M%VS_,QYC_SHD7/]"*%;_22Q1_T\O3O]5,4O_
M6C-(_UXU1O]B-D3_9C=#_VDX0?]L.$#_<#D__W,Z/O]W.CW_>SL\_WX\.O^#
M/#K_ACTZ_X8].O^&/3K_ACTZ_X8].O^&/3K_ACTZ_X8].O^&/?]U) ;_=C40
M_W=#'/^ 2B?_A5(S_X99/O^%8$C_@6A2_WQO6OQW>6+W<X-H]&^,;O%LDW+O
M:IIU[6>@>.QEI7KK9*I\ZF*O?>EAM7[H8+M_Z%_#@.=?RX'F7M6!X&#;@==B
MWH'48]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@?]U) ;_=C40_W=#
M'/^ 2B?_A5(S_X99/O^%8$C_@6A2_WQO6OQW>6+W<X-H]&^,;O%LDW+O:IIU
M[6>@>.QEI7KK9*I\ZF*O?>EAM7[H8+M_Z%_#@.=?RX'F7M6!X&#;@==BWH'4
M8]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@?]U) ;_=C40_W=#'/^
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MEW=\K)%^A::,AHR@B(V1FH65EI:"GIJ2@*>=CW^RGHV P9Z,@,F>BX#*G8J
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M5T#]IEA _*E80/RI6$#\J5A _*E80/RI6$#\J5A _*E80/RI6,:X! "VQ 0
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M7NAQV%[H<=A>Z''87NAQV%[H<?]K(P3_:C$*_W$\%/]Z0QW_@$LH_X%3,O^
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M?=1BX7W*8^!^PV3@?[UFWX"W9]^ MV??@+=GWX"W9]^ MV??@+=GWX"W9]^
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M9TCFWV=*X.QG2M_L9TK?[&=*W^QG2M_L9TK?[&=*W^QG2M_L9_^<#0#;L08
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M=%.UY'14L.=U5JSG=5:LYW56K.=U5JSG=5:LYW56K.=U5JSG=?^#$@'_EA$
M_Z@1 -FX"@#.Q D Q](* +_9&0&TV"L'J=8Y%)_31"*4T$TOBLU4.X'*6T1X
MR&)-<<=I4VO%;UEEQ'9>8,-^8ES"AV98P9%H5<&<:U+!J&Q0P;=M3\+*;4_"
MY&Q/O>QN4+GL;U"Y[&]0N>QO4+GL;U"Y[&]0N>QO4+GL;_^)$ '_G0X VJ\(
M ,V[" #$QP< O-8+ +/?&@&JWRL'H-XY$I;=0QZ,VDLJ@MA3-7G56C]QTV%&
M:M)H3&71;U)@T'966]!^6E?/AUU3SY%?4,^<84[/J6-,S[AC2]#+8TS0Y6)*
MSO)E2\CR9DO(\F9+R/)F2\CR9DO(\F9+R/)F2\CR9O^2#0#>I@0 SK0& ,*_
M!@"YS @ L-T, *?E'0.>Y2T+E.4Y%HKD0B"!XTHJ=^)0,V_A6#MIX%]!8^!F
M1E[?;DI:WW5.5M]]45+?AE-/WY!63=^;5TO@IUA)X+592.'&64CAWUE'W_!9
M1MSU6T;<]5M&W/5;1MSU6T;<]5M&W/5;1MSU6^V<! #1K00 PK@% +?#!0"M
MT0@ I.T0 9OM( 62[2X.B>PZ&(#L0R%V[$HJ;NQ0,6;K5C=@ZUP\6^MD0%?K
M:T-3ZW)&4.MZ24WL@TM*[(Q-2.R63D7MH5!#[:Y10NZ\44'OS%)![^520.WQ
M44#M\5% [?%10.WQ44#M\5% [?%10.WQ4=2E  #$L@, MKP# *O)!0"@V @
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M3$;<WDQ&VNU,1-CY3T/8^T]#V/M/0]C[3T/8^T]#V/M/0]C[3]N:  #*J0(
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M)RG_OB<I_[XG*?^^)RG_OB<I_[XG*?^^)Z:V  "8P@  B\X  '[;  !U^0<
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M5!W_5V D_U1K*O]0>"__380S_TJ/-O]'F3G_1J$[_T6I//]$L#[_0[<__T+
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M(P/_B"L%_8TT"?.0.P[JD$,4XH]*&MJ*5"70@UTPR7YG.L-X;T*^='A(N7&
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M5C!ZMETX<[1D/VZR:D1HL7%)9+!Y35^N@5%;K8I46*V55U2LH5E2K*];4*S
M6U"LVEI/J^Y;3ZKZ6U&F^EM1IOI;4:;Z6U&F^EM1IOI;4:;Z6_^ "0#AD@$
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M*EO49R]7U&XS4]-V-E#3?SE,TX@[2M.4/D?3H#]%U*Y 1-2_04/5V$!$T^Q
M0M+V0D'1_D1!T?Y$0='^1$'1_D1!T?Y$0='^1-&8  ##I0  M:X  *FX  ">
MPP( E,T& (K9"@"$XQ@!?>0F W7D,@ANXSP/9^-%%6'C31M<XU4@5^-=)%3C
M9"=0XFLJ3>)S+4KC?#!(XX8R1>.0-$/CG#5!Y*DV0.2X-S_ERS<_Y>0W/^/S
M-CWB^S@]XOLX/>+[.#WB^S@]XOLX/>+[.,:A  "WJP  JK0  )Z^  "3R0(
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M2WTI_TB(+/]&DB[_19LP_T2B,O]#J3/_0K T_T*W-?]!OS;_0<DV_T#7-_]
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M6"Z(FU\U@IEF/'V6;4%XE'1&<Y)[2V^0@T]KCXQ29XZ6562-HEAAC*]97XS
M6E^,V5E?C.Y97XS[6&&*_5=AB?U788G]5V&)_5=AB?U788G]5_]O# #_?PD
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M24BP_TI(L/]*2+#_2DBP_TI(L/]*2+#_2N*&  #.E   PJ$  +:I  "KL0
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M(S3K^",TZ_@C-.OX([.E  "FK0  F;<  (W!  " RP  ==4! &GA!@!D\Q$
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M4&YWV5!N=^]/;G?\3FYW_TUO=_],;W?_3&]W_TQO=_],;W?_3/]D#0#_<@H
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M2E>._TI8CO])6([_25B._TE8CO])6([_2?]Q 0#@@   SXP  ,26 @"[G@(
MLJ0  *FJ!0"BK!4 FZPF I2K- >,JC\/A:A(%WZF4!YXI%@E<Z)>*VZA93!J
MGVPT99YS.6&=>SQ>FX1 6IJ.0U>9FD54F:='4IFV2%&9RDA1F.9(49?U2%&7
M_T=1EO]'49;_1U&6_T=1EO]'49;_1_9W  #8A0  R9$  +^; 0"TH@  JZ@
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M-T"W_S= M_\W0+?_-\Z+  "_F   LJ$  *>I  "<L   D;@  (;  @![R <
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M&P!6XR<!4N0R D[D/ 1*Y$0&1^5-"$7E50I"Y5P,0.5D#C[F;! [YG82.>:
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M1'UFV41\9^]#?&?\07QH_T!\:/] ?&C_/WQH_S]\:/\_?&C_/_];# #_9PD
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M0V9X_T)F>/]!9GC_0&9X_T!F>/] 9GC_0/]D P#N<0  V'P  ,N% @##C ,
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M/$^1_SQ/D?\\3Y'_/.1T  #/@0  PHP  +B6  "MG   HZ$  )BH  "0J@T
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M)+V1  "PFP  I*(  )BJ  ",L0  @+D  '6_  !JQ@0 7LP( %G/$@!7T"$
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M!R7PIP@D\;@((_',""+RY0@B\/,((N_U""+O]0@B[_4((N_U")ZF  "1KP
MA+@  '?!  !JR0  7=   %'7  !&W0  /^H% #SV#@ Y]A< -O<@ #/W*  Q
M^#  +ODV 2OY/0$I^D0!)_I* B7[4@(C^UH"(/QC Q[\;@,<_7L#&_Z)!!G^
MF 08_Z@$%_^W!!;_R 06_^ $%O_D!!;_Y 06_^0$%O_D!).N  "%MP  >,
M &K)  !=T@  4-D  $3?   ZY   -?<# #+_#  N_Q( *_\: "C_(0 F_R<
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M-)!6W32.5_ TC5?],XQ8_S.,6/\RC%C_,8Q8_S&,6/\QC%C_,?]1# #_6PD
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M.')G_S=R:/\V<FC_-7)H_S5R:/\U<FC_-?]9 @#V90  W6X  ,]V 0#'>P,
MP'\$ +F # "Q@AH JH(J J. -P6=?4(+EWM+$9)X5!>-=EL;B71B((5R:22!
M<7 G?F]W*WMN?RYX;8@Q=FR2-'-KG#9P:J@X;FJW.FUJR3IL:N0Z;6OU.&UK
M_S=M:_\V;6O_-FUK_S9M:_\V;6O_-O];  #K9P  V7$  ,QY  ##?@( NX(#
M +2$"0"MA1@ IH4H 9^$-069@D *DW])$(U]4A:)>UD;A'E@'X!W9R-\=6XG
M>71U*G9S?2YS<H8Q<'&0-&UPFS9K;Z<X:6^U.FAOQSIG;^(Z9V_T.&AO_S=H
M;_\V:&__-FAO_S9H;_\V:&__-O]>  #D:@  TW0  ,A\  "_@0$ MX4! *^'
M!P"HB14 H8DE 9N(,P24ACX)CH1'#XF!4!6$?U<:?WY>'GM\92)X>FPF='ES
M*G%X>RUN=X0P:W:.,VAUF39F=*4X9'.S.6)SQ#IB<^ Z8G/S.&-S_S=C<_\V
M8W/_-F-S_S9C<_\V8W/_-O]A  #@;0  SW<  ,1_  "[A0  LXD  *J+ P"C
MC!, G(TC 9:,, .0BSP(BHE%#H2'3A-_A548>X-<'7>"8R%S@&HE;W]Q*6Q]
M>2QI?((O9GN+,F-ZES5@>:,W7GFQ.%UYPCE<>=TY77GQ.%UX_C=>>/\V7GC_
M-5YX_S5>>/\U7GC_-?5D  #<<   RGH  ,"#  "VB0  KHT  *2/  "=D1
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M%S>]M1@VO<H8-[SG%S6[]ADUNO\:-+G_&S2Y_QLTN?\;-+G_&[B/  "JF
MGY\  ).F  "'K   >[,  &^Y  !CO@  6,0$ %#(# !-R!< 3,DE $K*,0!'
MRCL!1<I$ D/*3 -!RE0$/LI<!CS*9 <ZRVX).,MX"C;+A0PTRY(-,LNB#C'+
ML@\PS,</,,OE#B_)]0\NR/T1+L?_$B['_Q(NQ_\2+L?_$JZ7  "AG@  E:4
M (FM  !\M   <+L  &3!  !9Q@  3LL# $70"  ^U0X /=4: #S6)@ [US$
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M A#[Q@(0^]T"$/OI A#[Z0(0^^D"$/OI H^K  "!M   <[T  &;&  !9S0
M2],  $#9   UW@  +.,  ";Q   D_@H (?\0 !__%@ <_QP &?\B !?_*  5
M_RX $_\U !+_/  0_T, #O],  W_5@ +_V( "?]O  C_?P$'_Y !!?^@ 03_
MK@$$_[P! __' 0/_QP$#_\<! __' 8.T  !UO0  9\8  %K/  !+U0  /]P
M #/A   IY0  (>P  ![]   :_P4 %_\, !7_$  2_Q0 $/\9  [_'@ -_R,
M"_\H  C_+@ &_S4  _\]  #_1@  _U$  /]=  #_:P  _WL  /^+  #_F0
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M'ZI%XR"G1O,AI4;_(:-&_R*B1O\AHD;_(:)&_R&B1O\AHD;_(?]%#@#_2PH
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M*X!8_RJ 6/\J@%C_*8!8_RF 6/\I@%C_*?]/ @#]60  XF   -5G  #,:@,
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M*VIG_RMJ9_\K:F?_*_Y8  #A8P  SVP  ,1S  "[>   LWH  *MZ! "D>Q(
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M(T24LR-#E,@C0Y3E(T.2]21#D?\D0Y#_)$.0_R1#D/\D0Y#_),IU  "[@0
ML(L  *21  ":E0  CYD  (.=  !TH@  ;J,+ &JD%P!FI24 8Z4Q 5^D.P-;
MI$0%6*1+"%6C4PM2HUH-3Z)A$$VB:!-*H7$51Z![&$2@AAI"GY,<0)^B'3Z?
MLAX]G\8>/9_C'3V=]!X]G/\?/)O_'SR;_R \F_\@/)O_(,)\  "UB   J9
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M""K$\ @IPOL)*,'_"BC!_PLHP?\+*,'_"ZB5  "=FP  D:(  (2I  !XKP
M:[4  %^[  !4OP  2<,  #_(!  VS0D ,\X1 #+/'  QSR< ,- Q "_0.@ N
MT4, +=%, "O250 JTE\!*--I 2?3=@$ETX0")-24 B+4I@(AU;D"(=72 B#3
MZP(@TO8#']'_!!_1_P0?T?\$']'_!)^;  "4H@  AZD  'FQ  !MN   8+X
M %3#  !)QP  /LL  #70 0 MU08 )=L+ "3>$@ CWAP (M\E "'@+@ @X#<
M'^%  ![A2@ =XE, '.-> !OC:@ :Y'@ &.2( 1?EF@$6YJP!%>;  13GW0$3
MY>\!$^/Z 1/C^@$3X_H!$^/Z 9:B  ")J0  >[$  &ZY  !AP   5,8  $C*
M   ]SP  ,],  "K9   BW@( 'NL* !SL$  ;[1< &>T? !?N)@ 5[BT %.\U
M !/P/0 1\$8 $/%0  _R6P .\FD #?-X  STB@ +]9P "O6N  GVP@ )]MD
M"/7M  CU[0 (]>T "/7M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2   Q
MV   )]T  !_A   9Z   %O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI  K^
M,  (_S@ !O]!  /_3   _U@  /]F  #_=P  _XD  /^;  #_JP  _[L  /_.
M  #_SP  _\\  /_/ '^R  !QN@  8\,  %;+  !(T0  .M8  "_=   EX0
M'.4  !3I   1]P  #_\!  W_"0 +_PT "/\0  ;_%  #_Q@  /\>  #_(P
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M"<DQZ@K&,?<,PS'_#L$Q_P_ ,?\/OS'_#[\Q_Q"_,?\0OS'_$/\V$P#_.0\
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M')5&_QN41O\;DT;_&Y-'_QN31_\;DT?_&_]"!0#_2@$ \E   .%4 0#95@4
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M)6I?^R1J7_\C:E__(FI?_R)J7_\B:E__(O!2  #=70  RV4  ,!K  "W;@
MKV\  *=N 0"@;Q  FG ? )1P+ &/;S@#BFU"!H9L2PF":E(,?FE9#WMH8!)W
M9F84=69N%W)E=1IP9'X=;6.('VMCDB)I8IXD9V*K)65BNB9D8L\F9&+J)F5B
M^B1E8_\C96/_(F5C_R)E8_\B96/_(NM5  #88   R&@  +QN  "S<0  JW,
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M(E=O_R)7;_\B5V__(M]?  #*:0  O'(  +)X  "I?0  GW\  ))^  "*?P<
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M&\)S  "U?@  JH<  )^,  "4D   B),  'N5  !LF0  99L$ &"<$ !=G1T
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M""ZRI@@MLK@)+++0""RP[ DKK_D**Z[_"RJM_PLJK?\+*JW_"ZV+  "@D@
ME9@  (F=  !]HP  <:@  &2M  !9L0  3;0  $*X   [N@H .+L3 #>\'@ U
MO"D -+TR #.].P RO40 ,;Y, "^^50$NOEX!++YH 2J^= (IOH(")[^1 R:_
MH@,DO[0#([_+ R.^Z ,CO/<$(KO_!2*[_P4BN_\%(KO_!:22  "8F   C)X
M ("E  !SJP  9[   %NU  !/N0  1+P  #K    PQ 0 *L<+ "C($P GR1T
M)LDG "7),  DRCD (\I" "++2P ARU4 (,Q? !_,;  =S7H ',V* !O-G  9
MSJX!&,[% !C-Y  8S/0!&,K\ 1C*_P(8RO\"&,K_ IN9  "/GP  @J8  '6M
M  !HLP  7+D  %"]  !$P0  .<0  ##(   HS $ (- & !G5"P 6UQ  %=@9
M !79(@ 4V2L $]HT !/:/0 2VT@ $=Q3 !'=7P 0W6T $-Y^  [?D0 .X*0
M#>"X  S@T@ +W^T #-[W  S=^P ,W?L #-W[ )*?  "%IP  =ZX  &JU  !=
MO   4,$  $3%   XR0  +LT  "71   >U0  %MH! !'>!@ 0YPT #N<2  WH
M&0 ,Z"$ "^DI  KJ,0 )ZCL !^M%  7K40 $ZUX  ^MN  'K@   ZI0  .JG
M  #KO   Z](  .OI  #L[P  [.\  .SO (>G  !YKP  :[<  %Z^  !1Q0
M0\D  #?-   MT0  (]8  !O;   3WP  #N,   SN @ *]@H !_8.  7V$@ #
M]A@  /4>  #U)0  ]2X  /4W  #V0@  ]DX  /9=  #V;@  ]H$  /:5  #W
MIP  ][<  /C'  #XT   ^-   /C0 'NO  !MN   8,   %+(  !$S0  -]$
M "O7   AW   &.   !'D   ,YP  !^\   3Z   !_P,  /\(  #_#0  _A
M /X4  #_&@  _R$  /\I  #_,P  _SX  /]+  #_6P  _VP  /^   #_D@
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M#Z [S0^>.^80FSSU$9H\_Q&9//\1F#S_$9@\_Q&8//\1F#S_$?\Z 0#_0
M[T4  .%(  #92 4 TT8) ,Q%$@#$1R( O4@Q +A(/P&S1TH"L$94!*Q%706J
M1&0'IT-L"*5"<PJC0GH+H4&!#*!!B V>0) /G$"8$)I H1&80*P2ET"X$I5
MR!.30.$3D4'S%)!!_Q2/0?\4CD+_$XY"_Q..0O\3CD+_$_\\  #Y1   Y$H
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M?TKM&'Y+_!A^2_\7?4O_%WU+_Q9]2_\6?4O_%O]#  #F3   UE,  ,E8  #
M60  NE@! +16"0"L5Q8 IE@E *%8,@&=5SX"F%9(!)5540:25%@(CU)?"HQ2
M9@R*46T.B%!T$(5/>Q*#3X03@4Z-%7].EQ=]3J$8>TVN&7I.O1IX3M$:=T[K
M&G=/^AEV3_\9=D__&'9/_Q=V3_\7=D__%_A&  #B4   T%<  ,1<  "[7@
MM%T  *Y:!@"F6Q, H%PB )M<+P"76SL"DEI% X]930:+6%4(B%=<"H968PR#
M56H.@51Q$'Y4>!)\4X 4>E*)%GA2E!AV4I\9=%*K&G)2NAMQ4LT<<%+H&W!3
M^1IP4_\:<%/_&7!3_QAP4_\8<%/_&.])  #=4P  RUH  ,!?  "W8@  KV$
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M&F%>_QIA7O\:85[_&N12  #/7   P&0  +9I  "L;   HVP  )EI  "2:@L
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M&<Y@  "^:@  LG(  *AX  "=>P  D'H  (1Z  !Z>P  ='P, &]^%P!L?B0
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M$3R*IQ([BK@2.HK/$CN(ZQ([A_H3.X;_$SN&_Q,[AO\3.X;_$[QQ  "O>P
MI8,  )F'  ",B   ?XD  '.,  !ED   7),  %>5# !4EA8 4I8B %"7+0!-
MES8 2Y<_ 4F71P)'ETX#1995!$.6705!EF4&/I5O"#R5>@DZE8<+.)65##:4
MI0TUE+8.-)3,#323Z0TTDO@.-)#_#S20_P\TD/\/-)#_#[5X  "J@@  GH@
M ).-  "&C@  >9   &V3  !AEP  59L  $V>!@!)GQ  1Y\; $:@)@!$H#
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M,@ IMSH *+=# ">W3  FN%4 )+A? ".X:P BN'@!(+B( 1^XF0$=N:L!'+G
M 1RXWP$<MO(!&[7\ ANT_P(;M/\"&[3_ I^/  "4E0  B)L  'NA  !NI@
M8JL  %:P  !*LP  /[8  #6Y   LO   )+\& !_"#0 =PA0 ',(> !O#)@ :
MPR\ &<0X !C$00 7Q$H %L55 !7%80 4QF\ $\9_ !+&D0 1QZ0 $,>Y  _'
MU  0QNX $,3Z !##_P 0P_\ $,/_ )>6  "+G   ?J(  '&I  !DKP  6+0
M $NX  ! NP  -;X  "O!   CQ0  &\D! !3,!@ 0T L #M$1  W1&0 -T2$
M#-$J  S1-  +TCX "M))  G350 )TV( "--R  ;4A  %U)@ !-2K  /5P  !
MU=P  =7M  '5]@ !U?8  =7V (Z=  " I   <ZL  &:Q  !9N   3+T  #_
M   TPP  *L<  "'*   9S@  $M(   W6 0 )VP4 !MP-  3<$0 #W1@  =X@
M  #>*   WS$  . \  #A1P  XE0  .-C  #C=   Y(@  .2;  #EK@  Y<$
M .75  #FYP  YN<  .;G (.D  !UK   :+,  %J[  !-P0  0,0  #/(   H
MS   ']   !?4   0V0  "]T   7A    Y    .4'  #F#0  YQ$  .@6  #I
M'0  ZB4  .LN  #M.0  [T4  /!3  #Q9   \78  /**  #SG   \ZT  /2[
M  #TR   ],@  /3( '>M  !JM0  7+T  $_$  ! R0  ,\T  "?1   =U@
M%-P   [@   (XP   >8   #J    [@   .X   #O!   \ H  /$.  #S$@
M]!@  /8@  #X*@  ^C4  /U#  #^4@  _V,  /]V  #_B0  _YH  /^F  #_
ML   _[   /^P /\6(P#_%2$ _Q$A /\-) #_"2L _P8W /\#1 #_ %$ _P!=
M /\ : #_ '( _P![ /\ @P#_ (H _P"1 /\ E@#_ )P _P"A /T I@#[ *P
M^0"S /< NP#U ,4 \P#1 /( Y #Q /$ [P#Z .X _P#N /\ [0#_ .T _P#M
M /\ [0#_ /\9( #_&!T _Q4= /\0'P#_#BD _PPT /\*00#_!TT _P59 /\$
M9 #_!&X _P-W /\#@ #_ X< _P.- /T"DP#[ ID ^0*> /<"I #U JH \P&P
M /$!N #O <( [0'/ .L!XP#J >\ Z +[ .<$_P#F!?\ Y@;_ .8&_P#F!O\
MY@;_ /\<&P#_&QD _Q<8 /\5'0#_$R4 _Q$P /\0/0#_#DD _PQ5 /\+8 #_
M"VH _0MS /L+? #Y"H, ]PJ* /4*D #T"I8 \PJ; /$*H0#O":< [0FN .L)
MM@#H"<  Y@G- .0)X@#B"O  WPO[ -X,_P#<#?\ W W_ -L-_P';#?\!VPW_
M ?\?%P#_'A, _QL2 /\<&0#_&R( _Q@L /\5. #_$T0 _A)0 /D16P#U$&8
M\Q!O / 0=P#N$'\ [!"& .H0C #I$)( Z!"8 .8/G@#E#Z4 XP^L .$/M #@
M#[X W@_, -H0X0#5$?  TA+[ ,\2_P'.$_\!S1/_ <T3_P',$_\!S!/_ ?\B
M$@#_(@\ _R$/ /\B% #_(AP _R G /\=,@#X&SX \AE+ .X85@#J%V  YQ9J
M .06<@#B%GH X!:" -X6B #<%H\ VQ:5 -D6FP#6%J( U!:I -(6L0#0%[L
MSA?) ,P8W@#(&>X!Q1K[ <,:_P+!&_\"P!O_ L ;_P+ &_\"P!O_ O\F#@#_
M)0L _R@, /\I$ #_*!8 _B8@ /0D*P#L(3@ YB!$ .$?4 #='UL V1YE -4>
M;0#2'W4 T!]] ,X?@P#,'XH!RQ^0 <D?EP'('YX!QA^E <4@K0'#(+<!P2#$
M < AU@&\(NH"N2+X [8B_P.U(_\#M"/_!+,C_P2S(_\$LR/_!/\I"P#_*@4
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M#8H\^PV)//\-B3S_#(@\_PR(//\,B#S_#/\W  #J/P  W$4  ,Y)  #%20
MOT8" +I## "S1!D K44G *A&-0"D14$!H$5+ IU$4P*:0UL#F$-B!99":0:4
M07 'DD%V")! ?@F.0(8*C4"."XM F R)0*(-AT"N#H5 O ^$0,\/@D'I#X%!
M^0^ 0?\/@$+_#H!"_PZ 0O\.@$+_#OH[  #E1   TTL  ,=.  "^3P  N$P
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M$FM._Q%K3O\1:T[_$>A&  #34   Q%8  +E:  "P7   IEH  )]6  "85@T
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M$M93  #$7   MV,  *QH  "@:   E6<  (IC  "#90( ?68/ 'AF&@!T9R<
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M$4ELIQ)(;+@31VS-$T=LZA-(:_H22&O_$DAJ_Q%(:O\12&K_$<=>  "X9P
MK&X  *%R  "3<@  AW$  'IQ  !Q<@  :W0' &9U$0!C=AT 8'<H %YW,P!;
M>#P!67=# E9W2P-4=U($4G99!5!V8 =.=6@(2W5Q"DET? Q'=(@.17.6#T-S
MI1!"<[8107/+$4)RZ!%"<O@10G'_$$-P_Q!#</\00W#_$,%C  "S;   J',
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M!R^.X0<OC/0(+XO_""^*_P@OBO\)+XK_";!V  "E?P  F(0  (J$  !]A0
M<(<  &6*  !:C@  3Y(  $:5  !!F P /I@4 #V9'P [F2@ .IHQ #F:.@ W
MFD( -II* #6:4@$SFEH!,9ID 2^:;P(MFGL"+)J* RJ:F@,IFJP$*)K !">9
MW@,GE_($)Y;]!2>5_P4GE?\%)Y7_!:E^  ">A0  DHD  (2*  !VC   :H\
M %Z3  !4EP  29L  $"?   WH@0 ,J,. #&C%P PI"$ +J0J "VD,@ LI3H
M*Z5# "JE2P II50 **5> ":E:0 EI78!(Z6% 2*EE@$@IJ@!'Z6[ 1ZEUP$>
MI.\!'J+[ AZA_P(>H?\"'J'_ J*&  "7C   BX\  'V1  !OE   8Y@  %>=
M  !-H0  0Z4  #BH   PJP  **X' "2O$  CKQ< (:\A ""P*0 ?L#$ 'K Z
M !VQ0@ <L4P &[%6 !JQ80 9LF\ &+)^ !:RD  5LJ( %+*V !.RS@ 3L>L
M$Z_Y !.N_P$3KO\!$Z[_ 9J-  "0D@  A)<  '6:  !HGP  6Z,  %"H  !%
MK   .[   #&R   GM0  (+@  !BZ!P 4O X $[P5 !*\'@ 1O28 $;TN !"]
M-P 0OD$ #KY,  Z^5P -OF4 #+]T  N_A@ *OID "+ZL  >^P@ 'OM\ "+[P
M  B]^@ (O?P "+W\ ).4  "'F0  >I\  &RE  !@J@  4Z\  $>S   \M@
M,;@  ">[   ?O@  %\$  !'$ 0 ,R @ ",D.  ?)%  &R1P !<DD  3*+  #
MRC8  LI   #+3   RUD  ,MH  #+>0  S(P  ,N?  #+LP  R\@  ,SB  #,
M[P  S/$  ,SQ (J:  !\H0  ;Z<  &*M  !5LP  2+@  #N[   PO@  )L$
M !W$   5R   #\L   K.   $T@(  -,*  #3#P  U!0  -4:  #6(@  URH
M -DT  #:/P  W$L  -Q:  #=:@  W7T  -V1  #=I   WK8  -[(  #>W@
MWN(  -[B '^B  !QJ0  9+   %:W  !)O   /,   "_$   DQP  &\L  !//
M   -T@  !]8   #;    W@   -\#  #@"0  X0X  .(2  #C%P  Y1X  .8G
M  #H,0  ZCT  .Q+  #L6@  [6P  .Z   #NE   [J4  .ZT  #NP@  [L8
M .[& '2J  !FL@  6+D  $O    ]Q0  +\D  "3-   9T0  $=8   O;   #
MW@   .$   #E    Z    .D   #J    ZP8  .T+  #O#P  \!,  /(:  #T
M(P  ]RX  /D[  #[2@  _%L  /UM  #]@   _I,  /ZB  #^K0  _J\  /ZO
M /\0'P#_#AT _PH= /\!( #_ "@ _P U /\ 00#_ $X _P!: /\ 90#_ &X
M_P!W /\ ?P#^ (8 _ ", /L D@#Y )< ^ "< /< H@#V *< ]0"M /, M0#R
M +T \0#) .\ W #N .L [0#W .P _P#K /\ Z@#_ .H _P#J /\ Z@#_ /\3
M' #_$1D _PT9 /\&' #_ R4 _P Q /\ /@#_ $H _P!6 /\ 80#_ &L _0!S
M /H >P#W (, ]0") /0 CP#R )0 \0"9 /  GP#N *0 [0"K .P L@#J +H
MZ #& .< U@#E .@ Y #U ., _@#B /\ X0#_ .$ _P#A /\ X0#_ /\5& #_
M$Q0 _P\4 /\-&0#_"R( _P@M /\$.0#_ 48 _P!1 /X 7 #Z &8 ]@!O /(
M=P#O 'X [0"% .L BP#J )$ Z "6 .< G #F *$ Y "H ., KP#A +@ WP##
M -T T0#; .8 V0#S -< _0#5 O\ U +_ -0#_P#4 _\ U /_ /\8$P#_%1
M_Q(/ /\2%0#_$1T _PXH /\,- #_"D$ ^0A, /4&5P#Q!F$ [09J .D%<@#F
M!7H Y 6! .(%AP#@!HT WP:2 -T&F #;!IX V0:E -<&K0#4!K4 T@;  - '
MSP#.".4 S GT ,H+_P#(#/\ QPS_ ,<,_P#&#/\ Q@S_ /\;#@#_&0P _Q@-
M /\8$0#_%Q@ _Q0B /L1+@#S$#H [0Y& .@-4@#E#5P X0UE -X-;0#;#74
MV U\ -4-@@#3#8D T0V/ - -E0#.#9P S0ZC ,L.JP#)#K0 R [  ,8.SP##
M$.8 P!'U +T2_P"\$O\ NQ+_ +H2_P&Z$O\!NA+_ ?\?"@#_' 0 _Q\( /\?
M#0#_'1( ^!H; .X6)@#F%#, X!,_ -H32P#4$U8 T!-? ,X4: #+%&\ R11W
M ,<5?0#&%80 Q!6* ,,5D0#!%I@ P!:? +X6IP"\%[  NQ>\ +D7RP"W&.(
MLQGR ;$:_P&O&_\!KAO_ :X;_P&M&_\!K1O_ ?\B! #_(@  _R4" /PD!P#W
M(0P [!T2 .$:' #8&BH T!LX ,L=10#''5  PQY: , >8@"^'FH O!]Q +H?
M> "Y'WX MQ^% +8?C "T'Y, LQ^: ;$@HP&P(*P!KB"W :PAQ@&K(=T!IR+O
M J4B_0*C(_\"HB/_ J(C_P*A(_\"H2/_ O\E  #_*   \BH  .4K  #?* 4
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M"'H\_PAZ//\(>CS_".XW  #=00  RT8  +])  "V20  KD8  *E!! "C01$
MG4(> )A#*P"50S< D4-! (Y"2@&,0E(!B4%9 H=!7P.%068#@T!M!(% = 6
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M"]Q'  #'4   N58  *Y9  "B6   F%8  )!1  ")4@8 @U,1 ']3'0![5"D
M>%0T '54/0%R4T4!<%-, FU24P)K4ED#:5)@!&=19P9E46\'8U%X"&)1@PI@
M48\+7E";#5U0J0Y;4;D.6U'.#UI1Z@Y;4?H-6U'_#%M1_PQ;4?\+6U'_"]9*
M  ##4P  MED  *M<  ">6@  DUD  (M4  "$5@, ?E80 'I7&@!V5R8 <U@Q
M '!7.@!M5T(!:E=) FA64 )F5E<#9%9>!&)5905@56T'7E5V"%U5@0I;58T+
M652:#5A4IPY65;@/5E7,#U95Z0Y65?D-5E7_#5=4_PQ75/\,5U3_#-%-  #
M5@  LUP  *=>  ":70  CUP  (98  !_60  >5H- '1;%P!Q6R, ;ELN &M;
M-P!H6T !95M' 6-:3@)A6E4#7UI<!%U:8P5<6FL&6EET"%A9?PI668L+5%F8
M#5-8I@Y26;8.45G*#U%9YPY16/@-4EC_#5)8_PQ26/\,4EC_#,U1  "\60
ML%\  *-A  "68   BU\  (%;  !Y70  <UX, &]>%0!K7R  :%\K &9@-0!C
M8#T!85]% 5]?3 )=7U,#6U]:!%E>80577FD&55YR"%->?0E178D+4%V6#$Y=
MI U-7;0.3%W(#DQ=Y@Y-7?<-35S_#$U<_PQ.7/\,3ES_#,E4  "Y7   K6,
M )]C  "28P  AV(  'Q@  !T80  ;F() &EC$@!F8QT 8V0H &%D,@!>9#L
M7&1# 5ID2@)89%$"5F18 U1D7P128V<%4&-P!TYC>@A,8H8*2V*4"TEBH@Q(
M8K(-1V+'#4=BY U(8?8,2&'_#$A@_PM)8/\+26#_"\18  "U8   JF8  )MF
M  "-9@  @F4  '9D  !N90  :&8% &-G$ !@:!H 76DE %MJ+P!9:C@ 5VI
M 55J1P%3:DX"46I5 T]I701-:60%2VEM!DEH> =':(0)1FB2"D1GH0M#9[$,
M0F?%#$)GX@Q"9O4,0V;_"T-E_PM#9?\+0V7_"[]<  "Q9   IFH  )9I  ")
M:0  ?6D  '%I  !G:@  8FP! %UM#0!9;A8 5V\A %5P*P!3<#4 47 ] %!P
M10%.<$P!3'!3 DIP6@-(<&($1F]K!41O=09";X('0&Z/"3]NG@H];J\*/6["
M"CQNX H];?0*/6S_"CUK_PH^:_\*/FO_"KI@  "M:0  H&X  )%M  "$;0
M>&T  &QN  !A<   6W(  %9T"@!2=1( 4'8= $YW)P!,=S$ 2W@Y $EX00!(
M>$D!1GA0 41W5P)"=U\#0'=H SYW<P0\=G\&.G:-!SEVG @W=:T(-W7 "#9U
MW@@W=/((-W/^"#=R_P@W<O\(-W+_"+5F  "I;P  FG$  (MQ  !^<0  <W(
M &AS  !<=@  5'D  $Y[!0!*?0\ 2'X8 $9_(P!%?RP 0X U $* /0!!@$4
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M B"/_P(@C_\"((__ J1\  "7@   AW\  'N   !N@@  8H4  %>)  !-C@
M0I(  #J6   RF0  *IP) "B=$0 FG1D )9TB "2>*@ CGC( (IXZ "&>0@ @
MGDL 'Y]5 !Z?8  <GVT &Y]\ !J?C0 8GY\ %Y^R !:?R0 6GN@ %ISW !:;
M_P$7F_\!%YO_ 9V#  "/A@  @H8  '2'  !GBP  6X\  %"3  !&F   /)P
M #.@   KHP  (Z8  !RH"P :J1$ &*D8 !>I(0 6JBD %:HQ !2J.0 3JD,
M$ZM- !*K6  1JV4 $*MT  ZKA@ .JYD #:NL  RKP0 ,JM\ #*GR  VH_  -
MJ/\ #:C_ ):*  ")C   >HT  &R1  !@E0  5)H  $F?   _HP  -:<  "NJ
M   CK@  &[   !2S 0 /M0H #;80  RV%@ +MA\ "K8G  FV+P (MCD ![=#
M  :W3P $MUL  [=J  *W>P  MXX  +>A  "VM   MLL  +;E  "U\0  M?<
M +7W (^1  "!E   <I<  &6<  !8H0  3*8  $&K   WKP  ++(  ".U   :
MN   $[L   Z]   )P 4  \$-  #!$0  P1<  ,(>  #")@  PB\  ,,Y  #$
M1   Q%   ,1>  #%;P  Q8$  ,65  #%J   Q;P  ,31  #$Y@  Q.X  ,3N
M (:8  !YG@  :Z,  %VI  !0K@  1+,  #>V   LN0  (KP  !F_   1P@
M#,4   ;(    RP   ,P'  #,#0  S1$  ,T6  #.'0  SR0  - M  #2.
MU$0  -12  #580  U7,  -:'  #6FP  UJT  ->_  #8S@  V-T  -C= 'N@
M  !NI@  8*T  %.S  !%N   .+P  "N_   AP@  %\8  !#)   *S    M
M  #4    UP   -@   #:!0  VPL  -P.  #>$P  WQD  .$A  #C*@  Y38
M .=#  #G4P  Z&0  .EW  #IC   ZI\  .JN  #JN@  ZL,  .K# '"H  !B
MKP  5;8  $>\   YP   +,0  "#(   6S   #M    ?4    V0   -T   #A
M    XP   .0   #F    YP$  .D'  #K#   [!   .X5  #P'0  \R<  /8S
M  #W0P  ^%0  /EF  #Y>@  ^HX  /J>  #[J0  ^[   /NP /\+&P#_!QD
M_P 9 /\ ' #_ "4 _P R /\ /P#_ $L _P!7 /\ 8@#_ &L _P!S /T >P#[
M (( ^@"( /@ C0#W )( ]@"8 /4 G0#T *( \P"I /$ L #O +@ [@## .P
MT0#K .8 Z0#S .@ _@#H /\ Z #_ .@ _P#H /\ Z #_ /\.& #_"A4 _P$4
M /\ & #_ "( _P N /\ .P#_ $< _P!3 /T 7@#Z &< ]P!O /4 =P#S 'X
M\@"$ /  B0#O (\ [@"4 .P F@#K )\ Z0"E .@ K #F +0 Y "_ ., S #A
M .( WP#P -X ^P#> /\ W0#_ -T _P#< /\ W #_ /\0$P#_#1$ _P80 /\"
M%0#_ !X _P I /\ -@#_ $( ^@!. /0 60#Q &( [@!K .P <@#J 'D Z !_
M .< A0#E (L Y "0 .( E@#A )P WP"B -T J0#: +$ V "[ -4 R #2 -T
MT0#M -  ^0#/ /\ S@#_ ,T _P#- /\ S0#_ /\1#P#_#@T _PP- /\+$@#_
M!QD _P(D /\ , #V #P [P!) .H 4P#G %T Y !F .$ ;0#? '0 W0![ -L
M@0#9 (8 U@", -0 D@#2 )@ T "> ,X I@#, *X R@"X ,@ Q #& -< Q0#J
M ,, ]P#" /\ P0'_ , "_P#  O\ P +_ /\4"P#_$ 8 _Q ) /\0#@#_#A0
M_PH> /4&*0#K!#8 XP-" -\#3@#;!%< U@1@ -,$: #0!&\ S@5V ,P%? #*
M!8( R06( ,<%C@#&!90 Q 6; ,(%HP# !JL O@:U +T&P@"["-0 N@GI +<+
M^ "U#/\ M S_ +0,_P"T#/\ M S_ /\7! #_%   _Q8# /\4"0#_$0X \@X5
M .@,(0#>"BX U@L[ - ,1P#,#%$ R0Q: ,8-8@#$#6H P@UQ , -=P"_#7T
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M 9 C_P&0(_\!D"/_ ?\B  #K*0  W2X  ,\O  #'+0  P2<# +TB#0"V(QH
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M!>(Y  #,0@  OD<  +%(  "E1@  G4,  )<_  "2/@L C3\5 (D_(0"%0"T
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M!UU(I0A;2+0(6TC'"5I(Y A:2?8(6DG_!UI(_P9:2/\&6DC_!M%%  "_3
MLE(  *-1  "74   C4X  (9*  " 2@$ >DL. '9,%P!R3", ;TPM &U--@!J
M3#\ :$Q& &9,30%D3%,!8DQ: F%,80)?3&D#7DQR!%Q,? 5:3(@&64R5!U=,
MHPA63+((54S&"55,X@E53/4(54S_!U5,_P=63/\&5DS_!LQ(  "\4   KU4
M *!4  "34P  B5$  (%-  !Z3@  =4\, '!/%0!M4"  :E J &=0,P!E4#P
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M1@!664T!5%E4 5-96P)166,"3UAL TY8=@1,6((%2EB/!DE8G@=(6*X(1UC
M"$=8W0A'6/((1U?_!TA7_P=(5_\&2%?_!L%1  "R60  HUP  )1;  "'6P
M?5H  ')8  !K60  95H# &!;#@!=7!< 6EPA %A=*P!6730 5%X\ %->1 !1
M7DL!4%Y2 4Y>60),7F$"2UUJ TE== 1'78 %15V-!D1=G =#7:P'0EV^"$)=
MV@A"7/$'0ES^!T-;_P9#6_\&0UO_!KU5  "O70  GU\  )!>  "#7@  >%T
M &U<  !E70  7U\  %I@# !7810 56(> %)B* !18S$ 3V,Y $YC00!,8T@
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M!#%M_P0Q;/\$,6S_!*]D  "A:0  CV@  (%H  !U:0  :VD  &!K  !5;@
M37$  $9S  !"=0L /W82 #UW'  \=R4 .G@M #EX-0 X>3T -WE% #9Y30 U
M>54 ,WE> #%Y: $P>70!+GF# BUYD@(K>*,"*GBU BIXS (J=^H"*G;Y RIU
M_P,J=/\#*G3_ ZIJ  ":;0  B6P  'QM  !P;0  9FX  %MQ  !0=0  2'@
M $%[   Z?@4 -G\. #2 %@ S@2  ,H$H #"!,  O@C@ +H)  "V"2  L@E
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M )5]  "%?   >'P  &M^  !?@0  5(8  $J*  ! CP  -I,  "V7   FF@
M'IT  !>@ P 2H@P $*,2 !"C&0 /HR$ #J0I  ZD,0 -I#H #*1%  ND4  *
MI%P ":1J  >D>P &HXX !*.A  *CM  #HLL  Z+F  .A\P #H?L  Z'[ (V#
M  !_@@  <80  &2'  !8C   39$  $*6   XF@  +YX  ":B   >I0  %Z@
M !&K   ,K@< !Z\-  .O$@ "KQD  :\A  "O*0  L#(  + \  "P1P  L%,
M +!A  "P<0  L(,  *^7  "OJ@  K[\  *[9  "NZP  KO0  *[T (>)  !X
MB@  :HX  %V3  !1F   19T  #NB   PI@  )ZH  !ZN   6L0  $+0   NV
M   %N0,  +H*  "Z#@  NA,  +L9  "[(0  O"@  +PQ  "]/   OD@  +Y6
M  "^90  OG<  +Z,  "^GP  O;,  +['  "^W@  O>L  +WK '^2  !PE0
M8IH  %6?  !)I0  /:L  #*O   HM   'K8  !6Y   .O   ";\   +"
MQ    ,4$  #&"@  Q@X  ,<2  #(&   R1\  ,HG  #,,   SCP  ,Y)  #/
M60  SVH  ,]^  #/DP  SZ8  ,^X  #/R   S]L  ,_; '><  !HH0  6Z<
M $ZN  !!M   -+<  "BZ   =O0  $\    W$   &QP   ,H   #.    T
M -$   #2 @  TP@  -4,  #6$   V14  -L<  #=)   X"\  .(\  #C2P
MY%P  .1O  #E@P  Y9@  .6I  #EM@  Y<,  .7# &RE  !?K   4;(  $2Y
M   UO   *,   !S$   2R   #,L   //    TP   -@   #<    WP   -\
M  #A    XP   .0#  #F"   Z T  .D1  #L&   [B(  /$N  #S/   ]$T
M /5?  #V<P  ]X<  />9  #XI0  ^+   /BP /\#%P#_ !4 _P 5 /\ & #_
M ", _P O /\ / #_ $@ _P!4 /\ 7@#_ &< _0!O /L =@#Y 'T ^ "# /8
MB #U (X ] "3 /( F #Q )X \ "D .X JP#M +, ZP"] .H RP#H .$ YP#Q
M .8 _0#E /\ Y #_ .0 _P#D /\ Y #_ /\'$P#_ !$ _P 1 /\ %0#_ !\
M_P K /\ -P#_ $0 _@!/ /H 6@#W &, ] !K /( <@#P 'D [P!_ .T A #K
M (H Z@"/ .@ E #G )H Y0"@ .0 IP#B *\ X "Y -X Q@#< -H V@#L -@
M^0#6 /\ U@#_ -< _P#8 /\ V #_ /\*$ #_ PX _P - /\ $@#_ !H _P F
M /P ,@#W #\ ] !* /$ 50#M %X Z@!F .@ ;@#E '0 XP!Z .( @ #@ (4
MW@"+ -P D #; )8 V "< -4 HP#3 *L T0"U ,X P0#, -$ RP#G ,D ]0#(
M /\ R #_ ,@ _P#( /\ R #_ /\,# #_!@@ _P(* /\ #P#_ !4 _  @ /$
M+ #L #D Z0!% .4 3P#A %D W@!A -L : #7 &\ U !U -( >P#0 (  S@"&
M ,P C #+ )( R0"8 ,< H #% *@ PP"Q ,$ O "_ ,L O0#C +P \@"[ /T
MNP#_ +H _P"Z /\ N@#_ /\.!0#_"0  _PD% /\&"P#_ 1  \  9 .8 )0#A
M #( W  _ -8 20#1 %, S@!; ,L 8P#( &H Q@!P ,4 =@## 'L P0"! ,
MAP"^ (X O "4 +L G "Y *0 MP"N +4 N0"S ,@ L0#? + ![P"O ?L K@+_
M *T#_P"M _\ K0/_ /\0  #_#@  _PT  /8+ P#R!PH X@$1 -L"'0#2 RL
MS ,W ,@$0P#$!$T P016 +X%70"\!60 N@5K +@%<0"W!78 M05\ +,&@P"R
M!HD L :1 *\'F0"M!Z$ JP>K *D(MP"H"<8 I@K= *4+\ "C#/T H@W_ *$-
M_P"A#?\ H W_ /\1  #\$@  [!,  .(3  #;#P, U@D+ ,X(% #&"B( P PP
M +P-/ "X#48 M0U/ +(.5P"P#E\ K@YE *T.:P"K#G$ J@YX *@.?@"G#X4
MI0^- *0/E@"B$)\ H!"I )\0M0"=$<4 FQ'> )D2\0"7$_\ EA3_ )44_P"5
M%/\ E!3_ /\5  #M&P  X!\  -(?  #)&P  Q!0% ,$0#@"Z$AL M!,I + 4
M-0"L%4  J15) *854@"D%ED HA9@ *$69@"?%FP GA9R )P6>0";%X  F1>(
M )@7D0"6&)L E!BF ),9L@"1&<$ D!K8 (T;[@"+'/T BAS_ (H<_P")'/\
MB1S_ /0=  #D)0  TRD  ,<J  "\)@  MB   +09"P"N&A4 J!PC *0=+P"A
M'CH GAY$ )L>3 "9'E0 EQ]; )4?80"4'V< DA]M )$?= "/('P CB"$ (P@
MC0"*()< B2&B (<AK@"&(KT A2+1 8(CZP&!)/L!@"3_ 7\D_P%_)/\!?R3_
M >PE  #;+0  R3$  +PQ  "Q+@  JRD  *<D!0"C(Q$ GB0= )HE*@"6)C4
MDR8_ )$F1P"/)D\ C296 (LG7 "))V( B"=I (8G;P"%)W< @R=_ ($GB0&
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M FHUI0)I-;,#:#7& V<VX@-F-O4#9C;_ F8V_P)F-O\"9C;_ M@W  #$/@
MM4(  *9!  ";/P  DSP  (TX  "(-@< A#<1 ( W' !\."< >C@Q '<Y.@!U
M.4( <SE) '$Y4 !P.5< ;CE= &PY9 %K.6L!:3ET 6@Y?@)F.8D"9#F5 V,Z
MH@-B.K$#83K# V [X 1?._,#7SO_ U\[_P-?._\"7SO_ M$[  # 0@  L$4
M *%$  "50P  C4   (<]  "".P( ?3L. 'D\& !U/2, <STM ' ]-@!N/3\
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M!$]'U@5/1^\$3T?]!$]'_P-/1_\#4$?_ \1%  "U30  HTT  )5,  ")2P
M?TH  'A&  !Q1P  ;$<' &A($ !D2!H 84DD %])+0!=234 6TD] %E)1 !7
M24H 5DE1 %5*60%42F$!4DII 5%*= )/2G\#3DJ, TU*FP1,2ZH$2TN\!$I+
MTP5*2^X$2TO]!$M*_P-+2O\#2TK_ \%(  "R4   H$\  )%/  "%3@  >TT
M '-)  !L2@  9TL$ &),#@!?3!< 7$TA %I-*@!833( 5DTZ %1-00!33D@
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M SU6_P,]5O\#/5;_ [93  "E5P  E%<  (56  !Y5@  ;U8  &55  !<5@
M5U@  %)9!P!.6A  3%H8 $I;(0!(7"H 1UPR $5<.@!$74$ 0UU( $)=4 !
M75@ /UUA 3U=:P$\778".EV$ CE=DP(X7:,#-UVU S9=RP,V7.@#-USY S=;
M_P,X6_\#.%K_ [)7  "@6@  CUD  (%9  !U60  :UD  &!:  !66P  45T
M $Q> @!(8 T 16 4 $1A'@!"8B8 0&(N #]B-@ ^8SX /6-% #QC30 [8U4
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M :%E  ".9   ?V0  ')D  !H90  7F8  %1I  !);   0F\  #MR   T=0
M+G@* "MY$0 J>1@ *7HA "=Z*  F>C  )7LX "1[0  C>T@ (GM2 "%[7  @
M>V@ 'WQV !U\A@ <>Y@ &WNJ !I[OP :>]X &GGR !MX_@ ;=_\!&W?_ 9EI
M  "(:0  >6D  &UI  !C:@  66P  $]O  !%<P  /7<  #5Z   N?0  )X$#
M "*##0 @A!( 'X0: !V$(@ <A2H &X4Q !J%.0 9A4( &(9, !>&5@ 6AF,
M%89Q !2&@0 2AI, $8:F !&%NP 0A=8 $8/O !&"^P 2@O\ $H'_ )%N  "!
M;0  =&X  &EN  !=<   4W,  $EW  ! ?   -X   "^#   GAP  (8H  !J-
M!@ 5CPT $Y 3 !*0&@ 2D"( $9 J !"1,@ 0D3L #Y%$  Z13P -D5P #)%J
M  N1>@ *D8T ")"?  >0LP 'C\D !X_F  >.]  (C?P "(W_ (ES  ![<P
M;W,  &-U  !7>   37T  $.!   YA@  ,(H  "B.   AD0  &I4  !.7   .
MF@@ "YP.  F<$P (G!H !YPB  :<*@ $G#,  YP]  *=2   G50  )UB  "<
M<@  G(0  )R7  ";J@  F[\  )K;  ":[   FO4  )GX ()Y  !V>0  :'H
M %Q^  !1@@  1H<  #R,   RD0  *94  "&9   9G0  $J    ZC   )I@4
M Z<,  "G$   IQ4  *@<  "H(P  J"L  *DT  "I/P  J4L  *E9  "I:
MJ7H  *F.  "IH0  J+4  *C+  "GY   I^\  *?S 'V   !O@0  880  %6)
M  !)C@  /I0  #29   JG@  (:(  !FF   2J0  #:P   >O    L@   +,'
M  "S#   LQ   +05  "T&P  M2(  +8K  "W-0  MT   +A.  "X70  N&X
M +B"  "XEP  N*H  +>^  "WT@  M^8  +?J ':(  !GBP  6I   $Z6  !"
MG   -Z(  "RG   BJP  &:\  !&S   +M@  !+D   "\    O@   +X   "_
M!@  P L  ,$/  #"$P  PQD  ,0@  #%*0  QS0  ,A"  #)40  R6(  ,EU
M  #)B@  R9\  ,JQ  #*P0  R=$  ,G9 &Z3  !@F   4YX  $:D   ZJP
M+[   "2U   9N   $+P   J_   !P0   ,0   #(    R@   ,H   #,
MS0,  ,X(  #0#0  T1   -,6  #6'@  VB@  -TT  #>0P  WU0  -]G  #@
M?   X)$  ."D  #@L@  X+X  .## &:?  !9I@  3*T  #^T   RN   )+P
M !B_   0PP  ",<   #*    S0   -$   #5    V    -D   #;    W0
M -\   #A!   XPH  .4.  #G$P  ZAP  .TG  #P-0  \48  /)8  #S:P
M\X   /24  #THP  ]*X  /2R /\ $P#_ !$ _P 1 /\ %0#_ !\ _P L /\
M.0#_ $4 _P!0 /\ 6@#^ &, ^P!K /D <@#W '@ ]0!^ /0 A #R (D \0".
M /  DP#N )D [0"? .P I@#J *X Z "X .8 Q0#E -L XP#M .( ^P#B /\
MX0#_ .$ _P#A /\ X0#_ /\ $ #_  X _P - /\ $@#_ !L _P H /\ - #^
M $$ ^P!, /< 5@#T %\ \0!F .\ ;0#L '0 Z@!Z .D ?P#G (4 Y@"* .4
MCP#C )4 X0"; .  H@#> *H VP"T -D P #6 -  TP#H -( ]P#1 /\ T0#_
M -  _P#0 /\ T #_ /\ #0#_  D _P * /\ #P#_ !8 ^P B /< +P#T #L
M\ !' .T 40#I %H Y0!B .( :0#@ &\ W@!U -P >@#: (  V "% -4 BP#3
M )$ T0"7 ,\ G@#- *8 RP"O ,D N@#' ,D Q0#B ,0 \@## /X P@#_ ,$
M_P#" /\ P@#_ /\#!@#_  $ _P & /\ # #Y !$ \0 = .L *0#G #8 XP!!
M -\ 2P#; %0 U0!< -( 8P#/ &H S0!P ,L =0#) 'L R "  ,8 A@#% (P
MPP"3 ,$ F@"_ *( O0"K +L M@"Y ,0 MP#: +8 [0"T /H M #_ +0 _P"T
M /\ M #_ /\$  #_    _P   /\ !@#L  T Y0 6 -X (@#7 "\ T0 [ ,T
M10#* $X Q@!7 ,0 7@#! &0 OP!J +T < "\ '4 N@![ +D @0"W (< M0".
M +, E0"R )X L "G *X L@"L +\ J@#1 *@ Z "H /< IP#_ *< _P"F /\
MI@#_ /\&  #_!0  \0,  .@   #A  < U0 0 ,T &P#' "< PP S +\ /@"\
M $@ N0!1 +8 6 "T %\ L@!E +  :@"O '  K0!V *P ? "J (( J0") *<
MD0"E )H HP"D *$ K@"@ +L G@'- )T"Y@"<!/0 FP3_ )H%_P":!?\ F07_
M /\*  #Q#@  Y!   -D/  #."P  R ,+ ,( $P"\ A\ MP,L +,$-P"P!4(
MK09* *H&4@"H!UD I@=? *4'90"C!VL H@AQ * (=P"?"'X G0B% )L)C@":
M"9< F JA )8*K "5"[H DPO, )(,Y0"0#?8 CP[_ (X._P".#O\ C0[_ /81
M  #F%P  UAL  ,<9  "^%0  N1   +<*#0"Q"Q< K TD *@., "E#CL H@Y$
M )\/3 "=#U, FP]: )H/8 "8$&8 EQ!L )40<@"3$'D DA"! ) 0B@"/$90
MC1&? (L1J@"*$K@ B!++ (83Y@"%%/< @Q7_ (,5_P""%?\ @A7_ .T:  #<
M(0  RB4  +LB  "Q'P  JQH  *D4!@"E$A$ H!0> )P5*@"9%34 EA8^ )06
M1P"2%DX D!95 (X76P",%V$ BQ=G (D7;0"(%W0 AAA\ (48A@"#&9  @1F;
M ( :IP!^&K4 ?1O' 'P<X@!Z'?4 >1W_ '@=_P!X'?\ >!W_ .4B  #0*0
MORP  + J  "G)P  H",  )T?  ":&@X E1P8 )$=) ".'B\ C!XY (D>00"'
M'TD A1]0 (,?5@""'UP @!]B '\?:0!]('  ?"!X 'H@@0!Y(8P =R&7 '4B
MI !T(K( <R/# '(CWP!P)/, ;R3_ &\D_P!N)/\ ;B3_ -TI  #(,   MS(
M *@P  ">+@  ERH  ),G  "0(PH C",3 (@D'P"$)2H @B4T ( F/0!])D0
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M 5HUT@%9->T!637\ 5@U_P%8-?\!637_ <@X  "W/@  I#X  )8]  "+/
M@SH  'TW  !X-   =#0+ ' U$P!M-1T :C4G &@V, !F-C@ 9#8_ &,V1@!A
M-DT 8#93 %XW6@!=-V( 7#=J %HX= %9.'\!5SB, 58YF0%5.:@"5#FY E,Z
MSP)3.NL"4SK[ 5,Z_P%3.?\!4SG_ <0\  "R00  H$   ))   "&/P  ?CT
M '@Z  !S.   ;CD( &HY$0!G.1H 9#HD &(Z+ !@.C0 7CH\ %T[0P!;.TH
M6CM0 %@[5P!7.U\ 5CQG %0\<0%3/'P!4CV) 5$]EP%//:8"3CZW DX^S0).
M/ND"33[Z DX^_P%./?\!3CW_ < _  "N0P  G$,  (Y#  ""0@  >D   ',]
M  !M/   :#T% &0]#@!A/A< 7CXA %P^*0!:/C$ 6#XY %<^0 !5/T8 5#]-
M %,_50!20%P 4$!E $] ;P%.07H!34&' 4M!E@%*0:4"24*U DE"RP))0N@"
M24+Y DE!_P))0?\!24'_ ;U#  "J10  F$4  (I%  !_10  =D,  &]   !H
M0   8T$! %]!#0!<010 64(= %=")@!50BX 4T(V %%"/0!/0D, 3T-+ $Y#
M4@!-1%H 3$1C $I$;0%)17@!2$6% 4=%E %%1:,"14:T D1&R0)$1N<"1$7X
M D1%_P)%1?\"147_ ;I&  "F2   E$@  (9(  ![1P  <D8  &I"  !C0P
M7D0  %I%"P!611( 5$8; %%&(P!/1BL 3D8S $Q'.@!+1T$ 2D=) $E(4 !(
M2%@ 1TAA $9):P!$278!0TF# 4))D@%!2:("0$FS C]*QP(_2N4"/TGW D!)
M_P) 2/\"0$C_ ;9)  "B2@  D4H  (-*  !W2@  ;DD  &5%  !>1P  64@
M %5)" !12A  3TH8 $Q*(0!*2RD 24LQ $=+. !&3#\ 14Q& $1,3@!#358
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M :A2  "54@  A%(  '=2  !L4@  8E(  %A3  !/5   258  $17  ! 60@
M/5H0 #M:%P Y6R  .%LG #=<+P V7#8 -5P^ #1<1@ S74X ,5U7 #!=80 O
M76P +EUZ "Q=B0 K79H!*EVK 2I=OP$I7=X!*ESR 2I;_@$K6_\!*UK_ :-5
M  "/50  ?U4  ')5  !G5@  7E8  %17  !,60  15L  #]=   Z7P0 -F -
M #1A$P R8AP ,6(C #!B*P O8S( +F,Z "UC0@ L8TH *F13 "ED70 H9&D
M)V1V "9DA@ E9)< )&2I "-DO0 B9-H (V/Q "-B_0$D8?\!)&'_ 9Q8  ")
M6   >ED  &Y9  !C60  6EH  %!<  !(7@  06   #IC   T9@  +V@* "QI
M$  J:1< *6H? "AJ)@ G:BX )FLU "5K/0 D:T8 (VM/ ")L60 @;&4 'VQR
M !YL@@ =;)0 '&RF !MKN@ ::]0 &VKN !QI_  <:/\ '&C_ )5<  "#7
M=5P  &E=  !?70  5EX  $QA  !#9   /&<  #5J   O;0  *' $ "-R#0 A
M<A( (',: !]S(0 ><R@ '70P !QT.  ;=$  &G1* !ET5  7=6  %G5N !5U
M?@ 4=9  $W2B !)TM@ 1=,\ $G/L !)R^@ 3<?\ $W'_ (Y@  !]8   ;V$
M &5A  !;8@  460  $AG   ^:P  -VX  #!Q   I=0  (G@  !Q[!P 7?0X
M%GT3 !5]&P 4?B( $WXJ !)^,0 1?CH $7Y$ !!_3@ /?UH #G]H  U_>  ,
M?XH "WZ=  I^L  )?<8 "GWD  I\]  +>_T "WK_ (9E  !W90  :F4  &%F
M  !6:   3&L  $)O   Y<P  ,7<  "IZ   C?@  '($  !6$   0AP@ #8D.
M  R)%  ,B1L "XDC  J)*P )B3, "(D]  :)2  %B50 !(EA  *)<0 !B8,
M (F6  "(J0  A[X  (?:  "&[   AO4  (;Z 'YJ  !Q:@  9VL  %ML  !0
M<   1G0  #QX   S?0  *H$  ".%   <B   %8P  !"/   ,D@8 !I,,  *3
M$0  E!8  )0=  "4)   E2P  )4U  "50   E4P  )99  "6:0  E7H  )6.
M  "4H0  E+4  )/,  "2Y@  DO(  )+W 'AP  !M<   8'(  %1U  !)>0
M/WX  #6#   LB   (XT  !N1   4E   #Y<   J:   $G0,  )X)  "?#@
MGQ(  * 7  "@'0  H24  *(M  "B-P  HT,  *-0  "C7P  HW$  *.$  "B
MF0  HJT  *'"  "AW   H>L  *#R '-V  !F=P  67L  $V   !"A0  .(L
M "Z0   DE0  &YH  !2>   .H0  ":0   *G    J@   *L$  "K"@  K T
M *T1  "M%@  KAP  *\D  "P+0  L3D  +%&  "R50  LF8  +)Y  "RC@
ML:,  +*W  "QR@  L>   +'I &Q^  !?@@  4H<  $:-   [DP  ,)D  ":>
M   <HP  $Z<   VK   'K@   +(   "U    MP   +@   "Y @  N0@  +H,
M  "[$   O!0  +T;  "_(P  P2T  ,(Z  #"20  PUH  ,-L  #$@@  Q)<
M ,2K  #$O   Q,L  ,3: &6)  !8C@  2Y4  #^;   SH@  **@  !VM   4
ML0  #;8   :Y    O    +\   ##    Q    ,4   #&    QP   ,D$  #*
M"0  RPT  ,T1  #/&   TB$  -4M  #6/   V$T  -E?  #:<P  VHH  -N>
M  #;K@  V[H  -S# %Z6  !1G   1*,  #BJ   LL0  (+<  !6[   -O@
M!,(   #%    R0   ,T   #0    T@   -(   #5    U@   -D   #;
MW@4  . *  #B#P  Y18  .@@  #L+0  [3X  .U1  #N90  [WH  .^/  #P
MGP  \*L  /"S /\ $ #_  X _P . /\ $@#_ !T _P I /\ -0#_ $$ _P!-
M /X 5@#[ %\ ^ !F /8 ;0#T '0 \@!Y /$ ?P#P (0 [@") .T CP#K )4
MZ@"; .@ H@#F *H Y0"S ., P #A -( X #J -\ ^0#= /\ W0#_ -T _P#>
M /\ W@#_ /\ #0#_  H _P ) /\ #P#_ !@ _P D /X ,0#[ #T ^ !( /0
M4@#P %H [0!B .L :0#I &\ YP!U .4 >@#C '\ X@"% .  B@#> )  W "6
M -H G0#8 *4 U0"O -( N@#0 ,H S@#C ,T ] #+ /\ RP#_ ,L _P#+ /\
MRP#_ /\ " #_  , _P % /\ # #\ !0 ]P ? /( *P#O #< ZP!" .< 3 #D
M %4 X != -T 9 #: &H V !P -4 =0#2 'H T "  ,\ A0#- (L RP"2 ,D
MF0#' *$ Q0"J ,, M0#! ,, OP#: +X [@"] /P O #_ +P _P"\ /\ O #_
M /\   #_    _P   /D !P#Q !  Z@ : .0 )0#? #$ VP \ -< 1P#2 %
MS@!7 ,L 7@#) &4 Q@!J ,4 < ## '4 P0!Z ,  @ "^ (8 O "- +H E "Y
M )P MP"E +4 L "S +T L0#/ *\ Z "N /@ K@#_ *T _P"M /\ K0#_ /\
M  #_    _0   .X  0#C  P V@ 4 -$ 'P#, "L R  V ,4 0 #" $H OP!2
M +P 60"Z %\ N !E +8 :@"T &\ LP!U +$ >@"P ($ K@"( *T CP"K )@
MJ0"A *< JP"E +@ HP#( *( X@"A /, H #^ *  _P"@ /\ H #_ /\   #V
M    Z@   .    #3  8 R0 / ,( & "] "0 N0 O +8 .@"T $, L0!, *X
M4P"L %D J@!? *D 9 "G &H I@!O *0 =0"C 'L H0"" *  B@"> ), G "=
M )H IP"8 +0 E@## )4 W "4 .\ DP#[ ), _P"3 /\ D@#_ /D%  #J"P
MW T  ,L*  #"!0  O  * +8 $0"Q !P K@ H *H ,P"G #T I !% *( 30"@
M %, G@!9 )P 7P"; &0 F@!J )@ < "7 '8 E0!^ ), A@"2 8\ D &9 (X"
MI ", K$ BP/  (D%U@"(!NT B ?Z (<(_P"&"/\ A@C_ .\/  #>%   RA4
M +P2  "S$   K@P  *L&#0"G Q4 H@4@ )\'+ "<"#8 F0@_ )<)1P"5"4X
MDPE4 )$*6@"0"E\ C@IE (T*:P"+"G( B@MY (@+@@"'"XP A0R7 (,,H@"!
M#;  @ W  '\-V !]#N\ ? _] 'L/_P![$/\ >Q#_ .87  #1'@  O1T  *\<
M  "F&0  H14  )X0! "=#0\ F X9 )0.)0"1#R\ CQ Y (P000"*$$@ B!!/
M (<050"%$%L A!%A ((19P" $6X ?Q%U 'T1?@!\$H@ >A*4 '@2H !W$ZX
M=1.^ '04U0!S%>X <1;] '$6_P!Q%O\ <!;_ -P?  #&)0  LR4  *4C  "<
M(0  EAX  )(9  "1% L C104 (D5'P"&%BD @Q8S ($7/ " %T, ?A=* 'P7
M4 !Z%U8 >1A< '<88@!V&&D =!AQ ',9>@!Q&80 ;QJ0 &X:G0!L&ZL :QR[
M &H<T !I'>P :![[ &@>_P!G'O\ 9Q[_ -$F  "]*@  JRH  )TJ  "3*
MC24  (@B  "&'08 @QL0 '\<&@!\'20 >ATN '<>-@!V'CX =!Y% '(?2P!Q
M'U$ ;Q]8 &X?7@!L'V4 :R!M &D@=@!H(8$ 9B&- &4BF@!C(J@ 8B.X &$C
MS0!@).D 8"3Z %\D_P!?)/\ 7R3_ ,HL  "V+P  I"\  )8O  ",+0  A2H
M ( H  !])   >B(- '8C%0!S(R  <20I &\D,@!M)#H :R5! &HE1P!H)4T
M9B54 &4E6@!D)F$ 8B9I &$F<@!?)WT 7B>* %THEP!;*:4 6BFU %HJR@!9
M*N< 6"KX %@J_P!8*O\ 6"K_ ,4Q  "O,P  GC,  ) S  "&,@  ?R\  'DM
M  !U*@  <B@* &\H$@!K*1L :2DE &<J+0!E*C4 8RH] &(J0P!@*DH 7RM0
M %XK5P!<*UX 6RQF %DL;P!8+7H 5RV' %8NE0!4+J, 4R^S %,OQP!2+^4
M4B_W %(O_P!2+_\ 4B__ ,$V  "J-@  F38  (LV  "!-0  >3,  ',Q  !O
M+P  :RX& &@M$ !D+A@ 8BXA & O*@!>+S$ 7"\Y %LO0 !9+T8 6"]- %<P
M4P!6,%L 5#%C %,Q; !2,G< 43*$ $\SD@!.,Z$ 33.Q $TTQ0%,-.,!3#3V
M $PT_P!,-/\ 3#/_ +LY  "F.0  E3D  (<Y  !\.0  =#<  &XT  !I,P
M93(" &$R#0!>,A0 7#,> %HS)@!8,RX 5C,U %4T/ !3-$, 4C1* %$T4 !0
M-5@ 3C5@ $TV:@!,-G4 2S>" $HWD !).)\ 2#BP 4<XPP%'..$!1SCU 4<X
M_P%'./\!1SC_ ;<[  "B/   D3P  (,\  !X/   <#H  &HW  !D-@  8#8
M %PV"P!9-Q( 5C<: %0W(P!2-RL 4#<R $\X.0!-.$  3#A' $LX3@!*.54
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M :I"  "60P  AD,  'A#  !N0P  94,  %U   !60   44(  $U" @!)0PP
M1D,2 $1$&@!"1"( 040J #]%,0 ^13@ /44_ #Q&1P [1D\ .D97 #E'80 X
M1VP -T=Z #9(B0 U2)D -$BJ #1(O0 S2-D -$CP #1'_0 T1_\ -4;_ *9$
M  "210  @D8  '5&  !J1@  844  %E$  !11   3$8  $A'  !$1PH 04@0
M #])&  ]22  /$DG #I*+@ Y2C8 .$H] #=+1  V2TP -4M5 #1,7P S3&H
M,DQW #%,A@ P3)< +TVH "Y-NP N3=4 +DSO "],_0 O2_\ ,$O_ *%'  ".
M2   ?D@  '%(  !F20  74@  %5(  !,20  1TH  $)+   _3 8 .TT. #E.
M%0 W3AT -D\D #5/*P S3S, ,E Z #%00@ P4$H +U%2 "Y17  M46< +%%U
M "M1A  J4I4 *5*F "E2N0 H4M( *5'N "E0_  J4/\ *D__ )Q*  ")2@
M>DL  &U+  !C3   6DP  %%,  !(30  0T\  #U0   Y4@( -5,, #-4$@ Q
M5!D ,%4A "Y5*  M52\ +%8W "M6/@ J5D8 *59/ "A760 G5V0 )E=R "57
M@0 D5Y( (U>D ")7MP B5\\ (E?L "-6^@ C5?\ )%7_ )9-  "$3@  =4X
M &E.  !?3P  5D\  $U0  !%4@  /U,  #E6   S6   +UH( "M;#P J6Q4
M*%P= "=<)  F7"L )5PS "1=.@ C74, (EU, "%=5@ @7F$ 'UYN !Y>?@ =
M7H\ '%ZA !M>M  :7<P &UWI !M<^0 <6_\ '%O_ )!1  !^40  <%$  &12
M  !;4@  4E,  $I4  !!5P  .UD  #5;   N7@  *& # "1B#  B8Q$ (6,8
M !]D(  >9"< '60N !QD-@ ;93X &F5' !EE40 895T %V5J !9E>@ 598L
M%&6> !-EL0 29<@ $F3G !-C]P 48O\ %&+_ (E4  !X50  :U4  &!6  !7
M5@  3U<  $99   ]7   -E\  #!B   I9   (V<  !UJ!P 9; X &&P3 !9M
M&@ 5;2$ %&TI !1M,  3;3D _^)]$$E#0U]04D]&24Q%  <2$FY" !%N3  0
M;E@ #VYE  YN=0 -;H< #6Z:  QMK0 +;<( "VS@  QK\P -:_T #6K_ ()9
M  !R60  9ED  %Q:  !46@  2EP  $%?   Y8P  ,68  "II   D;   '6\
M !=R   2=0D #W</  YW%  .=QL #7<C  QW*@ +=S, "G<\  EW1P (=U(
M!W=?  5W;P $=X   W>4  %VIP  =KL  775  %TZP "=/8  G3\ 'M=  !M
M70  8EX  %E>  !.8   16,  #QG   S:P  *VX  "1R   >=0  %WD  !)\
M   -?P8 "8$,  6!$0 #@18  H$=  &!)   @2T  ((V  ""0   @DP  ()9
M  "":   @GD  (*-  "!H   @+0  (#+  !_YP  ?O(  '[Y '1B  !H8@
M7F(  %-D  !)9P  /VL  #9P   M=   )7@  !Y\   7@   $8,   V&   (
MB00  HL*  "+#@  BQ,  (P8  ",'P  C28  (TO  "..0  CD0  (Y1  ".
M8   CG$  (Z%  ".F0  C:T  (S#  ",WP  B^X  (OV &YH  !D9P  6&D
M $UL  !"<0  .'8  "][   F?P  'H0  !:(   0C   #(\   :2    E0
M )8'  "7#   EP\  )@3  "9&   FA\  )LF  ";,   G#L  )Q(  "<5P
MG&@  )Q[  "<D   FZ4  )NZ  ":T   FN<  )KQ &IM  !>;P  47(  $9W
M   [?   ,8(  ">'   >C   %I$  !"5   *F0  !)P   "@    H@   *,!
M  "C!@  I L  *4.  "F$@  IQ<  *@>  "J)@  JS$  *L^  "L30  K%T
M *QP  "LA0  K)L  *NO  "KPP  J]D  *KH &1U  !7>0  2WX  #^$   T
MB@  *9   !^6   6FP  $)\   FC   !IP   *H   "N    L    +    "Q
M    L@,  +0(  "U#0  MA   +<5  "Y'0  NR8  +PS  "]00  O5(  +UD
M  "^>0  OI   +VD  "]MP  O<8  +W7 %Q_  !0A0  1(L  #B2   LF0
M(9\  !>D   0J0  ":X   "R    M@   +D   "]    OP   +\   #
MP0   ,,   #$!0  Q@H  ,<.  #)$P  RQP  ,XF  #0-0  T44  -)7  #2
M:P  TX(  -.7  #3J0  TK@  -+$ %6,  !)DP  /9H  #"B   EJ   &JX
M !&T   )N0   +T   #!    Q    ,@   #+    S0   ,T   #/    T
M -(   #4    V    -H&  #=#   X!$  .,:  #F)P  YS@  .A*  #I70
MZG(  .N(  #KFP  [*@  .RR /\ #0#_  L _P + /\ $ #_ !H _P F /\
M,@#_ #T _P!( /L 4@#X %H ]@!B /, :0#Q &\ \ !U .X >@#L '\ ZP"$
M .D B@#H )  Y@"6 .0 G0#B *4 X0"O -\ NP#= ,L VP#F -D ]P#8 /\
MV #_ -< _P#7 /\ U #_ /\ " #_  0 _P $ /\ #0#_ !4 _@ A /H + #W
M #@ ] !# /  30#M %4 Z@!= .< 9 #D &H X@!P .  =0#> 'H W0!_ -L
MA0#9 (L U0"1 -, F0#1 *  SP"J ,T M0#+ ,0 R0#= ,@ \0#' /\ Q@#_
M ,8 _P#& /\ QP#_ /\   #_    _P   /\ "@#X !$ \0 < .P )P#I #(
MY@ ] .( 1P#= %  V0!8 -4 7P#2 &4 T !J ,X < #, '4 R@!Z ,D ?P#'
M (4 Q0", ,, E #! )P OP"E +T L "[ +T N@#0 +@ ZP"W /L M@#_ +8
M_P"V /\ M@#_ /\   #_    _0   /, !0#I  X X0 6 -L (0#5 "T T0 W
M ,X 00#* $H QP!2 ,0 60#" %\ P !E +X :@"\ &\ NP!T +D >@"W (
MM@"' +0 C@"R )< L "@ *X J@"M +< JP#( *D XP"H /4 IP#_ *< _P"G
M /\ I@#_ /\   #^    \0   .4   #7  H S0 1 ,< ' #" "8 OP Q +P
M.P"Z $0 MP!, +0 4P"R %D L0!? *\ 9 "M &D K !O *H = "I 'H IP"!
M *8 B0"D )$ H@"; *  I0"> +( G0#! )L V@": .\ F0#] )@ _P"8 /\
MF #_ /T   #P    X0   -$   #&  0 O0 - +< %0"S "  L  K *T -0"K
M #X J !& *8 30"D %0 HP!9 *$ 7P"@ &0 G@!I )T ;@"; '4 F@![ )@
M@P"6 (P E0"6 ), H0"1 *T CP"[ (T SP", .D BP#X (P _P", /\ C #_
M /,"  #B!P  S <  +\$  "W    L0 ( *L $ "G !D I  D *  +@"> #<
MG !  )H 1P"8 $X E@!4 )4 60"3 %X D@!D )  :0"/ &\ C0!V (L ?@"*
M (@ B "2 (8 G0"% *D @P"X ($ R@"  .4 @ #U '\ _P!_ /\ ?P#_ .@-
M  #0$   OA   +$.  "H#0  HP@  * "# "< !, F  = )4 )P"2 #$ D  Y
M (X!00", 4@ B@). (D"5 "' ED A@)? (0#9 "# VL @0-R ( $>@!^!(0
M?06. 'L%F@!Y!J< > :U '8'R !U"., =0GT '0*_P!S"O\ <PK_ -T5  #$
M%P  L1<  *46  "<$P  EA$  )0-! "3" T C@<5 (L)( "("2H A0HS (,+
M.P"!"T( @ M) 'X+3P!]#%0 >PQ: 'H,8 !X#&< =PQN '4-=@!T#8  <@V,
M ' -F0!O#J8 ;0ZU &P.R0!K#^8 :A#W &D0_P!I$/\ :1#_ - =  "Y'@
MJ!X  )L=  "2&P  BQD  (@5  "'$0< A0X0 ($/&@!^$"0 >Q M 'D0-@!W
M$3T =A%$ '012@!S$5  <1%6 ' 17 !N$F( ;1)J &L2<P!I$WT :!.) &83
ME@!E%*, 8Q6S &(5Q@!B%N, 81;V & 7_P!@%_\ 8!?_ ,<B  "P(P  GR0
M )(C  ")(@  @B   'X=  !\&0  >A4- '<5%0!T%A\ <18H &\7, !N%S@
M;!<_ &L710!I&$L :!A1 &886 !E&%X 8QEF &(9;P!@&7D 7QJ% %T;D@!<
M&Z$ 6QRP %H<PP!9'>  6![T %@>_P!8'O\ 6![_ +\G  "I*   F2@  (LH
M  "")P  >R4  '8C  !S(   <1P) &X<$0!K'!H :1TC &<=+ !E'3, 8QXZ
M &(>00!@'D< 7QY- %X>5 !<'UL 6Q]B %D@:P!8('8 5B&" %4AD !4(IX
M4R*N %(CP !1(]T 423R %$D_P!1)/\ 42/_ +DK  "C+   DRP  (8M  !\
M+   ="H  &\H  !K)0  :2(% &8A#@!C(A8 82(? %\C)P!=(R\ 7",V %HC
M/0!9)$, 5R1* %8D4 !5)%< 4R5? %(E: !1)G, 3R9_ $XGC0!-*)P 3"BL
M $LIO@!+*=H 2BGQ $HI_P!+*?\ 2RG_ +,N  ">+P  CC   ($P  !W+P
M;RX  &HK  !E*@  8R<! %\G# !<)Q, 6B<; %@H) !6*"L 52@R %,H.0!2
M*4  4"E& $\I30!.*50 32I< $PJ90!**W  22M\ $@LBP!'+9H 1BVJ $4N
MO !%+M8 12[O $4N_@!%+O\ 12W_ *XQ  ":,@  B3,  'PS  !R,P  :S$
M &4O  !@+0  72P  %DL"0!6+!  5"P8 %(L( !0+"@ 3BTO $TM-@!,+3P
M2BU# $DM2@!(+E$ 1RY9 $8O8P!%,&T 0S!Z $(QB0!!,9@ 03*H $ RNP _
M,M, /S+N $ R_0! ,O\ 0#+_ *HS  "6-0  AC4  'DV  !N-0  9C4  &$R
M  !<,   5S   %0P!@!1, X 3C 5 $PQ'0!*,24 2#$L $<Q,@!&,3D 1#%
M $,R1P!",D\ 03-7 $ S8  _-&L /C5X #TUAP \-I8 .S:G #LVN0 Z-M$
M.C;M #LV_  [-O\ .S;_ *8V  "2-P  @C@  '4X  !K.   8S<  %TV  !7
M,P  4S0  $\T P!+- P 2302 $8U&@!%-2( 0S4I $$U+P! -38 /S8] #XV
M1  ]-TP /#=5 #LX7@ Z.&D .3EV #@YA0 W.I4 -SJE #8ZN  U.L\ -CKL
M #8Z^P V.?\ -SG_ *(X  "..0  ?CH  '([  !H.P  7SH  %DY  !3-@
M3C<  $HX  !&. H 1#D0 $$Y%P _.1\ /CDF #PY+0 [.C0 .CH[ #D[0@ X
M.TH -SM3 #8\7  U/&< -#UT #,]@P S/I, ,CZD #$^M@ Q/LT ,3[J #$^
M^@ R/?\ ,CW_ )X[  "+/   >SP  &X]  !D/0  7#T  %4\  !..@  23L
M $4\  !!/0< /CT. #P]%0 Z/AP .3XC #<^*@ V/S$ -3\X #0_0  S0$@
M,D!0 #% 6@ P064 +T%R "Y"@0 M0I$ +4*B "Q"M0 K0LL +$+I "Q"^0 M
M0?\ +4'_ )D]  "'/@  =S\  &L_  !A0   63\  %(_  !)/@  1#\  $!
M   \000 .4(- #="$@ U0QD ,T,A #)#*  Q1"\ ,$0V "]$/0 N144 +45.
M "Q%6  K1F, *D9O "E&?@ H1H\ )T>A "9'LP F1\D )D;G "=&^  H1?\
M*$7_ )5   ""00  <T(  &="  !>0@  54(  $Y"  !%0@  /T0  #M%   W
M1@  -$<* #%($  O2!8 +DD> "Q))0 K22P *DDS "E*.@ H2D( )TI+ "9+
M50 E2V  )$MM "-+?  B2XT (4R? "%,L0 @3,< ($OF "%+]P B2O\ (DK_
M )!#  !^1   ;T0  &1%  !:10  4D4  $I&  !!1P  /$@  #=)   R2P
M+DT' "M.#@ I3A, )T\: "9/(0 E3R@ )$\P "-0-P B4#\ (5!( "!04@ ?
M45T 'E%J !U1>0 <48H &U&< !I1KP 94<4 &5'D !I0]@ ;3_\ '$__ (I&
M  !Y1P  :T<  &!(  !62   3D@  $=)   ^2P  .4P  #-.   N4   *%,"
M "14"P B51  (%46 !]6'@ >5B0 '58L !Q6,P ;5SL &E=$ !E73@ 85UD
M%UAF !58=0 46(< %%B: !-7K  25\( $E?A !-6]  45?\ %%7_ (1)  !T
M2@  9DL  %Q+  !32P  2TP  $1-   \3P  -5$  "]4   I5@  )%D  !Y;
M!P :70T &%T2 !==&0 67B  %5XG !1>+@ 37C< $EY  !%?2@ 17U4 $%]B
M  ]?<0 .7X, #5^6  U?J0 ,7KX #%[:  U=\  -7/P #ES_ 'Y-  !N3@
M8DX  %A/  !/3P  2%   $!2   X5   ,%<  "I:   D70  'U\  !EB 0 3
M90D $68/ !!F%  /9AL #F<B  UG*0 -9S( #&<[  MG10 *9U  "6==  =G
M;  &9WT !6>0  1FHP "9K<  V7/  1EZ0 $9/4 !&3\ '=1  !I4@  75(
M %12  !,4P  0U4  #M8   S6P  *UX  "5A   ?9   &6<  !-J   /;08
M"W ,  AP$0 '<!8 !7 =  1P)  #<"P  G U  !P/P  <$H  '!7  !P90
M<'8  '"*  !OG@  ;[(  &[(  !MY0  ;?(  &WY '!6  !C5@  658  %%7
M  !'6   /EL  #9?   N8@  )F8  !]J   9;0  $W    YS   +=@0 !7@+
M  %X#P  >1,  'D9  !Y'P  >B8  'HO  !Z.0  >D0  'I0  !Z7P  >G
M 'J#  !ZF   >JP  'G"  !XWP  >.\  '?W &I;  !?6P  5EL  $Q<  !"
M8   .6,  #!H   H;   ('   !ET   3=P  #GL   E^   $@0(  (((  "#
M#0  @Q   (04  "%&0  AB   (8H  "',0  ASP  (=)  "'5P  AV@  (=[
M  "'D   AJ4  (6Z  "%TP  A.H  (3T &5@  !<8   46$  $9D   \:0
M,FT  "ER   A=P  &7L  !*    -@P  "(<   **    C0   (X$  "."0
MCPT  ) 0  "1%   DAD  ),@  "4*0  E3,  )5   "63@  EE\  )5R  "5
MB   E9T  )2R  "4R   D^(  )/N &%E  !69@  2FH  #]N   U=   *WD
M "%_   9A   $8D   R-   &D0   )0   "8    F@   )L   "< @  G0<
M )X+  "?#@  H1(  *(8  "C(   I2D  *8V  "F1   IE4  *9H  "F?0
MII0  *6I  "DO0  I-$  *3D %ML  !/<   0W4  #A[   M@0  (X<  !F-
M   1D@  "Y<   2<    H    *,   "F    J    *D   "J    K    *T$
M  "N"0  L T  +$1  "S%P  M2   +8K  "W.@  MTL  +A<  "X<0  N(@
M +B=  "XL0  M\(  +?0 %1V  !(?   /((  #&)   FD   &Y<  !*=   ,
MH@   Z<   "K    K@   +(   "V    N    +@   "Z    NP   +T   "^
M    P 4  ,$+  ##$   QA8  ,D@  #*+@  RSX  ,Q0  #,9   S7H  ,V1
M  #-I   S;0  ,W  $V#  !!B@  -9$  "F9   >H   $Z8   RL   #L0
M +8   "Z    O@   ,(   #&    R    ,@   #*    RP   ,T   #.
MT    -(!  #5"   V0X  -T5  #A(0  XC$  .1#  #E5@  YFL  .:"  #G
ME@  YZ4  .:P /\ "0#_  4 _P & /\ #@#_ !8 _P A /\ +0#_ #@ _0!#
M /D 30#U %4 \@!= /  8P#N &D [ !O .H = #I 'H YP!_ .8 A0#D (L
MXP"1 .$ F0#? *$ W "J -H M@#7 ,8 U0#A -, ] #2 /\ T0#_ -$ _P#/
M /\ R@#_ /\  0#_    _P ! /\ # #_ !( ^@ = /8 * #S #, \  ^ .P
M2 #H %  Y0!8 .( 7@#? &0 W0!J -L ;P#9 '0 U@!Z -0 ?P#2 (4 T ",
M ,X DP#, )P R0"E ,< L #& +X Q #4 ,( [@#! /X P #_ ,  _P"_ /\
MO@#_ /\   #_    _P   /H !P#Q  \ ZP 8 .8 (P#B "X X  X -L 0@#5
M $L T0!2 ,X 60#+ %\ R0!E ,< :@#& &\ Q !T ,( >@#! (  OP"& +T
MC@"[ )8 N0"@ +< J@"V +< M #* +( Y@"Q /@ L #_ *\ _P"O /\ L #_
M /\   #_    ]P   .H  @#A  P UP 3 -  '0#, "@ R0 R ,8 / #" $4
MOP!- +P 4P"Z %D N !? +< 9 "U &D M !N +( = "Q 'H KP"  *T B "L
M )$ J@": *@ I0"F +$ I #! *, W "A /( H0#_ *  _P"@ /\ H0#_ /\
M  #W    Z    -D   #+  @ PP 0 +T & "Y "( M@ L +0 -@"R #\ KP!'
M *P 30"K %0 J0!9 *< 7@"F &, I0!H *, ;@"B '0 H !Z )X @@"< (L
MFP"5 )D GP"8 *P E@"Z )0 SP"3 .L D@#[ )( _P"2 /\ D0#_ /<   #G
M    TP   ,8   "[  ( LP , *T $@"J !P IP F *0 , "C #@ H !  )X
M1P"< $X F@!3 )D 6 "7 %T E@!C )4 : "3 &X D@!T )  ? "/ (4 C0"/
M (L F@"* *< B "U (8 QP"% .0 A #U (0 _P"# /\ @P#_ .P   #3
MP0$  +0   "L    I@ ' *  #@"= !8 F@ @ )< *0"5 #( DP Z )$ 00"/
M $@ C0!- (P 4P"+ %@ B0!= (@ 8P"' &D A0!O (, =P"" (  @ "* 'X
ME@!] *, >P"P 'H P@!Y -T > #Q '< _0!X /\ > #_ -X*  #$"P  L@P
M *8+  "="   F00  )4 "@"1 !$ C@ 9 (L (P") "P AP T (4 .P"# $(
M@@!( (  3@!_ %, ?0!8 'P 7@![ &0 >0!J '@ <@!V 'L = "& ', D@!Q
M )\ < "M &X O@!M =8 ;0+M &P#^@!L _\ ; /_ ,X0  "W$0  IA(  )H1
M  "1$   BPX  (D+ P"'!0P A $3 ($!' !^ B4 ? ,N 'H#-@!X!#P =P1#
M '4%2 !T!4X <P54 '$%60!P!E\ ;@9F &T&;@!K!W@ :@># &@(D !G"9T
M90FL &0)O !C"M0 8POL &(,^@!B#/\ 8@S_ ,,6  "M%P  G1@  ) 8  "'
M%@  @10  'T1  !\#@8 ? H. '@*%@!U"Q\ <@LH ' ,, !O##< ;0P^ &P,
M1 !K#4H :0U/ &@-50!G#5P 90UC &,.:P!B#G4 8 Z! %\.C@!=#YP 7!"K
M %L0O0!:$-8 61'P %D1_0!9$?\ 61'_ +D;  "E'0  E!X  (@>  !^'0
M>!L  '08  !Q%0  <1$) &\0$0!L$!D :1 B &<1*@!F$3( 9!$Y &,1/P!B
M$44 8!)+ %\240!=$E@ 7!)? %H3: !9$W( 5Q1] %84BP!4%9D 4Q6I %(6
MN@!1%M( 41?M %$7_0!1%_\ 41?_ +(@  ">(@  CB(  ($C  !W(@  <"$
M &P>  !I&P  9Q@$ &85#@!C%A4 818> %\6)@!=%BT 7!<T %H7.P!9%T$
M6!A' %8830!5&%0 4QA< %(99 !1&6X 3QIZ $X;B !-&Y< 2QRF $H<N !*
M'<\ 21WK $D=^P!)'?\ 2AW_ *PD  "8)0  B"8  'LG  !Q)@  :B4  &8C
M  !B(0  8!X  %X<"P!;&Q( 61P: %<<(@!5'"D 5!PP %,=-P!1'3T 4!U#
M $\=2@!-'E$ 3!Y8 $L?80!)'VL 2"!W $<@A0!&(90 1"*D $0BM@!#(LP
M0R/I $,C^@!#(_\ 0R+_ *8G  "3*0  @RH  '8J  !M*@  92D  & G  !<
M)0  62,  %<A!P!5(0\ 4B$6 % A'@!.(24 32(L $PB,P!*(CD 22)  $@B
M1@!'(TT 12-5 $0D7@!#)&D 0B5U $ F@P _)I( /B>C #XGM  ])\H /2CH
M #TH^0 ])_\ /B?_ *(J  ".*P  ?RT  '(M  !H+0  82P  %PK  !8*
M5"8  %$F! !.)0T 3"43 $HF&@!()B( 1R8I $4F+P!$)C8 0R<\ $$G0P!
M)TL /RA3 #XI7  ]*68 /"IR #LJ@0 Z*Y  .2NA #@LL@ W+,@ -RSF #@L
M^  X+/\ ."S_ )TL  "*+@  >R\  &\P  !E,   72\  %@N  !3*P  4"H
M $PJ  !)*@L 1BH1 $0J%P!"*A\ 02HE #\J+  ^*S, /2LY #PK0  [+$@
M.BQ0 #DM60 X+F0 -RYP #8O?P U+X\ -#"? #,PL0 R,,< ,C#E #,P]P S
M,/\ -"__ )DO  "',0  =S(  &LR  !B,@  6C(  %0Q  !/+P  2RT  $<N
M  !$+@@ 02X. #\N%  ]+AP .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -3%.
M #0Q5P S,F( ,C)N #$S?0 P,XT +S2> "XTL  M-,4 +33C "XT]@ O,_\
M+S/_ )4Q  "#,P  =#0  &@U  !>-0  5S0  %$T  !+,@  1C$  $(R   _
M,@4 /#(- #DS$@ X,QD -C,@ #0S)@ S,RT ,C0T #$T.P P-4, ,#5, "\V
M50 N-F  +3=L "PW>P K-XL *CB< "DXK@ H.,, *#CB "DX]0 J-_\ *C?_
M )(T  !_-0  <38  &4W  !;-P  5#<  $TV  !'-@  0C4  #TV   Z-@(
M-S<+ #0W$  R-Q8 ,3@= "\X)  N."L +3DR "PY.0 K.4$ *CI) "HZ4P I
M.UX *#MJ "<[>0 F/(D )3R; "0\K0 C/,( (SS@ "0\]  E._\ )3O_ (TV
M  !\.   ;3D  &(Y  !8.@  43D  $HY  !$.0  /3D  #DZ   U.P  ,CL(
M "\\#@ M/10 +#T: "H](0 I/2@ *#XO "<^-@ F/CX )3]' "0_4  C0%L
M(D!H "% =@ @0(< 'T&9 !]!JP >0<  'D'> !] \P ?0/X (#__ (DY  !X
M.@  :3L  %X\  !5/   33P  $<\  ! /   .#T  #0^   P0   +4$% "I"
M#  G0A$ )D,8 "1#'@ C0R4 (D,L "%$,P @1#L 'T1$ !Y%3@ =15D '$5E
M !M%=  :184 &4:7 !E&J0 81KX %T7< !A%\0 91/T &D3_ (0\  !S/0
M9CX  %L_  !2/P  2C\  $0_   ]0   -D$  #%#   L1   )T8! "1'"@ A
M2 \ ($D4 !Y)&P =22( '$DI !M*,  :2C@ &4I! !A*2P 72U4 %DMB !5+
M<0 42X( $TN4 !)+IP 22[P $4O9 !)*\  32OP %$G_ '\_  !O0   84$
M %="  !.0@  1T(  $%"   Z0P  ,D4  "U'   H20  (TL  !Y-!@ ;3PT
M&% 1 !=0%P 64!X %5 E !10+  3430 $E$] !%11P 145( $%%?  ]2;0 .
M4GX #5&1  U1I  ,4;@ #%'1  U0[  -4/H #D__ 'E#  !J1   740  %-%
M  !+10  1$4  #Y&   V2   +TH  "E,   D3P  'U$  !I3   45@D $5<.
M !!8$P 06!D #U@@  Y8*  -6#  #5@Y  Q80P +6$X "EA:  A8:  '6'D
M!EB,  58GP $6+, !%?*  57Y@ %5_, !E;\ '-&  !D1P  64@  %!(  !(
M2   04D  #I*   R30  *U   "52   @50  &E@  !5:   0708 #& ,  I@
M$  )8!4 "& <  =@(P %8"L !& T  -@/0 !8$D  &!5  !@8P  8',  &"&
M  !?F@  7ZX  %_$  !>X@  7O   %[X &Q*  !?2P  54L  $Q,  !%3
M/4X  #50   N4P  )U8  "!9   :7   %5\  !!B   -900 "&<+  -G#@
M:!,  &@8  !H'P  :28  &DN  !I.   :4,  &E/  !I70  :6T  &F   !I
ME   :*D  &B_  !GW   9NX  &;W &9/  !:3P  44\  $I/  !!40  .%0
M #!7   H6P  (5X  !IB   490  $&@   QK   ';@,  7 )  !P#0  <1
M '$4  !R&@  <R$  ',H  !S,0  <SP  '1(  !S5@  <V8  '-Y  !SC@
M<Z,  '*Y  !QT@  <>L  '#T &%3  !64P  3U,  $55   [6   ,EP  "I@
M   B9   &V@  !1L   /;P  "W(   9V    >0   'H&  !Z"@  >PX  'P1
M  !]%0  ?AL  '\B  " *@  @#4  (!!  " 3P  @%\  (!Q  " A@  @)T
M '^R  !^R@  ?N4  'WQ %Q8  !46   25H  #]=   U80  +&4  "-J   ;
M;P  %',   YW   )>P   W\   ""    A    (8!  "&!@  B H  (D-  "*
M$   BQ4  (P;  ".(@  CRP  (\X  "/1@  CU8  (]H  "/?@  CY4  (ZK
M  "-P0  C=P  (SK %E=  !.7P  0V(  #AF   N;   )'$  !QW   4?
M#H$   B%    B0   (T   "0    D@   ),   "4    E@,  )<(  "8#
MF@\  )L3  "=&@  GR,  * N  "@/   H$P  *!>  "@=   GXP  )^B  "?
MMP  GLL  )[@ %-D  !':   /&T  #%S   G>0  '7\  !2%   -BP  !I
M  "4    F    )P   "?    H0   *(   "D    I0   *<   "H!   J@D
M *P-  "M$@  L!D  +(C  "R,0  LD(  +)4  "R:0  LH   +*8  "QK
MLK\  +'. $QN  ! <P  -7H  "J!   ?B   %8X   Z5   &F@   )\   "D
M    J    *P   "O    L0   +$   "S    M0   +8   "X    N@   +P&
M  "^#   P!$  ,,9  #%)@  Q3<  ,9)  #&70  QW(  ,>*  #(GP  R*\
M ,B\ $9Z   Y@0  +HD  "*0   7F   #Y\   >E    J@   *\   "S
MMP   +P   "_    P0   ,(   #$    Q0   ,<   #)    RP   ,T   #/
M P  T@H  -80  #<&@  W2H  -X\  #?4   X&4  .%[  #AD0  XJ(  .*M
M /\  @#_    _P # /\ # #_ !, _P = /\ * #^ #, ^P ^ /< 2 #S %
M\ !7 .T 7@#K &0 Z !I .< ;P#E '0 XP!Y .( ?P#@ (4 W@", -P DP#9
M )P U@"F -, L0#1 ,  SP#: ,X \0#, /\ RP#_ ,L _P#& /\ P0#_ /\
M  #_    _P   /\ " #[ !  ]@ 9 /( ) #O "X [0 Y .@ 0@#C $L X !2
M -T 60#9 %\ U@!D -, :0#1 &X SP!T ,X >0#, '\ R@"& ,@ C@#& )8
MQ "@ ,( JP#  +D O@#- +P Z@"[ /P N@#_ +H _P"Z /\ M@#_ /\   #_
M    _@   /0 ! #K  T Y  4 -\ 'P#; "D V  S -, /0#. $4 R@!- ,<
M4P#% %D PP!? ,$ 9 "_ &D O0!N +L <P"Z 'D N "  +8 B "T )  L@":
M +$ I0"O +( K0#$ *P X0"K /8 J@#_ *H _P"J /\ J@#_ /\   #]
M[@   .(   #5  H S0 1 ,< &0#$ ", P0 M +\ -P"[ #\ MP!' +4 3@"R
M %, L !9 *\ 7@"M &, K !H *L ;0"I ', J !Z *8 @0"D (H HP"4 *$
MGP"? *P G@"[ )P T@"; .X F@#_ )H _P"9 /\ F0#_ /X   #N    W@
M ,L   #!  4 N0 - +0 % "Q !X K@ G *L , "J #D IP!! *0 2 "B $T
MH0!3 )\ 6 "> %T G0!B )L 9P": &T F !S )< >P"5 (0 E ". )( F0"0
M *8 C@"T (T R ", .8 BP#Y (H _P"* /\ BP#_ /    #;    QP   +H
M  "P    J  * *0 $ "@ !@ G0 A )L *@": #, F  [ )8 00"4 $@ D@!-
M )$ 4@"/ %< C@!< (P 80"+ &< B@!N (@ =0"' 'X A0"( (, E "" *
M@ "O '\ P !^ -T ?0#R 'T _P!] /\ ?0#_ .    #&    M0   *H   "B
M    FP % )4 #0"2 !, D  < (T ) "+ "T B@ T (@ .P"& $( A0!' (,
M30"" %( @0!7 '\ 7 !^ &( ?0!H 'L < !Z 'D > "# '8 CP!U )P = "J
M '( N@!Q -$ < #L '  ^P!P /\ < #_ ,T$  "W!@  IP<  )L&  "3!
MC@   (H " "&  \ A  6 ($ '@!_ "< ?0 N 'P -@!Z #P >0!" '< 1P!V
M $P =0!2 ', 5P!R %T <0!C &\ :P!N '0 ; !^ &L B@!I )@ : "F &<
MM@!F ,L 90#G &4 ]P!E /\ 90#_ , ,  "K#0  FPX  (\.  "&#0  @0L
M 'X' 0!\ 0L >0 1 '< & !U "$ <P I '$ , !O #8 ;@ \ &P 0@!K $<
M:@!- &D 4@!H %@ 9@!? &4 9P!C '  8@%Z & !AP!? I4 7@*C %P#LP!<
M \< 6P3D %L%] !;!OX 6P;_ +40  "A$@  D1,  (43  !\$@  =A$  ',.
M  !R# 0 <0<- &X$$@!L!!L :04C &<%*@!F!C$ 9 8W &,&/0!B!T, 80=)
M %\'3@!>"%4 70A< %L)8P!:"6T 6 IX %<*A0!6"Y, 5 NB %,+LP!2#,<
M4@SD %$-]0!1#?\ 40W_ *T5  "9%P  B1@  'T9  !T&   ;1<  &H4  !G
M$0  9PX' &8,#@!C#!4 80P= %\,)0!=#2P 7 TS %L-.0!:#3\ 6 U% %<-
M2P!6#E$ 50Y9 %,.80!2#FL 4 ]V $X0@P!-$)( 3!"B $L0L@!*$<@ 21'E
M $D1]P!)$O\ 21'_ *49  "2'   @QT  '8>  !M'0  9AP  &(:  !?%P
M7A0! %X1"@!;$!$ 61$8 %<1( !5$2< 5!$N %,1- !1$3L 4!)! $\21P!.
M$DX 3!)5 $L37@!)$V< 2!1S $84@ !%%8\ 1!6? $,6L !"%L4 0A?C $(7
M]@!"%_\ 0A?_ )\=  ",(   ?2$  '$B  !H(@  82$  %P?  !9'   5QD
M %46!@!4%0X 4144 $\6' !.%B, 3!8J $L6, !*%C< 21<] $<70P!&%TH
M11A2 $,86@!"&60 01EP #\:?0 ^&XT /1N= #P<K@ [',, .QSA #L=]0 [
M'/\ /!S_ )HA  "'(P  >"0  &PE  !C)0  7"0  %<C  !3(   41X  $\<
M @!-&PP 2QH1 $@;& !'&R  11LF $0;+0!#'#, 0APY $ <0  _'4< /AU/
M #T>6  \'F( .A]M #D?>P X((L -R&; #8AK0 U(<$ -2'? #4A\P V(?\
M-B'_ )8C  "#)@  ="<  &@H  !?*   6"<  %,F  !/)   3"(  $D@  !'
M( D 1!\/ $(?%0! (!P /R C #X@*0 \("\ .R$V #HA/0 Y(40 ."), #<B
M50 V(U\ -"-K #,D>0 R)8D ,26: # EJP P)K\ +R;< # F\@ P)O\ ,27_
M )$F  !_*   <2H  &4J  !<*@  52H  $\I  !+*   2"4  $0D  !!) 4
M/R0- #TD$@ [)!D .20? #<D)@ V)"P -24S #0E.@ S)D$ ,B9* #$G4P P
M)UT +RAI "XI=P M*8< +"F8 "LJJ@ J*KT *BK: "LJ\0 K*OX +"G_ (TH
M  !\*@  ;2P  &(M  !9+0  42T  $PL  !'*P  0R@  #\H   \* ( .2@+
M #<H$  U*!8 ,R@< #(H(P P*"D +RDP "\J-P N*C\ +2M' "PK40 K+%L
M*BQG "DM=0 H+84 )RV7 "8NJ  E+KP )2[8 "8N\  F+OT )RW_ (HK  !X
M+0  :BX  %\O  !6+P  3B\  $@N  !#+0  /RP  #LL   W+   -"P) #(L
M#@ P+1, +BT: "TM(  K+2< *BXM "HN-0 I+ST *"]% "<P3@ F,%D )3%E
M "0Q<P C,8, (C*5 "$RIP A,KL (#+4 "$R[P B,?P (C'_ (8M  !U+P
M9S   %PQ  !3,0  2S$  $4Q  ! ,   .S   #8P   S,   ,#$& "TQ#0 K
M,1$ *3(7 "@R'@ G,B0 )3,K "4S,@ D,SH (S1# "(T3  A-5< (#5C !\U
M<0 >-H$ '3:3 !PVI0 ;-KD &S;2 !PV[0 =-OL '37_ ((P  !Q,@  8S,
M %DT  !0-   230  $(S   ],P  -S,  #$T   N-0  *S4" "@V"P E-Q
M)#<5 "(W&P A."( (#@H !\X,  >.#< '3E  !PY20 ;.E0 &CI@ !DZ;@ 8
M.G\ %SN1 !<[I  6.[< %3O0 !8Z[  7.OH &#G_ 'TR  !M-   8#4  %4V
M  !--@  1C8  $ V   Z-@  -#8  "XX   J.0  )CH  ",["  @/ X 'CT2
M !T]&  </1\ &SXE !H^+0 9/C0 %SX] !8_1P 5/U$ %#]> !0_;  30'P
M$D"/ !% H@ 10+8 $$#. !$_ZP 2/_D $C[_ 'DU  !I-P  7#@  %(Y  !*
M.0  0SD  #TY   W.0  ,3H  "L\   G/0  (C\  !Y!!  :0@L &$,0 !=#
M%0 51!L %$0B !-$*0 31#$ $D0Z !%%0P 014X $$5;  Y%:0 .17D #46,
M  U%GP ,1;( "T7)  Q%Y0 -1/8 #43_ '0Y  !E.@  6#L  $\[  !'/
M0#P  #H\   T/   +CX  "A    C0@  'T0  !I&   52 @ $DH- !%*$@ 0
M2A@ #TL>  Y+)0 -2RT #4LV  Q+0  +2TH "DM6  E+9  (2W0 !TN'  5+
MF@ $2ZX !$K$  5*X  %2O  !DGZ &X\  !@/0  5#X  $L^  !$/@  /3X
M #<_   Q0   *D(  "1%   ?1P  &DD  !5,   13@4 #E$+  M1$  *410
M"5$;  A1(@ '42D !5$R  12.P #4D8  5)2  !27P  4F\  %*!  !1E@
M4:D  %&_  !0W   4.X  %#W &A   !;00  4$$  $A!  !!00  .T(  #1#
M   M10  )D@  "!+   ;30  %E   !%3   .500 "E@*  98#@ "6!(  %D7
M  !9'0  624  %DM  !9-@  64$  %E-  !:6@  6FD  %E\  !9D   6:4
M %BZ  !8U0  5^P  %?V &-$  !610  344  $5%   _10  -T<  "])   H
M3   (D\  !M2   650  $5@   U:   )70, !%\)  !@#0  8!   &$4  !A
M&0  8B   &(G  !B,0  8CL  &)'  !B50  8V0  &)V  !BBP  8J   &&V
M  !ASP  8.H  &#U %U(  !220  2D@  $-(   Z2@  ,DT  "I0   C4P
M'%<  !9:   170  #6    AC   #9@$  &<&  !H"P  :0X  &H1  !K%0
M;!L  &TB  !M*@  ;30  &U   !M3@  ;5T  &UO  !MA   ;)H  &RP  !K
MR   :^8  &KS %A-  !.30  2$P  #Y.   U40  +%0  "18   =7   %F
M !!D   ,9P  !VL   %N    <    '(#  !R!P  <PL  '4.  !V$0  =Q8
M '@<  !Y(P  >BT  'HY  !Z1P  >E8  'EH  !Z?   >90  'BJ  !XP0
M=]\  '?O %11  !,40  0E(  #A5   O60  )EX  !YB   69P  $&L   MO
M   %<P   '<   !Z    ?    'X   !_ @  @ 8  ($*  "##0  A!$  (85
M  "('   B24  (HP  "*/@  B4T  (E?  ")<P  B(L  (BB  "'N0  A]$
M (;H %)6  !'5P  /%H  #)?   H9   'VD  !9O   0=   "GD   )]
M@0   (4   "(    B@   (P   "-    CP   ) $  "2"   DPP  )40  "7
M%0  F1T  )LG  ";-   FT0  )I6  "::@  F8(  )J:  "8L   F,<  )?>
M $M<  ! 8   -64  "MJ   A<0  %W<  !!]   )@P   8@   ",    D0
M )4   "8    F@   )L   "=    GP   *    "B    I 4  *8*  "H#@
MJA0  *T=  "M*@  K3D  *U+  "M7P  K7<  *R0  "KIP  J[H  *O+ $5F
M   Y:P  +G$  "-X   9?P  $(8   F-    DP   )@   "=    H0   *4
M  "H    JP   *L   "N    KP   +$   "S    M0   +<!  "Y!P  O T
M +\3  #"'P  PBX  ,)   #"5   P6L  ,&#  # FP  P:T  ,&\ #YR   R
M>   )X   !R(   2D   "I<   "=    HP   *@   "M    L@   +8   "Y
M    NP   +P   "^    P    ,(   #$    Q@   ,@   #+    S@4  -$-
M  #6%   UR,  -@U  #920  VEX  -MU  #;C   W)\  -RK /\   #_
M_P   /\ "0#_ !  _P 9 /X ) #\ "\ ^0 Y /0 0P#P $L [0!2 .H 60#G
M %\ Y !D .( :0#@ &X W@!S -P >0#: '\ UP"& -0 C@#1 )8 SP"A ,P
MK #* +L R #2 ,8 [@#& /\ Q0#_ ,4 _P"_ /\ N@#_ /\   #_    _P
M /X !0#W  X \@ 5 .X 'P#K "H Z0 T ., /0#> $4 V0!- -0 4P#1 %D
MS@!> ,P 8P#* &@ R0!M ,< <P#% 'D PP"  ,$ B "_ )  O0"; +L I@"Y
M +0 MP#( +8 Y@"U /L M #_ +0 _P"S /\ K@#_ /\   #_    ^    .T
M  #E  L W0 1 -< &@#2 "0 SP N ,L -P#' $  PP!' ,  3@"^ %, O !9
M +H 7@"X &, M@!H +4 ;0"S ', L0!Y *\ @0"M (H JP"4 *D H "H *T
MI@"^ *4 VP"D /0 I #_ *, _P"C /\ H@#_ /\   #V    Y@   -<   #+
M  8 Q  . +X %0"[ !\ N0 H +< ,0"T #H L !! *T 2 "K $X J0!3 *<
M6 "F %P I !A *, 9P"A &P H !S )X >@"= (, FP". )D F0"7 *8 E@"V
M )4 S "4 .L DP#] ), _P"3 /\ DP#_ /<   #D    T    ,$   "W  (
MKP + *L $0"G !D I0 B *, *P"B #, GP [ )P 0@"; $@ F0!- )< 4@"6
M %< E0!; ), 80"2 &8 D !M (\ = "- 'T C "' (H DP"( *  AP"O (4
MP@"% .( A #W (0 _P"$ /\ A #_ .4   #-    O    *\   "F    G@ '
M )H #@"6 !0 E  = )( )0"1 "T D  U (T / ", $( B@!' (@ 3 "' %$
MA@!6 (0 6P"# &  @0!G (  ;@!^ '< ?0"! 'L C0!Z )H > "I '< N@!V
M -, =@#O '8 _@!U /\ =0#_ -    "[    JP   )\   "7    D  " (L
M"P"( !  A@ 7 (0 ( "" "< @0 O '\ -0!] #P ? !! 'L 1@!Y $L > !0
M '< 50!V %L = !A ', :0!Q '$ < ![ &X AP!M )4 :P"C &H M !J ,D
M:0#H &D ^0!I /\ :0#_ ,    "L    G (  ) "  "(    @P   '\ !@![
M  T >0 2 '< &@!V "( =  I ', , !Q #8 <  \ &\ 00!M $8 ; !+ &L
M4 !J %8 : !< &< 9 !E &P 9 !V &, @@!A )  8 "? %\ KP!> ,, 7@#A
M %X ] != /\ 70#_ +0'  "@"0  D L  (0+  !\"@  =P<  '0$  !Q  D
M;P / &T %0!K !P :0 C &@ *@!G #$ 90 V &0 / !C $$ 8@!& &  3 !?
M %( 7@!8 %T 7P!; &@ 6@!R %@ ?@!7 (P 5@"; %4 JP!4 +X 5 #: %,
M[P!4 /L 5 #_ *D-  "6#@  AQ   'H0  !R$   ; X  &D,  !G"0, 9@0+
M &0 $ !B !< 8  > %X )0!= "L 7  Q %H -P!9 #P 6 !" %<!1P!6 4X
M50)4 %,"7 !2 V4 40-O $\$>P!.!(H 3069 $P%J0!+!;P 2@;4 $H'[0!*
M!_D 2@?_ *$0  ".$@  ?A0  ',4  !J%   9!,  & 1  !>#P  70T% %T)
M#0!:!A( 6 <9 %8'( !5!R< 4P<M %((,P!1"#@ 4 @^ $\)1 !."4H 3 E1
M $L*60!*"F( 2 MM $<+>@!&#(@ 1 R8 $,,J0!"#;P 0@W5 $(-[@!"#?L
M0@W_ )H4  "'%@  >!@  &P9  !C&0  71@  %D6  !6$P  5!$  %0." !3
M#0X 40T4 $\-&P!-#2( 3 TH $L-+@!*#30 20TZ $<.00!&#D< 10Y/ $0.
M5P!"#V$ 01!L #\0>0 ^$(@ /1&8 #L1J0 [$;P .A'6 #H1\  Z$OT .Q'_
M ),8  "!&@  <QP  &<=  !>'0  6!P  %,;  !0&   3A8  $P3 P!,$0L
M2A 0 $@1%P!&$1X 11$D $01*@!"$3  01$W $ 2/0 _$D0 /1), #P35  [
M$UX .11I #@4=@ W%84 -A66 #06IP T%KH ,Q;3 #,6[@ T%OP -!;_ (X;
M  !\'0  ;A\  &,@  !:(   4R   $X>  !*'0  2!H  $88  !%%@< 0Q4.
M $$5$P _%1H /A4@ #T5)P [%2T .A8S #D6.@ X%D$ -Q=) #4740 T&%L
M,QEF #(9<P P&H, +QJ4 "X;I0 M&[@ +1O0 "T;[  N&_L +AO_ (H>  !X
M(   :B(  %\C  !6(P  3R(  $HA  !&(   0QX  $$;   _&@, /1H, #L9
M$0 Y&18 -QH= #8:(P U&BD -!HP #,;-@ Q&SX ,!Q& "\<3P N'5D +1UD
M "P><0 K'X$ *A^2 "D?I  H(+< )R#. "<@ZP H(/H *1__ (8@  !T(P
M9R0  %PE  !3)0  3"4  $<D  !"(P  /R$  #T?   Z'@  -QX) #4>#@ S
M'A, ,1X: # >(  O'B8 +A\M "T?,P L(#L *R!# "HA3  I(58 *")B "8B
M;P E(W\ )".0 ",CH@ B)+4 (B3, "(DZ0 C)/D )"/_ ((C  !Q)0  8R8
M %DG  !0*   22<  $,G   _)@  .R0  #@B   U(@  ,B(& # B#0 N(A$
M+"(7 "HB'0 I(B, *",J "<C,0 F)#@ )25! "0E2@ C)E0 (B9@ "$G;0 @
M)WT 'R>/ !XHH0 >*+0 '2C* !THZ  >*/@ 'R?_ 'XE  !N)P  8"D  %8I
M  !-*@  1BH  $$I   \*   -R<  #0F   P)@  +28# "LG"P H)Q  )R<4
M "4G&@ D)R$ (R@G "(H+@ A*38 ("D^ !\J2  >*E( '2M> !PK:P ;*WL
M&BR- !DLGP 8++( &"S) !@LYP 9*_< &BO_ 'HG  !J*@  72L  %,L  !*
M+   0RP  #XK   Y*P  -"H  # J   K*@  *2L  "8K"  C+ X (BP2 " L
M&  ?+!X 'BTE !TM+  <+3, &RX\ !HN10 9+U  &"]< !<O:0 6,'D %3"+
M !0PG@ 4,+$ $S#' !,PY0 4,/8 %2__ '8J  !G+   6BT  % N  !(+@
M02X  #LN   V+0  ,2T  "PM   G+P  )"\  "$P!0 ?,0P '#$0 !LR%0 :
M,AP &3(B !@R*0 7,S$ %C,Y !4S0P 4-$T $S19 !(T9P 1-7< $36) ! U
MG  0-;  #C7&  \TY  0-/4 $#3_ '(L  !C+@  5S   $TP  !%,   /C
M #@P   S,   +S   "DQ   D,@  (3,  !TU @ :-@D %S<. !4W$P 4.!D
M$S@? !(X)@ 2."X $3DV ! Y0  0.4L #CE7  XZ9  -.G0 ##J&  PZF0 +
M.:P "CG!  HYW@ +.?$ ##C\ &XO  !?,0  4S(  $HS  !",P  .S,  #8S
M   Q,@  +#,  "<T   A-@  '3@  !DY   5.P8 $CT, ! ^$  0/A4 #CX<
M  X^(P -/BH ##XS  P^/  +/T< "C]2  @_8  '/V\ !C^!  4_E  $/Z@
M SZ\  0^UP %/NP !3[W &DS  !;-   4#4  $<U   _-0  .34  #0U   N
M-0  *3<  ",X   >.P  &CP  !8_   2000 #D,*  Q$#@ *1!, "409  A$
M(  '1"< !D0O  5$.  #14(  D5.  !%6P  16H  $5\  !%D   1*0  $2Y
M  !$T0  1.H  $/U &0V  !7-P  3#@  $,X   \.   -S@  #$X   K.0
M)3L  " ]   :0   %D(  !)$   .1P0 "TD)  =*#0 $2Q$  4L6  !+'
M2R,  $LK  !+-   2SX  $Q)  !,5P  3&8  $QW  !+C   2Z$  $NU  !*
MS@  2ND  $KU %\Z  !2.P  2#L  $ [   Z.P  -#L  "X\   G/@  (D$
M !Q#   61@  $DD   Y+   +3@, !U (  )1#   41   %(3  !3&   4Q\
M %,F  !3+P  4SD  %-%  !34@  4V$  %-R  !3AP  4IP  %*Q  !1R@
M4><  %'T %D^  !./@  13X  #X^   X/@  ,$   "E"   C1   '4<  !=*
M   230  #E    M3   &50(  %<'  !8"P  60X  %H1  !:%0  6QH  %PA
M  !<*@  7#0  %P_  !<30  7%L  %QL  !<@0  6Y<  %NM  !:Q0  6N0
M %GS %1"  !*0@  0D(  #Q"   T0P  +$8  "5)   >3   %T\  !)3   .
M5@  "ED   5;    7@   & $  !A"   8@P  &,.  !D$0  918  &8<  !G
M(P  9RT  &<Y  !G1@  9U4  &=F  !G>@  9I$  &6H  !EP   9-X  &3P
M $]&  !'1@  0$4  #='   O2@  )DT  !]1   850  $ED   U<   (8
M F,   !F    :    &H   !K!   ; @  &T,  !O#@  <!(  '(7  !S'0
M="8  '0R  !T/P  =$X  '-?  !T<@  <XH  '*A  !QN   <=0  '#L $Q*
M  !%2@  .TL  #).   I4@  (%8  !A;   27P  #60   =H    :P   &\
M  !R    =0   '8   !W    >0(  'H&  !\"@  ?@X  ( 1  ""%@  A!X
M (0I  "$-@  A$4  (16  "#:@  @X$  (*9  "!L0  @,D  (#E $I.   _
M4   -5,  "M7   B7   &6(  !)G   ,;   !7$   !U    >0   'T   "!
M    @P   (4   "&    B    (D   "+!   C0@  (\-  "2$   E!8  )8@
M  "6+   ECL  )9,  "58   E78  )20  "3IP  DKT  )+5 $15   Y60
M+UT  "1C   ::0  $F\   QU   $>P   (    "%    B0   (T   "1
MDP   )0   "6    F    )H   "<    G@   * &  "B"P  I1   *@7  "I
M(P  J3$  *E#  "I5@  J&T  *:'  "GG@  IK,  *7' #Y>   R8P  )VH
M !UP   3>   #'\   .%    BP   )$   "6    FP   )\   "B    I
M *4   "G    J0   *L   "M    L    +(   "U @  MPD  +L0  "^&
MOB8  +XX  "^2P  O6$  +QZ  "[E   NJD  +JY #=J   K<   ('@  !:
M   -B   !8\   "6    G    *(   "G    K    +    "S    M@   +<
M  "Y    NP   +T   "_    P@   ,4   #(    R@   ,X(  #2$   U1L
M -4L  #40   U%<  --N  #4A@  U)L  -.K /\   #_    _P   /\ !0#_
M  X _P 5 /P ( #Y "H ]@ T /$ /0#M $8 Z0!- .8 4P#D %D X0!> -X
M8P#< &@ V0!N -4 <P#3 'D T "  ,X B #+ )$ R0"< ,8 IP#$ +< P@#,
M ,  [ "_ /\ O@#_ +T _P"W /\ L@#_ /\   #_    _P   /H  0#S  L
M[0 2 .@ &P#E "4 Y  N -\ . #8 $  T@!' ,X 3@#+ %0 R !9 ,8 7@#$
M &, P@!G ,  ;0"_ ', O0!Z +L @0"Y (L M@"5 +0 H0"R *\ L #" *X
MXP"N /H K #_ *T _P"I /\ I@#_ /\   #_    \@   .8   #=  < T@ .
M ,T %@#* "  R  I ,4 ,@#  #H O !" +D 2 "W $X M0!3 +, 6 "Q %T
ML !B *X 9P"L &P J@!S *D >P"G (0 I0". *, F@"A *@ GP"Y )X T@"=
M /( G #_ )T _P"< /\ F0#_ /P   #N    W0   ,P   #!  ( N@ , +8
M$@"R !H L  C *\ + "M #0 J0 \ *8 0@"D $@ H@!- *  4@"> %< G0!;
M )P 8 ": &8 F0!L )< = "5 'T DP"' )$ DP"0 *$ C@"Q (T Q@", .@
MBP#] (P _P", /\ C #_ .T   #8    Q0   +<   "L    I@ ( *$ #@"?
M !4 G0 > )L )@": "X EP U )4 / "3 $( D0!' )  3 ". %$ C0!5 (L
M6@"* &  B0!F (< ;0"% '8 A "  (( C "  )H ?P"I 'T O !\ -P ? #U
M 'P _P!\ /\ ? #_ -D   #!    L0   *0   "<    E  # )  # "- !$
MBP 8 (D ( ") "@ AP O (4 -@"# #P @@!! (  1@!_ $L ?0!/ 'P 5 ![
M %H >0!@ '@ 9P!V '  =0!Z ', A@!Q ), < "B &\ M !N ,P ;@#M &X
M_@!N /\ ;@#_ ,0   "O    H    )0   ",    A@   ($ " !^  X ?  4
M 'L &P!Y "( >  I '< , !U #8 =  [ '( 0 !Q $4 < !* &\ 3P!M %0
M; !; &L 8@!I &H : !T &8 @ !E (X 8P"= &( K0!A ,( 80#D &$ ^ !A
M /\ 80#_ +0   "@    D0   (8   !^    >0   '4  P!Q  L ;P 0 &T
M%@!L !T :P D &L *@!I #  :  V &8 .P!E $  9 !% &, 2@!A $\ 8 !6
M %\ 70!= &4 7 !O %H >@!9 (@ 6 "8 %< J !6 +L 5@#8 %8 \0!6 /\
M5@#_ *@!  "4!0  A0<  'H'  !R!@  ; 0  &D!  !G  < 9  - &, $0!A
M !@ 8  ? %\ )0!> "L 70 P %L -@!: #L 60!  %@ 10!7 $L 5@!1 %4
M6 !3 &$ 4@!J %  =@!/ (0 3@"3 $T I !, +8 3 #- $P ZP!, /H 3 #_
M )T)  "+"P  ? T  ' -  !H#0  8@P  %\*  !=!@$ 7 $) %H #@!8 !,
M5P 9 %8 ( !5 "8 4P K %( ,0!1 #8 4  [ $\ 00!. $< 30!- $L 50!*
M %T 20!G $< <P!& (  10"0 $0 H0!# +( 0P#( $, Y@!# /4 0P#_ )4-
M  "##P  =!   &D1  !@$0  6A   %8.  !4#0  4PH$ %,&"P!1 Q  3P$5
M $X!&P!, 2$ 2P$G $H"+ !) C( 2 (W $<#/0!% T, 1 -* $,$40!"!%H
M0 5D #\%<  ^!GX /0:. #P'GP [![$ .@?& #H'XP Z!_, .@C\ (X0  !\
M$@  ;A0  &(5  !:%0  5!0  % 3  !-$0  2PX  $L-!@!*"@P 20@1 $<(
M%@!%"!T 1 @C $((* !!"2X 0 DS #\).0 ^"D  /0I' #P*3P Z"U@ .0MC
M #@,;P V#'X -0R. #0-GP S#;$ ,@W' #(-XP R#?0 ,@W^ (@3  !W%0
M:1<  %X8  !5&   3Q@  $H6  !'%0  11,  $,0 @!##@@ 0@T. $ -$@ _
M#1@ /0T? #P-)  [#2H .0TP #@.-P W#CT -@Y% #4.30 S#U< ,@]B #$0
M;@ O$'T +A". "T1H  L$;( *Q'( "L1Y@ K$?8 +!'_ (,6  !R&0  9!H
M %D;  !1&P  2QL  $8:  !"&   /Q<  #X4   \$@0 .Q$* #H0$  X$!4
M-Q ; #41(0 T$2< ,Q$M #(1,P P$3H +Q)" "X22P M$U0 *Q-? "H4;  I
M%'L *!2, "<5G@ F%;  )17& "45Y  E%?8 )A7_ 'X9  !N&P  8!T  %8>
M  !-'@  1QX  $(=   ^'   .AH  #@8   W%@  -14' #04#0 R%!( ,!07
M "\4'0 M%", +!4J "L5,  J%3< *18_ "@62  G%U( )AA= "08:@ C&7D
M(AF* "$9G  @&:\ 'QG$ !\9X@ @&?0 (!G_ 'H;  !J'@  71\  %,@  !*
M(   1"   #X?   Z'@  -QT  #0<   R&0  ,!D$ "X8"P L&!  *A@4 "D8
M&@ G&"  )ADF "49+0 D&C4 (QH] "(;1@ A&U  (!Q; !\=:  >'7< '1V(
M !P>FP ;'JT &A[# !H>X  :'?, &QW_ '<=  !G(   6B$  % B  !((@
M02(  #LB   W(0  ,R   # ?   M'0  *QT  "@="  F'0X )1T2 ",=%P A
M'1T (1TD " >*@ ?'C( 'A\Z !T?0P <($T &R%9 !HA9@ 9(74 &"*' !<B
MF0 6(JP %2+! !4BWP 5(?( %B'^ ',@  !D(@  5R,  $TD  !%)0  /B0
M #DD   T(P  ,"(  "PB   I(0  )B$  "0A!@ B(0P ("$0 !XA%0 =(AL
M&R(A !LB*  :(R\ &2,X !@D00 7)$L %B57 !4E9  4)G, $R:% !(FF  1
M)JL $2;  ! FW0 1)?$ $B7] ' B  !A)   5"8  $HF  !")P  /"8  #8F
M   Q)0  +24  "DD   F)   (B4  !\E P =)@H &R8. !DG$@ 8)Q@ %R<?
M !8G)0 5*"T %"@U !,I/@ 2*4D $2E5 !$J8@ 0*G$ #RJ#  XJE@ .*JD
M#2J]  TJUP -*NX #BG[ &PD  !=)@  42@  $@H  ! *0  .2@  #0H   O
M*   *R<  "<G   B*   'BD  !LJ   8*P< %BL- !0L$0 3+!8 $BP< !$M
M(P 0+2H $"TR  \N/  .+D8 #2Y2  TN7P ,+VX "R]_  HOD@ )+Z4 "2ZY
M  @NT  )+ND "B[W &@G  !:*0  3BH  $4K   ]*P  -RL  #$J   M*@
M*2H  "0J   @*P  &RT  !@N   5+P0 $C$* ! R#@ /,A, #C(9  TR(  -
M,B< ##(O  LS.  *,T( "3-.  @S6P &-&H !31[  0SC@ #,Z(  C.V  (S
MS0 #,^< !#+S &0J  !6+   2RT  $(M   Z+0  -"T  "\L   K+   )BP
M "(M   =+P  &3$  !4R   2- , #S8)  PX#0 *.!$ "3@6  @X'0 '."0
M!C@L  0X-  #.#X  CE*   Y5P  .64  #EW   YBP  .)\  #BS   XR@
M..8  #?R %\M  !2+@  2"\  #\P   X+P  ,B\  "TO   I+P  )#   !\Q
M   :,P  %34  !(W   /.0, ##L(  @]#0 %/A   SX4   ^&@  /B$  #XH
M   ^,0  /SL  #]&   _4P  /V$  #]S   _AP  /IP  #ZP   ]QP  />0
M #WR %HP  !.,@  1#(  #PR   U,@  ,#$  "LQ   F,@  (#0  !LV   6
M.   $CL   \]   ,/P, "$$(  1##   0PX  $02  !%%@  11T  $4D  !%
M+0  1C8  $9"  !&3@  1ET  $9N  !%@@  19@  $2M  !$Q   0^,  $/R
M %4T  !*-0  034  #DU   S-   +C0  "@U   B-P  '3H  !<\   2/P
M#T$   Q$   (1@$  T@&  !)"@  2@T  $L0  !,%   31D  $X@  !.*
M3C(  $T]  !.2@  3E@  $UI  !-?0  3)0  $RJ  !+P0  2^$  $KR % X
M  !&.   /3@  #<X   Q-P  *CD  "0[   >/0  &$   !-#   /1@  "TD
M  =+   "3@   % $  !1"   4@L  %,.  !4$0  514  %8;  !7(P  5RP
M %<X  !71   5U(  %9C  !6=P  5HX  %6E  !4O0  4]T  %/P $L\  !"
M/   .SL  #4[   M/   )C\  !]"   910  $T@   Y+   +3P  !5$   !4
M    5P   %@!  !:!0  6P@  %P,  !=#@  7Q$  & 6  !B'0  8B8  &(Q
M  !B/@  84P  &%=  !A<   8(@  &"@  !?MP  7M0  %WN $=    _/P
M.C\  #%    I0P  (48  !I*   33@  #E$   I5   $6    %L   !>
M80   &,   !D 0  900  &<(  !H"P  :@X  &P2  !N%P  ;R   &\J  !O
M-@  ;D4  &Y5  !N:   ;7\  &V8  !LL   :\H  &KH $1$   ^0P  -40
M "M'   C2P  &T\  !-4   .6   "%P   )@    9    &<   !K    ;0
M &\   !P    <@   '0"  !U!@  =PH  'D.  !\$@  ?A@  '\B  !_+@
M?ST  'Y-  !]80  ?7<  'R0  ![J   >L   'G? $-'   Y20  +TP  "50
M   <50  %%L   Y@   '90   &H   !N    <@   '8   !Y    ?    'X
M  !_    @0   (,   "%    AP,  (H(  ",#0  CQ$  )(9  "2)0  DC,
M ))$  "15P  D&T  (^&  ".GP  C;4  (S- #U.   R40  *%8  !Y<   5
M8@  #F@   =N    =    'D   !^    @@   (8   ")    C    (X   "0
M    D@   )0   "6    F    )L   ">!@  H0P  *01  "F&P  IBD  *8Z
M  "E30  I6(  *1[  "CE   H:L  *&_ #97   L7   (6(  !=I   /<
M!W<   !^    A    (H   "/    E    )@   ";    G@   )\   "B
MI    *8   "H    JP   *T   "P    LP0  +<,  "[$@  NQ\  +LP  "[
M0P  NE@  +EP  "WBP  MZ$  +>S #!B   E:0  &G   !!X   )@    (@
M  "/    E@   )L   "A    I@   *H   "N    L    +$   "T    M@
M +@   "[    O0   ,    ##    QP   ,L#  #/#   TQ4  -(E  #2.
MT4X  -!E  #/?@  S98  ,RI /\   #_    _P   /\  P#_  L _  1 /D
M&P#W "4 \P O .X . #I $  Y@!( .( 3@#? %0 W !9 -D 7@#5 &, TP!H
M -  ;0#. ', RP!Z ,@ @@#& (P PP"7 ,  HP"^ +( O #( +H Z@"Y /\
MN #_ +$ _P"J /\ IP#_ /\   #_    ^P   /8   #M  < YP / .( %@#?
M "  W@ I -D ,P#1 #L S !" ,@ 2 #% $X P@!3 ,  6 "^ %T O !B +H
M9P"Y &T MP!T +4 >P"R (4 L "0 *X G "L *H J0"] *< W@"F /D I0#_
M *, _P"= /\ FP#_ /T   #V    ZP   -\   #1  , R@ , ,4 $@## !L
MP  D +X + "Y #4 M@ \ +, 0P"P $@ K@!. *P 4@"K %< J0!< *< 80"F
M &< I !M *( = "@ 'T G@"( )P E0": *, F "T )8 S0"5 /$ E #_ )4
M_P"0 /\ C@#_ /,   #F    T0   ,(   "X    L0 ( *T #P"J !8 J  >
M *@ )P"F "\ H@ V )\ / "= $( FP!' )D 3 "7 %$ E@!5 )0 6@"3 &
MD0!F )  ;@". '8 C "! (H C0"( )L A@"L (4 P0"$ .8 @P#] (0 _P"#
M /\ @0#_ .0   #+    N@   *P   "B    G  $ )@ # "6 !$ E  9 ),
M(0"2 "@ CP P (T -@"+ #P B0!! (@ 1@"& $L A0!/ (0 5 "" %H @0!@
M '\ 9P!^ &\ ? !Z 'H A@!X )0 =P"D '4 MP!T -0 <P#T '0 _P!T /\
M= #_ ,L   "V    I@   )H   "2    B@   (8 " "#  X @0 4 ($ &P"
M ", ?P J 'T , ![ #8 >@ [ '@ 0 !W $4 =0!) '0 3@!S %0 <0!: '
M80!N &D ;0!S &L ?P!I (T : "= &< K@!F ,< 90#J &8 _P!F /\ 9P#_
M +@   "D    E0   (H   "!    ?    '8 ! !T  P <@ 0 '$ %@!P !T
M<  D &X *@!M #  :P U &H .@!I #\ : !$ &< 20!E $X 9 !4 &, 6P!A
M &, 8 !M %X >0!= (< 6P"6 %H J !9 +T 60#? %D ^ !: /\ 6@#_ *@
M  "5    AP   'L   !S    ;@   &H  0!G  @ 90 . &0 $@!C !@ 8P ?
M &( )0!A "H 7P P %X -0!= #H 7  ^ %L 1 !9 $D 6 !/ %< 5@!6 %X
M5 !H %, <P!1 ($ 4 "1 $\ H@!. +4 3@#0 $X \ !. /\ 3P#_ )P   ")
M    >P,  ' #  !H P  8@$  %\   !=  0 6P + %D #P!8 !0 5P 9 %<
M( !6 "4 50 J %, , !2 #0 40 Y %  /P!/ $0 3@!+ $T 4@!+ %H 2@!C
M $D ;P!' 'P 1@", $4 G0!% +  1 #' $0 Z !$ /H 10#_ )($  " !P
M<0H  &8*  !>"@  60D  %4'  !4!   4@ ' %  # !/ !  3@ 5 $T &P!,
M "  2P F $H *P!) #  2  U $< .@!& $  10!& $, 3@!" %8 00!? $
M:P ^ '@ /0"( #P F0 \ *L / #! #L X  [ /0 .P#_ (D*  !X#   :@X
M %\.  !7#@  40X  $T,  !+"P  2@@" $D$"0!(  T 1@ 1 $4 %@!$ !P
M0P A $( )@!! "L /P Q #X -@ ] #P / !# #L 2@ Z %( .0!< #@ :  V
M '4 -0"% #0 E@ T *@ ,P"\ #, V  S .\ ,P#[ ((-  !Q#P  9!   %D1
M  !1$0  2Q$  $<0  !$#@  0@T  $$+!0!!!PL /P4. #X#$@ \ A@ .P(=
M #H#(@ Y R@ . ,M #<#,@ V!#D -00_ #0%1P S!5  ,09: # &9@ O!W,
M+@># "T'E0 L!Z< *P>Z "L'T@ K!^L *P?W 'T0  !L$0  7Q,  %04  !,
M%   1A0  $(3   ^$@  /!   #H. 0 Z#08 .@H, #@)$  V"!0 -0@9 #0)
M'P R"20 ,0DI # )+P O"C8 +@H] "T*10 L"TX *PM9 "D,90 H#', )PR#
M "8-E0 E#:< ) V[ ",-T@ C#>L (PWW '@2  !H%   6Q8  %$7  !(%P
M0A8  #T6   Y%0  -Q,  #41   S$ , ,PX( #(-#0 P#1$ +PT6 "T-&P L
M#2$ *PTG "H-+0 I#C0 * X[ "<.1  E#DX ) ]9 ",090 A$', (!"$ !\0
ME@ >$*D '1"] !P0V  =$.X '1#Y ',4  !D%@  5Q@  $T9  !%&0  /QD
M #H8   U%P  ,A8  # 5   N$P  +1$$ "P0"@ K$ X *1 2 "@0&  F$!X
M)1 D "00*@ C$3$ (A$Y "$10@ @$DL 'A)6 !T38P <$W$ &A." !D4E0 8
M%*< %Q2[ !<3U  7$^X &!/Z ' 6  !@&0  5!H  $H;  !"'   /!L  #8;
M   R&@  +QD  "P8   J%@  *!0! "83!P E$PP (Q,0 "(3%0 @$QH 'Q,A
M !X4)P =%"X '!4V !L5/P :%DD &194 !@780 6%W  %1B! !08DP 3&*8
M$ABZ !(7T@ 2%^P $Q?Z &P9  !=&P  41T  $<=   _'@  .1T  #0=   O
M'   *QL  "@:   F&0  )!@  "(7!  @%PH 'A<. !P7$@ :%Q< &1@> !D8
M)  8&2P %QDT !8:/0 5&D< %!M2 !,;7P 2'&X $1Q_ ! <D@ 0'*4 #QRY
M  X<T  .&^H #QOX &D;  !:'0  3A\  $4?   ](   -A\  #$?   M'@
M*1T  "4=   C'   (!L  !T; 0 ;&P< &1P- !<<$  6'!4 %1P; !0=(@ 3
M'2D $AXQ !$>.@ 1'T4 $!]0  \@70 .(&P #2!\  T@CP ,(*( "R"U  L@
MR@ +(.4 #!_T &4=  !7'P  3"$  $(A   Z(0  -"$  "\A   J(   )A\
M ",?   @'@  '1X  !D@   6( 0 %" + !(A#@ 1(1, $2(9 ! B'P /(B8
M#B,O  XC-P -(T$ #"1-  LD60 *)&< "21X  @DBP '))X !R2Q  8DQP &
M(^, !R/Q &(?  !4(0  22,  $ C   X(P  ,B,  "PC   H(@  )"$  "$A
M   >(0  &B$  !8C   3) , $24(  \F#0 .)Q$ #2<6  PG'0 +)R, "B<K
M  DH-  (*#X !RA)  8H50 %*60 !"ET  ,IAP "*9L  2BO   HQ0 !*.$
M 2?P %XB  !1)   1B4  #TE   U)0  +R4  "HD   F)   (B,  !\C   ;
M)   &"4  !0F   1* , #RD(  PL#  *+!  ""P4  <L&@ &+"$ !2PH  ,M
M,  "+3H  2U%   M4@  +F   "YQ   MA   +9D  "VM   LP@  +.   "SP
M %HD  !-)@  0R<  #HG   S)P  +2<  "@F   D)@  (28  !TF   9)P
M%2D  !$K   /+ , #2X'  DP#  &,0X  S$2  $R%P  ,AX  #(E   R+0
M,C8  #-"   S3@  ,UT  #-M   S@0  ,I8  #*K   QP0  ,=\  #'P %8G
M  !**0  /RH  #<J   P*@  *RD  "<H   C*   'BD  !HJ   6+   $BX
M  \P   -,0( "C0'  4U"P "-@X  #<0   X%   .!H  #@B   X*@  .3,
M #D^   Y2@  .5D  #EI   Y?0  .),  #BH   WOP  -]X  #;P %$K  !&
M+   /"P  #0L   N+   *BL  "4K   @+   &RT  !<O   3,0  $#,   TU
M   )-P( !3H&  $["@  / T  #T/   ^$@  /Q<  $ >  ! )0  0"\  $ Z
M  ! 1@  0%0  $!E   _>   /X\  #ZF   ^O0  /=P  #WP $TN  !"+P
M.2\  #(O   M+@  *"X  "(O   =,   &#(  !,U   0-P  ##H   D\   %
M/@   $$$  !""   0PL  $0-  !&$   1Q0  $@9  !((0  2"H  $@U  !(
M00  2$\  $A@  !'<P  1XH  $:B  !%N0  1=D  $3P $@R   ^,@  -C(
M # Q   K,0  )3(  !\T   9-@  $SD  ! \   ,/P  "$(   -$    1@
M $@"  !*!0  2P@  $P+  !.#@  3Q$  %$5  !2'   4B4  %(P  !2/
M44H  %%:  !1;0  4(0  $^=  !.M0  3=(  $WN $,V   [-@  -#4  "\T
M   G-0  (3@  !H[   4/@  $$$   Q$   '1P   DH   !-    3P   %$
M  !3 @  5 4  %4(  !7"P  60X  %L1  !=%P  71\  %TJ  !=-@  7$0
M %Q4  !;9P  6WX  %J7  !9KP  6,L  %?J #\Y   X.0  ,S@  "LY   C
M/   '#\  !5#   01P  "TH   5.    40   %0   !7    6@   %P   !=
M    7P   & $  !B!P  9 L  &8.  !H$@  :QD  &LC  !J+@  :CP  &I-
M  !I7P  :'4  &>/  !FJ   9<(  &3C #T]   W/   +CT  "5    =1
M%DD  !!-   *40  !%4   !:    70   &    !C    9@   &@   !J
M:P   &T   !O @  <08  '0*  !V#@  >1,  'L;  ![)P  >C4  'E%  !X
M60  >&T  '>&  !VGP  =;<  '32 #Q!   R0@  *$4  "!*   73@  $%0
M  I9   "7@   &,   !G    :P   &\   !R    =0   '<   !Y    >P
M 'T   !_    @@   (0#  "'"0  B@X  (X3  "/'@  CBL  (X[  "-3@
MBV,  (I\  "*E0  B*T  (?% #9'   L2P  (D\  !E5   06P  "F$   %G
M    ;0   '(   !W    >P   '\   "#    A@   (@   "*    C0   (\
M  "1    E    )<   ": 0  G0<  *$-  "E%   I"$  *0Q  "C1   HED
M *!P  "?BP  G:(  )VW #!0   E50  &UL  !)B   +:0   7    !W
M?0   (,   "(    C0   )$   "5    F    )H   "<    GP   *$   "C
M    I@   *D   "L    L    +0'  "X#@  NA@  +HG  "Y.0  N$X  +=E
M  "V?@  M98  +.K "E;   >8@  %&D   QQ   ">0   ($   ")    CP
M )8   ";    H    *0   "H    JP   *P   "O    L@   +0   "V
MN0   +P   #     Q    ,@   #-!P  TA   -(=  #1+P  T$0  ,];  #-
M<P  RXT  ,JA /\   #_    ^P   /H   #\  @ ^  / /4 %P#T "  \0 J
M .L ,P#F #L X@!# -X 20#: $\ U@!4 -, 60#0 %X S@!C ,L : #) &X
MQ@!U ,, ?0#! (8 O@"2 +L G@"Y *X M@## +0 Z "S /\ KP#_ *4 _P">
M /\ FP#_ /T   #W    \@   /    #G  , X0 , -P $@#8 !L U@ D -(
M+0#, #8 Q@ ] ,( 0P"_ $D O !. +H 4P"X %@ M@!= +4 8@"S &< L0!N
M *\ =@"L '\ J@"* *@ EP"E *8 HP"Y *$ V0"@ /D G@#_ )@ _P"2 /\
MCP#_ /,   #L    XP   -,   #(    P0 ) +T #P"[ !8 N0 ? +< )P"S
M "\ KP W *P /0"J $, J !( *8 30"D %( HP!6 *$ 6P"? &$ G@!G )P
M;P": '@ EP"# )4 D "3 )X D0"P )  R ". /  C0#_ (H _P"% /\ @@#_
M .<   #=    Q@   +@   "N    J  $ *4 # "A !( H0 9 *  (@"? "D
MFP P )@ -P"6 #T DP!" )( 1P"0 $L CP!0 (T 50", %H B@!A (@ : "'
M '  A0![ (, B "! )8 ?P"G 'T O !\ ., ? #] 'P _P!X /\ =@#_ -8
M  #     KP   *,   "9    DP   (\ "0"-  X BP 4 (H ' "* ", B  J
M (4 , "# #8 @@ [ (  0 !_ $4 ?@!* 'P 3P![ %0 >@!: '@ 80!V &D
M=0!S ', @ !Q (X ;P"? &X L@!M ,\ ; #T &P _P!K /\ :0#_ ,    "K
M    FP   (\   "'    @    'P ! !Z  P >  1 '@ %P!X !X =P D '4
M*@!S #  <0 U '  .@!N #\ ;0!$ &P 20!K $X :@!4 &@ 6P!G &, 90!M
M &0 > !B (< 8 "7 %\ J@!> ,( 7@#I %X _P!> /\ 70#_ *P   "9
MB@   '\   !W    <0   &T   !J  @ :0 . &@ $@!G !@ 9P ? &< )0!E
M "H 8P O &( - !A #D 8  ^ %\ 0P!> $@ 70!. %L 50!: %T 6 !G %<
M<@!5 ($ 5 "1 %, HP!2 +@ 40#< %$ ^0!2 /\ 4@#_ )T   "+    ?
M '$   !I    9    &    !>  4 7  + %L #P!; !0 6@ 9 %H 'P!9 "4
M5P J %8 +P!5 #0 5  X %, /0!2 $, 4 !) $\ 4 !. %@ 30!B $L ;0!*
M 'H 20"+ $@ G0!' +$ 1P#, $8 \ !' /\ 1P#_ )    !^    <    &8
M  !>    60   %8   !3  $ 4@ ( %  #0!/ !  3P 5 $X &@!. "  30 E
M $P *@!* "X 20 S $@ . !' #X 1@!$ $4 2P!$ %, 0P!= $$ : !  '4
M/P"% #X EP ] *L /0## #T Y@ ] /L /@#_ (<   !U P  : 8  %T'  !5
M!@  4 8  $P$  !* 0  20 $ $< "@!&  X 10 1 $4 %@!$ !L 0P @ $(
M)0!! "H 0  O #\ -  ^ #H /0!  #L 1P Z $\ .0!9 #@ 9  W '$ -@"!
M #4 DP T *8 - "[ #0 W0 T /4 -0#_ 'X&  !M"0  8 L  %8,  !.#
M2 L  $0*  !""   0 4! #\!!P ^  L /0 . #P $@ [ !< .P < #H (0 Y
M "4 -P J #8 ,  U #4 -  \ #, 0P R $P ,0!5 #  8  O &T +@!] "T
MCP L *( + "V "P T  L .X + #\ '<*  !G#   6@X  % .  !)#@  0PX
M #X-   [#   .0L  #@) P W!0@ -@(- #4!$  T !, ,P 8 #( '0 Q "(
M,  G "\ +  N #( +0 X "P 0  K $D *@!2 "D 70 H &L )P%Z "8!C  E
M )\ )0"R "4 R@ E .@ )0#W '(-  !B#@  5A   $P1  !$$0  /A$  #D0
M   V#P  ,PX  #$- 0 P"P4 , @* "\&#0 N!1$ + 04 "L#&0 J QX *0,C
M "@$*0 G!"\ )@4U "4%/0 D!48 (P90 "(&7  A!VD ( =Y !\'BP >!YT
M'@>P !T&Q@ =!N, '07S &T.  !>$0  4A(  $@3  ! $P  .A,  #42   Q
M$0  +A   "P/   J#@, *@T' "D+"P H"0X )PD1 "4(%@ D"!L (PD@ "()
M)@ A"2P ( HS !\*.P >"T0 '0M/ !P,6P ;#&D &@QY !@,BP 8#)X %PRP
M !8,Q0 6#.$ %@OP &D0  !:$@  3A0  $45   ]%0  -Q4  #$4   M$P
M*A(  "@1   F$ $ )! $ ",."  C#0P (@P/ " ,$P ?#!@ '@T= !T-(P <
M#2H &PTR !H..@ 8#D0 %PY0 !8/7  5#VH $Q![ !(0C0 1$*  $1"S ! /
MR0 0#^0 $0_R &42  !7%   2Q8  $(7   Z%P  -!<  "\6   J%0  )Q0
M "03   B$P  (!(# !X1!@ =$ D '! - !L/$  9$!4 &! ; !<0(0 6$"@
M%1$P !01.0 3$4, $A). !$26@ 0$FD $!-Y  X3C  .$YX #1.Q  T2Q0 ,
M$N$ #1+Q &(4  !4%@  21@  #\9   W&0  ,1D  "P8   H%P  )!8  "$6
M   ?%0  '!0" !H3!  9$@8 %Q(+ !42#@ 4$A( $Q,8 !(3'P 1$R8 $10M
M ! 4-@ /%4$ #A5,  X65P -%F4 #!=U  L7AP *%YH "1:M  @6P0 (%MT
M"17N %\6  !1&   1AH  #T:   U&P  +QH  "H:   E&0  (A@  !\8   <
M%P  &18! !<6 P 5%@0 $Q8) !$6#0 0%Q$ #Q<6  X7'  .&", #1@J  P9
M,P ,&3P "QI'  H:4P )&F$ !QMQ  8;@P %&Y< !!JJ  ,:OP #&=H !!GL
M %P8  !.&@  0QP  #H<   S'   +!P  "<<   C&P  (!H  !T9   :&0
M%Q@! !48 @ 2&00 $!L'  X;#  -'!  #!P3  L<&0 *'!\ "1TG  @=+P '
M'CD !AY#  0>4  #'UX  A]N  $?@   'Y4  !ZI   >O0  '=@  !WL %@:
M  !+'   01X  #@>   P'@  *AX  "4=   A'   'AP  !L;   8&P  %AL!
M !,; @ 1' 0 #AX'  P?"P *( X "" 2  8A%P %(1T !"$D  (B+  !(C4
M ")    C30  (UH  "-K   C?@  (Y,  "*G   BO   (=<  "'M %4=  !(
M'P  /B   #4@   N(   *"   ",?   @'@  '1T  !H=   6'0  $QX  !$?
M @ .( 0 #2('  HD"P &)0T !"40  (F%   )AH  "8A   G*0  )S(  "<]
M   G20  *%<  "AG   G>P  )Y   ">E   FNP  )M8  "7M %$@  !%(0
M.R(  #(B   L(@  )B$  "(A   >(   &Q\  !@@   4(   $2(   \C   -
M)0, "B8&  8H"@ #*0T  "L/   L$@  +!<  "P>   L)@  +2\  "TY   M
M1@  +50  "UD   M=P  +(T  "RD   KN@  *]8  "KN $TB  !!)   ."0
M # D   I)   )",  "$B   =(@  &2(  !4C   2)   #R8   TH   **@(
M!BP%  (N"0  +PL  # .   R$   ,Q4  #,;   S(@  ,RL  #,V   S0@
M,U   #-@   S<P  ,HH  #*A   QN   ,-8  ##O $DE   ^)@  -"<  "TG
M   H)@  (R4  !\D   ;)0  %B8  !(H   0*@  #2P   HN   &, $  C($
M   T!P  -0H  #<,   X#@  .A(  #H7   Z'P  .B<  #HR   Z/@  .DP
M #I<   Z;P  .88  #B>   XM@  -]0  #;O $0I   Z*0  ,2D  "LI   F
M*   (B<  !TH   8*0  $RL  ! N   -,   "3(   4U   !-P   #D"   [
M!0  / @  #X+   _#0  01   $,4  !#&P  0R,  $,N  !#.0  0T<  $)7
M  !":@  08$  $":   _L@  /L\  #[O #\L   V+   +RP  "HK   E*@
M'RL  !DM   4+P  $#(   TU   (.   !#H    \    /P   $$   !# @
M104  $8(  !("P  2@X  $P1  !-%@  31X  $TH  !--   3$(  $Q1  !+
M9   2WL  $J4  !)K0  2,H  $?L #LP   S+P  +2\  "@M   B+P  &S$
M !4T   0-P  #3H   @]   "0    $,   !&    2    $H   !,    3@$
M $\$  !1!P  4PL  %4.  !8$@  61D  %@B  !8+@  5SP  %=+  !67@
M5G,  %6-  !4IP  4L(  %+F #@S   Q,@  +#$  "4R   =-0  %C@  !$\
M   ,0   !T0   !'    2@   $T   !0    4P   %4   !7    60   %H
M  !< P  7@<  &$+  !D#@  9A,  &<<  !F)P  9C0  &5$  !D5P  9&L
M &*%  !AGP  8+D  %[< #4W   P-0  *#<  " Z   8/0  $4(   Q&   &
M2@   $\   !3    5@   %D   !<    7P   &$   !D    90   &<   !I
M    ; $  &X&  !Q"P  = \  '<5  !W(   =BT  '8]  !U3P  =&,  '-[
M  !RE0  <*\  &_) #4Z   K.P  (C\  !I#   22   #$T   52    5P
M %P   !@    9    &@   !K    ;@   '$   !S    =0   '<   !Z
M?    '\   ""!   A@H  (H/  ",%P  BR0  (HS  ")10  AUL  (9R  "%
MBP  @Z4  (*\ "]    E1   '$D  !-.   -5   !%H   !A    9@   &L
M  !O    =    'D   !]    @    (,   "%    AP   (H   ",    CP
M )(   "6    F0(  )X)  "B$   HAH  *$I  "@.P  GU   )UG  ":@0
MFID  )FO "E)   ?3@  %50   Y;   %8@   &D   !P    =P   'T   ""
M    A@   (L   "/    DP   )4   "7    F@   )T   "@    HP   *8
M  "J    K@   +(   "W"@  NQ$  +H?  "Y,   MT4  +5<  "T=   L8X
M *^D ")4   86P  $&(   =J    <P   'L   ""    B0   )    "5
MF@   )\   "C    I@   *@   "K    K@   +    "S    M@   +H   "]
M    P@   ,<   #, 0  TPL  -05  #3)@  T3H  -!1  #-:   RX$  ,J6
M /P   #V    \@   /$   #S  4 ]  , /( $P#P !P [0 E .@ +@#B #8
MW@ ^ -D 1 #4 $H T0!/ ,X 5 #+ %D R0!> ,8 8P#$ &D P0!P +X > "\
M ($ N0"- +8 F@"S *L L0#  *\ Y@"N /\ I0#_ )H _P"4 /\ CP#_ /0
M  #L    Z    .<   #?    V0 ) -( $ #/ !< SP @ ,P * #& #  P  W
M +P /@"Y $0 MP!) +4 3@"S %, L0!7 *\ 70"M &( JP!I *D <0"G 'H
MI0"% *( DP"@ *( G0"V )L U "9 /D E@#_ (T _P"( /\ A #_ .@   #?
M    V0   ,D   "_    N  $ +4 #0"S !( L0 : +  (@"M "H J0 Q *8
M. "D #T H@!# *  2 "> $P G !1 )L 5@"9 %P EP!B )4 :0"3 '( D0!]
M (\ BP"- )H BP"L (D Q0"( .X A@#_ '\ _P!Z /\ > #_ -D   #_XGT0
M24-#7U!23T9)3$4 "!+-    NP   *X   "E    GP   )P "0"9  \ F0 5
M )D '0"8 "0 E  K )$ ,0". #< C  \ (L 00") $8 B !+ (8 4 "% %4
M@P!; (( 8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V .  =0#_ '( _P!N
M /\ ; #_ ,<   "U    I0   )D   "/    B0   (4 ! "$  P @@ 1 ((
M%P"" !X @  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$ '4 20!S $\ <@!5
M '  7 !O &0 ;0!N &P >@!J (H : "; &< KP!F ,P 90#U &0 _P!A /\
M8 #_ +0   "@    D    (4   !]    =P   ',   !P  @ ;P . &\ $@!O
M !@ ;P ? &T )0!K "H :0 P &@ - !G #D 9@ ^ &4 0P!C $@ 8@!. &$
M50!? %X 7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J %< _P!6 /\ 5 #_
M *$   ".    ?P   '4   !L    :    &0   !A  0 8  + %\ #P!? !,
M7P 9 %\ 'P!= "4 7  J %L +P!9 #, 6  X %< /0!6 $, 50!) %, 4 !2
M %@ 40!A %  ;0!. 'L 30", $P GP!+ +4 2@#< $H ^@!* /\ 2@#_ )(
M  "     <@   &<   !?    6@   %<   !5  $ 4P ' %( # !2 !  4@ 4
M %( &@!1 !\ 3P D $X *0!- "X 3  S $L . !* #T 20!# $@ 2@!& %(
M10!< $0 9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!  /\ 0 #_ (4   !T
M    9P   %T   !5    3P   $P   !*    2  $ $< "@!'  T 1@ 1 $8
M%0!& !H 10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^ #T 10 \ $X .P!7
M #H 8@ Y &\ . "  #< DP V *< -@#  #8 Z  V /X -@#_ 'P   !K
M7@(  %0#  !- P  1P,  $,!  !!    /P ! #X !P ]  L /0 . #P $0 \
M !8 /  : #H 'P Y "0 .  I #< +@ V #, -0 Z #0 00 S $D ,@!3 #$
M7@ P &L +P![ "X C@ M *( +0"X "T W0 M /@ +@#_ ',!  !D!0  5P<
M $T(  !&"   0 @  #L'   X!0  -P,  #8 !  U  @ -  , #0 #P T !(
M,P 6 #( &P Q "  ,  D "\ *0 N "\ +0 V "P /0 K $4 *@!/ "D 6@ H
M &< )P!W "8 B0 F )T )0"S "4 SP E /  )@#_ &T&  !>"0  4@L  $@,
M  ! #   .@L  #8+   R"@  , @  "X& @ N P8 +0 * "P #0 L !  *P 3
M "H %P I !P *  @ "< )0 F "L )0 R "0 .0 C $( (@!+ "( 5P A &0
M( !S !\ A0 ? )D '@"N !X QP > .D 'P#Z &@)  !9#   30T  $,.   \
M#@  -@X  #$-   M#0  *@P  "@+   G"00 )@8( "8$"P E PX ) $0 "0!
M%  B 1@ (0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %) !L!5  : 6$ &@%P
M !D!@@ 8 )8 & "J !@ P0 8 .$ & #T &,,  !5#@  20\  $ 0   X$
M,A   "T/   I#@  )@X  ",-   B# , ( L& " )"0 ?!PP '@8. !X%$0 <
M!14 &P4: !H%'P :!24 &04K !@%,P 7!CP %@9& !8&4@ 5!U\ % =N !,'
M@  2!Y0 $@:G !(%O  2!-D $@/O %\.  !1#P  1A   #P1   U$0  +Q$
M "H1   F$   (A   " /   =#@( ' T% !H-!P :"PH &0H- !@)$  7"1(
M%@D7 !4)'  4"2( % HI !,*,0 2"CH $@M% !$+40 0#%\ #PQN  X,@  .
M#)0 #0NG  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3   R$P  +!,  "<2
M   C$0  'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+ !,,#0 2#!  $@P4
M !$,&@ 1#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX "P]M  H/?P )#Y,
M"0^F  @.N0 (#M  !P[H %@1  !+$@  0!,  #<4   P%   *10  "44   A
M$P  '1(  !H2   7$0( %1$% !,0!P 2$ D $0\* ! .#  .#@X #@\2  T0
M&  -$!X #! E  P0+0 +$38 "A%!  D130 ($EH !Q)J  82?  %$I  !!*D
M  ,1N  #$<\  A'H %42  !)%   /A4  #46   M%@  )Q8  "(5   >%
M&Q0  !@3   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,$@X "Q(1  H2%0 )
M$QL "1,B  @3*@ '%#, !10^  052@ #%5@  A5G  $5>@  %8X  !6C   4
MMP  %,\  !/I %(4  !&%@  .Q<  #(7   K%P  )1<  "$6   <%@  &14
M !84 0 4$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T "!80  86$P %%AD
M!!<?  ,7)P "&#   1@[   91P  &54  !ED   9=P  &8P  !BB   8MP
M%\\  !?J $\6  !#&   .1D  # 9   I&0  (QD  !\8   ;%P  &!8  !45
M @ 3%04 $10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.  (;$@ !&Q8  !L=
M   <)   '"T  !PX   =1   '5(  !UB   ==0  '8H  !R@   <M@  &]
M !KK $P8  ! &@  -AL  "T;   F&P  (1H  !T9   9&0  %Q@  !07 P 2
M%@0 $!<$  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @$   (!0  "$:   A
M(@  (2H  "$U   B00  (D\  ")?   B<@  (8@  "&?   @M@  ']$  !_M
M $@:   ]'   ,QT  "L=   D'0  (!P  !P;   8&@  %AD! !,9 0 1&0$
M#AH!  P< @ *'0, !Q\%  ,A"   (@H  "0,   F#@  )A(  "88   G'P
M)R<  "<R   G/@  )TL  "=<   G;@  )H4  ":=   EM   )-$  "/N $0=
M   Y'P  ,!\  "@?   C'@  'AT  !L<   8&P  %!P  !$<   .'0  #1\
M  HA   &(@$  R0$   F!@  * @  "H+   K#0  +1   "T5   M'   +20
M "XN   N.@  +D@  "U8   M:@  +8$  "R:   KL@  *M   "GO $ @   V
M(0  +2$  "8A   A(   '1\  !H>   6'@  $A\   \A   -(@  "B0   8F
M   "*    "L"   M!   +P8  # )   R#   - X  #42   U&   -2   #4J
M   U-@  -4,  #53   T9@  -'P  #.6   RKP  ,<T  ##O #PC   R)
M*B0  "0C   @(@  '"$  !<A   3(P  $"4   TG   )*0  !2L   $N
M,    #(    T 0  -@0  #@&   Z"0  / T  #X0   ^%   /AP  #XF   ^
M,0  /C\  #U.   ]80  /'<  #N1   ZJP  .<D  #CM #<G   O)P  *"8
M ",E   ?)   &24  !0F   0*   #2L   DN   %,    #,    U    .
M #H    \    /@$  $ #  !"!P  1 H  $8-  !)$0  21<  $@A  !(+
M1SH  $=)  !&6P  17$  $2+  !#I0  0L,  $'H #0J   L*@  )R@  "(G
M   <*   %BH  !$M   -,   "3,   ,V    .0   #P    ^    00   $,
M  !&    2    $H   !, P  3@8  % *  !3#@  5!,  %0<  !3)P  4S0
M %-#  !250  46H  %"#  !/G@  3;D  $S@ # M   K+   )BL  !\L   8
M+@  $C(   TU   (.0   CT   !     0P   $8   !)    3    $X   !1
M    4P   %4   !7    60$  %P&  !?"@  8@X  &,5  !C'P  8BP  &$\
M  !@3@  7V(  %Y[  !<E@  6[   %G/ "\P   J+P  (C   !HS   3-P
M#CL   @_   !1    $@   !,    3P   %(   !5    6    %L   !=
M8    &(   !D    9@   &D   !M!0  < L  '00  !T&   <R4  '(T  !R
M10  <%D  &]Q  !MBP  :Z8  &K  "XS   E-0  '3@  !0\   .00  !T<
M  !,    40   %4   !9    70   &$   !E    :    &L   !M    ;P
M '(   !T    =P   'H   !^    @@0  (8+  "*$0  B1P  (@K  "&/0
MA%(  (-G  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](   (3@   %0   !:
M    8    &0   !I    ;@   '(   !V    >@   'T   "     @@   (4
M  "(    BP   (X   "2    E@   )L#  "@#   HA,  * A  "?,P  G4<
M )I>  "8=P  EX\  )6G "-#   92   $4X   E5    7    &,   !J
M<0   '8   ![    @    (8   "*    C@   )$   "3    E@   )D   "<
M    H    *,   "G    JP   +    "V!   O T  +H7  "Y*   MSP  +12
M  "R:@  KX4  *V< !Q.   35   "UP   %D    ;    '0   !\    @P
M (D   "/    E    )H   "?    H@   *0   "G    J@   *X   "Q
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M______________________________________________________\
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
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MDYO=G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3F]WTP@T4]<,4,/;
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MT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G
MO)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6S[.!F="S@)W1LG^CT;!^I-&P
M?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^
MI-'_N!0._[@=)_^U*4;WL#5IWJA!D,><8;'$G'&VPIM^N;^=AKV]FHG!NY>)
MQ+F3BL>WCXS*M8R.S+2)D,ZSAY+0LH25TK&"F=.Q@9[4KH"BU*R H]*L@*/2
MK("CTJR H]*L@*/2K("CTJR H]*L@*/2K("CTJR H]*L@*/2K("CTJR H]+_
MN1,._[D<)_^V*$;WL#1JW:A D,>=8+'$G'&VPIQ\NK^>A;Z\G(C"NIF(Q;B5
MB<FVD8K,M(Z,S[*+CM&QB)'3L(:4U:^$F=:O@Y_7JH*AU:>"HM.G@J+3IX*B
MTZ>"HM.G@J+3IX*BTZ>"HM.G@J+3IX*BTZ>"HM.G@J+3IX*BTZ>"HM/_N1,.
M_[D<)_^V*$;WL3-JW:D_D<>=8+'$G7"VPIY[NK^?@[Z\GHC"N9N(Q[>7B,JU
ME(G.LY"+T;&-C=.OBI#6KHB3V*V&F=FJA9[9I82AU:2$HM2DA*+4I(2BU*2$
MHM2DA*+4I(2BU*2$HM2DA*+4I(2BU*2$HM2DA*+4I(2BU*2$HM3_NA(._[H;
M)_^W)T;WL3)JW:D^D<>>7['$G6^VP9]YNKZ@@K^[H(C#N)R'R+:9B,RSEHC0
ML9**TZ^/C-:NC([8K(J3VZN)F=RFAYW:HH:@UJ"&HM2@AJ+4H(:BU*"&HM2@
MAJ+4H(:BU*"&HM2@AJ+4H(:BU*"&HM2@AJ+4H(:BU*"&HM3_NA(._[H;)O^W
M)D;VLC%JW:H]D<>>7K'$G6^VP:!XNKZA@;^[H8C$N)Z'R;6;A\VRF(C1L)6)
MU:Z2B]BLCXW;JHV2WJB,FM^BBIW:GHF@UIR)H=2<B:'4G(FAU)R)H=2<B:'4
MG(FAU)R)H=2<B:'4G(FAU)R)H=2<B:'4G(FAU)R)H=3^NA$._[L:)O^X)D;V
MLC!JW:H\D<>>7;'$GFZVP:%VNKZB?[^[HXC$MZ"'RK2=A\^QFH?3KIB(UZR5
MBMNJDXW>J)&2XJ20F>">C9W;FHR@UYF+H=69BZ'5F8NAU9F+H=69BZ'5F8NA
MU9F+H=69BZ'5F8NAU9F+H=69BZ'5F8NAU9F+H=7^NQ$._KL:)O^X)4;VLS!J
MW*L[DL>?7;'$GVRVP:)TNKZD?K^ZI(?%MZ*'RK.?A]"PG(?5K9J(V:J9BMZH
MF([BI9>3YI^5F>":D9S;EX^?UY:.H=66CJ'5EHZAU9:.H=66CJ'5EHZAU9:.
MH=66CJ'5EHZAU9:.H=66CJ'5EHZAU9:.H=7]NQ$._KL:)O^Y)4;VLR]JW*LZ
MDL>?7+'$H&JVP:-SNKZE?,"ZI87%MJ.'R[.AA]&OGX?6K)Z)VZB<B]^DFHWA
MGYF/XYR:F.&7EIS<E).?V).2H-:3DJ#6DY*@UI.2H-:3DJ#6DY*@UI.2H-:3
MDJ#6DY*@UI.2H-:3DJ#6DY*@UI.2H-;]NQ$-_;P9)OZY)$;VM"YJW*LZDL>@
M7+'$H6BVP:5QNKZG>L"ZIX3%MJ:'S+*DA]&NHH?7J9^(VZ2=B=Z@FXK@FIJ,
MX9:;D^&5FYO=DI>>V)&5H->1E:#7D96@UY&5H->1E:#7D96@UY&5H->1E:#7
MD96@UY&5H->1E:#7D96@UY&5H-?\O! -_;P9)OZZ(T;VM"UJW*PYDL>@6['$
MHV:UP:9NNKZI>,"ZJ8+%MJB(S+"EA]*JHH?7II^'VJ&>A]R;G8C>EIR*WY&;
MD-^1G9G=CYN>V8^9G]>/F9_7CYF?UX^9G]>/F9_7CYF?UX^9G]>/F9_7CYF?
MUX^9G]>/F9_7CYF?UX^9G]?\O! -_+P8)OVZ(D7VM2QJW*TWD\>A6K'%I6.U
MPJEKNKZL=;^ZK7_%LZF'S*VEAM*GHH;6HJ&&V)V?AMJ8GH?;DIV)W8Z=C=V,
MGI3<C:">V8R>G]>,GI_7C)Z?UXR>G]>,GI_7C)Z?UXR>G]>,GI_7C)Z?UXR>
MG]>,GI_7C)Z?UXR>G]?[O1 -^[T7)?V[(D7VMBMJVZTVD\>B6;'%IU^UPJUF
MN;^Q<+ZWK7[&L*F'S:JFAM&DI(74GJ*%UIFAA=B4H(;9CY^'VHN?B]N(GY#;
MB*"8V(BAG=>(H9W7B*&=UXBAG=>(H9W7B*&=UXBAG=>(H9W7B*&=UXBAG=>(
MH9W7B*&=UXBAG=?ZO0X-^KX6)?R\($7VMRIJVZ\TE,BD5;'&JUBTP[-?M[NR
M;K^RK7['K*F&S*:GA="@I832FZ2$U):CA-61HH76C:&&UXFAB=B&H8W8A*&3
MUX2BE]:$HI?6A**7UH2BE]:$HI?6A**7UH2BE]:$HI?6A**7UH2BE]:$HI?6
MA**7UH2BE];YO@X,^;\5)?J]'T7VN"=JV[ QE,BH3:_'LDZRP;A8N+2Q<,&M
MK7_'J:J%RZ*HA,Z=IX/0EZ:#T9*EA-*.I(73BZ.&U(BCB-6$HXO5@J.0U8&C
MD]6!HY/5@:.3U8&CD]6!HY/5@:.3U8&CD]6!HY/5@:.3U8&CD]6!HY/5@:.3
MU8&CD]7TP T,]\ 3)/F_'43VNB5JVK(NE<JO0*W(O3VOM[9=NJZQ<L*IK7_&
MI:N%R9^J@\N9J8/-E*B#SI"GA,^,IH70B::&T8:EA]*$I8K2@:6-TH"EC]*
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ME7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B
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MBI>DT8J7I-'_MA((_[<<'?^T*#G_L#1:ZJE ?=6D29S(I%6PQJI;L\.O8[?
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M_ZHG%_^G-2__HT1*^IU19>F77G[;E&V4SY)WIL62@;3$DXBVPY*-N,&/C[K
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M1,3K$F:QWQB!H- SE9?&4*.3P&.MD;MQLY&X>[B0MH*[CK2%O8NSAK^(LH?
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MS(R-JL>*D;'$B)2VPX66N,*#F;G"@9NYP7^>NL%]H;O!>Z2[P'JGN\!YJKS
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MLJO+<+:KRV^\J\APP*O$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MJE=L[JE==^>H8X'AI&V+UIYYELN5@Z+ BXZMMH.:MJY^JKND?+.\GGZUNIJ
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M23G_ITHX_[%*-_^^2S?_PDLW_\)+-__"2S?_PDLW_\)+-__"2S?_PDN_LP
MKKX  *#-  "2W@  B?\- 8'_&@5W_R,,;?\J$V3_,1E<_S@>5?] (E#_2"9,
M_T\I2/]5*T3_6RU"_V$O/_]G,3W_;3([_W,S.?]Z-3?_@C8U_XLW,_^4.#+_
MG#DQ_Z0Z,/^O.S#_LCLP_[([,/^R.S#_LCLP_[([,/^R.S#_LCNPN   H,<
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M_X-I5_U\<F#X=G]G]'&*;O!LE73M:)]YZF2J?>AAMX#F7\B"W6';@\QDW(3
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MD8""F8R*BY&'E9&+A**6AH.RF8.$RYB$@\Z6A(/0E(2"TI*$@=.0A('4CH2
MUHR$@-:,A(#6C(2 UHR$@-:,A(#6C(2 UHS_=Q(!_W0; _^"'@3_E"<(_Z R
M#?^G-!/ZKC@8[[4]'.:\1B'<OTPLSKE4/\.Q75"WJF5?K:1L;*.=='>9F'R!
MD9.&BHF/DI&"C)^6?8JOF'J+QYA\B<Z6?8C0E'Z&TI)_A=.0?X34CH"#UHR
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M8$/N[&!'X_%?2-OQ84G2\F-)TO)C2=+R8TG2\F-)TO)C2=+R8TG2\F/^E0
MU*D  ,*U P"UP0, JL\% *#G"P&8_1H&C_XI$(;_-1M^_T E=/]&+6O_3#5C
M_U(Z7/]9/U;_8$-0_VA'3/]Q2D?_>TQ#_X=.0/^44#[_H5(]_[!4.__#53O^
MX54\^?!50/#T54/G]U1#Y_=40^?W5$/G]U1#Y_=40^?W5$/G]U3;H0  Q;
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M+";_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+2;_R2VJMP  FL4  (O3  !]X@
M=?\% &G_# %?_Q$"5_\7 U#_'P5)_R8'1/\N"3__-@L[_ST--_]##S/_21$P
M_T\2+O]5$RS_6Q0J_V(5)_]I%B7_<A<C_WL8(?^&&1__D1H>_YP;'O^E'!W_
ML!T=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!V<P   C,X  'S>  !P]0  9?\
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M!M:_-@_*ND0@O[1/,;2N6$"JJ&!.H:-G6IB>;V2/FG=MB): =8"2BWMZCY:
M=(ZDA'&-MH5OCM&%<8O=@W.)WX%UA^!^=H7A?7>$XWMW@^1Z=X/D>G>#Y'IW
M@^1Z=X/D>G>#Y'K_;!0!_W,6 O^%$P'_E!8!_Z(> ?6M( +GN"$"W<,F M##
M- W$OD(>N;E-+ZZS5CZDKEY,FJEE5Y&E;6*)H75K@)U^<GF:B'EREY1^;9:B
M@FF5LX1GELV#:9/>@FR/WX!OC.%^<(KB?'*(XWIRA^1Y<H?D>7*'Y'ERA^1Y
M<H?D>7*'Y'G_;1,!_W83 ?^($@'_F!, _Z<9 >^S%@'BP!4 U<H> <G',@R^
MPT <L[Y++*BZ5#R>M5Q)E+!C58JL:U^!J7)H>:5[;W*CA79KH)%[9I^??V*?
ML8%@G\J 8IS@?V67X7YHD^)\:I#C>VR-Y'EMC.5X;8SE>&V,Y7AMC.5X;8SE
M>&V,Y7C_;A,!_WL1 ?^-$ #_G1  ^JP1 -J["P#5R0L S<X; <+,+PJWR3T9
MK,5)*:' 4CB7O%I&C;AA48.U:%MZLG!D<J]Y:VNL@W%DJX]V7ZF>>ENIKWQ9
MJLE\6J?B>UZ@XWMAF^-Z8Y?D>6:4Y7=FDN9W9I+F=V:2YG=FDN9W9I+F=V:2
MYG?_<!(!_X . ?^2#@#RHPL V;,) ,^^"0#+S D Q-,7 +K2+ >PSSL6I<Q&
M)IK(4#6/Q%A!A<%?37R^9U9SO&]>:[EW962X@FM>MHYP6;6=<U6UKG54MLAU
M4[/G=E>KYG9:I.9V7*#G=5^<YW1@FNAT8)KH=&":Z'1@FNAT8)KH=&":Z'3_
M<A(!_X8, /N8"0#9J08 SK4' ,;!!P# SPD NML3 +':*06GV#<2G-1$(9+1
M33"'SE4\?<M=1W3)95!LQVU79<5V7E[$@6-9PXYH5,.=:U'#KFQ/Q,AM3L+M
M;5"XZV]3L.MP5:OJ<%BFZW!9H^MP6:/K<%FCZW!9H^MP6:/K<%FCZW#_=P\!
M_XT( -Z@ @#/K@4 Q+D% +O%!@"UTPH KN$6 :;A*0:=X#<1D]Y"'8G<3"E_
MVE0U===</VW59$AETVQ/7])V5%G2@5E4T8Y=4-&=8$W2L&)+T\EB2M+M8DO(
M\F9-O_%H3[CP:5&R\&E2K^]I4J_O:5*O[VE2K^]I4J_O:5*O[VG_?PH [98
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M1#[J_T0^YO]&/N;_1C[F_T8^YO]&/N;_1C[F_T;0GP  O:P  *ZU  "BP@
ME<\  (K= P"$_Q(!>_\> W3_*@EL_S,/9/\[%EW_0QM7_TH@4?]1)$S_6"=(
M_V J1/]H+$#_<2X\_WLQ.?^(,C7_EC0S_Z0V,?^V-R__T#@N_^\Y+?__.3'_
M_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.3/\_SG!J   K[$  **]  "4R@  A]@
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M$A/_PQ(3_\,2$__#$A/_PQ*7O@  ALP  '?;  !IYP  7/T  %3_  !+_P4
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MB,%T;8GD<V^'ZG%PA.QO<H/M;7.![FMT@/!I=(#P:72 \&ET@/!I=(#P:72
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M64RR^UI.K?I:3JWZ6DZM^EI.K?I:3JWZ6DZM^EK_?P  W),  ,JB  "\K $
ML;4  *C  P"?RP8 EMD+ )'@&P&*WRP&@M\Y#GG>0Q=QW4T@:MQ6*&/;7R]=
MVF<U6-EQ.E/9>SY/V8A"2]F614C9ID=&VKI(1=O;1T38]$E"T_]-1,G_3T7"
M_U!'N_]21[O_4D>[_U)'N_]21[O_4D>[_U+FB@  SYL  +^G  "RL   I[L
M )S& P"3T08 B^H. (7H'P)^Z"T&=N@X#F[H019FYTH=7^=2(UGG6RE5YV0M
M4.=M,4SG>#5)YX0X1NB1.D/HH#Q Z;(^/^K+/C[H[SX]YO\_/>#_0C_7_T1
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M*B_Y_RHO^?\J+_G_*B_Y_RJYI@  JJX  )RY  ".Q0  @=$  '7>  !M^@D
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M,_](GC;_1Z8X_T:O.?]%N#O_1<0\_T32//Q$Y3WX1/(]]47^//%%_S[F2/]
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M6ER1^UE>COQ87XW\5U^-_%=?C?Q77XW\5U^-_%?_:@H _WP  -R,  #-F
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M1$*Y_T1"N?]$0KG_1$*Y_T3=B   QY@  +BC  "KJP  H+0  )6^  "+R ,
M@-$' 'CA#0!TX1T!;N$K VC@-PAAX$(.7.!-%%?@5AE3X%\=3^!I(DO@<R5'
MX'XH1."+*T+@FBT_X:LO/N+!+S[BY2\\W_HQ.=[_-#G9_S8ZT/\X.\S_.3O,
M_SD[S/\Y.\S_.3O,_SG-D@  O*   *VH  "AL0  E;L  (G%  !^SP( =-H&
M &[K$0!HZQX!8NLJ UWL-097[#\+4NQ(#TWL41-*[5H61NUC&4/M;1Q [7@>
M/>Z%(3KNDR,X[Z,D-O"V)C7QTB8T[_,F-.S_)C+K_R@RY_\K,^3_+#/D_RPS
MY/\L,^3_+#/D_RS!G   L*8  *.N  "6N   B<,  'W-  !QV   9^8& &+V
M$0!<]QT!5_<G E+W,01-^#H&2/E""43Y2PM!^E0./OI<$#O[91(X^V\4-?M[
M%C+\B1@P_9@9+OVJ&RS^OQPK_^,=*OSZ'2KZ_QTJ]_\<*O?_'2KW_QTJ]_\=
M*O?_'2KW_QVSHP  I*L  )>V  ")P0  >\L  &_6  !CWP  6_4& %7_$ !0
M_QD!2_\C D;_+ -"_S0$/O\\!3K_0P8W_TL'-/]3"#'_6PDN_V0**_]O#"C_
M? TF_XL.)/^<$"+_KA$A_\42(/_I$Q___!,>__\3'O__$Q[__Q,>__\3'O__
M$Q[__Q.FJ0  F+,  (J_  ![R@  ;M4  &#?  !4YP  3O\$ $G_#@!#_Q0
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M285G_TF%9_])A6?_285G_TG_4A0!_U\. /]K"P#_=0P ^7X- /"%#@#CBQ
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M4EJ.WE);C?A07(O_3UZ(_TY@A?],88/_2V&#_TMA@_]+88/_2V&#_TO_9 4
M]70  -J"  #+C@  P9<  +B> 0"QI0  J:L' *.M&@"<K"P$E:LZ#(VH11:&
MID\??Z17*'FB7R]SH&8U;9YN.VB<=T!CFH%%7YF,25N8F4Q7EZA.59>[3U27
MW$Y4EO9.593_35B0_TQ9C?]+6XK_2EN*_TI;BO]*6XK_2EN*_TK_:   Y7D
M -&'  #%D@  NYP  +&B  "IJ0  H;$" )NS%0"5LR@"CK(V"8:P0A)_KDP;
M>*Q4(W*J7"ILJ&0Q9Z=L-F*E=3M=I'] 6:.*0U6BET=1H:=)3Z&Z2DZBV4E.
MH/5)3I__25"9_TE2EO](5)+_1U22_T=4DO]'5)+_1U22_T?_;@  WG\  ,J-
M  "^F   LZ   *JG  "AK@  E[8  )&Z$ ",NB,!A;DR!GZX/@YWMDD7<;52
M'FNS6B5ELF(K8+%J,%NP<S57KWTY4ZZ)/4^MED!,K:5"2JVY0TFNV$)(J_5#
M1ZK_1$FE_T1+H/]$39S_1$V<_T1-G/]$39S_1$V<_T3J=0  TH8  ,.3  "W
MG0  K*0  **K  "8LP  CKL! (7!# "!PAT >\(M W7!.@EOP$41:;]/&&.^
M5QY>O5\C6;QH*%6[<2U1NWLP3;J'-$JZE3='NJ4Y1;JX.D2ZUSE#N/4[0K;_
M/4*S_SY$KO\^1:G_/D6I_SY%J?\^1:G_/D6I_S[@?0  R8T  +N:  "NH@
MHZD  )BQ  ".N0  A,$" 'G)!P!TRQ0 <,PF 6O+-05ERT *8,I+$%O*5!97
MR5T:4LEE'T[(;R-+R'HF1\B&*43(E"Q"R*0N0,BX+S_)UR\_Q_4P/<3_,SO#
M_S4\OO\V/;C_-SVX_S<]N/\W/;C_-SVX_S?1A@  P)4  +*?  "EIP  FJ\
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M$R7Q_Q,E\?\3)?'_$R7Q_Q.MH0  H*D  )*S  "$O   =L8  &G/  !=V
M4=\  $GN! !&_ X 0OT7 #[^(0 [_BH!-_\S C3_.@(P_T(#+?]* RO_4P0H
M_UP%)?]F!2+_<P8@_X,''_^4"!W_I@@<_[P(&__B"1K_^0D:__\)&?__"1G_
M_PD9__\)&?__"1G__PFBIP  D[$  (6[  !VQ@  :=   %O:  !.X   0^4
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M.)=7_S>75_\WEU?_-Y=7_S?_210 _U,. /]<# #_90T _VL/ /IO$P#L<AD
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M26MUU$EK=?)':W7_16QU_T-M<_]!;7+_/VUR_S]M<O\_;7+_/VUR_S__60<
M_V4  .)R  #1?   QX0  ,"* @"YCP( LY(, *R4'0"FDR\$GI$\"YB/2!21
MC%$<BXE:)(:'8BJ!A6DP?()Q-7B!>CIT?X,^<'V.0FQ\FD5I>Z='9GJX2&1[
MT$AD>_!'97O_1&9Z_T-G>/]!:';_/VAV_S]H=O\_:';_/VAV_S__6P0 ]VD
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M0%*/_S]5B_\^5HC_/5>'_SU7A_\]5X?_/5>'_SWY9P  W78  ,F#  "]C0
MLY4  *F;  "@H   EJ<  (^I#P"+JB$!A:DP!'^H/ IXIT<2<Z50&&VC6!YH
MHF D9*%G*5^@<"Y;GGDR5YV$-E.<D3E0G)\[3INP/4R<QSU,F^H\3)G_/$R8
M_SQ-E?\\3Y'_.U"/_SM0C_\[4(__.U"/_SOK;0  TWP  ,.)  "WDP  K)H
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M*CBV_RLXMO\K.+;_*SBV_RO)A0  N9,  *R<  "@H@  E*H  (BQ  !\N
M<;X  &;% P!;RP@ 5\T3 %;.(P!3SC(!4,X^ TW/2 5)SU((1L];"T//90Y
MSV\0/L][$SO/B14YSYD7-\^K&#;0PQ@VS^@8-,W[&S++_QTQRO\?,,G_(2_(
M_R$OR/\A+\C_(2_(_R&^CP  KYH  **A  "6J0  BK   'VX  !QOP  9L8
M %O, @!0T@< 1]H, $;<& !%W"< 1-TU 4'=0 (_WDL#/=Y5!#K?7P8XWVD'
M-=]V"3/@A LQX)0,+^&F#2[AO XMXN .+=[X#RO=_Q(JW/\4*=K_%BC:_Q8H
MVO\6*-K_%BC:_Q:SF   I:   )FG  "+L   ?K@  ''   !ER   6<X  $[3
M  !$VP0 /^D- #WI%P [ZB, .>HN #;K. $TZT(!,>Q+ B_M50,M[5\#*NYK
M!"CN> 4F[X@&)>^:!R/PK@<B\<@'(O#M!R'L_P<AZ_\((.O_"A_J_PL?ZO\+
M'^K_"Q_J_PNHGP  FZ8  (VO  !_N   <<$  &3*  !8T   3-8  $'=   X
MY   -?8, #/W%  P]QX +O@G "OY,  H^3@!)OI  2/[20$A^U(!'OQ= AS]
M:0(:_7D#&/Z+ Q?_G@,5_[,$%/_3!!3^] 03_/\#$_K_ Q/Y_P,3^?\#$_G_
M Q/Y_P.=I0  CZX  ("X  !RP@  9,L  %;3  !)V@  /M\  #3D   N]
M*_\* "C_$  E_Q< (O\? !__)@ <_RT &?\T !?_/  4_T0!$O]. 1#_60$.
M_V<!#/]W 0O_B@(*_Y\""?^U @C_U0('__0"!___ @?__P('__\"!___ @?_
M_P*1K0  @K@  '/"  !DS   5M4  $C=   [X@  ,.<  "?N   C_P  (/\$
M !S_#  9_Q$ %O\6 !/_&P 1_R$ #O\G  W_+@ *_S8 !_\^  3_2   _U0
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M4"P!_4XW O9+0P3P25 'ZTA="N=&:0WC1700X$1^$]U#AQ7;0I 7V$&8&-5
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M.GMBSSMZ8NXY>F/_.'IC_S9Y8_\T>6/_,GEB_S%Y8O\Q>6+_,7EB_S'_3P<
M_UD  .9D  #7;   S',  ,1W @"_>00 N7H. +)\( "L?#$#I7H^"9]X2A":
M=5,7E7-<'9%Q9"*-;VPGB6UT*X5L?"^":H4R?VF/-7QHFSAY9Z<Z=F:V.W1F
MS#QS9^L[<V?_.'-H_S9S:/\U<V?_,W-F_S)S9O\R<V;_,G-F_S+_400 _UP
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M=@  OWT  +>"  "PA0  J(<& **)%P"<BBD!EHDW!I"'0PR+A4T3A8)5&8"
M71]\?V4D>'UM*71[=2UP>GXQ;7F(-&EWE#=F=J$Z8W:P.V%VQ#QA=N4[87;[
M.6)V_S=C=?\U8W/_-&1R_S-D<O\S9'+_,V1R_S/_6   YF8  -)Q  #%>@
MNX$  +*'  "KB@  HHP" )R.% "7CR8!D8XT!8N,0 N%BDH1@(A3&'N&6QUV
MA6,B<H-J)VZ"<BMJ@'LO9W^&,V-^D39@?9XY77RN.EM\P3M;?.,Z6WSZ.%Q[
M_S==>_\U7GG_-%]W_S-?=_\S7W?_,U]W_S/^7   X6H  ,UU  # ?@  MH8
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M+TN-_R]+C?\O2XW_+TN-_R_B:P  RGD  +R%  "QCP  II0  )N9  "1G0
MAJ(  'JF P!VIQ, <Z@D &ZH,@-JJ#T&9:='"V&F4 ]=I5@46:1@&%6C:!Q2
MHW$?3J)\(TNAB"9(H98H1:"F*D2ANBM#H=HJ0Y_U*T*=_RM"G/\L0IO_+$27
M_RM$E_\K1)?_*T27_RO7<@  PX   +:,  "JE   GYD  )2>  ")HP  ?J@
M '"N  !JL X :+$= &6Q+ %AL3@#7;!#!EFP3 I5KU0.4J]=$4ZN915+KF\8
M2*UY&T6MAAY"K)4@/ZRE(CZMN2,]K=@B/:OU(SRI_R4[I_\F.Z;_)CND_R8[
MI/\F.Z3_)CND_R;,>@  NX@  *Z2  "BF0  EYX  (RD  " J@  =:\  &FT
M  !>N08 6[H4 %F[) !6NS$!4[L] U"[1P5-NU '2KI9"D>Z8@U$NFP00;IW
M$SZYA!4\N9,7.;FC&#BYMQDWNM89-[CT&C6V_QPTM/\>,[/_'S.R_R SLO\@
M,[+_(#.R_R#!@P  M)$  *:8  ";G@  CZ4  (*K  !VL0  :[8  %^\  !4
MP0, 3,4- $O%&0!)QB@ 2,8U $7'0 %#QTH#0,=3!#['708[QV<(.<=S"C?'
M@ PTQY -,L>A#C'(M0\PR-,/,,;T$"[$_Q,MPO\5+,'_%BO _Q<KP/\7*\#_
M%RO _Q>XC0  JI<  )Z>  "1I0  A*P  'BR  !KN0  8+\  %3#  !*R (
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M"0 C\!$ (?$9 !_Q(@ =\BL &_,T !GT/@ 7]$@ %?52 !/V7P 2]FX!$?>
M 1#XE $/^:H!#OG& 0[Y[0$-]O\!#?3_ 0WS_P$-\_\!#?/_ 0WS_P&9HP
MBZP  'RU  !MO@  7\8  %+-  !%T@  .=@  "_>   FX@  '^H  !S[!@ 9
M_PX %_\3 !3_&@ 2_R$ $/\H  [_,  -_SD "_]#  G_3@ &_UP !/]L  +_
M@  !_Y8  /^M  #_R@  __   /__  #__P  __\  /__  #__P"-JP  ?;4
M &Z_  !@R   4M   $/7   WW0  *^(  "+F   9Z@  %?D  !+_   0_P@
M#O\.  S_$0 )_Q8 !O\<  /_(@  _RH  /\S  #_/0  _TD  /]7  #_:0
M_WX  /^5  #_K   _\<  /_H  #_^@  __H  /_Z  #_^@" M0  <+\  &')
M  !2TP  0]L  #7A   IY@  'NH  !7N   0^   #O\   O_   (_P  !/\&
M  #_"@  _PX  /\1  #_%0  _QL  /\C  #_*P  _S8  /]#  #_4P  _V4
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M248"U4=3!-!&7PC,16D+R41S#<9#?!##0H02P4*,$[]!E16]09T6NT"F%[I
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M*)%0T"B.4.PHC5'^)XM1_R:+4?\EBE+_)(E2_R.(4O\CB%+_(XA2_R/_10<
M_TL  /!5  #?6P  TV   ,QA P#(808 PV$1 +MD) "U9#0"KV-"!:IA3@JE
M7U</H5U@%)Y<:!B;6W ;F%EX'I58@2&35XHDD%:3)HY5GBB+5:DJB52W*X=4
MRRN%5>DKA%7\*H-6_RB#5O\G@E;_)8%6_R2!5O\D@5;_)(%6_R3_1P, _T\
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M+F]C_RQO8_\J;V/_*&]B_R=O8O\G;V+_)V]B_R?_30  ZU@  -EC  #):@
MOW   +=S  "P=   J70' *-V%P">=R@!F'8W!)-U0@B.<TP.B7%5$X5P71B!
M;F4<?FUL'WML="-X:GTF=&F'*7%HDBQN9YXN;&>L,&IGOC%I9]PP:6?U+FEG
M_RQI9_\J:F?_*6IF_RAJ9O\G:F;_)VIF_R?_4   YUL  --F  #%;@  NW,
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M*5IT_RA:=/\G6G3_)UIT_R?M60  UV8  ,5Q  "Y>@  KX   *:$  "=A@
MD8<  (J)# "&BAL @HLK 7V*. 1XB4((=(A,#6^'5!)LA5L6:(1C&F2#:QYA
M@G0A78%])%J B2A7?Y8J57ZD+%)^MBU1?LXM47WO+%)]_RM2?/\I4WO_*%1Z
M_R=4>O\G5'K_)U1Z_R?H7@  T&L  ,!V  "T?@  JX4  *&)  "7BP  B8T
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M(3^4_R'-<   O'T  +"(  "DCP  F90  (Z8  "#G0  =Z   &FD  !@IP@
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M!RO J@@JP<((*L#G!RF]_0HHO/\,)[K_#2>Y_PXGN?\.)[G_#B>Y_PZRC
MI90  )F:  "-H0  ?Z<  '*M  !FLP  6K@  $^[  !$OP  .L0" ##)"  N
MRA$ +<H= "S+*0 KRS4 *\Q  "K-2@ HS58 )\YA ";.;P$DSG\!(\^1 B'/
MI0(@T+T"(,_D A_-^@,>R_\$'LK_!1W)_P8=R?\&'<G_!AW)_P:HE   G)H
M )"A  ""J   =*\  &>V  !;O   3L   $/#   YQP  +\P  "?0!  ?U@H
M&]H0 !O;&@ :VR8 &MPQ !G=/  8W4@ &-Y5 !??8@ 6X'( %>"% !3AF@ 3
MXK$ $N// !+@]  2WO\!$=W_ 1';_P(1V_\"$=O_ A';_P*>F@  DJ$  (2I
M  !VL0  :+@  %N_  !.Q   0L@  #?,   MT   )-4  !S;   5WP4 %.D.
M !+J%  1ZQT $.LF  [L,  .[3H #>Y&  ON4P *[V( "?!T  CQB0 '\J
M!?*Z  3QY  "\?T  N__  /M_P #[?\  ^W_  /M_P"5H0  AJD  'BR  !I
MN@  6\(  $W(  ! S   --$  "K6   AVP  &>   !+D   /\ $ #?D*  OZ
M#P )^Q4 !_L<  3\)  !_"P  /PW  #\0@  _%   /QA  #]=0  _(P  /RD
M  #\P0  _.L  /S_  #]_P  _?\  /W_  #]_P")J0  >;(  &J[  !<Q
M3LP  #_1   RUP  )]T  !WA   5Y0  #N@   KQ   (_0  !?\#  '_"0
M_PX  /\2  #_%P  _Q\  /\G  #_,0  _SX  /]-  #_7P  _W4  /^-  #_
MI@  _\(  /_G  #__   __\  /__  #__P!\LP  ;+P  %W&  !.SP  /]8
M #'=   EX@  &N8  !'J   ,[@  !?(   #_    _P   /\   #_    _P4
M /\*  #_#@  _Q(  /\8  #_(0  _RL  /\Y  #_2@  _UT  /]S  #_C
M_Z0  /^Y  #_U   _]X  /_>  #_W@#_&"P _QDI /\9* #_%2L _Q P /\+
M. '_ T0!_P!1 ?\ 7@'_ &P!_P!X ?\ @@'_ (P!_P"4 ?\ G #_ *( _P"H
M /\ KP#_ +8 _P"^ /\ R #_ -< _P#G /\ \P#_ /T _P#_ /\ _P#_ /\
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M$:XZV1&J.^\2ISO_$Z4[_Q2D._\3HSO_$Z([_Q.B._\2HCO_$J([_Q+_. H
M_SP  /]!  #U10  YD8" .%%!P#C0@T U4,9 ,Q%+ #&1SP!P4=) KQ&502Y
M15\&M41H";-#<0NP0WD-KD*!#ZQ"B1"J09$2J$&:$Z= I!2E0*\5HT"\%J%
MT!:>0>H7G$'\%YI!_Q>80?\7F$'_%I=!_Q670?\5ET'_%9=!_Q7_.P8 _S\
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M('U1_Q]]4?\=?5'_''U1_QM]4?\:?5'_&GU1_QK_0@  \$H  -]4  #.6@
MQ%X  +Q?  "V7@  L5P+ *M>&@"E8"L H& Z IQ?10677E )E%Q8#)!;8!"-
M6F@3BUEP%HA8=QB%5X ;@U:)'8!6E!]^59\A>U6M(GE4O2-X5=<C=U7R(G96
M_R!V5O\?=E;_'796_QQV5O\;=E;_&W96_QO_10  [$X  -I8  #)7@  OV(
M +=D  "Q8P  JV$( *1C%P"?9"@ FF4W I9D0P618TT(CF%5#(I@71"'7V43
MA%YL%H%==!E^7'T<?%N&'GE:D2!W6ITB=%FJ)')9NB5Q6=(E<%KP(V]:_R)O
M6O\@<%K_'G!:_QUP6O\<<%K_''!:_QS_2   YU(  --;  #%8@  NV8  +-H
M  "L:   I68% )]G% "::24 E6DT I!H0 2,9TH(B&93#(1E6Q"!9&(3?F-J
M%GMB<AEX87H<=F"$'G-?CB%P7IHC;EZH)6Q=N"5J7LXF:5[N)&E>_R)J7O\@
M:E[_'VI>_QYJ7O\=:E[_'6I>_QWY2@  XU4  ,]?  #!90  MVH  *]L  "G
M;   GVH! )EK$0"4;2( D&XQ 8MM/02';$<'@VM0"W]J6 ]\:& 3>&=G%G9G
M;QES9G@<<&6!'FUDC"%J8Y@C:&*F)69BMB9D8LPF9&+L)61B_R-D8O\A96+_
M'V5B_QYE8O\=96+_'65B_QWR3   WU@  ,IB  "]:0  LVX  *MP  "B<
MF6X  )-P$ "/<A\ BG(N 89R.P."<44'?7!."WIN5@YV;5X2<VQE%7!K;1AM
M:G4;:FE_'F=IBB%E:)8C8F>D)6!GM"9?9\DF7F?J)5YG_B-?9_\A7V;_'V!F
M_QY@9O\>8&;_'F!F_Q[O3P  VEP  ,9E  "Z;0  L'(  *=U  "==   E',
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M'4]U_QW?7   R&@  +ER  "N>@  I8   )J"  ".@@  @(,  'F% @!TAA$
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M%3V4J!8[E+T6.Y3?%CJ2^!<ZD/\7.H__%SJ._Q<ZCO\7.H[_%SJ._Q?%;@
MMGL  *J%  ">BP  E(\  (B2  ![E   ;I<  &*;  !7G@  4J . %&@&P!/
MH2@ 3:$T $NA/@%)H4<"1Z%0 T2A6 5"H6$'/Z!K"3V@=PLZH(4-.*"4#C:@
MI@\UH+L0-*#=#S2=]Q SG/\2,YK_$C.9_Q,SF?\3,YG_$S.9_Q.]=P  KX,
M *.+  "8D0  C94  (&9  !SG   9Y\  %NB  !/I@  1ZD( $2J$@!#JA\
M0:LK $"K-P _K$$ /:Q* 3NL4P(YK%P#-ZQG!#6L<P4RK($&,*R1!RZLHP@M
MK+@)+*S9""RJ]0HKJ/\+*J;_#"JE_PTJI?\-*J7_#2JE_PVU@   J(L  )R1
M  "1E@  A9P  'B@  !KI0  7Z@  %.L  !(KP  /;(  #:U"P TM14 ,[8A
M #*V+  QMS< ,+=! "^X2P NN%4 ++A@ 2JX;0$IN7L")[F- B6YGP,DN;0#
M([G2 R.W] 0BM?\%(;3_!B&S_P<ALO\'(;+_!R&R_P>MB@  H)$  )67  "(
MG0  >Z,  &ZH  !AK0  5;$  $JT   _MP  -+L  "N^ P DP@P (L(4 "+#
M'P APRH (,0T !_$/P >Q4H '<96 !S&8P ;QW, &L>% !G'F0 8R*X %\C+
M !?&\0$7Q/\!%L/_ A;!_P,6P?\#%L'_ Q;!_P.CD0  F)@  (N>  !]I0
M<*L  &*Q  !6M@  2KD  #Z]   TP   *L0  "+(   9S 0 $] * !'2$0 0
MTAH $-,E  _3,  .U#P #M1(  W55@ -U64 #-9X  S6C0 +V*0 "MB^  G9
MY@ *UOX "]3_  O2_P +TO\!"]+_ 0O2_P&:F   CI\  ("F  !RK0  9+0
M %>Z  !)OP  /<(  #+&   HR0  '\T  !?1   1U@  #-L%  C>"P &WQ$
M!=\:  3@)  "X2X  >(Z  #C1P  Y%8  .1G  #E>P  YI(  .:J  #GR
MY_   .C_  #H_P  Z/\  .C_  #H_P"1GP  @J<  '2O  !EMP  5[X  $G#
M   \QP  ,,L  "7/   <U   %-D   [=   )X0   N4   #I!@  Z0T  .D1
M  #J&   ZR$  .TK  #O-P  \44  /)6  #S:   \WX  /27  #UL   ]M
M /?S  #W_P  ]_\  /?_  #W_P"%IP  =K   &:X  !8P0  2L@  #O,   N
MT0  (]8  !G<   1X   #.,   3G    Z@   /4   #T    ]04  /4+  #V
M#P  ]A0  /@=  #Z)P  _#0  /]#  #_50  _VD  /^!  #_F@  _[(  /_/
M  #_[0  __D  /_Y  #_^0!XL   :+H  %G#  !+RP  .]$  "W8   AW0
M%N(   [F   (Z@   .T   #P    ^    /\   #_    _P   /\   #_!@
M_PP  /\0  #_&   _R(  /\P  #_0   _U,  /]I  #_@0  _YD  /^O  #_
MPP  _]4  /_5  #_U0#_$R@ _Q,E /\1)0#_#2< _P8M /\ -0#_ $$ _P!/
M /\ 7 #_ &D _P!T /\ ?@#_ (@ _P"0 /\ EP#_ )T _P"D /\ J@#_ +
M_P"W /\ P #_ ,P _P#? /\ [ #_ /@ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_%B4 _Q8B /\4(0#_$", _PHH /\ , #_ #T _P!+ /\
M6 #_ &0 _P!P /\ >@#_ (0 _P", /\ DP#_ )H _P"@ /\ I@#_ *T _P"T
M /\ O #^ ,@ _0#9 /L Z0#Z /8 ^0#_ /@ _P#X /\ ^ #_ /@ _P#Y /\
M^0#_ /D _P#_&B( _QH> /\8'0#_$QX _PXB /\*+ #_!SD _P-& /\ 4P#_
M &  _P!K /\ =@#_ '\ _P"( /\ CP#_ )8 _P"= /\ HP#^ *D _ "P /H
MN0#W ,0 ]0#2 /, Y@#R /0 \0#_ /  _P#O /\ [P#_ .\ _P#P /\ \ #_
M /  _P#_'AT _QX9 /\<%P#_%Q@ _Q,> /\1* #_#C0 _PQ! /\*3@#_"%L
M_P=F /\&<0#_!GH _P:# /X&BP#\!I( ^@:9 /@&GP#V!J8 ] :M /(&M0#P
M!<  [07. .L%Y #I!O, Y@C_ .4*_P#D"_\ Y O_ >0+_P'D"_\!Y O_ >0+
M_P'_(1@ _R$3 /\@$0#_&Q( _QP: /\:) #_%B\ _Q,\ /\120#_$%4 _ YA
M /D.:P#V#G4 ] Y^ /(.A@#P#HX [@Z5 .T.FP#K#J( Z@ZJ .@.LP#F#[T
MY0_, .$/XP#=$/, V1'_ =82_P'4$_\!TQ/_ M(3_P+2$_\"TA/_ M(3_P+_
M)1, _R40 /\D#0#_(PX _R,4 /\B'@#_'RD _QPU /D90P#T&$\ [Q=; .P7
M9@#I%W  YA=Y .07@0#B%XD X!>1 -\7F #=%Y\ VQ>G -D8L0#6&+L U!G*
M - :X0',&_,!R1S_ L8<_P+$'/\#PQS_ \,<_P/#'/\#PQS_ \,<_P/_*!
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M#Y0\_P^2//\/DCS_#I$\_PV1//\-D3S_#9$\_PW_-0  _SD  .I!  #=1@
MT$<  ,E&  #&004 P$ 1 +E"(0"S1#( KT5  :M%2P*G154#I$1>!:%$9@>?
M0VX(G4-V"IM"?@N90H8-ET&/#I5!F0^30:01D4&P$I!!P!*.0=D2BT'Q$HE"
M_Q*(0O\1B$+_$(="_Q"'0O\/AT+_#X="_P__.   \ST  .-'  #23   R$X
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M%7!1_Q1Q4/\3<5#_$W%0_Q/U0   Y$L  ,]4  #!6@  MUT  *]>  "G6P
MH5@# )M9$@"66R( DEPQ 8Y</0**7$<$AUM0!H-:6 F!66 ,?EEG#GM8;Q!Y
M5W<3=E: %716BQ=R5989;U6C&FU4LAML5,8;:E7F&VI5^QEJ5?\7:E7_%FI5
M_Q5K5?\4:U7_%&M5_Q3R0P  WT\  ,M8  "]70  LV$  *MB  "B8   FUP
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M%5MA_Q7G30  SUD  +]B  "S:   J6T  )YM  "3:P  B6D  (-K"0!_;14
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M%TMSIAA)<[D92'/5&4ER\QA)<?\72G'_%DIP_Q5+</\42W#_%$MP_Q346@
MP&8  +-O  "H=@  G7D  (]X  "$>   =WD  &]\  !J?0T 9WX9 &1_)@!B
M@#(!7X ] ER 1@-:?TX%5W]5!U1^70E2?64,3WUO#DQ\>1%*?(831WN4%45[
MI!9$>[<60WO2%D-Z\A9#>?\50WC_%$1W_Q1$=O\31';_$T1V_Q/-7P  NVL
M *YT  "D?   EWX  (I]  !_?@  <G\  &:#  !AA @ 7H83 %R'(0!:ARX
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M""Z8[0@NEO\*+93_"BV3_PLMDO\++9+_"RV2_PNV=0  JH$  )Z(  "3C0
MAHX  'B/  !KD@  7Y4  %29  !)G0  0*   #JB#0 XHQ< -Z,B #:D+0 U
MI#< -*1! #.E2P QI50!,*5> 2ZE:@$LI7@"*J6( RBEF@,GI:T$)J7& R:D
MZP0EHO\%):#_!B2?_P8DGO\'))[_!R2>_P>O?@  HX@  )>.  "-DP  ?I4
M '"8  !CFP  5Y\  $RB  !"I@  .*D  "^L P JK@X *:X8 "BO(P GKRT
M)K W "6P00 DL$L ([%6 "*Q8P AL7$ '[&" !ZRE $<LJD!&[+! 1NQYP$;
MK_X"&JW_ AJL_P,:J_\#&JO_ QJK_P.HB   FX\  )&4  "$F@  =I\  &BB
M  !;I0  3ZD  $2M   YL   +[,  ":V   >N04 &+L. !>[%@ 7O"  %KPJ
M !6]-0 4O4  $[Y+ !*^6  2OF< $;]X !"_C  0P*( #L"Z  [ X0 /O?L
M#[S_ !"Z_P$0NO\!$+K_ 1"Z_P&?CP  E)4  (>;  !YH0  :Z<  %ZL  !2
ML0  1;0  #JV   ON0  );P  !V_   5PP  #\8%  O*#0 )RA0 ",H=  ?*
M)P 'RC( !LL^  7+2P $S%H  \QJ  +,?@ !S)0  ,RK  #-R   S.T  ,S_
M  #+_P !RO\  <K_  '*_P"7E@  BIP  'RC  !NJ@  8+   %*V  !%N0
M.;P  "Z_   CPP  &\8  !/*   -S0  "-$   '4"0  U X  -45  #6'@
MV"<  -DQ  #;/@  W$L  -U;  #>;@  WH0  -^;  #?M   WMD  -_W  #?
M_P  W_\  -__  #?_P"-G0  ?Z4  '"L  !ALP  4[H  $6_   XP@  +,8
M "')   8S0  $-$   O5   $V@   -X   #@ 0  X0D  .(.  #D$P  Y1L
M .<D  #I+P  ZSP  .U+  #N70  [G$  .^)  #PH@  \+P  /#C  #O^0
M\/\  /#_  #P_P"!I0  <JT  &.U  !4O0  1L0  #?(   JS   ']   !75
M   .V@  !]X   #B    Y@   .D   #J    [    .X%  #O#   \1   /,7
M  #U(   ^"L  /LY  #]2@  _EX  /]T  #_C0  _Z8  /_   #_X0  __4
M /_U  #_]0!TK@  9;<  %;   !'R   .,T  "K2   =V   $]T   SB   #
MY@   .D   #L    \    /,   #T    ]@   /@   #Z    _0<  /\-  #_
M$@  _QL  /\H  #_-P  _TH  /]>  #_=@  _X\  /^F  #_N@  _]$  /_1
M  #_T0#_#R0 _PXB /\+(0#_ R0 _P I /\ ,@#_ #X _P!, /\ 60#_ &4
M_P!P /\ >@#_ (0 _P", /\ D@#_ )D _P"? /\ I0#_ *L _P"R /\ N@#_
M ,4 _P#3 /\ YP#_ /0 _P#_ /X _P#_ /\ _@#_ /X _P#^ /\ _@#_ /X
M_P#_$2$ _Q > /\-'0#_!Q\ _P C /\ +0#_ #H _P!( /\ 50#_ &$ _P!L
M /\ =@#_ '\ _P"' /\ C@#_ )4 _P"; /\ H0#_ *< _@"N /T M@#\ ,
M^P#- /D X@#X /  ]P#\ /8 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#_
M%1T _Q,: /\0&0#_"QD _P = /\ *0#_ #8 _P!# /\ 4 #_ %P _P!G /\
M<0#_ 'H _@"# /P B@#Z )$ ^0"7 /@ G0#W *, ]0"J /0 L@#R +L \0#(
M .\ W #N .P [0#Z .L _P#J /\ Z@#_ .H _P#J /\ Z@#_ .H _P#_&!D
M_Q85 /\3$P#_#A, _PL: /\') #_ C  _P ^ /\ 2P#_ %< _P!B /P ; #X
M '4 ]0!^ /( A0#Q (P [P"3 .X F0#L *  ZP"F .D K@#G +< Y@## .0
MU #B .D X0#W -\ _P#= /\ W0#_ -T _P#= /\ W0#_ -T _P#_&Q, _QH0
M /\6#@#_$@X _Q(5 /\/'P#_#"L _PDX /\&10#[ U$ ]P)< /("9@#N G
MZ@)X .<"@ #F X< Y .. .(#E0#A YP WP2C -T$JP#;!+0 V 7  -8%T #3
M!N< T CX ,X*_P#,"_\ RPS_ ,L,_P#+"_\ RPO_ ,L+_P#_'Q  _QX+ /\:
M!P#_&0L _Q@1 /\6&0#_$B0 ^A P /,./@#N#4H Z0Q6 .4,80#B#&H W@US
M -L->P#9#8, U@V* -0-D0#2#9D T Z@ ,\.J0#-#K, RPZ_ ,H/T #&$>D
MPA+Y +\3_P"]$_\!O!/_ ;P3_P&\$_\!NQ/_ ;L3_P'_(@P _R$$ /\@  #_
M(04 _Q\, /\<$0#V&!P [!4H .43-@#?$D, V1-/ -,46@#0%60 S19M ,L6
M=0#)%WT QQ>% ,48C #$&)0 PAF< , 9I0"^&:\ O1J[ +L:RP"X&^4!M!SV
M ;(=_P*P'?\"KQW_ JX=_P*N'?\"KAW_ JX=_P+_)@8 _R4  /\F  #[)P
M\24# / A"P#H'!( WAD= -0;+0#-'3P R!]) ,4@50#!(5\ OR)H +PB< "Z
M(W@ N2-_ ;<CAP&U(X\!M"27 ;(DH &Q)*H"KR2V JTEQ@*K)=\"J";S Z4F
M_P.C)O\#HB;_!*$F_P.A)O\#H2;_ Z$F_P/_*0  _R@  /8M  #G,   WR\
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M"H$\_PF!//\(@3S_"($\_PC_,P  [#H  -I#  #*1P  OTD  +='  "Q0@
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M#&5/_PSL00  U$P  ,-4  "V60  K%P  *!:  "75P  D50  (M5# "&5QD
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M$E==I1-57;845%W.%%1=[A-47?\155S_$%5<_PY56_\.5EO_#59;_PW>3
MQU8  +A?  "M9   H&4  )-D  ")8P  ?V$  'EB P!U9!$ <F4> &]F*P!L
M9S<!:F=  F=F20-E9E$$8F58!F!E8 A=9&<*6V1P#%EC>PY68X805&*4$E)B
MHQ-08K033V+,$T]B[1)/8?\13V'_$%!@_PY08/\.4&#_#5!@_PW93P  PUH
M +1C  "I:0  FV@  (]G  "$9P  >64  '-G  !O:0X ;&H; &EK* !G;#0
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M#CUUZ X^<_T-/G+_#3YQ_PP_<?\,/W#_##]P_PS%7@  M6D  *EQ  "<=0
MC70  (!T  !U=   :78  %YY  !8? $ 5'T. %)^&@!1?R8 3W\Q $V .P!,
M@$,!2H!+ DA_5 )&?UP$0W]E!4%_< 8_?GP(/'Z*"3I^F@HY?JP+-W[#"S=]
MY@LW>_P+-WK_"S=Y_PHX>/\*.'C_"CAX_PJ^9   L&\  *5X  "6>0  AWD
M 'MY  !P>@  9'P  %B   !0@P  2X4* $B&% !'AR  18@K $2(-0!#B#X
M08E' 4")3P$^B%@"/(AA SJ(; 0WB'@%-8B'!C.(F <RAZH',(C !S"'Y <P
MA?L(,(/_"#""_P@P@?\(,('_"#"!_PBW:P  JG8  *!_  "0?@  @GX  '9_
M  !J@   7H,  %.'  !*BP  08X" #V0#@ [D!@ .I$C #F1+0 XDC< -Y)
M #:220 TDU( ,Y-< 3&39P$ODW0"+9*# RN2E ,JDJ<#*)*]!"B2X0,GD/H$
M)X[_!2>-_P4GC/\%)XS_!2>,_P6Q=   I7X  )F%  "*A   ?80  &^%  !C
MB   6(L  $V/  !#DP  .I<  #*:!P NFQ  +9L: "R<)  KG"X *ITX "F=
M00 HG4L )YY5 ":>80 EGFX (YY^ 2*>D $@GJ,!'YZY 1Z>W0$>G/@"'IK_
M AZ9_P,>E_\#'I?_ QZ7_P.J?0  GH4  ).+  "%B@  =8L  &B.  !;D0
M4)4  $:9   [G0  ,J   "JC   BI@D 'Z<1 !ZG&@ =J"0 '*@M !NH-P :
MJ4$ &:E, !BI6  7JF8 %JIV !6JB0 4JIX $ZNT !*KTP 2J/4 $Z?_ 1.E
M_P$3I?\!$Z3_ 1.D_P&CA@  EXP  (V1  !]D@  ;94  &"8  !4G   2*
M #ZD   TIP  *JL  "&N   9L0  $K,'  ^U$  .M1< #K4A  VU*P -M38
M#+9!  NV3@ *MEP ";9L  BV?P 'MI0 !K:J  6VQ0 &MNH ![7_  BT_P (
ML_\ ";+_  FR_P":C0  D),  (28  !TG   9:   %>D  !+J   0*P  #6P
M   JLP  (;4  !BX   1NP  #+X"  ; "P "P!$  <$9  #!(@  PBL  ,(V
M  ##0@  PU   ,1?  #$<0  Q(<  ,2=  #$M0  Q-H  ,3V  ##_P  P_\
M ,/_  ##_P"3E   AYH  'B@  !JI@  7*P  $^Q  !!M0  -;<  "FZ   ?
MO0  %L   !##   *Q@   \H   #,!0  S P  ,T1  #.&   SB$  - J  #1
M-0  TT,  -12  #48P  U7@  -6/  #5IP  UL(  -;I  #6_0  UO\  -;_
M  #6_P"*FP  >Z(  &RI  !>L   4+8  $*Z   TO0  *,$  !W$   4QP
M#<L   ;.    T@   -<   #9    V@4  -P+  #=$   WQ4  .$=  #C)P
MY3,  .="  #H5   Z&<  .E^  #IEP  ZJ\  .K.  #K[P  Z_X  .O_  #K
M_P!]HP  ;JL  %^R  !1N@  0L   #3#   GQP  &\L  !+/   +TP   M@
M  #=    X0   .0   #E    YP   .D   #K!P  [0T  .\1  #Q&0  ]"0
M /<Q  #Y00  ^E4  /IJ  #[A   ^YT  /RV  #\T@  _>T  /WT  #]] !Q
MK   8;4  %*]  !$Q   -,D  ";-   :T@  $-@   C=    X0   .4   #H
M    [    .\   #Q    \P   /4   #W    ^0$  /L(  #^#@  _Q4  /\A
M  #_+P  _T$  /]6  #_;0  _X<  /^@  #_M@  _\H  /_4  #_U #_"R
M_P<> /\ '0#_ "  _P E /\ +@#_ #L _P!) /\ 5@#_ &( _P!M /\ =@#_
M '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"M /\ M0#_ +X _P#+ /\
MX0#_ /  _@#] /T _P#] /\ _0#_ /T _P#\ /\ ^0#_ /D _P#_#1T _PL:
M /\$&0#_ !H _P ? /\ *@#_ #< _P!% /\ 40#_ %X _P!H /\ <@#_ 'H
M_P"" /\ B0#_ )  _P"6 /\ G #^ *( _ "I /L L #Y +D ^ #& /8 V0#U
M .L ] #Y /, _P#R /\ \P#_ /, _P#S /\ \P#_ /, _P#_$!D _PX5 /\(
M% #_ !0 _P 9 /\ )0#_ #( _P!  /\ 3 #_ %D _P!C /X ;0#\ '4 ^@!]
M /D A #W (L ]@"1 /0 EP#S )X \@"D /  K #N +0 [0#  .L SP#I .8
MZ #U .8 _P#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#_$A0 _Q 0 /\,#P#_
M Q  _P 5 /\ ( #_ "P _P Z /\ 1P#Z %, ]P!> /0 9P#Q '  [P!X .T
M?P#K (8 Z@", .@ DP#G )D Y0"@ ., IP#A +  WP"Z -T R0#; .  V #P
M -< _@#5 /\ U #_ -, _P#3 /\ TP#_ -, _P#_%1  _Q(, /\."0#_"PP
M_PD2 /\#&@#_ "8 _0 S /0 0 #O $T ZP!8 .@ 80#E &H X@!R .  >@#>
M (  W "' -H C@#8 )4 U "< -( HP#0 *P S@"V ,P Q #* -D R #M ,<
M^P#% /\ Q '_ ,,!_P#$ ?\ Q '_ ,0!_P#_& L _Q4% /\0  #_$ 8 _P\-
M /\,% #\!Q\ \0,K .< .0#B $8 W@%1 -H"6P#5 F0 T@-L ,\#= #-!'L
MRP2" ,H$B0#(!9  Q@68 ,0%H #"!JD P0:T +\&P0"]"-4 NPGL +@+_0"V
M#/\ M0W_ +0-_P"T#?\ M W_ +0-_P#_&P4 _Q@  /\7  #_%@  ^Q,& /H0
M#@#N#!8 XPDB -H), #3"CX S@M* ,H,50#'#5X Q0UG ,(.;P#!#G8 OPY^
M +T/A0"\#XT NA"5 +@0G0"W$*< M1&R +,1P "R$=4 KA/N *L4_@"I%?\
MIQ7_ *<5_P"F%/\!IA3_ :84_P'_'P  _QP  /H>  #K'@  XQP  -\5!0#>
M#@T TPX8 ,L1* #%$S< P!1$ +P63P"Y%UD MQ=A +08:0"S&7$ L1EX *\:
M@ "N&H@ K!N0 *L;F0"I&Z, IQRN *8<O "D'<\ H1[J 9X>_ &<'_\!FQ__
M 9H?_P&:'O\!F1[_ 9D>_P'_(@  _R$  .PG  #@*@  U"D  ,TD  #*' @
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M!7([_P7Q,@  WCT  ,E$  "\2   L$D  *9&  "?00  FST! )4]$ "1/QT
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M"F)+I MA2[0,7TO*#%Y+Z@M>2_X*7DO_"5Y*_PA>2O\'7DK_!UY*_P?C/P
MRTD  +Q1  "P50  H50  )92  "-4   ATP  (%-" !]3Q, >E A '=1+@!T
M4CD <E)" 6]22P%M4E(":U%9 VE1801G46@&95!Q!V-0>PAA4(8*7T^3"UU/
MH0Q;3[(-64_'#5E/Z Q83_T+6$__"5E/_PA93O\'64[_!UE._P??0P  QTT
M +A4  "L60  G5<  )%5  "(5   @5   'M2! !W4Q$ =%0> '%5*P!O5C8
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M#$E=XPQ)7/H*25O_"4I;_PA*6O\(2EK_!TI:_P?.3@  O%@  *Y@  "?80
MD6   (5?  ![7P  <%T  &I?  !E80H 8F(4 &!C(0!>9"T 7&0W %ID0 %8
M9$@!5F10 E1D5P-29%\$4&1G!4YC<09,8WT(26*+"4=BF@I&8JH+1&*_"T1B
MX0M$8?D*1&#_"41@_PA%7_\'15__!T5?_P?(4@  N%P  *MD  ";9   C&,
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M!3%S_P4Q<O\%,G+_!3)R_P6W8P  JFT  )QQ  "+<   ?7   ')P  !G<0
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M 2&,S@$ABO$!((C_ B"&_P(@A?\"(87_ B&%_P*K<@  H7P  (][  " >@
M<WH  &9\  !;?P  4((  $:&   \B@  -(T  "R1   FDPP ))03 ".4'  B
ME28 (94O ""5.  ?ED( 'I9, !V66  <EF0 &I=T !F7A@ 8EYD %Y>N !67
MR0 6E>X %I/_ 1:2_P$6D?\!%I#_ 1:0_P&E>P  F8,  (F!  ![@   ;((
M %^$  !4B   28L  #^0   UE   +9<  "6:   =G@$ %J , !2A$@ 4H1L
M$Z$E !*A+@ 1HC@ $:)# !"B3P /HEP #J-K  VC?0 -HY( #*.G  JBP  +
MHN8 #*#^  V?_P -GO\ #9W_  V=_P">A   DHD  (.(  !SB   98L  %B.
M  !,D@  09<  #>;   NG@  )*(  !RE   5J   #ZL$  JN#  'K1( !JT;
M  6M)  $KBX  JXY  &N10  KE(  *YA  "N<P  KH<  *Z=  "NM   KM4
M *WT  "M_P  K/\  *O_  "K_P"6BP  C)   'N0  !KD@  798  %":  !$
MGP  .:,  "^G   EJP  '*X  !2Q   .M   ";<   &X"0  N X  +D4  "Y
M'   NB4  +HO  "[.@  O$<  +Q6  "\9P  O'L  +R1  "\J0  O,0  +SK
M  "[_@  N_\  +O_  "[_P"0D@  @Y@  '.;  !CGP  5:,  $>H   [K0
M,+$  "6T   ;MP  $KH   R]   %OP   ,,   #$ @  Q0H  ,4.  #&%
MQQL  ,@D  #*+@  S#H  ,U)  #-60  S6P  ,Z#  #.FP  S;4  ,[:  #.
M]@  S?\  ,W_  #-_P"&F0  =Z   &FF  !:K   3+(  #ZV   PN0  )+P
M !F_   1P@  "L4   +)    S    -    #1    T@$  -,(  #5#0  UQ$
M -H8  #<(0  WRP  .$Z  #B2@  XUT  .1R  #DBP  Y:4  .7   #EY@
MY?@  .7_  #E_P!ZH0  :ZD  %RO  !-M@  /[P  #"_   CPP  %\<   _*
M   'S@   -$   #6    W    -\   #@    X@   .0   #F P  Z D  .D.
M  #L%0  [AX  /$K  #T.@  ]4T  /9A  #W>0  ^),  /BM  #YQ@  ^>0
M /GS  #Y\P!MJ@  7K(  $^Z  ! P0  ,<4  "+)   6S@  #=(   38
MW0   .$   #D    Z    .L   #M    [P   /$   #S    ]@   /@#  #Z
M"P  _1$  /\;  #_*0  _SL  /]/  #_9@  _W\  /^9  #_KP  _\,  /_6
M  #_U@#_!!P _P 9 /\ &0#_ !P _P B /\ *P#_ #@ _P!& /\ 4P#_ %X
M_P!I /\ <@#_ 'H _P"" /\ B0#_ (\ _P"5 /\ FP#_ *$ _P"H /\ KP#_
M +D _P#% /\ V0#^ .P _0#[ /L _P#[ /\ ^P#_ /H _P#T /\ \ #_ /
M_P#_!Q@ _P$5 /\ % #_ !8 _P ; /\ )@#_ #0 _P!" /\ 3@#_ %H _P!D
M /\ ;0#_ '4 _P!] /\ A #_ (H _0"0 /P E@#Z )T ^0"C /@ JP#W +0
M]0"_ /0 S@#S .8 \0#V /  _P#O /\ [P#_ .X _P#N /\ Z@#_ .H _P#_
M"Q0 _P81 /\ $ #_ !  _P 6 /\ (@#_ "X _P \ /\ 20#_ %0 _@!? /L
M: #Y '  ]P!X /4 ?P#S (4 \@"+ /  D@#O )@ [0"? .P I@#J *X Z "Y
M .< QP#E -X XP#P .( _@#@ /\ X #_ .$ _P#A /\ X0#_ .$ _P#_#1
M_PD- /\!# #_  P _P 2 /\ ' #_ "@ _  V /D 0P#V $X \@!9 .\ 8@#L
M &L Z@!R .@ >0#F (  Y "& .( C #A ), WP": -T H0#; *H V "T -4
MP #2 -, T #J ,X ^@#- /\ S0#_ ,T _P#, /\ S #_ ,P _P#_$ P _PP'
M /\# @#_  @ _P . /\ %@#V "( \  O .P / #I $@ Y0!3 .$ 7 #> &4
MVP!L -< <P#4 'H T@"  -  AP#. (X S "5 ,H G0#( *4 Q@"O ,0 NP#"
M ,L P #E +X ]0"] /\ O #_ +P _P"\ /\ O #_ +P _P#_$04 _PX  /\*
M  #_" $ _P0* /@ $ #I !H XP H -X -0#9 $$ TP!, ,\ 5@#+ %\ R0!F
M ,8 ;@#$ '0 P@![ ,$ @@"_ (D O0"0 +P F "Z *$ N "K +8 MP"T ,<
ML@#@ +$!\@"O O\ K@/_ *T$_P"M!/\ K03_ *T$_P#_%   _Q   /\/  #R
M#0  Z@H  .D#"0#= !( U  ? ,T!+0#( CH Q -% , #4 "]!%D NP5A +D%
M: "W!F\ M09V +0'?0"R!X0 L0B, *\(E0"M"9X JPFH *H*M0"H"L4 I@O?
M *0-] "B#O\ H [_ )\._P"?#O\ GP[_ )\._P#_%P  _Q,  .\8  #D&0
MVQ8  -(0 @#/"0L R @6 ,$*) "\##( MPT^ +0.20"Q#E, KQ!; *T08P"K
M$&H J1%Q *@1> "F$8  I1&( *,2D0"A$IL H!.F )X3LP"<$\, FQ3> )<6
M] "5%O\ E!?_ ),7_P"2%_\ DA;_ )(6_P#_&@  ]!T  .4C  #5)0  RB0
M ,(=  "^%@0 NQ 0 +03'0"O%2L JQ8X *<80P"E&4T HAE6 * :70">&V4
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M G,P_P)S+_\"<R__ G,O_P+P*@  W#4  ,<[  "Z/P  K#P  *(X  "<,P
MF"\  )4N$ "0,!P C#(I (DS-0"&-#\ A#5) ((U40" -5@ ?C5? 7TU9@%[
M-FX!>35V G@U@ )V-8L#=#67 W(VI -P-K0$;S;(!&TVYP1L-OP#:S;_ VLV
M_P)J-O\":C7_ FHU_P+J,   TSH  ,)!  "S0P  I4$  )L^  "5.@  D#8
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M UA$_P/:/0  Q$<  +5.  "D3@  EDP  (M+  "#20  ?44  'A& @!T1Q
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M!4Q3EP9+4Z<'25.Z!TA3U0=(4O,&2%+_!4A1_P1)4?\$25#_ TE0_P/*2
MN5(  *I7  "85@  BE4  ']4  !V4P  ;%$  &=3  !B5 @ 7U82 %U7'@!;
M5RD 65@S %A8/ !6640 55E, 5-94P%165L"3UAD DU8;0-+6'@$25B&!4=7
ME09%5Z4&1%>X!D-8T@9#5_(&0U;_!4-5_P1$5?\$1%3_ T14_P/&3   M58
M *5:  "460  AE@  'M8  !Q5P  9E8  &%8  !=600 65H0 %=;&P!57"8
M4UTP %)=.0!17D$ 3UY) $U>40%,7E@!2EYA DA=:P-&778#1%V#!$)=D@5
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M S%IRP,Q:.T#,6?_ S%F_P,R9?\#,F3_ S)D_P.W6P  J60  )9D  "&8P
M>&,  &UC  !D9   664  %!H  !):P  0VT$ $!N#@ ^;Q@ /6\B #QP*P Z
M<#0 .7$] #AQ10 W<4X -G%7 #1Q80$R<6T!,7%Z 2]QB@(M<9P"*W&O BIQ
MR (J<.L"*F__ BIM_P(J;/\"*VS_ BML_P*Q80  I&D  )!H  " 9P  =&<
M &EG  !?:   56L  $MN  !#<0  /'0  #=V"@ T=Q( ,W@< #)X)0 Q>2X
M,'DW "]Y/P N>4@ +'I2 "MZ7  J>F@ *'IV "9ZAP$E>ID!(WJL 2)ZQ0$B
M>>D!(G?_ 2)V_P$B=?\"(G3_ B-T_P*L:   G6X  (IM  ![;   ;VP  &5L
M  !:;@  4'$  $5U   ]>   -GP  "Y_ @ I@0T )X(4 ":"'@ E@B< )((O
M ".#.  B@T( (8-+ ""$5@ ?A&( 'H1Q !R$@@ ;A)4 &H2I !B$P0 8@^8
M&('] !F _P$9?_\!&7[_ 1E^_P&F<   E7,  (1R  !V<0  :W$  %YS  !4
M=@  27D  #]]   W@0  +X0  ">(   @BP4 &XT. !J-%0 9C1X &(XG !>.
M,  6CCD %8Y# !2/3P 3CUL $H]J !&/>P 0CX\ #X^D  Z/NP -C^  #HWZ
M  ^+_P 0BO\ $(G_ !")_P"A>@  CGD  'YW  !R=P  9'@  %A[  !-?@
M0H(  #F&   OB@  )XX  ""1   8E0  $I@%  Z:#@ -FA0 #)H=  N:)@ +
MFC  "IH[  F:1@ (FE, !IMA  6:<@ $FH8  IJ;  ":L0 !F<\  IGP  *8
M_P $E_\ !9;_  66_P"9@0  AW\  'I^  !K?@  78$  %"%  !%B0  .XT
M #&2   HE@  'YD  !B=   1H   #*,"  :E"@ !I1   *46  "F'P  IB@
M *8R  "G/0  ITH  *=8  "G:   IWP  *>1  "FJ   IL,  *7I  "E_
MI?\  *3_  "D_P"1AP  @H8  '*&  !CB   58P  $F1   ]E@  ,IH  "B>
M   ?H@  %Z8  !"I   +K   !*\   "Q!@  L0P  +(1  "R%P  LQ\  +,H
M  "T,@  M3\  +5-  "U70  M7   +6&  "UG0  M;8  +7<  "T]P  M/\
M +3_  "T_P"+CP  >HX  &J1  !;E0  39H  $"?   UI   *J@  ""L   6
ML   #[0   FW   !N0   +T   "^    O@8  +\,  # $   P18  ,(=  ##
M)P  Q3(  ,9   #&40  QV,  ,=X  #'D0  QZD  ,?'  #'[   Q_X  ,?_
M  #'_P"#EP  <9H  &&>  !2HP  1:D  #BN   LLP  (+<  !:Z   .O0
M!L    ##    QP   ,D   #*    S    ,T#  #."0  T X  -(3  #4&P
MV"4  -LR  #=0@  W50  -YI  #>@0  WIP  -^U  #?V0  W_,  -__  #?
M_P!WGP  :*8  %FM  !*LP  .[@  "V[   ?OP  %,(   S&   #R0   ,P
M  #0    U0   -D   #:    W    -X   #@    X@4  .0+  #G$   ZA@
M .TD  #P,@  \40  /)8  #S;P  ](H  /2D  #TOP  ]-\  /3S  #T] !J
MJ   6Z\  $RW   ]O0  +<$  !_&   3R@  "\X   #2    UP   -P   #@
M    Y0   .<   #I    ZP   .T   #O    \0   /,   #V!P  ^0X  /P6
M  #_(@  _S,  /]'  #_70  _W8  /^1  #_J0  _[X  /_8  #_VP#_ !@
M_P 6 /\ %0#_ !@ _P > /\ )P#_ #8 _P!# /\ 3P#_ %H _P!D /\ ;0#_
M '4 _P!] /\ A #_ (H _P"0 /\ E@#_ )P _P"C /\ JP#_ +0 _@"_ /T
MSP#[ .< ^@#X /D _P#Y /\ ^0#_ /4 _P#N /\ Z0#_ .< _P#_ !0 _P 1
M /\ $0#_ !( _P 7 /\ (P#_ #$ _P ^ /\ 2@#_ %8 _P!@ /\ : #_ '
M_P!X /T ?@#\ (4 ^@"+ /D D0#X )@ ]P"> /4 I@#T *X \@"Y /$ QP#O
M .  [@#R .P _P#L /\ [ #_ .L _P#E /\ X #_ -X _P#_ Q  _P . /\
M#0#_  T _P 3 /\ '@#_ "L _P X /\ 10#^ %  ^P!: /@ 8P#U &L \P!R
M /$ >0#O '\ [@"& .P C #J )( Z0"9 .< H #F *D Y "S .$ P #@ -,
MW@#K -P ^P#; /\ V@#_ -H _P#9 /\ U #_ -( _P#_!PT _P ) /\ !@#_
M  D _P / /\ & #[ "4 ^  R /4 /P#R $H [0!4 .H 70#G &4 Y !L .(
M<P#@ 'H W@"  -P A@#: (T UP"4 -0 FP#2 *0 SP"M ,T N0#+ ,D R0#D
M ,@ ]@#& /\ Q0#_ ,8 _P#' /\ QP#_ ,< _P#_"@8 _P$  /\   #_  0
M_P + /0 $@#O !\ Z@ L .4 . #B $, W0!. -D 5P#4 %\ T0!G ,X ;0#,
M '0 R@!Z ,@ @ #& (< Q0". ,, E@#! )X OP"H +T LP"Z ,( N0#; +<
M\ "U /\ M@#_ +4 _P"U /\ M0#_ +4 _P#_#   _P0  /\   #^    ]@ #
M .@ #0#@ !< V0 D -$ ,0#- #P R@!' ,8 40## %D P !@ +X 9P"\ &X
MN@!T +D >P"W (( M0") +, D0"R )H L "D *X KP"L +T J@#0 *@ ZP"G
M /L I@#_ *8 _P"E /\ I0#_ *4 _P#_#0  _P<  /0)  #J"0  X@0  -H
M!P#/ !$ R  < ,( *0"^ #4 NP!  +< 2@"T %, L@!; +  8@"N &@ K !O
M *L =0"I 'T J "$ *8 C0"D )8 HP"@ *$ JP"? ;D G0/, )P$Z ":!OD
MF0?_ )@(_P"7"/\ EPC_ )<(_P#_$   ]Q   .@4  #<%0  SA$  ,8-  #"
M! L O  4 +<!(0"R RX K@4Z *L&1 "H"$T I@A5 *0)7 "B"F, H IJ )\+
M<0"="W@ G N  )H,B0"9#), EPR> )4-J@"4#;@ D@W, ) .Z@".$/P C!#_
M (L0_P"+$/\ BQ#_ (H0_P#[$P  [1H  -T@  #,(0  OQT  +<7  "S$0
ML@L- *L-&0"G#B8 HP\S )\0/@"=$4< FA%0 )@25P"6$EX E1-E ),3; "2
M$W, D!1\ (\4A0"-%8\ BQ6: (H5IP"(%K4 AA;) (07YP""&/L @!G_ '\9
M_P!_&?\ ?QC_ '\8_P#U&@  Y",  ,\I  # *@  LR8  *HB  "E'   I!4(
M * 4$P";%B$ EQ@M )09. "1&D( CQM+ (T<4@"+'%D B1U@ (@=9P"&'F\
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M 6,O_P'B+@  RC@  +H]  "H/   FCH  )$W  "*,P  AC   (,N"0!_+Q,
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M E9 E0)40*0#4T"V U) SP-10.\#4$#_ E __P)0/_\"43[_ 5$^_P'/.P
MO44  *I'  "91@  BT4  (%$  !Y0@  =#X  &\_  !K0 P 9T$5 &5"(0!C
M0RL 84,U %]$/@!>1$4 745- %M%5 !915P!6$5D 59%;0%417@"4D6% E%$
MDP-/1*,#346T TQ%S -+1>T#2T3_ DM$_P)+0_\"3$+_ DQ"_P+*/P  N4@
M *9*  "520  AT@  'U'  !U10  ;D(  &E#  !E1 D 8D43 %]&'@!=1R@
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M SU2Q@,\4ND"/%'^ CQ0_P(]3_\"/4__ CU._P*^2P  KE,  )I2  ")40
M?%$  '%0  !H4   7DX  %A1  !44@  45,, $Y4% !,51\ 2U8I $E6,@!(
M5CH 1U=" $972@!$5U( 0U=: $%79 % 5VX!/E=[ CQ7BP(Z5YL".%>M C=7
MQ (W5^<"-U;] C=5_P(W5/\"-U/_ CA3_P*Z3P  J58  )55  "%5   >%0
M &U4  !D5   6%0  %)6  !.5P  2ED) $=:$0!&6AL 1%LE $-;+@!"7#8
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M 2-G_P$C9O\!(V;_ 21E_P&L8   F&   (5@  !V7P  :E\  &%@  !78
M36,  $1F   ]:   -FL  #!N!  L< X *G$5 "EQ'@ H<28 )W(O "9R-P E
M<D  )')* ")R5  A<V  ('-M !YS?0 =<Y  &W.C !ISN0 9<]P &G'W !IP
M_P ;;_\ &V[_ 1MM_P&F9@  D64  ']D  !Q9   9F0  %UD  !29@  2&D
M #]L   W;P  ,',  "EV   B>0@ 'WL0 !Y[%P <>Q\ &WLH !I[,  9?#D
M&'Q# !=\3@ 6?%H %7QG !1]>  2?8L $7V? !!]M0 /?=4 $'OU !%Y_P 1
M>/\ $G?_ !)W_P">:P  BFH  'II  !M:0  8FD  %=J  !,;0  0W   #ET
M   Q>   *7L  ")_   ;@@  %(4) !&&$  1AA< $(<? !"'*  .AS$ #H<[
M  V'1@ ,AU, "X=A  J'<0 )AX0 !X>8  :&K@ %ALD !H7L  >$_P (@_\
M"8+_  F"_P"5<0  @V\  '1N  !I;@  7&\  %!R  !&=0  /'D  #)]   J
M@0  (H4  !N)   4C   #X\#  J2"P &DA$ !)(8  *2(  !DBD  )(S  "3
M/@  DTL  )-9  "3:0  DWL  )*0  "2I@  D;\  )'E  "0^@  C_\  (__
M  "/_P"-=P  ?74  '!T  !B=0  57@  $E\   _@   -(0  "N)   BC0
M&I$  !.4   .EP  "9L   &="   G0X  )T3  ">&@  GB(  )\K  "?-0
MH$(  *!0  "@7P  H'$  *"'  "?G0  G[4  )[:  "=]@  G?\  )S_  "<
M_P"&?0  >'P  &E\  !;?P  3H,  $&(   VC   +)$  ".6   :F@  $IX
M  VA   &I    *<   "I P  J0H  *H.  "K$P  K!D  *TB  "N*P  KS<
M *]%  "O5   KV8  *][  "NE   KJL  *[)  "N[P  K?\  *W_  "M_P"!
MA   <80  &&'  !3BP  1I   #F6   NFP  (Z   !JD   2J   #*P   2O
M    L@   +8   "W    MP(  +@(  "Y#0  NA(  +L8  "](0  OBL  , X
M  # 2   P%H  ,%N  #!A@  P:   ,&Z  #!XP  P/D  ,#_  # _P!YC0
M:)   %F4  !+F@  /:   #&E   EJP  &J\  !&S   +N    KL   "^
MP0   ,0   #%    Q@   ,<   #(!0  R@L  ,P/  #.%0  T!\  -,K  #5
M.@  U4P  -9@  #8=P  V)(  -BL  #9R0  V>P  -G[  #8_P!PF0  8)X
M %&D  !#J@  -;   "BV   <N@  $;X   G!    Q0   ,@   #+    SP
M -(   #3    U@   -@   #;    W0   -\'  #B#0  Y1,  .@=  #L*@
M[3P  .U1  #N9P  [X$  .^<  #PMP  \-,  /#L  #P] !GI@  6*T  $FT
M   ZN@  *KX  !S"   0Q@  !\H   #.    T@   -8   #<    X    .,
M  #D    Y@   .@   #K    [0   .\   #R @  ]0H  /@1  #\'   _RP
M /\_  #_50  _VX  /^*  #_I   _[H  /_1  #_X0#_ !0 _P 2 /\ $@#_
M !0 _P 9 /\ )0#_ #( _P _ /\ 2P#_ %8 _P!@ /\ : #_ '  _P!X /\
M?P#_ (4 _P"+ /\ D0#_ )@ _P"> /X I@#] *X _ "Y /H R #Y .( ^ #T
M /< _P#V /\ ]@#_ .\ _P#G /\ X@#_ -X _P#_ !$ _P . /\ #@#_  \
M_P 4 /\ ( #_ "T _P Z /\ 1@#_ %$ _P!; /\ 8P#^ &L _ !S /H >0#Y
M (  ]P"& /8 C #U )( \P"9 /( H #P *D [@"S .T P0#K -8 Z@#N .D
M_@#G /\ YP#_ .4 _P#= /\ U0#_ -$ _P#_  T _P * /\ " #_  D _P 0
M /\ &P#_ "@ _P U /\ 0 #Z $L ]@!5 /, 7@#Q &8 [@!M .P = #K 'H
MZ0"  .< A@#F (T Y "3 .( FP#@ *, W@"M -P N0#: ,H UP#F -0 ^ #2
M /\ T@#_ -( _P#. /\ R0#_ ,8 _P#_  @ _P # /\   #_  , _P - /P
M%@#W "( \P N .\ .@#L $4 Z !/ .0 6 #A &  W@!G -L ;0#9 '0 U0!Z
M -, @ #1 (< SP". ,T E0#+ )X R0"G ,< LP#% ,( PP#< ,$ \0"_ /\
MOP#_ +X _P"^ /\ O0#_ +L _P#_    _P   /\   #_    ]@ ( .X $0#G
M !L X0 G -T ,P#9 #X TP!) ,\ 4@#+ %D R !A ,8 9P#$ &T P@!S ,
M>@"_ (  O0"( +L D "Y )@ N "B +4 K0"S +L L0#. +  Z@"O /P K0#_
M *T _P"N /\ K@#_ *X _P#_ @  _P   /T   #R    Z    -X # #3 !4
MS  A ,@ + #$ #@ P0!" +T 2P"Z %, N !: +8 80"T &< L@!M +  = "O
M 'H K0"" *P B@"J ), J "= *8 J "D +4 H@#& *$ XP"? /8 G@#_ )X
M_P"> /\ G@#_ )X _P#_!@  ^P   .X%  #B!   U0   ,L !@##  \ O0 9
M +@ )0"T #$ L0 [ *X 10"L $T J0!5 *< 6P"E &( I !H *( ;@"A '4
MGP!\ )X A0"< (X F@"8 )@ I "6 +  E0#! ), W "2 /( D0#_ )  _P"0
M /\ CP#_ (\ _P#]"@  \ X  .$1  #.$   P@T  +L'  "W  H L0 2 *P
M'@"H "D I0 T *( /@"? $< G0!/ )L 5@"9 5P EP%C )8":0"4 G  DP-X
M )$#@ "0!(H C@25 (P%H0"*!:X B0:^ (<(V "&"?  A K_ (,+_P"#"_\
M@PO_ (,+_P#V$   YA<  -(<  # &@  LQ8  *P2  "H#0  I@<- *(%%@"=
M!R( F0DN )8*. "4"T$ D@Q* ) ,40".#5@ C U> (L-90")#6P B YT (8.
M?0"%#H< @PZ3 ($/GP" $*T ?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W$O\ =Q+_
M '<2_P#O%P  VR$  ,8D  "T(P  J"   * <  ";%P  F1$$ )@.$ "3$!L
MCQ$G (P2,@")$SP AQ-$ (443 "#%%, @15: ( 58 !^%F@ ?19O 'L6> !Y
M%X, >!>/ '88G !T&*H <QF[ '(9U !O&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:
M_P#G(   T"D  +PK  "K*@  GB@  )8D  "0(   C1P  (P7# "(&!8 A!HB
M ($;+0!^'#< ?!U  'H=2 !Y'D\ =QY5 '8?7 !T'V, <Q]K '$@= !P('\
M;B&+ &PAF !K(:< :2*X &@BSP!F(NX 92/_ &0C_P!D(O\ 9"+_ &0A_P#@
M)@  R"\  +0Q  "C,   EBX  (TK  "'*   A"0  ((@" !^(!( >R(> '@C
M*0!U)#, <R4\ '$E0P!P)DL ;B92 &TG60!K)V  :B=H &DH<0!G*'L 92B(
M &0IE0!B*:0 8"FU %\IRP!>*NP 7"K_ %PI_P!<*?\ 7"G_ %PH_P#8+
MPS4  *TU  "=-   D#,  (8Q  " +0  ?"L  'DH P!V)Q  <BD: ' J)0!M
M*R\ :RPX &HL0 !H+4< 9RU. &4N50!D+ET 8RYE &$O;@!?+W@ 7B^$ %PO
MD@!:+Z$!62^R 5@PR %6,.D!53#^ 54O_P!5+_\ 52[_ %4N_P#0,0  O3H
M *@Y  "7.   BC<  ( V  !Z,@  =3   '(N  !N+@T :R\6 &DP(0!F,2L
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M 44_P0%$/^,!1#[[ 40^_P%$/?\!1#W_ 44\_P'#/@  KT,  )I"  "*0@
M?4$  '-   !K/P  93P  & \  !</@0 63X/ %<_& !50"( 4T$K %)!- !0
M0CP 3T)# $Y"2P!-0U( 2T-: $I#9 !(0VX 1T-[ 45#B0%#0YD!0D.K 4!#
MP $_0^$!/T/Y 3]"_P$_0?\!0$'_ 4! _P&_00  JD4  )9%  "&10  >40
M &]$  !G0@  8#\  %M!  !70@  5$,- %%$%0!/11\ 3D4H $Q&,0!+1CD
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M 2]/_P$P3O\!,$[_ 3!-_P&T30  G4T  (I-  !Z30  ;DT  &1-  !;30
M44T  $M/  !&4   0E(# #]3#0 ]5!4 /%0> #I5)P Y52\ .%4W #=6/P V
M5D< -590 #-660 R5V0 ,%=Q "]7@  M5Y$ *U>C "I7N  I5]8 *5;U "E5
M_P J5/\!*E/_ 2I2_P&O40  F%$  (51  !V4   :E   &!0  !840  3E(
M $=3  !!50  .U@  #A9"@ U6A$ -%H: #-;(@ R6RL ,5LS "]<.P N7$,
M+5Q, "Q<5@ K76  *5UM "A=?  F78X )%VA "-=M0 B7=( (ESS ");_P C
M6O\ (UG_ "18_P"H50  DE0  (!4  !Q5   9E0  %Q4  !450  2E8  $-8
M   \6P  -ET  #!@!0 M80X *V$5 "IB'0 I8B4 *&(N "=C-@ F8SX )6-'
M "-C40 B9%P (61I !]D>0 >9(H '&2> !MDLP 99,X &F/Q !MA_P ;8/\
M'&#_ !Q?_P"A60  C%@  'M8  !M6   8E@  %E8  !060  1UL  #Y>   W
M8   ,6,  "IF   D:0D (6H0 "!J%P ?:B  'FLH !UK,  <:SD &VM" !IL
M3  9;%@ %VQE !9L=  4;(8 $VR: !)LKP 1;,H $6OO !)I_P 3:/\ $VC_
M !-G_P"970  A5T  '5<  !H7   7EP  %5<  !+7@  0F$  #ED   R9P
M*VH  "1M   >< $ %W,+ !5T$0 4=!@ $W0A !)U*0 1=3( $74[ !!U1@ /
M=5( #G5?  UU;@ ,=8$ "W65  IUJ@ (=,, "73G  IS_0 +<?\ #''_  QP
M_P"18@  ?V$  '!A  !D80  6F$  $]B  !%90  /&@  #-L   K;P  )'(
M !UV   7>0  $7P$  U_#  +?Q( "G\9  E_(@ (?RH !G\T  5_/P $?TL
M G]8  %_9P  ?WD  '^.  !_HP  ?KL  'W@  !]]P  ?/\  'O_  ![_P")
M9P  >&<  &MF  !A9@  5&<  $EI   _;0  -7$  "QU   D>0  '7P  !:
M   0@P  #(8"  :)"@ !B0\  (D4  "*&P  BB,  (LL  "+-P  BT,  (M0
M  "+7P  BW$  (N&  "+G   BK,  (G3  "(\P  B/\  (?_  "'_P"";0
M<VP  &AL  !:;0  3F\  $)S   X=P  +GL  "6    =A   %8@  !",   +
MCP  !)(   "4!@  E0P  )40  "6%0  EQP  )@D  "8+@  F3D  )E'  "9
M5@  F6@  )E]  "9E   F*L  )?(  "6[@  EO\  )7_  "5_P![=   ;W,
M &%S  !3=@  1GH  #M_   PA   )H@  !V-   4D@  #I8   F9   !G
M *    "A    H@8  *(,  "D$   I10  *4<  "G)   J"\  *@]  "I3
MJ5X  *ER  "HB0  J*(  *B\  "GY0  IOL  *;_  "E_P!W>P  :'L  %E^
M  !+@@  /H<  #*-   GD@  '9<  !2<   .H   !Z0   "H    JP   *X
M  "O    L    +$$  "S"@  M X  +43  "V&P  N"0  +HQ  "Z0   NE(
M +ME  "[?0  NI<  +JQ  "ZT@  NO,  +G_  "Y_P!O@P  7X8  %&+  !#
MD   -I<  "J=   ?H@  %:<   VL   %L    +0   "W    NP   +X   "_
M    P    ,$   ## 0  Q <  ,4-  #'$0  RAD  ,TD  #.,P  ST0  -!8
M  #0;@  T8@  -"D  #0P0  T>8  -'X  #1_P!GCP  5Y0  $F:   [H0
M+J<  "&M   6LP  #K@   :\    P    ,,   #&    RP   ,T   #.
MT    -$   #4    U@   -H"  #<"0  WP\  .,7  #F)   YS8  .A)  #I
M7P  ZG@  .N4  #KKP  Z\P  .SH  #L]@!?G@  4*0  $*K   TL@  )KD
M !F^   .P@  !,4   #*    S0   -$   #8    VP   -\   #@    X@
M .0   #F    Z0   .L   #N    \04  /4-  #Y%@  _"4  /TY  #^3P
M_V<  /^"  #_G0  _[4  /_+  #_Y #_ !$ _P / /\ #P#_ !$ _P 6 /\
M(@#_ "\ _P [ /\ 1P#_ %( _P!; /\ 9 #_ &P _P!S /\ >@#_ (  _P"&
M /\ C #^ ), _0"9 /L H0#Z *D ^ "T /< P@#V -H ]0#Q /0 _P#S /\
M\P#_ .D _P#@ /\ V #_ -, _P#_  X _P + /\ "@#_  L _P 1 /\ '0#_
M "H _P V /\ 00#_ $P _P!6 /X 7P#[ &8 ^0!M /< = #U 'H ] "  /(
MA@#P (T [P"4 .T FP#L *0 Z@"N .D N@#G ,T Y0#I .0 ^P#C /\ X@#_
M -X _P#1 /\ S #_ ,@ _P#_  D _P $ /\  0#_  0 _P . /\ & #_ "0
M_0 P /L .P#W $8 \P!0 .\ 60#L &  Z@!G .< ;@#F '0 Y !Z .( @ #@
M (< W@". -P E0#: )X U@"H -0 LP#1 ,, SP#? ,X ] #, /\ RP#_ ,L
M_P#% /\ OP#_ +P _P#_  ( _P   /\   #_    _0 + /< $P#Q !X [0 J
M .H -0#G $  X@!* -T 4@#9 %H U0!A -( 9P#0 &T S@!S ,P >@#* (
MR "' ,8 CP#$ )@ P@"A ,  K0"^ +L O #0 +H [0"Y /X N #_ +@ _P"W
M /\ LP#_ +  _P#_    _P   /\   #Y    [@ % .4 #@#> !@ V  C -(
M+@#/ #D RP!# ,< 3 #$ %0 P0!; +\ 80"\ &< NP!M +D <P"W 'H M0"!
M +0 B0"R )( L "; *\ IP"L +0 JP#& *D Y "G /@ I@#_ *8 _P"E /\
MI0#_ *0 _P#_    _P   /4   #J    W@   -  "@#( !( P@ = +X * "[
M #, N0 ] +4 1@"R $T L !5 *T 6P"L &$ J@!G *@ ;0"G ', I0!Z *0
M@@"B (P H "6 )\ H0"= *X FP"^ )D V "7 /$ E@#_ )8 _P"7 /\ EP#_
M )< _P#_    ]0   .<!  #4    R0   ,  ! "X  X LP 6 *\ (0"K "P
MJ  V *8 /P"C $< H0!/ )\ 50"= %L FP!A )H 9P"8 &X EP!U )4 ?0"4
M (8 D@"1 )  G ". *D C "X (L S0") .L B #] (@ _P"( /\ B #_ (@
M_P#Y!@  Z0P  -0.  ###   MPD  + "  "K  D I@ 0 *( &@"> "4 FP P
M )@ .0"6 $$ E !) )( 4 "0 %8 C@!< (T 8@"+ &D B@!P (@ > "' ($
MA0", (0 F "" *4 @ "T 'X R !] >< ? +Y 'L#_P![!/\ >P3_ 'L$_P#Q
M#@  WA4  ,45  "T%   J1$  *$.  ">"@  FP,, )< $P"3 !X D $I (T"
M,P"* SP B 1# (8%2P"%!E$ @P97 (('7@" !V0 ?PAL 'T(= !\"'X >@F)
M '@)E@!W"J, =0JS ',+QP!R#.8 < W[ ' -_P!O#?\ ;PW_ &\-_P#H%@
MT!X  +D=  "I'   G1H  )46  "0$P  CPX# (X*#@")"Q< A@PC (,-+0"
M#38 ?@X^ 'P.1@![#DT >0]3 '@06@!V$&$ =1!H ',0<0!Q$7L <!&' &X1
ME !L$:( :Q*R &D2QP!H$^< 9A/] &44_P!E%/\ 91/_ &43_P#?'@  QB0
M + D  "@(P  E"$  (L?  "&&P  @Q<  ((2" !_$1( ?!(= 'D4* !V%#$
M=!4Z '(600!Q%D@ ;Q=/ &X75@!L%UT :QAD &D8;0!H&7< 9AF# &09D !C
M&I\ 81JO & :Q !>&^0 71S[ %P<_P!<&_\ 7!O_ %P;_P#5)0  O2H  *@I
M  "8*0  C"@  (,E  !](@  >1\  '@; P!V&0\ <AH8 &\<(P!M'2T :QTU
M &D>/0!H'D0 9A]+ &4?4@!C(%D 8B!A &$@:0!?(7, 72%_ %PAC0!:(IP
M62*L %<BP !6(^$ 52/Y %0C_P!4(O\ 5"+_ %0B_P#-*P  MBX  *(N  "2
M+@  A2T  'PK  !V*   <B8  &\C  !M(0P :B(5 &<C'P!E)"D 8R0Q &(E
M.0!@)D$ 7R9( %TF3P!<)U8 6R== %DG9@!8*'  5BA\ %0HB@!3*9D 42FJ
M % IO@!/*=X 3BGW $TI_P!-*?\ 32C_ $XH_P#(,   L#(  )PR  ",,@
M@#$  '8P  !P+0  :RL  &@I  !F* D 8R@1 & I' !>*B4 7"LN %LK-@!9
M+#T 6"Q$ %<M3 !5+5, 5"U; %,M8P!1+FX 4"YZ $XNB !,+Y< 2R^H $DO
MNP!(+]L 2"_V $<O_P!'+O\ 1RW_ $@M_P#$-   JS4  )<U  "'-0  >S4
M '(T  !K,@  9B\  &(N  !?+04 7"X0 %HO& !8,"( 5C K %4Q,P!3,3H
M4C)" %$R20!0,E  3C-8 $TS80!+,VL 2C-W $@TA0!'-)4 132F $,TN0!"
M--8 0C3T $(T_P!",_\ 0C+_ $(R_P# .   IS@  ),X  "#.   =S@  &TW
M  !F-@  83,  %TR  !9,@( 5S,- %0T%0!2-1\ 434H $\V, !.-C@ 3#<_
M $LW1@!*-TX 23A6 $<X7P!&.&D 1#AU $,X@P!!.9, 0#FD #XYN  ].=,
M/#GS #PX_P ]-_\ /3?_ #TV_P"[.P  HCL  (\[  !_.P  <SL  &HZ  !B
M.0  73<  %@V  !4-P  43@+ $\Y$P!-.1P 2SHE $HZ+0!(.S4 1SL\ $8\
M1 !%/$L 1#Q3 $(\7 !!/6< /SUS #X]@0 \/9$ .CVC #D]M@ X/=$ -SWR
M #<\_P X._\ .#O_ #@Z_P"V/0  GCX  (L^  !\/@  ;SX  &8]  !>/0
M6#L  %,Z  !/.P  3#P( $D]$0!'/AD 1C\B $0_*@!#/S( 0D Z $% 00!
M0$D /D%1 #U!6@ \060 .D%P #A!?P W08\ -4*A #1"M  R0LX ,D'P #)
M_P S0/\ ,S__ #0^_P"Q0   FD   (=   !X00  ;$$  &)   !;0   5#\
M $X_  !*0   1D$% $1"#@!"0Q8 0$,? #]$)P ^1"\ /$0W #M%/@ Z148
M.45. #A&6  V1F( -49N #-&?  Q1HT ,$:? "Y&LP M1LP +4;O "U%_P N
M1/\ +D/_ "Y#_P"L0P  ED,  (-#  !T0P  :$,  %]#  !70P  4$,  $A#
M  !$10  048! #Y'#  \2!, .D@< #E))  X22P -DDT #5*.P T2D, ,TI,
M #)*50 P2U\ +TMK "U+>@ L2XL *DN= "A+L0 G2\H )TOM "=*_P H2?\
M*$C_ "E'_P"G1@  D48  ']&  !P1@  948  %M&  !41@  3$<  $1(   _
M2@  .TL  #=,"0 U31  ,TX8 #).(  Q3R@ ,$\P "]/.  N3T  +%!( "M0
M4@ J4%P *%!H "=0=P E4(@ )%"; ")0KP A4,@ (%#K "%/_P B3O\ (DW_
M "--_P"A20  C$D  'I)  !L2@  84H  %A*  !02@  24L  $!,   [3@
M-5   #%2!  M4PT +%04 "I4'  I520 *%4L "=5,P F53P )59% "163@ B
M5ED (59E !]6=  >5H4 '%:8 !M6K  95L4 &5;I !I5_P ;5/\ &U/_ !Q2
M_P";30  ADT  '5-  !H30  74T  %1-  !-3@  14\  #Q1   V4P  ,54
M "M8   F6@D (UL0 ");%P A7!\ (%PG !]<+@ =7#< '%U  !M=2@ :754
M&%UA !==<  578$ %%V5 !-=J@ 17<( $5WG !);_@ 36O\ $UK_ !19_P"4
M40  @%$  '!1  !D40  65$  %%1  !)4@  05,  #A6   R60  *UL  "5>
M   ?80, &F,, !AD$0 79!D %F0A !5D*0 493$ $V4Z !)E1  195  $&5=
M  ]E:P .97T #661  QEI0 *9+P "F3@  MC^0 ,8O\ #6'_  UA_P"-50
M>E4  &M5  !?50  5E4  $Y5  !$5P  /%D  #1<   L7P  )F(  !]E   9
M:   $VL% !!M#0 .;A( #6X:  QN(@ ,;BL "VXT  IN/@ (;DH !VY7  9N
M90 $;G8  FZ*  !MGP  ;;8  &S6  !L\P !:_\  FK_  -J_P"%6@  =%H
M &9:  !<60  4UD  $A:   _70  -F   "YC   F9P  'VH  !EM   3<0
M#G0#  IW"@ %=Q   7<5  !W'   =R0  '@M  !X-P  >$,  'A0  !X7@
M>&\  'B$  !XF0  =[   ';-  !U\   =?\  '3_  !T_P!^7P  ;E\  &)>
M  !97@  35\  $)B   Y90  ,&@  "=L   ?<   &'0  !)W   ->P  "'X
M  * "   @0T  ($1  ""%P  @QX  (,F  "$,   A#L  (1(  "$5P  A&@
M (1\  "$DP  @ZH  (+%  "!ZP  @?X  (#_  " _P!W90  :60  %]C  !2
M9   1V<  #QK   Q;P  *',  "!W   8?   $7\   R#   &AP   (H   ",
M P  C D  (T.  ".$0  CQ<  ) >  "1)P  DC(  )(_  "23@  DE\  ))S
M  "2BP  D:(  )&\  "0Y0  C_P  ([_  "._P!Q:P  9FH  %AK  !+;0
M/W$  #1V   J>P  ((   !>%   0B0  "XT   21    E0   )@   "9
MF@,  )L(  "<#0  GA$  )\6  "@'@  HB@  *(U  "C1   HU4  *-I  "B
M@   HIH  *&S  "@V   H/8  )__  "?_P!N<0  7W(  %%U  !$>0  -WX
M "R$   AB@  %X\  !"4   *F0   9T   "@    I    *<   "H    J0
M *H   "L!@  K0L  *\0  "P%0  LAX  +0I  "T.0  M$H  +5=  "U<P
MM8X  +6H  "TQ@  L^T  ++_  "R_P!F>@  5WT  $F"   \AP  +XX  ".4
M   8F@  $)\   FD    J0   *T   "P    M    +<   "X    N0   +L
M  "\    O@(  , (  #"#@  Q!0  ,<>  #(+   R3T  ,I0  #*9@  RG\
M ,J;  #*N   RMT  ,KU  #*_P!>A@  3XL  $&1   SF   )Y\  !NE   1
MJP  ";    "U    N0   +T   #!    Q@   ,@   #)    RP   ,P   #.
M    T    -(   #4!0  V0P  -T2  #A'@  XBX  .-"  #D5P  Y6\  .:,
M  #FJ   Y<4  .7G  #F]@!6E   2)L  #JB   LJ0  '[   !.V   +O
M ,$   #%    R0   ,T   #2    U@   -H   #;    W@   .    #B
MY    .<   #I    [0   / *  #T$0  ^!\  /DR  #Z2   ^U\  /QZ  #]
MEP  _:\  /W'  #]Y #_  X _P - /\ # #_  X _P 3 /\ '@#_ "H _P V
M /\ 0@#_ $T _P!7 /\ 7P#_ &< _P!N /\ = #_ 'H _P"! /T AP#\ (T
M^@"4 /D G #W *4 ]0"O /0 O #S ,\ \0#L /  _@#O /\ [P#_ ., _P#7
M /\ S@#_ ,H _P#_  H _P & /\ ! #_  @ _P 0 /\ &0#_ "4 _P Q /\
M/0#_ $< _@!1 /L 60#Y &$ ]@!H /0 ;@#S '0 \0!Z .\ @0#N (< [ ".
M .H E@#H )\ Y@"I ., M0#B ,8 X #C -\ ^ #= /\ W0#_ -0 _P#) /\
MP@#_ +X _P#_  , _P   /\   #_  $ _P - /\ % #] "  ^@ K /< -@#S
M $$ [P!+ .P 5 #H %L Y@!B ., : #A &X WP!T -P >@#: ($ V "( -0
MD #2 )@ SP"B ,T K@#+ +P R0#3 ,< \ #& /\ Q #_ ,0 _P"[ /\ M@#_
M +, _P#_    _P   /\   #_    ]P ( /  $ #K !H YP E .0 , #A #L
MW !% -4 30#1 %4 S@!; ,L 8@#) &< QP!M ,4 <P## 'H P0"! +\ B0"]
M )( NP"< +D IP"W +4 M0#( +, Y@"R /L L0#_ +  _P"N /\ J@#_ *<
M_P#_    _P   /X   #Q    Y0 " -P #0#3 !0 S0 ? ,H *@#' #0 Q  ^
M ,  1P"\ $X N@!5 +< 6P"U &$ LP!G +( ;0"P ', K@!Z *P @@"J (L
MJ "5 *< H "E *T HP"^ *$ VP"@ /0 GP#_ )X _P"? /\ G0#_ )L _P#_
M    _    .X   #@    T    ,4 " "^ !  N0 9 +4 (P"S "X L  W *T
M0 "J $@ J !/ *4 50"C %L H@!@ *  9@"? &P G0!S )L >P": (0 F ".
M )8 F@"5 *< DP"W )$ S "0 .P CP#_ (X _P". /\ C@#_ (\ _P#\
M[P   -L   #)    O0   +4  @"N  P J0 3 *4 '0"B "< H  Q )T .@":
M $( F !) )8 3P"4 %4 DP!; )$ 8 "0 &< C@!M (T =0"+ 'X B0") (@
ME0"& *( A0"Q (, Q "! .0 @ #Y '\ _P"  /\ @ #_ (  _P#T @  X D
M ,<(  "W!P  K ,  *8   "@  < FP / )@ %P"5 "$ D@ J (\ ,P"- #P
MBP!# (D 20"' %  A@!5 (0 6P"# &$ @0!H (  < !^ 'D ? "$ 'L D !Y
M )T > "L '8 O@!U -T <P#T ', _P!S /\ <P#_ ', _P#I#0  SQ   +D0
M  "I$   G@X  )<+  "3!@  D  + (P $0") !H A@ D (, +@"! #8 ?P ^
M 'T 1 !\ $L >@!1 'D 5P!W %T =@!D '0 ; !S 74 <0&  &\"C0!N IH
M; .J &L#NP!I!-8 : ;Q &@'_P!G!_\ 9P?_ &<'_P#?%   PQ<  *X7  ">
M%@  DQ4  (L2  "&$   A P" (,&#0"  Q0 ? 4> 'D'* !W"#  =0@X ',)
M0 !R"48 < I, &\*4P!M"UD ; MA &H+:0!I#'( 9PQ^ &8,BP!D#9D 8@VI
M &$-NP!@#=@ 7@[S %T._P!=#O\ 70[_ %T._P#4'   N1T  *0>  "5'0
MB1P  ($:  ![%P  >!,  '@0!@!W#0\ <PX8 ' .(@!N#RL ;! S &H0.P!I
M$$( 9Q%) &813P!D$58 8Q)= &$29@!@$F\ 7A)[ %P3B !;$Y< 61.G %<4
MN@!6%-4 517S %05_P!4%?\ 5!7_ %04_P#*(@  L"(  )TC  "-(P  @2(
M 'DA  !S'@  ;QL  &X7  !M$PP :A04 &<5'@!E%B< 8Q8O &$7-P!@%SX
M7AA% %T82P!<&5( 6AE: %D98@!7&FP 5AIW %0:A0!2&Y0 41ND $\;MP!.
M&]  31SQ $P<_P!,'/\ 31S_ $T;_P##)@  JB<  )8G  "'*   >R<  '(F
M  !L)   :"$  &8>  !D&P@ 8AL1 %\<&@!='2, 6QXK %H>,P!8'SH 5Q]!
M %8@2 !4($\ 4R!7 %$A7P!0(6D 3B%T $TA@@!+(I$ 22*B $@BM !'(LT
M1B/O $4C_P!%(O\ 1B+_ $8A_P"\*@  I"L  )$K  ""+   =BL  &TJ  !F
M*0  8B8  %\D  !=(@0 6R$. %@B%@!6(Q\ 5"0H %,D, !2)3< 4"4^ $\F
M10!.)DP 3"94 $LG7 !))V8 2"=Q $8G?P!%*(\ 0RB@ $$HL@! *,L /RCM
M #\H_P _*/\ 0"?_ $ G_P"W+0  GRX  (PO  !]+P  <2\  &@N  !A+0
M72L  %HH  !7)P  5"<, %(H$P!0*1P 3BDE $TJ+ !+*C0 2BL[ $DK0@!(
M+$D 1BQ1 $4L6@!$+&0 0BUO $ M?0 _+8T /2V> #PML  Z+<@ .BWK #HM
M_P Z+?\ .BS_ #HL_P"R,   FS$  (@R  !Y,@  ;3(  &0R  !=,0  6"\
M %4L  !1+   3RT) $PM$0!*+AD 22\B $<O*@!&,#$ 13 X $,P/P!",4<
M03%/ $ Q5P ^,6$ /3)M #LR>P Y,HL .#*< #8RKP U,L< -#+I #0R_P U
M,?\ -3'_ #4P_P"M,P  EC0  (0U  !U-0  :34  & U  !9-   5#,  % P
M  !,,0  23$& $<R#P!%,Q8 0S,? $(T)P! -"X /S4V #XU/0 ]-40 /#9,
M #HV50 Y-E\ -S9K #8V>  T-XD ,C>: #$WK0 O-\4 +S?H "\V_@ P-?\
M,#7_ # T_P"I-@  DC8  ( W  !R.   9C@  %TW  !6-P  4#8  $LT  !'
M-0  1#8# $$W#0 _.!0 /C@< #PY)  [.2P .CDS #DZ.@ X.D( -CI* #4Z
M4P T.UT ,CMH # [=@ O.X< +3N9 "P[K  J.\, *3OF "HZ_0 J.O\ *SG_
M "PX_P"D.   CCD  'PZ  !N.@  8SH  %HZ  !3.@  33H  $8X  !".@
M/SL  #P\"P Z/!$ .#T9 #<](0 V/BD -#XP #,^-P R/S\ ,3]' # _4  N
M/UH +4!F "M =  I0(0 *$"7 "9 J@ E0,$ )$#E "0__  E/O\ )CW_ "8]
M_P"?.P  BCP  '@]  !J/0  7ST  %8]  !//0  23T  $(]   \/@  .3\
M #9!"  T00\ ,D(6 #%"'@ O0R4 +D,M "U#-  L1#P *T1$ "I$30 H1%@
M)T5C "5%<0 C18( (D65 "!%J  ?1;\ 'D3C !]$^P ?0_\ ($+_ "%!_P":
M/@  A3\  '1   !G0   7$   %-   !,0   1D   #Y!   X0P  -$4  #!&
M P M1PT *T@2 "I(&@ I2"( *$DI "=),0 E23D )$E! "-*2@ B2E4 ($IA
M !]*;P =2G\ &TJ2 !I*I@ 82KT %TK@ !A)^@ 92/\ &D?_ !I'_P"50@
M@$(  '!#  !C0P  6$,  %!#  !)0P  0D0  #M%   U1P  ,$D  "M+   F
M30D )$X0 ").%@ A3QT ($\E !]/+  >3S4 '4\] !Q01P :4%$ &5!= !=0
M:P 64'P %%"/ !-0I  14+H $5#> !%/^  23O\ $TW_ !1-_P"/10  >T8
M &M&  !?1P  54<  $U'  !&1P  /T<  #=*   Q3   *TX  "90   @4P,
M'%4, !I6$0 95A@ %U8@ !96)P 55C  %%8Y !-70@ 25TT $5=9 !!7:  /
M5WD #E>,  U7H  +5[8 "U;4  M6]  ,5?\ #53_  Y3_P"(20  =DH  &=*
M  !;2@  44H  $I*  !#2@  .TP  #-.   L40  )E0  "%6   ;60  %5P'
M !%>#0 07A, $%X:  Y>(@ .7BH #5XS  Q>/0 +7D@ "EY4  A>8@ '7G,
M!5Z&  ->FP "7K$  EW,  )=[@ #7/\ !%O_  5;_P"!3@  <$X  &).  !7
M3@  3DX  $=.   ^3P  -E$  "Y4   G5P  (5H  !M=   58   $&,#  QF
M"P (9Q  !F<5  5G'  $9R0  F<M  %G-P  9T(  &=.  !G7   9VT  &>
M  !FE0  9JP  &7'  !EZP  9/P  &3_  !C_P!Z4@  :E,  %U2  !44@
M2U(  $)3   Y50  ,%@  "A;   A7P  &F(  !1E   0:   #&L!  9N"0
M;PX  &\2  !O&   <!\  ' G  !Q,   <3L  '%(  !Q5@  <68  '%Y  !Q
MCP  <*<  &_!  !OYP  ;OP  &W_  !M_P!S6   95<  %I7  !15@  1E<
M #Q:   R70  *F$  ")D   ::   %&P   YO   *<@  !'8   !X!0  > L
M 'D.  !Z$P  >QD  'P@  !]*0  ?3,  'U   !]3@  ?5X  'UR  !]B
M?*$  'RZ  ![X@  >OH  'G_  !X_P!M70  8%P  %=<  !+70  0%\  #5C
M   K9P  (VL  !IO   3<P  #G<   A[   "?@   ((   "# 0  A 8  (4+
M  "&#P  B!,  (D9  "*(0  BRL  (LW  ",1@  BU8  (MI  "+@   BYD
M (JS  ")V   B/<  (C_  "'_P!H8P  7F(  %%B  !$90  .&D  "YN   D
M<P  &G@  !-]   -@0  !H4   ")    C0   )    "2    D@   )0%  "5
M"@  EPX  )@2  ":&   FR$  )PM  "=/   G4P  )Q?  "<=@  FY$  )NK
M  ":R0  FO   )G_  "8_P!E:0  5VD  $EL   ]<0  ,'8  "5\   ;@0
M$H<   R,   $D0   )4   "9    G0   *    "A    H@   *0   "E 0
MIP<  *D,  "J$0  K1@  *\B  "O,   KT$  *]4  "O:P  KH4  *ZA  "N
MO@  K>8  *S\  "L_P!><0  3W0  $)Y   U?P  *(4  !V,   3D@  #)@
M  .=    H@   *8   "J    K@   +    "Q    LP   +0   "V    N
M +H$  "\"@  OA   ,$7  ##)   PS4  ,1)  #$7@  Q7<  ,63  #%KP
MQ=$  ,/R  ##_P!6?   1X(  #J(   LCP  ()8  !2=   -HP   ZD   "N
M    L@   +<   "[    OP   ,(   #"    Q0   ,8   #(    R@   ,T
M  #/    T@@  -4.  #;&   W2<  -XZ  #?4   X&@  ."$  #AH0  X;T
M .'B  #@] !.BP  0)(  #*9   EH0  &*@   ZO   %M0   +H   "_
MQ    ,@   #.    T0   -0   #5    V    -H   #=    WP   .(   #D
M    YP   .L%  #O#@  ]!D  /4K  #V00  ]U@  /AR  #YD   ^:L  /C$
M  #XX0#_  L _P ( /\ "0#_  P _P 2 /\ &@#_ "8 _P R /\ /@#_ $@
M_P!2 /\ 6@#_ &( _P!I /\ ;P#_ '4 _@![ /P @0#[ (@ ^0"/ /< EP#U
M *  \P"J /( MP#O ,D [0#F .P ^P#K /\ ZP#_ -T _P#. /\ Q@#_ ,(
M_P#_  0 _P   /\   #_  4 _P - /\ %0#_ "$ _P L /\ . #_ $, _0!,
M /D 5 #W %P ] !C /( :0#P &\ [@!U .P >P#J (( Z ") .< D0#D )H
MX@"D .  L #= ,  V@#< -@ ] #5 /\ TP#_ ,L _P#! /\ NP#_ +< _P#_
M    _P   /\   #_    _P * /T $0#Y !L ]@ G /0 ,@#P #P [ !& .@
M3@#D %8 X0!< -X 8P#< &@ V0!N -4 = #2 'L T "" ,T B@#+ ), R "=
M ,8 J #$ +< P0#, ,  ZP"^ /\ O0#_ +T _P"T /\ K@#_ *L _P#_
M_P   /\   #Z    \@ % .H #@#E !8 X  A -T *P#; #8 TP _ ,X 2 #*
M $\ QP!6 ,0 7 #" &$ P !G +X ;0"\ ', N@!Z +@ @@"V (L M "6 +(
MH0"P *\ K@#! *T X "K /< J@#_ *D _P"F /\ H0#_ )\ _P#_    _P
M /<   #H    W    -  "@#* !$ Q0 ; ,( )0"_ "\ O  X +@ 00"U $@
ML@!/ +  50"N %L K !A *H 9@"H &P IP!S *4 >P"C (0 H0". )\ F@"=
M *< FP"X )H T "9 .\ F #_ )< _P"6 /\ E #_ )( _P#_    ]@   .0
M  #2    Q0   +L !0"U  X L  5 *P 'P"J "D J  R *4 .@"B $( H !)
M )X 3P"< %4 F@!: )@ 8 "6 &8 E0!L ), = "2 'T D "' (X DP", *$
MBP"P (H Q0"( .8 AP#[ (8 _P"' /\ AP#_ (8 _P#X    Y0   ,T   "]
M    LP   *H   "C  H GP 1 )L &0"9 ", EP L )4 - "2 #P D !# (X
M20", $\ B@!4 (D 6@"' &  A@!F (0 ;@"# '< @0"! '\ C0!^ )L ? "J
M 'L O !Z -L > #U '@ _P!X /\ > #_ '@ _P#M    T0(  +L"  "L 0
MH@   )L   "6  4 D0 - (T % "+ !T B  F (8 +@"$ #8 @@ ] (  0P!^
M $D ?0!/ 'P 50!Z %L >0!A '< :0!U '$ = !\ '( B !Q )8 ;P"E &X
MM@!M ,X ; #N &L _P!K /\ :P#_ &L _P#?"P  P@P  *X,  ">#   DPL
M (P'  "( @  A0 ) ($ $ !_ !< ?  @ 'H * !X #  =@ X '0 /@!S $0
M<0!* '  4 !N %8 ;0!= &P 9 !J &T : !W &< A !E )( 9 "A &, L@!A
M ,D 8 #I &  _ !@ /\ 8 #_ &  _P#0$   MA$  *(2  "3$@  B!$  ( /
M  !\#0  >0D! '@#"P!U !$ <P : '  (P!N 2L ; $S &H".0!I T  9P-&
M &8$3 !E!%( 8P59 &(%80!@!6H 7P9T %T&@0!<!X\ 6@>? %D'L !7!\8
M5@GG %8*^P!5"O\ 50K_ %8*_P#&%0  K1<  )D8  "*&   ?Q<  '86  !Q
M$P  ;A   &T-!0!M"0T :@D4 &<*'0!E"B8 8PLN &(,-0!@##P 7PQ" %X-
M2 !<#4\ 6PU6 %D-7@!8#F@ 5@YS %4.@ !3#H\ 40Z? % .L0!.#L@ 31#J
M $T0_0!-$/\ 31#_ $T0_P"\&P  I1P  )(=  "#'@  =QT  &\<  !I&@
M9A<  &04  !D$ @ 8@\0 %\0& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^ %8210!4
M$DP 4Q-3 %$36P!0$V4 3A1P $P4?0!+%(P 212< $<5K@!&%<4 117H $46
M_@!%%O\ 117_ $45_P"U'P  GB$  (LB  !\(@  <2(  &@A  !B'P  7QT
M %P:  !;%P( 6A4- %<6% !5%AT 5!<E %(8+0!1&#0 3Q@[ $X90@!-&4@
M2QI0 $H:6 !(&F( 1QIM $4;>@!#&XD 0AN: $ ;K  _&\( /ASE #T<_  ^
M'/\ /AO_ #X;_P"O(P  F"0  (8E  !W)@  ;"8  &,E  !=)   62(  %8?
M  !4'0  4QP+ %$<$@!.'1H 31TB $L>*0!*'C$ 21\W $<?/@!&($4 12!-
M $,@50!"(%\ 0"%J #\A=P ](8< .R&8 #DAJ@ X(L  -R+C #<B^P W(O\
M."'_ #@A_P"J)@  E"<  ($I  !S*0  9RD  %\I  !8*   5"8  %$C  !/
M(@  3"(' $HB$ !((A< 1R,? $4D)@!$)"X 0B0T $$E.P! )4, /R5* #TF
M4P \)EP .B9G #DF=0 W)X0 -2>6 #0GJ  R)[X ,2?A #$G^0 R)O\ ,B;_
M #,E_P"E*0  CRH  'TL  !O+   9"T  %LL  !5*P  4"H  $PH  !*)@
M1R<$ $0G#0!"*!0 02@< #\I(P ^*2L /2DR #PJ.0 [*D  .2I( #@K4  V
M*UH -2ME #,K<@ Q*X( ,"R4 "XLIP L++P *RS> "PL^  L*_\ +2K_ "TJ
M_P"A+   BRT  'DN  !K+P  8"\  %@O  !1+@  3"X  $@L  !%*P  02L
M #\L"P ]+!$ .RT9 #HN(0 Y+B@ -RXO #8O-@ U+SX -"]% #,O3@ Q,%@
M,#!C "XP<  L,(  *C"2 "DPI0 G,+H )C#< "8P]P G+_\ *"__ "@N_P"<
M+@  AS   '8Q  !H,@  73(  %4R  !.,0  2#$  $0P  ! +P  /#   #HQ
M"0 W,1  -C(6 #4R'@ S,R4 ,C,L #$S,P P-#L +S1# "TT3  L-%8 *C5A
M "DU;@ G-7X )360 ",UHP B-;D (379 "$T]@ B-/\ (S/_ ",R_P"8,0
M@S,  '(T  !E-   6C4  %$U  !+-   130  $ T   Z,P  -S0  #0U!@ R
M-@X ,#<3 "\W&P N-R( +3@I "LX,0 J.#@ *3E  "@Y20 F.5, )3E? ",Y
M;  A.GP (#J. !XZH@ <.K< &SG5 !PY]0 =./\ '3C_ !XW_P"3-   ?S8
M &XW  !A-P  5S<  $XW  !(-P  0C<  #PW   U.   ,CD  "\Z @ L.PL
M*CP1 "D\&  H/1\ )CTF "4]+@ D/34 (SX] "(^1@ @/E  'SY< !T_:0 ;
M/WD &C^, !@_H  6/[4 %3[2 !8^\P 7/?\ &#S_ !@\_P".-P  >C@  &HY
M  !>.@  4SH  $LZ  !%.@  /SH  #DZ   R/   +CX  "E    F00@ )$(.
M ")"%  A0AL ($,C !]#*@ >0S( '$,Z !M$0P :1$T &$19 !=$9P 51'<
M$T2* !)$G@ 11+, $$30 !!#\@ 10O\ $D+_ !-!_P").P  =CP  &8]  !:
M/0  4#T  $@]  !"/0  /#T  #8^   O0   *D(  "5$   A1@, '4@, !M)
M$0 921< &$D> !=))@ 622X %4HV !1*0  32DH $4I6 !!*9  /2G0 #DJ'
M  U*FP ,2K  "DK*  M)[  ,2/\ #4?_  U'_P"#/@  <3\  &)   !60
M34   $5    _0   .4$  #)"   K10  )D<  "%)   <2P  %DX' !-0#@ 2
M4!, $5 9 !!0(0 /4"D #E Q  U0.P -448 "U%1  I17P )46\ !U"!  50
ME@ #4*L  E#%  -/Z  #3_L !4[_  9-_P!]0@  :T,  %U$  !21   2D0
M $-#   \1   -44  "Y'   G2@  (4P  !Q/   740  $E0#  Y7"@ +6!
M"E@5  A8'  '6"0 !E@L  58-@ #6$   5A,  !86@  6&D  %A\  !8D0
M5Z<  %?   !6Y0  5OD  %7_  !5_P!V1P  9D<  %E(  !/1P  1T<  $!'
M   X2   ,$H  "E-   B4   '%,  !95   16   #5L"  E>"0 $7PX  %\2
M  !?&   8!\  & G  !@,   8#L  &!'  !@5   8&,  &!V  !@BP  7Z(
M %^[  !?X@  7OD  %W_  !=_P!O2P  84P  %5,  !,2P  1$L  #M,   R
M3@  *U$  "-4   <5P  %EL  !%>   -8   "&,   )F!P  9PP  &</  !H
M$P  :1D  &HA  !J*0  :C0  &I   !J30  :ET  &IO  !JA0  :IT  &FV
M  !HW0  :/<  &?_  !F_P!I40  7%   %)0  !*3P  /U   #53   M5@
M)%D  !U=   68   $&0   QG   &:@   &X   !O P  < @  '$-  !R$
M=!0  '4;  !V(P  =RP  '<X  !V1@  =E8  '9H  !V?@  =I<  '6Q  !T
MTP  <_4  '/_  !R_P!C5@  6%4  %!4  !$50  .5@  "];   F7P  '6,
M !5G   0;   "G    1S    =@   'H   !\    ? ,  'X(  !_#   @1
M ((4  "$&P  A20  (8O  "&/0  ADT  (5?  "%=0  A8\  (2I  "#R0
M@O$  ('_  " _P!?6P  5EH  $E;   ]7@  ,F$  "=F   >:P  %7    YU
M   )>0   7X   "!    A0   (@   "*    BP   (T!  ".!@  D L  )$/
M  "3%   E1L  )<F  "7-   ET0  )=6  "6;   E88  )6B  "4P0  D^H
M )+_  "2_P!=80  3V$  $)D   V:0  *FX  !]T   5>0  #G\   >$
MB0   (X   "2    E@   )@   ":    FP   )T   "?    H0,  *,(  "E
M#0  IQ,  *D<  "J*   JCD  *I+  "J80  J7H  *B9  "HM0  I]T  *?X
M  "F_P!6:   2&P  #IP   N=@  (GT  !>$   .B@  !Y    "6    F@
M )\   "C    IP   *H   "K    K0   *\   "Q    LP   +4   "X!0
MN@P  +T2  # '   P"T  ,!   "_50  OVX  +Z+  "^J   OLD  +WO  "\
M_@!.=   0'D  #)_   EAP  &8X  !"5   'G    *(   "G    K    +
M  "U    N0   +P   "]    OP   ,$   ##    Q@   ,@   #*    S0(
M - +  #5$@  UB$  -<T  #820  V6   -I\  #:F@  V[4  -O9  #;\@!&
M@@  .(D  "N0   =F   $J    JG    K@   +0   "Y    O@   ,(   #(
M    RP   ,X   #/    T@   -0   #6    V@   -T   #?    X@   .8
M  #J"@  [Q,  / E  #R.@  \U$  /1K  #TB0  ]:4  /6_  #UW0#_  8
M_P # /\ !0#_  L _P 0 /\ %P#_ "( _P M /\ .0#_ $0 _P!- /\ 50#_
M %T _P!D /\ :@#_ '  _0!V /L ? #Y (, ]P"* /4 D@#S )L \ "F .X
MLP#K ,0 Z0#D .< ^0#F /\ Y0#_ -, _P#' /\ OP#_ +L _P#_    _P
M /\   #_  ( _P + /\ $@#_ !T _P H /\ ,P#_ #X _ !' /@ 3P#T %<
M\0!= .X 8P#L &D Z@!O .@ =0#F 'P Y "# .( BP#? )4 W "? -D JP#5
M +L T@#4 ,\ \@#- /\ S #_ ,4 _P"Z /\ M #_ +  _P#_    _P   /\
M  #_    _P & /D #P#U !< \P B /$ +0#M #< YP!  .( 20#? %  VP!7
M -< 70#4 &, T0!H ,\ ;@#, '4 R@!\ ,@ A #% (T P@"8 ,  I "] +(
MNP#& +D Z "X /T MP#_ +8 _P"M /\ IP#_ *, _P#_    _P   /\   #U
M    ZP ! .0 # #> !, V0 < -, )@#1 #  S  Z ,@ 0@#$ $H P !0 +T
M5@"[ %P N0!A +< 9P"U &T LP!T +$ ? "O (4 K0"0 *H G "H *H I@"[
M *4 V@"C /4 HP#_ *( _P"> /\ F@#_ )< _P#_    _@   .\   #?
MT    ,< !P#!  \ O  7 +D ( "W "H M0 S +  .P"M $, JP!) *@ 3P"F
M %4 I !: *, 8 "A &8 GP!M )T = "< 'T F@"( )@ E "6 *( E "R )(
MR0"1 .L D0#_ )  _P"0 /\ C #_ (H _P#\    [    -D   #'    N@
M +$  @"K  P IP 2 *0 &P"A "0 H  L )X -0"; #P F !# )8 20"4 $\
MD@!4 )  6@"/ %\ C0!F (L ;0") '8 B "  (8 C "$ )H @@"J ($ O@"
M .  @ #Y '\ _P!_ /\ ?P#_ 'X _P#Q    V    ,(   "S    J    *
M  "9  < E0 . )( %0"0 !X C@ F (T +@"* #8 AP ] (4 0P"$ $D @@!.
M ($ 5 !_ %D ?@!@ 'P 9P!Z &\ >0!Z '< A@!U )0 = "C '( M0!R ,\
M<0#Q '  _P!P /\ < #_ '$ _P#A    Q    +    "B    EP   )$   "+
M  ( A@ + (, $0"! !@ ?P A 'T *0!\ #  >0 W '@ /0!V $, = !) ',
M3@!R %0 < !: &\ 8@!M &H :P!T &H @ !H (X 9P"= &4 KP!E ,8 9 #H
M &0 _0!C /\ 8P#_ &0 _P#/!0  M@<  *,(  "4"   B0<  ((#  !^
M>P & '< #@!U !, <@ ; '$ (P!O "L ;0 R &P . !J #X :0!$ &< 20!F
M $\ 90!6 &, 70!B &4 8 !O %\ >P!= (D 7 "9 %L J@!9 +\ 60#A %@
M^ !8 /\ 6 #_ %D _P#"#   J@T  )<.  ")#@  ?0X  '8-  !Q"@  ;P8
M &T "@!K !  :0 6 &< '@!E "8 8P M &$ ,P!@ #D 7P _ %T 10!< $L
M6P!2 %H 60!8 &( 5P!L %4 > !3 (8 4@"6 %$ IP!0 +L 3P'; $X"] !.
M _\ 3@3_ $X#_P"X$   H1(  (X3  !_$P  =!,  &P2  !G$   90X  &,+
M P!C!@P 8001 %X#&0!<!"$ 6P4H %D&+P!8!C4 5@<[ %4'0@!4!T@ 4PA/
M %$(5@!0"5\ 3@EI $T)=@!+"H0 20J4 $@*I@!'"KH 1@K8 $4+\P!%#/\
M10S_ $4,_P"P%   F18  (<8  !X&0  ;1@  &47  !?%@  7!,  %H1  !:
M#@8 6@P- %<,% !5#!P 4PTD %(-*P!0#3$ 3PXX $X./@!-#D4 2PY- $H.
M50!(#UX 1P]H $4/=0!#$(0 01"5 $ 0I@ ^$+L /1#< #T1]@ ]$?\ /1#_
M #X0_P"I&0  DAL  ($<  !R'0  9QT  %\<  !9&P  51D  %,6  !2$P
M4A$* % 0$ !.$1@ 3!$@ $H2)P!)$BX 2!,T $<3.P!%$T( 1!-) $,44@!!
M%%L /Q1E #X5<@ \%8$ .A62 #@5I  W%;D -178 #46]0 V%O\ -A;_ #<5
M_P"C'   C1X  'L@  !M(0  8B$  %HA  !4'P  4!X  $T;  !,&0  2Q8&
M $D6#@!'%Q4 11<< $08) !"&"H 01@Q $ 9.  _&3\ /1E& #P:3P Z&E@
M.1IC #<;;P U&WX ,QN0 #(;H@ P&[< +QO3 "\<\P O&_\ ,!O_ # ;_P"=
M'P  B"(  '<C  !I)   7B0  %8D  !0(P  2R(  $@@  !&'0  11P" $,<
M# !!'!( /QT9 #X=(0 \'B< .QXN #H?-0 Y'SP -Q]$ #8?3  T(%8 ,R!@
M #$@;0 O('P +2&. "PAH  J(;4 *2'0 "DA\@ I(?\ *B#_ "L@_P"9(@
MA"4  ',F  !E)P  6R<  %,G  !,)@  1R4  $0D  !"(0  /R$  #TA"0 [
M(1  .2(6 #@B'@ V(R4 -2,K #0D,@ S)#D ,B1! # D2@ O)5, +25> "LE
M:P J)7H *"6, "8EGP D);, (R7. ",E\  D)?\ )23_ "4D_P"4)0  @"<
M &\I  !B*@  5RH  $\J  !)*0  1"@  $ G   ])@  .B4  #<F!@ U)@X
M-"<4 #(G&P Q*"( ,"@I "\H,  M*3< +"D_ "LI1P I*5$ *"I< "8J:0 D
M*G@ (RJ* "$JG0 ?*K( 'BK, !XJ[P ?*?\ ("G_ "$H_P"0*   ?"H  &PK
M  !?+   5"P  $PL  !&+   02L  #PK   X*@  -2H  #(K P P*PP +BP1
M "TL&  L+!\ *BTF "DM+0 H+30 )RX\ "8N10 D+D\ (RY: "$O9P ?+W8
M'2^( !POFP :+[  &"_* !@N[0 9+O\ &RW_ !LM_P",*P  >"T  &@N  !;
M+P  42\  $DO  !#+P  /BX  #DN   T+@  ,"X  "TO   K, H *3$0 "<Q
M%0 F,1P )3(C "0R*@ C,C$ (3,Y " S0@ ?,TP '3-7 !LS9  :-'0 &#2&
M !8TF@ 4,ZX $S/( !,S[  4,_\ %3+_ !8Q_P"'+@  ="\  &4Q  !8,0
M3C(  $8R  ! ,0  .S$  #8Q   Q,0  *S,  "@T   E-08 (S8- "$V$@ @
M-QD 'S<@ !XW)P =."X &S@V !HX/P 9.$D %SE5 !4Y8@ 4.7$ $CF$ !$Y
MF  0.:T #CC'  XXZP 0./\ $#?_ !$V_P"#,0  <#(  &$T  !5-   2S0
M $0T   ]-   .#0  #,T   M-0  *#<  "0Y   @.@( '3L+ !L\$  9/14
M&#T< !<](P 6/2L %3XS !0^/  2/D8 $3Y2 ! ^7P //F\ #CZ!  P^E0 +
M/JD "C[!  H]Y  +/?L ##S_  T[_P!]-   :S8  %TW  !1-P  2#<  $$W
M   [-P  -3<  # W   J.0  )3L  " ]   </P  %T$& !1##0 20Q( $4,8
M !%#'P 01"< #T0O  Y$.0 -1$, #$1.  M$6P )1&H !T1\  9$D  $0Z4
M D.]  -#X  #0_8 !$+_  9!_P!X.   9SD  %DZ  !..@  13H  #XZ   X
M.@  ,SH  "T[   G/0  (4   !Q"   71   $T8#  ])"@ -2@\ #$H4  M*
M&P )2B, "$HK  =*-  %2CX !$I)  )*5@  2F4  $IW  !*BP  2J$  $FY
M  !)W0  2?4  $C_  !(_P!R/   8CT  %4^  !*/@  0CT  #P]   V/0
M+SX  "E    C0@  '44  !='   32@  #TP"  M/"0 '4 T  U$1  !1%P
M41X  %$F  !1+P  43D  %%$  !240  4F   %%R  !1AP  49T  %&U  !0
MV   4/4  $__  !/_P!L0   74$  %%!  !'00  0$   #E    R00  *D,
M "1&   >2   %TL  !).   .40  "U,!  96!P  5PP  %@0  !8$P  61D
M %HA  !:*0  6C,  %H_  !:3   6EH  %IL  !:@0  69D  %FQ  !8T0
M6/0  %?_  !7_P!E10  6$4  $U%  !%1   /D0  #5%   M1P  )4H  !Y-
M   84   $E,   Y6   *60  !%P   !>!   7PD  & -  !A$   8A4  &,;
M  !D(P  9"T  &0X  !D10  9%0  &1F  !D>P  8Y,  &.M  !BS   8?(
M &'_  !@_P!?2@  4TH  $I)  !#2   .4D  "],   G3P  'U(  !A5   2
M60  #5T   A@   "8P   &8   !H 0  :04  &H*  !K#0  ;1$  &X6  !P
M'0  <28  '$Q  !P/@  <$X  '!?  !P<P  ;XT  &^G  !NQ@  ;>\  &S_
M  !L_P!:3P  4$X  $A-   ]3@  ,U$  "E4   @6   &%P  !%@   ,9
M!F@   !K    ;P   '(   !T    =0   '<$  !X"0  >@T  'P0  !]%@
M?QX  ( H  " -0  @$4  ']6  !_:P  ?X0  'Z@  !]O@  ?.D  'O_  !Z
M_P!65   3E,  $)4   W5@  +%H  ")?   88P  $6@   MM   #<@   '8
M  !Z    ?0   (    "#    A    (8   "' @  B0<  (L,  "-$   D!8
M )(?  "2+   DCL  ))-  "18@  D7H  (^7  "/M   CN$  (S[  ",_P!5
M60  2%H  #M=   O80  )&8  !EL   1<@  "G<   )]    @@   (8   "+
M    C@   )$   "3    E0   )<   "9    FP   )T$  "?"@  H@\  *06
M  "F(0  IC$  *9#  "E5P  I'   *..  "CJP  H=   *#U  "?_P!.80
M0&0  #-I   G;@  &W4  !%\   +@P   (D   ".    DP   )@   "=
MH0   *0   "E    IP   *D   "K    K0   +    "R    M0@  +@.  "\
M%@  O"4  +PW  "[3   NF0  +F!  "WH@  M\   +?J  "W_ !&:P  .7
M "MW   ??P  $X8   N.   !E0   )L   "A    I@   *L   "P    LP
M +<   "W    N@   +P   "_    P0   ,0   #'    R@   ,T%  #1#@
MU!D  -0K  #40   TU@  --T  #3D@  TK   -+3  #2\@ ^>0  ,8   ".(
M   7D0  #9D   .@    IP   *X   "S    N    +T   #"    Q@   ,H
M  #*    S0   ,\   #2    U0   -D   #=    WP   .,   #G!0  ZP\
M .P?  #M,P  [DL  .]D  #O@@  \)\  /&Y  #QV #_    _P   /\ ! #_
M  D _P . /\ %0#_ !X _P I /\ - #_ #\ _P!( /\ 4 #_ %@ _P!> /\
M90#] &L ^P!Q /D =P#X 'X ]@"% /, C0#Q )< [@"B .L KP#H ,  Y@#@
M ., ^ #B /\ VP#_ ,L _P#! /\ N0#_ +0 _P#_    _P   /\   #_
M_P ) /\ $ #_ !D _P C /\ +@#] #D ^0!" /4 2@#R %( [@!8 .L 7@#I
M &0 Y@!J .0 < #B '8 WP!] -T A@#9 (\ U0": -$ IP#. +8 RP#. /_B
M?1!)0T-?4%)/1DE,10 ,$LD \ #' /\ Q0#_ +L _P"T /\ K0#_ *D _P#_
M    _P   /\   #_    ^P " /8 #0#Q !, [0 > .P * #I #( XP [ -T
M1 #8 $L TP!1 -  6 #- %T RP!C ,D : #& &\ Q !V ,( ?@"_ (< O "2
M +H GP"W *T M0#! +( Y "Q /T KP#_ *P _P"E /\ H #_ )P _P#_
M_P   /L   #N    Y    -P " #3 !  SP 8 ,L (@#) "L Q@ T ,$ /0"]
M $0 N@!+ +< 40"U %8 L@!< +  80"N &< K !N *H =@"H '\ I@"* *,
ME@"A *4 GP"V )T T0"< /, FP#_ )P _P"6 /\ DP#_ )  _P#_    ]@
M .<   #3    Q@   +T  P"X  T LP 3 +$ ' "O "4 K@ N *D -@"F #T
MHP!$ *$ 2@"? $\ G0!5 )L 6@": &  F !F )8 ;@"4 '< D@"! )  C@".
M )P C "M (H PP") .@ B #_ (D _P"' /\ A0#_ (( _P#S    XP   ,P
M  "\    L    *<   "A  @ G@ / )L %@"9 !\ F  G )8 +P"3 #< D0 ]
M (X 0P", $D BP!. (D 5 "' %D A0!@ (0 9P"" &\ @ !Z 'X A@!\ )0
M>@"D 'D N !X -@ =P#W '@ _P!X /\ =P#_ '4 _P#F    RP   +<   "H
M    G@   )8   "/  0 BP , (@ $@"' !D A0 A (0 *0"" #  ?P W 'T
M/0!\ $, >@!( 'D 30!W %, =@!9 '0 80!R &D <0!S &\ ?P!M (T ; "=
M &H KP!I ,@ : #M &D _P!I /\ :0#_ &D _P#2    N    *4   "7
MC0   (8   "!    ?  ( 'D #@!W !0 =@ < '0 (P!S "L <0 Q &\ -P!N
M #T ; !# &L 2 !J $X : !4 &< 6P!E &, 8P!M &( > !@ (< 7P"6 %T
MJ != +X 7 #D %P ^P!< /\ 7 #_ %P _P#"    J@$  )@#  ")!   ?P(
M '@   !T    <  $ &T # !K !$ :0 7 &@ '@!F "4 90 L &, ,@!B #@
M8  ] %\ 0P!> $D 7 !/ %L 5@!: %X 6 !H %< <P!5 ($ 5 "1 %( HP!1
M +< 40#6 %$ ]0!1 /\ 40#_ %( _P"V!P  GPD  (T+  !^#   <PL  &P*
M  !H!P  90,  &, !P!A  T 7P 3 %T &@!< "$ 6P G %D +0!8 #, 5@ Y
M %4 /P!4 $4 4P!+ %$ 4@!0 %H 3P!D $T ;P!, 'T 2@"- $D GP!( +(
M1P#, $< [P!& /\ 1P#_ $< _P"L#   E0X  (,0  !U$   :Q   &,/  !>
M#@  6PP  %H) @!9! H 5P / %4 %0!3 !P 4@ C %$ *0!/ "\ 3@ U $T!
M.P!, 4$ 2@)( $D"3P!( E< 1@-A $4#;0!# WH 0@.+ $ #G  _ Z\ /@/(
M #T$Z@ ]!?P /0;_ #X&_P"D$   CA(  'P3  !N%   9!0  %P3  !6$@
M4Q$  %$.  !0# 4 4 D, $\'$0!-!Q< 2P@? $D()0!("2L 1PDQ $8). !$
M"CX 0PI% $(*30! "U4 /PM? #T+:P \"WD .@R* #@,G  W#*\ -0S' #4,
MZ0 U#?T -0W_ #8,_P"=$P  AQ4  '87  !I&   7A@  %88  !0%P  314
M $H3  !)$0  20X' $@-#@!&#1, 1 T: $,.(0!"#B@ 0 XN #\.-0 ^#SP
M/0]# #L02P Z$%0 .!!> #80:P T$'D ,A"* #$0G  O$+  +1#) "T1[  M
M$?\ +A'_ "\0_P"7%@  @AD  '$;  !D'   61P  %$<  !,&P  1QH  $08
M  !#%0  0A," $$2"P! $1  /A(7 #P2'@ [$R4 .A,K #@3,@ W$SD -A1
M #042  S%%$ ,11< # 5:  N%7< +!6( "H5F@ H%:X )Q7' "85Z@ G%?\
M*!7_ "D5_P"1&@  ?1P  &T>  !@'P  5A\  $X?  !('@  0QT  $ <   ^
M&@  /1@  #L7!P Y%@X .!<4 #87&P U&"( ,Q@H #(8+P Q&38 ,!D] "X9
M1@ M&D\ *QI9 "H:9@ H&G0 )AJ& "0:F0 B&JT (1K% " :Z  A&OX (AK_
M ",:_P"-'0  >1\  &DA  !<(@  4B(  $HB  !$(0  /R$  #P@   Y'@
M.!L  #4<!  T' T ,AP2 # =&  O'1\ +ATE "T>+  K'C, *AX[ "D?0P G
M'TT )A]7 "0?9  B'W( (!^$ !\?EP ='ZL &Q_# !L?YP ;'_T '1__ !X>
M_P")(   =2(  &4C  !9)   3R4  $<E  !!)   /",  #@C   U(@  ,R
M # @ 0 N(0H +"$0 "LA%0 J(AP *"(C "<B*0 F(S  )2,X ",C00 B)$H
M(215 !\D80 =)'  &R2" !DDE0 7)*H %B3! !4DY0 6)/P %R/_ !DC_P"%
M(@  <20  &(F  !6)P  3"<  $0G   ^)P  .28  #4F   Q)0  +B0  "LE
M   I)0< )R8. "4F$P D)QD (R<@ "(G)P A*"X ("@V !XH/@ =*$@ &RE3
M !DI7P 8*6X %BF  !0IE  2*:@ $2G  !$HY  1*/L $RC_ !0G_P" )0
M;B<  %\H  !3*0  22H  $(I   [*0  -BD  #(H   N*   *B@  "8I   D
M*@0 (BL, " K$0 ?+!8 '2P= !PL)  ;+2L &BTS !@M/  7+44 %BY0 !0N
M70 2+FP $2Y^ ! ND@ .+J< #2V]  TMWP -+?D #BS_ ! L_P!\*   :BH
M %LK  !0+   1BP  #\L   Y+   -"L  "\K   K*P  )BP  "(N   ?+P
M'# ) !HQ#@ 9,1, %S$: !8R(0 5,B@ %#(P !,R.0 2,T, $3-. ! S6P .
M,VD #3-Z  PSC@ *,Z( "#*Y  @RV0 (,O0 "C'_  LQ_P!W*P  9BT  %@N
M  !-+P  0R\  #PN   V+@  ,2X  "TN   I+@  (S   !\R   ;,P  %S4%
M !0V#  2-Q$ $3<6 !$W'0 0."0 #S@L  XX-0 -.#\ ##A*  LX5P ).&4
M!SAV  4XB@ #.)\  3>U  $WTP "-_$  S;_  4V_P!S+@  8C   %0Q  !)
M,0  03$  #DQ   T,0  +S   "LP   E,@  (#,  !LV   7.   $SH" ! \
M"0 -/0X ##T3  L]&0 */2$ "3TI  @],0 &/CL !3Y&  ,^4@ !/F$  #YR
M   ^A@  /9P  #VR   ]T   //   #S_   \_P!M,@  73,  % T  !&-
M/C0  #<T   R,P  +3,  "<T   B-@  '3@  !@Z   4/0  $#\"  U!"  )
M0PT !D01  -$%@ "1!T  $0D  !$+0  1#8  $1!  !$3@  1%P  $1M  !$
M@0  1)@  $.O  !#S0  0O   $+_  !"_P!H-@  6#<  $PX  !#.   .S<
M #4V   P-@  *3<  ",Y   >.P  &#T  !-    00@  #44!  A'!P #20P
M $D/  !*$P  2QD  $L@  !+*   2S(  $L]  !,20  3%<  $MH  !+?0
M2Y0  $JL  !*R@  2>\  $G_  !)_P!B.@  5#L  $D[  ! .P  .3H  #,Y
M   L.@  )3P  !\_   900  $T0  !!'   ,20  "$P   )/!0  4 H  % -
M  !1$   4A4  %0;  !4(P  5"P  %0W  !41   5%(  %1C  !4=P  5(\
M %.H  !2Q@  4NT  %'_  !1_P!</P  3S\  $4_   ^/@  -ST  "\^   G
M0   ($,  !E&   320  #TP   M/   &4@   %0   !7 @  6 <  %D+  !:
M#@  6Q$  %T6  !>'0  7R8  %\Q  !>/0  7DP  %Y=  !><0  78D  %VC
M  !<P0  6^L  %K_  !:_P!61   2T,  $-"   \00  ,D(  "E%   A2
M&DL  !-.   .4@  "E4   -9    6P   %X   !@    8@(  &,&  !E"@
M9@X  &@1  !J%P  :Q\  &LI  !K-@  :T4  &M6  !J:@  :H(  &F=  !H
MNP  9^<  &;_  !E_P!12   2$@  $%&   W1P  +$H  "--   ;40  $U4
M  Y9   (70   6$   !D    9P   &H   !L    ;@   '    !R!0  <PD
M '4-  !W$0  >A@  'LA  ![+@  >CT  'I.  !Y8@  >7D  'B6  !WLP
M=>   '3\  !S_P!.30  1TP  #M-   P3P  )E,  !Q8   37   #6$   9F
M    :@   &\   !R    =@   'D   !\    ?0   '\   "!    @P(  (8'
M  "(#   BQ$  (X8  ".)   CC,  (U$  ",6   BV\  (J,  ")J@  B,\
M (;W  "%_P!-40  05,  #15   I6@  'E\  !1E   -:@  !7    !V
M>P   '\   "#    AP   (H   "-    C@   )$   "3    E0   )@   ":
M!0  G0P  * 1  "C&@  HR@  *(Z  "A3@  H&4  *"!  ">H   G<$  )ON
M  ":_P!&60  .5P  "UA   A9P  %FX   YU   %>P   ($   "'    C0
M )(   "6    F@   )T   "?    H0   *0   "F    J    *L   "N
ML0,  +0+  "X$0  N1X  +DO  "X0P  MUH  +5V  "TEP  M+4  +'B  "P
M_  _9   ,6D  "5O   8=P  #W\   :'    C@   )0   ":    H    *4
M  "J    K@   +$   "R    M0   +<   "Z    O    +\   ##    Q@
M ,D   #."@  TA,  -(C  #1-P  T$\  ,YJ  #-B@  RJL  ,O+  #+[P W
M<0  *7@  !V    1B0  ")$   ":    H0   *<   "M    LP   +D   "^
M    P@   ,4   #&    R0   ,P   #.    T@   -4   #:    W@   .$
M  #E    Z@L  .L7  #J*P  ZD,  .I>  #J>@  ZYD  .NU  #KU0#_
M_P   /\  0#_  < _P - /\ $@#_ !L _P E /\ +P#_ #H _P!# /\ 2P#_
M %, _P!: /T 8 #[ &8 ^@!K /@ <@#V '@ ] "  /$ B0#O )( [ "= .D
MJ@#F +P XP#< -\ ]P#= /\ S #_ +X _P"U /\ L #_ *T _P#_    _P
M /\   #_    _P & /\ #0#_ !0 _P ? /\ *0#[ #, ]P ] /, 10#O $T
M[ !3 .@ 60#E %\ XP!E .  :@#= '$ V@!X -8 @ #2 (H SP"5 ,P H@#(
M +( Q0#) ,( [0#  /\ NP#_ +  _P"H /\ I #_ *$ _P#_    _P   /T
M  #Z    ^    /  "0#L !$ Z  9 .< (P#E "T W@ V -8 /@#1 $8 S0!,
M ,H 4@#( %@ Q0!= ,, 8P#  &D O@!P +P > "Y ($ MP"- +0 F@"Q *D
MK@"\ *P X0"J /P J #_ *  _P"9 /\ E@#_ )0 _P#_    ^0   /(   #G
M    VP   -$ ! #*  T QP 4 ,0 '0#" "8 OP O +L -P"W #\ M !% +$
M2P"N %$ K !6 *H 7 "H &$ I@!H *, < "A 'D GP"$ )T D0": *  F "Q
M )8 S "5 /$ E #_ )$ _P"+ /\ B #_ (8 _P#W    [    -X   #)
MO    +0   "O  H JP 0 *D %P"H "  IP H *( , "? #@ G  ^ )H 1 "8
M $H E@!/ )0 50"3 %H D0!A (\ : "- '$ BP![ (D B "' )< A0"H (,
MO@"! .0 @ #_ (  _P!\ /\ >P#_ 'D _P#I    UP   ,$   "Q    I@
M )T   "7  4 E  - )( $@"0 !H CP B (X *@"+ #$ B0 X (< /@"% $,
M@P!( ($ 3@!_ %0 ?@!: 'P 80!Z &D > !S '8 ?P!U (X <P"? '$ LP!P
M -  ;P#V &\ _P!O /\ ;0#_ &P _P#:    OP   *P   ">    DP   (P
M  "%    @@ ) '\ #P!^ !4 ?0 < 'P ) !Z "L =P Q '4 -P!T #T <@!"
M '$ 2 !O $T ;@!3 &P 6@!K &( :0!L &< > !F (8 9 "7 &( J@!A ,(
M8 #K &$ _P!A /\ 80#_ &  _P#%    K0   )L   "-    @P   'P   !W
M    <@ % '  # !N !$ ;  7 &P '@!K "4 :0 L &< ,0!F #< 9  ] &,
M0@!B $@ 8 !. %\ 50!= %T 7 !F %H <@!9 (  5P"0 %8 HP!5 +D 5 #>
M %0 ^P!4 /\ 50#_ %4 _P"V    GP   (T   !_    =0   &X   !I
M9@ ! &, "0!A  X 8  3 %\ &0!> "  70 F %L + !: #( 6  W %< /0!6
M $, 50!) %, 4 !2 %@ 40!A $\ ; !. 'H 3 "* $L G !* +$ 20#. $D
M\P!) /\ 20#_ $H _P"J 0  E 4  (('  !T"   :@@  &,&  !>!   6P
M %D !0!7  P 5@ 0 %0 %0!3 !L 4@ B %$ * !0 "T 3@ S $T . !, #X
M2P!% $H 3 !( %0 1P!= $8 : !$ '4 0P"% $$ F !  *L 0 #% #\ Z@ _
M /\ 0 #_ $  _P"@"   B@L  'D-  !L#0  80T  %H-  !5"P  4@D  % &
M  !/ @@ 3@ - $P $@!+ !< 2@ > $D (P!' "D 1@ O $4 - !$ #H 0@!!
M $$ 2 !  %  /@!: #T 9  \ '( .@"" #D E  X *< -P"^ #8 XP V /D
M-@#_ #< _P"8#0  @PX  '(0  !E$0  6Q$  %,0  !.$   2@X  $@-  !'
M"@, 1P<* $4$#@!$ A, 0@(: $$"( !  R4 /@,K #T$,0 \!#< .P0^ #H%
M10 Y!4X -P57 #8%8@ T!G  ,@:  #$&D@ P!J4 +P6[ "X%W0 N!O4 +0?_
M "X'_P"1$   ?1$  &P3  !?%   510  $X4  !($P  1!(  $$0  ! #@
M0 T& $ *#  ^"1  / D6 #L*'  Y"B( . HH #<++@ V"S4 -0L[ #,+0P R
M#$P , Q6 "\,80 M#&\ *PQ_ "H,D@ H#*4 )PR[ "4,W0 E#?4 )@W_ "<-
M_P"+$@  =Q0  &<6  !;%P  41@  $D7  !#%P  /Q4  #P4   Z$@  .1$!
M #D/"  X#@T -PX2 #4.&  T#A\ ,@XE #$/+  P#S( +Q Z "T00@ L$$L
M*A!5 "@080 F$&\ )!"  ",0DP A$*< 'Q"] !X0X  >$?< 'Q#_ " 0_P"&
M%   <Q<  &,9  !7&@  31L  $4:  ! &@  .QD  #@8   U%@  -!0  #,2
M!  R$@L ,1(0 "\2%0 M$AP +!,B "L3*0 J$S  *!,W "<4/P F%$@ )!13
M "(47P @%6T 'Q5^ !T5D0 ;%:4 &16[ !@5W@ 8%?@ &13_ !H4_P""%P
M;QH  %\<  !3'0  2AT  $(=   \'0  -QP  #0;   Q&@  +QD  "X6   L
M%P@ *Q8. "D7$P H%QD )Q@@ "48)@ D&"T (Q@T "(9/0 @&48 'AE1 !T9
M70 ;&FL &1I\ !<:CP 5&J, %!FZ !(9VP 3&?8 %!G_ !48_P!]&@  :QT
M %P?  !0(   1R   #\@   Y'P  -!\  #$>   M'0  *QP  "D;   G&P4
M)1L, "0<$0 B'!8 (1P= " =(P ?'2H 'ATR !P>.@ ;'D0 &1Y. !<>6P 6
M'FD %!]Z !(>C0 1'J( $!ZX  X>V  /'O4 $!W_ !$=_P!Z'0  9Q\  %DA
M  !-(@  1"(  #PB   V(@  ,B$  "XA   J(   )R   "0?   B( ( (" *
M !XA#P =(10 '"$: !LB(0 9(B< &"(O !<B.  5(T$ %"-, !(C6  1(V<
M$"-X  XCBP -(Y\ #".T  LCT  +(O  #"+_  TA_P!V'P  9"(  %8C  !+
M)   020  #HD   T)   +R,  "LC   H(P  )",  " C   =)   &R4' !DF
M#0 7)A$ %B87 !4G'@ 4)R4 $R<L !(G-0 1*#\ $"A*  XH5@ -*&0 #"AT
M  HHAP )*)L !R>Q  4GS  &)^P !R;^  @F_P!Q(@  8"0  %,F  !()P
M/R<  #<F   Q)@  +28  "DE   E)0  (B4  !TG   9*   %BH$ !0K"P 2
M+!  $2P4 ! L&P 0+"( #BPI  XM,@ -+3L "RU&  HM4@ (+6  !BUP  0M
M@P "+9@  "RN   LR0  +.L  2O\  (K_P!M)0  72<  $\H  !%*0  /"D
M #4I   O*   *R@  "<G   C)P  'R@  !LJ   7+   $RX" ! P"  .,0T
M#3$2  PQ%P +,1X "C$F  @R+@ ',C< !3)"  ,R3@ !,EP  #)L   R?P
M,I4  #&L   QQP  ,.H  ##\   P_P!H*0  6"H  $PK  !!+   .2P  #(K
M   M*P  *2H  "4J   @*P  '"P  !<N   3,   $#("  XT!P *-PP !S<0
M  4W%  #-QL  C<B   W*@  .#,  #@^   X2@  .%@  #AH   X?   -Y(
M #>I   VQ0  -NH  #;]   U_P!C+   5"X  $@O   ^+P  -BX  # N   K
M+0  )RT  "(M   =+P  &#$  !0S   0-0  #C<!  HZ!P &.PL  CP.   ]
M$@  /A<  #X>   ^)@  /B\  #XZ   ^1@  /E0  #YD   ^=P  /H\  #VG
M   ]PP  /.D  #S]   [_P!>,   4#$  $0R   [,@  -#$  "XP   I+P
M)#   !XR   9-   %#8  ! Y   -.P  "CT   5 !0  00H  $(-  !#$
M1!0  $4:  !&(@  1BL  $8U  !&00  1D\  $9?  !&<P  18H  $6D  !$
MP   0^@  $/^  !"_P!8-   2S4  $$U   Y-0  ,C0  "TS   F-   (#4
M !HX   4.@  $#T   U    )0@  !$4   !' P  2 <  $H+  !+#@  3!$
M $X5  !/'   3R4  $\O  !//   3TH  $]:  !.;0  3H4  $V@  !,O
M2^<  $O^  !*_P!3.0  1SD  #XY   W.   ,3<  "DW   A.0  &SP  !4_
M   00@  #$4   =(   "2@   $T   !/    400  %('  !4"P  50X  %<1
M  !9%P  6A\  %DI  !9-@  640  %E4  !89P  6'\  %>:  !6MP  5>,
M %3]  !4_P!./0  0ST  #P\   U.P  +#P  "0^   <00  %40  !!(   +
M2P  !4X   !1    5    %<   !9    6P   %T"  !>!@  8 L  &(.  !D
M$@  9Q@  &<B  !F+@  9CP  &9-  !E8   97<  &23  !CL0  8=T  &#\
M  !?_P!)0@  04$  #H_   P0   )D,  !Y&   52@  $$X   I2   #5@
M %H   !=    8    &,   !E    9P   &D   !K 0  ;04  &\*  !R#@
M=1(  '<;  !V)@  =C4  '5&  !T60  =&\  '.+  !RJ0  <,T  &_W  !N
M_P!&1@  0$4  #5&   J2   ($P  !=1   05@  "5H   %?    8P   &@
M  !K    ;P   '(   !U    =P   'D   ![    ?0   ( #  "#"   A@T
M (D3  "*'0  BBL  (D\  "(3P  AF8  (6!  "$H   @L(  ('P  !__P!&
M2P  .DP  "Y/   C4P  &%@  !!>   )9    &D   !O    =    '@   !\
M    @0   (0   "'    B    (L   ".    D    ),   "6    F0<  )T-
M  "A%   H"$  * Q  ">1   G5L  )QV  "9E@  F;4  );E  "5_@ _4@
M,E4  "9:   ;8   $6<   EM    =    'L   "!    A@   (L   "0
ME    )<   "9    G    )\   "A    I    *<   "J    K0   +$&  "U
M#0  N!8  +<F  "V.0  M5   +1J  "RB0  L*H  *[/  "M]0 W7   *V$
M !YH   3<   "W@   "     AP   (X   "5    F@   )\   "D    J
M *P   "M    L    +,   "U    N    +L   "_    PP   ,<   #+!0
MT0X  -$;  #0+@  ST4  ,U?  #+?@  R9X  ,B^  #%Z0 O:0  (W   !9Y
M   -@0   8L   "3    FP   *(   "H    K@   +0   "X    O0   ,
M  #"    Q0   ,@   #+    S@   -$   #6    VP   -\   #D    Z 8
M .L1  #J(P  ZCH  .E4  #G<@  Y9,  ..S  #CU #_    _P   /\   #_
M  0 _P + /\ $ #_ !< _P A /\ *P#_ #4 _P ^ /\ 1P#_ $X _P!5 /P
M6P#Z &$ ^ !F /8 ;0#T ', \@![ .\ A #M (X Z@"9 .8 IP#C +D WP#5
M -L ]P#6 /\ P #_ +( _P"J /\ I0#_ *( _P#_    _P   /X   #\
M_  # /X "P#_ !$ _P : /T ) #Y "X ]  X /  0 #L $@ Z0!. .8 5 #B
M %H WP!? -P 90#8 &L U !R -  >P#- (4 R@"1 ,< G@## *X P #% +T
MZP"[ /\ L #_ *0 _P"< /\ F #_ )4 _P#_    ^@   /0   #Q    \@
M .H !0#G  X X@ 5 .$ '@#A "@ V  Q -  .0#+ $  R !' ,4 30#" %,
MOP!8 +T 7@"[ &0 N0!K +8 <P"T 'P L0"( *X E0"K *0 J "X *8 W "C
M /L GP#_ )4 _P"/ /\ BP#_ (D _P#Y    [P   .<   #?    SP   ,@
M  #!  H OP 1 +P & "[ "$ N0 J +0 ,@"Q #H K@!  *L 1@"H $P I@!1
M *, 5@"A %P GP!C )T :@"; ', F0!^ )8 C "4 )L D@"M )  QP". /
MC0#_ (8 _P"  /\ ?0#_ 'P _P#M    X    -$   "_    LP   *H   "F
M  4 H@ - *$ $P"@ !L GP C )L *P"8 #( E0 Y ), /P"1 $0 CP!* (X
M3P", %4 B@!; (@ 8P"& &L A !V (( @@"  )( ?@"C 'P N@!Z .$ >0#_
M '< _P!R /\ < #_ &\ _P#=    RP   +8   "G    G0   )0   ".  $
MBP * (D $ "( !4 AP = (< )0"$ "P @@ R '\ . !] #T >P!# 'D 2 !X
M $X =@!4 '4 6P!S &, <0!N &\ >@!M (D ; ": &H K@!I ,P : #V &<
M_P!E /\ 9 #_ &, _P#*    M    *$   "3    B0   ((   ![    >  %
M '8 # !U !$ =  8 ', 'P!R "4 <  L &X ,@!L #< :@ \ &D 0@!H $@
M9@!. &4 50!C %T 8@!F &  <@!> (  70"2 %L I0!: +X 60#I %D _P!9
M /\ 6 #_ %@ _P"Y    H@   )    "#    >0   '$   !M    :0 ! &8
M"0!E  X 9  3 &, &0!C "  80 F &  + !> #$ 7  W %L / !: $( 6 !(
M %< 3P!6 %< 5 !@ %, ; !1 'D 4 "* $\ G@!. +0 30#: $T ^P!- /\
M30#_ $T _P"J    E    ((   !U    :P   &0   !@    70   %H !0!8
M  P 5P 0 %8 %0!6 !L 50 A %, )P!2 "P 40 Q $\ -P!. #T 30!# $P
M2@!* %( 20!; $@ 9@!& ', 10"$ $0 EP!# *P 0@#) $( \0!" /\ 0P#_
M $, _P">    B0   '@#  !J!   800  %H#  !5 0  4@   %   @!.  D
M30 - $P $0!+ !< 2@ < $D (@!( "< 1P M $4 ,@!$ #@ 0P ^ $( 10!!
M $T /P!6 #X 80 ] &X .P!^ #H D0 Y *8 . "_ #@ Z  X /\ .0#_ #D
M_P"5 P  @ <  &\)  !B"@  6 L  %$*  !,"   208  $<#  !&  8 1  +
M $, #P!" !, 00 8 $$ '@ _ ", /@ I #T +@ [ #0 .@ Z #D 00 X $D
M-P!2 #8 70 T &H ,P!Z #( C  Q *$ , "X "\ W@ O /D +P#_ #  _P",
M"0  > P  &@-  !<#@  4@X  $L.  !%#0  00P  #\*   ^" ( /00( #P!
M#0 [ !  .@ 5 #D &@ X "  -@ E #4 *P T #  ,P W #( /@ Q $8 +P!0
M "X 6@ M &< *P!W "H B0 I )T * "S "< T0 G /( )P#_ "< _P"&#
M<@X  &,0  !6$0  31$  $41  ! $   / \  #D.   W#0  -@L$ #8("@ U
M!@X - 42 #($%P Q!1P , 4B "\%*  N!BX +08T "L&/  J!D0 *0=. "<'
M60 F!V4 ) =U ",'AP B!YL ( :P " &RP ?!>T 'P;^ !\'_P" #@  ;1$
M %X2  !2$P  2!,  $$3   [$P  -Q(  #01   R$   , \! # -!@ P"PL
M+PH0 "T*%  L"QD *@L? "D+)0 H#"L )PPR "8,.@ D#$, (PQ- "$-6  @
M#64 '@UU !P-B  :#9P &0VQ !@,R@ 7#.L %PW\ !@,_P![$0  :1,  %H5
M  !.%@  118  #T6   X%0  ,Q4  # 4   M$P  *Q(  "H0 P J#P@ *0X-
M "@.$0 F#A8 )0\= "0/(P C#RD (1 Q " 0.0 >$$( '1!, !L06  9$&8
M%Q!V !40B0 4$)X $A"S !$0S@ 1$.X $A#^ !(0_P!W$P  914  %<7  !+
M&   0AD  #H9   T&   ,!<  "P7   I%@  )Q4  "84 0 E$@0 (Q(+ "(2
M#P A$A0 (!(: !X3(  =$R< '!,N !H3-@ 9%$  %Q1* !845@ 4%&0 $A1T
M !$4AP 0%)P #A2Q  T4R@ -%.L #A/^  X3_P!S%0  81@  %,:  !(&P
M/QL  #<;   R&@  +1H  "D9   F&   )!@  "(7   @%@$ 'A8( !T6#0 ;
M%Q( &A<7 !D7'0 8&"0 %A@K !48-  4&#T $AE( !$95  0&6( #AER  T9
MA  ,&9@ "AFM  D8Q@ )&.< "1CZ  H7_P!O&   7AH  % <  !%'0  /!T
M #4=   O'0  *AP  "8;   C&P  (1H  !X:   <&@  &AL% !@;#  6'!
M%1P5 !0<&P 3'"( $ATI !$=,0 0'3L #AU%  T>40 ,'EX "AYM  D>@  '
M'I0 !1VJ  ,=P@ #'>8 !!SX  4<_P!K&@  6QT  $T>  !"'P  .A\  #(?
M   M'P  *!X  "0>   A'0  'AT  !P=   8'@  %1\" !,@"0 2(0X $"$2
M ! A&  .(1\ #B(F  TB+@ ,(C< "B)!  DB30 '(EH !2)I  ,B?  !(I$
M "*H   AP   (>4  "#X   @_P!G'0  5Q\  $HA  ! (0  -R(  # A   J
M(0  )B   "(@   ?'P  '!\  !D@   6(0  $B," ! D!P .)@P #"80  LF
M%0 *)AP "28B  @F*@ &)S, !"<]  ,G20 !)U8  "=F   G>0  )X\  ":F
M   FOP  )>0  "7Y   D_P!C(   5"(  $<C   ])   -"0  "XC   H(P
M)"(  "$B   >(0  &B(  !<C   3)   $"8"  XH!P +*@L ""L.  8K$P $
M*Q@  BL?  $L)P  +#   "PZ   L10  +%,  "QC   L=@  +(P  "ND   K
MO@  *N0  "KZ   I_P!?(P  4"4  $0F   Z)@  ,B8  "LF   F)0  (R0
M !\D   ;)   %R4  !0G   1*0  #BL"  LM!@ '+PL !# .   P$0  ,14
M #$<   Q(P  ,BP  #(V   R0@  ,D\  #)?   R<@  ,8D  #&B   PO
M,.0  "_[   O_P!:)P  3"@  $ I   W*0  +RD  "DH   E)P  (28  !PG
M   8*   %"H  !$L   .+@  "S !  <R!0 #- D  #4,   V#P  -Q(  #@8
M   X(   ."@  #@R   Y/0  .4L  #E;   X;@  .(4  #>?   WN@  -N0
M #7\   U_P!5*@  2"P  #TL   T+   +2L  "@J   D*0  'BH  !DK   4
M+0  $2\   TQ   *-   !S8   (X!   .@<  #L*   ]#0  /A   $ 4  !
M&P  0"0  $ N  ! .0  0$<  $!6  ! :0  0(   #^;   ^MP  />,  #S\
M   \_P!0+P  0R\  #DO   R+P  +"T  "<L   @+0  &B\  !4Q   1,P
M#38   DX   %.P   #T   !  0  000  $,'  !%"P  1@X  $@1  !*%@
M2AX  $HH  !*-   24(  $E1  !)9   2'L  $B7  !'M   1N   $7\  !$
M_P!*,P  /S,  #8S   P,0  *C   ",Q   <,P  %C4  !$X   -.P  "#X
M  -!    0P   $8   !(    2@   $P$  !.!P  3PL  %$.  !4$@  51D
M %4B  !4+@  5#P  %1+  !37@  4W0  %*0  !1K@  4-<  $_[  !._P!%
M-P  /#<  #4V   O-   )C4  !XW   7.@  $3T   Q!   '1    $@   !*
M    30   %    !3    50   %<   !8 @  6P8  %T+  !?#@  8A,  &(;
M  !B)P  8C0  &%%  !@5P  8&T  %^)  !=IP  7,P  %KX  !9_P!!/
M.CL  #0Y   J.@  (3P  !A    10P  #$<   9+    3P   %,   !6
M60   %P   !?    80   &,   !E    9P$  &H%  !M"@  < X  ',5  !R
M(   <BT  '$]  !P3P  ;V4  &Z   !MGP  :\$  &GQ  !H_P _0   .3X
M "X_   D0@  &D8  !)*   ,3P  !%0   !8    70   &$   !E    :
M &L   !N    <0   ',   !U    >    'L   !^ P  @0H  (4/  "'%P
MAB0  (4T  "$1@  @ET  (%V  !_E@  ?K8  'SG  !Z_P _1   ,T4  "A(
M   =3   $U(   Q7   #70   &,   !H    ;0   '$   !V    >@   'X
M  "!    @P   (8   ")    BP   (X   "2    E0$  )D)  ">$   GAH
M )TI  "</   FE(  )AL  "6BP  E*H  )+4  "0^@ X2P  +$X  "!3   5
M60  #6    -G    ;@   '0   !Z    @    (0   "*    C@   )(   "5
M    EP   )H   "=    H    *,   "G    JP   *\   "T"0  N!   +<>
M  "U,   LT8  +%@  "O?@  K*   *O!  "I[@ Q50  )%L  !AA   .:0
M!7$   !Y    @0   (@   "/    E    )H   "?    I    *@   "I
MK    *\   "S    M0   +D   "]    P0   ,8   #+    T0H  -,4  #1
M)0  T#L  ,U4  #*<0  R)(  ,6S  ##W@ I8@  '&D  !%Q   '>P   (0
M  "-    E0   )T   "C    J0   *\   "T    N0   +P   "^    P@
M ,4   #(    S    -    #4    V@   -\   #D    Z@   .X,  #M&@
M["\  .I)  #H90  YH8  .2E  #BQ@#_    _P   /\   #\  $ _  ( /X
M#@#_ !0 _P = /\ )@#_ #  _P Z /\ 0@#_ $D _@!0 /L 5@#Y %P ]@!B
M /0 : #R &\ \ !V .T ?P#J (D YP"5 .0 HP#@ +4 VP#0 -4 ]@#* /\
MM@#_ *@ _P"? /\ F@#_ )8 _P#_    ^P   /8   #S    \P   /8 "0#Z
M  X _0 6 /L ( #W "H \@ S .T .P#I $, Y@!) .( 3P#> %4 VP!; -8
M8 #2 &< SP!N ,P =@#) (  Q@", ,( F@"_ *H NP#! +@ Z0"V /\ IP#_
M )H _P"2 /\ C0#_ (H _P#Z    \0   .H   #G    YP   .0  0#@  L
MVP 1 -H &@#; ", T0 L ,H - #& #L P@!" +\ 2 "\ $X N@!3 +@ 60"V
M %\ LP!F +$ ;@"N '< K "# *D D0"F *$ HP"U *  V "> /L E0#_ (L
M_P"% /\ @ #_ 'X _P#O    XP   -H   #3    Q@   +\   "Y  8 MP .
M +0 % "T !T LP E *X +0"K #0 IP [ *0 00"A $8 GP!, )T 40"; %<
MF0!> )< 90"5 &X DP!Y )  AP". )< C "I (D Q "( .\ A0#_ 'P _P!V
M /\ <P#_ '( _P#@    T    ,8   "V    J0   *$   "=  $ F0 * )@
M$ "8 !8 EP > )0 )@"1 "T CP T (P .@"* #\ B !% (< 2@"% %  @P!6
M ($ 7@"  &8 ?@!Q 'P ?0!Y (T =P"@ '4 M@!S -\ <@#_ &X _P!I /\
M9P#_ &4 _P#,    O@   *L   "=    DP   (H   "%    @@ % (  #0!_
M !$ ?P 8 (  ( !] "8 >@ M '< ,P!U #@ =  ^ '( 0P!P $D ;P!/ &T
M5@!L %X :@!H &@ =0!G (0 90"6 &0 JP!B ,D 80#V &  _P!< /\ 6P#_
M %H _P"]    J0   )<   ")    ?@   '@   !S    ;P ! &T "0!L  X
M:P 3 &L &0!J "  :  F &8 + !E #( 8P W &( / !@ $( 7P!( %T 3P!<
M %< 6@!A %D ;0!7 'L 5@". %4 H@!3 +L 4@#I %( _P!0 /\ 3P#_ $\
M_P"M    F    (8   !X    ;@   &<   !C    8    %T !0!<  L 6P 0
M %L %0!; !L 6@ A %@ )@!6 "P 5  Q %, -@!2 #P 40!" $\ 20!. %$
M30!; $L 9@!* '0 20"% $@ F0!' +$ 1@#8 $8 _ !% /\ 10#_ $4 _P"?
M    B0   '@   !L    8@   %L   !6    4P   %$  @!/  @ 3P - $X
M$0!. !8 30 < $P (0!* "8 20 L $@ ,0!' #< 10 ] $0 1 !# $P 0@!5
M $  8  _ &X /@!^ #T D@ \ *D .P#' #L \P [ /\ .P#_ #P _P"3
M?@   &X   !A    6    %$   !,    20   $<   !%  4 1  + $, #@!#
M !( 0P 7 $( '0!  "( /P G #X +  ] #( .P X #H /P Y $< . !0 #<
M6P U &@ - !X #, C  R *( ,0"\ #$ YP Q /\ ,@#_ #, _P")    =@,
M &8%  !9!P  4 <  $D&  !#!0  0 ,  #X!   \  , .P ( #H #0 Z !
M.0 4 #D &0 W !X -@ C #4 *  T "X ,P T #( .P P $, +P!, "X 5P M
M &0 + !S "L AP J )P *0"U "D W  I /L *0#_ "H _P"!!   ;@@  %\*
M  !3"P  2@L  $(+   ]"@  .0D  #8(   U!0  - (& #, "@ R  X ,0 1
M #$ %0 P !H +P ? "X )  L "H *P P "H -P I #\ * !) "< 5  F &
M) !O ", @@ B )< (0"N "$ S  A /, (0#_ "( _P!["0  : P  %H-  !.
M#@  10X  #T.   X#0  ,PT  # ,   N"P  +0D# "T&"  L! P *P(/ "H!
M$@ I 1< * $< "< (0 F "< )0 M "0 -  C 3T (@%& "$!40 ? 5T '@%L
M !P!?P ; )0 &@"J !H Q0 : .L &0#_ !H _P!U#   9 X  %4/  !*$
M0!   #D0   S$   +P\  "P.   I#@  )PT! "<,!0 G"@H )@@- "4'$  D
M!A0 (@89 "$&'P @!R0 'P<K !X',@ =!SH ' A$ !H(3P 9"%P %PAK !8(
M?0 5!Y$ % >G !,&OP 2!>0 $@7Z !(%_P!Q#@  7Q   %$1  !&$@  /1(
M #82   P$@  *Q$  "@1   E$   (Q   "(.!  A#0< (0P+ " +#@ ?"Q(
M'0L7 !P,'  ;#"( &@PI !D,,0 8##D %@U# !4-3P 3#5P $@UK ! -?@ /
M#9( #@VG  T,O@ -#.  #0SU  T,_P!M$   7!$  $X3  !#%   .A0  #(4
M   M%   *!,  "43   B$@  (!$  !X1 P <$ 4 ' \( !L/#  :#A  &0\4
M !</&@ 6#R$ %1 H !00,  2$#D $1!$ ! 04  .$%T #1!K  P0?  +$)
M"1"E  @0O  '$-\ !Q#T  </_P!I$0  6!0  $L5  ! %@  -Q8  # 6   J
M%@  )A4  "(5   ?%   '1,  !H3 @ 9$@0 %Q(& !82"@ 5$@X %!(2 !(2
M&  1$QX $1,E ! 3+@ .$S< #11   P42P +%%@ "11G  <4>  &%(T !!2C
M  ,3NP "$]T  1+T  (2_P!E$P  518  $@7   ]&   -!@  "T8   H&
M(Q<  " 7   =%@  &A4  !@5 @ 6%00 %!4% !(6"  1%@T $!<0  X7%0 .
M%QL #1<B  P7*0 +&#( "1@\  <81P %&%0 !!AC  (8=0 !&(L  !>A   7
MN0  %]T  !;U   6_P!A%@  4A@  $4:   [&@  ,AH  "L:   E&@  (1D
M !X8   ;&   &!<  !87 @ 4%P, $A@% ! 9!P .&PL #!L/  L;$P *&Q@
M"!P?  <<)@ %'"\ !!PX  (<1   '5$  !U@   =<@  '(@  !R@   ;N0
M&]X  !KV   :_P!>&   3QH  $(<   X'   +QT  "D<   C'   'QL  !P:
M   9&0  %QD! !09 @ 2&@, $!L$  X=!P ,'@L "1\.  8@$0 %(!8  R <
M  $A(P  (2L  "$U   A0   (4X  "%=   A;P  (88  "">   @N   ']X
M ![X   >_P!:&P  2QT  #\>   U'P  +1\  "<>   B'0  'AT  !L<   8
M&P  %1L  !(<   0'0( #A\$  PA!@ )(@H !2,-  (D$   )1,  "49   F
M(   )B@  "8R   F/0  )DH  "9:   F;   )H,  "6<   EMP  )-\  "/Y
M   C_P!5'@  1R   #PA   R(0  *R$  "4@   @'P  '1X  !H=   6'@
M$QX  ! @   .(0  #","  @E!0 %)PD  "@+   J#@  *Q$  "P6   L'0
M+"4  "PN   L.@  +$<  "Q6   L:0  +(   "N:   JM0  *=\  "G[   H
M_P!1(@  1",  #@D   O)   *",  ",B   ?(0  '"   !<@   3(0  $",
M  XD   +)@  ""@   0J!   + <  "X)   P#   ,0\  #,3   S&0  ,R$
M #,J   S-0  ,T,  #-2   S90  ,GL  #*7   QLP  ,-X  "_[   N_P!,
M)0  /R8  #4G   M)@  )R4  "(D   >(P  &2,  !0D   1)@  #B@   LJ
M   '+    R\    Q @  ,P0  #4'   W"@  .0T  #H0   [%0  .QT  #LF
M   [,0  .SX  #M.   [8   .G<  #F2   XL   -]L  #;\   U_P!'*0
M.RH  #(J   K*0  )2<  "$F   ;)P  %2@  !$J   .+   "B\   8Q   !
M-    #8    X    .P$  #T$   _!P  00H  $,.  !%$0  11@  $4A  !%
M+   1#D  $1(  !$6P  0W$  $*-  !!JP  0-(  #_Z   ^_P!"+0  ."X
M "\M   I*P  )"H  !TJ   7+   $2X   TQ   )-   !#<    Z    /
M #\   !!    1    $8   !( P  2@<  $P+  !.#@  4!,  % <  !0)P
M3S0  $]#  !/50  3FH  $V&  !,I   2LH  $GX  !(_P ^,@  -3$  "XO
M   I+@  ("X  !DQ   2,P  #C<   DZ   "/0   $    !$    1P   $D
M  !,    3P   %$   !3    50$  %@&  !:"P  70X  %\5  !>(   7BP
M %T\  !<3@  6V,  %I^  !8G0  5\   %7R  !4_P Z-@  ,S0  "TR   D
M,P  &S8  !,Y   ./0  "$$   !%    20   $P   !0    4P   %8   !9
M    6P   %T   !@    8@   &4   !H!0  :PL  &\0  !O&   ;B4  &TT
M  !M1@  :UL  &IU  !HE   9K8  &3I  !B_P X.0  ,C<  "@Y   >.P
M%3\   Y$   '20   $T   !2    5@   %H   !>    8@   &4   !H
M:P   &T   !P    <P   '8   !Y    ?00  ($+  "%$0  A!T  ((L  "
M/@  ?E0  'YK  ![B@  >JH  '?6  !U_0 X/0  +#X  ")!   71@  #TL
M  =1    5P   %P   !B    9@   &L   !O    =    '@   ![    ?@
M (    "#    A@   (H   "-    D0   )8#  ";#   G1,  )LA  ":,P
METD  )1B  "3?P  D*   ([%  ",\P Q1   )4@  !I-   04P  "%H   !A
M    :    &X   !T    >0   '\   "$    B0   (T   "1    DP   )8
M  "9    G0   *    "D    J    *P   "R P  MPT  +<7  "U*   LCX
M +!6  "L<P  JI0  *FT  "EY0 J3P  'E0  !);   *8@   &H   !S
M>P   ((   ")    C@   )0   ":    GP   *0   "F    J0   *T   "P
M    LP   +<   "[    P    ,4   #+    T00  -4.  #3'0  T#(  ,U+
M  #*9@  QH<  ,*I  #!RP B6P  %F(   QK   !=    'T   "'    D
M )<   ">    I    *L   "Q    M@   +H   "\    P    ,0   #(
MRP   ,\   #4    V@   .    #F    ZP   /$&  #P$P  [B<  .P_  #J
M6P  YWH  .2;  #@NP#_    ^P   /8   #S    ]  % /8 # #Z !$ _P 9
M /\ (@#_ "P _P U /\ /0#_ $4 _ !, /H 4@#W %@ ]0!> /, 9 #Q &H
M[@!R .P >@#I (4 Y0"1 .$ H #= +( V #. -( ]@#! /\ K0#_ )X _P"6
M /\ D #_ (P _P#Z    \@   .P   #I    Z0   .P !0#R  P ^  2 /<
M&P#U "4 \  N .L -P#F #X X@!% -T 2P#8 %  TP!6 -  7 #- &( R@!J
M ,@ <@#% 'P P@"( +X E@"Z *@ MP"_ +0 Z "N /\ G0#_ )  _P"( /\
M@P#_ (  _P#P    Y0   -X   #:    VP   -P   #8  < T0 . -$ %0#2
M !X RP G ,4 +P#  #< O0 ] +H 1 "W $D M0!/ +( 50"P %L K@!A *P
M:0"I ', IP!_ *0 C0"A )X G@"R )L U0"9 /P C #_ (( _P![ /\ =@#_
M '0 _P#B    TP   ,H   #'    O    +8   "P  $ KP + *P $0"M !@
MK0 @ *@ * "D "\ H  V )T / "; $( F0!' )< 30"5 %, DP!9 )$ 80"/
M &H C !U (H @P"( )0 A@"G (, P@"" /  ? #_ ', _P!M /\ :@#_ &@
M_P#/    P0   +D   "M    H    )@   "4    D0 & )  #0"0 !( CP 9
M (X (0"+ "@ B  O (8 -0"$ #H @@!  (  10!^ $L ? !2 'H 60!X &(
M=@!L '0 >0!R (D <0"= &\ M !M -\ ; #_ &4 _P!@ /\ 7@#_ %P _P"^
M    L0   *    "2    B0   ((   !\    >@ ! '@ "0!W  X >  4 '<
M&@!T "$ <@ G '  +0!N #, ;  X &L /@!I $0 : !* &8 40!D %H 8P!D
M &$ < !? '\ 7@"3 %T J0!< ,@ 6P#W %< _P!4 /\ 4@#_ %$ _P"P
MGP   (T   !_    =    &X   !J    9@   &4 ! !C  L 8P 0 &, %0!C
M !L 80 A %\ )P!= "P 7  R %H -P!9 #T 5P!# %8 2P!5 %, 4P!< %(
M: !0 '< 3P") $X GP!- +H 3 #I $L _P!) /\ 1P#_ $< _P"B    C0
M 'P   !N    90   %X   !9    5P   %4  0!4  < 4P - %, $0!4 !8
M4@ ; %$ (0!/ "8 3@ K $P ,0!+ #< 2@ ] $D 1 !' $P 1@!6 $0 80!#
M '  0@"! $$ EP!  *\ /P#7 #\ _P ^ /\ /0#_ #X _P"4    ?P   &\
M  !C    60   %$   !-    2@   $@   !'  0 1P * $8 #@!& !$ 1P 6
M $4 ' !$ "$ 0@ F $$ *P!  #$ /@ W #T /@ \ $< .@!0 #D 6P X &D
M-P!Z #8 CP U *< -0#& #0 ]0 T /\ - #_ #4 _P"(    =    &4   !8
M    3P   $@   !#    /P   #T    \  ( /  ' #L #  [  \ .P 2 #H
M%P Y !P -P A #8 )@ U "P -  R #, .0 Q $$ , !+ "\ 5@ N &, +0!S
M "P B  L *  *P"[ "L Z@ K /\ *P#_ "P _P!_    ;    %T!  !1 @
M2 ,  $ #   [ @  -P   #0    S    ,@ % #( "0 R  T ,0 0 #$ $P P
M !@ +P = "T (@ L "@ *P N "H -0 I #T * !& "< 40 F %X )0!N "0
M@@ C )D (P"S "( W@ B /\ (P#_ "0 _P!W    900  %8&  !+!P  0@@
M #H(   U!P  , 8  "T%   L P  *P # "H !P I  L *0 . "D $0 H !4
M)P 9 "8 '@ E "0 )  J ", ,0 B #D (0!# "  3@ ? %H '@!I !T ?  <
M ), &P"L !L S0 ; /8 &P#_ !P _P!P!0  7P@  %$*  !&"P  /0L  #4+
M   P"P  *PH  "@)   E"   ) <" ",$!@ C @D (@$, "( #P A !( (  6
M !\ &P > "  '0 F !P +@ ; #8 &@ _ !D 2@ 8 %< %P!F !8 >  5 (\
M%0"F !0 PP 4 .X % #_ !4 _P!K"   6PL  $T,  !"#0  .0T  #$-   L
M#0  )PT  ",,   A#   'PL! !X*!0 =" @ '08+ !P%#0 <!!  &P04 !D$
M&  9!!X & 0C !<$*P 6!#, %00\ !0$1P 3 U0 $@-C !$#=0 0 HH $ &B
M  \ O  / .4 #P#^ !  _P!G"P  5PT  $D.   ^#P  -0\  "X/   H#P
M) X  " .   =#@  &PT! !D-!  8# < & L) !<)#  7"0X %@D2 !4)%@ 4
M"1L $PDA !()*  2"3  $0DZ ! )10 /"5( #@EA  T)<P ,"(@ "PB?  H'
MMP *!ML "@7V  H$_P!C#0  4PX  $80   [$0  ,A$  "L1   E$   (1
M !T0   :#P  & \! !8.!  5#@< % T) !,-"P 3# T $@P0 !$,%  0#!D
M$ P?  \,)P .#2\ #0TY  P-10 +#5$ "0U@  @-<0 &#88 !0V=  0,M  #
M#-(  @SQ  (+_P!?#@  4!   $,1   X$@  +Q(  "@2   C$@  'A$  !L1
M   8$0  %1 " !00!0 2$ < $0\) ! /"@ 0#@P #@X.  X/$@ -#Q< #! =
M  P0)  *$"P "1 V  @000 &$$X !1!=  ,0;P !$(0  !"<   /M   #M0
M  [S   ._P!<$   31(  $ 3   V%   +10  "84   A$P  '!,  !D2   6
M$@  %!$# !(1!@ 1$0@ $! *  X0"P -$0L #!$-  L2$0 *$A4 "1(:  @2
M(0 &$RD !1,S  ,3/@ "$TL  !-:   3;   $X(  !*;   2M   $=<  !'U
M   1_P!8$@  210  #T5   S%@  *Q8  "05   ?%0  &A0  !<4   4$P$
M$Q($ !$2!P 0$@D #A()  T2"0 +$PH "10-  <5#P &%A, !!88  ,6'P "
M%B<  !<P   7.P  %T@  !=8   7:@  %H   !:9   5M   %=D  !3W   3
M_P!5%   1A8  #H7   P&   *!@  "(7   =%@  &18  !85   3% , $A,&
M ! 3!P /$P< #10'  L5"  )%@D !A@,  ,:#@ !&A$  !H6   ;'   &R0
M !LM   ;.   &T8  !Q5   ;9P  &WT  !N7   :LP  &=L  !CY   7_P!1
M%@  0Q@  #<9   N&@  )AH  " 9   ;&   &!<  !46 0 3%04 $14$  \5
M!  -%@0 "Q<%  D9!@ &&@@  AP*   >#0  (!   " 3   @&0  ("$  "$J
M   A-0  (4(  "%2   @9   ('H  !^5   ?L0  'ML  !WZ   <_P!-&0
M/QL  #0<   K'   )!P  !X;   :&@  %Q@  !07 @ 2%P( $!@!  T9 0 +
M&@( "!P#  4=!  "'P8  "$(   C"P  )0X  "81   F%@  )AX  "<G   G
M,@  )S\  "9.   F8   )G<  "62   DKP  (]H  "+[   A_P!('0  /!X
M #$?   H'@  (AX  !T<   9&P  %AH  !(:   0&P  #1P   L=   ('P
M!"$   $C @  )00  "<&   I"0  + P  "X/   N$P  +AH  "XC   N+@
M+CL  "Y*   M7   +7(  "R.   KK   *M0  "G[   H_P!$(   ."$  "XA
M   F(0  ("   !P>   8'0  %!T  ! >   .'P  "R$   <C   #)0   "<
M   I    + $  "X#   P!@  ,PH  #4-   V$0  -A<  #8?   V*0  -C8
M #9%   U5P  -6T  #2)   RJ   ,<\  ##Z   O_P _)   -"0  "LD   D
M(P  'R$  !L@   6(   $2$   XC   *)0  !B@   (J    +0   "\    R
M    -    #<    Y P  .P8  #X*  ! #@  01(  $$:  ! )0  0#$  $!
M   _4@  /F<  #V"   \H@  .L<  #GX   X_P Z*   ,"@  "DG   C)0
M'R,  !@D   2)0  #B@   HJ   %+0   #     S    -@   #@    [
M/@   $    !"    10(  $<&  !*"@  30X  $T5  !,'P  3"L  $LZ  !*
M3   26$  $A\  !'FP  1;\  $/S  !"_P V+   +2L  "<I   C)P  &R@
M !0J   .+0  "C    0S    -P   #H    ]    0    $,   !&    2
M $L   !-    4    %,!  !6!@  60L  %L0  !;&0  6B4  %DT  !81@
M5UH  %5T  !4DP  4K4  %#J  !/_P S,   +"X  "<L   >+0  %B\  ! R
M   *-@   SH    _    0@   $8   !)    3    $\   !2    50   %@
M  !:    70   &    !C    9P8  &L,  !L$@  :QX  &LL  !I/0  9U(
M &9J  !DB0  8:L  %_<  !=_P Q,P  +#$  "(R   9-0  $3D   H]   "
M0@   $<   !,    4    %0   !8    6P   %\   !B    90   &@   !K
M    ;@   '$   !U    >0   'T&  ""#0  @A8  ( D  !^-0  ?$D  'MA
M  !X?P  =I\  '/&  !P]P Q-@  )C@  !P[   20   "T4   )+    40
M %8   !;    8    &4   !I    ;@   '(   !V    >0   'P   !^
M@@   (4   ")    C@   ),   "8!@  G X  )L:  "8*P  ED   ))9  "1
M<P  C94  (NU  "(Z  K/@  ($$  !5'   -30   E0   !;    80   &@
M  !N    <P   'D   !^    @P   (@   ",    CP   )(   "5    F0
M )T   "A    I0   *H   "P    MP<  +@1  "U(0  LC4  *]-  "J:0
MJ(@  *:H  "BT0 C2   &$X   Y4   $7    &0   !M    =0   'P   "#
M    B0   (\   "5    FP   *    "C    I@   *D   "M    L0   +4
M  "Y    O@   ,0   #*    T@   -H*  #6%@  TBD  ,Y!  #*7   Q7P
M ,*=  #!O0 <50  $5P   =E    ;@   '<   !_    B    )    "8
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M________________________________________________
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MV=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0
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MG]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5CI_8_Z B!?^?+0S_HS<4_ZY
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M ,;4"0"X]Q0$J_\I#I[_-!B0_SHAA/]!*7K_23!R_U(V;/]>.FC_:#UD_V]
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MC340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R
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M6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>^KD. ,W+"0#
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MQ6?#IL!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ'
M:<>A_XT< _^*)PC_BC$-_Y8W$_^>0!O_I4DG_Z=3-/^G74/_I&A3_*!R8O*:
M?'#JE(5]XXN+B-V$DI'8?IB8TWJ>G]!UI*3-<JJHRV^PJ\EMN*[":;RPO&O
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MAYB;P(27I<* EJ_"?Y*SO("1N+6 D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6
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M>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X_Z(5 ?^W%0#8SPL
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M@\2EC8/$I8V#Q*6-@\2E_XD9 _^') ;_DRD)_Y\Q#?^I.1/_L4$<_[E)*?;
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M-Q=E_S\;7O]''EC_3B%4_U<C4?]?)4[_929-_VPG2_]Q*$K_=BE)_WLJ2/^
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ME)%_T)21?]"4_X$9 _]^) ;_C28'_YHM"O^D-0__K#T7_K)%(O:X3##MO%1
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MKC)#_ZXRN+H" *K(  "=V0  DO\, HG_&@1]_R$(<O\H#&C_,!!@_S@46O]
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MI6EEO9YP<K27=WRMD7Z%IHR&C*"(C9&:A966EH*>FI* IYV/?[.>C8#"GHN
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M!/^O+ ;WNC,)[,0[#^+.0AC3SD@LQL=20+G 6E&MNF%?H[1G;)FP;7>0JW2
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M4"7_B5TO_X5I.OV!=43Z?(!-]WB+5?1SE5SQ;YUB[VRE9^UIK6OK9K9OZ&/
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M ]31,@W'S$$?NL=,,:[!5$*CO%Q0F;=B7)"S:6:'L&]N@*UV=7FJ?7MSJ(2
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MN4Q*]\A-2?C@34CW\TU(]_1-2/?T34CW]$U(]_1-2/?T34CW]$U(]_1-VJ,
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M(S7_N",U_[DC-?^Y(S7_N2,U_[DC-?^Y(S7_N2,U_[DCK;8  )_$  "2T@
MA.$  'W_#0%R_Q,":/\;!%__(P98_RL)4?\S"TS_.@U'_T$/0_]($4#_3A(]
M_U03._]:%#G_7Q0W_V45-?]K%C/_<A8Q_WH7+_^"%R[_BQ@L_Y,8*_^<&2K_
MIQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9H;\  )+,  "$W   >/<
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M8?Y5_V(? _]C)03_;R0%_WDH!O^!, K_A3D/_XA"%O^)2Q[_B58H^H5B,_6
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M,=*:7D#(DV=-P(QO6+F'=V&S@G]HKGV';JEZCG.D=Y9XH'2?>YUSJ'Z:<;2
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M:EVD[VI=I.]J7:3O:EVD[VI=I.]J_WD1 ?^,#@#_G@T W*X( -*["0#,R D
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MEQLP_Z$;+_^J'"__M1PN_[\<+O^_'"[_OQPN_[\<+O^_'"[_OQPN_[\<J;4
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M7VZ,]U]NC/=?;HSW7VZ,]U]NC/=?_VP3 ?]]#P'_C1  _YL0 /2H#P#EM0T
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MLSA"\,0X0?#?.4'O[SA [?TX0.S_.$#L_SA [/\X0.S_.$#L_SA [/\XRZ
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M%BC_LQ8G_\(6)__'%B?_QQ8G_\<6)__'%B?_QQ8G_\<6I+0  );   "'S
M>MH  &WK  !D_P4 7/\. 53_% %-_QP"2/\D!$+_+ 4^_S,&.O\Y!S;_0 @S
M_T4(,/]+"2[_40HK_U<**?]="R?_9 LD_VP,(O]V#2#_@ T>_XP.'?^7#AS_
MH0X;_ZP/&_^N#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/E[P  (C)  !YU@  :^,
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M5L57[%7#6_E/PE[_2L!?_T:]8/]"NF#_0+I@_T"Z8/] NF#_0+I@_T"Z8/]
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M47Y]_U%^??]1?GW_47Y]_U%^??]1_V,4 ?]R#P'_@1  _XT1 /R8$@#LH1,
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MH?]0_W<' /")  #6F   RZ0# ,&M! "YM@, LL $ *O%% "CQ2@$F\(W#I'
M0QF)O4PD@+I5+GFX7#9RMF,];;1J0V>S<4ABL7E,7K"!4%JOBU16KY=64ZZC
M6%"NLEE/KL993Z[D6%&N]E13KO]05*S_352L_TU4K/]-5*S_352L_TU4K/]-
M_WT  -^/  #.G0  PZ@" +FP @"PN@( J,0% *',#P";S","DLHS"HG(/Q6!
MQDD?><12*'+"6C!KP6$W9K]H/&&^<$%<O7A%6+R!252\BTQ1NY9/3KNC44R[
MLU)*N\922KOD44R[]DY-NO]+3KG_24ZY_TE.N?])3KG_24ZY_TE.N?])[X4
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M+CWJ[RX]Z/PN/>?_+3WG_RT]Y_\M/>?_+3WG_RT]Y_\MQ9\  +6I  "HL0
MG+P  )#'  "$T@$ >M\& '3T$P!M]" "9O0J!%_T- A:]3T+5/5%#T_U3!),
M]5442?9=%T;V91A$]FX:0?9W'#_W@1T]]XT?._>9(#GXIB$X^+4B-_G((C;Y
MXR(V^/,B-O?\(C;W_"(V]_PB-O?\(C;W_"(V]_PBMZ8  *FN  "<N0  D,0
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M"A3_LPH4_[,*%/^S"A3_LPH4_[,*D[L  (3'  !UTP  9^$  %CH  !.^P
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M_W(9 ?]Y'P+_?B<#^8 P!?"!.0KG@$,1X'Q0&M9W6R3/<F8NR6UO-<1J>#O
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M&0'[AR ![XPG N2., 7:C3T,SX=*&,>"52._?5\MN7AH-;-T<#RO<7A"JVZ
M1J=LB$JD:9!.H&B849UFH5.;9:M5F&2X5Y9DR%B49.%8E6CT4)9K_TJ7;/]%
MEFW_099M_T"6;?] EFW_0)9M_T"6;?] _UD5 ?]F$ '_<A  _WT2 /^%%@#V
MC!L!ZI$B =^4*P/3D3H+R8Q'%\"'4R*Y@EPLLGUE-:UY;3RH=75"HW-]1Z!P
MA$N<;HQ.F6R54I5KGE22::A7D&FT68YHPUF,:-Q:C6SR4X]N_TR0</]'CW'_
M0X]Q_T&/<?]!CW'_08]Q_T&/<?]!_UL4 ?]H#P#_=0\ _X 1 /^)$P#RD!<
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M14FV\D-*M?]!2[7_/DNT_SU+M/\]2[3_/4NT_SU+M/\]XH,  ,V2  #!GP
MM*<  *JO  "@N   EL # (S*!P"&S10 @<TF GK,-0ASRT$/;,I*%V;)4QUA
MR%LC7,=B*%C&:BQ4QG(P4,5\,TW%AC9*Q)(Y1\2?.T7$KCQ$Q<$\0\7?/$3$
M\SM$P_\Y1<+_-T7!_S=%P?\W1<'_-T7!_S=%P?\WU8L  ,6:  "WI   JZP
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M&3'Q_QDQ\?\9,?'_&3'Q_QDQ\?\9LJ0  *6K  "8M@  B\   '[*  !QU0
M9=X  %[U"@!9_!, 4_P> 4[\)P)*_3 #1?TY!4']0 8^_D@'._Y/"3C_5PHV
M_UX+,_]G##'_< TN_WP.+/^)#RO_EA I_Z00*/^T$2?_QQ$G_^$1)O_R$2;_
M]A$F__81)O_V$2;_]A$F__81IZD  )FS  "+O@  ?LD  '#3  !DW@  6.<
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M2U>2[T=:DOU"7)/_/EV3_SM=D_\[79/_.UV3_SM=D_\[_VX  .!^  #.BP
MQ)4  +J=  "QHP  J:D  *&N"P";KQT!E*XN!(RL.PR%JD85?JA.''BF5B-R
MI%TJ;:)D+VFA:S1DGW,X8)Y[/%R=A3]9G(]"59N<15.;JD=1F[I'4)O11U&;
M[D13F_Q 59O_/%:;_SI6F_\Z5IO_.E:;_SI6F_\Z\70  -F#  #(D   OIH
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M+D&\_RU!O/\M0;S_+4&\_RU!O/\MSHH  +^8  "QH   IJ@  )NP  "0N
MA;\  'K'! !OSPD :]$5 &?1)@%CT30$7M! "%G02@Q5SU,04<];%$[/8QA+
MSFL;2,YU'D7.?R!"SHPB0,Z9)#[.J"8\SKHF/,_4)CS-[R4[S/LE.\O_)3O*
M_R4[RO\E.\K_)3O*_R4[RO\EPY,  +6>  "HI@  G:X  )&V  "%OP  ><<
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M"B#\_ H@_/P*HJ<  )6Q  "'NP  ><8  &S/  !?V0  4M\  $CH  !#_P@
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M169Y[D!H>_TZ:GO_-FM\_S)K?/\R:WS_,FM\_S)K?/\R_V$  .IO  #9>@
MS(0  ,.+  "[D0$ M)4! *R7#@"EER$!GI8Q!9>3/@R0D$@4BHY1&X2+62%_
MB6 G>X=G*W>%;C!SA'4T;X)]-VN!ASMH@)$^97^<06)^J4-@?KE$7W[/1&!_
M[$!B@/PZ9(#_-F6!_S-F@?\R9H'_,F:!_S)F@?\R_V0  .5R  #3?@  QX<
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M,U*6_S!2EO\P4I;_,%*6_S!2EO\PYG(  -"   #"C   N)8  *V<  "CH0
MF:8  (ZM  "(KA$ @ZXB 7VM,01WK#T*<JI'$&RI3Q9GJ%<;8Z=>'U^F921;
MI&TG6*1U*U2C?RY1HHDQ3J&6-$NAI#9)H;0V2*'(-TB@YS5)H/DR2I__,$N?
M_RY+G_\M2Y__+4N?_RU+G_\MW7D  ,F&  "\D@  L9H  *:@  "<I@  D:P
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M'#;$_QPVQ/\<OI$  +";  "DHP  F*H  (RR  " N0  =,   &C'  !=S04
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M> (1_X@"$/^: A#_JP,._[X##O_5 P[_[0,.__ ##O_P P[_\ ,.__ #DZX
M (2X  !VP@  9\P  %K5  !,W   /^$  #7F   M]   *O\" ";_"P C_Q$
M(/\7 !W_'0 9_R, %O\I !3_+P 2_S4 $/\]  [_10$,_TX!"O]8 0?_90$%
M_W0! _^% 0+_E@$!_Z8! /^U 0#_Q@$ _\H! /_* 0#_R@$ _\H!AK<  '?!
M  !HS   6M<  $O>   ^Y   ,ND  "?M   C_P  '_\  !O_!0 7_PP %/\0
M !'_%  /_Q@ #?\=  O_(@ (_R@ !?\N  +_-0  _ST  /]'  #_4@  _UX
M /]M  #_?@$ _XX! /^; 0#_J0$ _ZL! /^K 0#_JP$ _ZL!_RHM ?\N*P'_
M,"L!_S N O\N-0+_*3T#_R5)!/\C5P3_(60%_Q]R!O\=?P;_'8H&_QV4!O\=
MG ?_'*,'_QRJ!_\<L0?_'+@&_QR_!O\<R0;_'-8&_QWE!O\=[P;_'?D%_QW_
M!?\=_P7_'?\%_QW_!?\=_P7_'?\%_QW_!?\=_P7_'?\%_RPK ?\P* '_,R@!
M_S,K O\Q,0+_+3H#_RM'!/\H5 7_)F$%_R1O!O\B? ?_(H<'_R*1!_\AF0?_
M(:$(_R&G"/\AK@C_(;4(_R&\"/\AQ@?_(=$'_R'B!_\B[0?_(O<'_R+_!OTB
M_P;\(O\&_"+_!OPB_P;[(O\&^R+_!OLB_P;[(O\&_RXH ?\S)0'_-B4!_S<G
M ?\U+0+_-#@#_S)$!/\O407_+%X&_RIK!_\I=P?_*(,(_R>-"/\GE@G_)YT)
M_R>D"?\GJPG_)[()_R>Y"?\GP@G_)\T)_R?>"?\GZPG\)_8(^2C^"/<H_PCV
M*/\(]2C_"/4H_PCU*/\(]2C_"/4H_PCU*/\(_S(E ?\W(@'_.B$!_SLC ?\[
M*0+_.S0"_SE !/\V307_-%H&_S%F!_\P<PC_+G\)_RZ)"O\ND@K_+9D+_RVA
M"_\MIPO_+:X+_RVU#/\MO@S^+<D,^RW9#/@MZ OT+O0+\2[^"^\N_PON+O\+
M[2[_"^PN_PKL+O\*["[_"NPN_PKL+O\*_S4B ?\['@'_/QT!_T ? ?]")@'_
M0C$"_T \ _\^2 7_.U4&_SEB"/\W;@K_-GD+_S6$#/TTC0W\-)4-^C2<#ODS
MHP[W,ZH/]C.R#_4SN@_S,\4/\C/2#^XSY0_J-/(/YS3]#^4T_P_D-/\.XC7_
M#N(U_PWA-?\-X37_#>$U_PWA-?\-_SD> ?\_&@'_0Q@!_T8: ?])(P'_22T"
M_T@X _]%1 7_0U '_T!="?L^:0OX/70-]3Q_#O,[B _Q.Y 0[SJ8$>TZGQ+L
M.:83ZCFN$^DYMA3G.<$4YCG.%>(YXQ7>.?$5VSK\%-@Z_Q/5._\2TSO_$M([
M_Q'2._\0TCO_$-([_Q#2._\0_ST; ?]#%@#_2!0 _TP7 ?]/'P'_4"@!_T\S
M O]-/P3[2DH&]4=7"?%&9 SM1&\.Z4-Y$>="@Q/D08L4XD"3%N _FQ??/Z(8
MW3ZJ&=L^LQK8/KT:UC[*&](^WQO./N\;RS_[&LE _QC'0/\7QD'_%<5!_Q3$
M0?\4Q$'_%,1!_Q3$0?\4_T$7 /]'$@#_3!  _U(4 /]6&P#_5R0!_U8N OA4
M.0/Q444&ZT]2">9-7@SA2VD0W4ET$]E(?1;51H88TD6.&M!%EAS.1)T=S$2E
M'LI#K1_(0[8@QD/#(<5#TR'!0^DAOD3W'[Q%_QVZ1O\;N4?_&;A'_QBX1_\7
MN$?_%[A'_Q>X1_\7_T04 /]+$ #_40X _U<1 /];%@#_71X ^5TH >];,P+G
M63\$X%=-"-I460W34F02SE!N%LI.=QG'3( <Q4N('L)*D"# 2I<AODF?([Q(
MIR2Z2+ EN$B\)K=(RR>T1^,GLDGS);!*_R*N2_\?KDS_':U,_QNM3?\:K4W_
M&JU-_QJM3?\:_T<1 /]/#0#_5@P _UP. /]@$@#]8A@ \&,A .9B+ '>8#H#
MU%Y(!\U;5 W'6%\3PU9I%[]4<AN\4GH>N5&"(;90BB.T3Y$ELDZ9)[!-HBBN
M3:LJK$RV*ZI,Q"RH3-LLIDWO*J1/_2:D4/\CHU'_(*-2_QZB4O\=HE+_':)2
M_QVB4O\=_TH/ /]2"@#_6@D _V + /]E#@#U9Q$ Z&@8 -UG) #29C4"RF1$
M!\-A4 V]7EL3N5QD&+5:;1RQ6'4@KE=](ZQ5A"6I5(PHIU.4*J52G2RC4J8M
MH5&Q+Y]1OC"=4=$PFU'J+YI3^BJ:5?\FF5;_(YE6_R&95_\?F5?_'YE7_Q^9
M5_\?_TT- /]5!@#_704 ^V0' .]I"0#I:PP X6P0 --M'@#);#$"PFI ![MG
M3 VU9%<3L&%@&:Q?:1VH77$AI5QX)*):@">@68<JG5B0+)M7F"Z95J(PEE6L
M,I15N3.35<HSD57E,Y%7]RV16?\ID5K_)9%;_R.16_\AD5O_(9%;_R&16_\A
M_T\+ /]7 @#_80( ZF@! -YM! #8< @ U7 + ,MR&P#"<2X"NF\]!K1L20VN
M:503J6==&:1D91VA8FTAG6%T)9I??"B87H,KE5V++9);E#"06YXRC5JH-(M9
MM36*6<8VB%GA-HA<]#"(7?\KB5[_*(E?_R6)7_\CB5__(XE?_R.)7_\C_U$)
M /]:  #U9   X&P  -=Q P#0= 8 S74) ,1V%P"\=BH!M'0Z!:YQ1@RG;E$2
MHFM:&)YI8AV:9VDAEF5Q)9-D>"B08H KC6&(+HM@D3&(7YHSAEZE-8->LC>"
M7L(W@%[<.(!?\C.!8?\M@F+_*8)C_R:"9/\E@F3_)8)D_R6"9/\E_U,& /]=
M  #G9P  VV\  -!T @#*> 4 QGD' +YZ%0"V>B@!KW@W!:AV1 NB<TX2G'!7
M&)AM7QV4:V<AD&IN)8UH=2B*9WTKAV6%+H1DCC&!8Y<T?V*B-GQBKSAZ8KXY
M>6+5.7EC[S1Z9?XO>V;_*WQG_RA\9_\F?&?_)GQG_R9\9_\F_U4# /]@  #C
M:@  U7(  ,QX 0#%>P, P'T% +E^$@"Q?B4!JGTU!*-Z00J==TP1EW15%Y)R
M71R.<&0@BFYK)(=L<BB$:WHK@6J"+GYIBS%[9Y4T>&>@-G9FK#AT9KPY<V;1
M.G-G[39T:?TP=6K_+'9K_REW:_\G=VO_)W=K_R=W:_\G_U<  /9C  #?;0
MT74  ,A[  #!?P( NX # +2!$ "L@B,!I8$R!)Y^/PF8>TH0DGE3%HUV6QN)
M=&(@A7)I)(%Q<"=^;W<K>VY_+GAMB#%U;)(T<VN>-W!JJCEN:KDZ;6K..FUK
MZS=O;?PQ<&[_+7%N_RIQ;_\H<6__*'%O_RAQ;_\H_UD  .ME  #;<   S7@
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MB@  K(P  *.."@"=CAH EXXK I",. :*BD,,A(=,$G^%51AZA%P==H)C(7.
M:B5O?W$I;'YY+&A]@B]E?(PR8GN8-5]ZI#==>K,X7'K'.5QZY3=>>_@R7WO_
M+F!\_RMA?/\I87S_*6%\_REA?/\I]6(  -YO  #,>@  P(,  +>)  "OC@
MII$  )V2!@"7DQ< D9,H 8N2-@6%D$$+?XY*$7J,4A9UBEH;<8AA'VV':"-J
MAF\G9H1W*V.#@"Y@@HHQ78&6-%J!HS98@+(W5H#%-U: XS98@?<Q68'_+5N"
M_RI;@O\I6X+_*5N"_RE;@O\I[&8  -AS  #'?@  O(<  +..  "ID@  H)4
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M)$>:_R1'FO\DU'<  ,*$  "VCP  JY8  *&<  "6H   BZ4  '^J  !TK@4
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MF DMTZD)+-.^"BS3WPDKT?,**L_^"RG._PPIS?\-*<W_#2G-_PTIS?\-KI@
M **?  "6I@  B:X  'RV  !OO0  8\,  %?(  !,S0  0M(# #G9"0 UWQ
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M 0G_I@$(_[H!!__4 0?_ZP$&__8!!O_V 0;_]@$&__8!CZP  ("V  !ROP
M8\D  %;1  !(V   .]T  ##B   FY@  '_   !S_   9_PD %O\. !3_$P 1
M_QD #_\>  W_)  +_RL "?\R  ;_.P #_T0  /]/  #_7   _VL  /]]  #_
MD   _Z,  /^T  #_Q@  _]8  /_6  #_U@  _]8 @K4  '._  !DR0  5M,
M $?;   ZX   +N4  "/I   :[0  %?T  !+_   0_P( #O\)  O_#0 (_Q
M!/\3  '_&   _QX  /\D  #_*P  _S,  /\]  #_20  _U8  /]F  #_>
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M+(-7[RF#6/XD@UG_((1:_QZ$6O\<A%K_'(1:_QR$6O\<_TX! /]7  #E7P
MV&8  ,YJ  #'; , PVL% +QL$@"T;24 K6PU Z=J0@>A9TT,G&56$9AC7A64
M8F48D6!L&XY?=!Z,7GLAB5V#)(9<C":$6Y4H@5J@*G]:K"Q]6KLM?%K/+GM;
M["M\7/PF?%W_(GU>_Q]]7O\=?5[_'7U>_QU]7O\=_U   /59  #A8P  TFH
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M)6QI_R)L:O\@;&K_(&QJ_R!L:O\@_U<  .1B  #2;   QG,  +UX  "U>P
MK7P  *5\"@"??1H F7PJ 9-[. 2->4,)B'=,#H-U5!)_<UL6>W)B&7AP:1UU
M;W @<FYX(V]M@29L;(LI:FR7+&=KHRYE:[(O9&O$,&)KX2]D;/8J9FW_)F9M
M_R-G;O\@9V[_(&=N_R!G;O\@]ED  .!E  #.;P  PG8  +E\  "Q?P  J8
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M(%=\_R!7?/\@Y60  ,]P  #!>@  MH,  *V)  "CC   F8X  (V/  "&D X
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M(DF+_R!*B_\>2HO_'DJ+_QY*B_\>U6X  ,-[  "WA0  K(T  **2  "7E@
MC)D  '^<  !UG@4 <)\3 &V?(P!IGS !99X[!&&>10==G4T*6IQ4#5>;7!%4
MFF,449IK%TZ9=!E+F'\<2)B+'D67F2!#EZ@A0I>Z(D&7TR)!EN\@0I7^'D*5
M_QU#E/\<0Y3_'$.4_QQ#E/\<S'4  +R!  "QC   II(  )N7  "1FP  A9\
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M#BRX_PXLN/\.LX\  *:7  ";G0  CZ,  (.J  !VL   :K4  %ZZ  !2O@
M1\(! #W'!@ XR1  -\D; #;*)P URC, -,L] #/+1P QRU$!,,M; 2[,90(L
MS'$"*LQ_ RG,D 0GS*$$)LVT!"7-S@0ER^X$),G\!B/(_P<CQ_\'(\?_!R/'
M_P<CQ_\'J98  )Z=  "2HP  A:L  'BR  !KN   7[X  %+"  !'Q@  /<H
M #3/!  KU D )MD/ "79&0 EVB4 )-HP "/;.P CVT4 (MQ0 "'=6P @W6@
M'MYV !W>AP$<WYD!&M^L 1G?Q $8WN<!&-SX 1C;_P(7VO\"%]K_ A?:_P(7
MVO\"H)P  )2C  "'JP  >;,  &RZ  !?P0  4L8  $;*   [S@  ,=,  "G9
M   AW@4 'N@. !WH%0 ;Z1X &>DG !CJ,  6ZCD %>M# !3L3@ 2[%H $>UG
M !#N=P 0[HH #N^>  [PLP -\,T #._L  SM_  ,Z_\ #.O_  SK_P ,Z_\
MEZ,  (FK  ![M   ;;P  %_$  !2R@  1<X  #G3   OV   )=T  !WA   8
M[ ( %O<+ !3W$0 1^!< $/@>  [Y)0 -^2T "_HU  G[/P '^TH !/Q7  /]
M9@ "_G<  /V+  #]GP  _+4  /S1  #\[0  _/P  /S]  #\_0  _/T BZL
M 'VT  !NO0  8,8  %+-  !$T@  -]@  "S=   BX0  &>4  !/J   0^@
M#O\&  W_#  *_Q  !_\4  3_&@ !_R   /\G  #_,   _SH  /]%  #_4P
M_V(  /]U  #_B@  _Y\  /^S  #_QP  _^4  /_E  #_Y0  _^4 ?[0  '"]
M  !AQP  4]   $/6   VW0  *N(  !_F   6Z@  $.T   SZ   )_P  !O\
M  +_!   _PD  /\-  #_$   _Q0  /\:  #_(0  _RD  /\T  #_0   _TX
M /]>  #_<@  _X<  /^:  #_J@  _[D  /^Y  #_N0  _[D _R I ?\B)P'_
M(B<!_Q\J ?\9, '_$CD!_Q!% ?\-4P'_#& !_PIM O\)>0+_"80"_PF. ?\)
ME@'_"9T!_PFC ?\)J0'_"; !_PBW ?\(O@'_",@!_PC6 ?\(Y@'_"/$!_PC[
M /\(_P#_"/\ _PG_ ?\)_P'_"?\!_PG_ ?\)_P'_"?\!_R,F ?\E) #_)20
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M!-@D_P37)/\$UB3_!-8D_P36)/\$_S$6 /\T$@#_-A$ _S<3 /\Y&P#_."4
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M#J)!_PZB0?\._S\) /]$  #_2@  ]TX" .Q0!@#J3PL XTP0 -9,'@#-33
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MJB&!4;@B?U'+(GY2YR%^4_D=?E3_&GY5_Q=^5?\6?E7_%7Y5_Q5^5?\5_TH
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M)FE>WB9J7_0A:V#_'6MA_QML8?\9;&'_&&QA_QAL8?\8]5$  .)<  #/90
MPVL  +EO  "Q<0  JG$  *)O" ";;Q< EG G )!O-0*+;D %AFQ)"()J4@Q^
M:5D/>VA@$G=F9A1U9FX7<F5V&G!D?AUM8X@?:V.3(FEBH"1F8JXE96*_)F1B
MVB9D8_(B963_'F9D_QMG9/\99V7_&&=E_QAG9?\8\%,  -U?  #+:   OV\
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M'E=Q_QQ7<?\:6''_&5AQ_QE8<?\9XUX  ,UI  "_<P  M'H  *M_  "B@@
MF(,  (N!  "$@0T ?X(: 'N"*0%V@38"<H% !6Y_20AJ?E +9WU7#F1\7A%A
M>V847GIM%UMZ=AE9>8 <5GB+'U-XF"%1=Z8B4'>W(T]WSB-/=^PA4'?]'E%W
M_QM2=_\94G?_&5)W_QE2=_\9WF(  ,AN  "[=P  L'\  *>$  "=AP  DH<
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M%3Z/_Q4^C_\5Q7,  +=_  "LB0  H8\  ):3  "+E@  ?YD  '.<  !DGP
M7* ) %F@% !7H2( 5:$O %*A.0%0H4,"3:!+!$J@4P5(H%H'19]C"4.?; M
MGG8./IZ#$#N>D1$YG: 2.)VR$S>>R!,WG>@2-IOZ$C::_Q(VF?\1-YG_$3>9
M_Q$WF?\1OGL  +&'  "ECP  FY0  )"8  "$G   =Z   &ND  !?IP  4JH
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MA@$@QI@!'\:K 1['P0$>QN0!'<3X AS"_P,<P?\#','_!!S!_P0<P?\$I90
M )J:  ".H0  @:<  '.N  !GM   6KD  $Z]  !"P   .,,  "_'   FRP0
M'M * !O1$0 :TAH &=(E !C3+P 8TSH %]1$ !;44  5U5T %-5K !/6?  2
MUX\ $=BD !#9NP 0V=X $-7S !#3_P 0TO\!$-'_ 1#1_P$0T?\!G)H  )&A
M  "#J   =;   &BW  !;O0  3L$  $+%   WR   +<P  "30   <U0  %=H%
M !#B"P 0XQ$ #N0:  [D(P -Y2T #.4W  OF0@ *YD\ ">==  CG;0 &YH
M!>:5  3FJP "YL0  >;F  #G^0  Y_\  .;_  #F_P  YO\ DZ$  (6I  !W
ML0  :;D  %O   !.Q@  0<H  #7.   JT@  (=8  !G;   2WP  #>,   OQ
M"  )\PX !_,3  3R&@ "\B(  /(J  #R-   \C\  /),  #R7   \FT  /*"
M  #RF   \ZT  //&  #TY0  ]/8  /3[  #T^P  ]/L AZD  'FR  !JN@
M7,(  $[)  ! S@  ,],  "C8   >W0  %>$   _D   *Z   !?,   /] 0
M_ @  /L-  #[$0  ^Q8  /P>  #\)@  _#   /T\  #^20  _EH  /YM  #_
M@@  _Y@  /^L  #_P   _]@  /_D  #_Y   _^0 >[(  &R[  !=Q   3\T
M $#2   RV0  )MX  !OB   2Y@  #.H   7M    ]    /\   #_    _P
M /\$  #_"0  _PX  /\2  #_&   _R$  /\K  #_-P  _T8  /]8  #_:P
M_X   /^5  #_I@  _[,  /^[  #_NP  _[L _QLF /\<) #_&B0 _Q4G /\0
M+0#_"C8 _P5# /\!4 '_ %X!_P!K ?\ =@'_ ($ _P"* /\ D@#_ )H _P"@
M /\ I@#_ *P _P"R /\ N0#_ ,( _P#- /\ WP#_ .P _P#X /\ _P#] /\
M_0#_ /T _P#] /\ _0#_ /T _P#] /\ _Q\C /\?(0#_'B$ _QDC /\3*0#_
M#C( _PQ  /\)30'_!UH!_P1G ?\#<P'_ WT!_P.' ?\#CP#_ I8 _P*< /\"
MH@#_ J@ _P*O /\!M@#_ ;X _P') /\!VP#_ .H _ #V /@ _P#W O\ ]P/_
M /8$_P#V!/\ ]@7_ /8%_P#V!?\ _R(? /\B' #_(1P _QX? /\8) #_%2\
M_Q(\ /\020#_#E8!_PQB ?\+;@'_"WD!_PN" ?\+BP'_"Y(!_PJ9 ?\*GP#_
M"J4 _PJK /\*L@#_"KL _0K& /L*U #W"N< \PKT / *_P#O"_\ [@S_ .T,
M_P'M#/\![0S_ >T,_P'M#/\!_R4; /\F& #_)1< _R$8 /\@(0#_'BL _QHW
M /\710#_%%$!_Q)> ?\1:0'_$70!_Q%] ?\0A@']$(X!_!"5 ?H0FP'Y$*$!
M]Q"H ?80KP'T$+< \Q#" /$0T #M$.4 Z!'R .81_@'D$O\!XQ+_ >(2_P'B
M$O\!X1+_ >$2_P'A$O\!_RD6 /\J$P#_*1( _R<3 /\H' #_)R< _R,S /\@
M/P#_'4P _QM8 ?P99 'X&6X!]AAX ?,8@0'Q&(D![QB0 >X8EP'L&)X!ZABD
M >D8K 'G&+0!YAB_ >08S0'@&>,!W!KQ =@:_@+4&_\"TAO_ M$;_P+0&_\"
MT!O_ M ;_P+0&_\"_RT2 /\N#P#_+@T _R\0 /\O%P#_+B$ _RPM /\I.0#Y
M)D8 ]"13 >\B7@'K(FD!Z"%S >8A? 'C(80!X2&, > ADP'>(9H!W"&A =HA
MJ0'8(;$"U2&\ M,BR0+0(M\"S"/P \@C_0/&)/\#Q"3_ \,D_P/")/\#P23_
M \$D_P/!)/\#_S / /\R"P#_,P@ _S8- /\V$@#_-1H _3(E /0P,@#M+3\
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ML1&:/K\1F#[4$I8_[1&4/_P/DT#_#I) _PR20?\+DD'_"Y)!_PN20?\+_ST
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M&GE-WQIX3O07>$__%'A/_Q)X4/\0>%#_#WA0_P]X4/\/_48  .=/  #65P
MR%P  +]?  "W7P  L5P  *I9# "D6AH GELJ )E;. &46D,#D%E,!8Q850B)
M5UP*AE9C#(-5:@Z!5'$0?U-Y$GU3@11Z4HL6>%*5&'91H1ET4:\;<U' &W%1
MVQQQ4O(9<5/_%7%4_Q-R5/\1<E3_$')4_Q!R5/\0\T@  .-3  #06P  Q&
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M&&%?_Q5A7_\38E__$F)?_Q)B7_\2ZE$  -1<  #$9   N6H  +!N  "G<
MGFX  )1K  "-:A  AVL> (-K+ !^:S@">FI" W9I2@9S:%((<&=9"FUF8 UK
M96</:&1N$69D=Q1D8X$686.,&%]BF!I=8J8<6V*V'5IBS!U:8NH<6V/\&%QC
M_Q9<8_\476/_$UUC_Q-=8_\3YE4  ,]?  #!:   MFX  *QR  "D=   FG,
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M$DUR_Q)-<O\2U&   ,)K  "U=   JWL  *)_  "7@0  C($  'I^  !S?P(
M;G\1 &N '@!H@"P 98 W 6* 0 -??T@$7'Y0!EE^5PA7?5X+5'QF#5%\;@]/
M>W@13'N#%$IZD19(>I\71GJO&$5ZQ!A$>N0817GX%D9Y_Q1&>/\21WC_$4=X
M_Q%'>/\1S64  +UP  "Q>0  IX   )R$  "2A@  AH8  '>&  !KA@  9H<-
M &.'&0!@B"< 7H@S 5N(/ )8AT4#5H=-!%.&5 90AEL(3H5C"DN$; Q)A'8/
M1H.!$42#CQ-"@YT40(*N%3^#PA4^@N(5/X'W$S^!_Q) @/\10(#_$$" _Q!
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MB@HUF)H+,YBK"S*8OPPRF-\+,9;U"S&5_PLQE/\+,9/_"S&3_PLQD_\+N'H
M *R%  "ABP  EI   (N4  !_EP  <IL  &:=  !:H   3J(  $6D"0!"I!,
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M !; M@ 4P-, %;[Q !6\_P$5N_\!%+K_ A2Z_P(4NO\"H9(  ):8  "*G@
M?:0  &^J  !BKP  5K0  $JW   ^N@  ,[T  "K    AQ   &<<% !/+"P 1
MS!( $<P; !#,)0 /S2\ #LTZ  [-1@ -S5( #<Y@  S.<  +SH, "LZ7  G.
MK  (SL8 ",[H  C-^P )R_\ "<O_  G+_P )R_\ F)@  (V>  !_I0  <:P
M &2S  !7N0  2KT  #[    RPP  *,8  !_*   7S0  $=$   S6!0 (V0P
M!MD2  7:&P $VB0  ]LN  ';.0  W$4  -U2  #>8@  WG,  -Z(  #?G0
MW[,  -_.  #@[@  W_H  -__  #?_P  W_\ CY\  (&F  !SK@  9;4  %B]
M  !*P@  /<4  #')   FS   '=   !34   .V0  "=T   /A    XP<  .,-
M  #D$@  Y1D  .8B  #G*P  Z38  .M#  #L4@  [&(  .UV  #NC   [J$
M .^W  #OT0  [^L  /#V  #P]@  \/8 A*<  '6O  !GMP  6;\  $O&   \
MR@  +\X  "32   :V   $MP   S@   %XP   .<   #K    ZP   .T%  #N
M"P  \!   /$5  #S'@  ]"<  /<S  #Y0   ^E$  /MC  #\=P  _8T  /VC
M  #^M@  _LD  /_?  #_WP  _]\ =[   &BY  !:P0  3,H  #S/   NU
M(MH  !?>   0X@  ">8   #I    [    /    #V    ]@   /<   #X
M^@<  /L-  #]$0  _QD  /\C  #_+P  _SX  /]/  #_8@  _W<  /^-  #_
MGP  _ZX  /^Z  #_N@  _[H _Q8C /\5(0#_$B$ _PXD /\&*@#_ #, _P!!
M /\ 3@#_ %P _P!H /\ = #_ 'X _P"' /\ CP#_ )8 _P"< /\ H@#_ *@
M_P"N /\ M0#_ +T _P#' /\ U@#_ .< _@#S /X _@#] /\ _ #_ /L _P#[
M /\ ^P#_ /L _P#[ /\ _QH@ /\9'@#_%AX _Q @ /\*)0#_!#  _P ] /\
M2P#_ %@ _P!D /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J
M /\ L0#] +D ^P## /H T #X ., ]P#Q /8 _ #T /\ ] #_ /, _P#S /\
M\P#_ /, _P#S /\ _QT< /\<&0#_&1D _Q0; /\.(0#_#"P _PDY /\%1@#_
M E, _P!? /\ :P#_ '4 _P!^ /\ A@#_ (X _P"4 /X FP#\ *$ ^@"G /@
MK@#U +4 \P"_ /$ RP#P -\ [@#N .P ^0#K /\ Z@#_ .H!_P#I ?\ Z0'_
M .D!_P#I ?\ _R 7 /\?% #_'!, _Q<5 /\6'0#_$R@ _Q T /\-00#_#$X
M_PE: /\(9@#_"'  _@=Y /P'@0#Z!XD ^ >0 /8&E@#S!IT \0:C .\&J@#M
M!K( Z@:[ .@&R #F!MP Y ;L .((^@#@"O\ W@O_ -T+_P#=#/\ W S_ -P,
M_P#<#/\ _R,2 /\C$ #_(0X _QX0 /\>& #_'", _Q@O /\4.P#_$DD _!!5
M /@/8 #T#VH \0]T .\.? #M#H0 ZPZ+ .D.D@#G#ID Y@Z@ .0.IP#B#J\
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M /\O  #_,@  _S," /DR" #W+PX ZRL6 .$G(@#8)S( T"E! ,LJ3@#&*ED
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M"Y$YY0N/.O<*C3K_"8P[_PB,._\'C#O_!XP[_P>,._\'_S@  /$^  #C10
MU$D  ,M*  #%1P  P4$$ +H_$0"S02$ K4(Q *A#/@"D0TD!H$)3 IU!6P.;
M06($F$!J!99 <0:4/W@'DC]_") _B J//I$+C3Z;#(L^I@V)/K,-B#[$#H8_
MX Z$/_0-@T#_"X- _PJ"0/\)@D'_"()!_PB"0?\(_SP  .M#  #<2@  S$\
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M$&Q/_PYL3_\,;$__"VQ/_PML3_\+[D4  -Q0  #)5P  O5P  +1>  "L7@
MI%L  )Q6! "55A( D%<A (M8+P"'5SL!@U9$ G]630-\550%>E1;!G=48@AU
M4V@)<U-P"W%2> UO4H(/;5&-$6M1F1)I4:849U&V%691RQ5E4ND495+[$693
M_P]F4_\-9E/_#&93_PQF4_\,ZDD  -53  #%6@  NE\  +!B  "H8@  GU\
M )9:  "/6A  BEL> (5;+ "!6S@!?5M! GI:2@-W65$$=%A8!G%87P=O5V8)
M;5=M"VM6=@UI5G\/9U6*$655EQ-C5:04856T%6!5R!9?5><58%;Z$F!6_P]A
M5_\.85?_#6%7_PQA5_\,YTP  -%6  #!7@  MF,  *UF  "D9@  FV0  )!>
M  ")7@X A%\; (!?*0!\7S4!>%\_ G1>1P-Q74\$;UQ6!6Q<7 =J6V,):%MK
M"V9:<PUD6GT/8EJ($5]9E!->6:(47%FR%5M9QA9:6>456UKY$EM:_Q!<6O\.
M7%K_#5Q:_PU<6O\-XT\  ,U9  "^80  LV8  *EI  "@:@  EV@  (MB  "#
M8@P ?F,8 'IC)@!V8S( <V,\ 6]B10)L84P$:F%4!6=@6@=E8&$(8U]I"F%?
M<0Q?7GL.75Z&$5I>DQ)87: 45UVP%59>Q!957N,55E[W$E9>_Q!77O\.5U[_
M#5=>_PU77O\-WE,  ,A=  "[9   L&H  *9M  "=;@  DVT  (5G  !^9PD
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M' !F<B@ 8W(T &!R/0%><D4"6W%- UEQ5 57<%L&5'!C"%)O:PI0;W0,36Z
M#DMNC1!);IL11VVK$D9NOA-%;MP21FWT$49M_P]';?\.1VS_#4=L_PU';/\-
MS%\  +QI  "P<0  I7<  )Q[  "1?   AGL  '5X  !K=P  97<, &%X%P!?
M>"0 77DP %IY.@%8>4("5GA* E-X4011=U@%3W=@!TQV: A*=G(*2'5]#$5U
MB@Y#=9D/0G6I$$!UO!! ==D00'3S#T!T_PY!<_\-07/_#$%S_PQ!<_\,QF0
M +=N  "K=@  HGP  )=_  ",@0  @8$  '*   !E?P  77\( %E_$P!7@"
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M!BV2MP8LDM$&+)'O!BN/_P8KCO\&*XW_!RN-_P<KC?\'LW@  *>"  "<B
MD8P  (>0  !ZDP  ;94  &&7  !5F0  29L  #^< 0 YG0X -YT7 #:>(@ T
MGBP ,YXU #*>/@ QGD< ,)]0 "Z?6@ MGV0!*Y]Q 2F>?P(GGI ")IZA B2>
MM0(CGLX"(YWN R.;_@,BFO\$(IG_!"*9_P0BF?\$K($  *"(  "5C@  BY(
M '^6  !RF@  99T  %F@  !.HP  0J0  #>F   NJ 4 *:D/ "BI&  GJB(
M)JHL "6J-0 DJC\ (ZI( "*K4P AJUX (*MJ !ZK>0 =JXL &ZN= !JKL0 9
MJ\H &:KL 1FH_0$8I_\"&*;_ ABF_P(8IO\"I8D  )F/  "/E   @YD  '6>
M  !HH@  7*8  %"I  !$K   .:X  "^P   FLP  'K4& !FW#P 8MQ< %[<A
M !:W*@ 5MS0 %+@^ !.X20 2N%0 $KEB !&Y<0 0N8, #[F7  ZYK  -N<0
M#;CG  ZV^P .M?\ #K3_  ZT_P .M/\ G)   )*5  "&FP  >:   &NF  !>
MJP  4J\  $:R   ZM0  +[<  "6Z   =O0  %<   !##!@ +Q@X "L45  G%
M'@ (Q2@ !\4R  ;&/0 %QDD !<97  /&9@ "QG<  <:+  #&H   Q;8  ,;2
M  #%[P  Q?P  ,7_  #%_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3M
M1K@  #J[   NO@  ),$  !O$   3QP  #LH   C. 0 !T H  - 0  #0%@
MT1X  -(G  #3,0  U#P  -5)  #66   UFD  -9\  #6D@  UJ<  -:_  #6
MX   UO,  -;^  #6_P  UO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0  .<$
M "W$   BQP  &<L  !'.   ,T@  !=4   #;    W ,  -T*  #>#P  WQ0
M .$<  #B)   Y"X  .8Z  #G20  Z%D  .AK  #I@0  Z9@  .FM  #IQ0
MZ>(  .GR  #I]0  Z?4 @*4  '&M  !CM0  5;P  $?"   YQ@  +,H  "#.
M   6T@  #]8   C;    WP   .,   #E    YP   .@!  #J!P  ZPT  .T1
M  #O&   \2$  /,K  #V.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP  ^L(
M /K:  #ZWP  ^M\ =*X  &6V  !6O@  2,8  #G+   KT   ']0  !3:   -
MWP  !>,   #F    Z0   .T   #O    \0   /,   #U    ]@(  /@)  #Z
M#@  _1,  /\<  #_*   _S8  /]'  #_6@  _VX  /^%  #_F@  _ZL  /^Y
M  #_O   _[P _Q$@ /\0'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_ %D
M_P!E /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L #_
M +@ _P#" /\ S@#_ .( _@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_ /H
M_P#Z /\ _Q0< /\2&@#_#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4 _P!A
M /\ ; #_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[ +0
M^0"] /@ R0#W -P ]0#L /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /  _P#P
M /\ _Q<8 /\5%@#_$14 _PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!< /\
M9P#_ '$ _P!Z /P @@#Z (D ^ "0 /< E@#U )P ] "B /, J #Q +  \ "X
M .X PP#L -, Z@#G .D ]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E /\
M_QH3 /\8$0#_%!  _P\1 /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X 8@#Z
M &P ]0!U /( ?0#P (0 [@"+ .P D0#K )< Z0"> .< I #F *P Y "T .(
MOP#@ ,T W@#C -P \@#: /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\ _QX0
M /\<#0#_%PL _Q4. /\4%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N!&8
MZ@1O .8#=P#D!'\ X@2& . $C #>!), W06: -L%H #8!:@ U06Q -(%NP#0
M!LD S@?@ ,P(\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$, /\@
M!@#_' , _QT* /\;$ #_&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6  W0UI
M -D-<0#5#7D TPV! -$-B #/#8\ S0Z6 ,L.G0#*#J4 R ZN ,8/N0#$$,@
MPA#? +X1\@"[$O\ N1/_ +<3_P&V$_\!MA/_ ;83_P&V$_\!_R4& /\C  #_
M(P  _R0# /\A"@#]'1$ \1H; .@6)P#A%#4 VA-# -,43P#.%5D RQ5C ,@6
M:P#%%G, PQ=[ ,$7@@# &(D OAB0 +P8F "[&:  N1FI +<9M "U&L( M!K6
M + ;[0&M'/P!JQW_ :D=_P&I'?\!J!W_ :@=_P&H'?\!_R@  /\G  #^*@
M[RH  .<G 0#G(@D Y!T0 -D;'0#/'2T R1X\ ,0@20"_(%, O"%= +DA90"W
M(FT M2)T +,B? "Q(H,!L"** :XBD@&L(YL!JR.D :DCKP&G([P!IB3. :,D
MZ *@)?D"GB7_ ITE_P*<)?\"FR7_ ILE_P*;)?\"_RP  /\M  #M,@  XC0
M -HS  #3+@, TB4* ,DE%P#!)R< NRDV +8J0P"R*TX KRM7 *PK8 "J*V<!
MJ"MO :8K=@&D*WT!HRN$ J$KC0*?*Y4"GBN? IPKJ@.:*[8#F2S' Y<LX@.4
M+?4$DBW_ Y$M_P.0+O\#D"W_ Y M_P.0+?\#_S   /(S  #D.@  UCT  ,P\
M  #'.0  PS$% +TN$0"U,"$ L#(P *LS/0"G,TD I#-2 *$S6@&?,V(!G#-I
M IHS< *9,W<"ES)_ Y4RAP.3,I $DC*:!) RI06.,K$%C3/"!HLSW :)-/(&
MAS3_!88T_P6&-/\$A33_!(4T_P2%-/\$_#,  .LZ  #<00  S40  ,-$  "]
M00  N#L! +(W#@"K.!P I3DK *$Z. "=.T0 FCM- 9<Z5@&4.ET"DCID I Z
M:P...7(#C#EZ!(HY@@6).8L%ASF5!H4YH >#.:T'@CF\"($YTPA_.NX(?3K^
M!WP[_P9\._\%?#O_!7P[_P5\._\%]#<  .5   #21P  Q4H  +Q+  "U20
MKT,  *D^"P"B/Q< G4 F )A!- "403\ D4%) 8Y!40&+0%D"B4!@ X= 9P.%
M/VT$@S]U!8$_?09_/H<'?3Z1"'L^G EZ/JD)>#ZX"G<_S0IU/^H*=$#\"'1
M_P=T0/\&<T#_!G- _P9S0/\&\3L  -]%  #,3   OT\  +90  "N3P  ITH
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M"&!._PA@3O\(XT<  ,U0  "^5P  LUL  *I=  "A70  F%H  (U3  "&4@P
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M'P!N7"L :UPV &A;/P%E6T<!8UM. F%:50-?6EP$75IC!5M::P99674(5UF
M"E59C M469H-4EFJ#E%9O Y06=@.4%GR#5%9_PM16?\*45G_"5%9_PA16?\(
MU%$  ,):  "T80  JF8  *!H  "7:0  C&<  'U@  !U7P, ;U\0 &M?' !H
M8"@ 9F S &-@/ %A8$0!7U], EQ?4P-;7UH$65]A!5=>:0957G,(4UY^"5%=
MB@M/79D,35VH#4Q>N@Y+7M0.2U[Q#$Q>_PM,7?\*3%W_"4Q=_PA,7?\(SU0
M +Y>  "Q90  IVH  )UM  "4;0  B6P  'AE  !O9   :60. &5D&0!B9"4
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M"3MPM0H[<,T*.F_L"3MN_@@[;O\(.VW_!SMM_P<[;?\'OV(  +%K  "F<P
MG7D  ))[  "'?   >WP  &UZ  !@>   5G<! %!W#@!.>!@ 3'@D $MY+@!)
M>3< 2'E  $9Y2 %$>4\!0GE7 D%Y8 (_>&D#/'AT!#IX@@4X>)$&-WBA!S5X
MLP<T>,L'-'?K!S1V_0<T=?\'-77_!C5T_P8U=/\&N6@  *UQ  "B>0  F'X
M (V   ""@0  =H(  &F!  !;@0  48$  $B "@!%@1, 0X$> $*"*0!!@C(
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M 1R5^@$;E/\!&Y/_ AN3_P(;D_\"IW\  )R&  "1BP  AX\  'J2  !ME0
M89@  %6;  !)G0  /9X  #.?   JH0  (:,* !^C$0 >HQH ':0D !RD+0 ;
MI#8 &J0_ !FD2@ 8I%4 %J5A !6E<  4I8$ $Z64 !*EJ  1I;\ $*3B !&B
M^  1H?\ $:#_ 1&@_P$1H/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@  6*$
M $RD  ! I@  -:<  "JI   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .L2L
M#;$U  VQ0  ,L4L "[%8  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P[P %
MK_X !J[_  :N_P &KO\ F(X  (^3  ""F   =9T  &>B  !:IP  3JL  $&M
M   UKP  *[$  "&T   8M@  $;D   V\ P 'O@P  [T2  &]&0  OB(  +XK
M  "^-@  OD$  +].  "_7   OVT  +^   "^E0  OJH  +["  "]Y   O?8
M +W_  "]_P  O?\ DI0  (6:  !XH   :J8  %RK  !/L   0K,  #6V   J
MN   (+L  !>^   0P0  "\0   3'    R0<  ,D-  #)$@  RAD  ,LB  #+
M*P  S34  ,Y!  #.4   SV   ,]R  #/AP  SYT  ,^S  #/S@  S^L  ,[X
M  #._@  SOX B)L  'JB  !LJ   7J\  %"U  !"N0  -;P  "F_   >P@
M%<8   [)   (S    -    #3    U0   -8&  #8#   V1$  -L6  #<'P
MWB@  . T  #B00  XE$  .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J  #E
M\P  Y?, ?*,  &ZJ  !@L@  4;D  $.^   UP@  *,8  !S)   3S0  #-$
M  35    V@   -X   #A    X@   .0   #E P  YPD  .D.  #K$@  [1H
M .\D  #R,0  ]$$  /13  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #WWP
M]]\ <*P  &&T  !3NP  1<,  #;'   GS   &]   !'5   *VP   -\   #B
M    Y0   .D   #L    [0   /    #Q    \P   /4$  #W"@  ^A   /P6
M  #_(0  _RX  /]   #_4P  _V@  /^   #_E@  _Z@  /^V  #_OP  _[\
M_PT< /\*&P#_ AL _P > /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\ ;0#_
M '< _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"] /\
MR0#^ -T _0#M /P ^@#[ /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\ _Q 9
M /\-%P#_!A8 _P 8 /\ '@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_ '(
M_P![ /\ @@#_ (D _P"0 /X E@#] )P _ "A /L J #Y *\ ^ "X /8 PP#T
M -( \P#G /( ]@#P /\ [P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4 /\/
M$@#_"Q( _P 2 /\ &@#_ "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T ^P!V
M /D ?0#W (0 ]0"+ /0 D0#S )< \0"= /  HP#N *H [ "S .H O0#H ,L
MYP#A .4 \0#C /T XP#_ .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1#@#_
M#0T _P</ /\"%0#_ "  _P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P .T
M> #K '\ Z0"% .@ C #F )( Y0"8 ., GP#A *8 WP"N -P N #: ,4 U@#9
M -0 [ #2 /D T0#_ ,\ _P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_#P4
M_PX+ /\,$0#_!QH _P$F /P - #T $$ [0!- .D 6 #F &( XP!J .  <@#>
M 'D VP"  -D A@#6 (T TP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0 ,4
MZ ## /8 P0#_ , "_P"_ _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%   _Q,%
M /\1#0#_#A0 ^0H? / &+ #F SD X -& -P#40#6!%L T@1D ,\%; #,!7,
MR@5Z ,@%@0#&!8< Q0:. ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*Y0"U
M"_< LPW_ +$-_P"P#?\ L [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH  /46
M!0#V$0T ZPX5 .(+(@#8"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT O0YT
M +L/>P"Y#X( MQ"* +80D0"T$)H LA"C + 1K0"O$;H K1'* *H2Y0"G%/<
MI17_ *,5_P"B%?\ HA7_ *(5_P"B%?\ _R(  /\@  #P(P  YB0  . A  #<
M&04 VQ , - 1&0#($RD PA4W +T61 "Y%TX M1=7 +,88 "P&&< KAAN *P9
M=0"K&7P J1F$ *@:C "F&I0 I!J> *,;J "A&[0 GQS% )X<WP":'?,!F![_
M 9<>_P&6'_\!E1__ 94?_P&5'_\!_R8  /0G  #F+0  VB\  ,\M  #*)P
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M VTZ_P-M.O\#ZCD  -5"  #$2   N4L  *]+  "G20  GT0  )@^ 0"1/!
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M(@!V2"X <T@X '%(00!N2$D!;$A0 6I(5@%H2%T"9D=D F5'; -C1W8$84>
M!6!'C09>1YH'7$>I"%M(NPA:2-0(6DCQ!UI)_P9:2?\%6DC_!5I(_P1:2/\$
MVT0  ,9-  "X4P  K5<  *-9  ":6   D50  (9.  !]2P@ =TL2 '-,'P!P
M3"L ;4PU &M,/@!H3$8 9DQ- 61,4P%B3%H"84QB E],:@->3',$7$M^!5I+
MB@982Y@'5TRG"%9,N0E53-$)5$SO"%1-_P953/\&54S_!55,_P553/\%U4@
M ,)1  "U5P  JEL  *!<  "77   C5D  (%3  !W3P0 <4\0 &Y0' !J4"@
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M!T=9LPA&6<H(15GJ"$99_09&6/\&1EC_!4=8_P5'6/\%QU(  +A;  "K80
MH68  )AH  ".:0  @V<  ')@  !H7@  85T) %Q=$P!:71X 5UTI %9>,P!4
M7CL 4EY# %%>2@%/7E(!3EY9 DQ>80)*7FH#2%YU!$9>@@5$79 &0UZ@!T%>
ML0= 7L@'0%[H!T!=_ 9!7?\%05W_!4%<_P5!7/\%PU8  +1?  "H9@  GFH
M )5M  "*;0  ?VP  &]G  !D9   6V(% %9B$ !48AL 4F,E %!C+P!.9#@
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M RYQ^ ,N</\#+F__ RYO_P,N;_\#LV8  *=O  "==@  DWH  (A\  !^?0
M<GT  &1\  !7>P  3'H  $)Y P \>0X .GH7 #EZ(0 X>BH -WLS #9[.P T
M>T0 ,WM, #)[50 P>U\ +WMJ 2U[=P$K>X<!*GN8 BA[J@(G>[\")GOA B9Z
M]P(F>/\")GC_ B=W_P(G=_\"KFP  *-V  "9?   CG\  (2"  !X@P  ;(0
M %^$  !1A   1X0  #R$   SA D ,(01 "^$&@ MA"0 +(4M "N%-0 JA3X
M*85' "B&4  GAEH )H9F "2&<P CAH, (8:5 ""&IP$>AKP!'H;> !Z$]0$>
M@O\!'H+_ 1Z!_P$>@?\!J'0  )Y]  "3@@  B84  'Z(  !QB@  98L  %B,
M  !,C0  0(X  #:.   LCP  )9 , ".0$P BD!P (9 E ""1+@ ?D38 'I%
M !V120 <D50 &I%@ !F1;@ 8D7X %I*0 !62I  4D;D $Y'8 !./]  4CO\
M%(W_ !2,_P$4C/\!HWT  )B#  ".B   A(P  '>/  !ID0  79,  %"5  !%
MEP  .9@  "Z9   EF@  '9L" !:=#  5G1, %)T; !.=)  2G2T $9XW !&>
M00 0GDP #YY8  Z>9P -GG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X "YK_
M  N9_P +F?\ G(0  )&*  "(C@  >Y(  &V6  !@F0  5)P  $B?   \H
M,*$  ":C   =I0  %:<  !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J.  "
MJD0  :I0  "J7@  JFX  *J!  "JE0  J:H  *G!  "HY   J/8  *?_  "G
M_P  I_\ E8L  (R0  !_E0  <9H  &.>  !6H@  2J8  #VH   QJ@  )JL
M !VM   4L   #K(   FU 0 "M@H  +8/  "V%0  MQT  +<E  "W+P  N#D
M +A&  "X5   N&0  +AV  "XBP  MZ   +>V  "WTP  MN\  +;\  "V_P
MMO\ CY(  (*7  !TG0  9J(  %BG  !+K   /J\  #&Q   FLP  '+8  !.X
M   -NP  !KX   #!    P@0  ,(+  ##$   Q!4  ,0<  #%)   QBX  ,@Z
M  #)1P  R5<  ,EI  #)?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0  R/T
MA9D  '>?  !HI@  6JL  $VQ   _M0  ,;@  "6Z   :O0  $<    O#   #
MQP   ,H   #-    S@   ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM  #=
M.0  WDD  -Y:  #?;@  WX4  -^<  #?L@  WLL  -[F  #?]   W_0 >:$
M &NH  !<KP  3K4  $"[   QO@  ),$  !G%   0R   "<P   #/    TP
M -D   #<    W0   -\   #A    X@4  .0+  #F$   Z!8  .H@  #M*P
M\#H  /%+  #Q7@  \G,  /.+  #SH@  \[8  //)  #SX0  \^$ ;:H  %ZQ
M  !0N0  0;\  #+$   DR   %\P   [0   &U0   -H   #>    X@   .8
M  #I    Z@   .P   #N    \    /(   #T!@  ]@P  /D2  #\'   _RD
M /\Z  #_30  _V(  /]X  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!%P#_
M !< _P : /\ (0#_ "L _P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![ /\
M@P#_ (H _P"0 /\ E@#_ )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4 _ #J
M /L ^ #Z /\ ^0#_ /@ _P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_ !,
M_P 4 /\ &@#_ "< _P T /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\ ?@#_
M (4 _@"+ /T D0#[ )< ^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C .\
M\P#N /\ [0#_ .P _P#K /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \ _P 0
M /\ %@#_ "( _P O /\ /0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T '\
M\P"& /$ C #O )( [@"8 .P GP#K *8 Z0"N .< N #E ,4 XP#: .$ [0#?
M /L W@#_ -T _P#= /\ W0#_ -T _P#= /\ _P\- /\,"P#_ PD _P , /\
M$@#_ !T _P I /L -P#X $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H Y0"
M ., A@#A (P WP"3 -T F0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#, /8
MR@#_ ,H _P#) /\ R #_ ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\ #@#_
M !8 ]P B .\ , #K #T Z !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z -
M@ #. (< S "- ,H E #( )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$ NP#^
M +D _P"X /\ N #_ +@ _P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X 1
MZ  : ., * #= #8 V !" -( 30#. %< R@!? ,< 9@#% &T PP!T ,$ >@"_
M ($ O0"( +L CP"Y )< MP"? +4 J "S +, L0#" *\ V "N NT K /[ *L%
M_P"J!O\ J0;_ *D&_P"I!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@ W0,2
M -0#( #-!"T R 0Z ,,%1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q"'L
MKPB" *X)B@"L"9( J@F; *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T._P"<
M#_\ FP__ )L/_P";#_\ _QH  /<9  #J'@  WQX  -4:  #0$P( S@P+ ,<+
M%@# #24 N@XR +8./P"R#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78 HA%]
M *$1A0"?$HX G1*7 )P2H@":$ZT F!.\ )<4T "4%>P DA;] ) 7_P"/%_\
MCA?_ (X7_P".%_\ ^AT  .XC  #?*   T"H  ,<G  #!(0  O1D% +D2$ "R
M%1X K18L *@7. "D&$, H1E, )\95 "<&EP FAIB )D::0"7&W  E1MW )0;
M?P"2'(@ D!R2 (\<G0"-':D BQVW (H>R@"('^< AB#Z (0@_P&#(/\!@R#_
M 8(@_P&"(/\!]20  .4L  #3,0  QC,  +PQ  "V+0  L"4  *P=# "F'A@
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MC )E.)D#9#FH V(YN0-A.M #8#KN V Z_P-?.O\"7SK_ E\Z_P)?.O\"W3L
M ,=#  "Y20  KDL  *1,  ";2@  DD4  (D_  "!.@D >SH4 '<[( !T/"L
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M!%!'L01/1\<$3D?G!$Y'^P1.1_\#3D?_ T]'_P-/1_\#S$8  +M.  "O5
MI%<  )I8  "15P  AE0  'M.  !P2@  :4@- &5(%@!B22$ 7TDK %U)- !;
M23P 64E# %=)2@!625( 54I9 51*80%22FH!44IU D]*@0-.2H\#3$N?!$M+
ML 1*2\4$24OF!$E+^@1)2_\#2DO_ TI+_P-*2_\#R$D  +A1  "L5P  H5L
M )A<  ".7   @UD  '93  !K3@  9$T* %],$P!<31X 6DTH %A-,0!633H
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M SI8]P,Z6/\#.U?_ SM7_P,[5_\#O%0  *Y<  "C8P  F6<  )!I  "%:0
M>6<  &MB  !@8   55T  $Y;# !+6Q0 25P? $=<* !&73$ 15TY $-=00!"
M74@ 05Y0 $!>6  ^7F$!/%YL 3M>> (Y7H<"-UZ7 C9>J0,U7KT#-%_= S1>
M]0,U7?\"-5W_ C5<_P(U7/\"N%D  *IA  "@9P  EFP  (QN  "!;@  =FP
M &=I  !<9@  460  $AB"0!$8A$ 0F(; $%C)  _8RT /F,U #UD/0 \9$4
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M 2!Q_P$@<?\!J6L  )YS  "4>0  BGP  (!^  !T?P  9W\  %I_  !-?@
M0WX  #A]   O?0( *'T- "9]%  D?1P (WXE ")^+0 A?C8 (7X_ !]_2  >
M?U( '7]> !Q_:P :?WH &7^, !=_GP 6?[, %7_. !5^[P 6?/\ %GO_ !9[
M_P 7>_\ I'(  )IZ  "/?P  A8(  'N$  !MA@  8(<  %2'  !(B   /(@
M #*(   HB   ((@% !J)#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3BDP
M$HM8 !&+90 0BW4 #XN'  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&_P .
MAO\ GWL  )2!  "*A0  @(@  '.+  !EC0  68\  $R0  !!D@  -)(  "J2
M   ADP  &90  !*6!@ .EPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0 ")=0
M  :77@ %EVX  Y:   &6E   E:@  )6^  "4X   E/0  )/_  &2_P !DO\
MF((  (Z(  "%C   =X\  &J2  !=E0  4)@  $2:   XFP  +)P  "*=   9
MG@  $J    VB @ 'HPL  :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(  "D
M5@  I&4  *-W  "CBP  HZ   **V  "AT@  H?   *#[  "@_P  H/\ D8H
M (F.  ![D@  ;9<  &";  !3G@  1J$  #FC   MI   (Z8  !FH   1J@
M#*P   6N    KP<  *\-  "O$0  L!@  + @  "Q*   L3(  +(^  "R3
MLEL  +)L  "R@0  L9<  +&L  "PQ@  L.@  *_W  "O_P  K_\ C)   '^5
M  !QF@  8Y\  %6D  !'J   .JH  "VL   BK@  &+   !"S   *M0   K@
M  "[    NP   +P'  "\#0  O1$  +X6  "_'@  P"<  ,$R  #"0   PT\
M ,-@  ##=   PXL  ,.A  ##N   PM<  ,+O  #"^@  P?X @9<  '.=  !E
MHP  5Z@  $FM   [L0  +;,  "&V   6N0  #KL   >^    P0   ,4   #'
M    R    ,D   #*!0  RPL  ,T/  #.%   T!P  -,F  #6,@  V$$  -A3
M  #99@  V7P  -F4  #9JP  V<,  -GA  #9\   V?0 =I\  &>F  !9K
M2[(  #RW   NN@  (;T  !7    -Q   !<<   #*    S@   -(   #5
MU@   -D   #;    W0   -\'  #A#   XQ$  .89  #I)   [#(  .U#  #N
M5@  [VL  .^$  #OG   [[(  ._&  #OW0  [^0 :J@  %NO  !,M@  /KP
M "_    @Q   %,@   S,   "T    -0   #9    W@   .(   #E    Y@
M .@   #I    [    .X   #P @  \@D  /4/  #X%P  _",  /\S  #_1@
M_UH  /]Q  #_B0  _Y\  /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7 /\
M'0#_ "@ _P W /\ 1 #_ %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4 _P"+
M /\ D0#_ )< _P"= /\ I #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X /\
M]P#_ /< _P#W /\ \ #_ .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\ %P#_
M "0 _P R /\ /P#_ $P _P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "& /H
MC #Y )( ^ "8 /8 GP#U *8 ] "N /( N0#P ,8 [@#> .T \ #K /X Z@#_
M .D _P#I /\ YP#_ ., _P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_ !\
M_P L /\ .@#_ $8 _@!2 /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X AP#L
M (T Z@"3 .D F@#G *$ Y@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_ -<
M_P#5 /\ U0#_ -4 _P#4 /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D ^P F
M /< - #T $  \@!, .X 5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#< (<
MV@"- -8 E #4 )L T0"C ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,, _P##
M /\ PP#_ ,, _P## /\ _PL! /\#  #_    _P # /\ "P#S !( [@ ? .H
M+0#F #H X@!% -X 3P#9 %@ U !@ -$ : #. &X S !T ,H >P#( ($ Q@"'
M ,0 C@#" )8 P "> +X IP"[ +( N0#  +< U "U .P LP#[ +, _P"R /\
ML@#_ +$ _P"Q /\ _PT  /\&  #_ P  ]P   /0  P#G  T X  8 -H )0#3
M #( S@ ^ ,H 20#& %( PP!: ,  80"^ &@ O !N +H = "X 'L M@"! +0
MB "R )  L "9 *X H@"L *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\ H@#_
M *( _P"B /\ _Q   /L,  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$ "H
MOP W +L 0@"W $L M !4 +( 6P"O &( K0!H *L ;@"I '4 J ![ *8 @P"D
M (L H@"4 *  G@"> :@ G *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_ )0)
M_P"4"?\ _!$  /$5  #C&0  UAD  ,P5  #'$   Q <* +T#% "W!"$ L@8N
M *X(.@"J"40 IPE- *0*50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7#(8
ME@R0 )0,F@"2#:8 D0VS (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1_P"'
M$?\ ]AD  .<@  #6)   R"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G *$0
M,P"=$3X FA%' )@23P"5$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$ B12+
M (<4E@"&%:( A!6P (,6P0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![&?\
M[R$  -TI  #*+0  OB\  +4L  "N)P  J"   *,7" ">%A, F1<A )09+0"1
M&C@ CAI! (L;20")&U  AQM7 (4<7@"$'&0 @AQK ( <<P!_'7P ?1V& 'P>
MD0!Z'IX >!^K '<?O !V(-0 ="'P '(A_P!Q(O\ <2'_ '$A_P!Q(?\ Z"@
M -(P  #"-0  MS<  *TU  "E,0  GBL  )@C @"2'A  C2 ; (DA)P"&(C(
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M 5PSL0%;-,8!6C3F 5DU^P%9-?\!633_ 5DT_P%9-/\!TC@  ,!   "S10
MJ$@  )Y(  "51@  BT   (([  !Y-00 <S,0 &\T&@!L-"4 :34O &<U-P!E
M-C\ 8S9& &(V30!@-E0 7S9; %TW8P!<-VL 6S=V 5DW@@%8.(\!5CB> 54X
MKP)4.<,"4SGD E,Z^0%3.?\!4CG_ 5,Y_P%3.?\!S3P  +Q$  "O20  I$P
M )I,  "12P  AT8  'U   !S.P  ;#@- &@Y%P!E.2( 8SHK & Z- !>.CP
M73I# %LZ2@!:.U  6#M8 %<[8 !6.V@ 53QS 5,\?P%2/(T!4#V< 4\]K ).
M/L$"33[A DT^^ )-/O\!33[_ 4T]_P%-/?\!R4   +A(  "L30  H5   )=1
M  ".3P  A$L  'E%  !N0   9CT+ &(]% !?/1X 7#XH %H^,0!8/C@ 5SY
M %4_1@!4/TT 4S]5 %) 70!00&8 3T!P 4Y ? %,08H!2T&: DI!JP))0KX"
M2$+> DA"]@)(0O\"2$+_ 4A!_P%(0?\!Q40  +5+  "I4   GE0  )54  "+
M4P  @%   '5*  !J1@  84(( %Q!$0!90AL 5T(E %5"+@!30C4 44(] $]"
M0P!/0TL 3D-2 $U$6@!+1&, 2D1N 4E%>@%'18@!1D68 D5&J0)$1KT"0T;<
M D-&]0)#1O\"0T;_ 4-%_P%#1?\!P4<  +)/  "F5   G%<  ))8  "(6
M?E4  '%/  !F2@  7$8% %=&#P!41A@ 448B $]&*P!.1C, 3$<Z $M'00!*
M1TD 24A0 $A(6 !'2&$ 14EL $1)> %"288!04F6 4!*IP(_2KL"/DO8 CY*
M\P(^2O\"/DG_ 3])_P$_2?\!O4H  *]2  "C6   F5L  )!=  "&7   >UD
M &U3  !B3P  5TP! %%*#0!.2A4 3$L? $I+* !)2S  1TLX $9,/P!%3$8
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M 2Y7_P$N5O\!LE<  *5?  ";90  D6D  (=J  !\:@  <6@  &-E  !88@
M35\  $-= @ \6PT .EP4 #A<'0 W7"8 -5TN #1=-@ S73X ,EU& #%>3@ P
M7E< +UYB "U>;@ L7WT *E^. "E?H  H7[,!)U_, "=?[0$G7O\!)UW_ 2A=
M_P$H7/\!K5P  *)D  "8:@  CFX  (-O  !Y;P  ;FX  &!K  !4:0  26<
M #]E   U8PD ,F,1 #!C&0 O9"$ +F0I "UD,0 L9#D *V5" "IE2@ H950
M)V5? "9F:P D9GH (V:+ ")FG0 @9K$ 'V;) !]FZP @9?X (&3_ "!C_P$A
M8_\!J6(  )YJ  "5<   BG,  (!U  !U=0  :70  %QR  !/<0  1&\  #IN
M   P;0, *6P- "=L%  F;!P )6TD "1M+  C;30 (FT] "%N1@ @;E  'FY;
M !UN9P <;G8 &FZ' !EOF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8:_\
MI&D  )IQ  "0=@  AGD  'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X   K
M=P  (G8' !UV#P <=Q8 &W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6 !-X
M8P 2>'( $7B# !!XEP />*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\ GW$
M )5X  "+?   @G\  '>!  !J@@  78(  %""  !$@@  .((  "Z"   D@@
M'((  !2""0 1@Q  $(,6 !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#70 )
M@VP "(-^  :#D0 %@J4  X*[  2!VP $@?( !8#_  9__P &?_\ FGD  )!^
M  "&@P  ?84  &^'  !BB0  58H  $F+   ]C   ,8P  ":,   =C0  %8X
M  ^/ P *D P !I 1  2/&  #CR   8\I  "/,@  D#T  )!)  "/5@  CV4
M (]V  "/B@  CI\  (ZT  "-SP  C.X  (S[  "+_P  B_\ E(   (N%  ""
MB0  =(P  &:/  !9D0  3),  $"5   TE@  *)8  !Z7   5F   #YH   J;
M   "G D  )P.  "<$P  G!H  )PB  "=*P  G34  )U   "=3@  G5P  )UN
M  "<@0  G)<  )RL  ";Q@  FN@  )GY  "9_P  F/\ CH@  (:,  !XD
M:I0  %R7  !/F@  0IT  #:>   IGP  'Z$  !6B   .I   "*8   "H
MJ00  *D*  "I#@  J1,  *H:  "J(@  JRL  *PV  "L1   K%,  *QC  "L
M=P  JXX  *ND  "KO   JMX  *GT  "I_0  J?\ B8X  'N3  !MEP  7YP
M %&@  !$I   -J8  "JH   >J0  %*L   VN   &L    +(   "U    M0
M +4#  "V"0  MPX  +@2  "X&0  NB$  +LK  "\.   O4<  +U8  "]:P
MO8$  +V9  "]L   O<P  +SJ  "\]P  N_X ?I4  '";  !BH   4Z4  $:J
M   XK0  *J\  !ZQ   3M   #+<   .Y    O    +\   #"    P@   ,,
M  #$    Q@8  ,<,  #($   RA8  ,P@  #/*P  T#H  -%+  #17@  TG,
M -*+  #2I   T[L  -/8  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS   J
MM@  ';D  !*\   *OP   ,,   #&    R0   ,T   #/    T    -(   #4
M    U@   -D"  #;"   W@X  .$3  #D'0  Z"H  .@\  #I3P  Z60  .I\
M  #KE0  ZZP  .O"  #LU0  [.4 9J8  %BL  !)LP  .[D  "N\   =P
M$<0   G(    S    ,\   #3    V0   -T   #@    X0   .,   #E
MYP   .H   #L    [@0  /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ  #_
M@P  _YL  /^N  #_O@  _\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8 _P T
M /\ 00#_ $T _P!8 /\ 8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_ ),
M_^)]$$E#0U]04D]&24Q% ! 2_P"9 /\ H #_ *< _@"O /P N@#Z ,D ^0#A
M /@ \P#W /\ ]@#_ /4 _P#Q /\ Z0#_ .0 _P#A /\ _P / /\ #0#_  T
M_P . /\ % #_ "$ _P N /\ / #_ $@ _P!3 /\ 70#_ &8 _@!M /P =0#[
M 'L ^0"" /@ B #W (X ]@"4 /0 FP#S *( \0"J .\ M #M ,$ ZP#5 .H
M[ #H /P YP#_ .4 _P#F /\ X #_ -D _P#4 /\ _P + /\ " #_  8 _P )
M /\ $ #_ !P _P I /\ -@#_ $( ^P!. /< 5P#T &  \@!H .\ ;P#M '8
M[ !\ .H @@#H (@ YP". .4 E0#C )P X0"D -\ K@#= +D V@#* -< Y #4
M /8 T0#_ -  _P#0 /\ SP#_ ,L _P#' /\ _P # /\   #_    _P $ /\
M#0#Z !8 ]@ C /, , #P #P [0!' .D 40#E %H X@!B -\ :0#= &\ V@!V
M -@ ? #4 (( T@"( -  CP#- )8 RP"> ,D J #' +, Q0#! ,( V #  .\
MOP#^ +X _P"] /\ O #_ +P _P"\ /\ _P(  /\   #_    _P   /0 !P#M
M !$ Z  < ., *0#? #4 VP!! -8 2P#1 %0 S0!< ,H 8P#( &D Q@!O ,,
M=0#! 'L OP"" +X B "\ )  N@"8 +@ H@"U *P LP"Y +$ RP"O .< K@#X
M *P _P"K /\ K #_ *P _P"K /\ _P0  /\   #V    [@   .<   #?  P
MU@ 5 ,\ (@#* "X QP Z ,, 1 #  $T O !5 +D 7 "W &, M0!I +, ;P"Q
M '4 KP![ *T @@"K (H J0"2 *< G "E *8 HP"S *$ PP"? -X G@#R )T
M_P"< /\ G #_ )L _P"; /\ _P<  /8)  #I"P  WPH  -4$  #.  4 Q@ 0
M ,  &@"[ "< MP R +, /0"P $8 K0!/ *H 5@"H %P I@!C *0 : "B &\
MH0!U )\ ? "= (0 FP"- )D EP"7 *( E0"N ), O0"1 -, D #M (\ _ ".
M /\ C0'_ (T!_P"- ?\ ^0X  .H2  #<%0  S14  ,01  "^#   N@(* +0
M$@"N !X J@ J *8 -0"B #\ H !( )T!4 "; E8 F0)< )<#8P"5 VD DP-O
M )$$=@"0!'\ C@6( (P%D@"*!IX B :J (8'N@"%",\ A KK ((+_ "!#/\
M@ S_ ( ,_P" #/\ \14  . =  #-(   P2$  +@=  "Q%P  K!   *@)#0"B
M!Q8 G0DC )D*+@"5"S@ DPQ! ) ,20".#5  C U7 (H-70"(#6, APUJ (4.
M<0"##GH @@Z$ ( .CP!^#YL ? ^H 'L0N !Z$,X >!'L '82_P!U$O\ =!/_
M '03_P!T$_\ Z!X  -,F  ##*@  N"H  *XH  "G(P  H!P  )L3 P"6#Q
MD! ; (P1)P")$C( AA,[ (030P""%$L @!11 'X45P!\%%X >Q5E 'D5; !W
M%70 =A9^ '06B@!R%Y8 <1>D &\8M !N&,D ;1GH &L:_ !J&_\ :AO_ &H;
M_P!J&_\ X"8  ,HM  "\,0  L#,  *<Q  "?+   ER8  ) ?  "*%PP A1@6
M ($9(@!^&BP >QLV 'D;/@!W'$4 =1Q, ',<4P!Q'5D <!U@ &X=9P!M'G
M:QYZ &H>A0!H'Y( 9Q^@ &4@L !D(<4 8R'D &(B^@!A(O\ 82+_ &$B_P!A
M(O\ URP  ,,T  "V.   JCD  *$X  "8-0  D"\  (@H  " (0@ >R 2 '<A
M'0!T(B< <2(Q &\C.0!M(T$ :R-( &DC3@!H)%4 9B1; &4D8P!C)6L 8B5U
M &$E@0!?)HX 7B:= %TGK0!;*,$ 6RC@ %HI]P!9*?\ 62G_ %DI_P!9*/\
MSS(  +XY  "Q/0  IC\  )P_  "3/   BC8  ($P  !Y*@, <B8/ &XG&0!K
M*", :2@L &8I-0!E*3P 8RE# &$J2@!@*E$ 7BI7 %TJ7P!<*V@ 6BMR %DL
M?0!8+(L 5BV: %4MJ@!4+KT 4R[< %(O]0!2+_\ 4B[_ %(N_P!2+O\ RC8
M +H]  "M0@  HD0  )A$  "/00  A3P  'LW  !R,0  :RP, &<M%0!D+1\
M82XH %\N,0!=+CD 7"]  %HO1@!8+TT 5R]4 %8P7 !5,&0 4S%N %(Q>@!1
M,8@ 4#*7 $XRJ !-,[L 3338 $PT\P!,-/\ 3#3_ $PS_P!,,_\ QCH  +9"
M  "I1@  GDD  )5)  "+1P  @4(  '<]  !M-P  9#() & R$@!=,AP 6C(E
M %@S+0!6,S4 53,\ %,T0P!2-$H 4311 % T60!/-6$ 335L $PV=P!+-H4
M2C>5 $@WI@!'.+@!1SC3 48X\0%&./\!1CC_ $8X_P!&-_\ P3X  +)%  "F
M2@  G$T  ))-  "(2P  ?D<  '-"  !I/0  7S<& %HV$ !7-Q@ 5#<B %(W
M*@!0-S( 3S@Y $TX0 !,.$< 2SA. $HY5@!).5\ 2#II $<Z=0!%.X, 1#N3
M $,\I %"/+8!03W0 4$]\ %!/?\!03S_ 4$\_P%!//\ OD(  *])  "C3@
MF5   (]1  "%4   >TP  &]&  !E0@  6CT" %0[#@!1.Q4 3SL? $T[)P!+
M.R\ 23PV $<\/0!'/$0 1CU+ $4]5 !$/EP 0SYG $(_<P! /X$ /S^1 #Y
MH@ ]0+4!/$'. 3Q![@$\0?\!/$#_ 3Q _P$]/_\!ND4  *Q,  "A40  EU0
M (U5  "#5   >%$  &Q+  !A1P  5D(  $] # !,/Q, 24 < $= ) !&0"P
M1$ S $- .@!"04( 04%) $!"40 _0EH /D-E #U#<0 [0W\ .D2/ #E$H  X
M1;,!-T7+ 3=%[ $W1?\!-T3_ 3A$_P$X0_\ MTD  *E0  ">50  E%@  (M9
M  " 6   =E8  &A0  !=3   4T@  $I%"0!&1!$ 1$09 $)$(@!!12D /T4Q
M #Y%.  ]13\ /$9' #M&3P Z1U@ .4=B #A(;@ V2'P -4B- #1)G@ S2;$
M,DG) #%)ZP R2?X ,DC_ #)(_P S2/\ M$P  *=4  "<60  DEP  (A=  !^
M70  <UH  &55  !;4@  4$X  $9*!0! 20X /DD6 #U)'@ [2B8 .DHN #E*
M-0 X2ST -TM$ #9+30 T3%8 ,TQ@ #),;  Q37H ,$V+ "Y-G  M3J\ +$['
M "Q.Z0 L3?T +4W_ "U,_P M3/\ L%   *18  "970  CV$  (9B  ![80
M<%\  &);  !86   3E4  $-1 0 [3PP .$\3 #9/&P U3R, -% K #-0,@ R
M4#H ,5!" #!12@ N45, +5)= "Q2:0 K4G@ *5*( "A3F@ G4ZT )E/% "93
MYP F4_P )U+_ "=1_P G4?\ K%4  *!<  "68@  C68  (-G  !X9@  ;64
M &!A  !57@  2EL  #]8   U5@@ ,540 #!6%P N5A\ +58G "Q6+P K5S8
M*E<^ "E71P H5U  )EA: "589P D6'4 (UF& "%9F  @6:L 'UG" !]9Y0 ?
M6/H (%C_ "!7_P A5_\ J%H  )UB  "39P  BFL  ']L  !U;   :FL  %UH
M  !190  1F,  #M@   Q7@, *ET- "A=$P F71L )5XC "1>*@ C7C( (EXZ
M "%>0P @7TP 'U]7 !Y?8P <8'$ &V"" !E@E0 88*D %V#  !9@X@ 77_D
M&%[_ !E>_P 97?\ I&   )EH  "0;@  AG   'QR  !R<@  9G$  %AN  !,
M;   06L  #9I   M9P  (V8( !]F#P =9A4 '&8= !MF)0 :9BT &6<U !AG
M/@ 79T@ %F=3 !5H7P 3:&X $FA_ !%HD@ 0:*8 #VB]  YHX  09_< $&;_
M !%E_P 19?\ GV<  )9O  ",<P  @G8  'AX  !M>   8'<  %-V  !&=
M.W,  #%R   G<0  'G$  !9P"@ 3<!  $W 7 !)P'P 1<2< $'$O !!Q.  .
M<4( #G%.  UQ6P ,<6D "W%Z  IQC0 (<:$ !G&V  9PT@ '<.\ "&__  EN
M_P );O\ FV\  )%U  "'>0  ?GP  '1^  !F?@  67X  $U^  ! ?0  -7T
M "I\   A?   &'P  !%\!  ,? P "GP1  E\&0 (?"$ !WPI  9\,@ $?#T
M WQ(  %\50  ?&,  'QT  !\AP  >YP  'NQ  !ZRP  >>L  'GZ  !Y_P
M>/\ EG<  (Q\  "#@   >8,  &R$  !>A0  488  $6'   YAP  +8<  ".'
M   :AP  $H<   V( 0 &B0H  8D/  ")%   B!L  (@C  ")+   B38  (E"
M  "(3@  B%T  (AM  "(@0  AY4  (>K  "&Q   A>8  (3X  "$_P  A/\
MD'X  (>#  !^AP  <8D  &.+  !6C0  28\  #R1   PD0  ))$  !J2   2
MDP  #90   :5    E@8  )8,  "5$   EA4  )8=  "6)   EBX  )8Y  "6
M1@  EE4  )9E  "6>   E8X  )6D  "4O   D]\  )/U  "2_P  DO\ BX8
M (.*  !UC0  9Y   %F4  !,EP  /YD  #*:   FFP  &YP  !*=   ,GP
M!*    "B    HP$  *,'  "C#   HQ   *05  "D'   I24  *8O  "F/
MIDL  *9;  "F;@  I80  *6;  "DLP  H]   */O  "B_   HO\ AHT  'B1
M  !JE0  7)D  $Z=  !!H   ,Z(  ":C   ;I0  $:<   JI   !JP   *T
M  "O    L    +    "P!0  L0L  +(/  "S%   M!L  +4D  "W,   MS\
M +=0  "W8@  MW@  +>0  "VJ0  ML(  +;D  "V]0  M?X >Y,  &V8  !?
MG0  4*(  $*F   TJ0  )JL  !JM   0KP  ";(   "T    MP   +H   "\
M    O0   +X   "^    P (  ,$(  #"#0  Q!(  ,89  #))   RC(  ,M#
M  #+50  S&H  ,R#  #,G   R[4  ,S.  #,Z0  S/8 <)L  &&A  !2I@
M1*L  #:P   GL@  &K4  !"X   'NP   +X   #!    Q    ,@   #+
MRP   ,T   #.    T    -(   #5 P  V H  -L0  #>&   XB0  .,U  #D
M2   Y5P  .9S  #FC0  YJ4  .:\  #FTP  Y^< 8Z0  %6J  !&L   .+4
M "BY   :O   #\    7$    QP   ,L   #/    U    -@   #<    W0
M -\   #A    XP   .4   #H    Z@   .T&  #Q#@  ]18  /@E  #Y.
M^4T  /IC  #[?   _)4  /RJ  #\NP  _<L _P / /\ #@#_  X _P 0 /\
M%@#_ ", _P P /\ /0#_ $D _P!4 /\ 7@#_ &8 _P!N /\ =@#_ 'P _P""
M /\ B0#_ (\ _P"5 /X FP#] *, ^P"K /H M0#Y ,, ]P#; /8 \ #T /\
M\P#_ /( _P#L /\ X@#_ -P _P#6 /\ _P , /\ "0#_  @ _P * /\ $@#_
M !X _P K /\ . #_ $0 _P!/ /\ 60#^ &$ _ !I /H < #X '< ]P!] /8
M@P#T (D \@"/ /$ E@#O )T [0"E .P KP#J +P Z #- .8 Z #D /H XP#_
M .( _P#@ /\ U0#_ ,X _P#+ /\ _P & /\  0#_    _P $ /\ #@#_ !D
M_P E /T ,@#[ #X ]P!) /, 4P#P %P [@!C .P :@#J '$ Z !W .8 ?0#D
M (, X@") .  D #> )< W "? -D J0#6 +0 TP#$ -  W@#. /, S #_ ,L
M_P#* /\ R #_ ,( _P"^ /\ _P   /\   #_    _P   /L "P#V !, \0 @
M .T + #J #@ YP!# ., 30#@ %8 W != -D 9 #5 &L T@!Q -  =@#. 'P
MS "# ,H B0#( )$ Q@"9 ,0 HP#! *T OP"[ +T SP"[ .L N0#\ +< _P"W
M /\ M@#_ +0 _P"Q /\ _P   /\   #_    ]@   .X !0#G  \ X0 9 -L
M)0#5 #$ T@ \ ,X 1@#* $\ QP!7 ,0 7@#! &0 OP!J +T < "[ '8 N0!\
M +@ @P"V (H LP"3 +$ G "O *< K0"S *L Q0"I .$ IP#U *8 _P"E /\
MI #_ *0 _P"D /\ _P   /P   #Q    Z    .    #4  L S  3 ,< 'P#"
M "H OP U +P /P"X $@ M0!0 +, 5P"P %X K@!D *P :0"K &\ J0!U *<
M? "E (0 HP", *$ E@"? *$ G0"M )H O "8 -( EP#N )4 _@"4 /\ E0#_
M )4 _P"5 /\ _ $  / %  #C!P  U04  ,P   #%  0 O@ . +@ %P"S ",
MKP N *L . "I $$ I@!* *, 40"A %< GP!= )T 8P"; &D F@!O )@ =@"6
M 'T E "& )( D "0 )L C@"G (P M@"* ,D B #G (< ^0"' /\ A@#_ (8
M_P"& /\ ] P  .00  #1$@  Q1$  +T.  "V"   L0 ( *L $0"F !L H0 F
M )X ,0": #H F !# )4 2@"3 %$ D0!7 (\ 70". &, C !I (H < "( '<
MA@"  (0 BP"" )8 @ "C 'X L0!] ,0 >P+A 'H#]0!Z!?\ >07_ '@&_P!X
M!O\ ZA,  -8:  #&'0  NAP  +$9  "J$P  I T  )\%# "9 !0 E0 ? )$"
M*0"- S, BP0\ (@%1 "&!DL A 91 (('5P"!!UT ?P=C 'T(:@!["'( >@A\
M '@)A@!V"9( = J@ ',*KP!Q"\$ < S? &\-]@!N#O\ ;0[_ &T._P!M#O\
MX1P  ,LC  "\)@  L28  *@D  "@'@  F1@  ),0 @"."PX B L7 (0,(@"!
M#2P ?@TU 'P./0!Z#D4 > Y+ '<.40!U#U@ <P]> '$090!P$&X ;A!W &P0
M@@!K$(\ :1&= &@1K0!F$L  91+? &03]@!C%/\ 8Q3_ &(4_P!B%/\ UB0
M ,,J  "U+@  JB\  * M  "8*   D"(  (D;  ""$P@ ?1$2 'D2' !V$R<
M<Q0P '$4. !O%3\ ;15& &P53 !J%E, :!99 &<680!E%FD 9!=R &(7?@!A
M&(L 7QB9 %X9J0!<&;P 7!K8 %H;\P!:'/\ 61S_ %D<_P!9'/\ S2H  +TQ
M  "O-0  I#8  )LT  "2,0  B2L  ($E  !Y'0, <Q@. &\9& !L&B( :1LK
M &<;,P!E'#L 9!Q! &(=2 !@'4X 7QU5 %T=7 !<'F0 6QYN %D?>0!8'X<
M5B"6 %4@I@!4(;@ 4R'2 %(B\0!2(_\ 4B/_ %(B_P!2(O\ R"\  +@V  "K
M.@  H#P  )8[  "-.   @S(  'HM  !R)@  :B , &8@$P!C(1T 82$F %\B
M+P!=(C8 6R(] %HC1 !8(TH 5R-1 %4C6 !4)&$ 4R1J %$E=@!0)8, 3R:3
M $XGHP!,)[4 3"C. $LH[@!+*?\ 2RC_ $LH_P!+*/\ PS0  +,[  "G/P
MG$$  ))   ")/@  ?SD  '4S  !L+0  8R<( %XF$0!<)AD 62<B %<G*P!5
M*#( 5"@Y %(H0 !1*$8 4"E- $XI50!-*5T 3"IG $LJ<P!)*X  2"N0 $<L
MH0!&+;, 12W+ $4N[ !$+O\ 1"[_ $4M_P!%+?\ OC@  + _  "D0P  F44
M (]%  "%0P  >SX  '$Y  !G-   7BX$ %@K#@!5*Q8 4BP? % L)P!/+"\
M32TV $PM/ !*+4, 22U* $@N4@!'+EH 1B]D $4O< !#,'X 0C"- $$QG@!
M,K$ /S+( #\SZ@ _,_X /S+_ #\R_P _,O\ NSP  *U#  "A1P  EDD  (Q)
M  "#2   >$0  &T^  !C.0  6C0  %(P# !/,!, 3# < $HP) !),2L 1S$R
M $8Q.0!$,4  0S)' $(R3P!!,U@ 0#-B #\T;0 ^-'L /36+ #PVG  [-J\
M.C?& #DWZ  Y-_P .C?_ #HV_P Z-O\ MT   *I&  ">2P  E$T  (I.  "
M3   =4@  &I#  !@/@  5CD  $TU"0!)-!$ 1S49 $4U(0!#-2@ 034O $ U
M-@ _-CT /C9% #TW30 \-U4 .SA@ #HX:P Y.7D .#F) #<ZFP U.JT -3O$
M #0[Y@ T._L -3O_ #4Z_P U.O\ M$,  *=*  "<3@  DE$  (A2  !^4
M<TT  &=(  !<1   4C\  $@Z!@!$.0\ 03D6 #\Y'@ ^.28 /#DM #LZ-  Z
M.CL .3M" #@[2@ W/%, -CQ= #4]:0 T/7< ,SZ' #$^F0 P/ZL +S_" "\_
MY  O/_H ,#__ # ^_P P/O\ L4<  *1-  "94@  CU4  (96  !\50  <5(
M &1,  !920  3T4  $5  P _/@T /#X3 #H^&P Y/B, -SXJ #8_,0 U/S@
M-#]  #- 2  R0%$ ,4%; #!!9P N0G4 +4*% "Q#EP K0ZH *D/  "E$X@ J
M0_D *D/_ "M"_P K0O\ KDH  *%1  "75@  C5D  (-:  !Y6@  ;E<  &%2
M  !73@  34L  $-'   Z0PH -D,1 #1#&  S0R  ,D0G #%$+P P1#8 +T4]
M "U%1@ L14\ *T99 "I&9  I1W( *$># "9'E0 E2*@ )$B^ "-(X  D2/<
M)4?_ "5'_P F1_\ JD\  )]5  "46@  BUX  (%?  !W7@  :UP  %]8  !5
M50  2U$  $!-   U2@< ,$D. "Y)%0 M21T +$DD "M**P J2C, *$H[ "=+
M0P F2TP )4M6 "1,8@ C3'  (4R  "!-DP ?3:8 'DV[ !U.W0 >3?8 'DS_
M !],_P @2_\ IU,  )Q:  "27P  B&,  'YD  !T8P  :6$  %Q>  !26P
M1U@  #Q5   R4@( *E , "=/$@ F4!D )5 @ "10*  C4"\ (E$W "%10  @
M44D 'E)3 !U27P <4FT &E-] !E3D  84Z0 %E.Y !53V0 64_0 %U+_ !A1
M_P 94?\ HUD  )A@  "/90  A6@  'MI  !Q:0  9F<  %ED  !-80  0E\
M #A<   N6@  )5@( "!7#@ >5Q0 '5<< !Q8(P ;6"L &E@S !E8/  86$4
M%EE0 !596P 466D $UIZ !):C0 16J$ $%JW  Y:U0 06?, $%G_ !%8_P 1
M6/\ GU\  )5F  ",:P  @FT  'AN  !N;P  8FT  %5J  !(:   /F8  #-E
M   I8P  (&$! !A@"P 58!  %& 7 !-@'@ 28"8 $F N !%A-P 084  #V%+
M  YA6  -868 #&)V  MBB0 *89T "6&R  AARP (8>L "6#]  I?_P +7_\
MFV8  ))M  "(<0  ?G,  '5U  !J=   7',  $]R  !#<   .&\  "UN   D
M;   &VL  !-K!  .:@P #6H2  QJ&0 +:B$ "FHI  EJ,@ (:CP !VM'  5K
M4P $:V$  FMQ  !JA   :I@  &JM  !IQ@  :><  &GX  !H_P  :/\ EVT
M (US  "$=P  >WH  '![  !C>P  5GH  $EZ   ]>0  ,7@  "=W   ==@
M%78   ]V @ )=@H !'8/  !V%0  =AP  '8D  !U+   =38  '5!  !U3@
M=5P  '5L  !U?@  =),  '2H  !SP   <^,  '+W  !R_P  <?\ DG4  (EZ
M  " ?@  =H   &F!  !;@@  3H(  $&"   U@P  *8(  !^!   6@0  $((
M  J"   "@P<  ((-  ""$0  @A<  ((>  "")@  @B\  (([  ""1P  @E4
M (%E  "!>   @8T  ("B  !_N@  ?]T  '[T  !]_P  ??\ C7P  (2!  ![
MA   ;H8  &"(  !2B@  18L  #F,   LC   (8P  !>,   0C0  "8X   */
M    D ,  (\)  "/#@  CQ(  ) 8  "0'P  D"@  ) R  "0/P  D$T  )!=
M  "/<   CX4  (Z<  ".LP  C=   (SP  "+_@  B_\ B(0  ("(  !RBP
M9(T  %:0  !(DP  .Y4  "Z6   BE@  %Y<   ^8   (F0   )L   "=
MG0   )T#  "="0  G0T  )X1  ">%P  GQ\  )\I  "@-0  H$,  *!4  "@
M9@  GWL  )Z3  ">JP  G<8  )WI  "<^0  G/\ @XL  '6.  !GD@  698
M $N9   ]G   ,)X  ".?   7H   #J(   >D    I@   *@   "J    J@
M *H   "K 0  JP<  *P,  "M$   KA8  *\>  "Q*0  L3@  +%(  "Q6@
ML6\  +&(  "QH   L+H  *_=  "O\@  K_T >)$  &J6  !<F@  39\  #^C
M   QI@  (Z<  !>I   .JP  !:X   "P    L@   +4   "W    MP   +@
M  "Y    N@   +P#  "]"0  O@X  , 4  ##'@  Q2L  ,4\  #&3@  QF(
M ,9Z  #&E   QJT  ,;(  #%Y0  Q?, ;)D  %Z>  !/I   0:@  #*L   D
MKP  %K$   VT   #MP   +H   "]    P    ,0   #&    Q@   ,@   #)
M    RP   ,P   #.    T 8  -,-  #8$P  W!X  -XM  #?0   X%0  .%K
M  #AA0  X9\  .&W  #ASP  X>8 8*$  %*G  !#K0  -+(  "6U   7N0
M#;P   &_    PP   ,<   #*    SP   -,   #6    UP   -H   #<
MWP   .$   #C    Y@   .D!  #L"P  \!(  /,?  #T,0  ]D8  /=<  #X
M=   ^(\  /FF  #YN   ^,D _P - /\ "P#_  L _P . /\ $P#_ !\ _P L
M /\ .0#_ $4 _P!0 /\ 60#_ &( _P!J /\ <0#_ '< _P!^ /\ A #^ (H
M_0"0 /P EP#Z )X ^0"G /< L0#V +X ]0#2 /, [ #Q /X \ #_ /  _P#F
M /\ W #_ -( _P#- /\ _P ' /\ ! #_  ( _P & /\ $ #_ !L _P G /\
M,P#_ #\ _P!* /X 5 #[ %T ^0!D /< :P#U '( \P!X /( ?@#P (0 [P"*
M .T D0#L )D Z@"A .@ JP#F +8 Y #' .( XP#@ /< W@#_ -T _P#9 /\
MS #_ ,4 _P#! /\ _P   /\   #_    _P ! /\ #0#_ !8 _  B /D +@#V
M #D \P!% .\ 3@#L %< Z0!> .8 90#D &P X@!R .  =P#? 'X W0"$ -L
MBP#8 )( U0"; -( I #/ *\ S0"^ ,L U0#) .\ QP#_ ,4 _P#$ /\ O@#_
M +@ _P"U /\ _P   /\   #_    _@   /< "0#Q !$ ZP < .< * #D #,
MX0 ^ -T 2 #8 %$ TP!8 -  7P#. &4 S !K ,H <0#( '< Q@!] ,0 A #"
M (P P "4 +X G@"[ *@ N0"V +< R "U .8 LP#Z +$ _P"P /\ L #_ *P
M_P"I /\ _P   /\   #Z    \0   .@  P#@  T V  6 -$ (@#- "T R@ W
M ,8 00#" $H OP!2 +T 60"Z %\ N !E +< :@"U '  LP!V +$ ?0"O (4
MK0"- *L EP"I *$ IP"N *4 O@"B -@ H #R )\ _P"> /\ G@#_ )X _P"<
M /\ _P   /<   #K    X0   -8   #+  D Q0 1 +\ &P"[ "8 MP Q +0
M.@"Q $, K@!+ *L 4@"I %@ IP!> *8 9 "D &D H@!P *  =@"> 'X G "&
M )H D "8 )L E@"G )0 M@"2 ,H D #I (\ _ ". /\ C0#_ (P _P"- /\
M^    .D"  #; P  S $  ,0   "]  ( M@ - +  %0"K "  IP J *0 - "A
M #P G@!$ )P 2P": %( F !8 )8 70"5 &, DP!I )$ < "/ '< C0"  (L
MB@") )4 AP"A (4 KP"# ,$ @0#@ (  ]0!_ /\ ?P#_ '\ _P!_ /\ [@H
M -P.  #*$   O@X  +4+  "O P  J0 ' *, $ "> !@ F0 C )8 + "3 #4
MD  ^ (X 10", $L B@!1 (@ 5P"& %T A0!C (, :@"! '$ ?P!Z 'T A ![
M (\ >0"< '< J@!U +L = #4 '( \ !R /\ <@#_ '$ _P!Q /\ XQ$  ,T7
M  "_&0  LQD  *H5  "C$   G0H  )<!"@"1 !( C0 ; (D )0"% "\ @P W
M (  /@!^ $4 ?0!+ 'L 40!Y %< > != '8 9 !T 6L <@%T ' "?P!N HL
M; .8 &L#I@!I!+< : 7. &<'[ !F"/T 9@G_ &4)_P!E"?\ UAH  ,0@  "V
M(P  JR,  *$@  "9&P  DA0  (P. 0"&!PT @ 04 'P&'@!Y!R@ =@@P '0(
M. !R"3\ < E% &\*3 !M"E( ; I8 &H+7P!H"V< 9PMP &4,>@!C#(< 8@R5
M & -I !?#;8 7@W. %P.[0!<#_\ 6Q#_ %L0_P!;$/\ S2$  +PH  "O*P
MI"L  )HI  "2)   B1\  ((8  ![$04 =0T/ '$-%P!N#B$ :PXJ &D/,@!G
M$#D 91!  &001@!C$$T 81!3 %\16@!>$6( 7!%K %L1=@!9$H, 6!*2 %83
MH@!5$[0 5!/+ %,4[ !2%?\ 4A;_ %(5_P!2%?\ QB@  +8N  "I,@  GS(
M )4Q  ",+0  @R<  'HA  !R&@  :Q,+ &<3$P!D%!P 810E %\5+0!=%30
M7!4[ %L60@!9%D@ 6!9/ %875@!5%UX 4Q=G %(8<@!0&'\ 3QF. $X:GP!,
M&K  2QO' $L;Z0!*'/T 2AS_ $H<_P!*'/\ P2T  +$T  "E-P  FC@  ) W
M  "'-   ?2\  '0I  !L(P  9!P' %X9$ !;&A@ 61LA %<;*0!5&S  5!PW
M %(</0!1'$0 3QU+ $X=4@!-'5H 2QYC $H>;@!)'WP 1Q^+ $8@G !%(:X
M1"'$ $,BY@!#(OP 0R+_ $,B_P!#(O\ O#(  *TX  "A/   ESX  (T]  "#
M.@  >34  &\P  !F*@  7B0" %<@#0!4(!0 42 = $\A)0!.(2P 3"$S $LB
M.@!)(D  2")' $<B3@!&(U< 1"-@ $,D:P!")'D 026( #\FF0 ^)JL /2?!
M #TGXP ]*/H /2C_ #TG_P ])_\ N#8  *H]  ">0   E$(  (I"  " /P
M=CL  &PV  !B,   62H  %$E"P!-)1$ 2R49 $DE(0!')B@ 128O $0F-@!#
M)CT 0B=$ $$G2P _*%0 /BA= #TI:0 \*78 .RJ& #DKEP X*ZD -RR_ #<L
MX  W+/@ -RS_ #<L_P X+/\ M3H  *=   "<1   D48  (=&  !]1   <T
M &@[  !?-@  53$  $PK!P!'*0\ 12H6 $,J'@!!*B4 /RHL #XK,P ]*SD
M/"M! #LL2  Z+%$ .2U; #@N9@ V+G, -2^# #0OE0 S,*< ,C"] #$QW@ Q
M,?< ,C'_ #(P_P S,/\ L3X  *1$  "92   CTH  (5*  ![20  <$4  &5
M  !;.P  4C8  $@Q! !"+@T /RX3 #TN&P [+B( .2\I #@O+P W+S8 -C ^
M #4P1@ T,4\ ,S%9 #(R9  Q,G$ ,#.! "\TDP N-*8 +#6[ "PUVP L-?4
M+37_ "TT_P N-/\ KD$  *)(  "73   C4X  (-.  !Y30  ;DH  &)%  !8
M0   3CP  $4W   ],PL .3,1 #<S&  V,Q\ -#,F #,S+0 R-#0 ,30\ # U
M1  O-4P +C96 "TV8@ L-V\ *S=_ "HXD0 H.*0 )SFY "8YV  G.?0 *#G_
M "@X_P I./\ JT4  )]+  "43P  BU(  (%3  !W4@  ;$\  %])  !61@
M3$(  $(]   X. @ -#@/ #(X%0 Q.!T +S@D "XX*P M.3( +#DY "LZ00 J
M.DH *3M4 "@[7P G/&T )3Q] "0]CP C/:( (CVW "$^U  A/O, (CW_ ",]
M_P C//\ J$D  )U/  "24P  B58  ']7  !U5@  :E,  %U/  !33   2D@
M $!$   V0 4 +ST- "T]$P K/1H *CXA "D^*  H/B\ )SXW "8_/P D/T@
M(T!2 ") 70 A06H ($%Z !Y!C0 =0J  '$*U !M"T0 ;0O$ '$+_ !U!_P >
M0?\ I4T  )I3  "06   AEL  'U<  !R6P  9U@  %M4  !14@  2$X  #U*
M   S1P  *D,+ "9#$  E0Q8 )$,> "-$)0 B1"P (40T "!%/  >144 '45/
M !Q&6@ ;1F@ &49X !A'B@ 71YX %D>S !1(S@ 51^\ %D?_ !=&_P 71O\
MHE(  )=8  "-70  A&   'IA  !P8   95X  %E:  !/6   1%0  #E1   O
M3@  )DL& "!*#@ >2A, '4H: !Q*(0 ;2R@ &DLP !E+.  72T( %DQ, !5,
M5P 43&4 $TUU !)-B  139P $$VQ  Y.S  /3>X $$W_ !%,_P 13/\ GE<
M )1=  "+8@  @64  '=F  !M9@  8V0  %9A  !*7@  /UL  #58   K5@
M(E0! !I2"@ 64A  %5(6 !12'0 34B0 $E(L !%2-  14CX $%-(  ]35  .
M4V( #51R  Q4A  +5)@ "52M  A4Q0 )5.< "E/[  M2_P +4O\ FUT  )%D
M  "(:   ?FL  '1L  !K;   7VH  %)G  !%9   .F(  #!@   F7@  '5T
M !5;!0 06@P #EH1  Y:&  -6R  #%LG  M;,  *6SH "5M%  =;40 &6UX
M!%MM  -;@  !6Y0  %NH  !;P   6N(  %KV  %:_P "6?\ EV0  (YK  "$
M;@  >W   ')R  !G<0  67   $QN  ! ;   -6L  "II   A9P  &&8  !%F
M 0 ,90H !V4/  1E%  #9!L  F0C  !D+   9#4  &1   !D3   9%H  &1I
M  !D>P  9(\  &.D  !CNP  8MT  &+T  !B_P  8?\ DVP  (EQ  " =0
M>'<  &UX  !@=P  4G8  $9U   Y=   +G0  "-R   :<0  $G$   UQ   &
M<0@  ' -  !P$@  <!<  &\?  !O)@  ;S   &\[  !O1P  ;U0  &]D  !O
M=0  ;HH  &V@  !MM@  ;-8  &OR  !K_P  :_\ CG,  (5X  !]>P  <WT
M &5^  !8?@  2WX  #Y^   R?@  )GT  !Q\   3?   #7P   9]    ?04
M 'P+  !\#P  ?!,  'P9  !\(0  ?"D  'PT  ![0   >TX  'M>  ![;P
M>H0  'J:  !YL0  >,X  '?O  !V_@  =O\ B7H  (%_  !X@@  :X,  %V%
M  !/A@  0H<  #6(   IAP  '8<  !2'   -B   !HD   "*    B@   (D&
M  ")#   B0\  (D3  ")&@  BB(  (HL  "*.   BD8  (E6  "):   B7P
M (B4  "'JP  AL8  (7J  "%^P  A/\ A8(  'V&  !OB   88L  %.-  !%
MCP  .)$  "N1   ?D@  %)(   V3   $E    )8   "7    F    )<   "7
M!0  EPL  )@.  "8$P  F1H  )DB  ":+@  FCT  )E-  "97@  F7,  )B+
M  "8HP  E[P  );B  "6]P  E?\ @(D  '*,  !DCP  5I,  $B6   ZF0
M+)H  !^;   4G   #)X   .?    H0   *,   "E    I0   *4   "E
MI@(  *<(  "G#0  J!$  *D9  "K(P  JS$  *M!  "L4P  K&<  *N   "J
MF@  JK,  *K0  "I[P  J?L =8\  &>4  !9F   2IP  #R?   MH@  (*,
M !.E   +IP   :D   "K    K@   +$   "R    L@   +,   "T    M0
M +8   "X!   N0L  +L0  "]&   OR0  +\U  # 1P  P%L  ,!R  # C0
MP:8  ,#!  "_XP  OO, :I<  %N<  !-H0  /J4  "^I   AJP  $ZT   NP
M    LP   +4   "X    O    +\   #!    P0   ,,   #$    Q@   ,<
M  #)    RP   ,X(  #1#P  U1@  -@G  #9.0  VDT  -MD  #;?@  W)D
M -RP  #<R0  W., 79\  $^E  ! J@  ,J\  "*R   4M0  "K@   "[
MOP   ,,   #&    RP   ,X   #1    T0   -0   #6    V0   -L   #>
M    X    .0   #G!@  ZPX  .\9  #P*@  \C\  /-5  #T;0  ](@  /2A
M  #TM@  ],< _P ) /\ !@#_  < _P , /\ $0#_ !P _P H /\ - #_ $$
M_P!, /\ 50#_ %T _P!E /\ ; #_ '( _@!X /P ?@#[ (0 ^@"+ /D D@#W
M )D ]@"B /0 K #S +D \0#+ /  Z #N /L [0#_ .P _P#A /\ T@#_ ,D
M_P#$ /\ _P ! /\   #_    _P $ /\ #@#_ !< _P C /\ +P#_ #L _0!&
M /H 4 #W %@ ] !? /( 9@#P &P [P!R .T > #L 'X Z@"% .D C #G ),
MY0"< ., I@#A +$ WP#! -T W0#; /0 V0#_ -8 _P#/ /\ Q #_ +T _P"Y
M /\ _P   /\   #_    _P   /\ "P#\ !, ]P > /0 *@#R #4 [@!  .D
M2@#F %( XP!9 .  8 #> &8 W !L -H <@#7 '@ U !^ -( A0#0 (T S@"5
M ,P GP#) *H QP"X ,4 S0## .L P #^ +\ _P"^ /\ M@#_ +  _P"M /\
M_P   /\   #_    ^0   /( !@#K  \ Y@ 9 .$ ) #> "\ V@ Y -, 0P#/
M $P S !3 ,D 6@#' &  Q0!F ,, :P#! '$ OP!W +T ?@"[ (8 N0". +<
MF "U *, LP"P +$ P@"N .  K #W *L _P"J /\ J #_ *, _P"@ /\ _P
M /\   #U    ZP   .$   #6  P SP 3 ,H '@#& "D P@ S +\ /0"[ $4
MN !- +8 5 "S %H L0!? +  90"N &H K !P *L =P"I '\ IP"' *4 D0"C
M )P H "I )X N "< ,X F@#N )D _P"7 /\ E@#_ )8 _P"3 /\ _0   /$
M  #E    V0   ,T   #$  8 O0 / +< & "S "( L  L *T -@"I #X IP!&
M *0 30"B %, H !9 )\ 7@"= &0 FP!J )H < "8 '< E@"  )0 B@"1 )4
MCP"B (T L "+ ,, B0#C (@ ^0"& /\ A@#_ (8 _P"& /\ \P   .,   #1
M    Q0   +T   "V    K@ + *@ $@"D !P H  F )P +P": #< EP _ )4
M1@"2 $P D0!2 (\ 6 "- %T BP!C (H :@"( '$ A@!Y (0 @P"" (\ ?P";
M 'X J0!\ +L >@#5 '@ \@!X /\ =P#_ '< _P!W /\ YP<  -$,  ###0
MN P  *X(  "H    H@ % )L #@"6 !4 D@ ? (X * "+ #$ B  Y (8 0 "$
M $8 @@!, (  4@!_ %< ?0!= 'L 8P!Z &L > !S '8 ?0!T (@ <0"5 '
MI !N +0 ; #* &L Z@!J /P :@#_ &H _P!J /\ VA   ,84  "X%@  K14
M *02  "<#@  E@<  )  "0"* !  A0 8 ($ (0!^ "H >P R 'D .0!W $
M=0!& ', 3 !R %$ < !7 &X 7@!M &4 :P!N &D =P!G (, 90"1 &, GP!B
M *\ 8 #$ %\ Y !? ?@ 7@+_ %X"_P!> O\ SA@  +T=  "P(   I1\  )L<
M  "3%P  BQ$  (0,  !^! L >0 2 '4 &P!R ", ;P K &T!,P!K 3H :0)
M &<#1@!F TP 9 12 &,$60!A!&  7P5I %X%<P!<!G\ 6@:- %D'G !7"*T
M5@C! %4)X0!4"_8 5 O_ %0+_P!4"_\ QA\  +8E  "I*   GB@  )0E  "+
M(0  @QL  'L4  !T#@, ;@D- &D(% !F"1T 9 HE &(*+0!@"S0 7@LZ %T+
M0 !;#$< 6@Q- %@,5 !7#5P 50UD %0-;P!2#7L 4 Z* $\.F@!.#JP 3 _"
M $P0XP!+$/D 2Q#_ $L1_P!+$/\ OR8  + K  "D+P  F2\  (\M  "&*0
M?20  '0>  !L%P  91$' %\.$ !<#Q< 6A ? %@0)P!6$"X 5! U %,0.P!2
M$4( 4!%( $\14 !.$5< 3!)@ $L2:P!)$G@ 2!.' $83EP!%%*D 1!2^ $,5
MWP!#%O@ 0Q;_ $,6_P!#%O\ NBL  *LQ  "@-   E34  (LT  "!,0  >"L
M &\F  !F(   7AD! %<4#0!4%!, 410; $\5(P!.%2H 3!4Q $L6-P!)%CX
M2!9$ $<73 !%%U0 1!== $,89P!!&'0 0!F# #\:E  ]&J8 /!N[ #L;VP [
M'/8 /!S_ #P<_P \'/\ M3   *@V  "<.0  D3L  (<Z  !^-P  <S(  &HM
M  !A)P  62$  %$;"0!,&1  2AH7 $@:'P!&&B8 11LM $,;,P!"&SH 01Q!
M $ <2  ^'%  /1U9 #P>9  ['G$ .1^  #@?D@ W(*0 -B"X #4AU@ U(?0
M-2+_ #4A_P V(?\ LC0  *0Z  "9/@  CS\  (4_  ![/   <#@  &<R  !=
M+0  5"@  $PB!0!&'PX 0Q\4 $$?&P _'R( /B I #T@,  [(#8 .B$] #DA
M10 X(DT -R)7 #8C8@ T(VX ,R1^ #(DCP Q):( +R6V "\FT@ O)O( +R;_
M # F_P P)O\ KS@  *(^  "60@  C$,  ()#  !X00  ;CT  &,X  !:,P
M42X  $@H 0! ) P /2,1 #LD&  Y)!\ ."0F #8D+  U)3, -"4Z #,F0@ R
M)DH ,2=4 # G7P O*&P +BA[ "PIC0 K*J  *BJT "DJSP I*_  *BO_ "HJ
M_P K*O\ K#P  )]"  "41@  BD<  (!'  !V10  ;$(  &$]  !7.   3C,
M $0N   \*0D -R@0 #4H%0 S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T@
M+"M2 "LL70 J+&H *"UY "<MBP F+IX )2ZS "0OS0 D+^X )2__ "4O_P F
M+O\ J3\  )U%  "220  B$L  'Y,  !T2@  :D<  %Y"  !4/0  2SD  $$T
M   X+P8 ,BT- # M$P N+1D +2T@ "LM)P J+BX *2XU "DO/0 H+T8 )S!/
M "4P6P D,6@ (S%W "(RB0 A,IT 'S.Q !XSRP >,^T 'S/_ " S_P A,O\
MID,  )I)  "030  AD\  'Q0  !S3P  :$P  %Q&  !20P  23\  #\[   V
M-@( +C(, "LR$0 I,A< *#(> "8R)  E,RL )#,R ",T.@ B-$, (35- " U
M6  ?-F4 'C9U !PWAP ;-YL &C>O !DXR  9..L &CC_ !LW_P ;-_\ HT<
M )A-  ".40  A%,  'M4  !Q4P  9E   %I,  !020  1T4  #U!   S/0
M*CD) "4W#@ C-Q0 (C@; "$X(@ @."@ 'S@P !XY.  =.4$ '#I+ !HZ5@ 9
M.V, &#MR !8[A0 5/)D %#RM !,]Q@ 3/>D %#S] !4\_P 6._\ H$L  )51
M  "+50  @E@  'E9  !N6   9%8  %A1  !.3P  14L  #I'   P0P  )T %
M " ^#0 =/A$ '#X7 !L^'@ :/B4 &3XM !@_-0 6/SX %3]( !1 4P 30&
M$D%P !%!@@ 009< #T&L  Y"Q  .0N< #T'\ !!!_P 00/\ G5   )-6  ")
M6@  @%T  '9>  !L70  8EL  %97  !,50  05$  #9.   L2P  (T@  !M%
M"0 71 \ %404 !1%&P 312( $D4I !%%,0 113L $$9%  ]&4  .1UX #4=M
M  Q'?P +1Y, "4>G  A'O@ (1^  "4?V  I&_P +1O\ FE4  )!;  "'8
M?6(  '-C  !J8@  8&$  %->  !'6@  /%<  #)5   H4@  'U   !=.!  1
M3 P #TP1  Y,%P .3!X #4TE  Q-+@ +33< "DU"  E-30 '3EH !DYI  1.
M>P "3H\  4ZD  !-N@  3=L  4WR  %-_P "3/\ EEL  (UB  "$9@  >F@
M '%I  !H:0  7&<  $]D  !"80  -U\  "U<   C6@  &E@  !)7 0 -5@D
M"54.  =5$P &51H !%4B  -5*@ "530  %4^  !52@  5E<  %9E  !5=P
M58L  %6@  !5M@  5-0  %3Q  !3_0  4_\ DV(  (IH  " ;   =VX  &]O
M  !C;@  5FP  $EJ   ]:   ,F8  "=E   =8P  %6(   YA   )8 @  V -
M  !?$0  7Q<  %\>  !?)@  7R\  %\Z  !?10  7U,  %]A  !><@  7H<
M %V<  !=L@  7,\  %SO  !;_0  6_\ D&H  (9O  !]<@  =70  &IU  !=
M=   3W,  $)R   V<   *V\  "!N   7;0  $&P   IL   ":P8  &L+  !J
M#P  :A0  &H:  !J(0  :2H  &DT  !I0   :4X  &E<  !I;0  :((  &B8
M  !GK@  9LH  &7M  !E_   9/\ BW$  ()V  !Z>0  <'L  &)[  !5>P
M2'H  #MZ   O>@  (WD  !EX   1=P  "G<   -W    =P(  '<(  !V#0
M=A   '85  !V&P  =B,  '8N  !U.@  =4<  '56  !U:   ='P  '22  !S
MJ@  <L0  ''I  !P^P  </\ AGD  ']]  !V?P  :($  %J"  !,@@  /X,
M #*$   E@P  &H,  !&#   *@P   H,   "$    A0   (0#  "#"   @PT
M (,0  "#%0  A!P  (0F  "$,@  A#\  (-/  "#8   @G4  (*,  "!I
M@+T  '_C  !^^0  ?O\ @H   'J$  !LA@  7H@  %"*  !"BP  -8T  ">-
M   ;C0  $8X   J.    CP   )$   "2    D@   )(   "2 0  D@<  )(,
M  "2$   DQ4  ),=  "4*   E#8  )1%  "35P  DVL  )."  "2G   D;8
M )#8  "/\P  C_\ ?H<  '"*  !AC0  4Y   $63   WE0  *98  !R7   1
MF   "9D   ";    G    )X   "@    H    *    "@    H0   *$$  "B
M"0  HPX  *04  "E'0  IBH  *8Z  "F3   I6   *5X  "ED@  I*P  *3)
M  "CZP  HOH <XX  &21  !6E0  1YD  #F<   JG@  ':   !&A   (HP
M *4   "G    J0   *P   "N    K@   *X   "O    L    +$   "R
MLP8  +4-  "W$P  N1X  +DN  "Z0   NE0  +MJ  "ZA0  N:$  +F[  "Z
MW@  N?( 9Y4  %B9  !*G@  .Z(  "RF   =J   $:H   >L    KP   +$
M  "T    N    +L   "\    O    +X   "_    P    ,(   #$    Q@
M ,@#  #+"P  SQ(  -$@  #1,@  TD8  --=  #4=@  U)(  -6K  #5Q
MU.( 6YT  $RB   ]IP  +ZP  !^O   1L0  ![4   "X    NP   +X   #"
M    QP   ,H   #,    S    ,X   #0    T@   -4   #8    VP   -\
M  #B    Y@L  .L3  #L)   [3@  .Y.  #O9P  \((  /"<  #PL@  \<4
M_P # /\  0#_  0 _P ) /\ #P#_ !@ _P D /\ , #_ #P _P!' /\ 40#_
M %D _P!@ /T 9P#\ &T ^@!S /D >0#X '\ ]@"% /4 C #S )0 \@"= /
MIP#N +, [ #$ .L X0#J /@ Z0#_ .< _P#9 /\ RP#_ ,( _P"] /\ _P
M /\   #_    _P   /\ # #_ !0 _P @ /\ *P#^ #< ^@!" /8 2P#R %,
M\ !; .X 80#L &< Z@!M .@ <P#G 'D Y0!_ ., A@#A (X WP"6 -T H #;
M *P V "[ -0 T0#3 /  T #_ ,X _P#( /\ O0#_ +8 _P"R /\ _P   /\
M  #_    _P   /T " #W !  \P : .\ )@#M #$ Z  [ ., 10#@ $T W !5
M -D 6P#6 &$ TP!G -$ ; #/ '( S0!X ,L ?P#) (< QP"0 ,4 F@## *4
MP "R +X Q0"\ .4 N@#[ +@ _P"W /\ L #_ *D _P"E /\ _P   /\   #^
M    ]0   .P  P#E  T WP 5 -H ( #4 "H T  U ,L /@#( $< Q0!. ,(
M50#  %L O@!A +P 9@"Z &P N !R +8 > "U (  LP"( +$ D@"N )X K "J
M *D NP"H -4 I@#S *0 _P"C /\ H0#_ )L _P"8 /\ _P   /L   #P
MY0   -@   #.  D QP 1 ,( &@"^ "0 NP N +< . "T $  L0!( *X 3@"L
M %0 J@!: *D 7P"G &4 I0!K *0 <0"B '@ H "! )X BP"< )8 F0"C )<
ML@"6 ,< DP#H )( _@"1 /\ D #_ (T _P"+ /\ ^0   .L   #=    SP
M ,8   "\  0 M0 - +  %0"L !X J  H *4 ,0"B #D GP!! )T 2 "; $X
MF0!3 )< 60"6 %X E !D )( :@"0 '$ C@!Z (P @P"* (\ B "< (8 J@"$
M +P @@#< ($ ]@"  /\ ?P#_ '\ _P!^ /\ [    -H   #)    O@   +8
M  "N    IP ) *$ $ "< !@ F  B )4 *@"2 #( D  Z (T 00"+ $< B0!-
M (< 4@"& %@ A != (( 9 "! &L ?P!S 'T ?0![ (@ > "5 '8 HP!U +0
M<P#, '$ [0!P /\ < #_ '  _P!P /\ WP4  ,H*  "\"P  L0D  *@$  "A
M    FP # )0 # "/ !, B@ ; (< ) "$ "P @0 S '\ .@!] $$ >P!' 'D
M3 !W %( =@!7 '0 70!R &0 < !M &\ =@!L (( :@"/ &D G0!G *X 90##
M &0 Y !C /H 8P#_ &( _P!C /\ T X  +\2  "R$P  IQ(  )T0  "5"P
MCP,  (D !P""  X ?@ 5 'H '@!V "4 =  M '$ - !O #H ;@!  &P 1@!J
M $P :0!2 &< 6 !F %\ 9 !G &( <0!@ 'P 7@") %P F !; *D 60"\ %@
MW !8 /0 6 #_ %< _P!7 /\ QA8  +8:  "J'0  GQP  )49  "-%   A0\
M 'X)  !W 0H <@ 0 &X %P!J !\ :  G &4 +@!D #0 8@ [ &  0 !? $8
M70!, %P 4P!: %H 6 !B %< ; !5 '< 4P"% %( E !0 :4 3P&X $X"T@!-
M!/  307_ $T%_P!-!?\ OQT  + B  "C)0  F24  (\B  "%'0  ?1@  '42
M  !N#0( 9P8, &,#$0!? AD 70,A %L$* !9!"\ 5P4U %8%.P!4!D$ 4P9'
M %$&3@!0!U4 3@=> $T(9P!+"', 20F! $@)D@!'"J, 10JV $0+T !$#.\
M0PW_ $,-_P!$#?\ N20  *HI  ">+   E"P  (HJ  " )@  =R$  &X;  !F
M%   7P\% %D+#0!5"A, 4PL; %$+(@!/#"D 30PO $P,-@!+#3P 20U" $@-
M20!&#5$ 10Y: $0.9 !"#G  0 Y_ #\/D  ^$*( /!"V #L0T0 [$?$ .Q'_
M #L1_P \$?\ M"D  *8O  ":,@  D#(  (8Q  !\+0  <B@  &DC  !A'0
M618  %$1" !,#Q  2A 6 $@0'0!&$"0 11 K $,1,0!"$3< 01$^ $ 110 ^
M$DT /1)6 #P280 Z$VT .1-\ #<4C0 V%)\ -16S #05S0 S%NX -!;_ #06
M_P T%O\ KRX  *(T  "7-P  C#@  ((V  !X-   ;BX  &4J  !<)   5!X
M $P8! !&% T 0A02 $ 4&0 _%"  /14G #P5+0 [%30 .18Z #@60@ W%DH
M-A=3 #477@ S&&H ,AEY # 9B@ O&IT +AJQ "T;R@ M&^P +1S_ "X;_P N
M&_\ K#(  )\X  "4.P  BCP  ( \  !V.0  :S0  &(O  !9*@  4"4  $<?
M  ! &@H /!D0 #H9%@ X&1T -AHC #4:*0 T&C  ,QHW #(;/@ Q&T< +QQ0
M "X=6P M'6< +!YV "H>B  I'YL *!^N "<@QP F(.H )R#^ "@@_P H(/\
MJ38  )T\  "2/P  AT$  'U   !T/@  :3H  %\U  !6,   32L  $0E   [
M( < -AX. #,>$P R'AD ,!X@ "\>)@ N'RT +1\T "P@.P K($0 *B%. "DA
M6  G(F4 )B)T "4CA0 C(YD (B2M "$DQ0 A)>@ (B7] "(D_P C)/\ ICH
M )H_  "/0P  A44  'M$  !R0P  9S\  %TZ  !3-@  2C$  $$L   X)@,
M,2,, "XB$0 L(A8 *B(= "DB(P H(RH )R,Q "8D.0 E)4$ )"5+ ",F5@ B
M)F, (2=R !\G@P >*)< '2BK !LIPP ;*>8 '"G[ !TI_P >*/\ HSX  )A#
M  "-1P  @TD  'I)  !P1P  9D0  %H_  !1.P  1S<  #XR   U+0  +"@)
M "@G#P G)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3\ 'RI) !XJ5  =*V
M&RMO !HL@0 9+)4 %RVI !8MP0 6+>0 %RWZ !@M_P 9+?\ H4$  )5'  "+
M2P  @DT  'A-  !N3   9$D  %A$  !/0   1CT  #TX   S-   *B\& "0L
M#0 A+!( ("P8 !\M'@ >+24 '2TL !PN-  ;+CP &B]& !@O40 7,%X %C!M
M !4Q?P 3,9, $C&H !$ROP 1,N( $C+Y !,Q_P 3,?\ GD4  )-+  ")3P
M@%$  '92  !M4   8DX  %9)  !-1@  1$,  #L_   Q.@  )S8# !\R"P <
M,A  &S(5 !DR&P 8,B( %S,I !8S,0 5-#H %#1$ !,T3P 2-5P $35K ! V
M?0 /-I$ #C:F  TWO  --]T #3;V  XV_P /-O\ FTD  )%/  "'4P  ?E8
M '56  !J50  8%,  %5/  !,3   0DD  #A%   N00  )#T  !PZ"  6. X
M%3@2 !0X&  3.1\ $CDF !$Y+@ 0.3< #SI!  XZ3  -.UD #3MH  L[>@ *
M.XT "3RB  <\N  '/-4 "#SP  D[_P *._\ F$X  (Y4  "%6   ?%L  ');
M  !H6@  7E@  %-5  !)4@  /DX  #1+   J1P  (40  !A" P 20 L $#\0
M  X_%0 ./QP #4 C  Q *P +0#0 "D ^  E!2@ '058 !D%E  1!=@ #08H
M 4&?  !!M   0=   4'N  %!_  "0/\ E50  (Q9  "#7@  >6   '!@  !F
M8   75X  %%;  !%5P  .E0  "]1   E3P  '$P  !1*   .2 @ "T<.  A'
M$@ '1QD !D<@  5(*  #2#$  D@[  !(1P  2%,  $AB  !(<P  2(8  $B;
M  !(L0  1\P  $?M  !'^P  1_\ DEH  (E@  " 8P  =V4  &YF  !E9@
M660  $Q@  ! 70  -5L  "I9   @5P  %U4  !!3   +4@< !5$-  %0$0
M4!8  % =  !0)0  4"X  % X  !00P  4%   %!>  !0;P  4(,  $^8  !/
MK@  3LD  $[K  !-^P  3?\ CV$  (9F  !]:0  =&P  &QM  !A:P  4VD
M $9G   Z9   +V,  "1A   :7P  $EX   Q<   &7 8  %L+  !:#P  6A,
M %H9  !9(0  62D  %DS  !9/P  64P  %E:  !9:P  6'X  %B4  !7JP
M5\4  %;I  !5^P  5?\ C&@  ()M  !Z<   <G(  &=R  !:<0  3'   #]N
M   S;0  *&L  !UJ   4:   #6<   =G    9@,  &8)  !E#0  91$  &05
M  !D'   9"0  &0N  !D.@  8T<  &-5  !C9@  8WH  &*0  !AIP  8,$
M %_F  !?^@  7O\ AV\  ']T  !X=P  ;G@  &!X  !2=P  17<  #AV   K
M=@  ('0  !9S   .<P  !W(   !R    <@   '$%  !Q"@  <0X  ' 1  !P
M%P  <!X  ' G  !P,P  ;T   &]0  !O8   ;G0  &Z+  !MH@  ;+P  &OB
M  !J^   :?\ @W<  'Q[  !S?0  97X  %=_  !)?P  /'\  "^    B?P
M%WX   ]^   '?@   '\   !_    ?P   'X   !^!0  ?@H  'X-  !^$0
M?A<  'X@  !^*P  ?3D  'U(  !]60  ?&T  'R$  ![G   >K8  'G:  !X
M]0  =_\ @'\  '>"  !I@P  6X4  $V&   _B   ,HD  "2)   8B0  #XD
M  >*    BP   (P   "-    C0   (P   ",    C ,  (P(  "-#0  C1$
M (T7  ".(@  CB\  (X_  "-4   C60  (Q[  ",E0  BZX  (K-  ")[P
MB?\ >X4  &V(  !>B@  4(T  $*/   TD0  )I(  !F3   .E   !I4   "6
M    F    )H   ";    FP   )L   ";    FP   )P   "=!0  G0L  )X0
M  "?%P  H"0  * T  "@1@  H%D  )]P  "?B@  GJ4  )["  "=Z   G/D
M<(P  &&/  !3D@  1)8  #:9   GFP  &9P   ^=   %GP   *$   "C
MI0   *@   "I    J0   *D   "J    JP   *P   "M    K@$  + )  "R
M#P  LQ@  +0G  "T.0  M4T  +1D  "T?@  LYH  +.T  "SU0  L_  9),
M %67  !'FP  .)\  "FB   :I   #J8   2H    JP   *T   "P    M
M +8   "X    N    +D   "Z    O    +T   "_    P    ,,   #%!P
MR0\  ,H:  #++   S$   ,U6  #.;P  S8L  ,RH  #,P@  S.( 6)L  $F@
M   ZI0  +*D  !RK   /K@  !+$   "T    MP   +H   "^    PP   ,8
M  #(    R    ,H   #+    S0   ,\   #2    U0   -D   #=    X04
M .8/  #G'@  Z#(  .E(  #J8   ZWL  .N7  #LK@  [,( _P   /\   #_
M    _P & /\ #0#_ !4 _P A /\ + #_ #@ _P!# /\ 3 #^ %0 ^P!; /H
M8@#X &@ ]@!N /4 = #T 'H \@"  /$ AP#O (\ [0"7 .L H0#I *T YP"]
M .4 V #D /, X@#_ .  _P#0 /\ Q #_ +P _P"V /\ _P   /\   #_
M_P   /\ "0#_ !$ _P < /T )P#Y #( ]0 ] /$ 1@#M $\ ZP!6 .@ 7 #F
M &( Y !H ., ;@#A ', WP!Y -T @ #: (@ V "1 -0 FP#2 *8 SP"T ,P
MR0#) .D R #_ ,< _P#! /\ MP#_ *\ _P"K /\ _P   /\   #_    _P
M /@ !0#R  X [@ 7 .H (@#F "P X0 W -T 0 #8 $D TP!0 -  5@#. %P
MS !B ,H 9P#( &T Q@!S ,0 >0#" ($ P "* +X E "\ )\ N0"L +8 O@"T
M -T LP#W +$ _P"P /\ J #_ *( _P"> /\ _P   /\   #Y    [P   .8
M  #?  L U@ 2 -  ' #, "8 R  P ,0 .@#  $( O0!* +L 4 "X %8 M@!;
M +4 80"S &8 L0!L +  <@"N 'H K "" *D C "G )@ I0"E *, M "@ ,L
MGP#N )T _P"< /\ F0#_ )0 _P"1 /\ _P   /8   #J    W0   ,\   #'
M  8 P  / +L %P"W "  LP J +  ,P"M #L J@!# *< 20"E $\ HP!5 *(
M6@"@ %\ G@!E )T :P"; '( F0![ )< A0"4 )  D@"= )  K ". +\ C #B
M (L ^@") /\ B0#_ (8 _P"# /\ ]    .0   #4    R    +\   "U  $
MK@ + *D $@"E !L H0 C )X + "; #0 F  \ )8 0P"4 $D D@!. )  4P".
M %D C0!> (L 9 ") &L AP!S (4 ?0"# (@ @0"5 '\ I !] +4 >P#/ 'D
M\0!X /\ =P#_ '< _P!U /\ Y0   -$   ##    N    *\   "H    H  &
M )H #@"5 !4 D0 > (X )@"+ "T B  U (8 / "$ $( @@!' (  30!_ %(
M?0!8 'L 7@!Y &4 > !M '8 =@!S ($ <0". &\ G0!M *X ; #$ &H YP!I
M /T : #_ &@ _P!I /\ U0,  ,,'  "V"   JP8  *(   ";    E    (T
M"@"( !  @P 8 '\ ( !\ "< >@ N '< -0!U #L = !! '( 1P!P $P ;P!2
M &T 6 !K %\ :0!F &< < !E 'L 8P"( &( EP!@ *< 7@"[ %T W !< /8
M7 #_ %L _P!; /\ R0T  +D0  "L$0  H1   )<-  "/"   B    (( !0![
M  T =P 2 ', &@!O "$ ;  H &H +P!H #4 9P [ &4 00!C $8 8@!, &
M4@!? %D 70!A %L :@!9 '4 5P"" %4 D0!4 *( 4P"U %$ SP!0 .\ 4 #_
M %  _P!0 /\ OQ0  + 8  "D&@  F1D  (\6  "'$0  ?PT  '<&  !Q  @
M:P . &< % !D !L 80 B %X *0!= "\ 6P U %D .P!8 $$ 5@!& %4 30!3
M %0 4@!< %  90!. '  3 !] $L C0!) )X 2 "P $< QP!& .D 1@#[ $8
M_P!% /\ N!L  *H@  ">(@  DR(  (D?  " &@  =Q4  &\0  !H"P  800*
M %T $ !9 !8 5@ = %0 (P!2 "H 4  P $\ -0!. #L 3 !! $L 2 !) $\
M1P%7 $8!80!$ FP 0P)Y $$#B0!  YH /@2M #T$Q  \!>4 / ?X #P'_P \
M!_\ LB(  *4G  "9*0  CBD  (0G  ![(P  <1X  &D8  !A$@  6@T# %,(
M# !/!1$ 3 47 $H&'@!(!B0 1P8J $4', !$!S8 0P@] $$(0P! "$L /@E3
M #T)70 ["F@ .@IV #@+AP W"YD -0NL #0,P@ S#.0 ,PWY #,-_P T#?\
MK2<  * L  "5+P  BR\  ( N  !W*@  ;24  &0@  !<&@  5!0  $P/!@!&
M# T 0PP2 $$,&  _#!\ /@PE #P-*P [#3( .@TX #@-/P W#D< -@Y0 #0.
M6@ S#F8 ,0]T # /A0 N$)@ +1"K "P0PP K$>4 +!'Z "P1_P M$?\ JBP
M )TQ  "2-   AS4  'TT  !T,0  :BL  & G  !8(0  3QL  $<6  ! $0D
M.Q / #D0%  W$!L -A A #00)P S$2T ,A$T #$1.P P$4, +A)- "T25P L
M$F, *A-Q "D3@@ G%)4 )A2I "45P  D%>, )1;Z "86_P F%?\ IC$  )HV
M  "/.0  A3H  'LY  !Q-@  9S$  %TM  !4*   3"(  $,=   [%P4 -10-
M #(3$0 Q%!< +Q0= "X4)  L%"H *Q4Q "H5.  I%D  *!9* "<75  F%V
M)!AO ",8@  A&9, (!FG !\9O@ >&N  'QKX " :_P @&O\ HS0  )@Z  "-
M/0  @SX  'D]  !O.P  93<  %LR  !2+0  22@  $ C   X'@$ ,!D* "P8
M#P J&!0 *1@: "<8(  F&2< )1DM "0:-0 C&CX (AM' "$;4@ @'%X 'QUL
M !T=?@ <'9$ &AZE !D>O  8']T &1_V !H?_P ;'O\ H3@  )4]  "+00
M@4(  '="  !M0   8SP  %DW  !/,P  1BX  #TI   U)   +2 ' "<=#0 E
M'1( (QT7 "$='0 A'20 (!XK !\>,@ >'SL '1]% !P@3P :(5P &2%J !@B
M>P 6(H\ %2*C !0CN@ 3(]H %"/U !4C_P 6(_\ GCP  )-!  ")1   ?T8
M '5&  !L1   8D$  %<\  !-.   1#0  #PP   S*P  *B8# ",B"P @(1
M'B$5 !PB&P ;(B$ &B(H !HC,  9(S@ &"1" !8E30 5)5D %"9H !,F>0 2
M)HT $2>B ! GN  .)]8 $"CT !$G_P 1)_\ G$   )%%  "'2   ?4H  '1*
M  !J20  8$8  %5!  !,/@  0SH  #HV   Q,@  *"T  " I"0 ;)PX &2<2
M !@G&  6)Q\ %2@E !0H+0 3*#8 $BE  !(I2P 1*E< $"IF  XK=P .*XL
M#2R?  PLM0 ++,\ #"SO  TL_P -*_\ F40  (])  "%3   ?$X  '-/  !I
M3@  7DL  %-'  !*1   0D   #D]   O.   )30  !TP!0 6+0P %"P0 !,M
M%0 2+1P $2TC ! M*@ /+C, #BX]  TO2  -+U4 ##!C  HP=  ),(@ "#&<
M  8QL0 &,<L !C'K  <P_  (,/\ ET@  (U-  "#40  >E,  '%4  !G4@
M75   %),  !)2@  0$8  #5"   K/@  (CH  !HW 0 2- D #S,.  XS$P -
M,QD #3,@  PT*  +-#$ "C4[  @U1@ '-5( !39@  0V<0 "-H0  #:9   V
MKP  -L@  #;H   V^0 !-?\ E$T  (I2  "!5@  >%@  &]9  !E6   6U4
M %%2  !'3P  /$P  #%(   G1   'D$  !8_   0/ < "SH-  DZ$0 (.Q<
M!CL>  4[)@ $.RX  CLX  $\0P  /$\  #Q>   \;@  /($  #R7   \K
M.\4  #OG   [^   ._\ D5(  (A8  !_7   =ET  &U>  !C70  6EP  $Y8
M  !"5   -U$  "U.   C2P  &DD  !)&   -1 8 !T,,  -#$   0Q4  $,;
M  !#(P  0RL  $,U  !#0   0TT  $-;  !#:P  0WX  $.4  !"J@  0L,
M $'F  !!^0  0?\ CE@  (9>  !]80  <V,  &MD  !B8P  5V$  $E=   ]
M6@  ,E@  "=5   >4P  %5$   Y/   )304  DT+  !,#@  3!,  $L8  !+
M'P  2R@  $LR  !+/0  2TD  $M7  !+9P  2GL  $J0  !)IP  2<   $CD
M  !(^   1_\ BU\  (-D  !Z9P  <6D  &EJ  !>:0  4&8  $-D   W80
M+%\  "%=   86P  $%D   I8   #5P,  %<)  !6#0  51   %45  !4&P
M5",  %0M  !4.0  5$4  %13  !49   4W<  %.-  !2I   4;T  %#B  !0
M^   3_\ B&<  ']K  !W;@  ;W   &5P  !7;@  2FP  #UK   P:0  )6@
M !IF   19   "V,   1B    8@$  &$&  !@"P  8 X  %\2  !?%P  7QX
M %XH  !>,P  7D   %Y/  !>7P  77(  %V(  !<H   6[D  %K?  !9]P
M6/\ A&X  'QR  !U=0  :W8  %UU  !/=   0G,  #5S   H<@  '7   !-O
M   ,;@  !&X   !N    ;@   &P"  !L!P  :PL  &L.  !K$@  :AD  &HB
M  !J+0  :CH  &E)  !I6@  :6P  &B#  !GFP  9K4  &78  !D]0  9/\
M@'4  'IY  !P>P  8GL  %1\  !&?   .7P  "Q\   ?>P  %'H   UZ   $
M>@   'H   !Z    >@   'D   !Y 0  > 8  '@+  !X#@  >!,  '@:  !X
M)0  >#(  '=!  !W4@  =V4  '9\  !UE0  =*\  '/.  !R\0  <?\ ?GT
M '6   !G@0  6((  $J#   \A   +H4  "&%   5A0  #84   .%    A@
M (<   "(    B    (<   "'    AP   (<$  "'"0  APX  (@3  "('
MB"D  (@X  "'2@  AUT  (9S  "&C0  A:<  (3%  "#[   @OX >(0  &J&
M  !<B   38H  #^,   QC@  (X\  !:/   -D    I$   "2    DP   )4
M  "6    E@   )8   "6    E@   )<   "7    EP<  )@-  "9$P  FA\
M )HM  ":/P  FE(  )IH  "9@P  F9\  )BZ  "7X@  EO@ ;8H  %^-  !0
MD   09,  #.6   DEP  %I@   V9   !FP   )T   "?    H0   *0   "E
M    I    *4   "E    I@   *<   "H    J0   *H$  "L#   KA,  *XA
M  "N,P  KD<  *Y=  "N=@  KI,  *ZN  "MS0  K.\ 89$  %.5  !$F
M-9P  ":?   7H0  #:,   "E    IP   *H   "L    L    +(   "T
MLP   +0   "U    MP   +@   "Y    NP   +T   "_ 0  PPL  ,45  #%
M)0  QCD  ,=/  #':   QH4  ,:B  #&O   QMX 59D  $>=   XH@  *:8
M !FH   -JP   *T   "Q    M    +<   "Z    OP   ,$   #$    PP
M ,4   #&    R    ,H   #-    SP   -(   #6    VP   . ,  #A&
MXRL  .1!  #E6@  YG0  .:1  #EK   Y<0 _P   /\   #_    _P ! /\
M"@#_ !( _P = /\ * #_ #0 _P ^ /T 2 #Z %  ]P!7 /4 70#T &, \@!I
M /  ;P#O '0 [0![ .L @0#I (D Z "2 .8 G #D *@ X@"W -\ S0#< .X
MV0#_ -D _P#* /\ O@#_ +4 _P"P /\ _P   /\   #_    _P   /\ !@#_
M  \ _  8 /@ (P#T "X \  X .L 0@#H $H Y0!1 .( 6 #@ %T W@!C -P
M: #9 &X U@!T -0 >P#1 (( SP"+ ,T E0#* *$ R "O ,4 P0#" ., P #[
M ,  _P"[ /\ L #_ *@ _P"D /\ _P   /\   #_    ^P   /,  0#M  P
MZ  3 ., '@#@ "@ V@ R -, / #/ $0 S !+ ,D 40#& %< Q != ,( 8@#!
M &< OP!M +T = "[ 'L N0"$ +< C@"T )D L@"G *\ MP"M -  JP#R *H
M_P"I /\ H0#_ )L _P"7 /\ _P   /\   #T    Z0   .    #5  @ S@ 0
M ,D & #% "( P0 K +P -0"Y #T M@!% +, 2P"Q %$ KP!6 *X 6P"L &$
MJ@!F *D ;0"F '0 I !\ *( A@"@ )( G@"? )P K@"9 ,, EP#G )8 _P"5
M /\ D@#_ (T _P"* /\ _    /    #C    U    ,@   "_  , N0 - +,
M$P"O !P K  E *D +@"E #8 HP ^ *  1 "> $H G0!0 )L 50"9 %H EP!?
M )8 9@"4 &P D@!U )  ?@". (H BP"7 (D I@"' +@ A0#6 (0 ]@"" /\
M@0#_ 'X _P!\ /\ [0   -T   #,    P0   +@   "N    IP ) *( $ ">
M !< F@ ? )< )P"4 "\ D0 W (\ /0"- $, BP!) (D 3@"( %, A@!9 (0
M7P"" &4 @ !M 'X =P!\ (( >@"/ '@ G@!U *\ <P#' '( [ !Q /\ < #_
M '  _P!N /\ W0   ,D   "\    L0   *D   "A    F0 # ), # ". !(
MB@ 9 (< (0"$ "D @0 P '\ -P!] #T >P!" 'D 2 !X $T =@!2 '0 6 !R
M %\ <0!G &\ < !L 'L :@"( &@ EP!F *@ 90"\ &, X0!B /H 80#_ &$
M_P!A /\ S0$  +P%  "O!0  I0(  )P   "4    C0   (8 " "!  X ?  4
M '@ &P!U ", <@ I '  , !N #8 ;0 \ &L 00!I $< : !, &8 4@!D %D
M8P!@ &$ :0!? '0 70"! %L D !9 *$ 5P"T %8 T !5 /( 50#_ %0 _P!5
M /\ P0P  +(.  "F#P  FPX  )(+  ")!0  @@   'L  @!U  L <  0 &P
M%@!H !T 9@ C &, *@!A #  8  V %X .P!= $$ 6P!& %H 3 !8 %, 5@!;
M %0 9 !2 &X 40![ $\ B@!- )L 3 "N $L Q@!* .H 20#^ $D _P!) /\
MN1(  *H6  ">%P  E!8  (H3  "!$   >0L  '$#  !K  8 90 - &$ $0!=
M !@ 6@ > %@ ) !6 "H 5  P %, -@!1 #L 4 !! $X 1P!- $X 2P!6 $D
M7P!' &D 1@!V $0 A0!# )< 00"I $  OP _ .( /P#X #X _P _ /\ LAD
M *0>  "8'P  CA\  (0<  !Z&   <A(  &H.  !B"   7 $( %< #@!3 !,
M4  9 $X 'P!, "4 2@ K $@ , !' #8 1@ \ $0 0@!# $D 00!1 #\ 6@ ^
M &4 / !R #H @0 Y ), . "E #8 N@ V -L -0#T #4 _P U /\ K"   )\D
M  "4)@  B28  '\D  !U(   ;!L  &05  !<$   5 P! $X&"@!* @\ 1P 4
M $0 &@!" "  0  E #\ *P ^ 3$ / $W #L"/@ Y D4 . -- #8#5@ U!&$
M,P1N #$%?@ P!9  +P6C "T&N  L!M0 + ?P "P(_P L"/\ J"4  )LJ  "0
M+   ABT  'LK  !R)P  :"(  %\=  !7%P  3Q(  $@.! !!"@L /@<0 #L&
M%0 Y!QL . <A #8()@ U""P ,P@R #().0 Q"4$ +PE) "X*4P L"EX *PML
M "D+?  H#(\ )@RB "4,MP D#-, (PWP "0-_P E#?\ I"H  )@O  "-,@
M@S(  'DQ  !O+@  92D  %PD  !3'P  2QD  $,3   \$ 8 -0T, #,,$0 Q
M#!8 +PP< "X-(@ M#2@ *PTN "H--0 I#3T )PY& "8.4  D#EP (P]J "(/
M>P @$(X 'Q"B !T0MP <$-0 '1'R !T1_P >$?\ H2\  )4S  "*-@  @#<
M '8V  !M,P  8R\  %DJ  !0)0  2"   #\:   X%0  ,!$( "P0#@ J$!(
M*! 8 "<0'@ E$"0 )! J ",1,@ B$3H (1%# " 23@ >$EH '1-H !L3>  :
M$XL &!2@ !<4M0 6%-$ %A7Q !<5_P 8%/\ GC,  ),W  "(.@  ?CL  '0[
M  !K.   830  %<O  !.*P  128  #TA   T'   +1<% "83#  C$Q  (A,5
M " 3&@ ?$R$ 'A0G !T4+P <%3< &Q5! !H62P 9%E< %Q=E !87=@ 4&(D
M$QB> !(8LP 1&<X $1GO !(9_P 3&?\ G#8  )$[  "&/@  ?#\  ',_  !I
M/0  7SD  %4U  !,,   0RP  #HG   R(@  *AX! "(9"0 >%PX '!<2 !H7
M%P 9&!X &1@D !@9+  7&30 %AH^ !4:20 3&U4 $AMC !$<=  0'(< #QV<
M  X=L0 -'<L #1WL  X=_P /'?\ F3H  (\_  "$0@  >T0  '%#  !H0@
M7CX  %,Z  !*-@  03(  #DM   Q*0  *"4  " @!@ :'0P %QP0 !4<%0 4
M'1L %!TB !,=*0 2'C( $1\\ ! ?1@ 0(%, #B!A  TA<0 ,(84 "R*9  HB
MK@ )(L< "2+G  HB^P +(?\ ESX  (Q#  "#1@  >4@  '!(  !G1@  7$0
M %(_  !).P  0#@  #@T   O,   )RP  !XG P 6(PH $B$. !$A$P 0(AD
M$"(@  \B)P .(R\ #20Y  PD1  +)5  "B5>  DF;P ')H( !B:6  0FK  #
M)L0 !";E  0F]P &)O\ E4(  (I'  "!2@  >$P  &],  !E2P  6T@  %!$
M  !'00  /SX  #<[   M-@  )#$  !LM   3*@< #R@-  TG$0 -*!8 #"@=
M  LH)0 **2T "2DW  <J0@ &*DX !"M<  ,K;  !*W\  "N4   KJ0  *\$
M "OC   K]@  *O\ DD8  (A+  !_3P  =E$  &U1  !C4   6DT  $]*  !'
M1P  /D0  #-    I/   (#@  !<T   1,04 #"\,  DN$  '+A4 !B\;  4O
M(P #+RL  C U   P/P  ,$P  #%9   Q:0  ,7P  #&1   QIP  ,+\  ##A
M   P]0  +_\ D$L  (90  !]5   =58  &M6  !B50  6%,  $Y0  !%30
M.DD  "]%   E0@  '#X  !0[   ..04 "3<+  0V#P !-A,  #89   V(
M-BD  #8R   W/0  -TD  #=7   W9P  -WD  #>/   VI0  -KT  #;@   U
M]0  -?\ C5   (16  !\6@  <EL  &E;  !@6P  5UD  $Q6  ! 4@  -4X
M "I+   @2   %T8  !!#   +000 !$ *   _#@  /A$  #X6   ^'0  /B8
M #XO   ^.@  /D8  #Y4   ^9   /G8  #V,   ]HP  /+L  #S>   []0
M._\ BE<  ()<  !Y7P  <&$  &AA  !?80  5%X  $=;   Z5P  +U4  "52
M   ;4   $DT   Q+   &2@,  $D)  !(#0  1Q   $<4  !&&@  1B(  $8L
M  !&-P  1D,  $91  !&8   17,  $6)  !$H   1+@  $/<  !"]0  0O\
MB%T  ']B  !W90  ;F<  &=H  !;9@  3F,  $%A   T7@  *5P  !]:   5
M5P  #E8   =4    4P$  %(&  !1"P  40X  % 1  !/%@  3QX  $\G  !/
M,@  3S\  $]-  !.70  3F\  $Z%  !-G0  3+4  $O8  !*]0  2O\ A64
M 'QI  !T;   ;6X  &)M  !4:P  1VD  #IG   M90  (F0  !AB   08
M"5\   !>    7@   %T#  !<"   6PP  %H/  !:$P  61D  %DB  !9+0
M63H  %E(  !86   6&L  %>!  !7F0  5K(  %72  !4]   4_\ @6P  'EP
M  !S<P  :',  %IR  !,<0  /W   #)O   E;@  &FP  !%K   ):@   &H
M  !I    :0   &@   !G P  9@@  &8,  !F#P  910  &4<  !E)P  9#0
M &1#  !D4P  9&4  &-[  !BE   8:T  &#-  !?\0  7O\ ?70  '=W  !N
M>0  7WD  %%Y  !#>0  -G@  "EX   <=P  $78   IU    =0   '4   !V
M    =0   '0   !T    <P(  ','  !S#   <A   '(5  !R(   <BP  '([
M  !Q3   <5\  '%T  !PC@  ;Z@  &[&  !L[0  :_\ >WL  ')^  !D?@
M57\  $>    Y@0  *X(  !Z!   2@0  "H$   "!    @@   (,   "#
M@P   ((   ""    @@   ((   ""!0  @@H  ((/  ""%P  @B,  ((R  ""
M0P  @58  (%L  " A@  ?Z$  'Z]  !]Y@  ?/P =H(  &B#  !9A0  2X<
M #R)   NB@  ((L  !.+   *BP   (P   "-    CP   )$   "2    D0
M )$   "1    D0   )$   "2    D@(  ),)  "4#P  E!D  )0G  "4.
ME$P  )-B  "3?   DY@  )*S  "1V   D/8 :H@  %R*  !-C0  /Y   #"2
M   AE   %)4   J6    EP   )D   ";    G0   )\   "@    H    *
M  "@    H0   *(   "C    I    *4   "F!P  J!   *@<  "H+0  J4
M *E6  "I;P  J8L  *BH  "GQP  INP 7X\  %"2  !!E@  ,YD  ".<   4
MG0  "I\   "A    HP   *8   "H    K    *X   "O    KP   +    "P
M    L@   +,   "T    M@   +<   "Z    O0<  +\0  "_'P  P#,  ,!)
M  # 8@  P'X  ,";  # MP  O]@ 4Y<  $2;   UGP  )J,  !:E   +IP
M *H   "M    L    +,   "V    NP   +T   #     OP   ,$   #"
MQ    ,8   #(    R@   ,P   #/    TP   -H'  #;$P  W24  -X[  #?
M4P  X&X  -^,  #=J0  W<( _P   /\   #_    _P   /\ !P#_ !  _P 9
M /\ ) #_ "\ _  Z /D 0P#U $L \P!2 /$ 60#O %X [0!D .L :0#I &\
MYP!U .8 ? #D (0 X@"- .  EP#= *( V@"Q -4 Q0#2 .@ T #_ ,\ _P#$
M /\ N #_ *\ _P"I /\ _P   /\   #_    _P   /\  @#[  T ]P 5 /,
M'P#O "D Z@ T .8 /0#B $4 W@!, -L 4P#8 %@ U !> -( 8P#0 &D S@!N
M ,P =0#* 'T R "% ,8 D #" )L P "I +X N@"[ -D N0#W +@ _P"T /\
MJ0#_ *( _P"= /\ _P   /\   #_    ]@   .X   #G  H X0 1 -P &@#7
M ", T  N ,L -P#' #\ Q !& ,$ 30"_ %( O0!8 +L 70"Y &( N !H +8
M;@"T '4 L0!^ *\ B "M ), J@"A *@ L0"F ,@ I #M *( _P"B /\ FP#_
M )4 _P"1 /\ _P   /P   #N    XP   -@   #-  4 Q@ . ,$ %0"] !X
MN0 G +4 , "R #@ KP!  *P 1@"J $P J !1 *< 5@"E %L HP!A *$ 9P"?
M &X G@!V )L @ "9 (P EP"9 )0 J "2 +P D #? (X ^P". /\ BP#_ (8
M_P"# /\ ^    .D   #<    S    ,$   "X    L@ * *P $0"H !@ I0 A
M *( *0"> #( G  Y )D /P"7 $4 E0!* )0 4 "2 %4 D !: (\ 8 "- &<
MBP!O (D > "& (0 A "1 (( H "  +( ?0#, 'P \0![ /\ >@#_ '< _P!U
M /\ Y@   -,   #&    NP   +$   "G    H0 % )L #0"7 !, DP ; )
M(P", "L B@ R (@ . "& #X A !$ (( 20"! $X ?P!3 'T 60![ &  >0!H
M '< <0!U 'P <P") '  F !O *D ;0"_ &L Y@!J /\ :0#_ &D _P!G /\
MTP   ,,   "U    JP   *,   ";    D@   (P "@"' !  @P 6 '\ '0!]
M "0 >@ K '@ ,@!V #@ =  ] '( 0@!Q $@ ;P!- &T 4P!L %D :@!A &@
M:@!F '0 9 "! &$ D0!? *( 7@"V %P U0!; /< 6P#_ %H _P!: /\ Q0
M +8"  "I @  GP   )8   ".    AP   (  !0!Z  P =0 1 '$ & !N !X
M:P E &D *P!G #$ 9@ W &0 / !C $$ 80!' %\ 30!> %, 7 !; %H 9 !8
M &X 5@![ %0 B@!2 )L 40"N %  R !/ .X 3@#_ $X _P!- /\ NPH  *P-
M  "@#0  E0P  (P(  "# @  ?    '4   !N  @ :0 . &4 $P!B !D 7P ?
M %T )0!; "L 60 Q %@ -@!6 #L 50!! %, 1P!1 $X 4 !5 $X 7@!, &@
M2@!U $@ A !' )4 10"H $0 OP!# .0 0@#\ $( _P!" /\ LA$  *44  "9
M%0  CA,  (01  ![#0  <P@  &P   !E  , 7P + %L #P!7 !0 5  : %$
M'P!/ "4 3@ K $P , !+ #8 20 \ $@ 0@!& $@ 10!0 $, 60!! &, /P!O
M #X ?@ \ )  .P"C #H N  Y -D . #U #@ _P X /\ K!<  )\;  "3'0
MB1P  '\9  !U%0  ;!   &0,  !=!@  5@ & %$ # !- !  2@ 5 $< &@!%
M "  1  F $( *P!! #$ /P V #X /0 \ $0 .P!+ #D 5  W %\ -@!K #0
M>@ R (P ,0"> #  LP O ,X +P#O "X _P N /\ IQX  )HB  "/)   A"0
M 'HA  !Q'0  9Q@  %\3  !7#@  4 H  $D#" !%  T 00 1 #X %@ \ !L
M.@ A #D )@ W "P -@ R #0 .  S #\ ,0!' #  4  N %L +0!G "L =@ J
M (@ * "< "< L  F ,D )0#J "4!^P#_XGT024-#7U!23T9)3$4 $1(E ?\
MHB,  )8H  "+*@  @2H  '<H  !M)0  9"   %L;  !2%0  2Q   $,, @ ]
M!PD .0,. #8!$@ S 1< ,0$< # !(@ O B< +0(M "P#-  J SL *01# "@$
M30 F!5@ )05E ",&=  B!H8 ( :: !\'K@ >!\8 '0?G !T(^  ="?\ GR@
M ),M  "(+P  ?B\  '0N  !J*P  828  %@A  !/'   1Q<  #\2   X#@0
M,0L* "X(#@ K!Q( *0<7 "@('0 G"", )0@I "0),  C"3< (0I  " *2@ ?
M"U4 '0MB !L,<@ :#(4 & R9 !<,K0 6#,8 %0WF !4-^0 6#?\ G"T  ) Q
M  "&-   ?#0  '(S  !H,0  7RP  %4G  !,(P  1!T  #P8   T$P  +1 &
M "8-"P D# \ (@P3 "$,&0 ?#!\ '@TE !T-+  ;#30 &@X] !D.1P 7#E,
M%@YA !0/<0 3$(0 $A"8 !$0K@ 0$,8 $!#H ! 0^P 1$/\ F3$  (XU  "$
M.   >CD  ' X  !G-@  73(  %,M  !**   0B0  #D?   Q&@  *A4! ",1
M!P =$ T &P\0 !D/%0 8$!L %Q A !80*0 5$#$ %!$Z !,110 2$E$ $1)?
M ! 2;P .$X( #A.6  T3JP +$\( "Q3C  P4^@ -$_\ ES4  (PY  ""/
M>#T  &\]  !E.@  6S<  %(R  !)+@  0"H  #<E   O(0  *!P  " 8 P 9
M% H %1(. !02$@ 3$Q@ $A,? !$4)@ 1%"X $!0X  \50@ .%D\ #19<  P7
M;  +%W\ "1B3  @8J  &&+\ !QC@  <8]0 )&/\ E3@  (H]  " 0   =T$
M &U!  !D/P  6CP  % X  !',P  /C   #8K   N)P  )R,  !\?   7&@@
M$A<- ! 7$0 /%Q8 #A@<  X8(P -&2P #!HU  L:0  *&TP "1M:  <<:0 %
M''P !!V1  (=I@ !';P  AS=  (<\@ #'/\ DSP  (A!  !_1   =44  &Q%
M  !C1   64$  $\]  !&.0  /C8  #4R   N+@  )2H  !TE   4(00 #QT+
M  T=$  ,'10 "QT:  H>(@ ('BH !Q\S  8@/@ $($H  R%7  $A9P  (7D
M "&.   AI   (;H  "';   A\@  (/X D$   (9%  !]2   =$H  &M*  !B
M20  6$8  $Y"  !%/P  /3P  #4Y   K-   (B\  !DK   2* 0 #20*  DC
M#@ &(Q( !2,9  0D(  ")"@  24Q   E/   )4@  "95   F90  )G<  ":,
M   FH@  )KD  ";9   E\@  )?X CD4  (1)  ![30  <T\  &I/  !@3@
M5TL  $U(  !$10  /$(  #$]   G.0  'C4  !4R   /+@, "BP*  4K#@ !
M*A$  "H6   J'@  *B8  "LO   K.0  *T4  "Q3   L8@  +'4  "R*   K
MH   *[<  "O6   J\@  *O\ C$D  ().  !Z4@  <50  &A4  !?4P  5E$
M $Q.  !#2P  -T<  "U#   C/P  &CP  !(X   ,-@, !C,)   R#0  ,A
M #$4   Q&P  ,2,  #$L   R-P  ,D,  #)0   R8   ,G(  #*'   QG@
M,;4  ##4   P\@  +_\ B4\  (!4  !X5P  ;UD  &99  !>60  55<  $E3
M   ^3P  ,DP  "A(   >10  %4(   Y    (/0(  3P(   [#   .@\  #D2
M   Y&   .2   #DI   Y-   .4   #E.   Y70  .6\  #B%   XG   -[,
M #?2   V\@  -?\ AU4  ']:  !V70  ;5\  &5?  !=7P  4EP  $18   X
M50  +5(  ")/   83   $$H   I(   #1@$  $4&  !$"@  0PT  $(0  !!
M%0  01T  $$F  !!,0  03T  $%*  !!6@  06P  $"!   _F0  /[$  #[0
M   ]\@  //\ A%P  'Q@  !S8P  ;&4  &1F  !99   2V$  #Y>   R6P
M)ED  !Q6   25   #%(   11    3P   $X#  !-"   3 P  $L.  !+$@
M2AD  $HB  !*+   2CD  $I'  !*5@  26@  $E^  !(E@  1Z\  $;-  !%
M\0  1/\ @6,  'EG  !R:@  :VP  &!K  !2:0  1&8  #=D   J8@  'V
M !5>   -70  !EL   !:    60   %@   !7!   5@@  %8,  !5$   5!0
M %0=  !4)P  5#0  %1"  !34@  4V0  %)Y  !2D@  4:L  %#*  !/[P
M3O\ ?FH  '=N  !P<0  9G$  %AP  !*;P  /&T  "]L   B:@  %VD   YG
M   &9@   &4   !E    90   &,   !B    8@0  &$(  !A#0  8!   & 7
M  !@(0  7RX  %\\  !?30  7EX  %YT  !=C0  7*<  %O%  !:[0  6?\
M>W(  '5V  !K=P  778  $]V  !!=0  ,W4  "9T   9<P  $'(   =Q
M<0   '$   !Q    <0   &\   !O    ;@   &X"  !N"   ;0P  &T1  !M
M&@  ;28  &PU  !L1@  :U@  &MM  !JA@  ::$  &B^  !GZ   9OX >7H
M '!\  !A?   4WT  $1]   V?@  *'X  !M]   0?0  !WT   !]    ?0
M 'X   !_    ?@   'T   !]    ?    'P   !\    ? 8  'P,  !\$@
M?!T  'PL  !\/   ?$\  'ME  ![?@  >IH  'FV  !XWP  =_H <X   &6!
M  !6@P  2(0  #F&   KAP  '8<  !&'   'B    (@   ")    B@   (P
M  "-    C0   (P   ",    C    (P   ",    C0   (T$  ".#   CA,
M (\A  ".,@  CD8  (Y;  "-=   C9   (RM  "+S@  BO, :(8  %J(  !+
MBP  /(T  "V/   >D   $9$   >2    DP   )4   "7    F0   )L   "<
M    FP   )L   "<    G    )T   ">    G@   )\   "A P  H@P  *(6
M  "C)@  HSH  *-/  "C:   HH8  **B  "BP   H>@ 7(T  $V0   _DP
M,)8  "&9   2F@  !YL   "=    H    *(   "D    J    *H   "K
MJ@   *L   "L    K0   *X   "O    L0   +(   "T    MP$  +D-  "Y
M&@  NBT  +I#  "Z6P  NG<  +N4  "[L0  N=( 4)4  $&8   RG   (Z
M !.B   (I    *<   "J    K    *\   "R    MP   +D   "[    N@
M +P   "]    OP   ,    #"    Q    ,8   #)    S0   -(!  #4#P
MU1\  -<U  #830  V&D  ->&  #7HP  UKT _P   /\   #_    _P   /\
M P#_  T _P 5 /\ ( #\ "L ^  U /0 /P#P $< [@!. .L 5 #I %H YP!?
M .4 9 #C &H X0!P -\ =@#= 'X VP"' -@ D0#3 )T SP"K ,T O0#+ .
MR0#[ ,< _P"] /\ L0#_ *D _P"C /\ _P   /\   #_    _P   /P   #V
M  L \0 1 .T &P#I "4 Y  P -\ .0#: $$ U0!( -$ 3@#/ %0 S0!9 ,L
M7@#) &, QP!I ,4 ;P## '< P !_ +X B@"[ )4 N "C +8 M "T ,T L@#R
M +  _P"L /\ HP#_ )P _P"7 /\ _P   /\   #Z    \0   .@   #@  8
MV0 . -( %@#. !\ R  I ,0 ,@#  #H O0!! +H 2 "X $T M@!3 +0 6 "R
M %T L !B *X :0"L &\ J@!X *@ @@"F (X I "; *$ JP"? ,  G0#F )L
M_P": /\ E #_ (X _P"* /\ _P   /8   #H    W    ,X   #&  $ OP +
M +H $0"V !H L@ B *X *P"J #0 J  [ *4 00"C $< H0!, )\ 40"> %8
MG !< )H 8@"9 &@ EP!P )4 >@"2 (8 D "3 (T H@"+ +4 B0#3 (< ]P"&
M /\ A #_ '\ _P!\ /\ \@   .,   #2    Q0   +H   "Q    JP ' *4
M#@"A !0 G@ < )H )0"7 "T E  T )( .@"0 $  C@!% (T 2@"+ %  B0!5
M (@ 6P"& &$ A !I (( <@!_ 'T ?0"+ 'L F@!X *L =@#$ '0 ZP!S /\
M<P#_ '  _P!N /\ WP   ,P   "_    M    *L   "A    F@ " )0 "P"0
M !  C  7 (@ '@"% "8 @P M ($ ,P!_ #D ?0 _ 'L 1 !Y $D > !. '8
M5 !T %H <P!B '  :P!N '4 ; "# &H D@!H *, 9@"X &0 W@!C /L 8@#_
M &( _P!@ /\ S    +P   "O    I0   )T   "4    C    (8 !P"!  T
M?  2 '@ &0!U !\ <P F '$ +0!O #( ;0 X &L /0!J $( : !( &< 3@!E
M %0 8P!; &$ 9 !? &X 70![ %L B@!9 )L 5P"O %8 RP!5 /( 5 #_ %0
M_P!4 /\ O@   +    "D    F0   )    "(    @0   'D  @!S  H ;P /
M &L % !G !H 90 @ &, )@!A "P 7P R %X -P!< #P 6P!" %D 1P!7 $X
M5@!5 %0 7@!2 &@ 4 !T $X @P!, )4 2@"H $D P !( .@ 1P#_ $< _P!'
M /\ M D  *8+  ";#   D H  (8%  !^    =@   &\   !H  4 8P , %\
M$ !; !4 6  : %8 (0!4 "8 4P L %$ ,0!0 #8 3@ \ $T 0@!+ $@ 20!0
M $@ 6 !& &( 1 !N $( ?0!  (X /P"B #T N  ] -T / #X #P _P \ /\
MK!   )\2  "4$@  B1$  '\/  !V#   ;@4  &8   !@  $ 60 ( %4 #0!1
M !$ 3@ 6 $L &P!) "$ 2  F $8 *P!% #$ 0P V $( / !  $, /@!+ #T
M4P [ %T .0!I #< >  V (D - "< #, L0 R ,X ,@#Q #$ _P Q /\ IA8
M )H9  ".&@  A!H  'H6  !P$@  : X  %\*  !8 P  40 $ $P "@!(  X
M1  2 $$ %@ _ !L /0 A #P )@ Z "P .0 Q #< -P V #X - !& #, 3P Q
M %D +P!E "X <P L (4 *P"8 "H K0 I ,8 * #J "@ _@ H /\ H1P  )4@
M  "*(0  ?R$  '4?  !L&@  8Q8  %H1  !2#0  2P<  $0 !@!   L /  /
M #@ $@ V !< -  < #, (0 Q "< ,  L "X ,P M #H *P!" "H 2P H %4
M)@!A "4 <  D ($ (@"5 "$ J0 @ ,$ ( #D !\ ^0 ? /\ G2(  )$F  "&
M*   ?"<  '(E  !I(@  7QT  %<8  !.$P  1@X  #\+   X!0< -  , #$
M$  N !, +  8 "H '0 I "( )P H "8 +@ D #8 (P ^ "( 1P @ %( 'P!>
M !T ;0 < 'X &@"2 !D IP 8 +T %P#? !<!]0 7 O\ FB<  (XK  "$+0
M>2T  ' K  !F*   720  %0?  !+&@  0Q0  #L0   T#0( +0D) "D%#0 F
M Q  ) $3 "("&0 A AX ( (D !X#*@ = S( &P0Z !H%1  9!4\ %P9< !8&
M:@ 4!WP $P>0 !('I0 1![L $ ?; ! (\@ 0"?\ ERL  (PO  "!,0  =S(
M &XQ  !D+@  6RH  %$E  !)(   0!L  #@6   Q$@  *0X$ ",,"0 ?"0T
M'0<0 !L'%0 9"!H & @@ !<))P 6"2X %0HW !,*00 2"TT $0M: ! +:0 .
M#'L #@R0  T,I0 ,#;L "PW9  L-\0 ,#?\ E2\  (HS  !_-@  =C8  &PU
M  !C,P  62\  % K  !')@  /B$  #8=   N&   )Q,  " 0!0 9#@H %0P.
M !0,$0 3#!8 $@P< !$-(P 0#2L #PTT  X./P -#DH # ]8  L/9P *$'D
M"!"-  <0H@ &$+@ !1#4  40[P &$/\ DC,  (@W  !^.@  =#L  &LZ  !A
M.   6#4  $XP  !%+   /2<  #4C   M'P  )AH  !X6 0 7$P8 $1 +  X.
M#@ .#Q, #1 9  T0(  ,$"@ "Q$R  H1/  ($D@ !Q)5  8390 $$W8  Q.+
M  $4H   $[8  !/1   3[@  $_L D#8  (8[  !\/@  <S\  &H_  !@/0
M5SD  $TV  !$,0  /"X  #0J   L)@  )2(  !X>   6&@( $!4)  P3#@ *
M$Q( "107  @4'P '%28 !A4O  06.@ #%D8  1=3   78@  &'0  !B)   8
MGP  &+4  !?0   7[0  %_L CCH  (0_  ![0@  <D,  &A#  !?0@  5C\
M $P[  !#-P  .S0  #,P   L+   )"D  !LD   3'P( #1L)  D9#0 &&1$
M!!D6  (9'0 !&B0  !HM   ;.   &T0  !Q1   <8   '7(  !V'   <G0
M'+,  !S.   ;[0  &_P C#X  ()#  !Y1@  <$@  &A(  !>1@  540  $M
M  !#/0  .SH  #,W   J,@  ("T  !<I   0)0( "R()  4@#0 !'Q   !\4
M   ?&P  ("(  " K   A-@  (4$  "%/   A7@  (G   "*%   AFP  (;(
M "'-   @[0  '_P BD,  (!(  !X2P  ;TP  &9-  !=2P  5$D  $I&  !"
M0P  .D   "\[   E-P  '#,  !,O   -+ ( !RD(  $G#   )@X  "42   F
M&0  )B$  "8I   F,P  )S\  "=-   G7   )VT  ">"   GF0  )K   "7,
M   E[@  )/T B$@  '],  !V4   ;E$  &52  !<40  4T\  $I,  !!20
M-40  "M    A/   %SD  ! V   *,@$  S '   O"P  +@X  "T1   M%@
M+1X  "TG   M,0  +3T  "U*   M60  +6L  "V    LEP  +*\  "O+   J
M[@  *OX A4T  'U2  !U50  ;%<  &-7  !;5@  4U4  $=1   [30  ,$D
M "5&   <0P  $S\   T]   &.@   #@%   W"0  -@T  #4/   T%   -!L
M #0D   T+@  -#H  #1'   T5P  -&@  #1]   SE0  ,JT  #'*   Q[@
M,/\ @U,  'M8  !S6P  :ET  &)=  !;70  3UH  $)6   V4@  *D\  "!,
M   620  #D<   A$    0@   $$#   _!P  /@L  #T.   ]$0  /!@  #PA
M   \*P  /#<  #Q$   \4P  /&4  #MZ   ZD@  .JL  #G(   X[0  -_\
M@5H  'E>  !Q80  :6,  &)D  !78@  25X  #Q;   O6   )%4  !E3   0
M40  "D\   %-    3    $H   !)!   2 @  $<,  !&#P  1A0  $4<  !%
M)P  13,  $5   !%4   1&$  $1V  !#CP  0J@  $'&  ! [   /_\ ?F$
M '9E  !O:   :&H  %UI  !/9@  0F0  #1A   H7P  '5T  !);   +60
M E@   !6    5@   %0   !3    4@0  %$)  !0#0  4!   $\8  !/(@
M3RX  $\\  !/2P  3ET  $YR  !-BP  3*4  $O"  !)Z@  2/\ >VD  '1L
M  !N;P  9&\  %5M  !';   .6H  "QI   @9P  %&4   UD   #8@   &(
M  !A    8    %\   !>    70   %P$  !<"0  6PT  %L2  !;'   6B@
M %HV  !:1@  65@  %EM  !8A0  5Z   %:]  !5Z   4_X >7   '-T  !I
M=0  6W0  $QS   ^<P  ,'(  "-Q   6;P  #6X   1M    ;0   &T   !M
M    ;    &L   !J    :0   &D   !I P  : D  &@.  !H%0  9R$  &<O
M  !G/P  9E(  &9F  !E?P  9)H  &.W  !BX0  8?P =W@  &UZ  !?>@
M4'H  $)Z   S>P  )7L  !AZ   .>0  !'D   !Y    >0   'H   !Z
M>@   '@   !X    =P   '<   !W    =P$  '<(  !W#@  =Q@  '<F  !V
M-@  =DD  '5?  !U=P  =),  '.O  !RTP  <?< <7X  &-_  !4@   18(
M #:#   HA   &H0   Z#   $A    (0   "%    A@   (@   ")    B
M (<   "'    AP   (<   "'    B    (@   "(!P  B1   (D<  ")+
MB#\  (A5  "(;0  AXD  (:G  "%QP  A.\ 9H0  %>&  !(B   .8H  "J,
M   ;C0  #XT   2.    D    )$   "3    E0   )<   "8    E@   )<
M  "7    EP   )@   "8    F0   )H   ";    G0<  )T1  "=(0  G3,
M )U)  "<8@  G'\  )R<  "<N0  F^( 6HL  $N.   \D0  +9,  !Z5   0
ME@  !)@   ":    G    )X   "A    I    *8   "G    I@   *<   "G
M    J    *D   "J    K    *T   "O    L0   +,)  "S%0  M"<  +0]
M  "U50  M7   +2.  "TK   M,P 39(  #^6   OF@  ()T  !&?   %H0
M *,   "F    J0   *P   "O    LP   +4   "W    M@   +<   "X
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M______________________________________________\
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M^?K[_/W^_VUF=#$      P$A   !                     0
M          $    ! @,$!08'" @)"@L,#0X/$!$2$Q05%A<8&1H:&QP='A\@
M(2(C)"4F)R@I*BLL+2XO,#$Q,C,T-38W.#DZ.SP]/C] 04)#1$5&1TA)2DM,
M34Y/4%%24U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM;F]P<7)S='5V=WAY
M>GM\?7Y_@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@H:*CI*6F
MIZBIJJNLK:ZPL;*SM+6VM[BYNKN\O;Z_P,'"P\3%QL?(R<K+S,W.S]#1T]35
MUM?8V=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_Q\O/T]?;W^/GZ^_S]_O\  0$"
M @,#! 0%!@8'!P@("0D*"PL,# T-#@\/$! 1$1(3$Q04%186%Q<8&1D:&AL<
M'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C]
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M__________^6-        $^G______________________________9I'0
M"0P&"5*Q_____________________________\L[#A,U3%M-3%[#________
M_____________________ZE@-F"&G[:LJ;C9________________________
M_____^"7C;[E_______________________________________M^?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____Z]G*O,?__________________________________\^:@6U:1HCJ____
M____________________________Q'P^)A   %2P____________________
M___________@@SP      "Z'[?____________________________^L4Q
M     !=MUO____________________________N ,0        EAS/______
M_____________________]): @        !=S/______________________
M_____Z@U          !<T____________________________WT-
M  !4UO__________________________[GU%          !$U/__________
M_________________*ID+P(   0B-TE8SO__________________________
M_^FD:T$H/V-_E:>ZVO______________________________U;*LLLSD^O__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________Y;N7=V+(____________________
M_____________]N>9S8*  *,________________________________R'\_
M!0    !>S______________________________9@3D        \JO______
M______________________^>3          CD/______________________
M_____]QO&@         0??G__________________________Z](
M    ;^[__________________________X03            9.;_________
M________________[%$             5][_________________________
MN!4             2-;_________________________=!0
M.,_________________________YHEH3            (\7_____________
M____________WYM<+           #;K__________________________^^Q
M?54Y(A$' 0(1(K+______________________________]^_I9F8FJ"LO=K_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^.^G8!\^_________________________________*WA%<P#@ =K/______
M________________________THI,%0      <O/_____________________
M_______6?S8         2\G___________________________J1/@
M    +ZO__________________________\!:            &I7_________
M_________________XTD            "(3_________________________
MYUX              '?_________________________M"4
M &K_________________________?0               %OT____________
M___________]*P               $SK______________________^E
M             #SA______________________\P#                "W9
M_____________________YF*82<              "?7________________
M_______MOHE5)P           "7<__________________________[*G79=
M2CPR+2PP.4?>_______________________________]YMW6TM#3V>3_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________[]2[UO______________________
M___________GN(]J2R\5;_______________________________Y*%G- <
M    /,G____________________________6@CL         $I?_________
M_________________^V%,0           &__________________________
M_Z9"             %#A________________________[&D
M #?)________________________LR\              "*V____________
M____________>0               !"G_______________________R-
M              "9______________________^I                  ",
M______________________]&                  !_________________
M_____]\                   !T_____________________Y<
M          !J_____________________\X                   !C____
M__________________\I(@$               !A____________________
M__^YHX!7-Q<           !H___________________________ZTZZ4AGQU
M<7!R=X&4____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________]NZG8)I:=/_________
M_____________________\B393T9    '9[_________________________
M___;CDP3         &[__________________________]M\+
M $77_________________________XLJ             "*T____________
M____________PD0               .7________________________?0$
M              !________________________G-@                !J
M______________________^=                  !8________________
M______]&                  !'^/___________________^D
M           UZ?___________________Y8                    EV___
M_________________[P                    8SO__________________
M_^L                    /PO____________________\
M       *N?____________________\G                   *M?______
M______________]P                   -N?_____________________@
MG(QP54(S)AL4#PT.$AHFO_____________________________GDV-+.S,O,
MS];@_/______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^O3O./________________________________2J85E2"P2
M 87____________________________QJW$\#P       $_@____________
M_____________]5_-0           !^R________________________XW4=
M              ")________________________D",               !G
M_______________________50P                !(]O______________
M______^*                   NW?____________________\X
M           7R/___________________[X                    $MO__
M_________________YP                     I?__________________
M_[H                     D____________________]P
M        @O____________________\                     =/______
M______________\3                    :/____________________]"
M                    8/____________________]Z
M    7?_____________________1                    8?__________
M____________)                   9O______________________R:R9
MB7UV<6QI9V9G:W!ZC/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^+%JI%Y87?_____________________________
MW:9W4"P,     #'$_________________________^"23A,           "/
M________________________TG =              !@________________
M_______N;P\                WXO____________________^6'
M           4P/____________________]                     H___
M_________________ZX                     B?__________________
M_YX                     <O___________________[P
M        7____________________]H                     3?______
M______________H                     ._____________________\.
M                    *OG___________________\S
M    &^G___________________]>                    #]O_________
M__________^/                    !M#____________________0
M                 ,K_____________________*P
M ,C_____________________@                    ,O_____________
M________]Q8!!04# 0       08-&,O_______________________SKX=C/
MS,W/T-+4U]SBZO______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________QVL;_
M______________________________'&HX1H33(8 !6K________________
M__________^Y?$88          !Q________________________UWPO
M           [X______________________?9 D                ,M?__
M__________________]T P                  C?__________________
M_\45                    :O___________________YD
M        2____________________[8                     ,/W_____
M_____________]<                     &>?___________________8
M                    !=/___________________\.
M     ,'___________________\O                     *__________
M__________]2                     )[___________________]Y
M                 ([___________________^E
M (#____________________8                     '3_____________
M________-@                   &W_____________________?
M             &G_____________________UPT                  &C_
M_____________________W                   &'_________________
M______]0/$9.5%E=861H;'!V?HG_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^_5NZ.+<UJ5___________________________XOXYD02$%      !2_/__
M____________________]YU6&              7P?__________________
M___E;!8                 C?____________________]C
M        7O___________________YT                     -?S_____
M_____________Z$                     $=G__________________\H
M                     +O__________________^X
M     *'___________________\,                     (K_________
M__________\M                     ';___________________]-
M                 &3___________________]O
M %+___________________^4                     $#_____________
M______^\                     ##____________________J#@
M             "+_____________________1                    !7_
M____________________@0                    OU________________
M____R L                   +L_____________________UX
M          #E_____________________\D<                  #:____
M__________________^= 0             '#A?%____________________
M____U;F\P<?.U=OAYNWT^_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________^-_/____________________
M_________^S&I8AM5#LA!P RWO_______________________]>262D
M        H/______________________B38                 9_______
M______________]F                    ,O;__________________Y4
M                     \C__________________Z<
M     *#__________________]<                      'S_________
M__________\                      %[___________________\E
M                 $/___________________](
M "S___________________]J                     !C_____________
M______^+                      7S__________________^O
M              #A___________________5                      #/
M____________________)                     "^________________
M____5                     "N____________________BP
M          "?____________________RPX                   "2____
M_________________U<                   "&____________________
M_ZH*                  !Y______________________]M
M      !F_______________________W50                !%________
M_________________VHC*S4_2E5@:G5^AY&<________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________HS[:=@VE.N?______
M___________________LLH-<.AT"        >_______________________
MQ6TI                0/____________________^#&P
M    !\O__________________Y(                      )C_________
M_________Z0                      &K__________________]T
M                 $'___________________\.
M !W___________________\Y                      #H____________
M______]@                      #.__________________^%
M              "W__________________^H                      "C
M___________________+                      "0________________
M___O%@                    !]____________________/@
M          !L____________________:0                    !:____
M________________F0                    !)____________________
MTA8                    Y_____________________U@
M       I_____________________Z(                    9________
M______________56                   $______________________^[
M+P                  ^/______________________JRD
M    S________________________\E'      <3("X^4FB$[?__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________35R?____________________________K2L))W74(H
M#   2O_______________________\5]11<             $=C_________
M___________$4                    )___________________Z(,
M                 &C__________________Y0
M #;__________________]H                       ?L____________
M______\5                      #$__________________](
M              "B__________________]U                      "#
M__________________^=                      !I________________
M___#                      !2___________________G#P
M           ^____________________,P                     K____
M________________6                      8____________________
M@0                     %____________________K
M        ____________________WB(                     \O______
M_____________UP                     W____________________Y\
M                    S/___________________^A*
M    M_____________________^@%@                  G/__________
M____________>@(                 =________________________WH+
M               %3/________________________^B5VAT@(V<J[S0Y___
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________MX___________________________
MTJ-Z6#HI(QP6#@8  )______________________K%(.
M &G__________________^1#                     #3_____________
M_____WD                       #C_________________\T
M              "R__________________\3                      "%
M__________________]/                      !=________________
M__^#                       Z__________________^R
M           <___________________; P                     "____
M________________*@                      ^___________________
M3P                      Y___________________=
M        U/__________________FP                      P/______
M____________Q <                     K?__________________\#,
M                    FO___________________V<
M    AO___________________Z,                     <O__________
M_________^-$                    7/____________________^1!@
M                0?_____________________K7P
M'?______________________RDL                  /______________
M_________\M7   ,&"0Q/TY@=(NGQ___________________________U^?R
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________Z]3-Q\*^NK>SL*VIJ*7____________________=?E,_,",9
M$0D"          #;_________________W8                       "G
M_________________[H                       !U________________
M__\'                      !&__________________].
M           :__________________^,                        _?__
M_______________!                        V__________________Q
M&0                      OO__________________1
M        I/__________________:P                      C?______
M____________D0                      >?__________________MP
M                    9O__________________WB$
M    4____________________TH                     /___________
M_________W<                     *____________________ZP*
M                %O___________________^=%
M /____________________^*                     /______________
M_______630                   /W_____________________IRX
M             -7______________________Y@J           &&"U%8.#_
M______________________^H8W2!CYRKN\WB^O______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___B,X!)0T-?4%)/1DE,10 2$O__________________________________
M____________________________Y\NWJ9V5CHF$@'QX='!L:&60________
M_________[QJ2"T9"@                 Q__________________\
M                   #__________________]"
M    W/________________^.                        LO__________
M_______.                        C?__________________*0
M                :___________________6@
M3O__________________A@                      -/______________
M____K@                      'O__________________U!<
M            "O__________________^CT                      /__
M_________________V4                      /__________________
M_XX                      /___________________[P9
M         .____________________%.                     -C_____
M______________^+                     +_____________________,
M0P                   *'_____________________D1D
M     'K_____________________\G0*                $5__________
M_____________^AT$Q\L.$538G*%F[32]?__________________________
MU^CT________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________[]_/Q[NSK
MZ^SQ___________________9LIF'>6UD75912T9!/#@R+2@CQ/__________
M______]+)0L                     DO________________^(
M                9O_________________7
M/?__________________,P                      &/______________
M____;                        /__________________G0
M             /__________________R0P                      /;_
M________________\34                      -__________________
M_UL                      ,O__________________X(
M         +?__________________ZD&                     */_____
M_____________],O                     (W___________________]>
M                     '?___________________^3!P
M     %[____________________-0P                   $#_________
M____________AQ                   !S_____________________V%X
M                  #______________________[].       .'"P^4FJ&
MI<C________________________"?(R:I[;%UNC]____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________NX=?/R<.^NK:QK:FGIJ:G
MKO________________^^AFU;3$ W+R@B'!80"P0     %/______________
M___7!0                       /__________________-
M             /;_________________=@                       -+_
M________________L                        ++_________________
MX20                      );__________________U$
M         'S__________________WD                      &;_____
M_____________Z                       %'__________________\<C
M                     #S__________________^Y+
M     "?___________________]T                     !#_________
M__________^C%@                    #____________________83
M                  #_____________________B \
M  #_____________________RU,                   #_____________
M_________Z4X           )'31.:XS_______________________^9.4-1
M7VY]CJ"UR^7_____________________________Z_G_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________Z\RYK*&9D8N&@7QX='!K:&9F:/'_
M________________844R(Q@.!@               )[_________________
M?@                       '7_________________PP
M         %+_________________^S<                      #+_____
M_____________VH                      !;__________________Y8
M                      #__________________[\;
M      #__________________^9"                      #_________
M__________]I                      #___________________^0 @
M                  #___________________^Y+
M  #T___________________H7                     #9____________
M________D1@                   "\____________________RE,
M              "=_____________________Y@N             ! I1F;$
M_____________________^Y_'0P:*#=&5VE^E:_,[O__________________
M_______GH*JYR-CI_/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________WU\.OFXM_;
MV-32T=#2U^#_________________SIZ*?'%I85M644Q(0SXZ-C(O+C'_____
M____________TB41 P                    #__________________T(
M                      #__________________WT
M      #__________________[ +                      #V________
M_________]TY                      #<__________________]B
M                  #%__________________^)
M  "O__________________^O(@                    "9____________
M_______62                     ""____________________<@
M              !I____________________H2@                   !.
M____________________TUP                    S________________
M_____Y8N               5,E)W_____________________^!R$P   0\?
M+T)8<(NHR.S________________________*;VY^CIZPP]CO____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________G@TLC NK6PK*BEHI^=
MFYN<H*?__________________X)D5DM#/#8P*R<B'1@3#@D$  #4________
M_________Y(                       "M_________________\P>
M                  "+__________________M2
M  !M__________________^                       !1____________
M______^I&P                     Z___________________00@
M               C___________________U:                      ,
M____________________CQ0                     ________________
M____N#X                     ____________________Y6T#
M            _____________________Y\W               0+U!T____
M_________________]UR%      &%RI!6G64MMK_____________________
M__^\6$149'6&FJ_(X_______________________________TLWA\?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________/OZ^_W______________________^ZYJ)V6CXJ&@G][>'9T<G-U
M>'^0_________________^M/.C H(1L5$ L' @         C____________
M______]I                        __________________^;"@
M                ___________________(.0
M___________________P8P                      ________________
M____B@X                     ____________________L#0
M            ____________________U5L                     ____
M_________________X4:                   #[/__________________
M_[%)               8.5V!_____________________^5['@      #"$X
M4F^/L]G_______________________^[6"DY25IL@)>PS>W_____________
M________________LYZTQ=?K____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________^N_GX=S9
MUM32T-#0T=/9X.OW__________________^XBGYW<6QH9&%>6UE85U=97F5Q
M__________________^_,1\6$ H%                ________________
M___M5@                      Z/__________________@@0
M            S/__________________JR\                     L___
M________________TE<                     F___________________
M]WP0                    A?___________________Z(W
M      4KE/___________________\MA @            PL4':>T?______
M______________6-,       #2,[5W:9ON7________________________#
M8Q@J.TQ?=(VGQN?_____________________________J'^6J+O0Y_______
M______________________________W_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________W<[%O[RYMK2S
ML;*RM;G R=7C____________________EVQD7EE544],2DA'1DA+4%EFH?__
M________________IR8.!P(                 5O__________________
MSE                      .O__________________]'D+
M        (?___________________Y\R                    #O______
M_____________\18                "#%:A/___________________^E_
M'P          !B=+<9K"Z?____________________^G20     "%R]*:(JN
MU?S________________________3=1XF.$I>=8^KR^__________________
M____________KG*%F*S"V_;__________________________________]_O
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________[^RJJ:CH:"?GZ&C
MIJRTP,W=[/___________________XI:4T]+2$9$0T)!0D-'3EEI??______
M_____________YXN!@                   /___________________\-6
M                   50?___________________^=[&@             )
M-&"+M/____________________^?/P         $)4IQF<+K____________
M___________&9@\    3*D1B@Z?-]?_________________________KCC4K
M/E%H@9V\WO______________________________OG9_E*G!W/G_________
M_________________________]+8\_______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M]O+P[^_O\?/X_?____________________________BPGYJ7EI:6F)N?I*RV
MPM'A[O____________________Z.4$I'141$1$5&1TM16FB#J?__________
M__________^F00$           <V8X^ZX?_____________________&90H
M      0G3'.<Q.S________________________EB"\  !,J1&*"ILST____
M________________________JU V2F%[EK36^O______________________
M________TH=\F+'+Z?___________________________________]3.[?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________[>7C
MX^3FZ.WQ^?_____________________________]L922DI69G:.ILKS0[?__
M________________________G5-'24U15F!SBJ_6_/__________________
M________LE8 &C50;8NNTO?_____________________________S6\^7WN9
MM]?Y________________________________[I^#IL+A________________
M_____________________^/.Z___________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________P
M
M
M        ____________________________________________________
M____________________________________________________________
M__________________________________________________________\
M  #_[@ .061O8F4 9(      _]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,#_\
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M(Y672)EUIY.*.1LE(U58Y'=BH8 ?$4^T1; ] .YERV2J>GG?;<[=&BM5KO\
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M>US7L:YJHDRCEBE3FBD9(GI8Y':>SHO!2Y)-"\1R
M
M
M
M
M
M
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M\DH84X)/*:X4]2B(CN[>O_:Y-$5?^"OT7?"9)RZ1F0(X
M
M
M
M
M
M
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M ^1FMULT]=11=]&RH=3U#E@;4%/5PU*?H;M')VQNX/3VOSR>M#N@5R9(R)
M
M
M
M
M
M
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MS0]O#R]'EVG$YNG%.SX 4S5TW;P[/9]DE,T6A\ I>L@^EY?#Z"4S1]OK\O?
M*7JX>WAY?$2F9G;Y>PO8 =2-T<.?:+K+>Z5LC[?=JF669557NI;A*JRS,D<[
MF<K*IRND8J]B\S>&B:]7]R<06T7)UWHXW+;KG,]\B)JJ4E=)J^6-RKJJ1U#M
M7L\R+JW@B)KU]S[$TM-:MTHXT2W7"5RO:B?-I*MVKWQZ=B13<7,\R<6\$1-9
M!=YI:-&RHJ]R]>77^H?VHU?4Y$U3VRU:1>?E]U?B52VB1>I$]GC\I;Y(O95/
M4GYI3$EY_K^WU_)V_ ?7=>IOE[1])'[">PGYA]=SZE]U/S2%=>>/T]/;^)!W
M7J;Y>T?O=^OWONG[W7];[_W3C^_/K\O^,.Z]3?+VC\6/7T+[*?FGYW/J7W4^
MZI]MO7I?[Z_'JBGRL?\ 6^Y\B*?*Q>I/:X?(?*Q>RGLI^814=Y_KO7V^6A\+
M&GK3V3X6+U*GOH?"Q>I%]Y280WGS\_OE2V6X2*Z.@FY7HNK:>15TDUT3EIUU
MX2(NFD:?2U^:FOS43M/T\[OOQRL@P?)*I5Q^X3\MFK9WKI9KA._A2O<Y=&6R
MND7TZ0S+S:(U[W)K<>.SX4:]1N(W'J[Z?L8CEW\V_L;7;G8K9Z5&5^\> 6.D
MTCN5'30,1+KN/@UM@TIT5/K=UL\7U)KI9J2W4SOJHGCJE21JHDB)H[^O1.SV
M7)[OF]!4QW[-&PA              #GC9Z?;]7J]DY&-\Z^U\I^HFJZ'TUNJ
M^KS_ "$QBB]7M?%\IS-;KV]B>^<[6^9/+UJ<Q-H(==.'Q$2UNO'S)[_W")8S
MS>9.U?+T@G5/!V</=]PB6-\ZI[!%L;V+[B KC$[]D6'7VU91B5^O6,9+9*N.
MNLV08]<ZVSWJU5L>J1U=NN=OFIZVBJ&(Y41\;VNT54UXDRHIZFBJ(:JCJ)Z2
MK@<DD-332O@GA>G8Z*6)S9&.37M144K+"<RS';G*;%G.WV59'@^:XQ7Q77'<
MNQ&]W+',EL%RA1R15]FOEHJ:2Y6VLC:Y422&5C]%5-=%4YH^9BH]%5KD^BJ*
MJ*WUHJ<44V9N@[QHHKNZR[5]84]/05S_ *K;+'OE14L=-;:J16MAACW,ME*C
M(;9+(]$1;O11I2ZN1:F"!C9:I>U6WN^"3=Q:,T<V.1>2*GO[&(V-Z_11+K"Q
M$;$JJG]F8G+Q^<UJ(KS=9\*;[3%1WZ7&MA?$:JZ*SW27ZC8\5ZI;90Q45DKI
ME8VGIX][['1-CIK%/-(U&NR*VPMH>:1KJVDI8V3UZSNFN.NC*CAV(DJ=G_5I
MYO90V**&NHKG14=RMM92W"W7"EIZZ@KZ&HBJZ*NHJN)E12UE'54[Y(*FEJ8)
M&OCD8YS'L<BHJHIV5CD9*QDL3V21R,;)')&Y'LD8]$<Q['M56N8YJZHJ<%0W
M(K5=;9?;9;KW9+C07BS7B@H[K:+O:JRGN%LNMLN%/'5T%QMU?2234E=05U),
MR6&:)[HY8W(YJJBHI-T77BG%%XHJ><BC[(\
M
M
M
M
M
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M6\JTELO3G4K'Q15MNI&5+0U\=4G)JB2(FNG]4B=JIZT\Y,SLX:UQ,0
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MK**KB@K*.IC?#-''(QS4G;'M>U',5'-7L5/+M*V(XNH?0
M
M
M
M
M
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MVBJ&LGIIV*UR=BK.F/:]J.:NJ+Y:+Z%0N 3 O2?0
M
M
M
M
M
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M-$5%1%1=47BBD\.<K(_0
M
M
M
M
M
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M0.Y/FN7@JZI_6JOF]LV%2_AOGD8
M
M
M
M
M
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M(O:B)[9D!*X-@(^P
M
M
M
M
M
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MHZZG5ROIJR"6)WSF*AS%0',7,
M
M
M
M
M
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MJ!<NW6K5K?F+YM$T7C[/H*JI:/7153WCE!4C;3\WZ+>ST>@F:4?#Z*Z>PG
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M2.7F<U%_3(R5D;3X
M
M
M
M
M
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M015*1SQ<RNBF:YB\6J";'(5L
M
M
M
M
M
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M0C5FD=)4?>W*::[PNY/F4].^E9HW5NH[>E0F=0
M
M
M
M
M
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M^;7W9KY&)3K<*^&._P")R=V_YKJJ7*+#2T<3DTD:VL>B*J.<UPRM%=F[$
M
M
M
M
M
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MNE!*CDT1R24M4Q=?/J"-/HJ$
M
M
M
M
M
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M78<4J\#J62.5TE.S;^^W7#[9"Y>*<OWDLU*]B(JHD;VIP5%1!=PCSO>
M
M
M
M
M
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MIZT3VE\Q R)P7U+\>A 2^?\ X7RDNF\_K1/AT+IV=WT/<]SBGO$%)VN]CXB
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MJONL5<O!K&*G9J[G4'9PG)F<
M
M
M
M
M
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MZ9))&HNO.QKM-&ZCN"3\V!P
M
M
M
M
M
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M1+HY5UXHK4]8.Z14!L>@
M
M
M
M
M
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MBIZF*#N:3\V.
M
M
M
M
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MZ(OZ%2U#W>PYK8OAE0SOF;PTC2^8 !^M3540 $4Q..OH^,$7"WL3VO=XKI[
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M[F5TTF?U=8B\.;O8$@@TT7327CKYAVT)T9^0
M
M
M
M
M
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M1_*%WR_?7SO_ "BN/]N '^NL\6__ 'C76!_#CG'ZZC^4+OE^^OG?^45Q_MP
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M7U<W+W5LJ*S[T7B17KHB16>\LM]SET<J(O+$J(JHB]J:@9'R[(
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MM4_U>*2=SW,A[Z5SN5.&KE4 VO#NR
M
M
M
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M)L-;EU5E&95C4CY%<ETR"NH[7*]_!9G36&V4C^9431%1J:HU%476(T[]
M     \X/[;S^-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK- -(,QU@
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ML<B.:YKFJJ.:Y%U14X*AW-145$5%145-45.**B]BHOG10#Z/T
M    TPOMM'X@O2C^5_3_ ,3&Z)C^\0[]S+"?P[;^U^\@'FB&(@
M ]+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
M
M
M
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M\:?H?_)_W"_C%@,3?B)_X:;=?@O=/U6: :09CK
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M\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M
M
M
M                                              =3>N?:Y^\'2=O;
MAM+!]8NK,.J<IL,3(UDJ);Y@]13YA;:.DT17-J+I-9/JB*G:E0J+\U5+4;XX
MN[+]J<ULT4?>526>6Z4#4;S2/KK))'=Z:&+1%5)*I]%W*>J147@JD+6Q][2S
M,3MY.9/98J/1$]:\N@-+FDJM-./W/5[9AFAF]?EY=I2(*EI:OL^=H36*;LX^
M7EYSE:[7@O;\()]!6=G'W_+0F$<_KT\O1VI[1]@FD==Z]?+M(ME0OI^3WOD
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MX:;=?@O=/U6: :09CK
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MV8 W/3("
M
M
M
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M:@ET]=V_.U\O>U^$AI)^WCKY>[[I\J]5]7EZ026HJ^W5R^_Z_,0$L_K\OC^
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M?*KHK<U8HUX+4O1.]=YOT)B\(TT\ZZN]2%O[GESY5=%;D6)BJJ+4R)^B._\
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M           'G!_;>?QI^A_\G_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L
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M']S+-OP[=^U^S &YZ9 0
M
M
M
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M\%[I^JS0#2#,=8
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M         :87VVC\07I1_*_I_P")C=$Q_>(=^YEA/X=M_:_>0#S1#$0
M      >EW]B7_$%ZKOROZC^)C:XR[^'C^YEFWX=N_:_9@#<],@(
M
M
M
M
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MMOFD9I37#<"X,6*PTK=>7O?O'1.GN+U8[FAJ(Z7F3EE!W3)\;,H
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MGQ:!7N=DN-MGJZ>D@;Q;+>*!T3:^T(C53G>]KZ9KEY4F<NFH&!XZU
M        &TK]DMZ\JGI6\2FW=/>3WN2AVEZW+''M1<:2HG6.U46\F.MN-_V4
MOLD:R-5]PN-QFN6+TS6M>KYLE8KD1K.9G<WH?W+?A>[D6+5E0L=CW$IDLDK'
M.TACO]*DM5CU2J:\99972T;-$75U6FO!-4 ]6,S5@        &F%]MH_$%Z4
M?ROZ?^)C=$Q_>(=^YEA/X=M_:_>0#S1#$0           >EW]B7_ !!>J[\K
M^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M
M
M
M                                                :C/C#]-<FR_4
M>_=6P6]*? ]^F5>2L=30\E+;-PK>E-#F]N?R(J,DO,U1#>&O>Y%FFKZAK&\L
M"Z8D.L';9V&;CKE5O@2.PYZV6Y)W;-(J;(:?NF7NG735&NK7R,K$5517OGD1
MJ:,4IJZ4_=3]XU/F3:N]22)]-/\ JNWVP8EF5/K\OE]HZFMET^[Q3Y26 YTJ
ME[-?@7XSE2;U^X[\T ^EJE3SI[GRZ'[WRIVZI_U0!Q.JEX\?-[7QGPZ;U_&O
MN]@!>? ^G#J!W5Q3)LYV[VASO+,0Q*Q7W(;SD=MLE0RS?4,<MU3<[K3VRYUJ
MTM%?;U%2TC^[MU%)45\\G+'%"][VM6K[-MYG^36:[9!C^'W^[V:RVZXW2NN-
M)02+2_5[932U=7%1S2]U#7U[887<E- Z2HD=HUK%<J(J1)(Z:HJ^YFDBIH99
MY.YC=(]60L=(](V-XRR<K5T:FJJO! 8]LBWOK*CO(,<M[:1BZHE?<>6:IT_J
MHZ2-SJ>)Z>97NE14_.H=1;]O'53=Y#C]"E*Q>"5U>C9:C3^JBI6.=3Q.3S*Y
MTJ:>9"Q]YW6J).>*QT24S5X)65R-EG]F.F8YT$;D_KG2(OH!9:YWFZWFH6JN
ME?4UT_'E?42*YL:+VMBCX10L7^I8B)ZBT-QN]SN\ZU-RKJFMFXZ.GD5S6(O:
MV*/A'$SA]%J(GJ+7UUUN-TF6HN-9/62^99GJYK$_J8HTTCA;ZFHB$+44K9TX
M]NFB:KJB)ZO0037^G@OI\NPA&R>TOO' R3\Q>WVBEZVTZZ_,][L3Y5.=LGI]
MU#G;)Z]/8[%^$B62>O7X4*3K+3V_-][R[/A.9LGL+\)SMD_-0YVRZ^OU+P4I
MFJM';\SWCE23T*J>SY:',DFOG1?>4YTE]?N_*4_46?M^;[WL^;SG(DGJ1?8\
ME.5)?6J>SQ]SM.5LOL^TO DLUG[?F>GS>7W3[21/2J>7J/M)>SBU?A_-.1)?
M6GMII\B$LDLW;\SWO>X]NA]=[_7>]\:H?7>>KW_N'UWJ>?3W?S2$=9OZSWOB
M7TG[WB_U2>\.\]7O_<'>)VZ)I[/W#B^\J?U"_P#%7Y3\[W^N][7X$'>>KW_N
M#O4]7NG(VS?UGO::^TG'4^5D3TJON_&?BR?\%/97[J'RLOK3VDU^5"*CLW]9
M[WO^?3X2I,.P[+]P\DM6'8'C%]S#*KW4)2VC'L<ME9>+O<)U17*VFH*"*:HD
M2-C5>]VG+&QJN<J-152:V"QW[*[O0V#&;1=+_>[E+W%!:;/15%?7U4NBN5L-
M+31OE>C&HKG+IHUJ*JJB(JD#77.CMM+/77&KIZ&BIV=Y45=9/%34T#-4:CI9
MI7-B8U7*B<53BI-Z.P35$K(8('S2O71D<;%>]R]NB-:BJNGYIGFZ3O TS7)9
M+;E_5ED2X-8M:>K9M7AM?17',;@SF9-]5R;)X4K;%C=/(U.62&A6OJGQO<G?
M4DK44R;;&>&SDEY?1W_?*Z_L8M>L4[<*Q^JIJS(:MJ*C^YO%YC2HMEGB>B(C
MF4WUJ=S7*G/ ]-3J]GO4S;+>R:@P>F2[5FCF+>:^*6"V0KHWY]+2.[JLK7IJ
MY-7]Q&UR(J=XU="ZMBVQ<O)/>9.XCX.^IP.:Z9WGY99DU9$B^=&\SN/:BFQ?
MM!LCM+L!B%-@FSF!V# \:IU;)+26:E5*NY536\GWPOMXJGU%XR"Z.9\U:JMG
MJ)^1$;S\K41,M> ;;8+M;88<:P#&;7C%GB5'O@M\*_6*R9$Y?K5SN$[IKA=:
MU6\.^J999>5$;S:(B)TSRC+K_EE>^YY%=:JZ5BHK6/J'HD4#%77NJ2EC2.FH
MX5=QY(F,:KE5RIJJJ7:H+=0VR!*:@IHJ6%.*MC;HKW?U4CUUDE?ZW*JES'.\
MR=GG7R\Q6Y1DTW;Q\O+W2-(9[_<^$XW.UX)[:DIGGTUX^7R@A7O\Z^TAQDGF
MF[>/EY>X"&>_SKV^9/+S E4TW;Q!#/?IZU7WCC<[7@GMJ2B>?77CY?*"&<[S
M)V^=?+SG&2F:;MX^7E[H(5SO,G9YU\O,"4S3=O'R^7X 2RXT=%=*2HH+C2T]
M;0U,;HJBEJHF303QNX*V2*1'-<GHX=OK."9&2L=$]K7QN31S7(CFN3T:+PT*
M5O\ ;+3D-LKK+?;=17>T7&GDI:ZVW&FBJZ*JIY&JU\4]/,U\;VJB^=."\4X@
MZEY]T[(UTUTP.31JN?+)CM;/IR\-49:ZZ9>.JIPCJ'<./Z+V-*2K\=XK+0KP
MUU=3O=__  GK\#E]OS&,7>SH3B;+5Y%LO.C&N66>?!;M6:-;HW5(L<O%4Y51
M'*FC8*V3@JJOUA$T8@ZUU-MKK75RT%RI*BAK*=W)-3543X)HW?27FCD:UVBI
MQ1>Q475.!3SXWQ.5DC',>U=%:Y%:J>TIC]N&/WG&[G4V:_VNNL]UHI.[JJ"X
MTTM)50O1>"NBF:URL?VM<B*US5U153101D#/N_"I],3AKZ?B)E1Q]G;YO+V@
M3JG9V>7OIZ_@.9B<=?05911=G#T>UZE]0)]3,[/:^+[ASM35R>KCY>V5C01?
M1X?*GRH"H:5G9[7Q?<(AJ:JGNE:V^'Z/#X_=0%1TL?9P]KR]PB&IJOL<2NK=
M#V>UV</>7@"I:2/L\ON=G$B6)QU]!7MN@UY>'H[=%!4])'V?%Y>VA$L3M7VB
MX-L@^CPT[/1\2 K"TT-1755-1TL+IZJKGAIJ>!FG/-/.]L<43=51.:21R(FO
MG4BHFJNB(FKGJB(GG5571$]M2[6&XW=\IOEDQK'[?/=;[D-UM]DLMLI41U1<
M;K=*J*BM]% CW,8LU55SL8W5435W%40&2;!L5@PW&K?9(N1T\;/K%QG9V5-Q
MG1KJJ5%5&JYC51(V:HB]VQNO$JNGA2"%D?G1-7+Z7KQ<OL:]GJ-SOI7V%M73
M=LEB&V-%]7GNU)3+=\RNE-JL=ZS.[1PRWVO8]T<3Y*6&2-E)2JYK7I14T*.3
MF15!5QSG8@            'G!_;>?QI^A_\ )_W"_C%@,3?B)_X:;=?@O=/U
M6: :09CK           /2[^Q+_B"]5WY7]1_$QM<9=_#Q_<RS;\.W?M?LP!N
M>F0$                     ^7L9(QT<C6O8]KF/8]J.8]CD5KFN:Y%1S7(
MNBHO!4/Q4145%1%14T5%XHJ+VHJ>=% -,CQQ/LL>U74C8\MZFO#?Q#%]G.H^
MCCN&1YAL!:W4^-;1[Y+%#)55:85;VMCL>UFZ%;W?+3L@2DQR[5"M2J90SRSW
M%W0#J,Z,++EM-79AM-0T=@RR-):JOQB'EI+%D?*U7O\ O=$B)366\R::-1O)
M23NTYTC<KI5 \U:_6&]XM?+UC&2VBY8_D>.7:XV'(+#>:*HMMXLE[M%9-;[K
M:+K;JR.&KH+E;:^GDAG@E8V2*5CFN1%14,1U335%%4U%'6034M723RTU535$
M;HIZ>H@D=%/!-$]&OBFAE8K7-5$5JHJ* 2DX           "M-M]P,KVFW#P
M+=3 [I)9,XVSS3%MP,-O4*(Z6T97AE\H<CQVZ1-5419*"[VV&5J>EA,+3=*V
MQW6V7JVS+3W&T7"BNEOJ&_2@K;?4QU=+,GKBGB:[V@#W6.FO>RP]2G3OL3U#
MXNV./'=\]G]M]V[/3QS=_P#4J#</$+1E<%ODDT:[ZQ;FW7N)6N1KV21N:Y&N
M1439'Q'(:;+L5QK*J-$2ER2PVF^0,1W-W<=UH(*UL2KP^?$DW*[7145%1>(!
M>PJ$       Z8=;7AZ]('B+X#B>U_63M%_GBP7!\P;GN+V/]GVY^WOWKRQME
MNF/-NOWSVLS7![Q6Z6>]5,/<5%1-3?HO/W?.UCFV_P!Q-K<$W7ME#9L^L7W^
MMMNKTN=%3??.\VON:Y*>:E2?OK+<+=/)^@5#V\KW.9QUTU1%0#&A_1<? H_F
M,_\ XS/6'_\ E!%H?Y&O3;^]Q_\ AAGG_.@ ?T7'P*/YC/\ ^,SUA_\ Y00_
MD:]-O[W'_P"&&>?\Z !_1<? H_F,_P#XS/6'_P#E!#^1KTV_O<?_ (89Y_SH
M ']%Q\"C^8S_ /C,]8?_ .4$/Y&O3;^]Q_\ AAGG_.@ ?T7'P*/YC/\ ^,SU
MA_\ Y00_D:]-O[W'_P"&&>?\Z !_1<? H_F,_P#XS/6'_P#E!#^1KTV_O<?_
M (89Y_SH ,E_1+X>O2!X=& Y9M?T;;1?YG<%SC,'9[E%C_9]N?N%]],L=9;7
MCSKK]\]T\USB\46MGLM-#W%/40TWZ%S]WSN>YUWMN]K<$VHME=9L!L7WAMMQ
MKUN=;3??.\W3OJY:>&E6?OKU<+C/'^@4[&\K'-9PUTU554#N>7
M
M                                                  *?DRS%8<HI
M,'FR;'XLUK['69/0XA)>;<S**W&K=74=LN&0TF/NJ4NU18Z&Y7"GIYJMD*T\
M4\\<;GHY[46%6NHFUK+<ZLI6W"6FDK(Z!:B)*V2DBDCAEJF4JO[]]-%-*UCG
MHWE:YR(JZJ@!4!%
M
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MX@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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MHG];Z #8D.U0
M
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M.95XJB^8 ]:TSA
M
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MOJJEJ**JJ:*KB=!54D\U+4P/T1\-13R.BFB?HJIS1R,5%]: $G.
M   ]+/[$MFM7<.A+JTV\D[Q:/%.K./+Z5SDB6-)L[V?V^L]7%&Y$[_YJ;>QN
M5KEY$5^K417/5<NOAXW!\NVV<6I=>[HLW2O8JZ:<USL5K@>U%^EP^]2+IV<>
M':H!NBF0,
M
M                    L#U ]5?31THXK^S;J6WZVEV*QA[95H[GNCGF.8<E
MVEA:KWT=@H[S<*6OR&Y.1/F4M#%45,B\&L5>!3&49KB&$T7WQR[)K'C=&J.Y
M)KS<J2@[]6IJL=-'42LEJIE\S(VO>OF0 UA.LC[9%X?&RT=SL/2AM]NAUB9C
M3\\5)?6TE5LAL[WJ.?"]TF4YS9:S<6MDII41Z,@Q-:6I8GS*MNJ..G6?=?&U
MV/)-383:[SGM>W5K*E&/QVPZIJU56MN-/)=9%:[CHVAY'IV/3M -4?K!^U5>
M+5U2I=+'A6Z.,]).!5[9*=,=Z;;!)CV5/I.=RT\M7NUD]9D^Y5%=HV+I)462
MX62*14U2!J<#I1GG6GOAF??4UOO-'@]LE16_5,2IEI:U6:KRJ^^5DE9=XYT3
MM=3RT[5_J4 ->3-\]SG<W)[KFVY&9Y9N#F=]J'5=\R[-\BO&5Y/>:MZJKZJZ
MW^_5E?=;C4/5557S2O<OI.K%QN=RO%9/<;M<*ZZ7"I>KZBNN-7/6UE0]>*OG
MJ:F26>5ZKYW.50"DR!   .ZOAN[PKT_^()T3[T/JW4=!MQU2[%Y+?I6RL@[S
M%:3<?'69=1OGDT9##<<8EJZ>1R\&LE52X6TM^_8ONAMYD"O5D5IS/&ZNI5%1
MNM$R[4J5T:N7@ULM&Y[57S(H![D9L;
M
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MM.">VOEYR433=O'R\O=!#/?IZU7WCB)3--V\?+Y?@!P@EKWJ]=5[/,@ /@
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M3E+X@                \X/[;S^-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK-
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MM6FGJ^[=%003R1M[BF>O,J(W5--=5 ,57]+ \$K^<;N!_P"SOO?_ ,R"RO\
M+:Z>/\:[I_DKD7ZW #^E@>"5_.-W _\ 9WWO_P"9 _EM=/'^-=T_R5R+];@!
M_2P/!*_G&[@?^SOO?_S('\MKIX_QKNG^2N1?K< /Z6!X)7\XW<#_ -G?>_\
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M5CFOJ]S]PZI[6\C7U.:Y).YK=57E:Z6YN5&ZJJZ=FH!)?]83U]?SX>K_ /\
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M45U-<;374UQH:A$715@JZ.6:GE1%_J7* 5P3$
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M355*3J-W-UZQZ2U>YVX=5(UB,;)49IDD[T8BN<C$?+<G.1B.<JZ=FJJ 2?\
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MJ*US535%14X*BH <A^@
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M>Q3 ;U7RQS=0NYSXGH]J7B@B54[$D@L5IAE9[,<L;FKZT ,)IUY
M  /1U^Q"8B^BZ8>N7/%AF;'DF_.VF(LJ'5%.ZGE?A.WMPO,D,5*U?K4,T#<_
M:Z21Z=W*V1B,XQR:98?#KH5CP[<>Y<KN6KR6T4*.5S%:JV^URU"M1B?/:YJ7
M--57@J*FG8H!O!F1<       TPOMM'X@O2C^5_3_ ,3&Z)C^\0[]S+"?P[;^
MU^\@'FB&(@           ]+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S
M&YZ9 0                  #6;\3[[49T%= U5?]L-H*MO65U'6EU9;ZS"M
MJ\AHJ;:S![Q UK/JNXF\C*6\6-M=35#GLFMM@I[Y7T\]/)3UK:!_*Y>H.\76
M5MGMD^JLUBD3/LL@62*2WV6JC99;=.U$3DNM_1D]-WC'JJ.AI6U,K'-5LB1+
MHH!H+]?GV@3Q-O$*FO=BW%WUN6TVSEV=5P-V(V ?<-L]OY+55(^-]KRBNM]P
MGSC<2EFIU:DL-_NUPHUD;SQ4\.JM,96YW5!O!NDZHIKKDDUCL$ZO:F-8PLMH
MM:POU18:R2*5UQNK'-TYFU4\L>J:M:WL ,*9UZ                   .SO
M2YUH]5O11G#-Q>E/?S<K8[*5FI);A+A&0U%)8\C902]]2T69XA6)68AG%IBE
MX_4KQ0UU([\]&I6.&[@YMM[<4NN%9-=\<K>:-TKK=5/93U:1NYF1W"AD[RAN
M,"._[7/')&OG0 W;O#4^V84]PKK%M?XGVV-':(ZB2&@BZG=C++6.M]*KGM8R
MMW-V<;-75L=.UJN?4W'&9IG(O*R*RZ*Z1N1#:+K];+)36;>*SQP(]6Q-S''*
M=ZQ,U5$22\6!'22(Q$XOEHW.7L1*?M4 WE=D=]MFNI/;;'=X=@]S<+W=VPRR
MG6HL&;8'?J'(;%7=WHVII'55#+(M%=+?*O=55'4-BJZ29%CFCCD:YJ9',=R6
MP9;:*2_8Q>+??;/7,YZ:XVRICJJ:333G8KXW+W<T2KH^-R->QW!R(J: %V"=
M@                        &!CQ2?M$'05X8GW[P&\9')U#=35!3U+(>GG
M:&\6RJN./76/YL-)N[G*MN&/[41ND5%DIIXJ^_,A>V:.US1.1Z]:-YNJC;/9
M[ZQ;*BK7*<PB8]&XM8IX7RTLR<&QWVY:2TMD37M8Y)*E&JCDA<U=0#S\^OW[
M2UXH'754WS':+=JHZ6MF+E)54]/M1TW5]WP>HJK/,K(V468[H0UG^<G+9*FD
MC[NNB;7T-HK.\D3[WQ1O[I,7VYW5UO'N2^II8[X_#,?F5[663$I9[<]\#M&I
M'7WELGWVKE>Q-)&]['!)JOZ$B+H :_TLLL\LL\\LDT\TCY9II7NDEEED<KY)
M99'JKY))'JJN<JJJJNJG6!SG.<KG*KG.57.<Y55SG*NJJJKQ554 XS\
M                                  /8:^S0[Q?YYO!7Z,*^IK/K5YV]
MQ_/]G;U$ZL^NR6__ #8[HYGC6,T<DBZ20\V!TUHG9"YK>YBF8QO,Q&N=GDZ0
M[]]_^GS;^5\G/46NENEAJ&K)WBQ?>>\W"DHXU7M;_P"#&0.1JI\UKD1-4T50
M,[QV4           );>;S9\=M-ROV076VV*Q6:AJKG>+U>:ZEMEIM5MH87U%
M;<+E<:V6"CH:&CIXW22RRO9'&QJN<J(BJ<-1404D$U553PTU-3QOFGJ*B1D,
M$$,;5?)+-+(YL<<<;457.<J(B)Q -0KQ-/M>?27TS5%\VPZ%,>MO61NY035U
MLK-QI[E<;%TW8I<:5_<I/1Y!0PQW_>1K9V.T;8I*&SU,+FRP7F3Z"]%=W^NK
M!\0=46;;:EASZ^Q.DADNSII:;$J*5B\O-'51M2IOZ(Y%_P#M98X'MXMJ%[ #
M1.ZZ?&3\1?Q%*^Z0]2/4=EU9M[<)GNI]D-OYG[=;)VZD2I?54E%)@&,RTM%E
M+K=(_2"NR"2\75&(B.JGZ)IC:W(W]W6W5EF;EN65S[7*Y>7';6Y;5CT3.=7L
MC6V4;F1UJQ*OS9*I9YM.UZ@&+\LX                   7=V2W_P!\>FO/
M+;N?T^[N[C;+;A6ES?J68;9YA?<-OJ0(]KY:"JK;%6T4EPM-6C>2HHZCO:6I
MB5T<L;V.<U9[CN3Y'B-RAO&+WV[8_=(%3NZ^SU]3;ZGEUU6)\E-)&LL#^Q\;
MM6/;JCD5%5 #<I\-K[9/O7M_66';?Q*]O(=\,,?-#12=0NTEEL6);N6.&1W)
M]\,OVXHFV3;S/:6!5;SNM28Y5PP-<_NZ^;1CN_>TG7UD-K?36G=VU-R.WJYL
M:Y38Z>FH;Y3M7AWM?:8_J]JN;&^=8/JCVM15TD=P4#?>Z5>L'IIZW-J+3O9T
ML[PX?O%MW=>6*2Z8S7.^^=@N2LYY+!F.,U\5'DN%Y)3LT=);[K24E6V-S9.[
M6-['NR985GF(;B62#(<,OU!?K5/HU9J.1>^I9M-5IJ^CE2.KM]6U.*Q3,8_3
M1=-%15 [*%7                 'G!_;>?QI^A_\G_<+^,6 Q-^(G_AIMU^
M"]T_59H!I!F.L         VO?L;?^UPR/\D#>7]NVT)W9Z!OW<JO\!+_ /JC
M8@#U.S,^     =-NN;KZZ7/#GV.O&_W55N10X-B-&Z6@QNPTK8[IGNY.4=PZ
M:CPK;7$8YX:_*<FKD356M6*CH8.:JKJBDHHIJF.@=Q]S<,VHQR?)\UNT=MH8
MU=%24S$2:YW>LY5=';[10HYLM;62>A-(XVZOD<R-KGH!YAOBU?:5>M+Q(JW)
M-L-M;I>.E7I)K/K]J;M)@&0U$6:;E6.9)Z59MZ]P[>R@N=_I[K13/2?'K>M'
MCS8Y$BJ(;A+"RL=AWWPZN=P=VI*NSVB:?"L'D[R!+':ZIR7"[T[N9G-D-UB2
M*:J;-&Y>:EB[NE1%Y7ME<U)% UPCJ:               9E/#6\=KQ!/#&NU
MEM&T^Z-5N3L-1U4?WVZ;-WZNYY7M=-;I)D?71X:DE8R^;77:1CGOCJ;%4TM.
MZI5LE92UL;5A=?W:/J3W1V>GIX+)>7W?&HWIW^)7Y\U;9G1*[61*#61*FS3J
MFJH^F>QJOT61DB)RJ!Z4_A.^/5T6>*U9*3&<*O3MF>INAMJUF4]-.XUUH6Y3
M,VFI^^N-YVOR%K**U[JXK3=W(Y\M%'!=:.*/O*^WT<;X7RY<=D>IC;[>NG91
MV^H7'\PCB[RLQ&[3QI6N1C.:6HLU4B1PWJB9HJJL:-GC:FLD4:*U5 S>G8H
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MB*NNMO7?&9+N]N7>X7]Y35V;9&ZCDU1W/0P72IIJ%^K5<WYU'"Q>"JB>950
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MEIYN[O\ ?H.+7+>[A3O7N*2=O;1T[DBY7*V5\Z:*@&KX=.
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MEE>^221[GR2/<KWO>]5<][WN57.>YRZJJ\54 ASX
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MQ]\RI1WAL+%?/78U-.]9*F)&-5\E*]5J:=J.7]$C:LJ@;$!VI
M    /.#^V\_C3]#_ .3_ +A?QBP&)OQ$_P##3;K\%[I^JS0#2#,=8
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M"[:<D-%?)%T;%(U&PU;EY=&3<J3 ;K)D*
M                  )'>\?H;Y#R5#>[J&-5(*N-J=[%Y^5>Q)8E7M:OM:+Q
M!9K>#8[#=Y+3]5OD'U"^TD+V6;***)BW.VN55>V*5JNC;<;:Z155]-*[E^<J
MQNC>O.@LG>K'7V.7DJX^:)RJD%5'JZ"9.W1'::L>B=K7:*GK315&(3=G9G-]
MGKI]2R:@[VV5,CVVG(Z!'S6:ZL:G,B1SJU'4M8UOTZ>9&2MTU1',5KW"GGO\
MZ]OF3R\P+*33=O'R\O<!#/?IZU7WCB<[7@G9\)*9Y]->/E\@(9SO,G;YU\O.
M?!*)INWB"%<[S)V>=?+S E4TW;Q\O+W00SW^Y\)QN=KP3VU)3//IKQ\OE!"O
M?YU]I#C)/--V\?+R]P$,]_G7M\R>7F!*IINWB"&>_3UJOO'&YVO!/;4E$\^N
MO'R^4$,YWF3M\Z^7G.,E,TW;Q\O+W00KG>9.SSKY>8$IFF[>/E\OP AGOU]2
M)[YQN=KP3VU)1//V\?+R]P$,]_G7L\R>7G.,E,TW;Q!#/?YU]I 2F>?MX^7Q
MJH(9[_.O;YD\O,?#G:<$]M?+SDHFF[>/EY>Z"&>_3UJOO'$2F:;MX^7R_ #A
M!+7O5ZZKV>9  ?         +G8+M?>\R?'5R(^UV)'?HERFC7GJ4:[1\=NA=
MRK4/7BG>+I$U47BJIRK%4](^?C]"/^J5.WU-3S_ =[.D_H,W2ZEJJCR&MBJ,
M#VG;,BU>;72C<M1>XHI.6>CPRV3+$^\5#E:YBU;E;0P.1VKY)&=PX=Q<>QNS
MXO;X[;9J1E- W1TLB_/J*J731T]5.J(Z:9WKX-3@U$:B(DZCB9$WE8W1//Z5
M7TJOG4V5-FMDMMMA,-I,'VSQZ"R6F'EEKJMZI4WF_7!&<LMVO]T>UL]RN$W'
MB[ECB;I'$R.)K6-$].0NP                      #S@_MO/XT_0_^3_N%
M_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6           >EW]B7_$%ZKOROZC^)C:X
MR[^'C^YEFWX=N_:_9@#<],@(                        !T*\4#J_L_0=
MT"=4G5)<;A2T-XVVVIR%-O8:J1&)=]VLHA3$MI[(QJ-?*]MSW!O=N9,L;)'0
MTO>S*U61NTMGO'G<&VNV.9YG+*R.>T62J^]37KIW]\K&_4;)3HG%RI-=*B)'
M:(JM9J[31% /$ EEEGEEGGEDFGFD?+--*]TDLLLCE?)++(]5?))(]55SE555
M5U4UU'.<YRN<JN<Y5<YSE57.<JZJJJO%550#C/P         CK9;+C>KE;[/
M:**JN=VNU=26RV6VA@DJ:VX7&OGCI:*BHZ:%KI:BJJZF5L<;&HKGO<B(FJG)
M##+4314\$;YIYY&0PQ1M5\DLLKD9''&QJ*KGO>Y$1$XJJ@'N4>'WTT4_1QT0
M]*O3 RFI:>X;+;&[?89E*T4K)J6NSVEL%)5[B7B&6)SXI&WW.ZRXUNK%5BK4
M?-X:&QQM=B#<!VZPK#D8QDN/XY:[?6]VY',DN;*9DEUG:Y-6JE3<I)9.'#YW
M  [A%>       &F%]MH_$%Z4?ROZ?^)C=$Q_>(=^YEA/X=M_:_>0#S1#$0
M         >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
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MVS<:D@7ZM,Q&TM#F%-3QZR55%$J]W3WN*-BOJ:5NC7HBRPHC$?'"!M8'=4
M             X:BHIZ.GGJZN>&EI:6&6HJ:FHE9!3T]/ QTLT\\TKFQPPPQ
MM5SG.5&M:BJJZ'R][8VN>]S6,8U7O>]4:UC6HJN<YRJB-:U$U55X(@!YAOVC
M[[0Q?NM?*LOZ(.CC+JBT='&)7AUHW*W%L%54TM?U/Y)9JABU$$=4UM/-!LG8
M;M J4-(U59D%1 VX3N?3_4XHL._5EU35.X=;7[=8%7/@P&AJ%@N]UI7O9+F-
M73O3G:CT1CFX]33M_0F)PJG-25VK>[:T#3_.B(
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MAZNJ,GQ^)8X6UTLCN,UVMKY&Q5*K\Z5CF2_.<LJM VR#NZ
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M,@IZ:G@8V*"""")K8H888FHUC&HC6M1$1- ?0.8
M   'G!_;>?QI^A_\G_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L           ]
M+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
M        #S9_M?\ XJMLWTWBQ;PW-E<EI[KMSTZ9(N9]1%VM%5%/17[J CH*
M^T6?;_ZW2O>R>GV@L%UJVW*)'JS[_P!SEIIXF5-I:IB3Z[MZH<DOU%M+CU8V
M:TXI5_?#*IX'M='4Y0D4L%/:^=BJCFV*EG>DK==/K,SF.1'P( :3YCS
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MLJR6;NXF\]+8[-"]RT%AM*2.?#0TK51.\E77FGF<B/GDU<NC4:UH&/ M6
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M6+)$RKA;(^EJ.[<YK*NCE5T4S=5Y)6.:O% "^Q4@
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MU)1//KKQ\OE!#.=YD[?.OEYSC)3--V\?+R]T$*YWF3L\Z^7F!*9INWCY?+\
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MV(V7#[!3(U4H;/2I$^JE:WD^MW.NE=+<+O7O:FCZBJEFG?\ GGJ":'V5X
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MV[RFH6ZT..V;O.>&RV2&1[J:E;I\Q]5*KEEJ)$3]$F>JIHU&M:!C5+1@
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M>&I*[5$7GK^U4X- W>S(H
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MFFJ:F:6HJ*B62>>>>1\LT\TKUDEFFED5SY997N5SG.55<JZJ 2\X@
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M)69D<U9R,K,BO/=\E1?+Y)$QM76R:_.93,5O=T\6J]U UK55SN9S@,CY=D
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MD3ZB[8D^9WS:6_00+)<K8U[G<K(KK0P++&W@G?P*B:OFX@>CH980
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M)9ZC#J]NNG?-O\7<6R)%7@B_?^.C=Y]>73M75 /80,\(
M                                          !+:NS6>X*JU]JMM:J]
MJU=#2U*KQUX]]$_7B?*L8[Z3&N]EJ+\*%#Y'MCMMF#GNRW;W!\I=*NLCLCQ.
MPWMTB\W/J];G052O7GX\?/Q!3E1MSA%4JK+CEO;K_P#6$FI4[-."4LL*(<:T
M\*_]K;[6J? J%E;QT5=*]\<Y]=LGAT2N=S*EICN./MUY%9P98:^VL:U47BB(
MB*O'MX@E$NT& 2::666+377N[I=EYM=-->]K9=--/-IVGPM) OYQ4]AS_P#L
MBW5=X;W1]6=WW6V-=;N3GY_J6?;@O[[GY=.\^^&3U^G=\JZ<G)KS+KKPT' N
MS. +_P#VNI_32X?\H/GZC3?U"_\ '?\ *2MWAF=(+NW KXO_ )>9BGP7@'+#
ML[MY%HJV%TSD=S(Z:Z7=WM*QE<R-S?9:I^I14R?]KU]E[_\ LB8T'AL=&E#W
M;I-I9KE-'+WK)KCGFXLO9IRQ/IH,LIJ&6)JIV/B=KJNNJ G--MS@M)IW6+6A
M_+II]9IDK>S5>/UQ9^;M\^I]I34Z=D3/;3F_^EJ7*L?15TH8\K%H-A-N:CN^
M7E^_EC9DZ+RJ]R<Z9+)=DEXO77FUU31%X(F@JBCMEMMZ<M!;Z&A;III1TD%,
MFBKKII#&Q--5U]DY6M:WZ+6M_P""B)\!??',&PK#X^ZQ'#\6Q:+D6/N\<Q^T
MV2/NU>Z16<ELI*5O(KW*[333554$:?15(
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M_;BYO=H'\%I:[*+U/1HBM8QR-HWUJTK.=(TYM&)S*FJZJ =+BWP
M     !N)?9]OLUN:=8=\PKK%Z[<0NV$](=OFH\DV[VDO<=?8\RZEI(TIJZSW
M"X4BLIJ_'=C:I'I)+6<\5;D$34BHD923?7D[Y]+W2/<,]J;?GNY-!/;L%B='
M5VJQU"2TUPR]4Y)()96:,EI,<?KJZ35LE4U.6/1CN\ /32L=CLN,V6SXWC=G
MM>/8[CUKM]CL%@L=OI+39;'9;320T%JL]GM5!#3T-MM=MH:>.&GIX8V10Q,:
MQC4:B(F7^FIJ>CIX*2D@AI:2EABIJ6EIHF04]-3P,;%#!!#$UL<,,,;4:UK4
M1K6HB(F@!-#F           -,+[;1^(+TH_E?T_\3&Z)C^\0[]S+"?P[;^U^
M\@'FB&(@           ]+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &Y
MZ9 0      #J_P!:?57M[T/]*>^W5ANE)_\ >;LAM_=<OJK>RH92U.27SF@M
M.&X7;JB5KX8;QG69W.WV:B<].[2KKH^94;JI1VX6:VO;K"LES>\K_P"#\=M<
M]>^)'(Q]74ZM@H+?$]45K9[E<)HJ>-5X<\B:\ #Q&NIKJ(W,ZM>H'=_J5WCO
M,E]W*WISR_9[E-8LD[Z6EJKS5NDH[%9XJF6>2AQO&+6R"VVND1RQT5NI(((T
M2.-J)KN9AE5XSC*+]EU_J%J;OD-SJ;G6R:N5C'U#U6.F@1RN6.DHX4;#"S72
M.)C6IP1 "QA38          !L'^ #X)&6^++OW4Y;N+%=L6Z+MC[]:I=Z\QI
M5J:"MW!ONE-=:/8W [E"^&6/(K_;)&3WBO@?K8;1,R95;55=OCG[1],/3O7;
MWY,^NNJ3T6WV.5,"Y#7LYXY+I4_,GCQRV2M5JI5U4*HZ>5J_W- Y'<'OB1P'
MK1[1;1;8[";9X5LWLS@^.[;;7;=6&DQG"L(Q2WQ6RQ8_9J)'+'34E-'JZ2:>
M:1\]142NDJ:NIEDGGDDFD>]V;^Q6*SXS9[=8,?MU):+-:J:.CM]NHHDAIJ6G
MCUT8QB<5<YRJY[G*KWO<KG*KE55 N,38             T[OM*7V?C&^K_!\
MWZ\ND'$([3U=8+8Y;_NQMYC5 UM-U,8A8J1%K[A36RD8U7;V8U:*=7T=1$U9
ML@I(/J,K9:I*)[.AG5QTO4F=VZX[EX)0)!G5MIEJKW:J2)$9E]!3,_1960L1
M-<AI(&:QN1.:J8WNW(Y_=J@'F-/8Z-SF/:YCV.5CV/16N8YJJCFN:J(K7-5-
M%1>**8>U14545%147147@J*G:BIYE0 ^3\           /5<^R@>)*_K)Z!6
M=-NXN0NN>^W1(ZR;<U#[C5K-=LIV(NL-8NS.2<TSVR53L7H[768M.V)K_J]/
M9J&6=_>UK=<U/1+NVN?;9)B5UJEFR7;M:>TN65_-/6XU.V3[P5>KEU>M''#)
M1.T1>5M/&YRZR( ;3AW/       /)F^UJ;X56[7C*[K8:M<ZLM/3MM-LKLU9
MT9*V2EA^NX=#O+>XX$8JM2:#(MVZN"=5^>DL"L7@QJ)A#ZX,C??-_;W0=XLD
M&*V/'K! B*BL;WE V_U#6Z+IS-JKX]KO/S-T\P!K0'4,           WA/L6
M/1+;<\W[ZBNO'+[1]9I=A,?MVR^SU54P(^FCW$W2M]?6[B7ZW3\O-#>,6VYI
M*>VNXZ.I,LE145=%3(OX?.WD5SR;*]RZ^#G9C-+%C]A>]NK$NMYBEDNM3$[\
M[/16EC85]+*Y0#T=#+"                 6IWUV8P/J+V6W6V$W0M3;UMW
MO)M[EVVF9VWYB2SX[F5CK;#<GT<SV2?5+E34]<LM+4-3O*>I8R5BH]C5229)
MC]MRO'[WC-YA2HM5_M==:+A%PYG4MPII*:98W*B\DS&R<S')Q8]$5.* 'A<;
M_;.9/T[[Z;S;!9JWER_9+=3/]I\G5(5IV27W;W*KKB=TGAB66?DIZBLM+Y(]
M))&K&Y%1SD5'+K?9/8*S%<DO^,7%-*_';U<[)6?-Y46IM=;-13.:W5VC'R0*
MJ<531>U0"TA(P        #DBEE@EBG@EDAGAD9+#-$]T<L4L;D?'+%(Q4?')
M&]$5KD5%14U0_6N<UR.:JM<U4<US55'-<BZHJ*G%%10#W*/#LZ@ZGJNZ#^D'
MJ,N51]:OV[_3OM3F.72HBHU,YKL0M<6>0LU?(YT=-F4%=&URKJYK$5=%70V.
M-JLI?FVVN"97*_GJ;[BMDKZYW_\ DI*"%MR:G%=497MD1%\Z( =S"OP    #
M&1XP7B!6/PS^@+?'J>GJ+>[<"BLZ8#L38K@D,L>3;Y9S!66[ J-:*?2.YV_'
M9(JC(+I3<S72V:S5G(O.C=;/[[[H4VT.V.1YBYT2W2.#[V8W32\KDK,CN+9(
MK9'W;N$T5*K7U4S."K3T\FG'0 \5[+,JR/.\IR7-\QO5PR3+LRR"\Y5E617:
MH?5W6_9'D-QJ;O?+U<ZJ35]3<+I<ZR6>:1W%\DBJO::^-=6U=RK:RXU]1+5U
MU?55%;6U4[E?-4U=5*^>IJ)GKQ?+--(YSE\ZJ 4^0H        !LQ_9J_!CB
M\3/J4KMZ-],?FJNC+IIO5IK,]HJJ*2.AWGW/>R"[XSLM!.JQ)-88Z+DNF4NA
M5\D5K=34:I$Z[0U,/;WI'Z?TW?RZ3(,DI7/V_P 1J()+G&]%2/(+PJ-GH\?:
M[AS4R1Z35JMU5L*LC^:L[7M ]8FW6ZWVBWT-IM-#1VNUVNCIK=;;;;J:&BM]
MNM]%"RFHZ&AHZ9D5/24=)3Q-CBBC:UD;&HUJ(B(AFWBBB@BC@@CCAAAC9%##
M$QL<444;49'''&Q$8R-C$1$1$1$1-$ (PY               "UN]NRNUO4;
MM+N!L7O9AEIW!VIW1QFXXCG.'WMLRT%ZLERC1LL7?TLM/76^NI9F,J*2LII8
M:NBJXHZB"2.:-CVR;(L>LV66.Z8WD-O@NEDO-'+0W*@J$=W513RIQ3F8YLD4
MC'(CF2,<U\;VHYJHY$5 /'!\9KPL=P/"<ZQLFV,N\UVR?9O+X:G/>G+<^XPP
M<^<;7UE?+3PV^]5-##!;VY]@E:BVN^PLBIN>>.*NCIX:.OI.; AO_LQ=-D<]
MK,;G=/66"O:^YXG>)6MUN-FDE<UL50^-K8DN=MD_0:EJ(S5R)(C6QRLU Q+E
MCP        "N]K=S,WV7W+V_W?VSO]9BNXFUN:8SN#@N2V]S6UMARW#[S1W_
M !Z[4_.CHWR4%UH(I$:Y%8_EY7(K55"9V:\7''[O:[]:*J2BNMFN%'=+;5Q+
MI)35U!41U5+.S7@JQS1(NB\%TX@'M[>'UU@XCU\=&/3QU;X8E'346\NW=KOM
M^LM#,Z>#%,^MSY\>W)PM)))))I/V'Y]:+C;FO>O-*RF;)V/0V)]KL\H=S=O\
M5SFW]VR._P!JAJ:FGC<KFT5SA5U+=[?JJN<OU"YP2Q(J\7(Q%\X!W'*^
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M;W7"SUS)*[&+^V+NH;Q;$>C')(Q%<V"Y4+W)'4PZKR.5KDUC?&YP&*<LH
M        5KMKGM]VKW&P#<_%IW4N3;<9MBN>XY4LD?"^GON'WV@R&T3MEC_1
M(G17"W1N1S>+535.),;1<ZFRW:V7BB<K*RTW&BN=(]%5JLJ:"IBJH'(Y.+5;
M+$BZIV 'O+X%F=DW'P;"]P\:G^M8YGF)XYF=@J=6K]8LF46>COEJGU8KFKWM
M#71NX*J<399MEPI[M;;?=:-W/27.AI+A2OX?/IZV".I@=PX?.BD10"K".
M
M                                                  /.#^V\_C3]
M#_Y/^X7\8L!B;\1/_#3;K\%[I^JS0#2#,=8
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MZ5$ZPV.^SMQ7(T5RI$EKO4T,,=7+IKHRUW)D%4Y417*R%S4^D >R09\@
M  #Q9?'1R2X95XP/B)7.Y.YJBEZH-Q<;C7O)I?\ P?AU='B%I;S5$DLB<MKL
M<*<J*C&:<K$:Q&M37TZD*N6MWWW5FF75[,RNM(G%SOT*@D2A@35RN7A#3MX=
MB=B:)H@!BA+)           'K0?9*]IK=MQX+>S&6T5/2P5F_&[6_N[-[= V
M5L]1<;7N3==DJ:HN'>1L:ZJ=8MG*)K%8KF+3-BXZZHF;[H?L<5IZ?<?KHVL;
M)DM\R>^5"M14<^6&[38ZQTNJ)J]::P1HFFJ<B- -E@[=
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MLK9E=W'+F5@:Y47EBD=2VN_T[5<O,C6RNHY6,;JFKY7:(NJJ!OTF38
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MQ
M                                                      'G!_;>
M?QI^A_\ )_W"_C%@,3?B)_X:;=?@O=/U6: :09CK
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MW+W-S/-9'O=!>;U4K:VOUUALE'RT%D@5%TT=%:J6%':(FK]5T34 Z&EM
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MM<UR(YKD5%34U['L=&YS'M<Q['*Q['HK7,<U51S7-5$5KFJFBHO%% .$^0
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MTT51TZ[:/B=SM;07N%5Y7-TEILIOM/,W1R-7YDT3DU[%TU35-% ,YYV/
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MNDUK;FZLL6&I,S7ZO;87]Q>KS!S(J))75<;J.-Z:/;'#,GT9>(&]N9)@
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M
M                                                     \X/[;S^
M-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK- -(,QU@
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M/NIE5)U%X!%$G=TC[)O=2_LPR&&WT^B,I+;9=R:B^VRGA9I'%%0M:Q$8C43
M?U580W!-\\WH*>%(+=>JUF5VMK4T8M-D3/K]4V)NB(R&GNSZF%K4X-;&B)P
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M/K.)97=Z%8%75S**ZMI[W33HB)HD<U575+4XJO-$[S: &V =V@
M        #Q&?%QWKINHCQ.^N_=ZW5?U^R9-U0;MT.+U_UA*IM=AN(957X3AE
M:R5/F)'5XICE'(UC5<R)KD8USFM1RZ[F^60LRK>'<J^Q/[VFK,QOD=%+S\_>
M4%#6RV^WR(Y.&CZ*DC5$35&HNB*NFH!CM+5           'M1^!UM)4;)>$7
MX?."5<#J6MFZ:L#W KJ62-\4U)7[PP5&[U=2U$4DTSXZJFJ\Y?'*U5321KOF
ML^@W8.Z<[&_'=C-KK;(U62.Q&VW21BHK7,EOS77V1CVJYRH]C[DJ.]:=B=B
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M(UUN]@N]@J)&M7D1;!<(+A3)(Y/FI)(W(I.77151BZ:HW@!HWF.0
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M9L&*6>/N[9CUIH;11(J-1[X:&GC@2:7E1$=45"L621W:Y[E5>*@%Z"H
M            #S2_MLFUL5BZZ.E'>&"F[ANY/2W5815RL8UD59<MJ]T<MNDM
M3(Y&HZ6L;;-SZ2%[E55[F*)O!$XXBO$-LS:;<C";\UG*EVPQ]N>Y$1$DFLMY
MKIE>O#C(D-X8U5_J4:GF -+LQ^           'K ?9$JBHG\&K XIIYIHZ/?
MK?BGI(Y97R,I:=V2456Z"G8]RM@A=554LJM;HU9)'.TU<JKFTZ%WN=L%;4<Y
MSDCR;)6,15548U:N-ZM8BKHUJO>JZ)PU55\X!L\'<0
M
M                                   \X/[;S^-/T/\ Y/\ N%_&+ 8F
M_$3_ ,--NOP7NGZK- -(,QU@
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M<B(EXO\ =,@J6-7YW)C]!%04R/TX]U(_(GJB+P<Z/7M: ><D8H
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M:EM/8MQ:>GLW/*]&0P9)2RR28[,]SET_NIU1/1M1$U=+51JJHC5 /59,U
M              !C*\87KILWAV>'CU&=24]VAMV=4.&UV";)4KI8FU=WWPS^
MDJL?VYAH:>5K_KK;!=)W7NMB:G,EJM54_@C%5+/[\;D4^U6U>5Y:Z=L5RCM\
MEMQUFJ(^?(KHQ]+:6QM5%[SZM,Y:B1/_ *S ]?, >)\][I'.>]SGO>Y7O>]5
M<Y[G*JN<YRJJN<Y5U55XJIKT*JJJJJJJJNJJO%55>U57SJH!\GX
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M;58KID=3&U>#I+[7LMM*LB:Z<\++!+R\$5$E7T@&C28XP          #VA?
M5VJ@V;\'/P\\1IX/J\=WZ=,7W5='R0LYI]]JVZ[WU,^D#G,7ZS4[AODU5>=W
M/J]$>KD38%Z9[*VP;";64+6\J3XI1WI4T:FKLEDGR)[M&JJ?/==57TKKQXZ@
M&7,OF                       :4WVV_$*6MZ*NCO/7TDCZ[&NJ.\XA3UR
M4D;XJ:ES?:?*KS64CZY8734\E;-M] ]L39&-F2G<YS7K$U68]?$0H62;>X%<
MU8JR4F95%"V3D16L9<;)6U$C%DY5<Q9'6MJHU%1'<JJJ+RIH!YL!B1
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MY45VGCYZ7"[#=LB7F:JQNK96PV.@C54X)*R6[NG9KYX-?, >KV9LP
M           #S^?MS-%1QUOAA7)E-"VOJZ7K-HJFL;&U*B>CM\O2K/0TTLNG
M,^&EFN=0Z-J\&NF>J?24Q@>(['&DFSLJ,:DKV;@1OD1$YG1Q.PIT;%7M5K'3
M.5$\RN7T@&@:8Q@          #U>OLAO^QMPO\H#?;]7+69LNA7]P.W_ (49
M)_WQ  ;/QW&
M
M    /.#^V\_C3]#_ .3_ +A?QBP&)OQ$_P##3;K\%[I^JS0#2#,=8
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M<4         TPOMM'X@O2C^5_3_Q,;HF/[Q#OW,L)_#MO[7[R >:(8B
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M9"[1/T.OO%SMU-$_5>/&AIZENFG'F[>&B@>G89A@
M  #5?^V$[20[A>$-59TE+"^KV'ZDMFMQ6UJT_/4T]!D:9/L[5TT=2V2-]/2U
M=7N?2ND:[GBD?#'JSG;&]G2_KQL;;IL4^Y<C5DQK+;!=4DY=7LBJ_KEA>Q'H
MJ*UDC[PQ51=456IPU1%0#RIS"N           9"/"9W6?LEXG70)N6M4VBH;
M!U;;$TM_JG/IXTBQ+)=P[%BN9*DE744E)$YV*7NL:CI98XFJJ*]S6HJI=+9"
M]KCN\.V-WYTCBI<XQME4]5:G+0U=UIJ*OXO?&Q%6BJ).+G(U/.J( >W@;$P
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MGI:>)JTZJD<$$;6M3T( 5-_K]_&2_P!X3U ?IQ8_UA(S^4WOY^^EE']\4_\
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M?F(F3KPY[RO/NICTCUT5N*WFDC\R*U;W0W!_%VFKN:F3@GFXKV 'H!&3X
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M_P!\0 &S\=Q@
M
M    #S@_MO/XT_0_^3_N%_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6
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M[JWIS-75%9B=KB>JM^:E'!?JNH8U$=SISK71*NJ:+RIHO: ;ZIDP
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M')B.!K)QLE+4K)<;TUFG))D-PC2-)XN9.=M+$UM.Q53G[YS&R(!KA'4T
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M&-TLEQ;&5='5N6>%R8]9:5%C71(U3E1K6HC4UV]\[FZ\;S;IW!7*]LN?95#
MY>=%6EH[S64=)JCUYFK]5IV</-V:(G  QWEJP
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M:'H(MS:+8RHJD1$==\XO]>Y45RJO=45FM::\R:)HEN[&\//VJH!M;'=<
M               T _MSG_RN_P#IL_\ PCF,/Q'O_0U_ZP__ #& - ,QA@
M        'J]?9#?]C;A?Y0&^WZN6LS9="O[@=O\ PHR3_OB  V?CN,
M
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MFZ^7LDBR/<3,+I32MY9*&6^U\5M>FB(NMLIIH+?JJ)Q7N]5\X!T/+:
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MK^*^=0"RQ3P
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MH5_<#M_X49)_WQ  ;/QW&
M
M              /.#^V\_C3]#_Y/^X7\8L!B;\1/_#3;K\%[I^JS0#2#,=8
M         !Z7?V)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
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M           #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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MBH8ZIH9J>:6GJ(I()X)'PSP3,=%-#-$Y6212QO1KXY(WM5'-5$5%310"!.,
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ME371-9&NJ?KM;65G)W?UNJJ*GN^;G[OOY7R\G/RLY^7FTUT37T $@(4
M                                              V/?LH'^VUZ<?P
MZB/XCLX.V71+^,/BG_ZKRK]KMQ /6[,XP    !YP?VWG\:?H?_)_W"_C%@,3
M?B)_X:;=?@O=/U6: :09CK           /7Z^RX_["CH9_Z3/_OA]01G:Z-?
MQ;=N/_+#]OF4 &?X[/                   &@']N<_^5W_ --G_P"$<QA^
M(]_Z&O\ UA_^8P!H!F,,           ]7K[(;_L;<+_* WV_5RUF;+H5_<#M
M_P"%&2?]\0 &S\=Q@
M
M         #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\ PTVZ_!>Z?JLT T@S'6
M         >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
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M$0           >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M    >*CXW5OK;9XNWB+TU?3R4L\G5IO!<&1RHB.=17;**NZVZH315_0ZRWUD
M4K/2QZ&O=U$Q21;Z;K-D:K'+G%]E1%[5CFK'S1.]A\4B.3U* 8M2S
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M(LDNE7>;W=)N_K[C72=[45$B,;&WF71&LCBB8UC&-1K&,:C6HC41 "UA)0
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ML@_68 ?T)CK[_G7='_\ ?.]'^BT?ZO'<W_';!/\ C9!^LP _H3'7W_.NZ/\
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MFQBZ45MMUXIF4EH==?K;JBY4,M#&]4K+;3PK"QD[E7YZ+KIIKV &ZN9"0
M #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\ PTVZ_!>Z?JLT T@S'6
M >OU]EQ_V%'0S_TF?_?#Z@C.UT:_BV[<?^6'[?,H ,_QV>
M     - /[<Y_\KO_ *;/_P (YC#\1[_T-?\ K#_\Q@#0#,88          !Z
MO7V0W_8VX7^4!OM^KEK,V70K^X';_P *,D_[X@ -GX[C
M
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MMK-I]L*MC7-95;>854L:_3F:V?&[9*UKM%5.9$=QT734 [M%PP
M                                  #S@_MO/XT_0_\ D_[A?QBP&)OQ
M$_\ #3;K\%[I^JS0#2#,=8          !Z_7V7'_ &%'0S_TF?\ WP^H(SM=
M&OXMNW'_ )8?M\R@ S_'9X                   T _MSG_ ,KO_IL__".8
MP_$>_P#0U_ZP_P#S& - ,QA@          'J]?9#?]C;A?Y0&^WZN6LS9="O
M[@=O_"C)/^^( #9^.XP
M
M           !YP?VWG\:?H?_ "?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
M        #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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M*ZV[XPW'DTCR'#;%<>\1%Y72TE1<K+(Q5TT61D=LC54\S7-](!JE'2@
M      WL/L/6Y4=NWC\0/9^2;67,=L]B=RJ2G=J[ECVURG<3%[A-#K,C8^=V
MZ]*V72-5?RQZN3D1'9)/#HNZ17_="PJ[C7V?&[NQJZKHEHK;K1RN;\[1NJWM
MB+PXZ)QX 'HD&50                       US?M6>Y,> ^"?U)69*KZG7
M;KYIL)MM;9&SN@FED=O+AN>W2E@Y7M67ZYCF!UL4K/G(ZG=)JFFJIU1ZUKNE
MKZ><MI^?NY;W<,9M$*H[E<JK?Z"YS,;HJ<W>4ELD1R>=JJ >1R8-0
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MA+6MGWQW6HU:K$?G.07%C51$Y8[Q7RW>)&HC(T2/NZY.5-.#=.*]J@8P2S@
M         ![6O@FY8[-/"-\.:\/J9*I:/I$V5Q-)9::*E<UN!8=;L%93)%"R
M-CHZ-F.)"R14YYF,21RN<Y7+L*=/%<MPV,VHG5ZO[O!<>H=58UBHELH(K:C-
M&HB*D:4G*B]KD35=54 RAEY
M        #S@_MO/XT_0_^3_N%_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6
M    >OU]EQ_V%'0S_P!)G_WP^H(SM=&OXMNW'_EA^WS* #/\=G@
M         #0#^W.?_*[_ .FS_P#".8P_$>_]#7_K#_\ ,8 T S&&
M   >KU]D-_V-N%_E ;[?JY:S-ET*_N!V_P#"C)/^^( #9^.XP
M
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M1R/2.+*K%?\ &WO<J(WF6E9?:9CE5>V:LL4;&^E[D0 ]9TS>@
M           &DM]MMWMCQ[I%Z.>GB"N[FMW4Z@\JW8JZ2&H='-4V?97;ZKQA
M8ZN*-Z++;WW7>RGE1LB*QT],QR?.B16X\?$0R)*7!<"Q5LG+)>LIK;W(QKM'
M/@QZUOH^5[475T2SY"QVB\%<Q%[4 /-P,2H          !G[^S#;*2;T^-+T
ME]_0NK;#M,_<K>O(GM9*Y*"/ ]MLG7%*YZQJU&-CW'NED9JY4;K(B+S*J-=V
M=Z.\>7(>H+!^:-9*:QK=\AJET<O=I;+36?4I%TTT1+M-3IQX<?/V 'K^F=L
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MJ8]4UCJ8*"FAA14[8ZJ1/. >BX96@
M           #R7/M9^T#ML/&?WDR=M)]3HM]]J-B]WZ"-E/%34TK:? Z/:"Y
M5=,V%K&R?7;]M+62SR*G/)5/E<Y5555<('6_8EL_4#?ZQ(^[CR6R8W?8D1K6
M,<C;9'8II&(U$1>\J;'(KE[5>KE4 UJCJ,           >O)]EHW+AW%\$OI
M1HUG;/=-M+MO?MI>E;P2*:T;VY[?K) K=/FNBP_);8B\5YE^=PUT3.GT97=M
MUZ>,)CYD=-:)\BM%1I^==!D5SJ:=NGI2@K(=?3V@&PH=I0
M                              #S@_MO/XT_0_\ D_[A?QBP&)OQ$_\
M#3;K\%[I^JS0#2#,=8          !Z_7V7'_ &%'0S_TF?\ WP^H(SM=&OXM
MNW'_ )8?M\R@ S_'9X                   T _MSG_ ,KO_IL__".8P_$>
M_P#0U_ZP_P#S& - ,QA@          'J]?9#?]C;A?Y0&^WZN6LS9="O[@=O
M_"C)/^^( #9^.XP
M
M       !YP?VWG\:?H?_ "?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
M    #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
M                ..::*GBEGGEC@@@C?---,]L<4,4;5?)++(]6LCCC8U5<
MY51$1-5/QSFM:KG*C6M17.<Y41K6HFJJJKP1$0 \.SQ+NH^EZN_$!ZP^I"UU
M[KGC>Z_4%N3D&#UKT<CY=N*;(JNS;:L=SLB=S4^ VNVQKJUJZL[$[#7.W=RQ
MF=;H9YEL,BS4E[RB[U5ND775;2RJDI[0BZHBZMMD,2=B=@!T>+<@
M  &?;[,!C'[*/'&Z)(Y:6HJ*&QU&_63UTE._N_J?WBZ9=Y:NU54[NWZO^R'Z
MG&Y.//WB-[%54[.='-']=ZC=NT<Q[XZ9^35DBM73N_JV(7]\#W+_ %'UKNT7
MTZZ 'L!&=P     TPOMM'X@O2C^5_3_Q,;HF/[Q#OW,L)_#MO[7[R >:(8B
M          #TN_L2_P"(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
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MRO35$7@;(5'5TUPI*6OHIF5%'6TT%725#->2>FJ8FS03,U1%Y)8GHY-41=%
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M,L%V?;6V2RR,>Z.>*Z7^>*TP55,]KF*E1;8JI]4WC_VCS]B@>+L:_(
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MJY%;&4:,C:JZ]W'48Z]RZ<$=+Q[0#=I,AP
M                  !YP?VWG\:?H?\ R?\ <+^,6 Q-^(G_ (:;=?@O=/U6
M: :09CK           /7Z^RX_P"PHZ&?^DS_ .^'U!&=KHU_%MVX_P#+#]OF
M4 &?X[/                   &@']N<_P#E=_\ 39_^$<QA^(]_Z&O_ %A_
M^8P!H!F,,           ]7K[(;_L;<+_ "@-]OU<M9FRZ%?W [?^%&2?]\0
M&S\=Q@
M                                                          #S
M@_MO/XT_0_\ D_[A?QBP&)OQ$_\ #3;K\%[I^JS0#2#,=8          !Z7?
MV)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
M        &OG]I4\1N@Z /#;W%LV,WV&@W]ZKJ&_]/^S5#3UOU:]VZWY%:'4N
MZ^Y%"R&6*O@AV_P:YO9!6P__ &G?KK:N9425#J[U<[L1;8;27:GHZEL63YM'
M58O8(VR<E1%%5P<E[NT:-5)&MM=MF5&R-^A4S0Z]H!Y"9@I
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M<T5*_'+W<K+4KIRMDDMU7+3=_'Q5%AJ&QH]BHJHYCD5%5% +'%.
M  'K??9;>N.#K"\*[;'"+]>)+ANKT@UB]..;0U=0^:NFQ3':2*X;-7QC99)9
MOO7-MK5TEHCD<[]$K+'5Z(C6HAG'Z,]QFYYLO9[=4U"RWK!)/V)W%LCU=*ZB
MI6)+8*E$<JN[EUH>R!%5>,E,_P! !L=';$                   H7=#<G#
MMF]M=P=W=Q+Q#CV ;783E.X>;7VH170V;$\,L==D60W.1K?G/;0VFW2R<J?.
M=RZ)Q4EMYN]!8+1=+[=9VTMLLUNK;K<:EW%M/0V^FDJZJ943BO=P1.73M70
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MEO-'4R1(J\7SQ0QIQ<@!Z=AF&
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M #/\=G@                  #0#^W.?_*[_ .FS_P#".8P_$>_]#7_K#_\
M,8 T S&&           >KU]D-_V-N%_E ;[?JY:S-ET*_N!V_P#"C)/^^( #
M9^.XP
M                                                         !YP
M?VWG\:?H?_)_W"_C%@,3?B)_X:;=?@O=/U6: :09CK           /2[^Q+_
M (@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
M    .O?5-U3;%]%^Q>>=1W4=GEKV[VIV[M;KA>[W<'++5U]7*O=6K&\;M46M
M=D669%7*VEMUNI6OJ*NH>UK6Z:JE+9IFF-[?8W<\LRRYPVJR6J%9:BHE7626
M1?FP4E) W]$JZZKDT9%$Q%>]ZZ( >.KXOGB@;F^*[U@93U"9?3W#%]N+)3R8
M1L'M945C:B#;C:VWU]556ZGK6T\CZ"IS3)JFH?<;[61\W?5DJ0QO6DI:6./
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M6FJ;]_,U6.KO;8U_1*'%:*H1[6/5-%C?>KG V-NBKS003M<FCDU \S(Q!
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MBFBD:CXY8I&*YDD<C'(K7(JHJ+JAW_:YKFHYJHYKD1S7-5%:YJIJBHJ<%14
M.0_0                                      "C]P\#QC=/ ,XVQS>V
MQWG#-QL/R; \NM$VG=77&,OLM;C]_MLNK7)W==:KA+$[5%31W80%UMM'>K9<
M;/<8DJ+?=J"LMM= [LFHZZGDI:J)>WA)!*Y/; /#&ZP>F_*^C_JFZ@.E_-6U
M#LAV+W8S3;F>NJ(/JRWVW8]>JJEQ_*:>%%5&V_+<>2EN=*J<'4U7&[SFN%GF
M)5N"9GE&'7!'+58W>[A:72/;R?68J6H>REK&M_\ K5=2\DS/2QZ '7 I,
M      JC",URO;;-,0W%P2_7#%LXP'*+!FN&Y/:9?J]UQS*\6NU)?,=OULG5
MKDAN%HN]!#40OT7EDC1=",MUPK;1<*&ZVVIEHKC;*REN%OK('<L])6T4[*FE
MJ87<>66">-KFKYE0 ]KGPIO$"P;Q,>A_9GJDQ2IM=/E%]L<&,;T8?;IVO=M[
MO9C-)24FX6*34RS355);WW*1MQM"S\LU38KA15+FM[[1-A793="W;O;<X_F=
M$^%E94TS:/(*")R*MKR*C8R.Z43F<SGLB694E@YOG/II8WK]( R+EUP
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M;]7+69LNA7]P.W_A1DG_ 'Q  ;/QW&
M
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M[*PWVGB1\V&Y1:KK4/1G,]MLN,=38JEK=$5R-6MN-*]WF1L>J]G #ROS"^
M           91NCCQH_$VZ#K;:\9Z<^K/<2R;>VCNHZ#:G-G6K=/:Z@HHT<U
MUNLF%;CV_)K3B5'.CU[S[RMMTJNT<CT<B.2\N ]06\&VD,-'B>;W6GM4&B16
M2XK#>K-%&FJ+%3V^[15D%#&[7C]72)=>.NH!G2VR^VI>(SC=+14.Y_3WTC[G
M1TD?=S7:UV#=/;[([FO=U7Z/<*BDW+R'&VU'UB2)?[EM--'W43F<G._O&]D;
M/X@^Z](R.*\8M@UX1B:.GAI;S:ZN;@_YTKH[O54B/YE;]"!B<J:::KJ@%Y/Z
M;SU3_P Q_I__ (0MQ?[03[_6)YI^]UB_Z:7;_L0!_3>>J?\ F/\ 3_\ PA;B
M_P!H'^L3S3][K%_TTNW_ &( _IO/5/\ S'^G_P#A"W%_M _UB>:?O=8O^FEV
M_P"Q ']-YZI_YC_3_P#PA;B_V@?ZQ/-/WNL7_32[?]B /Z;SU3_S'^G_ /A"
MW%_M _UB>:?O=8O^FEV_[$ ?TWGJG_F/]/\ _"%N+_:!_K$\T_>ZQ?\ 32[?
M]B /Z;SU3_S'^G_^$+<7^T#_ %B>:?O=8O\ II=O^Q ']-YZI_YC_3__  A;
MB_V@?ZQ/-/WNL7_32[?]B /Z;SU3_P Q_I__ (0MQ?[0/]8GFG[W6+_II=O^
MQ )U9/MP'4+3U$KLDZ"]F;K2NAY8(;)O#F^/U$=1SL7O9:FOQ3)HYH>[1R=V
MD4;N947GT3E6(IO$6RIKG+5[:8_.SET:VFOUQI7([5.+GRT58CFZ:\.5%U\X
M!=#&/MR5]BJ$CS/PV+374LM52-6JQCJLK+544-%SJE=*E!=>GN\1W6J2-4=$
MSZS1L5S>5ST1W,V<T?B-U*.TN&TD$C'/8G/1YK)"Z./7]$7NI\6J$G?IQ:G/
M&FJ:*O'5 .YNUOVV7H8OLM-!O#TH=4>V[I^1DM7@]7M=NK;:.5[FM=)4R73+
M-K[D^CB:JJY\-)+-HGS8G*NB7 LOB&[;U+F-OV$YE:.;1%DMS[->HHU54XO6
M:MLTRQHG:K6.=Z&J 9<^GS[29X,W434T=JM'65B>U615?==Y9.H/'LLV3IJ'
MOET9]<SG.+-;MK4^<BH[N[]+W>FK^5JM5U\L6ZMM@,J?'#!GU%9:I_+K3932
MUV.LCYNSO+E<:>*S=O;I4KIY]$TU S485G6$;DXU;,SVZS'%<^P^]0I46;*\
M*R&T95C5VIU[)[9?;%65]KKX5_JHI7M]9V$M]RMUWI(;A:J^BN=!4-YH*VWU
M4%;23M_JH:FFDEAE;ZVN4 JHC0          #SB_MGW0%4X)OQLQXBF$6.1,
M4WTL]#LCO?74=*OU>@W<V_L\DNVU_N]6KU<^LSO:V@DM<+4:D<46&IJO-,U%
MQ/>(#MB^VY+C^ZUNIE^I9)!'CN1R1L^9%?+7 KK153OUU62Y6:)86IIHU*#T
MN -'LQT           &>KP"/&3R?PFNJ+_[]JBZ7[I"WSK++CG4-AM*RJKZG
M&OJTTE/C^].&V^G;-.[+,!2ME^MTD+'_ '[LLM12*Q:IMOJ*3LQTQ[^UFR&9
M?^$7356"Y))3TF4T#$?(^CY'*VER&WQ,1SEKK9WCN=C47ZQ3JYFG.D3F >NM
MMIN7M_O)M_A^ZNU688_N!MQN!C]MRK"\TQ6Y4]WQ_),?N].RJM]TM=PI7OAG
MIYX7\4X.8Y%8]&O:YJ9S[1=[7?[707JRU]+=+3=*6&MM]PHIFSTM72SM1\4T
M,K%5KFN:OLHO!=%0 K@F(                !@Z\=CQAL$\)KI7N-YLE=9;
M_P!6.[]MO..=-FV]9R5K8[Q'#'2W/=?+[<FJI@.W2UL=1)%)R??>XK3V^-S&
MRU%12]<^I+?FV[(87+44\E/4YO?8:BDQ*TR:2:3HU&37NOB_\66I9$<J+IW\
MO+$FB.<]@'CY9IF>5[C9AE6X&=Y#=LMS;.,BO.6Y?E-^K)KC>\CR;(KC47>^
MWR[U]0Y\];<KK<ZN6>>5ZJY\CU5>TP/W"X5MVKZVZ7*JGKKC<:NHKJ^MJ9'2
MU%765<KYZFIGE<JNDFFF>KG*O%54 ID@P        #:O^R/=!%1U0^(PG4QE
MMD=6[2=$EA9N$M15TSY+9=-[\NAN5@VALW.J1HM5CZ173)XWQO5U/5V*D21J
MLG37NKT-[9/S+=?]E]=3+)8]NZ9+ISO8JPS9%7-FI;%3Z\/GTNDU8BHOS7TS
M-4T< >J29HP      #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\ PTVZ_!>Z?JLT
M T@S'6           >OU]EQ_V%'0S_TF?_?#Z@C.UT:_BV[<?^6'[?,H ,_Q
MV>                   - /[<Y_\KO_ *;/_P (YC#\1[_T-?\ K#_\Q@#0
M#,88          !ZO7V0W_8VX7^4!OM^KEK,V70K^X';_P *,D_[X@ -GX[C
M
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M999Y9)YY))III'RS32O=)+++(Y7R222/57OD>]5555555750"#.,
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M6XS;<SQ?(,3N[.>VY%9Z^SUFB(KV0U]-)3K/%KIRU%.YZ21N145KVHJ*BIJ
M>'IU6=->Y71YU'[S],&[UM=;-P]D\^OF#7]$AFAI+HVVU'/9LGLZ5#6RS8[F
M%AGI;K;)E32HM];#*G!Z&NAFN(W? LLR##K[$L-UQVYU-MJOFN:R9(7:T]9!
MS:.=2U],YD\+OST4C5\X!U^*7
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M_84=#/\ TF?_ 'P^H(SM=&OXMNW'_EA^WS* #/\ '9X
M  T _MSG_P KO_IL_P#PCF,/Q'O_ $-?^L/_ ,Q@#0#,88          !ZO7
MV0W_ &-N%_E ;[?JY:S-ET*_N!V_\*,D_P"^( #9^.XP
M
M                                    !YP?VWG\:?H?_)_W"_C%@,3?
MB)_X:;=?@O=/U6: :09CK
M              /IC'2.:QC7/>]R,8QB*YSW.5$:UK415<YRKHB)Q53]1%54
M1$555=$1.*JJ]B(GG50#UNOLSWA3U'AP=#E+G6ZV-.L_51U7ML.Y6[5+<8'Q
M7G ,+IZ.IDVJVAJ8IFQR4%=CEGNU1<[Q Z*.HAOEWJ:29TK*&G<W.-TA[*OV
MFVY9<KW2+!FF;?5KO?&2M5*BV6]D;ULMB>CM%CDI()W33M5$<VIG>QVJ1LT
MV/#MB       :87VVC\07I1_*_I_XF-T3']XAW[F6$_AVW]K]Y /-$,1
M       !Z7?V)?\ $%ZKOROZC^)C:XR[^'C^YEFWX=N_:_9@#<],@(
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M"*-B+WM?8.9ROX<TE(YWSOT"-C@/-$,1
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MH_7L=5NCT5>ZD: >F(9>@        #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\
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M6GB3?OGDFUCZVUL9'+4K6[?WQM)! K$D<Z6LLE93K1OY'\5E<J,>FCFZHK5
MS ^&!]K"Z,>MG),:V9ZF,<DZ+]]\BJ*>TV"LRC)Z;)-@\XO<[HZ>DMUHW/FH
M;#5X1?+O/S.AH<AH:6A:YT=-#=:NJDCC???9SK;V_P!PZNDL&7TB[?Y+5.9!
M2R5E8RKQFXU#E1C(H+PZ.F?;JF=VJMCJHV1IP8V=[U1% VMCNN
M
M                             ><']MY_&GZ'_P G_<+^,6 Q-^(G_AIM
MU^"]T_59H!I!F.L
M        W&/LK_@EUO5ENY9O$+ZDL1D_DQ;%Y8VHV4QJ_P!"B6_?C>O&*[GC
MNZ4=4Q4NVV>T=WIFRUDJM^J7/(8HJ!'3QT5VIF=]NB_IXDS>^T^Z>6T*_L.Q
MNNYL>HZJ/]"R7(:.35)^[>GZ/9['.S61=.2:J1(M7)'.Q /3@,P0
M!IA?;:/Q!>E'\K^G_B8W1,?WB'?N983^';?VOWD \T0Q$           'I=_
M8E_Q!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("           :2GVLCP7
M'[ZX#6^)GTUXDZIWCVGQV&DZHL2L5$LE=N5M%8*2."V;J4M+3:/J\NVEMT'<
MW1>[DEK<8:QZR,2SQQSX\.MSI]7)+9)N_B-"K[_9*5L>94--'K)=[%2L1L-Z
M8QG%]=8XF\LW!724:(NJ=PB. \W(Q+
M         &\)]EL\!BNWARO#/$PZP,+DI]G<,ND-_P"E7:[)J%\;MU<TM-1'
M-;-ZL@MM7$G/MOAUPB[RP0O1/OW=X&U:_P#@^DC;<LB_1GTT27ZMM^[V>6]6
MV&WS-JL*LU9&J+>KA ]'0Y#50O3C::"5NM*U?_MB=J/_ +$Q$E ]'0RP@
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MLE/2[BX]2,=71M5(X\DM<:1PI?Z.)=.2I9*Y&5L+=6LD<V1FC).2,#9@.W@
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M>][U5SGN<JJYSG*JJYSE7557BJDL555555555=55>*JJ]JJOG50#Y/P
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MY9'*KY9'.>Y5<Y54"[1/         #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\
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M7WRRI?JIU!8[C;)\6DU5M5)>K)7.8E,B*Z58>9O!($50/09,HH
M
M                          !YP?VWG\:?H?\ R?\ <+^,6 Q-^(G_ (:;
M=?@O=/U6: :09CK
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M,1           !Z7?V)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
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M!#2TE+#%34M+31,@IZ:G@8V*&""&)K8X888VHUK6HC6M1$1- ":',
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MZ)(]%>YK$CA:YRI'''&C6- L$4P
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M5YFQ2/1.2EN]+&Y$J*=='-=\YO-&YCW 8FRR(
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M_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L           ]?K[+C_L*.AG_I,_\
MOA]01G:Z-?Q;=N/_ "P_;YE !G^.SP                  !H!_;G/_ )7?
M_39_^$<QA^(]_P"AK_UA_P#F, : 9C#           /5Z^R&_P"QMPO\H#?;
M]7+69LNA7]P.W_A1DG_?$ !L_'<8   T4/MOF^M[LNS_ $(]-MLKW1V'<3<+
M>+>3,*"*2HB=)6;46#"L/P9U0C>6GJ:69-V[XY&+SJR6F:[1OS57&WXBF25%
M/8=M<2AE5*:ZW2_7^OB:KDU?9*6WT%M5^FC7L=]_*E=..CF(OH -P'H6Z9<7
MZ-.COIMZ7L1M-+9[9LOM#AN'W"*E; B7++X;7%79]DU6ZE?)2S7;+\ZKKC=J
MV6)5CEK*V5[?FN0[W;;X?1X!@6)8;0P,@AQ^Q4%!*UG+^BUS86R7.L>K%5CI
MZ^Y22SR*BZ.DD54X* >7+X!6YW2QM%XQN09EUC93LWAVRL&-]1UOKKUOL_&(
M\ CR&OJWQV"GJ'9=%-9_OI45#7I3<S>\YD7EXF&OIEO&%V+?NJK\]K;!08\V
MDRR*6HR1:-+6E5)(J4K'K7-=3]\YZ+R:\=>P V;/':ZPOL].XGA[;\XE@-^Z
M-MV.I&^X:VCZ=W]..%X5>MS;!N3%=J22P7://]O\=1F%XS:)9):F[QW"Y4=/
M<+8VHIF1U$T\4,G;_J3SSI:NNUN34-KJ<!O>6U- D>*KB=NM]1>*6[MG8M+.
MESM=)I;Z.!SG/G26:-LL*/8B.<Y&J!U[^P[8[NA!C?B&994PW"'9>YWSIZQV
MS5%4V;[U7+="QT&ZMRR6&QN6)].EPLF*9#:775&OC>L=PMW,V1$:L=+>'/2W
MEM)NG7/;*W'YJC%J6G<]'=S->::*]35;:9>56][3T55 L^BHNDL6J+PT M1X
MGNUM1T6?:V/#\WFVA;#CG\KS=;I,R[(VV^*&EHF7+>'<RY=)>]E%%34R0.;5
M9=AM!/<*Z1R.2IK;Y-*YSWOD:DEWBLK]ONN':_(+$C:3]G5[PBNJ^Z1K(TFO
MUXFPC(HT8SE5'UU!&Z65?S\E2Y55550#T-S*<
M
M              ><']MY_&GZ'_R?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
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M553'@][Y7OEE>^221[GR2/<KWO>]5<][WN57.>YRZJJ\54 ASX
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M4.1P0M5M#4IJC6SHB4TZJG*K7JL30-?8ZN@
M     &=KP<_ 6ZIO%CS"ARNDI;ALOTC6.\+2YWU%Y%9Y9*2[OH*IL5TP_9^S
MU3Z3]G^:)R/BFEC>VTV=S56MJ&S+!25/9/83IGS/>ZOCK6,EQ_!J:?DN65U=
M.Y8YUB?RS4%A@>K/OI<$T5'.1>X@7^R.1W*QX'JR=$G0UTU>'KL+C/3KTN[?
M4.$8+86MJ[O<Y64M9FFX>4RT\-/<\\W)R>*DI*K+,RO#:=C9:F5K(J>GCBI:
M2*FHJ>GIHLUFW>W&([6XS1XIAMKCMUMID1\\RHR2X76M5K6S7*[5B,8^NKYT
M:FKU1&M:C6,:R-K6- [=%<@            'G!_;>?QI^A_\G_<+^,6 Q-^(
MG_AIMU^"]T_59H!I!F.L           ]?K[+C_L*.AG_ *3/_OA]01G:Z-?Q
M;=N/_+#]OF4 &?X[/                   &@']N<_^5W_TV?\ X1S&'XCW
M_H:_]8?_ )C &@&8PP          #U>OLAO^QMPO\H#?;]7+69LNA7]P.W_A
M1DG_ 'Q  ;/QW&   -#'[<+LY>J[!/#^Z@:&CF=CN+9=OILYE%>O>NIX+UGM
MFV]S; Z-NC>YAFJJ';?(WKJO-(V%-$T8IC1\1>P5$EMVORB.-RTM'79)8*R7
MBK&U%SI[7<;9'_4M<^.TU:^E4;Z@#=.Z4M_,8ZINF;8/J/PVNH[ACN]VT>!;
MET,M"]'14TN68W;[M<;3,SF<^EN%CN=1-155/)I+355/)%(C9&.1,@V$Y-1Y
MIA^,99021RTF16*V7>-8UU:QU=213RP.3559+33.=&]B_.8]JM7BB@'DT>#1
MT";&>)3XK63],'4169Y0[;W6U[_YE53[<7^W8UDR7?$*^6KM38KI=;#D=(RC
M=+4.[YBTRN>FFCFF$38+;'&]W-[*S#LJ?<H[1/#E%>]UIJHJ.L[^AE=) C9I
MJ:K8D:N<O,G)JOI0 [<?:1? LVI\*";IRW5Z7*O="^]/^[4>1[?9C4[F7VU9
M3=<5WBL3ILCLT"WRT8[B]-';\YPJ:H=14BTSY&28]6R+*J2-:VN>K3INLFR3
ML3O6&/O-3B]\2KM=>^[U,-;-17ZF5U73M^LP4E&Q(KE;W/6-G(JHM+(NO%$0
M#T O!!W0Z<]YO"\Z2MQ>F+;3 =G<$O>W-+191MIMW;*:UV?$MWL8GEQ3=R@K
M(F,9<J^Y3YU8ZRH2X7%7W"Z4DT%9,^3OVR.R?=.MYQ2_[-X/=<.M%LL-MJ+2
MR.LM%JA9#!0WVC<M%?(I$1$FEF=<J:1W>RZRS1N;(Y5YD50-3OQ@-T&]2OVK
M_P ,O9K;.#[_ %PZ6]S.B+'<UAHECJ5@O=CWSGZG=P:ML\#7?W/CFU>044E1
M&JN6GFHZA'*UW,UO23?>\_LNZVMH+!:&_69<,O&W=+<&QZ/Y:BGR-V871_,U
M%^9266JC5Z?G71NUTXH@'H0F4<
M
M   \X/[;S^-/T/\ Y/\ N%_&+ 8F_$3_ ,--NOP7NGZK- -(,QU@
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MU;+E5UIV,^IN>UK966&V=Y/3VB-VBIWG-+5*USFK-R+R@&?0[-@
M   'R][(V.DD<UC&-<][WN1K&,:BN<YSG*B-:U$U55X(A^*J(BJJHB(FJJO!
M$1.U57S(@!Y>_P!I9\?&^];6Y.5=$'2=F\U'T9[9WYUHW#R_&:Y[(NIW<'':
M]%JJQ]RIN[6NV9Q"\TO)9J6-[Z.]UM/]]Y'5$7WL2EPX]774U4[AW>MVZPBX
MNCP"T5*P76OHY51,PNE)+\^196:=Y8*"H9I3L15CJ)&]^JN;W/(!J(G18
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M.:JM1'-5%3@4_/3STLBPU,$U/,U$5T4\;XI&HY$<U59(UKD1R+JG#B@!+3A
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M9EN^"9)(V'^Z4MK[A&ZWW-(?T:6SU]7$S1TB*6JWJVQH=WMN,APBJ?%3U5=
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M@FX=WP2NJXFMK9+K/8;I75V9I%(Q(V1OE:L%&G+W<D;Y7(WN^Z5P'HWF5\
M
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M<1Q_&V.9R2R6FUTE+55+45%UK*YD?UVM=P3YTLCW:(B:Z(@!V@*R
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M>U"PDT$U-+)3U$,M//$Y62PS1OBEB>WM9)'(C7L<GG1410"7G$
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M%             /;)\&C=.KWG\*7P^L_N-1)672KZ5-H,;O%=,L;I[A>]O\
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MN:O:A82:":FEDIZB&6GGB<K)89HWQ2Q/;VLDCD1KV.3SHJ(H!+SB
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M?K]MFEIII:;Z[E^07&EYI:2:HIW=]15<<B<KUT1VBZ+JB 9CB_8
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M!]5I?JOU'ZM3_4OJ_P!5^I]S']5^J]WW/U;ZOR]U]7[KYO)IR\O#30 G!S@
M
M
M
M                         '7W>WI,Z6NI6D6AZB.F_8G?2F2%((F[N;38
M)N))2L8U[8G4-1EEBNM1034_>*L4D+XY(7+S,<UW$I?(L(PS+F=WE6)8UDC.
M7E3[^V.VW56(FO+W;ZVFG?$YFOS5:J*U>*:* 8G=T_LS/@H;K2U5;6]%MEPB
M[5+G.;<]K-SMX]O(J57QQQN2EQO'\_I\*8W2%JHCK8Y&NU5$17OYK(WKI!Z>
M;VKY)-OJ>W3O552:RWB_VI&:HB+R4E+<VV]$^:G;"NB^RNH'1_+?L:WA)Y(^
M9]FRWK&P!LLU/*R+$MX\ K64[(:=(9*>%<[V9S65T-7(G?2+(Z21)%T8YC/F
M%NJ[H%V.JU<M/79[;-7-5$H;_;)$:C6\JL;]\L?N"\KU^<NNJZ]BHG  LQ=O
ML3GAW35TDEBZH.M&W6U6QI#27:^['7JN8](VI,Z2X4>RM@@E:^756HE*Q6-5
M$57*G,M/S^'EM6Z15ILRW!BAT3E9/4XY42(NB<VLL>/4K7(J]GS$T3T]H!.+
M-]BC\,^"C5F0]1O73=*_OGN2ILV<[ V&C2G5K.[B6AKNG3(YEF:Y'*Z3ZPC7
M(J(C$T55YZ?P]=H6QZ566;D32\RKST]RQBFCY=$T3NY,4JW<R+KQYM%] !V5
MP?[(;X-N)SMFOV%]0&YT;:A\RTN<;[7R@@?&YD#6TCG;;6O;VJ2GC="YS5;(
MDO-*[5ZHC$95UNZ%=@J)R.J;?E%X1'*[DN.2U,3514:B,5;3#:W\J<JKP7FX
MKQ[- ,ANSG@,>#SL3+23X'X??3]7U%!-]8I*K=.Q7;?BK@J$C;''.VJWRO6X
MM0LT'*CXG*Y712HDC%;)\XNI8.FC8;&G1NMFU^+ROB=S1OO--/DKVNTT1R/R
M.HNKN9NFJ+KJUW%./$ REXAA6&[?6*CQ; L2QG",9M[49;\<Q"PVK&K%0L1C
M(T;1VBS4M%;Z9J1QM;HR-J:-1.Q$+S4%OM]KIHZ*V4-';J.)-(J2@IH:2FC3
M1$TC@IV1Q,31$3@B=@!4Q&                     'CQ_:2.KVX]7OBZ=3
MU?%=W7'!>GZ_,Z7=MZ5LTDU);;3LS45MFS7ZI(JI#/#>=W:G([@R6-J,?%5L
M1'2-:V1V!KJUSN7.]\\QE;.LMMQ>J3#;2Q'*YD,%@=)3W#NU^BYM1?7U<J*B
M:*UZ=J)JH&",ZV       &3#P:-L+'O'XK/A_8!DL$-78+CU3;37J\4%2U7T
MUTH,+R6ES>HM%4Q&N5]+=X\=6FE;PYF2JFK==4N]L#9Z:_;U[7VNL:V2EES.
MQU$\3^+)HK?5LN+X'IHNK)TI>14\Z.\P![9!L-
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M"Q6>WVB%6M^BU8[?3T[%:WS)IH@!>(GP
M
M
M
M
M
M        !(\GR"WXEC60Y5=ED2UXS8[MD%R6%84E2WV:@J+E6+$M3-34Z2)3
MTSN7O)(V:_2<U-52&K*J*AI*JMGU[FCIIZJ;EY>;NJ>)TLFG.YC->1B]JHGI
M5 #P3L\S.][C9SF>X62S_6LCSO+,BS._U.KE^L7O*+Q67NZSZO5SE[ZNKI'<
M55>)K/7.X5%VN5PNE6[GJ[E75=PJG\?G5%9/)43.XZK\Z215 *4($
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MZ^XP\%5=4[FJ;HOYY./G ,RY?X
M
M
M
M
M
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M7+Q55U7B 7^*G
M
M
M
M
M
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MA<U5T6-[NU$T4#V)#/.
M
M
M
M
M
M                                  >,S]H Z7*WI+\7+K.P-+?)18QG
MNZ%PW]P.7NTCHJS%-^&MW,6*U-YG.^]^.9+?[E94UTTEM;T35J(JX ^I[#9,
M'WSW MG=+'1W.\RY/;'::1R462HEXY8$U5>ZI*NJEI_^%"OF ,-I8,
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MYIE@R7<-*2Z/BFC:D]OQR!LRV*D5517QR5T50ZKD35.$T;7-1T:@&TT=S@
M
M
M
M
M
M
M            #2$^V8>'=<=T-D=HO$5VYQYUPR+I[;%M!OS+0QQ.KEV8R^_R
M5FW^4U3>[;//;<#W+O=312HQ[WL;E7?*Q(8)I(\=?7[M5+><=L6ZUII5EJ\6
M1+%DRQHBR?L?KJE9+76O3EYG0VR[U#XW:*JHE;S:<K7*@'G!&)L
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M8*A9F\JOYHDAN#^\;R(JZIJFB:@%=?RLNEC^<OT__P ,NW7_ #C)C^S?"_\
M&_%_T_M/_*P!_*RZ6/YR_3__  R[=?\ .,?LWPO_ !OQ?]/[3_RL M_DGB%=
M F&_7_V7]<71_BOWJ[O[Z?LDZE]E['][>^[KNOK_ -],UI?J?>]^SE[SEYN=
MNG:A+*O=+;*@[WZ]N-@E%W&G??6\OQ^F[GFY>7O>^N#.[UYDTUT[4 .K6?\
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M6M:C6HC6M1&M:U$1K6HFB(B)P1$0 Y#]
M
M
M
M
M
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M2O;VIR7*U=XG]SSO:B,;=+8LC8JEFC=7:2-1(Y&:@8C2Q@
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M'20-1."?.EJ*B33GJ*RJE59)I7ZOED<KG*JJH!?(J,
M
M
M
M
M
M
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MR)NLU+(Y7L5%5JR1\LC@,4Y90
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M/4SOU?++(KI99%5[W.<JJH%X"?
M
M
M
M
M
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M[!%3;#[<7RFG^N4U5@^VMQ6M=E-ZM<W*V.\9%)5(LD$=526^VSIPRC[*]%N
M;</I+[F#H<^RV%8YHG5M*C,:M-2QW>,?;K1+WBUM1"[1$GJU?Q:CV10N -J
M[H
M
M
M
M
M
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MWINZ2-_MW;;='<M+E6+;:9,[ 8^S1]PW%N%#0X):85U1$DJ[C"Q55$1=2O\
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MP01LBAABC:C61Q11HUD<;&IHB(B(B $P.4
M
M
M
M
M
M
M             L_OA_F"_8%<OY2?^9__ #7\/OO_ )\/V%_L"[.'WR_9[_\
M>]V?_720Y'^QC[V2_LN^\/WF_P"W_LC^]_WL_P#WOWS_ +E]T U9>L;^AS][
M=_\ /;_(,^^'>?W=_)/_ &<_7_KG,_7N_P"0_P#-^N=_KWWFY_[/YSICGO\
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M+>7E3ETY=$Y>73EY=.&FG#30 Y#]
M
J                                                     /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
